FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Norris, K Beckles, G Cheng, YL Saydah, S Imperatore, G AF Norris, Keri Beckles, Gloria Cheng, Yiling Saydah, Sharon Imperatore, Giussepina TI SELF-RATED HEALTH AND ALL-CAUSE MORTALITY AMONG MIDDLE AGED AND OLDER ADULTS WITH AND WITHOUT DIABETES, NATIONAL HEALTH INTERVIEW SURVEY, 1997-2006. SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Meeting Abstract C1 [Norris, Keri; Beckles, Gloria; Cheng, Yiling; Saydah, Sharon; Imperatore, Giussepina] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. NR 0 TC 0 Z9 0 U1 1 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 15 PY 2013 VL 177 SU 11 BP S97 EP S97 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 157BL UT WOS:000319870300380 ER PT J AU Okoro, C Dhingra, S Coates, R Zack, M Simoes, E AF Okoro, Catherine Dhingra, Satvinder Coates, Ralph Zack, Matthew Simoes, Eduardo TI WHAT DOES THE MASSACHUSETTS EXPERIENCE TELL US ABOUT THE POTENTIAL IMPACT OF THE AFFORDABLE CARE ACT ON THE USE OF CLINICAL PREVENTIVE SERVICES? SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Meeting Abstract C1 [Okoro, Catherine; Dhingra, Satvinder; Coates, Ralph; Zack, Matthew; Simoes, Eduardo] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 15 PY 2013 VL 177 SU 11 BP S162 EP S162 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 157BL UT WOS:000319870300640 ER PT J AU Razzaghi, H Tinker, S AF Razzaghi, Hilda Tinker, Sarah TI SEAFOOD CONSUMPTION AMONG PREGNANT WOMEN AND NON-PREGNANT WOMEN OF CHILDBEARING AGE IN THE UNITED STATES, NHANES 1999-2010. SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Meeting Abstract C1 [Razzaghi, Hilda; Tinker, Sarah] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 15 PY 2013 VL 177 SU 11 BP S138 EP S138 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 157BL UT WOS:000319870300544 ER PT J AU Razzaghi, H Tinker, S Crider, K AF Razzaghi, Hilda Tinker, Sarah Crider, Krista TI BLOOD MERCURY LEVELS IN PREGNANT AND NON-PREGNANT WOMEN IN THE UNITED STATES (NHANES 1999-2010) SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Meeting Abstract C1 [Razzaghi, Hilda; Tinker, Sarah; Crider, Krista] Ctr Dis Control & Prevent, Atlanta, GA 30033 USA. NR 0 TC 0 Z9 0 U1 1 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 15 PY 2013 VL 177 SU 11 BP S86 EP S86 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 157BL UT WOS:000319870300339 ER PT J AU Reed, C Borse, R Gambhir, M Biggerstaff, M Meltzer, MI Finelli, L Rasmussen, S Swerdlow, D AF Reed, Carrie Borse, Rebekah Gambhir, Manoj Biggerstaff, Matthew Meltzer, Martin I. Finelli, Lyn Rasmussen, Sonja Swerdlow, David TI MODELING THE POTENTIAL IMPACT OF AN INFLUENZA A/H3N2V VACCINE IN THE UNITED STATES SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Meeting Abstract C1 [Reed, Carrie; Borse, Rebekah; Gambhir, Manoj; Biggerstaff, Matthew; Meltzer, Martin I.; Finelli, Lyn; Rasmussen, Sonja; Swerdlow, David] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 15 PY 2013 VL 177 SU 11 BP S111 EP S111 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 157BL UT WOS:000319870300438 ER PT J AU Reed, C Chaves, S Kirley, PD Emerson, R Aragon, D Hancock, E Butler, L Hollick, G Laidler, M Thomas, A Finelli, L AF Reed, Carrie Chaves, Sandra Kirley, Pam Daily Emerson, Ruth Aragon, Deborah Hancock, Emily Butler, Lisa Hollick, Gary Laidler, Matthew Thomas, Ann Finelli, Lyn TI ESTIMATING THE INCIDENCE AND SEVERITY OF INFLUENZA IN THE UNITED STATES: A BAYESIAN PERSPECTIVE SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Meeting Abstract C1 [Reed, Carrie; Chaves, Sandra; Kirley, Pam Daily; Emerson, Ruth; Aragon, Deborah; Hancock, Emily; Butler, Lisa; Hollick, Gary; Laidler, Matthew; Thomas, Ann; Finelli, Lyn] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 15 PY 2013 VL 177 SU 11 BP S110 EP S110 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 157BL UT WOS:000319870300435 ER PT J AU Tinker, S Devine, O Mai, C Hamner, H Reefhuis, J Gilboa, S Dowling, N Honein, M AF Tinker, Sarah Devine, Owen Mai, Cara Hamner, Heather Reefhuis, Jennita Gilboa, Suzanne Dowling, Nicole Honein, Margaret TI FOLIC ACID FORTIFICATION OF CORN MASA FLOUR AND NEURAL TUBE DEFECT PREVENTION. SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Meeting Abstract C1 [Tinker, Sarah; Devine, Owen; Mai, Cara; Hamner, Heather; Reefhuis, Jennita; Gilboa, Suzanne; Dowling, Nicole; Honein, Margaret] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 1 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 15 PY 2013 VL 177 SU 11 BP S20 EP S20 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 157BL UT WOS:000319870300078 ER PT J AU McLean, HQ Fiebelkorn, AP Temte, JL Wallace, GS AF McLean, Huong Q. Fiebelkorn, Amy Parker Temte, Jonathan L. Wallace, Gregory S. TI Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013 Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP) SO MMWR RECOMMENDATIONS AND REPORTS LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; SUBACUTE SCLEROSING-PANENCEPHALITIS; HIV-INFECTED CHILDREN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; POLYMERASE-CHAIN-REACTION; HIGHLY VACCINATED POPULATION; RESPIRATORY-TRACT INFECTION; HUMAN PLASMA FRACTIONATION; IMMEDIATE-TYPE REACTIONS AB This report is a compendium of all current recommendations for the prevention of measles, rubella, congenital rubella syndrome (CRS), and mumps. The report presents the recent revisions adopted by the Advisory Committee on Immunization Practices (ACIP) on October 24, 2012, and also summarizes all existing ACIP recommendations that have been published previously during 1998-2011 (CDC. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1998; 47[No. RR-8]; CDC. Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. MMWR 2001; 50: 1117; CDC. Updated recommendations of the Advisory Committee on Immunization Practices [ACIP] for the control and elimination of mumps. MMWR 2006; 55: 629-30; and, CDC. Immunization of healthcare personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011; 60[No. RR-7]). Currently, ACIP recommends 2 doses of MMR vaccine routinely for children with the first dose administered at age 12 through 15 months and the second dose administered at age 4 through 6 years before school entry. Two doses are recommended for adults at high risk for exposure and transmission (e.g., students attending colleges or other post-high school educational institutions, healthcare personnel, and international travelers) and 1 dose for other adults aged >= 18 years. For prevention of rubella, 1 dose of MMR vaccine is recommended for persons aged >= 12 months. At the October 24, 2012 meeting, ACIP adopted the following revisions, which are published here for the first time. These included: For acceptable evidence of immunity, removing documentation of physician diagnosed disease as an acceptable criterion for evidence of immunity for measles and mumps, and including laboratory confirmation of disease as a criterion for acceptable evidence of immunity for measles, rubella, and mumps. For persons with human immunodeficiency virus (HIV) infection, expanding recommendations for vaccination to all persons aged >= 12 months with HIV infection who do not have evidence of current severe immunosuppression; recommending revaccination of persons with perinatal HIV infection who were vaccinated before establishment of effective antiretroviral therapy (ART) with 2 appropriately spaced doses of MMR vaccine once effective ART has been established; and changing the recommended timing of the 2 doses of MMR vaccine for HIV-infected persons to age 12 through 15 months and 4 through 6 years. For measles postexposure prophylaxis, expanding recommendations for use of immune globulin administered intramuscularly (IGIM) to include infants aged birth to 6 months exposed to measles; increasing the recommended dose of IGIM for immunocompetent persons; and recommending use of immune globulin administered intravenously (IGIV) for severely immunocompromised persons and pregnant women without evidence of measles immunity who are exposed to measles. As a compendium of all current recommendations for the prevention of measles, rubella, congenital rubella syndrome (CRS), and mumps, the information in this report is intended for use by clinicians as baseline guidance for scheduling of vaccinations for these conditions and considerations regarding vaccination of special populations. ACIP recommendations are reviewed periodically and are revised as indicated when new information becomes available. C1 [McLean, Huong Q.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Fiebelkorn, Amy Parker; Wallace, Gregory S.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Temte, Jonathan L.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. RP Fiebelkorn, AP (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM aparker@cdc.gov NR 339 TC 87 Z9 87 U1 2 U2 16 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 1057-5987 EI 1545-8601 J9 MMWR RECOMM REP JI MMWR Recomm. Rep. PD JUN 14 PY 2013 VL 62 IS 4 BP 1 EP 34 PG 34 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 192NT UT WOS:000322492600001 PM 23760231 ER PT J AU Tanaka-Taya, K Satoh, H Arai, S Yamagishi, T Yahata, Y Nakashima, K Sugawara, T Ohkusa, Y Matsui, T Saito, T Kanou, K Shimada, T Kinoshita, H Yamashita, K Yasui, Y Tada, Y Mori, Y Takeda, M Sunagawa, T Oishi, K Strebel, P Schluter, WW Kamiya, H Reef, SE Chu, SY Martin, R AF Tanaka-Taya, Keiko Satoh, Hiroshi Arai, Satoru Yamagishi, Takuya Yahata, Yuichiro Nakashima, Kazutoshi Sugawara, Tamie Ohkusa, Yasushi Matsui, Tamano Saito, Takehito Kanou, Kazuhiko Shimada, Tomoe Kinoshita, Hitomi Yamashita, Kazuyo Yasui, Yoshinori Tada, Yuki Mori, Yoshio Takeda, Makoto Sunagawa, Tomimasa Oishi, Kazunori Strebel, Peter Schluter, W. William Kamiya, Hajime Reef, Susan E. Chu, Susan Y. Martin, Rebecca TI Nationwide Rubella Epidemic - Japan, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Strebel, Peter] WHO, CH-1211 Geneva, Switzerland. [Schluter, W. William] WHO, Western Pacific Reg Off, Manila, Philippines. [Reef, Susan E.; Chu, Susan Y.; Martin, Rebecca] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Reef, SE (reprint author), CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. EM sreef@cdc.gov NR 5 TC 24 Z9 24 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 14 PY 2013 VL 62 IS 23 BP 457 EP 462 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GM UT WOS:000322180700001 ER PT J AU Smith, DK Martin, M Lansky, A Mermin, J Choopanya, K AF Smith, Dawn K. Martin, Michael Lansky, Amy Mermin, Jonathan Choopanya, Kachit TI Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for Injecting Drug Users SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID WOMEN; MEN C1 [Smith, Dawn K.; Martin, Michael; Lansky, Amy; Mermin, Jonathan] CDC, Div HIV AIDS Prevent, Ctr HIV AIDS Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Choopanya, Kachit] Bangkok Tenofovir Study Grp, Bangkok, Thailand. RP Smith, DK (reprint author), CDC, Div HIV AIDS Prevent, Ctr HIV AIDS Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. EM dsmith1@cdc.gov NR 12 TC 40 Z9 40 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 14 PY 2013 VL 62 IS 23 BP 463 EP 465 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GM UT WOS:000322180700002 ER PT J AU Streit, T Desir, L Oscar, R Lemoine, JF Purcell, NC Keller, A Lammie, PJ Deming, M De Rochars, VEMB AF Streit, Thomas Desir, Luccene Oscar, Roland Lemoine, Jean Frantz Purcell, Nora Colleen Keller, Angela Lammie, Patrick J. Deming, Michael De Rochars, Valery E. Madsen Beau TI Mass Drug Administration for the Elimination of Lymphatic Filariasis - Port-au-Prince, Haiti, 2011-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Streit, Thomas; Desir, Luccene] Univ Notre Dame, Notre Dame, IN 46556 USA. [Streit, Thomas; Desir, Luccene] St Croix Hosp, St Croix, VI USA. [De Rochars, Valery E. Madsen Beau] CDC, Atlanta, GA 30333 USA. RP De Rochars, VEMB (reprint author), CDC, Atlanta, GA 30333 USA. EM madsenbeau@phhp.ufl.edu NR 4 TC 5 Z9 5 U1 1 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 14 PY 2013 VL 62 IS 23 BP 466 EP 468 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GM UT WOS:000322180700003 ER PT J AU Brammer, L Kniss, K Epperson, S Blanton, L Mustaquim, D Steffens, C D'Mello, T Perez, A Dhara, R Chaves, SS Abd Elal, A Gubareva, L Wallis, T Xu, XY Villanueva, J Bresee, J Cox, N Finelli, L Havers, F AF Brammer, Lynnette Kniss, Krista Epperson, Scott Blanton, Lenee Mustaquim, Desiree Steffens, Craig D'Mello, Tiffany Perez, Alejandro Dhara, Rosaline Chaves, Sandra S. Abd Elal, Anwar Gubareva, Larisa Wallis, Teresa Xu, Xiyan Villanueva, Julie Bresee, Joseph Cox, Nancy Finelli, Lyn Havers, Fiona CA World Hlth Org Collaborating Ctr S TI Influenza Activity - United States, 2012-13 Season and Composition of the 2013-14 Influenza Vaccine SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Brammer, Lynnette; Kniss, Krista; Epperson, Scott; Blanton, Lenee; Mustaquim, Desiree; Steffens, Craig; D'Mello, Tiffany; Perez, Alejandro; Dhara, Rosaline; Chaves, Sandra S.; Abd Elal, Anwar; Gubareva, Larisa; Wallis, Teresa; Xu, Xiyan; Villanueva, Julie; Bresee, Joseph; Cox, Nancy; Finelli, Lyn] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM fhavers@cdc.gov NR 6 TC 45 Z9 45 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 14 PY 2013 VL 62 IS 23 BP 473 EP 479 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GM UT WOS:000322180700005 ER PT J AU Gastanaduy, PA AF Gastanaduy, Paul A. TI Update: Severe Respiratory Illness Associated with Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - Worldwide, 2012-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID SAUDI-ARABIA C1 [Gastanaduy, Paul A.] CDC, Atlanta, GA 30333 USA. EM eocreport@cdc.gov NR 9 TC 18 Z9 18 U1 1 U2 6 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 14 PY 2013 VL 62 IS 23 BP 480 EP 483 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GM UT WOS:000322180700006 ER PT J AU Ehrhardt, D Marano, N AF Ehrhardt, Derek Marano, Nina TI Outbreak of Poliomyelitis - Somalia and Kenya, May 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Ehrhardt, Derek] CDC, WHO, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Ehrhardt, D (reprint author), CDC, WHO, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM dehrhardt@cdc.gov; nmarano@cdc.gov NR 3 TC 9 Z9 9 U1 1 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 14 PY 2013 VL 62 IS 23 BP 484 EP 484 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GM UT WOS:000322180700007 ER PT J AU Hill, J Dellicour, S Bruce, J Ouma, P Smedley, J Otieno, P Ombock, M Kariuki, S Desai, M Hamel, MJ ter Kuile, FO Webster, J AF Hill, Jenny Dellicour, Stephanie Bruce, Jane Ouma, Peter Smedley, James Otieno, Peter Ombock, Maurice Kariuki, Simon Desai, Meghna Hamel, Mary J. ter Kuile, Feiko O. Webster, Jayne TI Effectiveness of Antenatal Clinics to Deliver Intermittent Preventive Treatment and Insecticide Treated Nets for the Control of Malaria in Pregnancy in Kenya SO PLOS ONE LA English DT Article ID RURAL WESTERN KENYA; SULFADOXINE-PYRIMETHAMINE; PRESUMPTIVE TREATMENT; BIRTH-WEIGHT; TANZANIA; WOMEN; POLICY; ANTIMALARIAL; CHALLENGES; KNOWLEDGE AB Background: Malaria in pregnancy can have devastating consequences for mother and baby. Coverage with the WHO prevention strategy for sub-Saharan Africa of intermittent-preventive-treatment (IPTp) with two doses of sulphadoxine-pyrimethamine (SP) and insecticide-treated-nets (ITNs) in pregnancy is low. We analysed household survey data to evaluate the effectiveness of antenatal clinics (ANC) to deliver IPTp and ITNs to pregnant women in Nyando district, Kenya. Methods: We assessed the systems effectiveness of ANC to deliver IPTp and ITNs to pregnant women and the impact on low birthweight (LBW). Logistic regression was used to identify predictors of receipt of IPTp and ITN use during pregnancy. Results: Among 89% of recently pregnant women who attended ANC at least once between 4-9 months gestation, 59% reported receiving one dose of SP and 90% attended ANC again, of whom 57% received a second dose, resulting in a cumulative effectiveness for IPTp of 27%, most of whom used an ITN (96%). Overall ITN use was 89%, and ANC the main source (76%). Women were less likely to receive IPTp if they had low malaria knowledge (0.26, 95% CI 0.08-0.83), had a child who had died (OR 0.36, 95% CI 0.14-0.95), or if they first attended ANC late (OR 0.20, 95% CI 0.06-0.67). Women who experienced side effects to SP (OR 0.18, CI 0.03-0.90) or had low malaria knowledge (OR 0.78, 95% CI 0.11-5.43) were less likely to receive IPTp by directly observed therapy. Ineffective delivery of IPTp reduced its potential impact by 231 LBW cases averted (95% CI 64-359) per 10,000 pregnant women. Conclusion: IPTp presents greater challenges to deliver through ANC than ITNs in this setting. The reduction in public health impact on LBW resulting from ineffective delivery of IPTp is estimated to be substantial. Urgent efforts are required to improve service delivery of this important intervention. C1 [Hill, Jenny; Dellicour, Stephanie; Smedley, James; ter Kuile, Feiko O.] Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England. [Dellicour, Stephanie; Ouma, Peter; Otieno, Peter; Ombock, Maurice; Kariuki, Simon; Desai, Meghna] Ctr Dis Control Res & Publ Hlth Collaborat, Kenya Med Res Inst, Kisumu, Kenya. [Bruce, Jane; Webster, Jayne] London Sch Trop Med & Hyg, Dis Control Dept, London, England. [Desai, Meghna; Hamel, Mary J.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Hill, J (reprint author), Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England. EM j.hill@liv.ac.uk OI ter Kuile, Feiko/0000-0003-3663-5617 FU Malaria in Pregnancy (MiP) Consortium; Bill & Melinda Gates Foundation FX This work was supported by the Malaria in Pregnancy (MiP) Consortium, which is funded through a grant from the Bill & Melinda Gates Foundation to the Liverpool School of Tropical Medicine, United Kingdom. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 56 TC 18 Z9 18 U1 1 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 14 PY 2013 VL 8 IS 6 AR e64913 DI 10.1371/journal.pone.0064913 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 163UV UT WOS:000320363300006 PM 23798997 ER PT J AU Zhou, B Pearce, MB Li, Y Wang, JR Mason, RJ Tumpey, TM Wentworth, DE AF Zhou, Bin Pearce, Melissa B. Li, Yan Wang, Jieru Mason, Robert J. Tumpey, Terrence M. Wentworth, David E. TI Asparagine Substitution at PB2 Residue 701 Enhances the Replication, Pathogenicity, and Transmission of the 2009 Pandemic H1N1 Influenza A Virus SO PLOS ONE LA English DT Article ID ALVEOLAR TYPE-II; MOLECULAR-BASIS; EPITHELIAL-CELLS; HOST-RANGE; POLYMERASE; H5N1; DETERMINANT; VIRULENCE; SUBUNIT; FERRETS AB The 2009/2010 pandemic influenza virus (H1N1pdm) contains an avian-lineage PB2 gene that lacks E627K and D701N substitutions important in the pathogenesis and transmission of avian-origin viruses in humans or other mammals. Previous studies have shown that PB2-627K is not necessary because of a compensatory Q591R substitution. The role that PB2-701N plays in the H1N1pdm phenotype is not well understood. Therefore, PB2-D701N was introduced into an H1N1pdm virus (A/New York/1682/2009 (NY1682)) and analyzed in vitro and in vivo. Mini-genome replication assay, in vitro replication characteristics in cell lines, and analysis in the mouse and ferret models demonstrated that PB2-D701N increased virus replication rates and resulted in more severe pathogenicity in mice and more efficient transmission in ferrets. In addition, compared to the NY1682-WT virus, the NY1682-D701N mutant virus induced less IFN-lambda and replicated to a higher titer in primary human alveolar epithelial cells. These findings suggest that the acquisition of the PB2-701N substitution by H1N1pdm viruses may result in more severe disease or increase transmission in humans. C1 [Zhou, Bin; Wentworth, David E.] J Craig Venter Inst, Rockville, MD USA. [Zhou, Bin; Li, Yan; Wentworth, David E.] New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA. [Zhou, Bin; Wentworth, David E.] SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY USA. [Pearce, Melissa B.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA USA. [Wang, Jieru; Mason, Robert J.] Natl Jewish Hlth, Dept Med, Denver, CO USA. RP Wentworth, DE (reprint author), J Craig Venter Inst, Rockville, MD USA. EM dwentworth@JCVI.org RI Zhou, Bin/H-8688-2014; OI Zhou, Bin/0000-0002-1535-6283; Wentworth, David/0000-0002-5190-980X FU NIH/NIAID [U54-AI057158, P01AI059576-05]; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200900007C] FX This study was supported in part by NIH/NIAID U54-AI057158 (Northeast Biodefense Center-Lipkin). DEW was also supported by NIH/NIAID P01AI059576-05. DEW and BZ are also supported in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under contract number HHSN272200900007C. The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the funding agency. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 45 TC 20 Z9 21 U1 1 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 14 PY 2013 VL 8 IS 6 AR e67616 DI 10.1371/journal.pone.0067616 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 163UV UT WOS:000320363300113 PM 23799150 ER PT J AU Quinlivan, EP Crider, KS Zhu, JH Maneval, DR Hao, L Li, Z Rasmussen, SA Berry, RJ Bailey, LB AF Quinlivan, Eoin P. Crider, Krista S. Zhu, Jiang-Hui Maneval, David R. Hao, Ling Li, Zhu Rasmussen, Sonja A. Berry, R. J. Bailey, Lynn B. TI Hypomethylation of Serum Blood Clot DNA, but Not Plasma EDTA-Blood Cell Pellet DNA, from Vitamin B12-Deficient Subjects SO PLOS ONE LA English DT Article ID METHIONINE SYNTHASE ACTIVITY; MODERATE FOLATE-DEPLETION; X-CHROMOSOME INACTIVATION; COLORECTAL-CANCER RISK; DOUBLE-BLIND TRIAL; S-ADENOSYLMETHIONINE; HUMAN GENOME; METHYLENETETRAHYDROFOLATE REDUCTASE; METHYLTRANSFERASES DNMT3A; EPIGENETIC MECHANISMS AB Vitamin B12, a co-factor in methyl-group transfer, is important in maintaining DNA (deoxycytidine) methylation. Using two independent assays we examined the effect of vitamin B12-deficiency (plasma vitamin B12<148 pmol/L) on DNA methylation in women of childbearing age. Coagulated blood clot DNA from vitamin B12-deficient women had significantly (p<0.001) lower percentage deoxycytidine methylation (3.23 +/- 0.66%; n = 248) and greater [3 H]methyl-acceptance (42,859 +/- 9,699 cpm; n = 17) than DNA from B12-replete women (4.44 +/- 0.18%; n = 128 and 26,049 +/- 2,814 cpm; n = 11) [correlation between assays: r = -0.8538; p<0.001; n = 28]. In contrast, uncoagulated EDTA-blood cell pellet DNA from vitamin B12-deficient and B12-replete women exhibited similar percentage methylation (4.45 +/- 0.15%; n = 77 vs. 4.47 +/- 0.15%; n = 47) and [3 H]methyl-acceptance (27,378 +/- 4,094 cpm; n = 17 vs. 26,610 +/- 2,292 cpm; n = 11). Therefore, in simultaneously collected paired blood samples, vitamin B12-deficiency was associated with decreased DNA methylation only in coagulated samples. These findings highlight the importance of sample collection methods in epigenetic studies, and the potential impact biological processes can have on DNA methylation during collection. C1 [Quinlivan, Eoin P.] Univ Florida, Clin & Translat Sci Inst, Biomed Mass Spectrometry Lab, Gainesville, FL 32610 USA. [Crider, Krista S.; Rasmussen, Sonja A.; Berry, R. J.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Zhu, Jiang-Hui] China Natl Ctr Food Safety Risk Assessment, Dept Surveillance Program & Risk Assessment, Beijing, Peoples R China. [Maneval, David R.] Univ Florida, Food Sci & Human Nutr Dept, Gainesville, FL USA. [Hao, Ling] China Off, Ctr Dis Control & Prevent, Global Aids Program, Beijing, Peoples R China. [Li, Zhu] Peking Univ, Hlth Sci Ctr, Beijing 100871, Peoples R China. [Bailey, Lynn B.] Univ Georgia, Dept Foods & Nutr, Athens, GA 30602 USA. RP Quinlivan, EP (reprint author), Univ Florida, Clin & Translat Sci Inst, Biomed Mass Spectrometry Lab, Gainesville, FL 32610 USA. EM epq@ufl.edu OI Berry, Robert/0000-0002-7162-5046 FU BDB/DBDDD/NCBDDD/CDC (Birth Defects Branch, Division of Birth Defects and Developmental Disabilities, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention); NIH/NCATS Clinical and Translational Science Award [UL1 TR000064] FX Funding for this study was provided by a cooperative agreement from BDB/DBDDD/NCBDDD/CDC (Birth Defects Branch, Division of Birth Defects and Developmental Disabilities, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention). This work was supported in part by the NIH/NCATS Clinical and Translational Science Award to the University of Florida (UL1 TR000064). As a part of a public health scientific agency, CDC employees were directly involved in the study design, analysis, decision to publish and preparation of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 102 TC 0 Z9 0 U1 0 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 13 PY 2013 VL 8 IS 6 AR e65241 DI 10.1371/journal.pone.0065241 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 172XB UT WOS:000321038800105 PM 23785415 ER PT J AU Woodruff, RSY Winston, CA Miramontes, R AF Woodruff, Rachel S. Yelk Winston, Carla A. Miramontes, Roque TI Predicting US Tuberculosis Case Counts through 2020 SO PLOS ONE LA English DT Article ID STATES-MEXICO BORDER; UNITED-STATES; HIV-INFECTION; IMMIGRATION; EPIDEMIOLOGY; RIFAPENTINE; TRENDS; IMPACT AB In 2010, foreign-born persons accounted for 60% of all tuberculosis (TB) cases in the United States. Understanding which national groups make up the highest proportion of TB cases will assist TB control programs in concentrating limited resources where they can provide the greatest impact on preventing transmission of TB disease. The objective of our study was to predict through 2020 the numbers of U.S. TB cases among U.S.-born, foreign-born and foreign-born persons from selected countries of birth. TB case counts reported through the National Tuberculosis Surveillance System from 2000-2010 were log-transformed, and linear regression was performed to calculate predicted annual case counts and 95% prediction intervals for 2011-2020. Data were analyzed in 2011 before 2011 case counts were known. Decreases were predicted between 2010 observed and 2020 predicted counts for total TB cases (11,182 to 8,117 [95% prediction interval 7,262-9,073]) as well as TB cases among foreign-born persons from Mexico (1,541 to 1,420 [1,066-1,892]), the Philippines (740 to 724 [569-922]), India (578 to 553 [455-672]), Vietnam (532 to 429 [367-502]) and China (364 to 328 [249-433]). TB cases among persons who are U.S.-born and foreign-born were predicted to decline 47% (4,393 to 2,338 [2,113-2,586]) and 6% (6,720 to 6,343 [5,382-7,476]), respectively. Assuming rates of declines observed from 2000-2010 continue until 2020, a widening gap between the numbers of U.S.-born and foreign-born TB cases was predicted. TB case count predictions will help TB control programs identify needs for cultural competency, such as languages and interpreters needed for translating materials or engaging in appropriate community outreach. C1 [Woodruff, Rachel S. Yelk; Winston, Carla A.; Miramontes, Roque] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Woodruff, RSY (reprint author), Ctr Dis Control & Prevent, Atlanta, GA USA. EM ryelkwoodruff@cdc.gov OI Miramontes, Roque/0000-0001-9535-460X NR 34 TC 4 Z9 4 U1 1 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 13 PY 2013 VL 8 IS 6 AR e65276 DI 10.1371/journal.pone.0065276 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 172XB UT WOS:000321038800104 PM 23785416 ER PT J AU Huang, SS Septimus, E Kleinman, K Moody, J Hickok, J Avery, TR Lankiewicz, J Gombosev, A Terpstra, L Hartford, F Hayden, MK Jernigan, JA Weinstein, RA Fraser, VJ Haffenreffer, K Cui, E Kaganov, RE Lolans, K Perlin, JB Platt, R AF Huang, Susan S. Septimus, Edward Kleinman, Ken Moody, Julia Hickok, Jason Avery, Taliser R. Lankiewicz, Julie Gombosev, Adrijana Terpstra, Leah Hartford, Fallon Hayden, Mary K. Jernigan, John A. Weinstein, Robert A. Fraser, Victoria J. Haffenreffer, Katherine Cui, Eric Kaganov, Rebecca E. Lolans, Karen Perlin, Jonathan B. Platt, Richard CA CDC Prevention Epictr Program AHRQ DECIDE Network Healthcare-Associated Infections P TI Targeted versus Universal Decolonization to Prevent ICU Infection SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID RESISTANT STAPHYLOCOCCUS-AUREUS; INTENSIVE-CARE-UNIT; BLOOD-STREAM INFECTIONS; INTRANASAL MUPIROCIN; CHLORHEXIDINE; COLONIZATION; HOSPITALS; REDUCE; TRIAL; SURVEILLANCE AB BACKGROUND Both targeted decolonization and universal decolonization of patients in intensive care units (ICUs) are candidate strategies to prevent health care-associated infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA). METHODS We conducted a pragmatic, cluster-randomized trial. Hospitals were randomly assigned to one of three strategies, with all adult ICUs in a given hospital assigned to the same strategy. Group 1 implemented MRSA screening and isolation; group 2, targeted decolonization (i.e., screening, isolation, and decolonization of MRSA carriers); and group 3, universal decolonization (i.e., no screening, and decolonization of all patients). Proportional-hazards models were used to assess differences in infection reductions across the study groups, with clustering according to hospital. RESULTS A total of 43 hospitals (including 74 ICUs and 74,256 patients during the intervention period) underwent randomization. In the intervention period versus the baseline period, modeled hazard ratios for MRSA clinical isolates were 0.92 for screening and isolation (crude rate, 3.2 vs. 3.4 isolates per 1000 days), 0.75 for targeted decolonization (3.2 vs. 4.3 isolates per 1000 days), and 0.63 for universal decolonization (2.1 vs. 3.4 isolates per 1000 days) (P = 0.01 for test of all groups being equal). In the intervention versus baseline periods, hazard ratios for bloodstream infection with any pathogen in the three groups were 0.99 (crude rate, 4.1 vs. 4.2 infections per 1000 days), 0.78 (3.7 vs. 4.8 infections per 1000 days), and 0.56 (3.6 vs. 6.1 infections per 1000 days), respectively (P<0.001 for test of all groups being equal). Universal decolonization resulted in a significantly greater reduction in the rate of all bloodstream infections than either targeted decolonization or screening and isolation. One bloodstream infection was prevented per 54 patients who underwent decolonization. The reductions in rates of MRSA bloodstream infection were similar to those of all bloodstream infections, but the difference was not significant. Adverse events, which occurred in 7 patients, were mild and related to chlorhexidine. CONCLUSIONS In routine ICU practice, universal decolonization was more effective than targeted decolonization or screening and isolation in reducing rates of MRSA clinical isolates and bloodstream infection from any pathogen. (Funded by the Agency for Healthcare Research and the Centers for Disease Control and Prevention; REDUCE MRSA ClinicalTrials.gov number, NCT00980980.) C1 [Huang, Susan S.; Gombosev, Adrijana; Terpstra, Leah; Cui, Eric] Univ Calif Irvine, Sch Med, Orange, CA 92868 USA. [Septimus, Edward] Hosp Corp Amer, Houston, TX USA. [Moody, Julia; Hickok, Jason; Perlin, Jonathan B.] Hosp Corp Amer, Nashville, TN USA. [Septimus, Edward] Texas A&M Hlth Sci Ctr, Houston, TX USA. [Kleinman, Ken; Avery, Taliser R.; Lankiewicz, Julie; Hartford, Fallon; Haffenreffer, Katherine; Kaganov, Rebecca E.; Platt, Richard] Harvard Univ, Sch Med, Boston, MA USA. [Kleinman, Ken; Avery, Taliser R.; Lankiewicz, Julie; Hartford, Fallon; Haffenreffer, Katherine; Kaganov, Rebecca E.; Platt, Richard] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Hayden, Mary K.; Lolans, Karen] Rush Med Coll, Chicago, IL 60612 USA. [Weinstein, Robert A.] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA. [Jernigan, John A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Fraser, Victoria J.] Washington Univ, St Louis, MO 63130 USA. RP Huang, SS (reprint author), Univ Calif Irvine, Sch Med, Div Infect Dis, 101 City Dr,City Tower Suite 400,ZC 4081, Orange, CA 92868 USA. EM sshuang@uci.edu FU Agency for Healthcare Research; Centers for Disease Control and Prevention; AHRQ Healthcare-Associated Infections Program [HHSA290201000008I]; CDC Prevention Epicenters Program [1U01 CI000344]; 3M; Sage Products FX Funded by the Agency for Healthcare Research and the Centers for Disease Control and Prevention; REDUCE MRSA ClinicalTrials.gov number, NCT00980980.; Supported by a contract with the AHRQ Healthcare-Associated Infections Program (HHSA290201000008I) and by a grant from the CDC Prevention Epicenters Program (1U01 CI000344, to Dr. Platt).; Dr. Septimus reports receiving consulting fees from 3M and lecture fees from Sage Products; Dr. Hayden, conducting research involving a contributed product from Sage Products; Dr. Weinstein, serving as an unpaid consultant for Sage Products; and Dr. Fraser, owning stock in Express Scripts. No other potential conflict of interest relevant to this article was reported. NR 38 TC 255 Z9 262 U1 3 U2 46 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JUN 13 PY 2013 VL 368 IS 24 BP 2255 EP 2265 DI 10.1056/NEJMoa1207290 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 161YN UT WOS:000320230500001 PM 23718152 ER PT J AU Kang, G Desai, R Arora, R Chitamabar, S Naik, TN Krishnan, T Deshpande, J Gupte, MD Venkatasubramaniam, S Gentsch, JR Parashar, UD Mathew, A Anita, S Ramani, S Sowmynarayanan, TV Moses, PD Agarwal, I Simon, A Bose, A Arora, R Chhabra, P Fadnis, P Bhatt, J Shetty, SJ Saxena, VK Mathur, M Jadhav, A Roy, S Mukherjee, A Singh, NB AF Kang, Gagandeep Desai, Rishi Arora, Rashmi Chitamabar, Shobha Naik, Trilok Nath Krishnan, Triveni Deshpande, Jagdish Gupte, Mohan D. Venkatasubramaniam, S. Gentsch, Jon R. Parashar, Umesh D. Mathew, Ann Anita, Sr. Ramani, Sasirekha Sowmynarayanan, Thuppal V. Moses, Prabhakar D. Agarwal, Indira Simon, Anna Bose, Anuradha Arora, Ritu Chhabra, Preeti Fadnis, Prachi Bhatt, Jyoti Shetty, Sushmita J. Saxena, Vinay Kumar Mathur, Meenakshi Jadhav, Alka Roy, Soumyabrata Mukherjee, Anupam Singh, Ng Brajachand CA Indian Rotavirus Strain TI Diversity of circulating rotavirus strains in children hospitalized with diarrhea in India, 2005-2009 SO VACCINE LA English DT Article DE Rotavirus; India; G12; Strain ID CONTROLLED-TRIAL; G12 GENOTYPE; SOUTH-INDIA; EMERGENCE; SPECIFICITY; DISEASE; IDENTIFICATION; INFECTIONS; ARGENTINA; SEQUENCE AB Background: India accounts for 22% of the 453,000 global rotavirus deaths among children <5 years annually. The Indian Rotavirus Strain Surveillance Network provides clinicians and public health partners with valuable rotavirus disease surveillance data. Our analysis offers policy-makers an update on rotavirus disease burden with emphasis on regional shifts in rotavirus strain epidemiology in India. Methods: Children <5 years requiring hospitalization for acute gastroenteritis were selected from 10 representative hospitals in 7 cities throughout India between November 2005 through June 2009. We used a modified World Health Organization protocol for rotavirus surveillance; stool specimens were collected and tested for rotavirus using enzyme immunoassay and reverse-transcription polymerase chain reaction. Results: A total of 7285 stool specimens collected were tested for rotavirus, among which 2899 (40%) were positive for rotavirus. Among the 2899 rotavirus detections, a G-type could not be determined for 662 (23%) and more than one G type was detected in 240 (8%). Of 1997 (69%) patients with only one G-type, the common types were G1 (25%), G2 (21%), G9 (13%), and G12 (10%). The proportion of rotavirus infections attributed to G12 infections rose from 8% to 39% in the Northern region and from 8% to 24% in the Western region. Conclusions: This study highlights the large, ongoing burden of rotavirus disease in India, as well as interesting regional shifts in rotavirus strain epidemiology, including an increasing detection of G12 rotavirus strains in some regions. While broad heterotypic protection from rotavirus vaccination is expected based on pre- and post-licensure data from other settings, effectiveness assessments and rotavirus strain monitoring after vaccine introduction will be important. Published by Elsevier Ltd. C1 [Kang, Gagandeep] Christian Med Coll & Hosp, Vellore 632002, Tamil Nadu, India. [Desai, Rishi; Gentsch, Jon R.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Arora, Rashmi] Indian Council Med Res, New Delhi 110029, India. [Chitamabar, Shobha] Natl Inst Virol, Pune 411001, Maharashtra, India. [Naik, Trilok Nath; Krishnan, Triveni] Natl Inst Cholera & Enter Dis, Kolkata 700010, India. [Deshpande, Jagdish; Shetty, Sushmita J.; Saxena, Vinay Kumar] Enterovirus Res Ctr, Bombay 400012, Maharashtra, India. [Gupte, Mohan D.; Venkatasubramaniam, S.] Natl Inst Epidemiol, Madras 600077, Tamil Nadu, India. [Mathew, Ann] St Stephens Hosp, Dept Paediat, Delhi, India. [Anita, Sr.] Child Jesus Hosp, Tiruchchirappalli, India. [Ramani, Sasirekha; Sowmynarayanan, Thuppal V.; Moses, Prabhakar D.; Agarwal, Indira; Simon, Anna; Bose, Anuradha] Christian Med Coll & Hosp, Dept Gastrointestinal Sci, Vellore 632002, Tamil Nadu, India. [Ramani, Sasirekha; Sowmynarayanan, Thuppal V.; Moses, Prabhakar D.; Agarwal, Indira; Simon, Anna; Bose, Anuradha] Christian Med Coll & Hosp, Dept Child Hlth, Vellore 632002, Tamil Nadu, India. [Ramani, Sasirekha; Sowmynarayanan, Thuppal V.; Moses, Prabhakar D.; Agarwal, Indira; Simon, Anna; Bose, Anuradha] Christian Med Coll & Hosp, Dept Community Hlth, Vellore 632002, Tamil Nadu, India. [Arora, Ritu; Chhabra, Preeti; Fadnis, Prachi] Natl Inst Virol, Rotavirus Dept, Pune 411001, Maharashtra, India. [Bhatt, Jyoti] Reg Med Res Ctr Tribals, Jabalpur, India. [Mathur, Meenakshi] Lokmanya Tilak Municipal Gen Hosp, Bombay, Maharashtra, India. [Jadhav, Alka] Topiwalla Natl Med Coll, Bombay, Maharashtra, India. [Roy, Soumyabrata; Mukherjee, Anupam] Natl Inst Cholera & Enter Dis, Div Virol, Kolkata 700010, India. [Singh, Ng Brajachand] Reg Inst Med Sci, Dept Microbiol, Imphal, Manipur, India. RP Desai, R (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS-A34, Atlanta, GA 30333 USA. EM rdesai1@cdc.gov OI KRISHNAN, TRIVENI/0000-0002-9736-6716 NR 30 TC 36 Z9 36 U1 1 U2 10 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD JUN 12 PY 2013 VL 31 IS 27 BP 2879 EP 2883 DI 10.1016/j.vaccine.2013.04.030 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 171ZY UT WOS:000320970600006 PM 23624096 ER PT J AU Naleway, AL Gold, R Kurosky, S Riedlinger, K Henninger, ML Nordin, JD Kharbanda, EO Irving, S Cheetham, TC McCarthy, NL AF Naleway, Allison L. Gold, Rachel Kurosky, Samantha Riedlinger, Karen Henninger, Michelle L. Nordin, James D. Kharbanda, Elyse O. Irving, Stephanie Cheetham, T. Craig McCarthy, Natalie L. TI Identifying pregnancy episodes, outcomes, and mother-infant pairs in the Vaccine Safety Datalink SO VACCINE LA English DT Article DE Vaccine safety; Pregnancy ID MATERNAL IMMUNIZATION; HEALTH-CARE; SYSTEM; WOMEN AB Background: The need for research on the safety of vaccination during pregnancy is widely recognized. Large, population-based data systems like the Vaccine Safety Datalink (VSD) may be useful for this research, but identifying pregnancies using electronic medical record (EMR) and claims data can be challenging. Methods: We modified an existing data processing algorithm to identify pregnancies within seven of the ten VSD sites. We validated the algorithm by calculating the agreement in pregnancy outcome type, end date, and gestational age between the algorithm and manual medical record review. At each participating site, we randomly sampled 15 episodes within four outcome type strata (live births, spontaneous abortions, elective abortions, and other pregnancy outcomes) for a total of 60 episodes per site. We also developed and validated methods to link mothers to their infants in the electronic data. Results: We identified 595,929 pregnancy episodes ending in 2002 through 2006 among women 12 through 55 years of age. Of these pregnancies, 75% ended in live births, 12% in spontaneous abortions, and 9% in elective abortions. We were able to confirm a pregnancy within 28 days of the algorithm-estimated pregnancy start date for 99% of live births, 93% of spontaneous abortions, 92% of elective abortions, and 90% of other outcomes sampled. The agreement between the algorithm-identified and the abstractor-identified outcome date ranged from 70% (elective abortion) to 96% (live birth) depending on outcome type. When gestational age was available in the EMR, agreement ranged from 82% (other) to 98% (live birth) depending on outcome type. We confirmed 100% of the 350 sampled mother-infant linkages with manual medical record review. Conclusions: The VSD algorithm accurately identifies pregnancy episodes and mother-infant pairs across participating sites. Additional manual record review may be needed to improve the precision of the pregnancy date estimates depending on specific study needs. These algorithms will allow us to conduct large, population-based studies of the safety of vaccination during pregnancy. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Naleway, Allison L.; Gold, Rachel; Kurosky, Samantha; Riedlinger, Karen; Henninger, Michelle L.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR 97227 USA. [Nordin, James D.; Kharbanda, Elyse O.] Hlth Partners Inst Educ & Res, Minneapolis, MN 55440 USA. [Irving, Stephanie] Marshfield Clin Res Fdn, Epidemiol Res Ctr, Marshfield, WI 54449 USA. [Cheetham, T. Craig] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [McCarthy, Natalie L.] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30333 USA. RP Naleway, AL (reprint author), Kaiser Permanente Northwest, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA. EM allison.naleway@kpchr.org; rachel.gold@kpchr.org; samantha.k.kurosky@kpchr.org; karen.riedlinger@kpchr.org; michelle.henninger@kpchr.org; james.d.nordin@healthpartners.com; elyse.o.kharbanda@healthpartners.com; stephanie.irving@kpchr.org; craig.t.cheetham@kp.org; gvz7@cdc.gov OI Irving, Stephanie/0000-0001-7437-6797; Naleway, Allison/0000-0001-5747-4643 FU Centers for Disease Control and Prevention [200-2002-00732] FX Financial support for this study was provided in full by the Centers for Disease Control and Prevention (200-2002-00732), through America's Health Insurance Plans. The manuscript was reviewed and approved through the clearance process of the Centers for Disease Control and Prevention prior to submission. The findings and conclusions in this report are those of the authors and do not necessarily represent the official positions of the Centers for Disease Control and Prevention or America's Health Insurance Plans. NR 17 TC 20 Z9 20 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD JUN 12 PY 2013 VL 31 IS 27 BP 2898 EP 2903 DI 10.1016/j.vaccine.2013.03.069 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 171ZY UT WOS:000320970600009 PM 23639917 ER PT J AU Ioannidis, JPA Chang, CQ Lam, TK Schully, SD Khoury, MJ AF Ioannidis, John P. A. Chang, Christine Q. Lam, Tram Kim Schully, Sheri D. Khoury, Muin J. TI The Geometric Increase in Meta-Analyses from China in the Genomic Era SO PLOS ONE LA English DT Article ID WIDE ASSOCIATION; KNOWLEDGE INTEGRATION; GENETIC ASSOCIATIONS; CONTROLLED-TRIALS; COMMON DISEASES; COMPLEX TRAITS; EPIDEMIOLOGY; BIAS; POLYMORPHISMS; REPLICATION AB Meta-analyses are increasingly popular. It is unknown whether this popularity is driven by specific countries and specific meta-analyses types. PubMed was used to identify meta-analyses since 1995 (last update 9/1/2012) and catalogue their types and country of origin. We focused more on meta-analyses from China (the current top producer of meta-analyses) versus the USA (top producer until recently). The annual number of meta-analyses from China increased 40-fold between 2003 and 2011 versus 2.4-fold for the USA. The growth of Chinese meta-analyses was driven by genetics (110-fold increase in 2011 versus 2003). The HuGE Navigator identified 612 meta-analyses of genetic association studies published in 2012 from China versus only 109 from the USA. We compared in-depth 50 genetic association meta-analyses from China versus 50 from USA in 2012. Meta-analyses from China almost always used only literature-based data (92%), and focused on one or two genes (94%) and variants (78%) identified with candidate gene approaches (88%), while many USA meta-analyses used genome-wide approaches and raw data. Both groups usually concluded favorably for the presence of genetic associations (80% versus 74%), but nominal significance (P<0.05) typically sufficed in the China group. Meta-analyses from China typically neglected genome-wide data, and often included candidate gene studies published in Chinese-language journals. Overall, there is an impressive rise of meta-analyses from China, particularly on genetic associations. Since most claimed candidate gene associations are likely false-positives, there is an urgent global need to incorporate genome-wide data and state-of-the art statistical inferences to avoid a flood of false-positive genetic meta-analyses. C1 [Ioannidis, John P. A.; Chang, Christine Q.; Lam, Tram Kim; Schully, Sheri D.; Khoury, Muin J.] NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. [Ioannidis, John P. A.] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Dept Med, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Sch Humanities & Sci, Dept Stat, Stanford, CA 94305 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. RP Ioannidis, JPA (reprint author), NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. EM jioannid@stanford.edu NR 35 TC 12 Z9 12 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 12 PY 2013 VL 8 IS 6 AR e65602 DI 10.1371/journal.pone.0065602 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 163FW UT WOS:000320322400037 PM 23776510 ER PT J AU McAfee, T AF McAfee, Tim TI Encouraging Smokers to Talk With Their Physicians About Quitting SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 [McAfee, Tim] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP McAfee, T (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, 4770 Buford Hwy NE,MS F79, Atlanta, GA 30341 USA. EM mtt4@cdc.gov NR 6 TC 4 Z9 4 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUN 12 PY 2013 VL 309 IS 22 BP 2329 EP 2330 DI 10.1001/jama.2013.5975 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 161EV UT WOS:000320176000020 PM 23700193 ER PT J AU Horton, DK Adetona, O Aguilar-Villalobos, M Cassidy, BE Pfeiffer, CM Schleicher, RL Caldwell, KL Needham, LL Rathbun, SL Vena, JE Naeher, LP AF Horton, D. Kevin Adetona, Olorunfemi Aguilar-Villalobos, Manuel Cassidy, Brandon E. Pfeiffer, Christine M. Schleicher, Rosemary L. Caldwell, Kathleen L. Needham, Larry L. Rathbun, Stephen L. Vena, John E. Naeher, Luke P. TI Changes in the concentrations of biochemical indicators of diet and nutritional status of pregnant women across pregnancy trimesters in Trujillo, Peru, 2004-2005 SO NUTRITION JOURNAL LA English DT Article DE Micronutrients; Pregnant women; Trimester; Serum; Cord blood; Peru ID UMBILICAL-CORD BLOOD; SERUM SELENIUM LEVELS; 3RD NATIONAL-HEALTH; ALPHA-TOCOPHEROL; PLASMA; MICRONUTRIENTS; PREVALENCE; EXPOSURE; AGE AB Background: In developing countries, deficiencies in essential micronutrients are common, particularly in pregnant women. Although, biochemical indicators of diet and nutrition are useful to assess nutritional status, few studies have examined such indicators throughout pregnancy in women in developing countries. Methods: The primary objective of this study was to assess the nutritional status of 78 Peruvian women throughout pregnancy for 16 different nutritional indicators including fat-soluble vitamins and carotenoids, iron-status indicators, and selenium. Venous blood samples from which serum was prepared were collected during trimesters one (n = 78), two (n = 65), three (n = 62), and at term via the umbilical cord (n = 52). Questionnaires were completed to determine the demographic characteristics of subjects. Linear mixed effects models were used to study the associations between each maternal indicator and the demographic characteristics. Results: None of the women were vitamin A and E deficient at any stage of pregnancy and only 1/62 women (1.6%) was selenium deficient during the third trimester. However, 6.4%, 44% and 64% of women had ferritin levels indicative of iron deficiency during the first, second and third trimester, respectively. Statistically significant changes (p <= 0.05) throughout pregnancy were noted for 15/16 nutritional indicators for this Peruvian cohort, with little-to-no association with demographic characteristics. Three carotenoids (beta-carotene, beta-cryptoxanthin and trans-lycopene) were significantly associated with education status, while trans-lycopene was associated with age and beta-cryptoxanthin with SES (p < 0.05). Concentrations of retinol, tocopherol, beta-cryptoxanthin, lutein + zeaxanthin and selenium were lower in cord serum compared with maternal serum (p < 0.05). Conversely, levels of iron status indicators (ferritin, transferrin saturation and iron) were higher in cord serum (p < 0.05). Conclusion: The increasing prevalence of iron deficiency throughout pregnancy in these Peruvian women was expected. It was surprising though not to find deficiencies in other nutrients. The results highlight the importance of continual monitoring of women throughout pregnancy for iron deficiency which could be caused by increasing fetal needs and/or inadequate iron intake as pregnancy progresses. C1 [Adetona, Olorunfemi; Cassidy, Brandon E.; Naeher, Luke P.] Univ Georgia, Coll Publ Hlth, Athens, GA 30602 USA. [Horton, D. Kevin] Agcy Tox Subst & Dis Registry, Atlanta, GA USA. [Aguilar-Villalobos, Manuel] Asociac Aire Ambiental, Lima, Peru. [Pfeiffer, Christine M.; Schleicher, Rosemary L.; Caldwell, Kathleen L.; Needham, Larry L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Rathbun, Stephen L.; Vena, John E.] Univ Georgia, Coll Publ Hlth, Paul D Coverdell Ctr Biomed & Hlth Sci, Dept Biostat & Epidemiol, Athens, GA 30602 USA. RP Naeher, LP (reprint author), Univ Georgia, Coll Publ Hlth, 150 Environm Hlth Sci Bldg, Athens, GA 30602 USA. EM LNaeher@uga.edu FU International Society of Exposure Science (ISES); American Chemistry Council (ACC) FX This project has been funded in part by the International Society of Exposure Science (ISES) [formerly International Society of Exposure Assessment (ISEA)] and the American Chemistry Council (ACC) (Naeher LP). This work is a publication of the University of Georgia (UGA). The contents of this publication do not necessarily reflect the views or politics of UGA, nor does the mention of trade names, commercial products or organizations imply endorsement by UGA. NR 50 TC 4 Z9 4 U1 0 U2 13 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2891 J9 NUTR J JI Nutr. J. PD JUN 11 PY 2013 VL 12 AR 80 DI 10.1186/1475-2891-12-80 PG 11 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 166LX UT WOS:000320557200001 PM 23758715 ER PT J AU Mlacha, SZK Romero-Steiner, S Hotopp, JCD Kumar, N Ishmael, N Riley, DR Farooq, U Creasy, TH Tallon, LJ Liu, XY Goldsmith, CS Sampson, J Carlone, GM Hollingshead, SK Scott, JAG Tettelin, H AF Mlacha, Sheila Z. Kimaro Romero-Steiner, Sandra Hotopp, Julie C. Dunning Kumar, Nikhil Ishmael, Nadeeza Riley, David R. Farooq, Umar Creasy, Todd H. Tallon, Luke J. Liu, Xinyue Goldsmith, Cynthia S. Sampson, Jacquelyn Carlone, George M. Hollingshead, Susan K. Scott, J. Anthony G. Tettelin, Herve TI Phenotypic, genomic, and transcriptional characterization of Streptococcus pneumoniae interacting with human pharyngeal cells SO BMC GENOMICS LA English DT Article DE Streptococcus pneumoniae; Gene expression; Microarray; Adherence; Invasion; Genome; Mutagenesis; SP_1922; Ply operon ID FIBRONECTIN-BINDING PROTEIN; EPITHELIAL-CELLS; INVASIVE DISEASE; GENE-EXPRESSION; PNEUMOCOCCAL ADHERENCE; VIRULENCE; PNEUMOLYSIN; COLONIZATION; SEQUENCE; ADHESIN AB Background: Streptococcus pneumoniae is a leading cause of childhood morbidity and mortality worldwide, despite the availability of effective pneumococcal vaccines. Understanding the molecular interactions between the bacterium and the host will contribute to the control and prevention of pneumococcal disease. Results: We used a combination of adherence assays, mutagenesis and functional genomics to identify novel factors involved in adherence. By contrasting these processes in two pneumococcal strains, TIGR4 and G54, we showed that adherence and invasion capacities vary markedly by strain. Electron microscopy showed more adherent bacteria in association with membranous pseudopodia in the TIGR4 strain. Operons for cell wall phosphorylcholine incorporation (lic), manganese transport (psa) and phosphate utilization (phn) were up-regulated in both strains on exposure to epithelial cells. Pneumolysin, pili, stress protection genes (adhC-czcD) and genes of the type II fatty acid synthesis pathway were highly expressed in the naturally more invasive strain, TIGR4. Deletion mutagenesis of five gene regions identified as regulated in this study revealed attenuation in adherence. Most strikingly, Delta SP_1922 which was predicted to contain a B-cell epitope and revealed significant attenuation in adherence, appeared to be expressed as a part of an operon that includes the gene encoding the cytoplasmic pore-forming toxin and vaccine candidate, pneumolysin. Conclusion: This work identifies a list of novel potential pneumococcal adherence determinants. C1 [Mlacha, Sheila Z. Kimaro; Scott, J. Anthony G.] Wellcome Trust Res Programme, Kenya Med Res Inst, Kilifi, Kenya. [Mlacha, Sheila Z. Kimaro; Hotopp, Julie C. Dunning; Kumar, Nikhil; Ishmael, Nadeeza; Riley, David R.; Farooq, Umar; Creasy, Todd H.; Tallon, Luke J.; Liu, Xinyue; Tettelin, Herve] Univ Maryland, Sch Med, Inst Genome Sci, Dept Microbiol & Immunol, Baltimore, MD 21201 USA. [Romero-Steiner, Sandra; Sampson, Jacquelyn; Carlone, George M.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA. [Goldsmith, Cynthia S.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Hollingshead, Susan K.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Scott, J. Anthony G.] Univ Oxford, Nuffield Dept Clin Med, Oxford, England. RP Tettelin, H (reprint author), Univ Maryland, Sch Med, Inst Genome Sci, Dept Microbiol & Immunol, 801 W Baltimore St, Baltimore, MD 21201 USA. EM tettelin@som.umaryland.edu OI Romero-Steiner, Sandra/0000-0003-4128-7768 FU GlaxoSmithKline Biologicals; Wellcome Trust [081835]; University of Maryland; KEMRI-Wellcome Trust Research Programme [084538] FX JAGS reports receiving a grant from GlaxoSmithKline Biologicals (Anthony Scott, Kayla Laserson; $2,575,975; Oct 2010-Sep 2013) for a study entitled: 'A phase IV multi-site observational epidemiology study to assess potential risk for adverse events following immunization that may be associated with misuse of a two-dose vial of 10-valent Pneumococcal Conjugate Vaccine (Synflorix) in Kenya'.; This work was supported by grants from the Wellcome Trust to Prof. Anthony Scott (081835) and University of Maryland internal funds to Dr. Herve Tettelin. Sheila Z. Kimaro Mlacha was supported by strategic training award No. 084538 to the KEMRI-Wellcome Trust Research Programme. This paper is published with the permission of the Director, Kenya Medical Research Institute. The authors wish to thank the Pathogen Functional Genomics Resource Center (PFGRC) at The Institute for Genomic Research (TIGR) / J. Craig Venter Institute (JCVI) for providing microarray slides, Shankar Rajam, Yulanda Williamson (Centers for Disease Control and Prevention, CDC) and Pat Cohen (University of Alabama, Birmingham) for technical assistance, and Margaret Mackinnon and Greg Fegan (KEMRI/Wellcome Trust) for expert advice on statistical methods. NR 62 TC 6 Z9 6 U1 2 U2 15 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2164 J9 BMC GENOMICS JI BMC Genomics PD JUN 9 PY 2013 VL 14 AR 383 DI 10.1186/1471-2164-14-383 PG 18 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 181JG UT WOS:000321663200001 ER PT J AU Fowler, DR Mitchell, CS Brown, A Pollock, T Bratka, LA Paulson, J Noller, AC Mauskapf, R Oscanyan, K Vaidyanathan, A Wolkin, A Taylor, EV Radcliffe, R AF Fowler, David R. Mitchell, Clifford S. Brown, Alise Pollock, Tessie Bratka, Lynne A. Paulson, John Noller, Anna C. Mauskapf, Robert Oscanyan, Kathryn Vaidyanathan, Ambarish Wolkin, Amy Taylor, Ethel V. Radcliffe, Rachel TI Heat-Related Deaths After an Extreme Heat Event - Four States, 2012, and United States, 1999-2009 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Brown, Alise; Pollock, Tessie; Bratka, Lynne A.] Ohio Dept Hlth, Columbus, OH 43266 USA. [Vaidyanathan, Ambarish; Wolkin, Amy; Taylor, Ethel V.] CDC, Career Epidemiol Field Officer Program, Atlanta, GA 30333 USA. EM evtaylor@cdc.gov RI Mitchell, Clifford/K-3936-2015 NR 8 TC 9 Z9 9 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 7 PY 2013 VL 62 IS 22 BP 433 EP 436 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GK UT WOS:000322180500001 ER PT J AU Tarawneh, I Lampl, M Robins, D Wurzelbacher, S Bertke, S Bell, J Meyers, A AF Tarawneh, Ibraheem Lampl, Mike Robins, Dave Wurzelbacher, Steve Bertke, Steve Bell, Jennifer Meyers, Alysha TI Workers' Compensation Claims for Musculoskeletal Disorders Among Wholesale and Retail Trade Industry Workers - Ohio, 2005-2009 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Bell, Jennifer] NIOSH, Div Safety Res, Washington, DC 20201 USA. [Meyers, Alysha] CDC, Atlanta, GA 30333 USA. RP Meyers, A (reprint author), CDC, Atlanta, GA 30333 USA. EM armeyers@cdc.gov NR 9 TC 2 Z9 2 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 7 PY 2013 VL 62 IS 22 BP 437 EP 442 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GK UT WOS:000322180500002 ER PT J AU Schluter, WW Wang, XJ Mendoza-Aldana, J Jee, Y Diorditsa, S Dabbagh, A Mulders, M Gregory, C Goodson, JL AF Schluter, W. William Wang Xiaojun Mendoza-Aldana, Jorge Jee, Youngmee Diorditsa, Sergey Dabbagh, Alya Mulders, Mick Gregory, Christopher Goodson, James L. TI Progress Toward Measles Elimination - Western Pacific Region, 2009-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Schluter, W. William; Wang Xiaojun; Mendoza-Aldana, Jorge; Jee, Youngmee; Diorditsa, Sergey] Western Pacific Reg Off, WHO, Expanded Programme Immunizat, Manila, Philippines. [Dabbagh, Alya; Mulders, Mick] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. [Goodson, James L.] CDC, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA. RP Goodson, JL (reprint author), CDC, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA. EM jgoodson@cdc.gov NR 7 TC 11 Z9 11 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 7 PY 2013 VL 62 IS 22 BP 443 EP 447 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GK UT WOS:000322180500003 ER PT J AU Silk, BJ Mahon, BE Griffin, PM Gould, H Tauxe, RV Crim, SM Jackson, KA Gerner-Smidt, P Herman, KM Henao, OL AF Silk, Benjamin J. Mahon, Barbara E. Griffin, Patricia M. Gould, Hannah Tauxe, Robert V. Crim, Stacy M. Jackson, Kelly A. Gerner-Smidt, Peter Herman, Karen M. Henao, Olga L. TI Vital Signs: Listeria Illnesses, Deaths, and Outbreaks - United States, 2009-2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ACTIVE SURVEILLANCE NETWORK; MEXICAN-STYLE CHEESE; EPIDEMIC LISTERIOSIS; MULTISTATE OUTBREAK; FOODBORNE DISEASE; PASTEURIZED MILK; MONOCYTOGENES; PREVENTION; INFECTION; PATHOGENS AB Background: Older adults, pregnant women, and persons with immunocompromising conditions are at higher risk than others for invasive Listeria monocytogenes infection (listeriosis), a rare and preventable foodborne illness that can cause bacteremia, meningitis, fetal loss, and death. Methods: This report summarizes data on 2009-2011 listeriosis cases and outbreaks reported to U. S. surveillance systems. The Listeria Initiative and PulseNet conduct nationwide surveillance to rapidly detect and respond to outbreaks, the Foodborne Diseases Active Surveillance Network (FoodNet) conducts active, sentinel population-based surveillance to track incidence trends, and the Foodborne Disease Outbreak Surveillance System (FDOSS) receives reports of investigated outbreaks to track foods and settings associated with outbreaks. Results: Nationwide, 1,651 cases of listeriosis occurring during 2009-2011 were reported. The case-fatality rate was 21%. Most cases occurred among adults aged >= 65 years (950 [58%]), and 14% (227) were pregnancy-associated. At least 74% of nonpregnant patients aged <65 years had an immunocompromising condition, most commonly immunosuppressive therapy or malignancy. The average annual incidence was 0.29 cases per 100,000 population. Compared with the overall population, incidence was markedly higher among adults aged = 65 years (1.3; relative rate [RR]: 4.4) and pregnant women (3.0; RR: 10.1). Twelve reported outbreaks affected 224 patients in 38 states. Five outbreak investigations implicated soft cheeses made from pasteurized milk that were likely contaminated during cheese-making (four implicated Mexican-style cheese, and one implicated two other types of cheese). Two outbreaks were linked to raw produce. Conclusions: Almost all listeriosis occurs in persons in higher-risk groups. Soft cheeses were prominent vehicles, but other foods also caused recent outbreaks. Prevention targeting higher-risk groups and control of Listeria monocytogenes contamination in foods implicated by outbreak investigations will have the greatest impact on reducing the burden of listeriosis. Implications for Public Health Practice: Careful attention to food safety is especially important to protect vulnerable populations. Surveillance for foodborne infections like listeriosis identifies food safety gaps that can be addressed by industry, regulatory authorities, food preparers, and consumers. C1 [Silk, Benjamin J.; Mahon, Barbara E.; Griffin, Patricia M.; Gould, Hannah; Tauxe, Robert V.; Crim, Stacy M.; Jackson, Kelly A.; Gerner-Smidt, Peter; Herman, Karen M.; Henao, Olga L.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. RP Silk, BJ (reprint author), CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. EM bsilk@cdc.gov NR 17 TC 59 Z9 60 U1 2 U2 35 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 7 PY 2013 VL 62 IS 22 BP 448 EP 452 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GK UT WOS:000322180500004 ER PT J AU Baba, SP Jervase, A St Louis, M Dokubo, EK Clarke, K AF Baba, Samson P. Jervase, Ayat St Louis, Michael Dokubo, E. Kainne Clarke, Kevin TI Investigation of High HIV Prevalence in Western Equatoria State - South Sudan, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Dokubo, E. Kainne; Clarke, Kevin] CDC, Atlanta, GA 30333 USA. RP Dokubo, EK (reprint author), CDC, Atlanta, GA 30333 USA. EM kdokubo@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 7 PY 2013 VL 62 IS 22 BP 453 EP 454 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GK UT WOS:000322180500005 ER PT J AU Mlacha, SZK Peret, TCT Kumar, N Romero-Steiner, S Hotopp, JCD Ishmael, N Grinblat-Huse, V Riley, DR Erdman, DD Carlone, GM Sampson, J Scott, JAG Tettelin, H AF Mlacha, Sheila Z. Kimaro Peret, Teresa C. T. Kumar, Nikhil Romero-Steiner, Sandra Hotopp, Julie C. Dunning Ishmael, Nadeeza Grinblat-Huse, Valerie Riley, David R. Erdman, Dean D. Carlone, George M. Sampson, Jacquelyn Scott, J. Anthony G. Tettelin, Herve TI Transcriptional adaptation of pneumococci and human pharyngeal cells in the presence of a virus infection SO BMC GENOMICS LA English DT Article DE Streptococcus pneumoniae; RSV; HPIV3; Gene expression; Microarray; Adherence; Bacterial-viral co-infection ID RESPIRATORY SYNCYTIAL VIRUS; INFLUENZA-A VIRUS; STREPTOCOCCUS-PNEUMONIAE INFECTION; HUMAN EPITHELIAL-CELLS; INCREASED SUSCEPTIBILITY; GENE-EXPRESSION; BACTERIAL SUPERINFECTION; MICROARRAY ANALYSIS; ADHERENCE; DISEASE AB Background: Viral upper respiratory tract infections are associated with increased colonization by Streptococcus pneumoniae but the mechanisms underlying this relationship are unclear. The objective of this study is to describe a comprehensive picture of the cellular interaction between the adhering bacteria and host cells in the presence or absence of a viral co-infection. Results: Gene expression profiles of Detroit-562 pharyngeal cells, which were either mock-infected or infected with human respiratory syncytial virus (RSV) or human parainfluenza virus 3 (HPIV3), were analyzed using human microarrays. Transcription response of S. pneumoniae strain TIGR4 (serotype 4) in the presence of either mock- or viral-infected cells was analyzed by pneumococcal microarray. Significantly regulated genes were identified by both significance analysis of microarray (SAM) and a >= 2-fold change ratio cut-off. The adherence of S. pneumoniae to human pharyngeal cells was significantly augmented in the presence of RSV or HPIV3 infection. Global gene expression profiling of the host cells during infection with RSV or HPIV3 revealed increased transcription of carcinoembryonic antigen-related cell adhesion molecules (CEACAM1), CD47, fibronectin, interferon-stimulated genes and many other host cell adhesion molecules. Pneumococci increased transcription of several genes involved in adhesive functions (psaA, pilus islet), choline uptake and incorporation (lic operon), as well as transport and binding. Conclusions: We have identified a core transcriptome that represents the basic machinery required for adherence of pneumococci to D562 cells infected or not infected with a virus. These bacterial genes and cell adhesion molecules can potentially be used to control pneumococcal adherence occurring secondary to a viral infection. C1 [Mlacha, Sheila Z. Kimaro; Scott, J. Anthony G.] Kenya Govt Med Res Ctr, Wellcome Trust Res Programme, Kilifi, Kenya. [Mlacha, Sheila Z. Kimaro; Kumar, Nikhil; Hotopp, Julie C. Dunning; Ishmael, Nadeeza; Grinblat-Huse, Valerie; Riley, David R.; Tettelin, Herve] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Inst Genome Sci, Baltimore, MD 21201 USA. [Peret, Teresa C. T.; Erdman, Dean D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Romero-Steiner, Sandra; Carlone, George M.; Sampson, Jacquelyn] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA. [Scott, J. Anthony G.] Univ Oxford, Nuffield Dept Clin Med, Oxford, England. RP Tettelin, H (reprint author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Inst Genome Sci, Baltimore, MD 21201 USA. EM tettelin@som.umaryland.edu RI Dunning Hotopp, Julie/E-7762-2010; OI Dunning Hotopp, Julie/0000-0003-3862-986X; Romero-Steiner, Sandra/0000-0003-4128-7768 FU Wellcome Trust [081835]; University of Maryland FX This work was supported by grants from the Wellcome Trust to Prof. Anthony Scott (081835) and University of Maryland internal funds to Dr. Herve Tettelin. The authors wish to thank Dr. Norman Lee (George Washington University, Washington DC, USA) and the Pathogen Functional Genomics Resource Center (PFGRC) at the J. Craig Venter Institute (JCVI, Rockville, MD, USA) for providing microarray slides, Gowrisankar Rajam (Centers for Disease Control and Prevention, CDC, Atlanta, GA, USA) for technical assistance and Margaret Mackinnon and Greg Fegan (KEMRI/Wellcome Trust, Kilifi, Kenya) for expert advice on statistical methods. NR 45 TC 6 Z9 6 U1 0 U2 15 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2164 J9 BMC GENOMICS JI BMC Genomics PD JUN 7 PY 2013 VL 14 AR 378 DI 10.1186/1471-2164-14-378 PG 14 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 163GW UT WOS:000320325100001 ER PT J AU Leung, J Cannon, MJ Grosse, SD Bialek, SR AF Leung, Jessica Cannon, Michael J. Grosse, Scott D. Bialek, Stephanie R. TI Laboratory testing and diagnostic coding for cytomegalovirus among privately insured infants in the United States: a retrospective study using administrative claims data SO BMC PEDIATRICS LA English DT Article DE Cytomegalovirus; CMV; Laboratory testing; Screening; Infants; Newborns; Administrative data; Medical claims; MarketScan (R) ID INFECTION; PREVALENCE; MORTALITY AB Background: Rates of laboratory testing and diagnostic practices for congenital CMV in the United States are unknown. We determined rates of CMV testing and diagnostic coding for CMV among insured infants in the United States using a national healthcare claims database. Methods: We analyzed medical claims from 2011 Truven Health MarketScan (R) Commercial databases for infants who were <= 30 days of age. We used ICD-9-CM codes to identify infants with CMV and CMV-associated conditions. We computed frequencies of infants with CPT codes for CMV testing. Results: A total of 368,266 infants met the study criteria. We identified 61 (0.02%) infants with a diagnostic code for CMV. Among the 368,266 infants, 229 (0.1%) infants had a code for CMV-specific testing, of which 43% had codes for CMV polymerase chain reaction (PCR) and/or CMV direct florescent antibody (DFA) testing, 44% for CMV serologic testing alone, and 13% for CMV serology and non-specific PCR and/or culture. Over 80% (187/229) with CMV testing had a code for >= 1 CMV-associated conditions. Although infrequently coded for, CMV testing was more common among infants with a code for a condition possibly associated with CMV than infants without these conditions (0.14% (187/136,857) vs. 0.02% (42/231,409)). Conclusions: The low rates of CMV testing among infants with symptoms suggestive of congenital CMV infection and the substantial proportion of infants tested with only serologic assays instead of PCR or viral culture suggests gaps in awareness and knowledge of congenital CMV and its diagnosis among healthcare providers. Although claims databases presumably do not capture all diagnosed CMV cases or CMV-specific testing, healthcare claims are a potential source for surveillance and monitoring practices of CMV-specific testing and diagnostic coding for CMV among infants. C1 [Leung, Jessica; Bialek, Stephanie R.] Ctr Dis Control & Prevent, Nat Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Cannon, Michael J.; Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Leung, J (reprint author), Ctr Dis Control & Prevent, Nat Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS A-34, Atlanta, GA 30333 USA. EM JLeung@cdc.gov RI Cannon, Michael/E-5894-2011 OI Cannon, Michael/0000-0001-5776-5010 NR 12 TC 1 Z9 1 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2431 J9 BMC PEDIATR JI BMC Pediatr. PD JUN 7 PY 2013 VL 13 AR 90 DI 10.1186/1471-2431-13-90 PG 6 WC Pediatrics SC Pediatrics GA 163EN UT WOS:000320318700001 PM 23758752 ER PT J AU Killeen, GF Seyoum, A Sikaala, C Zomboko, AS Gimnig, JE Govella, NJ White, MT AF Killeen, Gerry F. Seyoum, Aklilu Sikaala, Chadwick Zomboko, Amri S. Gimnig, John E. Govella, Nicodem J. White, Michael T. TI Eliminating malaria vectors SO PARASITES & VECTORS LA English DT Review DE Plasmodium; Control; Anopheles; Mosquito; Eradication; Elimination; Resistance; Behaviour ID INSECTICIDE-TREATED NETS; NORTH-EASTERN TANZANIA; ANOPHELES-GAMBIAE; SOUTH-AFRICA; BED NETS; TRANSMISSION DYNAMICS; PHENOTYPIC PLASTICITY; CONTROL INTERVENTIONS; POPULATION-DYNAMICS; SPECIES COMPOSITION AB Malaria vectors which predominantly feed indoors upon humans have been locally eliminated from several settings with insecticide treated nets (ITNs), indoor residual spraying or larval source management. Recent dramatic declines of An. gambiae in east Africa with imperfect ITN coverage suggest mosquito populations can rapidly collapse when forced below realistically achievable, non-zero thresholds of density and supporting resource availability. Here we explain why insecticide-based mosquito elimination strategies are feasible, desirable and can be extended to a wider variety of species by expanding the vector control arsenal to cover a broader spectrum of the resources they need to survive. The greatest advantage of eliminating mosquitoes, rather than merely controlling them, is that this precludes local selection for behavioural or physiological resistance traits. The greatest challenges are therefore to achieve high biological coverage of targeted resources rapidly enough to prevent local emergence of resistance and to then continually exclude, monitor for and respond to re-invasion from external populations. C1 [Killeen, Gerry F.; Govella, Nicodem J.] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Killeen, Gerry F.; Seyoum, Aklilu; Sikaala, Chadwick] Univ Liverpool, Liverpool Sch Trop Med, Vector Biol Dept, Liverpool L3 5QA, Merseyside, England. [Sikaala, Chadwick] Natl Malaria Control Ctr, Lusaka, Zambia. [Zomboko, Amri S.] Ifakara Hlth Inst, Monitoring & Evaluat Themat Grp, Dar Es Salaam, Tanzania. [Gimnig, John E.] Ctr Dis Control & Prevent, Div Parasit Dis, Chamblee, GA USA. [White, Michael T.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, MRC, Ctr Outbreak Anal & Modelling, London, England. RP Killeen, GF (reprint author), Ifakara Hlth Inst, Dar Es Salaam, Tanzania. EM gkilleen@ihi.or.tz FU European Union [265660]; Bill & Melinda Gates Foundation through the Malaria Transmission Consortium [45114] FX We thank Dr Ian Hastings, Dr Phillip Eckhoff, Dr Heather Ferguson, Dr Tanya Russell, Prof Thomas Smith and Dr Olivier Briet for their comments on the manuscript. The research leading to this manuscript has received funding from the European Union Seventh Framework Programme FP7/2007-2013 under grant agreement no 265660 and from the Bill & Melinda Gates Foundation through the Malaria Transmission Consortium, award number 45114. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 99 TC 25 Z9 25 U1 5 U2 58 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD JUN 7 PY 2013 VL 6 AR 172 DI 10.1186/1756-3305-6-172 PG 10 WC Parasitology SC Parasitology GA 166ML UT WOS:000320558800001 PM 23758937 ER PT J AU De Cock, KM El-Sadr, WM AF De Cock, Kevin M. El-Sadr, Wafaa M. TI When to Start ART in Africa SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [De Cock, Kevin M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [El-Sadr, Wafaa M.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. RP De Cock, KM (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. FU NIAID NIH HHS [UM1 AI068619, UM1 AI069466] NR 0 TC 1 Z9 1 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JUN 6 PY 2013 VL 368 IS 23 BP 2238 EP 2238 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 158DN UT WOS:000319948900028 PM 23738561 ER PT J AU Tempalski, B Pouget, ER Cleland, CM Brady, JE Cooper, HLF Hall, HI Lansky, A West, BS Friedman, SR AF Tempalski, Barbara Pouget, Enrique R. Cleland, Charles M. Brady, Joanne E. Cooper, Hannah L. F. Hall, H. Irene Lansky, Amy West, Brooke S. Friedman, Samuel R. TI Trends in the Population Prevalence of People Who Inject Drugs in US Metropolitan Areas 1992-2007 SO PLOS ONE LA English DT Article ID HEPATITIS-C VIRUS; AUSTRALIAN-CAPITAL-TERRITORY; HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; UNITED-STATES; HIV-INFECTION; HEROIN USERS; RISK-FACTORS; SUBSTITUTION TREATMENT; ASSISTED TREATMENT AB Background: People who inject drugs (PWID) have increased risk of morbidity and mortality. We update and present estimates and trends of the prevalence of current PWID and PWID subpopulations in 96 US metropolitan statistical areas (MSAs) for 1992-2007. Current estimates of PWID and PWID subpopulations will help target services and help to understand long-term health trends among PWID populations. Methodology: We calculated the number of PWID in the US annually from 1992-2007 and apportioned estimates to MSAs using multiplier methods. We used four types of data indicating drug injection to allocate national annual totals to MSAs, creating four distinct series of component estimates of PWID in each MSA and year. The four component estimates are averaged to create the best estimate of PWID for each MSA and year. We estimated PWID prevalence rates for three subpopulations defined by gender, age, and race/ethnicity. We evaluated trends using multi-level polynomial models. Results: PWID per 10,000 persons aged 15-64 years varied across MSAs from 31 to 345 in 1992 (median 104.4) to 34 to 324 in 2007 (median 91.5). Trend analysis indicates that this rate declined during the early period and then was relatively stable in 2002-2007. Overall prevalence rates for non-Hispanic black PWID increased in 2005 as compared to other racial/ethnic groups. Hispanic prevalence, in contrast, declined across time. Importantly, results show a worrisome trend in young PWID prevalence since HAART was initiated - the mean prevalence was 90 to 100 per 10,000 youth in 1992-1996, but increased to >120 PWID per 10,000 youth in 2006-2007. Conclusions: Overall, PWID rates remained constant since 2002, but increased for two subpopulations: non-Hispanic black PWID and young PWID. Estimates of PWID are important for planning and evaluating public health programs to reduce harm among PWID and for understanding related trends in social and health outcomes. C1 [Tempalski, Barbara; Pouget, Enrique R.; Cleland, Charles M.; West, Brooke S.; Friedman, Samuel R.] Natl Dev & Res Inst Inc NDRI, Inst AIDS Res, New York, NY 10010 USA. [Cleland, Charles M.] NYU, Coll Nursing, New York, NY USA. [Brady, Joanne E.] Columbia Univ, Dept Epidemiol, New York, NY USA. [Cooper, Hannah L. F.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Hall, H. Irene] Ctr Dis Control, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Lansky, Amy] Ctr Dis Control, Div HIV AIDS Prevent Surveillance Epidemiol & Lab, Atlanta, GA 30333 USA. [Friedman, Samuel R.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. RP Tempalski, B (reprint author), Natl Dev & Res Inst Inc NDRI, Inst AIDS Res, New York, NY 10010 USA. EM tempalski@ndri.org OI Tempalski, Barbara/0000-0002-6128-2510 FU National Institute of Drug Abuse [R01 DA13336] FX The research described in this paper is supported by the National Institute of Drug Abuse grant # R01 DA13336. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 126 TC 29 Z9 29 U1 3 U2 15 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 5 PY 2013 VL 8 IS 6 AR e64789 DI 10.1371/journal.pone.0064789 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 166TB UT WOS:000320579400025 PM 23755143 ER PT J AU Ford, ES AF Ford, Earl S. TI Trends in Predicted 10-Year Risk of Coronary Heart Disease and Cardiovascular Disease Among U.S. Adults From 1999 to 2010 SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE cardiovascular diseases; coronary artery disease; risk; risk factors; trends AB Objectives The objective of this study was to examine trends in predicted 10-year risk for coronary heart disease (CHD) and cardiovascular disease (CVD) from 1999 to 2000 and from 2009 to 2010 among adults in the United States. Background Examining trends in predicted risk for CHD and CVD may offer insights into the direction of cardiovascular health. Methods Data from 7,751 fasting participants, ages 30 to 74 years, of 6 consecutive 2-year cycles of the National Health and Nutrition Examination Survey were used. Predicted 10-year risk for CHD and CVD was calculated using risk equations derived from data from the Framingham Heart Study. Results Mean predicted 10-year risk for CHD was 7.2% during 1999 to 2000 and 6.5% during 2009 to 2010 (p for linear trend = 0.005), and for CVD it was 9.2% during 1999 to 2000 and 8.7% during 2009 to 2010 (p for linear trend 0.152). Mean predicted risk for CHD and CVD declined significantly among participants ages 40 to 49 years, 50 to 59 years, 60 to 74 years, and among women. Mean predicted risk for CHD declined significantly among men and whites but nonsignificantly among Mexican Americans (p for linear trend = 0.067). Mean predicted risk increased nonsignificantly among African Americans for both CHD (p for linear trend = 0.063) and CVD (p for linear trend = 0.059). Of the modifiable cardiovascular risk factors included in the risk equations, favorable trends were noted for mean systolic and diastolic blood pressure, mean concentrations of total cholesterol and high-density lipoprotein cholesterol, and smoking status. The prevalence of diabetes mellitus worsened. Conclusions Predicted 10-year risk for CHD improved modestly. Reversing the seemingly rising trend in risk among African-American adults should be a high priority. (C) 2013 by the American College of Cardiology Foundation C1 [Ford, Earl S.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,MS K67, Atlanta, GA 30341 USA. EM eford@cdc.gov FU Intramural CDC HHS [CC999999] NR 11 TC 32 Z9 35 U1 0 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JUN 4 PY 2013 VL 61 IS 22 BP 2249 EP 2252 DI 10.1016/j.jacc.2013.03.023 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 166ZV UT WOS:000320600700004 PM 23563124 ER PT J AU Mesquita, JR Costantini, VP Cannon, JL Lin, SC Nascimento, MSJ Vinje, J AF Mesquita, Joao Rodrigo Costantini, Veronica P. Cannon, Jennifer L. Lin, Seh-ching Jose Nascimento, Maria Sao Vinje, Jan TI Presence of Antibodies against Genogroup VI Norovirus in Humans SO VIROLOGY JOURNAL LA English DT Article ID HEPATITIS-E VIRUS; CANINE NOROVIRUS; SWINE; DOGS; VETERINARIANS; GASTROENTERITIS; TRANSMISSION; OUTBREAK AB Background: Noroviruses are important enteric pathogens in humans and animals. Recently, we reported a novel canine norovirus (CaNoV) in dogs with diarrhea belonging to a new genogroup (GVI). No data are available on exposure of humans to this virus. Methods: Sera from 373 small animal veterinarians and 120 age-matched population controls were tested for IgG antibodies to CaNoV by a recombinant virus like particle based enzyme-linked immunosorbent assay. Results: Antibodies to CaNoV were found in 22.3% of the veterinarians and 5.8% of the control group (p<0.001). Mean corrected OD450 values for CaNoV antibodies were significantly higher in small animal veterinarians compared to the control group. Conclusions: These findings suggest that CaNoV may infect humans and small animal veterinarians are at an increased risk for exposure to this virus. Additional studies are needed to assess if this virus is able to cause disease in humans. C1 [Mesquita, Joao Rodrigo; Jose Nascimento, Maria Sao] Univ Porto, Fac Pharm, Dept Biol Sci, P-4100 Oporto, Portugal. [Mesquita, Joao Rodrigo] Polytech Inst Viseu, Agr Super Sch, Viseu, Portugal. [Costantini, Veronica P.; Lin, Seh-ching; Vinje, Jan] Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Cannon, Jennifer L.] Univ Georgia, Ctr Food Safety, Griffin, GA USA. RP Vinje, J (reprint author), Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Ctr Dis Control & Prevent, Mail Stop G-04,1600 Clifton Rd, Atlanta, GA 30333 USA. EM ahx8@cdc.gov RI Mesquita, Joao/B-6960-2016; OI Mesquita, Joao/0000-0001-8769-8103; Vinje, Jan/0000-0002-1530-3675; Costantini, Veronica/0000-0002-1532-4345; Garcia Alexandre, Maria Sao Jose/0000-0002-6157-4978 FU FEDER; Operacional Factores de Competividade - COMPETE and FCT - Fundacao para a Ciencia e a Tecnologia [PTDC/CVT/113218/2009, SFRH/BD/45407/2008]; Fundacao para a Ciencia e a Tecnologia FX The authors would like to thank Dr. Charles Humphrey (CDC) for performing electron microscopy analyses on the VLPs. The study received financial support from FEDER funds through Programa Operacional Factores de Competividade - COMPETE and FCT - Fundacao para a Ciencia e a Tecnologia (project PTDC/CVT/113218/2009), and by grant SFRH/BD/45407/2008 to J.R.M. from Fundacao para a Ciencia e a Tecnologia. The funding sources did have no influence on the design, collection, analysis, and interpretation of data; writing of the manuscript; or the decision to submit this manuscript for publication. NR 28 TC 19 Z9 22 U1 0 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-422X J9 VIROL J JI Virol. J. PD JUN 4 PY 2013 VL 10 AR 176 DI 10.1186/1743-422X-10-176 PG 5 WC Virology SC Virology GA 162NT UT WOS:000320272600001 PM 23735311 ER PT J AU Papafragkou, E Hewitt, J Park, GW Greening, G Vinje, J AF Papafragkou, Efstathia Hewitt, Joanne Park, Geun Woo Greening, Gail Vinje, Jan TI Challenges of Culturing Human Norovirus in Three-Dimensional Organoid Intestinal Cell Culture Models SO PLOS ONE LA English DT Article ID REVERSE TRANSCRIPTION-PCR; NORWALK VIRUS-INFECTION; BLOOD GROUP ANTIGENS; UNITED-STATES; CLINICAL SPECIMENS; MAMMALIAN-CELLS; DENDRITIC CELLS; CACO-2 CELLS; BINDING; TISSUE AB Human noroviruses are the most common cause of acute gastroenteritis worldwide. Recently, cell culture systems have been described using either human embryonic intestinal epithelial cells (Int-407) or human epithelial colorectal adenocarcinoma cells (Caco-2) growing on collagen-I porous micro carrier beads in a rotating bioreactor under conditions of physiological fluid shear. Here, we describe the efforts from two independent laboratories to implement this three dimensional (3D) cell culture system for the replication of norovirus. Int-407 and Caco-2 were grown in a rotating bioreactor for up to 28 days. Prior to infection, cells were screened for the presence of microvilli by electron microscopy and stained for junction proteins (zonula occludens-1, claudin-1, and b-catenin). Differentiated 3D cells were transferred to 24-well plates and infected with bacteria-free filtrates of various norovirus genotypes (GI. 1, GI. 3, GI. 8, GII. 2, GII. 4, GII. 7, and GII. 8). At 12 h, 24 h, and 48 h post inoculation, viral RNA from both cells and supernatants were collected and analyzed for norovirus RNA by real-time reverse transcription PCR. Despite observations of high expression of junction proteins and microvilli development in stained thin sections, our data suggest no significant increase in viral titer based on norovirus RNA copy number during the first 48 h after inoculation for the different samples and virus culture conditions tested. Our combined efforts demonstrate that 3D cell culture models using Int-407 or Caco-2 cells do not support norovirus replication and highlight the complexity and difficulty of developing a reproducible in vitro cell culture system for human norovirus. C1 [Papafragkou, Efstathia; Park, Geun Woo; Vinje, Jan] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Papafragkou, Efstathia] US FDA, Ctr Food Safety & Appl Nutr, Div Mol Biol, Laurel, MD USA. [Hewitt, Joanne; Greening, Gail] Inst Environm Sci & Res Ltd, Kenepuru Sci Ctr, Porirua, New Zealand. RP Vinje, J (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. EM jvinje@cdc.gov OI Vinje, Jan/0000-0002-1530-3675 FU ASM/CDC Fellowship Program in Infectious Disease and Public Health Microbiology; ESR Capability Fund FX This research was funded in part by the ASM/CDC Fellowship Program in Infectious Disease and Public Health Microbiology for EP. The New Zealand study was funded by the ESR Capability Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 39 TC 26 Z9 27 U1 4 U2 30 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 3 PY 2013 VL 8 IS 6 AR e63485 DI 10.1371/journal.pone.0063485 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 157CD UT WOS:000319872300010 ER PT J AU Edelman, EJ Gordon, KS Hogben, M Crystal, S Bryant, K Justice, AC Fiellin, DA AF Edelman, E. J. Gordon, Kirsha S. Hogben, Matthew Crystal, Stephen Bryant, Kendall Justice, Amy C. Fiellin, David A. TI PARTNER NOTIFICATION PRACTICES AMONG HIV-INFECTED MEN SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Edelman, E. J.; Justice, Amy C.; Fiellin, David A.] Yale Univ, New Haven, CT USA. [Gordon, Kirsha S.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Hogben, Matthew] Ctr Dis Control & Prevent, Atlanta, GA USA. [Crystal, Stephen] Rutgers, New Brunswick, NJ USA. [Bryant, Kendall] NIAAA, Potomac, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S134 EP S135 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301079 ER PT J AU Hurley, L Bridges, C Harpaz, R Allison, M O'Leary, S Crane, LA Stokley, S Beaty, B Brtnikova, M Clinger, A Ahmed, F Hales, CM Kempe, A AF Hurley, Laura Bridges, Carolyn Harpaz, Rafael Allison, Mandy O'Leary, Sean Crane, Lori A. Stokley, Shannon Beaty, Brenda Brtnikova, Michaela Clinger, Andrea Ahmed, Faruque Hales, Craig M. Kempe, Allison TI NATIONAL PHYSICIAN SURVEY REGARDING ADULT VACCINE DELIVERY: MISSED OPPORTUNITIES AND A CALL FOR A SYSTEMATIC APPROACH SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 36th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 24-27, 2013 CL Denver, CO SP Soc Gen Internal Med C1 [Hurley, Laura] Denver Hlth, Denver, CO USA. [Hurley, Laura; Allison, Mandy; O'Leary, Sean; Crane, Lori A.; Beaty, Brenda; Brtnikova, Michaela; Clinger, Andrea; Kempe, Allison] Childrens Hosp Colorado, Aurora, CO USA. [Bridges, Carolyn; Harpaz, Rafael; Stokley, Shannon; Ahmed, Faruque; Hales, Craig M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Allison, Mandy; O'Leary, Sean; Kempe, Allison] Univ Colorado, Aurora, CO USA. [Crane, Lori A.] Colorado Sch Publ Hlth, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2013 VL 28 SU 1 BP S124 EP S125 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AB6ZP UT WOS:000331939301058 ER PT J AU Kaminski, JW Perou, R Visser, SN Scott, KG Beckwith, L Howard, J Smith, DC Danielson, ML AF Kaminski, Jennifer W. Perou, Ruth Visser, Susanna N. Scott, Keith G. Beckwith, Leila Howard, Judy Smith, D. Camille Danielson, Melissa L. TI Behavioral and Socioemotional Outcomes Through Age 5 Years of the Legacy for Children Public Health Approach to Improving Developmental Outcomes Among Children Born Into Poverty SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID SOCIAL-CLASS GRADIENTS; UNITED-STATES; DIFFICULTIES QUESTIONNAIRE; LOW-INCOME; SOCIOECONOMIC DISADVANTAGE; PRESCHOOL-CHILDREN; EARLY INTERVENTION; CHILDHOOD POVERTY; CONDUCT PROBLEMS; SINGLE MOTHERS AB Objectives. We evaluated Legacy for Children, a public health strategy to improve child health and development among low-income families. Methods. Mothers were recruited prenatally or at the birth of a child to participate in Legacy parenting groups for 3 to 5 years. A set of 2 randomized trials in Miami, Florida, and Los Angeles, California, between 2001 and 2009 assessed 574 mother-child pairs when the children were 6, 12, 24, 36, 48, and 60 months old. Intent-to-treat analyses from 12 to 60 months compared groups on child behavioral and socioemotional outcomes. Results. Children of mothers in the intervention group were at lower risk for behavioral concerns at 24 months and socioemotional problems at 48 months in Miami, and lower risk for hyperactive behavior at 60 months in Los Angeles. Longitudinal analyses indicated that children of intervention mothers in Miami were at lower risk for behavior problems from 24 to 60 months of age. Conclusions. Randomized controlled trials documented effectiveness of the Legacy model over time while allowing for implementation adaptations by 2 different sites. Broadly disseminable, parent-focused prevention models such as Legacy have potential for public health impact. These investments in prevention might reduce the need for later intervention strategies. C1 [Kaminski, Jennifer W.; Perou, Ruth; Visser, Susanna N.; Smith, D. Camille; Danielson, Melissa L.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Scott, Keith G.] Univ Miami, Linda Ray Intervent Ctr, Miami, FL USA. [Beckwith, Leila; Howard, Judy] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA. RP Kaminski, JW (reprint author), Ctr Dis Control & Prevent, Child Dev Studies Team, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS-E88, Atlanta, GA 30333 USA. EM JKaminski@cdc.gov OI Danielson, Melissa/0000-0001-9461-0341 FU Centers for Disease Control and Prevention (CDC) under University of Miami [200-1998-0110]; Centers for Disease Control and Prevention (CDC) under University of California at Los Angeles [200-1998-0111]; Centers for Disease Control and Prevention (CDC) under Research Triangle International [200-94-0828] FX The Legacy for Children trials and their evaluation were sponsored and directed by the Centers for Disease Control and Prevention (CDC) under contracts with the University of Miami (200-1998-0110), the University of California at Los Angeles (200-1998-0111), and Research Triangle International (200-94-0828). NR 73 TC 8 Z9 8 U1 4 U2 9 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUN PY 2013 VL 103 IS 6 BP 1058 EP 1066 DI 10.2105/AJPH.2012.300996 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA3FI UT WOS:000330977900038 PM 23597356 ER PT J AU Bogart, LM Elliott, MN Kanouse, DE Klein, DJ Davies, SL Cuccaro, PM Banspach, SW Peskin, MF Schuster, MA AF Bogart, Laura M. Elliott, Marc N. Kanouse, David E. Klein, David J. Davies, Susan L. Cuccaro, Paula M. Banspach, Stephen W. Peskin, Melissa F. Schuster, Mark A. TI Association Between Perceived Discrimination and Racial/Ethnic Disparities in Problem Behaviors Among Preadolescent Youths SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID AFRICAN-AMERICAN ADOLESCENTS; OF-THE-LITERATURE; MENTAL-HEALTH; UNITED-STATES; RACIAL-DISCRIMINATION; ETHNIC DISCRIMINATION; EMOTION REGULATION; DEPRESSIVE SYMPTOMS; SOCIAL SUPPORT; SUBSTANCE USE AB Objectives. We examined the contribution of perceived racial/ethnic discrimination to disparities in problem behaviors among preadolescent Black, Latino, and White youths. Methods. We used cross-sectional data from Healthy Passages, a 3-community study of 5119 fifth graders and their parents from August 2004 through September 2006 in Birmingham, Alabama; Los Angeles County, California; and Houston, Texas. We used multivariate regressions to examine the relationships of perceived racial/ethnic discrimination and race/ethnicity to problem behaviors. We used values from these regressions to calculate the percentage of disparities in problem behaviors associated with the discrimination effect. Results. In multivariate models, perceived discrimination was associated with greater problem behaviors among Black and Latino youths. Compared with Whites, Blacks were significantly more likely to report problem behaviors, whereas Latinos were significantly less likely (a "reverse disparity"). When we set Blacks' and Latinos' discrimination experiences to zero, the adjusted disparity between Blacks and Whites was reduced by an estimated one third to two thirds; the reverse adjusted disparity favoring Latinos widened by about one fifth to one half. Conclusions. Eliminating discrimination could considerably reduce mental health issues, including problem behaviors, among Black and Latino youths. C1 [Bogart, Laura M.; Klein, David J.; Schuster, Mark A.] Boston Childrens Hosp, Div Gen Pediat, Dept Med, Boston, MA 02115 USA. [Bogart, Laura M.; Schuster, Mark A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Elliott, Marc N.; Kanouse, David E.] RAND Corp, Santa Monica, CA USA. [Davies, Susan L.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Hlth Behav, Birmingham, AL USA. [Cuccaro, Paula M.; Peskin, Melissa F.] Univ Texas Hlth Sci Ctr Houston, Ctr Hlth Promot & Prevent Res, Houston, TX 77030 USA. [Banspach, Stephen W.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adolescent & Sch Hlth, Atlanta, GA USA. RP Bogart, LM (reprint author), Boston Childrens Hosp, Div Gen Pediat, 300 Longwood Ave, Boston, MA 02115 USA. EM laura.bogart@childrens.harvard.edu OI Cuccaro, Paula/0000-0002-9551-4789 FU Centers for Disease Control and Prevention, Prevention Research Centers [U48DP000046, U48DP000057, U48DP000056] FX The Healthy Passages Study is funded by the Centers for Disease Control and Prevention, Prevention Research Centers (cooperative agreements U48DP000046, U48DP000057, and U48DP000056). NR 66 TC 6 Z9 6 U1 3 U2 16 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUN PY 2013 VL 103 IS 6 BP 1074 EP 1081 DI 10.2105/AJPH.2012.301073 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA3FI UT WOS:000330977900040 PM 23597387 ER PT J AU Dhingra, SS Zack, MM Strine, TW Druss, BG Simoes, E AF Dhingra, Satvinder S. Zack, Matthew M. Strine, Tara W. Druss, Benjamin G. Simoes, Eduardo TI Change in Health Insurance Coverage in Massachusetts and Other New England States by Perceived Health Status: Potential Impact of Health Reform SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID FACTOR SURVEILLANCE SYSTEM; QUALITY-OF-LIFE; CARE UTILIZATION; TRAINING-PROGRAMS; UNITED-STATES; MEDICAL-CARE; RELIABILITY; EARNINGS; UPDATE; ACCESS AB Objectives. We examined the impact of Massachusetts health reform and its public health component (enacted in 2006) on change in health insurance coverage by perceived health. Methods. We used 2003-2009 Behavioral Risk Factor Surveillance System data. We used a difference-in-differences framework to examine the experience in Massachusetts to predict the outcomes of national health care reform. Results. The proportion of adults aged 18 to 64 years with health insurance coverage increased more in Massachusetts than in other New England states (4.5%; 95% confidence interval [CI] = 3.5%, 5.6%). For those with higher perceived health care need (more recent mentally and physically unhealthy days and activity limitation days [ALDs]), the postreform proportion significantly exceeded prereform (P <.001). Groups with higher perceived health care need represented a disproportionate increase in health insurance coverage in Massachusetts compared with other New England states-from 4.3% (95% CI = 3.3%, 5.4%) for fewer than 14 ALDs to 9.0% (95% CI = 4.5%, 13.5%) for 14 or more ALDs. Conclusions. On the basis of the Massachusetts experience, full implementation of the Affordable Care Act may increase health insurance coverage especially among populations with higher perceived health care need. C1 [Dhingra, Satvinder S.; Strine, Tara W.] Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance & Informat Program Off, Atlanta, GA USA. [Zack, Matthew M.; Simoes, Eduardo] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Druss, Benjamin G.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Dhingra, SS (reprint author), Div Behav Surveillance, 2500 Century Pkwy,Mail Stop E-97, Atlanta, GA 30345 USA. EM sdhingra@cdc.gov OI Simoes, Eduardo/0000-0003-4371-4305 NR 34 TC 6 Z9 6 U1 0 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUN PY 2013 VL 103 IS 6 BP E107 EP E114 DI 10.2105/AJPH.2012.300997 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA3FI UT WOS:000330977900021 PM 23597359 ER PT J AU Walson, JL Sangare, LR Singa, BO Naulikha, JM Piper, BKS Yuhas, K Onchiri, FM Otieno, PA Mermin, J Zeh, C Richardson, BA John-Stewart, G AF Walson, Judd L. Sangare, Laura R. Singa, Benson O. Naulikha, Jacqueline Mulongo Piper, Benjamin K. S. Yuhas, Krista Onchiri, Frankline Magaki Otieno, Phelgona A. Mermin, Jonathan Zeh, Clement Richardson, Barbra Ann John-Stewart, Grace TI Evaluation of impact of long-lasting insecticide-treated bed nets and point-of-use water filters on HIV-1 disease progression in Kenya SO AIDS LA English DT Article DE bed nets; coinfection; diarrhoeal disease; HIV; long-lasting insecticide-treated nets; malaria; water filters ID PLASMODIUM-FALCIPARUM MALARIA; HUMAN-IMMUNODEFICIENCY-VIRUS; CD4 CELL COUNT; COTRIMOXAZOLE PROPHYLAXIS; PROSPECTIVE COHORT; INFECTED ADULTS; RURAL MALAWI; VIRAL LOAD; UGANDA; DIARRHEA AB Objectives: Among HIV-1-infected individuals in Africa, coinfection with malaria and diarrhoeal disease may be associated with more rapid HIV-1 disease progression. We sought to determine whether the use of long-lasting insecticide-treated bed nets and simple point-of-use water filters can delay HIV-1 disease progression. Design: A prospective cohort study. Setting: Two HIV care sites in Kenya. Participants: HIV-1-infected adults not yet meeting criteria for antiretroviral therapy. Interventions: One group received the standard of care, whereas the other received long-lasting insecticide-treated bed nets and water filters. Individuals were followed for up to 24 months. Main outcome measures: The primary outcome measures were time to CD4 cell count less than 350 cells/mu l and a composite endpoint of time to CD4 cell count less than 350 cells/mu l and nontraumatic death. Time to disease progression was compared using Cox proportional hazards regression. Results: Of 589 individuals included, 361 received the intervention and 228 served as controls. Median baseline CD4 cell counts were similar (P = 0.36). After controlling for baseline CD4 cell count, individuals receiving the intervention were 27% less likely to reach the endpoint of a CD4 cell count less than 350 cells/mu l (hazard ratio 0.73; 95% confidence interval 0.57-0.95). CD4 cell count decline was also significantly less in the intervention group (-54 vs. -70 cells/mu l per year, P = 0.03). In addition, the incidence of malaria and diarrhoea were significantly lower in the intervention group. Conclusion: Provision of a long-lasting insecticide-treated bed net and water filter was associated with a delay in CD4 cell count decline and may be a simple, practical and cost-effective strategy to delay HIV-1 progression in many resource-limited settings. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Walson, Judd L.; Sangare, Laura R.; Richardson, Barbra Ann; John-Stewart, Grace] Univ Washington, Dept Global Hlth, Seattle, WA 98104 USA. [Walson, Judd L.; Yuhas, Krista; John-Stewart, Grace] Univ Washington, Dept Med, Seattle, WA 98104 USA. [Walson, Judd L.; Naulikha, Jacqueline Mulongo; Piper, Benjamin K. S.; John-Stewart, Grace] Univ Washington, Dept Pediat, Seattle, WA 98104 USA. [Walson, Judd L.; John-Stewart, Grace] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA. [Onchiri, Frankline Magaki; Richardson, Barbra Ann] Univ Washington, Dept Biostat, Seattle, WA 98104 USA. [Walson, Judd L.; Singa, Benson O.; Naulikha, Jacqueline Mulongo; Piper, Benjamin K. S.; Otieno, Phelgona A.] Kenya Govt Med Res Ctr, Clin Res Ctr, Nairobi, Kenya. [Mermin, Jonathan; Zeh, Clement] Ctr Dis Control & Prevent, Atlanta, GA USA. [Richardson, Barbra Ann] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA. RP Walson, JL (reprint author), Univ Washington, Dept Global Hlth, 325 Ninth Ave,Box 359931, Seattle, WA 98104 USA. EM walson@uw.edu FU NIH [P30 AI027757]; NIH Institutes and Centers (NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA); Vestergaard Frandsen FX We would like to thank all of the participants and the clinics and organizations caring for persons living with HIV/AIDS who participated in this study. We would also like to acknowledge the staff of the University of Washington/KEMRI collaboration. This study was published with permission of the Director of the Kenya Medical Research Institute (KEMRI). This research and publication were made possible with support from the University of Washington Center for AIDS Research (CFAR), an NIH-funded programme (P30 AI027757), which is supported by the following NIH Institutes and Centers (NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA). The findings and conclusions in this study are those of the authors and do not necessarily reflect the views of their supporting institutions.; Funding was provided by a grant from Vestergaard Frandsen. The funder of the study had no role in the study design, data collection, data analysis, data interpretation or writing of the manuscript. The study was designed and implemented by the study investigators and the investigators conducted the analysis and prepared the manuscript. NR 30 TC 8 Z9 8 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD JUN 1 PY 2013 VL 27 IS 9 BP 1493 EP 1501 DI 10.1097/QAD.0b013e32835ecba9 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 301FV UT WOS:000330519100015 PM 23324658 ER PT J AU Tobin, K Kuramoto, SJ German, D Fields, E Spikes, PS Patterson, J Latkin, C AF Tobin, Karin Kuramoto, Satoko J. German, Danielle Fields, Errol Spikes, Pilgrim S. Patterson, Jocelyn Latkin, Carl TI Unity in Diversity: Results of a Randomized Clinical Culturally Tailored Pilot HIV Prevention Intervention Trial in Baltimore, Maryland, for African American Men Who Have Sex With Men SO HEALTH EDUCATION & BEHAVIOR LA English DT Article DE HIV prevention; African American men who have sex with men; randomized controlled trial; social cognitive theory; outcome evaluation ID INJECTION-DRUG USERS; BLACK-MEN; YOUNG MEN; RISK; PREVALENCE; INFECTION; COMMUNITY; WOMEN; BEHAVIORS; PROJECT AB Unity in Diversity was a randomized controlled trial of a culturally tailored HIV prevention intervention for African American men who have sex with men. The intervention condition was six group-based sessions and one individual session. The control condition was a single-session HIV prevention review. Participants were aged 18 years or older, identified as African American/Black race, reported having at least two sex partners in the prior 90 days (at least one of whom must be a male partner), unprotected anal sex with male partner in the prior 90 days, and willing to test for HIV. Retention exceeded 95% at 3-month follow-up. Results of multivariate logistic regression analysis adjusting for baseline risk, HIV status, and health insurance indicate intervention efficacy in decreasing the number of male sex partners and marginal effects on condom use with male partners and HIV-negative/unknown partners. Specifically, intervention condition was associated with increased odds of zero male sex partners (adjusted odds ratio [AOR] = 3.03, 95% confidence interval [CI] = 1.26-7.28), condom use with male partners (AOR = 2.64, 95% CI = 0.95-7.36), and HIV-negative/unknown status partners (AOR = 3.19, 95% CI = 0.98-10.38) at follow-up. These results contribute to the limited number of culturally appropriate models of HIV prevention intervention that are urgently needed for African American men who have sex with men to address their persistently high rates of HIV. C1 [Tobin, Karin; Kuramoto, Satoko J.; German, Danielle; Latkin, Carl] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. [Fields, Errol] Boston Univ, Sch Med, Boston, MA 02118 USA. [Spikes, Pilgrim S.; Patterson, Jocelyn] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Tobin, K (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, 2213 McElderry St,2nd Floor, Baltimore, MD 21205 USA. EM ktobin@jhsph.edu FU NCHHSTP CDC HHS [1UR6PS000355]; NICHD NIH HHS [1K01HD061269, K01 HD061269] NR 40 TC 5 Z9 5 U1 1 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1090-1981 EI 1552-6127 J9 HEALTH EDUC BEHAV JI Health Educ. Behav. PD JUN PY 2013 VL 40 IS 3 BP 286 EP 295 DI 10.1177/1090198112452125 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 298AC UT WOS:000330295200004 PM 22984216 ER PT J AU Dannenberg, AL Wu, P Frumkin, H AF Dannenberg, Andrew L. Wu, Philip Frumkin, Howard TI The Role of Physicians in Promoting Healthier Built Environments SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID US C1 [Dannenberg, Andrew L.] CDC, Hlth Community Design Initiat, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Wu, Philip] Kaiser Permanente Northwest Reg, Community Hlth Initiat, Portland, OR USA. [Frumkin, Howard] Univ Washington, Sch Publ Hlth, Off Dean, Seattle, WA 98195 USA. RP Dannenberg, AL (reprint author), Univ Washington, Sch Publ Hlth, Dept Environm & Occupat Hlth Sci, Hlth Sci Ctr Box 357234, Seattle, WA 98195 USA. EM adannen@uw.edu OI Frumkin, Howard/0000-0001-7079-3534 NR 9 TC 2 Z9 2 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD JUN PY 2013 VL 44 IS 6 BP E71 EP E73 DI 10.1016/j.amepre.2013.01.025 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 294JI UT WOS:000330041200003 PM 23683992 ER PT J AU Dunne, K Henderson, S Stewart, SL Moore, A Hayes, NS Jordan, J Underwood, JM AF Dunne, Katherine Henderson, Susan Stewart, Sherri L. Moore, Angela Hayes, Nikki S. Jordan, Jerelyn Underwood, J. Michael TI An Update on Tobacco Control Initiatives in Comprehensive Cancer Control Plans SO PREVENTING CHRONIC DISEASE LA English DT Article ID UNITED-STATES; CONTROL PROGRAM; SMOKING; SURVEILLANCE; NATION; IMPACT AB Introduction Comprehensive cancer control (CCC) coalitions address tobacco use, the leading cause of preventable death in the United States, through formal plans to guide tobacco control activities and other cancer prevention strategies. Best Practices for Comprehensive Tobacco Control Programs (Best Practices) and The Guide to Community Preventive Services (The Community Guide) are used to assist with this effort. We examined CCC plans to determine the extent to which they followed the Centers for Disease Control and Prevention's (CDC's) tobacco control and funding recommendations. Methods We obtained 69 CCC plans, current as of August 1, 2011, to determine which CDC recommendations from Best Practices and The Community Guide were incorporated. Data were abstracted through a content review and key word search and then summarized across the plans with dichotomous indicators. Additionally, we analyzed plans for inclusion of tobacco control funding goals and strategies. Results CCC plans incorporated a mean 4.5 (standard deviation [SD], 2.1) of 5 recommendations from Best Practices and 5.2 (SD, 0.9) of 10 recommendations from The Community Guide. Two-thirds of plans (66.7%) addressed funding for tobacco control as a strategy or action item; 47.8% of those plans (31.9% of total) defined a specific, measurable funding goal. Conclusion Although most CCC plans follow CDC-recommended tobacco control recommendations and funding levels, not all recommendations are addressed by every plan and certain recommendations are addressed in varying numbers of plans. Clearer prioritization of tobacco control recommendations by CDC may improve the extent to which they are followed and therefore maximize their public health benefit. C1 [Underwood, J. Michael] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Dunne, Katherine] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Henderson, Susan] Emory Univ, Atlanta, GA 30322 USA. [Stewart, Sherri L.; Moore, Angela; Hayes, Nikki S.; Jordan, Jerelyn] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Underwood, JM (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,MS K57, Atlanta, GA 30341 USA. EM jmunderwood@cdc.gov NR 23 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JUN PY 2013 VL 10 AR UNSP 120331 DI 10.5888/pcd10.120331 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285KD UT WOS:000329391900017 ER PT J AU Miranda, ML Casper, M Tootoo, J Schieb, L AF Miranda, Marie Lynn Casper, Michele Tootoo, Joshua Schieb, Linda TI Putting Chronic Disease on the Map: Building GIS Capacity in State and Local Health Departments SO PREVENTING CHRONIC DISEASE LA English DT Article ID GEOGRAPHIC INFORMATION-SYSTEMS; PRIMARY-CARE; NEEDS AB Techniques based on geographic information systems (GIS) have been widely adopted and applied in the fields of infectious disease and environmental epidemiology; their use in chronic disease programs is relatively new. The Centers for Disease Control and Prevention's Division for Heart Disease and Stroke Prevention is collaborating with the National Association of Chronic Disease Directors and the University of Michigan to provide health departments with capacity to integrate GIS into daily operations, which support priorities for surveillance and prevention of chronic diseases. So far, 19 state and 7 local health departments participated in this project. On the basis of these participants' experiences, we describe our training strategy and identify high-impact GIS skills that can be mastered and applied over a short time in support of chronic disease surveillance. We also describe the web-based resources in the Chronic Disease GIS Exchange that were produced on the basis of this training and are available to anyone interested in GIS and chronic disease (www.cdc.gov/DHDSP/maps/GISX). GIS offers diverse sets of tools that promise increased productivity for chronic disease staff of state and local health departments. C1 [Miranda, Marie Lynn; Tootoo, Joshua] Univ Michigan, Sch Nat Resources & Environm, Ann Arbor, MI 48109 USA. [Casper, Michele; Schieb, Linda] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Miranda, ML (reprint author), Univ Michigan, Sch Nat Resources & Environm, 440 Church St, Ann Arbor, MI 48109 USA. EM mlmirand@umich.edu FU NACDD; Duke University FX The training program was supported by a grant from the NACDD to UM and Duke University (the training team moved from the latter to the former mid-project). NR 14 TC 0 Z9 0 U1 3 U2 14 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JUN PY 2013 VL 10 AR UNSP 120321 DI 10.5888/pcd10.120321 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285KD UT WOS:000329391900010 ER PT J AU Braden, CR Dowell, SF Jernigan, DB Hughes, JM AF Braden, Christopher R. Dowell, Scott F. Jernigan, Daniel B. Hughes, James M. TI Progress in Global Surveillance and Response Capacity 10 Years after Severe Acute Respiratory Syndrome SO EMERGING INFECTIOUS DISEASES LA English DT Article ID SARS; CORONAVIRUS; HEALTH; TRANSMISSION; PREVENTION; TORONTO; ORIGIN AB Ten years have elapsed since the World Health Organization issued its first global alert for an unexplained illness named severe acute respiratory syndrome (SARS). The anniversary provides an opportunity to reflect on the international response to this new global microbial threat. While global surveillance and response capacity for public health threats have been strengthened, critical gaps remain. Of 194 World Health Organization member states that signed on to the International Health Regulations (2005), <20% had achieved compliance with the core capacities required by the deadline in June 2012. Lessons learned from the global SARS outbreak highlight the need to avoid complacency, strengthen efforts to improve global capacity to address the next pandemic using all available 21st century tools, and support research to develop new treatment options, countermeasures, and insights while striving to address the global inequities that are the root cause of many of these challenges. C1 [Braden, Christopher R.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Braden, Christopher R.; Dowell, Scott F.; Jernigan, Daniel B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hughes, James M.] Emory Univ, Atlanta, GA 30322 USA. RP Hughes, JM (reprint author), Emory Univ, 1462 Clifton Rd NE,Ste 446, Atlanta, GA 30322 USA. EM jmhughe@emory.edu NR 37 TC 17 Z9 17 U1 1 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2013 VL 19 IS 6 BP 864 EP 869 DI 10.3201/eid1906.130192 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LY UT WOS:000328173500003 PM 23731871 ER PT J AU Rasheed, JK Kitchel, B Zhu, WM Anderson, KF Clark, NC Ferraro, MJ Savard, P Humphries, RM Kallen, AJ Limbago, BM AF Rasheed, J. Kamile Kitchel, Brandon Zhu, Wenming Anderson, Karen F. Clark, Nancye C. Ferraro, Mary Jane Savard, Patrice Humphries, Romney M. Kallen, Alexander J. Limbago, Brandi M. TI New Delhi Metallo-beta-Lactamase-producing Enterobacteriaceae, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; ESCHERICHIA-COLI STRAINS; GRAM-NEGATIVE BACTERIA; KLEBSIELLA-PNEUMONIAE; PSEUDOMONAS-AERUGINOSA; DISSEMINATION; EXPANSION; IDENTIFICATION; EPIDEMIOLOGY; PREVALENCE AB We characterized 9 New Delhi metallo-beta-lactamase-producing Enterobacteriaceae (5 Klebsiella pneumoniae, 2 Escherichia coli, 1 Enterobacter cloacae, 1 Salmonella enterica serovar Senftenberg) isolates identified in the United States and cultured from 8 patients in 5 states during April 2009-March 2011. Isolates were resistant to beta-lactams, fluoroquinolones, and aminoglycosides, demonstrated MICs <= 1 mu g/mL of colistin and polymyxin, and yielded positive metallo-beta-lactamase screening results. Eight isolates had bla(NDM-1), and 1 isolate had a novel allele (bla(NDM-6)). All 8 patients had recently been in India or Pakistan, where 6 received inpatient health care. Plasmids carrying bla(NDM) frequently carried AmpC or extended spectrum beta-lactamase genes. Two K. pneumoniae isolates and a K. pneumoniae isolate from Sweden shared incompatibility group A/C plasmids with indistinguishable restriction patterns and a common bla(NDM) fragment; all 3 were multilocus sequence type 14. Restriction profiles of the remaining New Delhi metallo-beta-lactamase plasmids, including 2 from the same patient, were diverse. C1 [Rasheed, J. Kamile] Ctr Dis Control & Prevent, Antimicrobial Resistance & Characterizat Lab, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. [Rasheed, J. Kamile; Kitchel, Brandon; Zhu, Wenming; Anderson, Karen F.; Clark, Nancye C.; Kallen, Alexander J.; Limbago, Brandi M.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Ferraro, Mary Jane] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Savard, Patrice] Johns Hopkins Univ, Baltimore, MD USA. [Savard, Patrice] Johns Hopkins Hlth Syst, Baltimore, MD USA. [Humphries, Romney M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Rasheed, JK (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. EM jkr1@cdc.gov NR 40 TC 43 Z9 44 U1 2 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2013 VL 19 IS 6 BP 870 EP 878 DI 10.3201/eid1906.121515 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LY UT WOS:000328173500004 PM 23731823 ER PT J AU Iskander, J Strikas, RA Gensheimer, KF Cox, NJ Redd, SC AF Iskander, John Strikas, Raymond A. Gensheimer, Kathleen F. Cox, Nancy J. Redd, Stephen C. TI Pandemic Influenza Planning, United States, 1978-2008 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID A H1N1; AVIAN INFLUENZA; IMMUNIZATION; SURVEILLANCE; PREPAREDNESS; OUTBREAK AB During the past century, 4 influenza pandemics occurred. After the emergence of a novel influenza virus of swine origin in 1976, national, state, and local US public health authorities began planning efforts to respond to future pandemics. Several events have since stimulated progress in public health emergency planning: the 1997 avian influenza A(H5N1) outbreak in Hong Kong, China; the 2001 anthrax attacks in the United States; the 2003 outbreak of severe acute respiratory syndrome; and the 2003 reemergence of influenza A(H5N1) virus infection in humans. We outline the evolution of US pandemic planning since the late 1970s, summarize planning accomplishments, and explain their ongoing importance. The public health community's response to the 2009 influenza A(H1N1)pdm09 pandemic demonstrated the value of planning and provided insights into improving future plans and response efforts: Preparedness planning will enhance the collective, multilevel response to future public health crises. C1 [Iskander, John; Strikas, Raymond A.; Cox, Nancy J.; Redd, Stephen C.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Iskander, J (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop D50, Atlanta, GA 30333 USA. EM jxi0@cdc.gov NR 36 TC 17 Z9 17 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2013 VL 19 IS 6 BP 879 EP 885 DI 10.3201/eid1906.121478 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LY UT WOS:000328173500005 PM 23731839 ER PT J AU Goldsmith, CS Ksiazek, TG Rollin, PE Comer, JA Nicholson, WL Peret, TCT Erdman, DD Bellini, WJ Harcourt, BH Rota, PA Bhatnagar, J Bowen, MD Erickson, BR McMullan, LK Nichol, ST Shieh, WJ Paddock, CD Zaki, SR AF Goldsmith, Cynthia S. Ksiazek, Thomas G. Rollin, Pierre E. Comer, James A. Nicholson, William L. Peret, Teresa C. T. Erdman, Dean D. Bellini, William J. Harcourt, Brian H. Rota, Paul A. Bhatnagar, Julu Bowen, Michael D. Erickson, Bobbie R. McMullan, Laura K. Nichol, Stuart T. Shieh, Wun-Ju Paddock, Christopher D. Zaki, Sherif R. TI Cell Culture and Electron Microscopy for Identifying Viruses in Diseases of Unknown Cause SO EMERGING INFECTIOUS DISEASES LA English DT Article ID ACUTE RESPIRATORY SYNDROME; 4 TRANSPLANT RECIPIENTS; WEST-NILE-VIRUS; HEMORRHAGIC-FEVER; NIPAH VIRUS; ORGAN DONOR; TRANSMISSION; CORONAVIRUS; ZAIRE; MORBILLIVIRUS AB During outbreaks of infectious diseases or in cases of severely ill patients, it is imperative to identify the causative agent. This report describes several events in which virus isolation and identification by electron microscopy were critical to initial recognition of the etiologic agent, which was further analyzed by additional laboratory diagnostic assays. Examples include severe acute respiratory syndrome coronavirus, and Nipah, lymphocytic choriomeningitis, West Nile, Cache Valley, and Heartland viruses. These cases illustrate the importance of the techniques of cell culture and electron microscopy in pathogen identification and recognition of emerging diseases. C1 [Goldsmith, Cynthia S.; Rollin, Pierre E.; Comer, James A.; Nicholson, William L.; Peret, Teresa C. T.; Erdman, Dean D.; Bellini, William J.; Harcourt, Brian H.; Rota, Paul A.; Bhatnagar, Julu; Bowen, Michael D.; Erickson, Bobbie R.; McMullan, Laura K.; Nichol, Stuart T.; Shieh, Wun-Ju; Paddock, Christopher D.; Zaki, Sherif R.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Ksiazek, Thomas G.] Univ Texas Med Branch, Galveston, TX 77555 USA. RP Goldsmith, CS (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G32, Atlanta, GA 30329 USA. EM cgoldsmith@cdc.gov NR 32 TC 15 Z9 15 U1 2 U2 13 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2013 VL 19 IS 6 BP 886 EP 891 DI 10.3201/eid1906.130173 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LY UT WOS:000328173500006 PM 23731788 ER PT J AU Bruce, MG Zulz, T DeByle, C Singleton, R Hurlburt, D Bruden, D Rudolph, K Hennessy, T Klejka, J Wenger, JD AF Bruce, Michael G. Zulz, Tammy DeByle, Carolynn Singleton, Ros Hurlburt, Debby Bruden, Dana Rudolph, Karen Hennessy, Thomas Klejka, Joseph Wenger, Jay D. TI Haemophilus influenzae Serotype a Invasive Disease, Alaska, USA, 1983-2011 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID A DISEASE; EPIDEMIOLOGY; POPULATION; CHILDREN; VACCINE; CARRIAGE; STRAINS; CANADA; RISK; PCR AB Before introduction of Haemophilus influenzae type b (Hib) vaccines, rates of Hib disease in Alaska's indigenous people were among the highest in the world. Vaccination reduced rates dramatically; however, invasive H. influenzae type a (Hia) disease has emerged. Cases of invasive disease were identified through Alaska statewide surveillance during 1983-2011. Of 866 isolates analyzed for serotype, 32 (4%) were Hia. No Hia disease was identified before 2002; 32 cases occurred during 2002-2011 (p<0.001). Median age of case-patients was 0.7 years; 3 infants died. Incidence of Hia infection (200272011) among children <5 years was 5.4/100,000; 27 cases occurred in Alaska Native children (18/100,000) versus 2 cases in non-Native children (0.5/100,000) (risk ratio = 36, p<0.001). From 12/2009 to 12/2011, 15 cases of Hia disease occurred in southwestern Alaska (in children <5 years, rate = 204/100,000). Since introduction of the Hib conjugate vaccine, Hia infection has become a major invasive bacterial disease in Alaska Native children. C1 [Bruce, Michael G.; Zulz, Tammy; DeByle, Carolynn; Hurlburt, Debby; Bruden, Dana; Rudolph, Karen; Hennessy, Thomas; Wenger, Jay D.] Ctr Dis Control & Prevent, Anchorage, AK 99507 USA. [Singleton, Ros] Alaska Native Med Ctr, Anchorage, AK USA. [Klejka, Joseph] Yukon Kuskokwim Hlth Corp, Bethel, AK USA. RP Bruce, MG (reprint author), Ctr Dis Control & Prevent, Arct Invest Program, 4055 Tudor Ctr Dr, Anchorage, AK 99507 USA. EM zwa8@cdc.gov FU US CDC FX This work was supported by funding from the US CDC. NR 27 TC 17 Z9 21 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2013 VL 19 IS 6 BP 932 EP 937 DI 10.3201/eid1906.121805 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LY UT WOS:000328173500012 PM 23735653 ER PT J AU Garza, RC Basurto-Davila, R Ortega-Sanchez, IR Carlino, LO Meltzer, MI Albalak, R Balbuena, K Orellano, P Widdowson, MA Averhoff, F AF Garza, Roberto C. Basurto-Davila, Ricardo Ortega-Sanchez, Ismael R. Oreste Carlino, Luis Meltzer, Martin I. Albalak, Rachel Balbuena, Karina Orellano, Pablo Widdowson, Marc-Alain Averhoff, Francisco TI Effect of Winter School Breaks on Influenza-like Illness, Argentina, 2005-2008 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID PANDEMIC INFLUENZA; MITIGATION STRATEGIES; UNITED-STATES; US CITIES; CLOSURE; TRANSMISSION; CHILDREN; INTERVENTIONS; COMMUNITY; SPREAD AB School closures are used to reduce seasonal and pandemic influenza transmission, yet evidence of. their effectiveness is sparse. In Argentina, annual winter school breaks occur during the influenza season, providing an opportunity to study this intervention. We used 2005-2008 national weekly surveillance data of visits to a health care provider for influenza-like illness (ILI) from all provinces. Using Serfling-specified Poisson regressions and population-based census denominators, we developed incidence rate ratios (IRRs) for the 3 weeks before, 2 weeks during, and 3 weeks after the break. For persons 5-64 years of age, IRRs were <1 for at least 1 week after the break: Observed rates returned to expected by the third week after the break; overall decrease among persons of all ages was 14%. The largest decrease was among children 5-14 years of age during the week after the break (37% lower IRR). Among adults, effects were weaker and delayed. Two-week winter school breaks significantly decreased visits to a health care provider for ILI among school-aged children and nonelderly adults. C1 [Garza, Roberto C.; Ortega-Sanchez, Ismael R.; Meltzer, Martin I.; Albalak, Rachel; Widdowson, Marc-Alain; Averhoff, Francisco] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Basurto-Davila, Ricardo] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Oreste Carlino, Luis; Balbuena, Karina; Orellano, Pablo] Minist Salud Nac, Buenos Aires, DF, Argentina. RP Garza, RC (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D14, Atlanta, GA 30333 USA. EM RGarza@cdc.gov OI Widdowson, Marc-Alain/0000-0002-0682-6933; Orellano, Pablo/0000-0001-8911-663X NR 27 TC 7 Z9 7 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2013 VL 19 IS 6 BP 938 EP 944 DI 10.3201/eid1906.120916 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LY UT WOS:000328173500013 PM 23735682 ER PT J AU Emerson, GL Nordhausen, R Garner, MM Huckabee, JR Johnson, S Wohrle, RD Davidson, WB Wilkins, K Li, Y Doty, JB Gallardo-Romero, NF Metcalfe, MG Karem, KL Damon, IK Carroll, DS AF Emerson, Ginny L. Nordhausen, Robert Garner, Michael M. Huckabee, John R. Johnson, Steven Wohrle, Ron D. Davidson, Whitni B. Wilkins, Kimberly Li, Yu Doty, Jeffrey B. Gallardo-Romero, Nadia F. Metcalfe, Maureen G. Karem, Kevin L. Damon, Inger K. Carroll, Darin S. TI Novel Poxvirus in Big Brown Bats, Northwestern United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID METAGENOMIC ANALYSIS; HORIZONTAL TRANSFER; EMERGING VIRUSES; OSTEOMYELITIS; EVOLUTION AB A wildlife hospital and rehabilitation center in northwestern United States received several big brown bats with necrosuppurative osteomyelitis in multiple joints. Wing and joint tissues were positive by PCR for poxvirus. Thin-section electron microscopy showed poxvirus particles within A-type inclusions. Phylogenetic comparison supports establishment of a new genus of Poxviridae. C1 [Emerson, Ginny L.; Davidson, Whitni B.; Wilkins, Kimberly; Li, Yu; Doty, Jeffrey B.; Gallardo-Romero, Nadia F.; Metcalfe, Maureen G.; Karem, Kevin L.; Damon, Inger K.; Carroll, Darin S.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Nordhausen, Robert] Univ Calif Davis, Davis, CA 95616 USA. [Garner, Michael M.] Northwest ZooPath, Monroe, WA USA. [Huckabee, John R.; Johnson, Steven] PAWS Wildlife Ctr, Lynnwood, WA USA. [Wohrle, Ron D.] Washington State Dept Hlth, Tumwater, WA USA. RP Emerson, GL (reprint author), Ctr Dis Control & Prevent, Poxvirus Program, 1600 Clifton Rd NE,Mailstop G06, Atlanta, GA 30333 USA. EM gemerson@cdc.gov NR 15 TC 4 Z9 4 U1 1 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2013 VL 19 IS 6 BP 1002 EP 1004 DI 10.3201/eid1906.121713 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LY UT WOS:000328173500025 PM 23735421 ER PT J AU Ahmed, JA Moturi, E Spiegel, P Schilperoord, M Burton, W Kassim, NH Mohamed, A Ochieng, M Nderitu, L Navarro-Colorado, C Burke, H Cookson, S Handzel, T Waiboci, LW Montgomery, JM Teshale, E Marano, N AF Ahmed, Jamal A. Moturi, Edna Spiegel, Paul Schilperoord, Marian Burton, Wagacha Kassim, Nailah H. Mohamed, Abdinoor Ochieng, Melvin Nderitu, Leonard Navarro-Colorado, Carlos Burke, Heather Cookson, Susan Handzel, Thomas Waiboci, Lilian W. Montgomery, Joel M. Teshale, Eyasu Marano, Nina TI Hepatitis E Outbreak, Dadaab Refugee Camp, Kenya, 2012 SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID E VIRUS; INFECTION; RISK C1 [Ahmed, Jamal A.; Waiboci, Lilian W.; Montgomery, Joel M.; Marano, Nina] US Ctr Dis Control & Prevent, Nairobi, Kenya. [Moturi, Edna; Burton, Wagacha] United Nations High Commissioner Refugees, Nairobi, Kenya. [Spiegel, Paul; Schilperoord, Marian] United Nations High Commissioner Refugees, Geneva, Switzerland. [Kassim, Nailah H.] Kenya Red Cross, Nairobi, Kenya. [Mohamed, Abdinoor; Ochieng, Melvin; Nderitu, Leonard] Kenya Govt Med Res Ctr, Nairobi, Kenya. [Navarro-Colorado, Carlos; Burke, Heather; Cookson, Susan; Handzel, Thomas; Teshale, Eyasu] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Ahmed, JA (reprint author), KEMRI Compound, Mbagathi Rd,POB 606-00621, Nairobi, Kenya. EM JAhmed@ke.cdc.gov RI Moturi, Edna/P-2835-2015; OI Moturi, Edna/0000-0002-1694-1476; Navarro Colorado, Carlos/0000-0002-2185-0157 NR 10 TC 15 Z9 15 U1 1 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2013 VL 19 IS 6 BP 1010 EP 1012 DI 10.3201/eid1906.130275 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LY UT WOS:000328173500028 PM 23735820 ER PT J AU Gouandjika-Vasilache, I Mazitchi, A Gumede, N Manirakiza, A Manenegu, C Koyazegbe, TD Burns, C AF Gouandjika-Vasilache, Ionela Mazitchi, Arthur Gumede, Nicksy Manirakiza, Alexandre Manenegu, Casimir Koyazegbe, Thomas D'Aquin Burns, Cara TI Wild Poliovirus Importation, Central African Republic SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID TYPE-1 C1 [Gouandjika-Vasilache, Ionela; Mazitchi, Arthur; Manirakiza, Alexandre] Inst Pasteur, Bangui, Cent Afr Republ. [Gumede, Nicksy] Natl Inst Communicable Dis, Johannesburg, South Africa. [Manenegu, Casimir] World Hlth Org, Bangui, Cent Afr Republ. [Koyazegbe, Thomas D'Aquin] Minist Sante Populat & Lute SIDA, Bangui, Cent Afr Republ. [Burns, Cara] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Gouandjika-Vasilache, I (reprint author), Inst Pasteur, BP 923, Bangui, Cent Afr Republ. EM ionela512@yahoo.fr NR 9 TC 3 Z9 3 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2013 VL 19 IS 6 BP 1012 EP 1013 DI 10.3201/eid1906.121821 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LY UT WOS:000328173500029 PM 23735864 ER PT J AU Olive, MM Razafindralambo, N Barivelo, TA Rafisandratantsoa, JT Soarimalala, V Goodman, SM Rollin, PE Heraud, JM Reynes, JM AF Olive, Marie-Marie Razafindralambo, Nadia Barivelo, Tony Andrianaivo Rafisandratantsoa, Jean-Theophile Soarimalala, Voahangy Goodman, Steven M. Rollin, Pierre E. Heraud, Jean-Michel Reynes, Jean-Marc TI Absence of Rift Valley Fever Virus in Wild Small Mammals, Madagascar SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID MAINTENANCE C1 [Olive, Marie-Marie; Razafindralambo, Nadia; Rafisandratantsoa, Jean-Theophile; Reynes, Jean-Marc] Inst Pasteur Madagascar, Antananarivo, Madagascar. [Barivelo, Tony Andrianaivo; Soarimalala, Voahangy; Goodman, Steven M.] Assoc Vahatra, Antananarivo, Madagascar. [Barivelo, Tony Andrianaivo] Univ Antananarivo, Antananarivo, Madagascar. [Goodman, Steven M.] Field Museum Nat Hist, Chicago, IL 60605 USA. [Rollin, Pierre E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Reynes, Jean-Marc] Inst Pasteur, Lyon, France. RP Olive, MM (reprint author), Inst Pasteur Madagascar, Unite Virol, Antananarivo 101, Madagascar. EM mmolive@pasteur.mg RI HERAUD, Jean-Michel/O-1464-2013; Reynes, Jean-Marc/M-6108-2014 OI HERAUD, Jean-Michel/0000-0003-1107-0859; NR 10 TC 6 Z9 6 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2013 VL 19 IS 6 BP 1025 EP 1027 DI 10.3201/eid1906.121074 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LY UT WOS:000328173500036 PM 23735220 ER PT J AU Castrodale, LJ Gerlach, RF Preziosi, DE Frederickson, P Lockhart, SR AF Castrodale, Louisa J. Gerlach, Robert F. Preziosi, Diane E. Frederickson, Paul Lockhart, Shawn R. TI Prolonged Incubation Period for Cryptococcus gattii Infection in Cat, Alaska, USA SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID PACIFIC-NORTHWEST; EMERGENCE; CANADA C1 [Castrodale, Louisa J.] Alaska Div Publ Hlth, Anchorage, AK 99503 USA. [Gerlach, Robert F.] Alaska Div Environm Hlth, Anchorage, AK USA. [Preziosi, Diane E.] Vet Specialists Alaska PC, Anchorage, AK USA. [Frederickson, Paul] Hillside Pet Clin, Anchorage, AK USA. [Lockhart, Shawn R.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Castrodale, LJ (reprint author), Alaska Div Publ Hlth, Epidemiol Sect, Div Publ Hlth, Alaska Dept Hlth & Social Serv, 3601 C St,Suite 540, Anchorage, AK 99503 USA. EM louisa.castrodale@alaska.gov NR 10 TC 1 Z9 1 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2013 VL 19 IS 6 BP 1034 EP 1035 DI 10.3201/eid1906.130006 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LY UT WOS:000328173500041 PM 23735429 ER PT J AU Potter, P AF Potter, Polyxeni TI More Is More SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM pmp1@cdc.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2013 VL 19 IS 6 BP 1036 EP 1037 DI 10.3201/eid1906.AC1906 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LY UT WOS:000328173500042 PM 23735517 ER PT J AU Taylor, EV Nguyen, TA Machesky, KD Koch, E Sotir, MJ Bohm, SR Folster, JP Bokanyi, R Kupper, A Bidol, SA Emanuel, A Arends, KD Johnson, SA Dunn, J Stroika, S Patel, MK Williams, I AF Taylor, E. V. Nguyen, T. A. Machesky, K. D. Koch, E. Sotir, M. J. Bohm, S. R. Folster, J. P. Bokanyi, R. Kupper, A. Bidol, S. A. Emanuel, A. Arends, K. D. Johnson, S. A. Dunn, J. Stroika, S. Patel, M. K. Williams, I. TI Multistate Outbreak of Escherichia coli O145 Infections Associated with Romaine Lettuce Consumption, 2010 SO JOURNAL OF FOOD PROTECTION LA English DT Article ID NON-O157 SHIGA TOXIN; HEMOLYTIC-UREMIC-SYNDROME; UNITED-STATES; GERMANY; O157; MINNESOTA; DIAGNOSIS; DIARRHEA; STRAINS AB Non-O157 Shiga toxin-producing Escherichia coli (STEC) can cause severe illness, including hemolytic uremic syndrome (HUS). STEC O145 is the sixth most commonly reported non-O157 STEC in the United States, although outbreaks have been infrequent. In April and May 2010, we investigated a multistate outbreak of STEC O145 infection. Confirmed cases were STEC O145 infections with isolate pulsed-field gel electrophoresis patterns indistinguishable from those of the outbreak strain. Probable cases were STEC O145 infections or HUS in persons who were epidemiologically linked. Case-control studies were conducted in Michigan and Ohio; food exposures were analyzed at the restaurant, menu, and ingredient level. Environmental inspections were conducted in implicated food establishments, and food samples were collected and tested. To characterize clinical findings associated with infections, we conducted a chart review for case patients who sought medical care. We identified 27 confirmed and 4 probable cases from five states. Of these, 14 (45%) were hospitalized, 3 (10%) developed HUS, and none died. Among two case-control studies conducted, illness was significantly associated with consumption of shredded romaine lettuce in Michigan (odds ratio [OR] = undefined; 95% confidence interval [CI] = 1.6 to undefined) and Ohio (OR = 10.9; 95% CI = 3.1 to 40.5). Samples from an unopened bag of shredded romaine lettuce yielded the predominant outbreak strain. Of 15 case patients included in the chart review, 14 (93%) had diarrhea and abdominal cramps and 11 (73%) developed bloody diarrhea. This report documents the first foodborne outbreak of STEC O145 infections in the United States. Current surveillance efforts focus primarily on E. coli O157 infections; however, non-O157 STEC can cause similar disease and outbreaks, and efforts should be made to identify both O157 and non-O157 STEC infections. Providers should test all patients with bloody diarrhea for both non-O157 and O157 STEC. C1 [Taylor, E. V.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Taylor, E. V.; Nguyen, T. A.; Sotir, M. J.; Folster, J. P.; Stroika, S.; Patel, M. K.; Williams, I.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Machesky, K. D.; Bokanyi, R.] Ohio Dept Hlth, Columbus, OH 43215 USA. [Koch, E.; Kupper, A.; Emanuel, A.] Columbus Publ Hlth, Outbreak Response, Columbus, OH 43215 USA. [Bohm, S. R.; Bidol, S. A.; Arends, K. D.; Johnson, S. A.] Bur Dis Control Prevent & Epidemiol, Michigan Dept Community Hlth, Lansing, MI 48933 USA. [Dunn, J.] Tennessee Dept Hlth Foodborne Vectorborne & Zoono, Nashville, TN 37243 USA. RP Taylor, EV (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. EM idp4@cdc.gov NR 32 TC 17 Z9 18 U1 1 U2 19 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X EI 1944-9097 J9 J FOOD PROTECT JI J. Food Prot. PD JUN PY 2013 VL 76 IS 6 BP 939 EP 944 DI 10.4315/0362-028X.JFP-12-503 PG 6 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA 240FR UT WOS:000326080900004 PM 23726187 ER PT J AU Plumlee, GS Durant, JT Morman, SA Neri, A Wolf, RE Dooyema, CA Hageman, PL Lowers, HA Fernette, GL Meeker, GP Benzel, WM Driscoll, RL Berry, CJ Crock, JG Goldstein, HL Adams, M Bartrem, CL Tirima, S Behbod, B von Lindern, I Brown, MJ AF Plumlee, Geoffrey S. Durant, James T. Morman, Suzette A. Neri, Antonio Wolf, Ruth E. Dooyema, Carrie A. Hageman, Philip L. Lowers, Heather A. Fernette, Gregory L. Meeker, Gregory P. Benzel, William M. Driscoll, Rhonda L. Berry, Cyrus J. Crock, James G. Goldstein, Harland L. Adams, Monique Bartrem, Casey L. Tirima, Simba Behbod, Behrooz von Lindern, Ian Brown, Mary Jean TI Linking Geological and Health Sciences to Assess Childhood Lead Poisoning from Artisanal Gold Mining in Nigeria SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE artisanal mining; environmental health; lead poisoning; mercury contamination; ore deposit geology ID RELATIVE BIOAVAILABILITY AB BACKGROUND: In 2010, Medecins Sans Frontieres discovered a lead poisoning outbreak linked to artisanal gold processing in northwestern Nigeria. The outbreak has killed approximately 400 young children and affected thousands more. OBJECTIVES: Our aim was to undertake an interdisciplinary geological-and health-science assessment to clarify lead sources and exposure pathways, identify additional toxicants of concern and populations at risk, and examine potential for similar lead poisoning globally. METHODS: We applied diverse analytical methods to ore samples, soil and sweep samples from villages and family compounds, and plant foodstuff samples. RESULTS: Natural weathering of lead-rich gold ores before mining formed abundant, highly gastric-bioaccessible lead carbonates. The same fingerprint of lead minerals found in all sample types confirms that ore processing caused extreme contamination, with up to 185,000 ppm lead in soils/sweep samples and up to 145 ppm lead in plant foodstuffs. Incidental ingestion of soils via hand-to-mouth transmission and of dusts cleared from the respiratory tract is the dominant exposure pathway. Consumption of water and foodstuffs contaminated by the processing is likely lesser, but these are still significant exposure pathways. Although young children suffered the most immediate and severe consequences, results indicate that older children, adult workers, pregnant women, and breastfed infants are also at risk for lead poisoning. Mercury, arsenic, manganese, antimony, and crystalline silica exposures pose additional health threats. CONCLUSIONS: Results inform ongoing efforts in Nigeria to assess lead contamination and poisoning, treat victims, mitigate exposures, and remediate contamination. Ore deposit geology, pre-mining weathering, and burgeoning artisanal mining may combine to cause similar lead poisoning disasters elsewhere globally. C1 [Plumlee, Geoffrey S.; Morman, Suzette A.; Wolf, Ruth E.; Hageman, Philip L.; Lowers, Heather A.; Fernette, Gregory L.; Meeker, Gregory P.; Benzel, William M.; Driscoll, Rhonda L.; Berry, Cyrus J.; Crock, James G.; Goldstein, Harland L.; Adams, Monique] US Geol Survey, Denver, CO 80225 USA. [Durant, James T.; Neri, Antonio; Dooyema, Carrie A.; Behbod, Behrooz; Brown, Mary Jean] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dooyema, Carrie A.; Behbod, Behrooz] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Bartrem, Casey L.; Tirima, Simba; von Lindern, Ian] TerraGraph Environm Engn, Moscow, ID USA. [Bartrem, Casey L.; Tirima, Simba] Univ Idaho, Environm Sci Program, Moscow, ID 83843 USA. RP Plumlee, GS (reprint author), US Geol Survey, Denver Fed Ctr MS964, Denver, CO 80225 USA. EM gplumlee@usgs.gov FU USGS Mineral Resources Program; CDC Global Disease Detection Program; CDC Nigeria; U.S. Agency for International Development, Office of Foreign Disaster Assistance; United Nations Children's Fund (UNICEF) via Blacksmith Institute; TerraGraphics/University of Idaho International Research and Development Initiative FX This research was funded by USGS Mineral Resources Program; CDC Global Disease Detection Program; CDC Nigeria; U.S. Agency for International Development, Office of Foreign Disaster Assistance; United Nations Children's Fund (UNICEF) via Blacksmith Institute; TerraGraphics/University of Idaho International Research and Development Initiative. NR 26 TC 18 Z9 18 U1 2 U2 48 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD JUN PY 2013 VL 121 IS 6 BP 744 EP 750 DI 10.1289/ehp.1206051 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 208VN UT WOS:000323709400026 PM 23524139 ER PT J AU Cowling, BJ Ip, DKM Fang, VJ Suntarattiwong, P Olsen, SJ Levy, J Uyeki, TM Leung, GM Peiris, JSM Chotpitayasunondh, T Nishiura, H Simmerman, JM AF Cowling, Benjamin J. Ip, Dennis K. M. Fang, Vicky J. Suntarattiwong, Piyarat Olsen, Sonja J. Levy, Jens Uyeki, Timothy M. Leung, Gabriel M. Peiris, J. S. Malik Chotpitayasunondh, Tawee Nishiura, Hiroshi Simmerman, James Mark TI Aerosol transmission is an important mode of influenza A virus spread SO NATURE COMMUNICATIONS LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; AIRBORNE TRANSMISSION; SURVIVAL; INFECTION; COMMUNITY; SETTINGS; HYGIENE AB Influenza A viruses are believed to spread between humans through contact, large respiratory droplets and small particle droplet nuclei (aerosols), but the relative importance of each of these modes of transmission is unclear. Volunteer studies suggest that infections via aerosol transmission may have a higher risk of febrile illness. Here we apply a mathematical model to data from randomized controlled trials of hand hygiene and surgical face masks in Hong Kong and Bangkok households. In these particular environments, inferences on the relative importance of modes of transmission are facilitated by information on the timing of secondary infections and apparent differences in clinical presentation of secondary infections resulting from aerosol transmission. We find that aerosol transmission accounts for approximately half of all transmission events. This implies that measures to reduce transmission by contact or large droplets may not be sufficient to control influenza A virus transmission in households. C1 [Cowling, Benjamin J.; Ip, Dennis K. M.; Fang, Vicky J.; Leung, Gabriel M.; Peiris, J. S. Malik; Nishiura, Hiroshi] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China. [Suntarattiwong, Piyarat; Chotpitayasunondh, Tawee] Queen Sirikit Natl Inst Child Hlth, Bangkok, Thailand. [Olsen, Sonja J.; Levy, Jens] Thailand MOPH US CDC Collaborat, Influenza Program, Nonthaburi, Thailand. [Olsen, Sonja J.; Uyeki, Timothy M.] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Peiris, J. S. Malik] Univ Hong Kong, Li Ka Shing Fac Med, Influenza Res Ctr, Hong Kong, Hong Kong, Peoples R China. [Nishiura, Hiroshi] Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan. [Simmerman, James Mark] Sanofi Pasteur, Epidemiol & Med Affairs, Bangkok, Thailand. RP Cowling, BJ (reprint author), Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China. EM bcowling@hku.hk OI Nishiura, Hiroshi/0000-0003-0941-8537 FU National Institute of Allergy and Infectious Diseases [HHSN266200700005C]; NIAID Centers for Excellence in Influenza Research and Surveillance [N01-AI-70005]; Harvard Center for Communicable Disease Dynamics from the National Institute of General Medical Sciences [U54 GM088558]; Area of Excellence Scheme of the Hong Kong University Grants Committee [AoE/M-12/06]; United States Centers for Disease Control and Prevention [1 U01 CI000439]; JST PRESTO FX We thank Mark Dworkin, Heath Kelly, Yuguo Li, Marc Lipsitch, Don Milton, Jeffrey Shaman, Joe Wu, Peng Wu and Hui-Ling Yen for helpful discussions. We also thank Lincoln Lau and Nancy Leung for technical assistance; Rita Fung, Hau Chi So, Calvin Cheng, Winnie Wai, Joey Sin, Wing Hong Seto, Raymond Yung, Daniel Chu, Billy Chiu, Paco Lee, Ming Chi Chiu, Hoi Che Lee and Peter Houck for assistance with the Hong Kong trial; and Suchada Kaewchana, Robert Gibbons, Richard Jarman, Wiwan Sanasuttipun, Susan Maloney and Laurie Kamimoto for assistance with the Bangkok trial. This project was supported by the National Institute of Allergy and Infectious Diseases under contract no. HHSN266200700005C; ADB No. N01-AI-70005 (NIAID Centers for Excellence in Influenza Research and Surveillance), the Harvard Center for Communicable Disease Dynamics from the National Institute of General Medical Sciences (Grant no. U54 GM088558) and the Area of Excellence Scheme of the Hong Kong University Grants Committee (Grant no. AoE/M-12/06). The household trials in Hong Kong and Bangkok were supported by the United States Centers for Disease Control and Prevention (Grant no. 1 U01 CI000439). H.N. received funding support from JST PRESTO. The funding bodies had no role in study design and analysis or the decision to publish, but the CDC was involved in the design of the original studies and the preparation of this manuscript. This work represents the views of the authors and not their institutions, including the Centers for Disease Control and Prevention. NR 31 TC 36 Z9 36 U1 4 U2 28 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JUN PY 2013 VL 4 AR 1935 DI 10.1038/ncomms2922 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 207SM UT WOS:000323624100002 PM 23736803 ER PT J AU King, ME Schreiber, MD Formanski, SE Fleming, S Bayleyegn, TM Lemusu, SS AF King, Michael E. Schreiber, Merritt D. Formanski, Stephen E. Fleming, Sinclair Bayleyegn, Tesfaye M. Lemusu, Siitia S. TI A Brief Report of Surveillance of Traumatic Experiences and Exposures After the Earthquake-Tsunami in American Samoa, 2009 SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE surveillance; mental health; disasters AB Context: Rapid mental health surveillance during the acute phase of a disaster response can inform the allocation of limited clinical resources and provide essential household-level risk estimates for recovery planning. Objective: To describe the use of the PsySTART Rapid Mental Health Triage and Incident Management System for individual-level clinical triage and traumatic exposure assessment in the aftermath of a large-scale disaster. Methods: We conducted a cross-sectional, comparative review of mental health triage data collected with the PsySTART system from survivors of the September 2009 earthquake-tsunami in American Samoa. Data were obtained from two sources-secondary triage of patients and a standardized community assessment survey-and analyzed descriptively. The main outcome measures were survivor-reported traumatic experiences and exposures-called triage factors-associated with risk for developing severe distress and new mental health disorders following disasters. Results: The most common triage factors reported by survivors referred for mental health services were "felt extreme panic/fear" (93%) and "felt direct threat to life" (93%). The most common factor reported by persons in tsunami-affected communities was "felt extreme panic or fear" (75%). Proportions of severe triage factors reported by persons living in the community were consistently lower than those reported by patients referred for mental health services. Conclusions: The combination of evidence-based mental health triage and community assessment gave hospital-based providers, local public health officials, and federal response teams a strategy to match limited clinical resources with survivors at greatest risk. Also, it produced a common operating picture of acute and chronic mental health needs among disaster systems of care operating in American Samoa. C1 [King, Michael E.] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Bayleyegn, Tesfaye M.] Ctr Dis Control & Prevent, Hlth Studies Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Schreiber, Merritt D.; Fleming, Sinclair] Univ Calif Los Angeles, Sch Publ Hlth, Ctr Publ Hlth & Disasters, Ctr Hlth Sci, Los Angeles, CA 90024 USA. [Formanski, Stephen E.] US Dept HHS, Reg Off Preparedness & Emergency Operat 3, Off Assistant Secretary Preparedness & Response, Philadelphia, PA USA. [Lemusu, Siitia S.] Amer Samoa Dept Hlth, Pago Pago, AS USA. RP King, ME (reprint author), Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F-58, Atlanta, GA 30341 USA. EM nzk7@cdc.gov NR 19 TC 3 Z9 3 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD JUN PY 2013 VL 7 IS 3 BP 327 EP 331 DI 10.1001/dmp.2012.11 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 201SM UT WOS:000323163300015 PM 22508996 ER PT J AU Huhtamo, E Lambert, AJ Costantino, S Servino, L Krizmancic, L Boldorini, R Allegrini, S Grasso, I Korhonen, EM Vapalahti, O Lanciotti, RS Ravanini, P AF Huhtamo, Eili Lambert, Amy J. Costantino, Stefano Servino, Luca Krizmancic, Letizia Boldorini, Renzo Allegrini, Sara Grasso, Ivan Korhonen, Essi M. Vapalahti, Olli Lanciotti, Robert S. Ravanini, Paolo TI Isolation and full genomic characterization of Batai virus from mosquitoes, Italy 2009 SO JOURNAL OF GENERAL VIROLOGY LA English DT Article ID INFECTED MOSQUITOS; HEMORRHAGIC-FEVER; CACHE-VALLEY; BUNYAVIRUSES; REASSORTMENT; ORTHOBUNYAVIRUS; BUNYAMWERA; EVOLUTION; ALIGNMENT; INDIA AB In 2009, 2589 mosquitoes were collected in northwest Italy and screened for orthobunyavirus RNA by RT-PCR. One pool of Anopheles maculipennis complex mosquitoes was found to be positive and a virus was isolated from that pool. The isolate was identified as Batai virus (BATV) by sequencing. Previously, BATV was detected in Italy, but limited data and no prior isolates existed. Full-length sequences of the S, M and L segments were determined for the newly isolated Italian strain. For comparison, partial sequences were also determined for the BATV strain Calovo (former Czechoslovakia, 1960). Phylogenetic analyses revealed clustering of the newly derived Italian BATV along with a recent isolate from Germany and the historic strain Calovo. To the best of our knowledge, this represents the first isolation of BATV from Italy, which confirms a broader geographical distribution of BATV in Europe than was previously verified by isolation. C1 [Huhtamo, Eili; Korhonen, Essi M.; Vapalahti, Olli] Univ Helsinki, Fac Med, Haartman Inst, Dept Virol, FI-00014 Helsinki, Finland. [Lambert, Amy J.; Lanciotti, Robert S.] Natl Ctr Zoonot Vector Borne & Enter Dis, Ctr Dis Control & Prevent, Dept Hlth & Human Serv, Div Vector Borne Infect Dis,Publ Hlth Serv, Ft Collins, CO USA. [Costantino, Stefano; Servino, Luca; Krizmancic, Letizia; Ravanini, Paolo] Univ Maggiore Carita, Azienda Osped, UOA Microbiol & Virol, Mol Virol Lab, Novara, Italy. [Boldorini, Renzo; Allegrini, Sara] Univ Amedeo Avogadro Piemonte Orientale, Fac Med & Chirurg, Dipartimento Anat Patol, Novara, Italy. [Grasso, Ivan] Ist Piante Legno Ambiente, Turin, Italy. [Vapalahti, Olli] Univ Helsinki, Cent Hosp Lab, Dept Virol & Immunol, FI-00029 Helsinki, Finland. [Vapalahti, Olli] Univ Helsinki, Fac Vet Med, Dept Vet Biosci, FI-00014 Helsinki, Finland. RP Huhtamo, E (reprint author), Univ Helsinki, Fac Med, Haartman Inst, Dept Virol, POB 21, FI-00014 Helsinki, Finland. EM eili.huhtamo@helsinki.fi OI Vapalahti, Olli/0000-0003-2270-6824 FU Academy of Finland; HUSLAB; Emil Aaltonen Foundation FX The authors thank Irina Suomalainen for expert technical assistance. This study was supported by grants from the Academy of Finland, HUSLAB and the Emil Aaltonen Foundation. NR 31 TC 7 Z9 8 U1 1 U2 4 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-1317 J9 J GEN VIROL JI J. Gen. Virol. PD JUN PY 2013 VL 94 BP 1242 EP 1248 DI 10.1099/vir.0.051359-0 PN 6 PG 7 WC Biotechnology & Applied Microbiology; Virology SC Biotechnology & Applied Microbiology; Virology GA 170GJ UT WOS:000320838100013 PM 23515020 ER PT J AU Tierney, EF Burrows, NR Barker, LE Beckles, GL Boyle, JP Cadwell, BL Kirtland, KA Thompson, TJ AF Tierney, Edward F. Burrows, Nilka R. Barker, Lawrence E. Beckles, Gloria L. Boyle, James P. Cadwell, Betsy L. Kirtland, Karen A. Thompson, Theodore J. TI Small area variation in diabetes prevalence in Puerto Rico SO REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article DE Diabetes mellitus; prevalence; public policy; Puerto Rico ID HEALTH; STATISTICS; FRAMEWORK; ORIGIN; RICANS AB Objective. To estimate the 2009 prevalence of diagnosed diabetes in Puerto Rico among adults >= 20 years of age in order to gain a better understanding of its geographic distribution so that policymakers can more efficiently target prevention and control programs. Methods. A Bayesian multilevel model was fitted to the combined 2008-2010 Behavioral Risk Factor Surveillance System and 2009 United States Census data to estimate diabetes prevalence for each of the 78 municipios (counties) in Puerto Rico. Results. The mean unadjusted estimate for all counties was 14.3% (range by county, 9.9%-18.0%). The average width of the confidence intervals was 6.2%. Adjusted and unadjusted estimates differed little. Conclusions. These 78 county estimates are higher on average and showed less variability (i.e., had a smaller range) than the previously published estimates of the 2008 diabetes prevalence for all United States counties (mean, 9.9%; range, 3.0%-18.2%). C1 [Tierney, Edward F.; Burrows, Nilka R.; Barker, Lawrence E.; Beckles, Gloria L.; Boyle, James P.; Cadwell, Betsy L.; Kirtland, Karen A.; Thompson, Theodore J.] US Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. RP Tierney, EF (reprint author), US Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. EM ext5@cdc.gov FU Intramural CDC HHS [CC999999] NR 37 TC 3 Z9 3 U1 0 U2 1 PU PAN AMER HEALTH ORGANIZATION PI WASHINGTON PA 525 23RD ST NW, WASHINGTON, DC 20037 USA SN 1020-4989 J9 REV PANAM SALUD PUBL JI Rev. Panam. Salud Publica PD JUN PY 2013 VL 33 IS 6 BP 398 EP 406 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 200VN UT WOS:000323099100003 PM 23939364 ER PT J AU Talih, M AF Talih, Makram TI A REFERENCE-INVARIANT HEALTH DISPARITY INDEX BASED ON RENYI DIVERGENCE SO ANNALS OF APPLIED STATISTICS LA English DT Article DE Epidemiological methods; health inequalities; alpha-gamma divergence; survey data; Taylor series linearization; rescaled bootstrap ID COMPLEX SURVEY DATA; INEQUALITY MEASURES; INCOME INEQUALITY; POPULATIONS; ENTROPY AB One of four overarching goals of Healthy People 2020 (HP2020) is to achieve health equity, eliminate disparities, and improve the health of all groups. In health disparity indices (HDIs) such as the mean log deviation (MLD) and Theil index (TI), disparities are relative to the population average, whereas in the index of disparity (IDisp) the reference is the group with the least adverse health outcome. Although the latter may be preferable, identification of a reference group can be affected by statistical reliability. To address this issue, we propose a new HDI, the Renyi index (RI), which is reference-invariant. When standardized, the RI extends the Atkinson index, where a disparity aversion parameter can incorporate societal values associated with health equity. In addition, both the MLD and TI are limiting cases of the RI. Also, a symmetrized Renyi index (SRI) can be constructed, resulting in a symmetric measure in the two distributions whose relative entropy is being evaluated. We discuss alternative symmetric and reference-invariant HDIs derived from the generalized entropy (GE) class and the Bregman divergence, and argue that the SRI is more robust than its GE-based counterpart to small changes in the distribution of the adverse health outcome. We evaluate the design-based standard errors and bootstrapped sampling distributions for the SRI, and illustrate the proposed methodology using data from the National Health and Nutrition Examination Survey (NHANES) on the 2001-04 prevalence of moderate or severe periodontitis among adults aged 45-74, which track Oral Health objective OH-5 in HP2020. Such data, which use a binary individual-level outcome variable, are typical of HP2020 data. C1 Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Off Anal & Epidemiol, Hlth Promot Stat Branch, Hyattsville, MD 20782 USA. RP Talih, M (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Off Anal & Epidemiol, Hlth Promot Stat Branch, 3311 Toledo Rd,Room 6317, Hyattsville, MD 20782 USA. EM mtalih@cdc.gov FU Intramural CDC HHS [CC999999] NR 52 TC 4 Z9 4 U1 2 U2 9 PU INST MATHEMATICAL STATISTICS PI CLEVELAND PA 3163 SOMERSET DR, CLEVELAND, OH 44122 USA SN 1932-6157 J9 ANN APPL STAT JI Ann. Appl. Stat. PD JUN PY 2013 VL 7 IS 2 BP 1217 EP 1243 DI 10.1214/12-AOAS621 PG 27 WC Statistics & Probability SC Mathematics GA 197DO UT WOS:000322829800025 PM 26568778 ER PT J AU Haber, P Patel, M Pan, Y Baggs, J Haber, M Museru, O Yue, X Lewis, P DeStefano, F Parashar, UD AF Haber, Penina Patel, Manish Pan, Yi Baggs, James Haber, Michael Museru, Oidda Yue, Xin Lewis, Paige DeStefano, Frank Parashar, Umesh D. TI Intussusception After Rotavirus Vaccines Reported to US VAERS, 2006-2012 SO PEDIATRICS LA English DT Article DE rotavirus vaccines; intussusception; VAERS; safety monitoring; adverse event ID CASE-SERIES METHOD; ADVERSE EVENTS; UNITED-STATES; SAFETY; VACCINATION; INFANTS; RISK; CHILDREN; SURVEILLANCE; PENTAVALENT AB BACKGROUND: In 2006 and 2008, 2 new rotavirus vaccines (RotaTeq [RV5] and Rotarix [RV1]) were introduced in the United States. METHODS: We assessed intussusception events reported to the Vaccine Adverse Event Reporting System from February 2006 through April 2012 for RV5 and from April 2008 through April 2012 for RV1. For RV5, we conducted a self-controlled risk interval analysis using Poisson regression to estimate the daily reporting ratio (DRR) of intussusception comparing average daily reports 3 to 6 versus 0 to 2 days after vaccination. We calculated reporting rate differences based on DRRs and background rates of intussusception. Sensitivity analyses were conducted to assess effects of differential reporting completeness and inaccuracy of baseline rates. Few reports were submitted after RV1, allowing only a descriptive analysis. RESULTS: The Vaccine Adverse Event Reporting System received 584 confirmed intussusception reports after RV5 and 52 after RV1, with clustering 3 to 6 days after both vaccines. The DRR comparing the 3- to 6-day and the 0- to 2-day periods after RV5 dose 1 was 3.75 (95% confidence interval = 1.90 to 7.39). There was no significant increase in reporting after dose 2 or dose 3. Over all 3 doses, the excess risk of intussusception was 0.79 events (95% confidence interval = -0.04 to 1.62) per 100 000 vaccinations. From the sensitivity analyses, we conclude that under a worst-case scenario, the DRR could be 5.00 and excess risk per 100 000 doses could be 1.36. CONCLUSIONS: We observed a persistent clustering of reported intussusception events 3 to 6 days after the first dose of RV5 vaccination. This clustering could translate to a small increased risk of intussusception, which is outweighed by the benefits of rotavirus vaccination. C1 [Haber, Penina; Pan, Yi; Museru, Oidda; Yue, Xin; Lewis, Paige; DeStefano, Frank] Natl Ctr Emerging & Zoonot Infect Dis, Immunizat Safety Off, Div Healthcare Qual Promot, Atlanta, GA USA. [Patel, Manish; Parashar, Umesh D.] Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Baggs, James] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Haber, Michael] Emory Univ, Rollins Sch Publ Hlth Biostat & Bioinformat, Atlanta, GA 30322 USA. RP Haber, P (reprint author), 1600 Clifton Rd,MS D-26, Atlanta, GA 30333 USA. EM pyh0@cdc.gov OI Baggs, James/0000-0003-0757-4683 NR 25 TC 38 Z9 40 U1 0 U2 4 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD JUN PY 2013 VL 131 IS 6 BP 1042 EP 1049 DI 10.1542/peds.2012-2554 PG 8 WC Pediatrics SC Pediatrics GA 197HH UT WOS:000322840200046 PM 23669521 ER PT J AU Perrine, CG Scanlon, KS AF Perrine, Cria G. Scanlon, Kelley S. TI Prevalence of Use of Human Milk in US Advanced Care Neonatal Units SO PEDIATRICS LA English DT Article DE special care; intensive care; NICU; hospital; human milk; donor milk ID PREMATURE-INFANTS AB BACKGROUND AND OBJECTIVE: The American Academy of Pediatrics recommends all preterm infants receive human milk. The objective of this study was to describe the use of human milk in advanced care neonatal units of US maternity hospitals. METHODS: We used Centers for Disease Control and Prevention's national Maternity Practices in Infant Nutrition and Care survey from 2007, 2009, and 2011 to analyze 2 questions to describe the prevalence of US advanced care (special/level 2 or intensive/level 3) neonatal units routinely providing human milk to infants, and the use of any donor milk in these units. RESULTS: In 2011, 30.8% of maternity hospitals reported that most infants (>= 90%) were routinely provided human milk in advanced care units, compared with 26.7% in 2009 and 21.2% in 2007 (trend P < .001). States in the Northwest and Northeast had a higher prevalence of hospitals routinely providing human milk to >= 90% of infants in advanced care units. In 2011, 22.0% of maternity hospitals providing advanced care used banked donor milk, compared with 14.4% in 2009 and 11.5% in 2007 (trend P < .001). Most of this increase occurred in intensive care units (25.1% 2007 vs 45.2% 2011; trend P < .001). There was substantial geographic variation in the prevalence of advanced care units using donor milk; generally the prevalence was higher in the West and in states with a milk bank in the state or a neighboring state. CONCLUSIONS: The use of human milk in US advanced care neonatal units is increasing; however, only one-third of these units are routinely providing human milk to most infants. C1 [Perrine, Cria G.; Scanlon, Kelley S.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Perrine, Cria G.] United States Publ Hlth Serv Commissioned Corps, Atlanta, GA USA. RP Perrine, CG (reprint author), 4770 Buford Highway NE,Mailstop K-25, Atlanta, GA 30341 USA. EM cperrine@cdc.gov FU Intramural CDC HHS [CC999999]; NIDDK NIH HHS [T32 DK007734] NR 13 TC 28 Z9 28 U1 0 U2 4 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD JUN PY 2013 VL 131 IS 6 BP 1066 EP 1071 DI 10.1542/peds.2012-3823 PG 6 WC Pediatrics SC Pediatrics GA 197HH UT WOS:000322840200049 PM 23669517 ER PT J AU Lanzieri, TM Dollard, SC Josephson, CD Schmid, S Bialek, SR AF Lanzieri, Tatiana M. Dollard, Sheila C. Josephson, Cassandra D. Schmid, Scott Bialek, Stephanie R. TI Breast Milk-Acquired Cytomegalovirus Infection and Disease in VLBW and Premature Infants SO PEDIATRICS LA English DT Review DE breast milk; cytomegalovirus; premature infant; very low birth weight infant; sepsis-like syndrome ID BIRTH-WEIGHT INFANTS; PRETERM INFANTS; UNITED-STATES; TRANSMISSION; TERM; MOTHER; POPULATION; PREVENTION; STORAGE; RISK AB BACKGROUND: Very low birth weight (VLBW) and premature infants are at risk for developing postnatal cytomegalovirus (CMV) disease, including CMV-related sepsis-like syndrome (CMV-SLS) for which in the United States are lacking. METHODS: We performed a systematic review and meta-analysis to estimate the pooled proportions (and 95% confidence intervals) of VLBW and premature infants born to CMV-seropositive women with breast milk-acquired CMV infection and CMV-SLS. We combined these proportions with population-based rates of CMV seropositivity, breast milk feeding, VLBW, and prematurity to estimate annual rates of breast milk-acquired CMV infection and CMV-SLS in the United States. RESULTS: In our meta-analysis, among 299 infants fed untreated breast milk, we estimated 19% (11%-32%) acquired CMV infection and 4% (2%-7%) developed CMV-SLS. Assuming these proportions, we estimated a rate of breast milk-acquired CMV infection among VLBW and premature infants in the United States of 6.5% (3.7%-10.9%) and 1.4% (0.7%-2.4%) of CMV-SLS, corresponding to 600 infants with CMV-SLS in 2008. Among 212 infants fed frozen breast milk, our meta-analysis proportions were 13% (7%-24%) for infection and 5% (2%-12%) for CMV-SLS, yielding slightly lower rates of breast milk-acquired CMV infection (4.4%; 2.4%-8.2%) but similar rates of CMV-SLS (1.7%; 0.7%-4.1%). CONCLUSIONS: Breast milk-acquired CMV infection presenting with CMV-SLS is relatively rare. Prospective studies to better define the burden of disease are needed to refine guidelines for feeding breast milk from CMV-seropositive mothers to VLBW and premature infants. C1 [Lanzieri, Tatiana M.; Dollard, Sheila C.; Schmid, Scott; Bialek, Stephanie R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Josephson, Cassandra D.] Emory Univ, Dept Pathol & Pediat, Atlanta, GA 30322 USA. RP Lanzieri, TM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mail Stop A 34, Atlanta, GA 30333 USA. EM tmlanzieri@cdc.gov FU Intramural CDC HHS [CC999999] NR 46 TC 30 Z9 33 U1 0 U2 4 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD JUN PY 2013 VL 131 IS 6 BP E1937 EP E1945 DI 10.1542/peds.2013-0076 PG 9 WC Pediatrics SC Pediatrics GA 197HH UT WOS:000322840200028 PM 23713111 ER PT J AU Olsen, EO Shults, RA Eaton, DK AF Olsen, Emily O'Malley Shults, Ruth A. Eaton, Danice K. TI Texting While Driving and Other Risky Motor Vehicle Behaviors Among US High School Students SO PEDIATRICS LA English DT Article DE unintentional injury; adolescents; texting while driving; motor vehicle crashes ID TEENAGE DRIVERS; ADOLESCENTS; CRASHES; SCIENCE AB OBJECTIVE: To assess the prevalence of texting/e-mailing while driving (TWD) and association of TWD with other risky motor vehicle (MV) behaviors among US high school students. METHODS: Data were used from the Centers for Disease Control and Prevention's 2011 national Youth Risk Behavior Survey, which assessed TWD during the 30 days before the survey among 8505 students aged >= 16 years from a nationally representative sample of US high school students. TWD frequency was coded into dichotomous and polychotomous variables. Logistic regression assessed the relationship between TWD and other risky driving behaviors, controlling for age, race/ethnicity, and sex. RESULTS: The prevalence of TWD on >= 1 days during the 30 days before the survey was 44.5% (95% confidence interval: 40.8%-48.2%). Students who engaged in TWD were more likely than their non-TWD counterparts to not always wear their seatbelt (prevalence ratio; 95% confidence interval: 1.16; 1.07-1.26), ride with a driver who had been drinking alcohol (1.74; 1.57-1.93), and drink alcohol and drive (5.33; 4.32-6.59). These other risky MV behaviors were most likely to occur among students who frequently engaged in TWD. CONCLUSIONS: Nearly half of US high school students aged >= 16 years report TWD during the past 30 days; these students are more likely to engage in additional risky MV behaviors. This suggests there is a sub-group of students who may place themselves, their passengers, and others on the road at elevated risk for a crash-related injury or fatality by engaging in multiple risky MV behaviors. C1 [Olsen, Emily O'Malley; Eaton, Danice K.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA 30341 USA. [Shults, Ruth A.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Atlanta, GA 30341 USA. RP Olsen, EO (reprint author), Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, 4770 Buford Hwy NE,MS K-33, Atlanta, GA 30341 USA. EM eolsen@cdc.gov NR 49 TC 24 Z9 24 U1 4 U2 46 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD JUN PY 2013 VL 131 IS 6 BP E1708 EP E1715 DI 10.1542/peds.2012-3462 PG 8 WC Pediatrics SC Pediatrics GA 197HH UT WOS:000322840200001 PM 23669511 ER PT J AU Terranella, A Asay, GRB Messonnier, ML Clark, TA Liang, JL AF Terranella, Andrew Asay, Garrett R. Beeler Messonnier, Mark L. Clark, Thomas A. Liang, Jennifer L. TI Pregnancy Dose Tdap and Postpartum Cocooning to Prevent Infant Pertussis: A Decision Analysis SO PEDIATRICS LA English DT Article DE pertussis; pregnancy; Tdap; vaccines ID INFLUENZA VACCINATION; OBSTETRICIAN-GYNECOLOGISTS; COST-EFFECTIVENESS; YOUNG INFANTS; UNITED-STATES; DIPHTHERIA; TETANUS; ADULTS; WOMEN; IMMUNIZATION AB BACKGROUND: Infants <2 months of age are at highest risk of pertussis morbidity and mortality. Until recently, the US Advisory Committee on Immunization Practices (ACIP) recommended protecting young infants by "cocooning" or vaccination of postpartum mothers and other close contacts with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis, adsorbed (Tdap) booster vaccine. ACIP recommends pregnancy vaccination as a preferred and safe alternative to postpartum vaccination. The ACIP cocooning recommendation has not changed. METHODS: We used a cohort model reflecting US 2009 births and the diphtheria-tetanus-acellular pertussis schedule to simulate a decision and cost-effectiveness analysis of Tdap vaccination during pregnancy compared with postpartum vaccination with or without vaccination of other close contacts (ie, cocooning). We analyzed infant pertussis cases, hospitalizations, and deaths, as well as direct disease, indirect, and public health costs for infants in the first year of life. All costs were updated to 2011 US dollars. RESULTS: Pregnancy vaccination could reduce annual infant pertussis incidence by more than postpartum vaccination, reducing cases by 33% versus 20%, hospitalizations by 38% versus 19%, and deaths by 49% versus 16%. Additional cocooning doses in a father and 1 grandparent could avert an additional 16% of cases but at higher cost. The cost per quality-adjusted life-year saved for pregnancy vaccination was substantially less than postpartum vaccination ($414 523 vs $1 172 825). CONCLUSIONS: Tdap vaccination during pregnancy could avert more infant cases and deaths at lower cost than postpartum vaccination, even when postpartum vaccination is combined with additional cocooning doses. Pregnancy dose vaccination is the preferred alternative to postpartum vaccination for preventing infant pertussis. C1 [Terranella, Andrew] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Off, Atlanta, GA USA. [Terranella, Andrew; Clark, Thomas A.; Liang, Jennifer L.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA. [Asay, Garrett R. Beeler; Messonnier, Mark L.] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Liang, JL (reprint author), 1600 Clifton Rd,Mail Stop C-25, Atlanta, GA 30333 USA. EM jliang@cdc.gov NR 32 TC 45 Z9 46 U1 1 U2 12 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD JUN PY 2013 VL 131 IS 6 BP E1748 EP E1756 DI 10.1542/peds.2012-3144 PG 9 WC Pediatrics SC Pediatrics GA 197HH UT WOS:000322840200006 PM 23713104 ER PT J AU Estivariz, CF Pallansch, MA Anand, A Wassilak, SGF Sutter, RW Wenger, JD Orenstein, WA AF Estivariz, Concepcion F. Pallansch, Mark A. Anand, Abhijeet Wassilak, Steven G. F. Sutter, Roland W. Wenger, Jay D. Orenstein, Walter A. TI Poliovirus vaccination options for achieving eradication and securing the endgame SO CURRENT OPINION IN VIROLOGY LA English DT Article ID CONTROLLED-TRIAL; SEROLOGIC RESPONSE; WILD POLIOVIRUS; CLINICAL-TRIAL; VACCINES; IMMUNOGENICITY; POLIOMYELITIS; POTENCY; STRAINS; EPIDEMIOLOGY AB In 1988, the World Health Assembly resolved to globally eradicate poliomyelitis. As part of a four-pronged strategy with establishment of enhanced surveillance, institution of national immunization days, strengthening routine immunization, and carrying-out mopping-up activities, oral poliovirus vaccine (OPV) was selected as the vaccine-of-choice for eradication. Massive OPV use decreased the number of polio-endemic countries from >125 countries in 1988 to only 3 in 2012 and led to a >99.9% decrease in polio incidence in the corresponding period. In this communication, we will discuss polio vaccination options to accelerate eradication, to mitigate the risks during the planned withdrawal of type 2 OPV, and to secure eradication for future generations. C1 [Estivariz, Concepcion F.; Pallansch, Mark A.; Anand, Abhijeet; Wassilak, Steven G. F.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Sutter, Roland W.] WHO, CH-1211 Geneva, Switzerland. [Wenger, Jay D.] Bill & Melinda Gates Fdn, Seattle, WA 98109 USA. [Orenstein, Walter A.] Emory Univ, Sch Med, Atlanta, GA 30322 USA. RP Estivariz, CF (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM cge3@cdc.gov NR 50 TC 22 Z9 23 U1 0 U2 14 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1879-6257 J9 CURR OPIN VIROL JI Curr. Opin. Virol. PD JUN PY 2013 VL 3 IS 3 BP 309 EP 315 DI 10.1016/j.coviro.2013.05.007 PG 7 WC Virology SC Virology GA 191MD UT WOS:000322416300013 PM 23759252 ER PT J AU Honein, MA Devine, O Sharma, AJ Rasmussen, SA Park, S Kucik, JE Boyle, C AF Honein, Margaret A. Devine, Owen Sharma, Andrea J. Rasmussen, Sonja A. Park, Sohyun Kucik, James E. Boyle, Coleen TI Modeling the Potential Public Health Impact of Prepregnancy Obesity on Adverse Fetal and Infant Outcomes SO OBESITY LA English DT Article ID NEURAL-TUBE DEFECTS; GESTATIONAL DIABETES-MELLITUS; OF-THE-LITERATURE; BODY-MASS INDEX; MATERNAL OBESITY; BIRTH-DEFECTS; UNITED-STATES; PRETERM BIRTH; RISK-FACTOR; METAANALYSIS AB Objective: Approximately one-third of US reproductive-aged women are obese, and prepregnancy obesity is a strong risk factor for adverse fetal and infant outcomes. The annual number of preventable adverse fetal and infant outcomes associated with prepregnancy obesity in the US was estimated. Design and Methods: Adverse fetal and infant outcomes for which statistically significant associations with prepregnancy obesity had been reported by peer-reviewed meta-analyses, which included fetal deaths and nine different major birth defects, were assessed. The true prevalence of prepregnancy obesity was estimated by multiplying self-reported prepregnancy obesity by a bias factor based on the difference between measured and self-reported obesity in US adult women. A Monte Carlo simulation approach was used to model the attributable fraction and preventable number, accounting for uncertainty in the estimates for: (1) strength of the association with obesity, (2) obesity prevalence, and (3) outcome prevalence. Results: Eliminating the impact of prepregnancy obesity would potentially prevent the highest numbers of four outcomes: fetal deaths (6,990; uncertainty interval [UI] 4,110-10,080), congenital heart defects (2,850; UI 1,035-5,065), hydrocephalus (490; UI 150-850), and spina bifida (405; UI 305-505). If 10% of women with prepregnancy obesity achieved a healthy weight before pregnancy or otherwise mitigated the impact of obesity, nearly 300 congenital heart defects and 700 fetal deaths per year could potentially be prevented. Conclusion: This simulation suggests that effective prevention strategies to reduce prepregnancy obesity or the risk associated with obesity could have a measurable impact on infant health in the US. C1 [Honein, Margaret A.; Devine, Owen; Rasmussen, Sonja A.; Kucik, James E.; Boyle, Coleen] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Sharma, Andrea J.; Park, Sohyun] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Honein, MA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. EM MHonein@cdc.gov OI Sharma, Andrea/0000-0003-0385-0011 NR 41 TC 5 Z9 5 U1 3 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 J9 OBESITY JI Obesity PD JUN PY 2013 VL 21 IS 6 BP 1276 EP 1283 DI 10.1002/oby.20156 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 192LV UT WOS:000322487000032 PM 23913736 ER PT J AU Rodewald, LE AF Rodewald, Lance E. TI Notes from the Field: My Experience in China with WHO SO PEDIATRIC ANNALS LA English DT Article C1 [Rodewald, Lance E.] WHO Beijing, China Off, Expanded Program Immunizat, Beijing, Peoples R China. [Rodewald, Lance E.] US Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA USA. RP Rodewald, LE (reprint author), WHO Beijing, China Off, Expanded Program Immunizat, Beijing, Peoples R China. EM RodewaldL@wpro.who.int OI Rodewald, Lance/0000-0003-2593-542X NR 0 TC 0 Z9 0 U1 0 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0090-4481 EI 1938-2359 J9 PEDIATR ANN JI Pediatr. Annu. PD JUN PY 2013 VL 42 IS 6 BP 253 EP 255 DI 10.3928/00904481-20130522-13 PG 3 WC Pediatrics SC Pediatrics GA 188OE UT WOS:000322201500018 PM 23718248 ER PT J AU Williams-Newkirk, AJ Salzer, JS Carroll, DS Gillespie, TR Dasch, GA AF Williams-Newkirk, Amanda Jo Salzer, Johanna S. Carroll, Darin S. Gillespie, Thomas R. Dasch, Gregory A. TI Simple method for locating a suitable venipuncture site on the tail of the Virginia opossum (Didelphis virginiana) SO EUROPEAN JOURNAL OF WILDLIFE RESEARCH LA English DT Article DE Blood collection; Didelphis virginiana; Opossum; Tail vein; Venipuncture; Wildlife management ID TICKS AMBLYOMMA-CAJENNENSE; EXPERIMENTAL-INFECTION; TRANSMISSION; HUSBANDRY; AURITA AB We identified a site suitable for venipuncture on the tail of the Virginia opossum (Didelphis virginiana) that is reliably and easily located. The prominent hemal arch associated with the ventral surface of caudal vertebra 5 serves as an easily palpated anatomical landmark for locating the ventral caudal vein for blood collection. Because this venipuncture site is only thinly covered by fur and visualization of the vein is not necessary for its location, site preparation and total animal handling time for routine venipuncture are minimal. Blood may be collected from immature and adult male and female animals, and the technique is easily taught to new technicians with minimal danger of injury to the animal. C1 [Williams-Newkirk, Amanda Jo; Salzer, Johanna S.; Gillespie, Thomas R.] Emory Univ, Dept Environm Studies, Program Populat Biol Ecol & Evolut, Math & Sci Ctr, Atlanta, GA 30322 USA. [Williams-Newkirk, Amanda Jo; Dasch, Gregory A.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Vector Borne Dis, Atlanta, GA 30333 USA. [Salzer, Johanna S.; Carroll, Darin S.] Ctr Dis Control & Prevent, Poxvirus Branch, Div High Consequence Pathogens, Atlanta, GA 30333 USA. RP Williams-Newkirk, AJ (reprint author), Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Vector Borne Dis, 1600 Clifton Rd NE,MS G13, Atlanta, GA 30333 USA. EM igy7@cdc.gov OI Williams-Newkirk, Amanda/0000-0002-3466-2921 FU Centers for Disease Control and Prevention; Department of Environmental Studies at Emory University FX We would like to thank Jessica Harmon, Ryan Lash, Robert Newkirk, Tim Rose, Karen Wu, and Audrey Zeis for their invaluable assistance in the field. We are also grateful to Byron Freeman at the Georgia Museum of Natural History for providing access to opossum specimens for reference for Fig. 1, to Robert Newkirk for providing the illustration, and to Carl Brown at Emory University for his helpful suggestions. Images and video footage in the training video were kindly provided by Tim Rose, Jimmie Williams, and Kim Williams. This research was supported in part by the appointment of Salzer and Williams-Newkirk to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education and by the Department of Environmental Studies at Emory University. NR 16 TC 0 Z9 0 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1612-4642 J9 EUR J WILDLIFE RES JI Eur. J. Wildl. Res. PD JUN PY 2013 VL 59 IS 3 BP 455 EP 457 DI 10.1007/s10344-013-0706-y PG 3 WC Ecology; Zoology SC Environmental Sciences & Ecology; Zoology GA 184DD UT WOS:000321866400016 ER PT J AU Martin, WJ Glass, RI Araj, H Balbus, J Collins, FS Curtis, S Diette, GB Elwood, WN Falk, H Hibberd, PL Keown, SEJ Mehta, S Patrick, E Rosenbaum, J Sapkota, A Tolunay, HE Bruce, NG AF Martin, William J., II Glass, Roger I. Araj, Houmam Balbus, John Collins, Francis S. Curtis, Sian Diette, Gregory B. Elwood, William N. Falk, Henry Hibberd, Patricia L. Keown, Susan E. J. Mehta, Sumi Patrick, Erin Rosenbaum, Julia Sapkota, Amir Tolunay, H. Eser Bruce, Nigel G. TI Household Air Pollution in Low- and Middle-Income Countries: Health Risks and Research Priorities SO PLOS MEDICINE LA English DT Editorial Material ID RETROSPECTIVE COHORT; STOVE IMPROVEMENT; CARBON-MONOXIDE; EXPOSURE; GUATEMALA; CHILDREN; CHINA; DISEASE; XUANWEI; SMOKE C1 [Martin, William J., II] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Natl Inst Hlth, Bethesda, MD USA. [Glass, Roger I.] Natl Inst Hlth, John E Fogarty Int Ctr, Bethesda, MD USA. [Araj, Houmam] NEI, Natl Inst Hlth, Bethesda, MD 20892 USA. [Balbus, John] Natl Inst Environm Hlth Sci, Natl Inst Hlth, Res Triangle Pk, NC USA. [Collins, Francis S.] Natl Inst Hlth, Bethesda, MD USA. [Curtis, Sian] Univ N Carolina, Carolina Populat Ctr, MEASURE Evaluat Project, Chapel Hill, NC USA. [Curtis, Sian] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC USA. [Diette, Gregory B.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Elwood, William N.] Natl Inst Hlth, Off Behav & Social Sci Res, Bethesda, MD USA. [Falk, Henry] Ctr Dis Control & Prevent, Off Noncommunicable Dis Injury & Environm Hlth, Atlanta, GA USA. [Hibberd, Patricia L.] Massachusetts Gen Hosp, Div Global Hlth, Boston, MA 02114 USA. [Keown, Susan E. J.] Palladian Partners, Silver Spring, MD USA. [Mehta, Sumi] Global Alliance Clean Cookstoves, Washington, DC USA. [Patrick, Erin] Womens Refugee Commiss, New York, NY USA. [Rosenbaum, Julia] FHI 360, Washington, DC USA. [Sapkota, Amir] Univ Maryland, Sch Publ Hlth, College Pk, MD 20742 USA. [Tolunay, H. Eser] Natl Inst Hlth, Natl Heart Lung & Blood Inst, Div Cardiovasc Sci, Bethesda, MD USA. [Bruce, Nigel G.] Univ Liverpool, Dept Publ Hlth & Policy, Liverpool L69 3BX, Merseyside, England. [Bruce, Nigel G.] WHO, Dept Publ Hlth & Environm, CH-1211 Geneva, Switzerland. RP Martin, WJ (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Natl Inst Hlth, Bethesda, MD USA. EM wjmartin@mail.nih.gov RI Sapkota, Amir/A-5968-2011 FU NICHD NIH HHS [R24 HD041041, R24 HD050924, U01 HD058322, U10 HD078439] NR 48 TC 16 Z9 16 U1 2 U2 21 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD JUN PY 2013 VL 10 IS 6 AR e1001455 DI 10.1371/journal.pmed.1001455 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 172WB UT WOS:000321034800001 PM 23750119 ER PT J AU Li, CY Zhao, GX Okoro, CA Wen, XJ Ford, ES Balluz, LS AF Li, Chaoyang Zhao, Guixiang Okoro, Catherine A. Wen, Xiao-Jun Ford, Earl S. Balluz, Lina S. TI Prevalence of Diagnosed Cancer According to Duration of Diagnosed Diabetes and Current Insulin Use Among US Adults With Diagnosed Diabetes Findings from the 2009 Behavioral Risk Factor Surveillance System SO DIABETES CARE LA English DT Article ID CARDIOVASCULAR-DISEASE RISK; POPULATION-BASED COHORT; SELF-REPORTED CANCER; COLORECTAL-CANCER; BLADDER-CANCER; BREAST-CANCER; MELLITUS; METAANALYSIS; GENDER; SWEDEN AB OBJECTIVE-To estimate the prevalence of diagnosed cancer according to duration of diagnosed diabetes and current insulin use among U.S. adults with diagnosed diabetes. RESEARCH DESIGN AND METHODS-We analyzed data from 25,964 adults aged >= 18 years with diagnosed diabetes who participated in the 2009 Behavioral Risk Factor Surveillance System. RESULTS-After adjustment for potential confounders, we found that the greater the duration of diagnosed diabetes, the higher the prevalence of diagnosed cancers (P < 0.0001 for linear trend). Among adults with diagnosed type 2 diabetes, the prevalence estimate for cancers of all sites was significantly higher among men (adjusted prevalence ratio 1.6 [95% CI 1.3-1.9]) and women (1.8 [1.5-2.1]) who reported being diagnosed with diabetes >= 15 years ago than among those reporting diabetes diagnosis <15 years ago. The prevalence estimate for cancers of all sites was similar to 1.3 times higher among type 2 diabetic adults who currently used insulin than among those who did not use insulin among both men (1.3 [1.1-1.6]) and women (1.3 [1.1-1.5]). CONCLUSIONS-Our results suggest that there is an increased burden of diagnosed cancer among adults with a longer duration of diagnosed diabetes and among type 2 diabetic adults who currently use insulin. C1 [Li, Chaoyang; Zhao, Guixiang; Okoro, Catherine A.; Wen, Xiao-Jun; Balluz, Lina S.] Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance & Informat Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Ford, Earl S.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Li, CY (reprint author), Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance & Informat Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. NR 40 TC 5 Z9 5 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JUN PY 2013 VL 36 IS 6 BP 1569 EP 1576 DI 10.2337/dc12-1432 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 178UJ UT WOS:000321472600021 PM 23300288 ER PT J AU Kim, JH Roberge, R Powell, JB Shafer, AB Williams, WJ AF Kim, J. -H. Roberge, R. Powell, J. B. Shafer, A. B. Williams, W. Jon TI Measurement Accuracy of Heart Rate and Respiratory Rate during Graded Exercise and Sustained Exercise in the Heat Using the Zephyr BioHarness (TM) SO INTERNATIONAL JOURNAL OF SPORTS MEDICINE LA English DT Article DE physiological monitoring; portable metabolic system; reliability ID MONITOR AB The Zephyr BioHarness (TM) was tested to determine the accuracy of heart rate (HR) and respiratory rate (RR) measurements during 2 exercise protocols in conjunction with either a laboratory metabolic cart (Vmax) or a previously validated portable metabolic system (K4b(2)). In one protocol, HR and RR were measured using the BioHarness and Vmax during a graded exercise up to (V)over dotO(2max) (n = 12). In another protocol, HR and RR were measured using the BH and K4b(2) during sustained exercise (30% and 50% (V)over dotO(2max) for 20 min each) in a hot environment (30 degrees C, 50% relative humidity) (n = 6). During the graded exercise, HR but not RR, obtained from the BioHarness was higher compared to the Vmax at baseline and 30% (V)over dotO(2max) (p < 0.05), but showed no significant difference at other stages with high correlation coefficients for both HR (r = 0.87-0.96) and RR (r = 0.90-0.99 above 30% (V)over dotO(2max)). During the exercise in the heat, there were no significant differences between the BioHarness and K4b(2) system. Correlation coefficients between the methods were low for HR but moderately to highly correlated (0.49-0.99) for RR. In conclusion, the BioHarness is comparable to Vmax and K4b(2) over a wide range of (V)over dotO(2) during graded exercise and sustained exercise in the heat. C1 [Kim, J. -H.; Roberge, R.; Powell, J. B.] NIOSH, NPPTL, CDC, Technol Res Branch, Pittsburgh, PA 15236 USA. [Shafer, A. B.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Williams, W. Jon] NIOSH, CDC, Technol Res Branch, Pittsburgh, PA 15236 USA. RP Williams, WJ (reprint author), NIOSH, CDC, Technol Res Branch, 626 Cochrans Mill Rd, Pittsburgh, PA 15236 USA. EM aun7@cdc.gov FU Intramural CDC HHS [CC999999] NR 18 TC 18 Z9 19 U1 2 U2 13 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0172-4622 J9 INT J SPORTS MED JI Int. J. Sports Med. PD JUN PY 2013 VL 34 IS 6 BP 497 EP 501 DI 10.1055/s-0032-1327661 PG 5 WC Sport Sciences SC Sport Sciences GA 174FO UT WOS:000321140100005 PM 23175181 ER PT J AU Williams, BA Wolf, LE AF Williams, Brett A. Wolf, Leslie E. TI Biobanking, Consent, and Certificates of Confidentiality: Does the ANPRM Muddy the Water? SO JOURNAL OF LAW MEDICINE & ETHICS LA English DT Article AB In its Advanced Notice of Proposed Rule Making (ANPRM), the U.S. Department of Health and Human Services proposed substantial changes to how biospecimen research is treated under the regulations governing human subjects research. Currently, much of this research can be conducted without consent because it may not be considered human subjects research, is considered exempt, or consent may be waived. Responding to criticisms that scientific changes have made biospecimen research riskier than contemplated when the Common Rule was last amended, the ANPRM proposes to require written consent for biospecimen research, even if they have been stripped of identifiers or initially collected for a non-research purpose. The ANPRM's recognition of these risks is consistent with relatively recent NIH recommendations that research projects involving genetics, genomics, or biospecimen repositories should consider getting a Certificate of Confidentiality to provide additional protections to participants where breach of confidentiality is typically the primary risk. Ironically, the ANPRM proposals may make it more difficult to provide these protections. Our paper explores the implications of the conflicting requirements of the Certificate and the ANPRM proposals and makes recommendations for achieving the dual goals of appropriate consent and adequate confidentiality protections. C1 [Wolf, Leslie E.] Georgia State Univ, Coll Law, Atlanta, GA 30303 USA. RP Williams, BA (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. FU National Human Genome Research Institute (NHGRI) [R01HG005087] FX The project described was supported in part by Award Number R01HG005087 from the National Human Genome Research Institute (NHGRI). The content is solely the responsibility of the authors and does not necessarily represent the official views of NHGRI or the National Institutes of Health. NR 34 TC 5 Z9 5 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1073-1105 J9 J LAW MED ETHICS JI J. Law Med. Ethics PD SUM PY 2013 VL 41 IS 2 SI SI BP 440 EP 453 DI 10.1111/jlme.12054 PG 14 WC Ethics; Law; Medical Ethics; Medicine, Legal SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine GA 171MR UT WOS:000320934000006 PM 23802896 ER PT J AU Andrus, J Bottazzi, ME Chow, J Goraleski, KA Fisher-Hoch, SP Lambuth, JK Lee, BY Margolis, HS McCormick, JB Melby, P Murray, KO Rico-Hesse, R Valenzuela, JG Hotez, PJ AF Andrus, Jon Bottazzi, Maria Elena Chow, Jennifer Goraleski, Karen A. Fisher-Hoch, Susan P. Lambuth, Jocelyn K. Lee, Bruce Y. Margolis, Harold S. McCormick, Joseph B. Melby, Peter Murray, Kristy O. Rico-Hesse, Rebeca Valenzuela, Jesus G. Hotez, Peter J. TI Ears of the Armadillo: Global Health Research and Neglected Diseases in Texas SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Editorial Material ID WEST-NILE-VIRUS; TROPICAL DISEASES; CHAGAS-DISEASE; UNITED-STATES; RISK-FACTORS; VISCERAL LEISHMANIASIS; TRYPANOSOMA-CRUZI; EPIDEMIC DENGUE; NORTH-AMERICA; MEXICO BORDER C1 [Andrus, Jon] WHO, Pan Amer Hlth Org, Washington, DC USA. [Bottazzi, Maria Elena; Lambuth, Jocelyn K.; Murray, Kristy O.; Rico-Hesse, Rebeca; Hotez, Peter J.] Baylor Coll Med, Natl Sch Trop Med, Houston, TX 77030 USA. [Bottazzi, Maria Elena; Hotez, Peter J.] Sabin Vaccine Inst, Houston, TX USA. [Bottazzi, Maria Elena; Hotez, Peter J.] Texas Childrens Hosp Ctr Vaccine Dev, Houston, TX USA. [Chow, Jennifer] Res Amer, Alexandria, VA USA. [Goraleski, Karen A.] Amer Soc Trop Med & Hyg, Deerfield, IL USA. [Fisher-Hoch, Susan P.; McCormick, Joseph B.] Univ Texas Brownsville, Sch Publ Hlth, Brownsville, TX 78520 USA. [Lee, Bruce Y.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Margolis, Harold S.] Ctr Dis Control & Prevent, Dengue Branch, San Juan, PR USA. [Melby, Peter] Univ Texas Med Branch, Galveston, TX 77555 USA. [Valenzuela, Jesus G.] NIAID, NIH, Rockville, MD USA. [Hotez, Peter J.] Rice Univ, James A Baker III Inst Publ Policy, Houston, TX USA. RP Andrus, J (reprint author), WHO, Pan Amer Hlth Org, Washington, DC USA. EM hotez@bcm.edu OI Hotez, Peter/0000-0001-8770-1042 FU NIAID NIH HHS [R01 AI099483] NR 70 TC 6 Z9 6 U1 1 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD JUN PY 2013 VL 7 IS 6 AR e2021 DI 10.1371/journal.pntd.0002021 PG 6 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 175AL UT WOS:000321201300001 PM 23826397 ER PT J AU Tam, CC Tissera, H de Silva, AM de Silva, AD Margolis, HS Amarasinge, A AF Tam, Clarence C. Tissera, Hasitha de Silva, Aravinda M. de Silva, Aruna Dharshan Margolis, Harold S. Amarasinge, Ananda TI Estimates of Dengue Force of Infection in Children in Colombo, Sri Lanka SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID VIRUS TRANSMISSION; HEMORRHAGIC-FEVER; CLINICAL DENGUE; THAI VILLAGES; RISK-FACTORS; AGE; EPIDEMIOLOGY; ANTIBODIES; PREVALENCE; INFANTS AB Dengue is the most important vector-borne viral disease worldwide and a major cause of childhood fever burden in Sri Lanka, which has experienced a number of large epidemics in the past decade. Despite this, data on the burden and transmission of dengue virus in the Indian Subcontinent are lacking. As part of a longitudinal fever surveillance study, we conducted a dengue seroprevalence survey among children aged,12 years in Colombo, Sri Lanka. We used a catalytic model to estimate the risk of primary infection among seronegative children. Over 50% of children had IgG antibodies to dengue virus and seroprevalence increased with age. The risk of primary infection was 14.1% per year (95% CI: 12.7%-15.6%), indicating that among initially seronegative children, approximately 1 in 7 experience their first infection within 12 months. There was weak evidence to suggest that the force of primary infection could be lower for children aged 6 years and above. We estimate that there are approximately 30 primary dengue infections among children,12 years in the community for every case notified to national surveillance, although this ratio is closer to 100:1 among infants. Dengue represents a considerable infection burden among children in urban Sri Lanka, with levels of transmission comparable to those in the more established epidemics of Southeast Asia. C1 [Tam, Clarence C.; Tissera, Hasitha] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England. [Tissera, Hasitha; Amarasinge, Ananda] Minist Hlth, Epidemiol Unit, Colombo, Sri Lanka. [de Silva, Aravinda M.] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [de Silva, Aruna Dharshan] Genetech Res Inst, Colombo, Sri Lanka. [Margolis, Harold S.; Amarasinge, Ananda] Int Vaccine Inst, Pediat Dengue Vaccine Initiat, Seoul, South Korea. [Margolis, Harold S.] Ctr Dis Control & Prevent, Dengue Branch, San Juan, PR USA. RP Tam, CC (reprint author), London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England. EM clarence.tam@lshtm.ac.uk OI Tam, Clarence/0000-0003-1697-286X FU Bill & Melinda Gates Foundation through PDVI [23197] FX This study was funded by the Bill & Melinda Gates Foundation through PDVI (Grant No. 23197). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 25 TC 15 Z9 15 U1 0 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD JUN PY 2013 VL 7 IS 6 AR e2259 DI 10.1371/journal.pntd.0002259 PG 7 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 175AL UT WOS:000321201300021 PM 23755315 ER PT J AU Steinberg, ML Boulet, S Kissin, D Warner, L Jamieson, DJ AF Steinberg, Marissa L. Boulet, Sheree Kissin, Dmitry Warner, Lee Jamieson, Denise J. TI Elective single embryo transfer trends and predictors of a good perinatal outcome-United States, 1999 to 2010 SO FERTILITY AND STERILITY LA English DT Article DE Elective single ET; single ET; in vitro fertilization; singleton pregnancy; good perinatal outcome ID ASSISTED REPRODUCTIVE TECHNOLOGY; IN-VITRO FERTILIZATION; BLASTOCYST TRANSFER; LIVE BIRTH; PREGNANCY RATES; GESTATION; DISPARITY; TRIAL; WOMEN AB Objective: To assess trends in elective single ET and identify factors associated with a good perinatal outcome. Design: Retrospective cohort study. Setting: Clinic-based data. Patient(s): A total of 886,686 fresh, nondonor cycles reported to the National Assisted Reproductive Technology Surveillance System during 1999-2010, of which 17,166 met criteria for elective single ET. Intervention(s): None. Main Outcome Measure(s): Rates of elective single ET and good perinatal outcome (term, singleton infant with normal birth weight). Result(s): In 2010, elective single ET comprised 5.6% of all fresh transfers, representing an eightfold increase since publication of first guidelines in 2004 recommending elective single ET. Compared with other ETs, elective single ETs were nearly twice as likely to result in a good perinatal outcome (37.1% vs. 18.9%, respectively). Among women using elective single ET, those aged <35 and 35-37 years had a good perinatal outcome (40.2% and 32.5%, respectively). In multivariable, log-binomial analyses, factors positively associated with a good perinatal outcome included male factor infertility, day 5 ET, and having >= 3 supernumerary embryos for cryopreservation. Conclusion(s): Between 1999 and 2010, national rates of elective single ET increased. Given the frequency of good perinatal outcomes among women aged 35-37 years, guidelines for elective single ET could be expanded to include patients in this age group with favorable prognoses. 43. (C)2013 by American Society for Reproductive Medicine. C1 [Steinberg, Marissa L.] Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA USA. [Steinberg, Marissa L.; Boulet, Sheree; Kissin, Dmitry; Warner, Lee; Jamieson, Denise J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Steinberg, ML (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,MS K-34, Atlanta, GA 30341 USA. EM MLStei2@emory.edu FU Intramural CDC HHS [CC999999] NR 31 TC 14 Z9 14 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD JUN PY 2013 VL 99 IS 7 BP 1937 EP 1943 DI 10.1016/j.fertnstert.2013.01.134 PG 7 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 165TE UT WOS:000320505900033 PM 23453121 ER PT J AU McKinney, W Chen, B Schwegler-Berry, D Frazer, DG AF McKinney, Walter Chen, Bean Schwegler-Berry, Diane Frazer, Dave G. TI Computer-automated silica aerosol generator and animal inhalation exposure system SO INHALATION TOXICOLOGY LA English DT Article DE Aerosol; automated; exposure system; inhalation; silica ID CRYSTALLINE SILICA; RESTRAINT; TOXICITY; WORKERS; COHORT; BLOOD; RISK; RATS AB Inhalation exposure systems are necessary tools for determining the dose response relationship of inhaled toxicants under a variety of exposure conditions. The objective of this study was to develop an automated computer controlled system to expose small laboratory animals to precise concentrations of uniformly dispersed airborne silica particles. An acoustical aerosol generator was developed which was capable of re-suspending particles from bulk powder. The aerosolized silica output from the generator was introduced into the throat of a venturi tube. The turbulent high-velocity air stream within the venturi tube increased the dispersion of the re-suspended powder. That aerosol was then used to expose small laboratory animals to constant aerosol concentrations, up to 20 mg/m(3), for durations lasting up to 8 h. Particle distribution and morphology of the silica aerosol delivered to the exposure chamber were characterized to verify that a fully dispersed and respirable aerosol was being produced. The inhalation exposure system utilized a combination of airflow controllers, particle monitors, data acquisition devices and custom software with automatic feedback control to achieve constant and repeatable exposure environments. The automatic control algorithm was capable of maintaining median aerosol concentrations to within +0.2 mg/m(3) of a user selected target concentration during exposures lasting from 2 to 8 h. The system was able to reach 95% of the desired target value in <10 min during the beginning phase of an exposure. This exposure system provided a highly automated tool for conducting inhalation toxicology studies involving silica particles. C1 [McKinney, Walter; Chen, Bean; Schwegler-Berry, Diane; Frazer, Dave G.] NIOSH, CDC, Morgantown, WV 26505 USA. RP McKinney, W (reprint author), NIOSH, CDC, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM wdm9@cdc.gov FU Intramural CDC HHS [CC999999] NR 15 TC 2 Z9 2 U1 1 U2 11 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0895-8378 J9 INHAL TOXICOL JI Inhal. Toxicol. PD JUN PY 2013 VL 25 IS 7 BP 363 EP 372 DI 10.3109/08958378.2013.788105 PG 10 WC Toxicology SC Toxicology GA 170NV UT WOS:000320860300001 PM 23796015 ER PT J AU Tilburt, JC James, KM Koller, K Lanier, AP Hall, IJ Smith, JL Ekwueme, DU Nicometo, AM Petersen, WO AF Tilburt, Jon C. James, Katherine M. Koller, Kathryn Lanier, Anne P. Hall, Ingrid J. Smith, Judith Lee Ekwueme, Donatus U. Nicometo, Ann M. Petersen, Wesley O. TI Assessing Follow-up Care After Prostate-Specific Antigen Elevation in American Indian/Alaska Native Men: A Partnership Approach SO PROGRESS IN COMMUNITY HEALTH PARTNERSHIPS-RESEARCH EDUCATION AND ACTION LA English DT Article DE Community-based participatory research; community health partnerships; urogenital neoplasms; health care quality and access ID PARTICIPATORY RESEARCH; INDIAN COMMUNITIES; REFERENCE RANGES; ALASKA NATIVES; PUBLIC-HEALTH AB Background: Although many studies conducted among American Indian and Alaska Native (AI/AN) populations may help to advance medical science and lead to improvements in health and health care, historically few have endeavored to share their findings, benefits, and/or expected outcomes with the communities in which they are conducted. This perceived lack of responsiveness has contributed to a perception in some AI/AN communities that researchers are disrespectful and may not make community needs a priority. Objectives: In the context of a study assessing the care received by AI/AN men with incident elevated prostate-specific antigen (PSA) levels, this paper describes our experience building collaborative relationships, planning, conducting analyses, and disseminating findings with four AI/AN communities. Methods: We established formal partnerships with three Northern Plains AI communities and one AN tribal health organization, convened a 12-member Community Advisory Board (CAB), and obtained study approvals from all necessary tribal and institutional review bodies before implementing our study. A menu of options for study implementation was given to key collaborators at each site. CAB members and collaborating tribes contributed to each phase of the study. After data analysis, results were shared with tribal and institutional leaders. Lessons Learned: Face-to-face communication, flexibility, and adaptability, as well as clearly defined, respectful roles contributed to the success of the study on the part of both the researchers and community partners. Conclusions: This study demonstrates the importance and feasibility of forging collaborative relationships with AI/AN community leaders in regions of Alaska and the Northern Plains in cancer control initiatives for AI/AN men. C1 [Tilburt, Jon C.] Mayo Clin, Div Gen Internal Med, Rochester, MN 55905 USA. [Tilburt, Jon C.; James, Katherine M.] Mayo Clin, Biomed Eth Res Unit, Rochester, MN USA. [Tilburt, Jon C.] Mayo Clin, Healthcare Delivery Res Program, Rochester, MN USA. [Hall, Ingrid J.; Smith, Judith Lee; Ekwueme, Donatus U.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA USA. [Nicometo, Ann M.] Mayo Clin, Ctr Comprehens Canc, Off Canc Hlth Dispar Res, Rochester, MN USA. [Petersen, Wesley O.] Mayo Clin, Ctr Comprehens Canc, Behav Hlth Res Program, Rochester, MN USA. RP Tilburt, JC (reprint author), Mayo Clin, Div Gen Internal Med, Rochester, MN 55905 USA. FU Intramural CDC HHS [CC999999] NR 21 TC 1 Z9 1 U1 0 U2 2 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1557-0541 J9 PROG COMM HLTH PARTN JI Prog. Community Health Partnersh. PD SUM PY 2013 VL 7 IS 2 BP 153 EP 161 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 170ZS UT WOS:000320894700005 PM 23793246 ER PT J AU Adedinsewo, DA Thurman, DJ Luo, YH Williamson, RS Odewole, OA Oakley, GP AF Adedinsewo, Demilade A. Thurman, David J. Luo, Yao-Hua Williamson, Rebecca S. Odewole, Oluwaseun A. Oakley, Godfrey P., Jr. TI Valproate prescriptions for nonepilepsy disorders in reproductive-age women SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE anticonvulsants; congenital abnormalities; psychiatry; valproic acid; women's health ID ANTIEPILEPTIC DRUGS; UNITED-STATES; PERINATAL OUTCOMES; MANAGEMENT ISSUES; EPILEPSY-FOCUS; SPINA-BIFIDA; PREGNANCY; MALFORMATIONS; MEDICATIONS; EXPOSURE AB BACKGROUND Scientific evidence has consistently shown taking valproate during pregnancy increases risks of congenital malformations and cognitive impairment. As such, elimination of its use would be an important step in birth defects prevention. There are guidelines discouraging its use among women with epilepsy, but none exists for women without epilepsy, nor is the prevalence of valproate for nonepilepsy indications known. METHODS Using de-identified data from the National Hospital and Ambulatory Medical Care Surveys (1996-2007), we examined individual prescriptions for reproductive-age adolescent girls and adult women ages 15 to 44 years in the United States, and estimated the number of antiepileptic drug and valproate prescriptions in the aggregate. We classified our study population using International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes, as women with epilepsy and women without epilepsy. The prevalence of antiepileptic drug and valproate prescriptions among women without epilepsy was estimated as prescriptions per 1000 patient visits for every 3-year time interval and the overall study period. RESULTS We found 83% of valproate prescriptions were issued to women without epilepsy and 74% of these were for psychiatric diagnoses. The prevalence of antiepileptic drug prescriptions among women without epilepsy tripled during the study period (10.3 [1996-1998] vs. 34.9 [2005-2007] per 1000 patient visits), whereas valproate prescriptions remained relatively stable (3.1 [1996-1998] vs. 3.7 [2005-2007] per 1000 patient visits). CONCLUSION Most women of reproductive age who receive a valproate prescription do not have epilepsy. Valproate prescriptions did not decline, despite increasing knowledge of its teratogenicity. Reducing valproate use among women of reproductive age, especially among those who use the drug for psychiatric indications, would prevent birth defects and cognitive deficits. Birth Defects Research (Part A) 97:403-408, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Adedinsewo, Demilade A.; Williamson, Rebecca S.; Oakley, Godfrey P., Jr.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Adedinsewo, Demilade A.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Thurman, David J.; Luo, Yao-Hua] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Odewole, Oluwaseun A.] Emory Univ Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Atlanta, GA 30322 USA. [Oakley, Godfrey P., Jr.] Emory Univ, Rollins Sch Publ Hlth, Ctr Spina Bifida Res Prevent & Policy, Atlanta, GA 30322 USA. RP Oakley, GP (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd NE,Room 4007, Atlanta, GA 30322 USA. EM gpoakley@mindspring.com OI Adedinsewo, Demilade/0000-0002-8629-2029 FU Mr. Gerry Davy and Sophie's Voice Foundation FX Supported in part by unrestricted gifts from Mr. Gerry Davy and Sophie's Voice Foundation. NR 40 TC 9 Z9 9 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD JUN PY 2013 VL 97 IS 6 BP 403 EP 408 DI 10.1002/bdra.23147 PG 6 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 171ME UT WOS:000320932500004 PM 23733498 ER PT J AU Shiels, MS Engels, EA Linet, MS Clarke, CA Li, JM Hall, HI Hartge, P Morton, LM AF Shiels, Meredith S. Engels, Eric A. Linet, Martha S. Clarke, Christina A. Li, Jianmin Hall, H. Irene Hartge, Patricia Morton, Lindsay M. TI The Epidemic of Non-Hodgkin Lymphoma in the United States: Disentangling the Effect of HIV, 1992-2009 SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID FEATURING CANCERS; SURVEILLANCE DATA; TIME TRENDS; AIDS; RISK; MORTALITY; NATION; POPULATION; SARCOMA; PEOPLE AB Background: For decades, non-Hodgkin lymphoma (NHL) incidence has been increasing worldwide. NHL risk is strongly increased among HIV-infected people. Our understanding of trends inNHLincidence has been hampered by difficulties in separating HIV-infected NHL cases from general population rates. Methods: NHL incidence data during 1992-2009 were derived from 10 U. S. SEER cancer registries with information on HIV status at NHL diagnosis. The CDC estimated the number of people living with HIV in the registry areas. The proportion of NHL cases with HIV and NHL rates in the total and the HIV-uninfected populations were estimated. Time trends were assessed with Joinpoint analyses. Results: Of 115,643 NHL cases diagnosed during 1992-2009, 5.9% were HIV-infected. The proportions of NHL cases with HIV were highest for diffuse large B-cell (DLBCL; 7.8%), Burkitt (26.9%), and peripheral T-cell lymphomas (3.2%) with low proportions (<= 1.1%) in the other subtypes. NHL rates in the total population increased 0.3% per year during 1992-2009. However, rates of NHL in HIV-uninfected people increased 1.4% per year during 1992-2003, before becoming stable through 2009. Similar trends were observed for DLBCLs and follicular lymphoma in HIV-uninfected people; rates increased 2.7% per year until 2003 and 1.7% per year until 2005, respectively, before stabilizing. Conclusions: NHLincidence rates in the United States have plateaued over the last 5-10 years, independent of HIV infection. Impact: Although the causes of the long-term increase in NHL incidence rates in the United States remain unknown, general population rates of NHL have stabilized since the early 2000s, independent of HIV. (C) 2013 AACR. C1 [Shiels, Meredith S.; Engels, Eric A.; Linet, Martha S.; Hartge, Patricia; Morton, Lindsay M.] NCI, Div Canc Epidemiol & Genet, Rockville, MD 20892 USA. [Clarke, Christina A.] Canc Prevent Inst Calif, Fremont, CA USA. [Li, Jianmin; Hall, H. Irene] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Shiels, MS (reprint author), NCI, Infect & Immunoepidemiol Epidemiol Branch, Div Canc Epidemiol & Genet, 6120 Execut Blvd,EPS 7059, Rockville, MD 20892 USA. EM shielsms@mail.nih.gov RI Morton, Lindsay/B-5234-2015 OI Morton, Lindsay/0000-0001-9767-2310 FU National Cancer Institute FX This study was funded by the Intramural Research Program of the National Cancer Institute. NR 35 TC 39 Z9 43 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JUN PY 2013 VL 22 IS 6 BP 1069 EP 1078 DI 10.1158/1055-9965.EPI-13-0040 PG 10 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 167PF UT WOS:000320643200009 PM 23595542 ER PT J AU Chokkalingam, AP Chun, DS Noonan, EJ Pfeiffer, CM Zhang, M Month, SR Taggart, DR Wiemels, JL Metayer, C Buffler, PA AF Chokkalingam, Anand P. Chun, Danielle S. Noonan, Emily J. Pfeiffer, Christine M. Zhang, Mindy Month, Stacy R. Taggart, Denah R. Wiemels, Joseph L. Metayer, Catherine Buffler, Patricia A. TI Blood Levels of Folate at Birth and Risk of Childhood Leukemia SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID ACUTE LYMPHOBLASTIC-LEUKEMIA; FOLIC-ACID; MATERNAL FOLATE; PREGNANCY; SUPPLEMENTATION; NHANES; POPULATION; BIOMARKERS; CHILDREN; VITAMIN AB Background: A role for folate in cancer etiology has long been suspected because of folate's function as a cofactor in DNA methylation and maintenance of DNA synthesis. Previous case-control studies examining the association between risk of childhood acute lymphoblastic leukemia (ALL) and mothers' self-reported folate intake and supplementation have been inconclusive. Materials and Methods: We used a quantitative microbiologic assay to measure newborn folate concentrations in archived dried bloodspots collected at birth from 313 incident ALL cases, 44 incident acute myeloid leukemia (AML) cases, and 405 matched population-based controls. Results: Overall, we found no difference in hemoglobin-normalized newborn folate concentrations (HbFol, nmol/g) between ALL cases and controls (2.76 vs. 2.77, P = 0.97) or between AML cases and controls (2.93 vs. 2.76, P = 0.32). Null results persisted after stratification by both birth period (1982-94, 1995-98, and 1999-2002) to account for the start of folate fortification of grain products in the United States, and by self-reported maternal prepregnancy supplement use. Similarly, no association was observed for major ALL subgroups. Conclusions: Our results do not support an association between birth folate concentrations and risk of childhood AML or major ALL subgroups. Impact: However, they do not rule out a role for folate through exposures after birth or in early stages of fetal development. C1 [Chokkalingam, Anand P.; Chun, Danielle S.; Noonan, Emily J.; Metayer, Catherine; Buffler, Patricia A.] Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA. [Month, Stacy R.] Kaiser Permanente, Oakland, CA USA. [Taggart, Denah R.] Kaiser Permanente, Santa Clara, CA USA. [Wiemels, Joseph L.] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA USA. [Pfeiffer, Christine M.; Zhang, Mindy] Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Chokkalingam, AP (reprint author), UC Berkeley Sch Publ Hlth, 1995 Univ Ave,Ste 460, Berkeley, CA 94704 USA. EM anandc@berkeley.edu FU National Institute for Environmental Health Sciences [PS42ES04705, R01ES09137]; Children with Cancer UK Foundation [2008/081] FX This work was supported from the National Institute for Environmental Health Sciences (PS42ES04705 and R01ES09137) and the Children with Cancer UK Foundation (2008/081). NR 26 TC 5 Z9 5 U1 3 U2 12 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JUN PY 2013 VL 22 IS 6 BP 1088 EP 1094 DI 10.1158/1055-9965.EPI-12-1438 PG 7 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 167PF UT WOS:000320643200011 PM 23576692 ER PT J AU Surie, D Dunne, EF Naleway, AL Weinmann, S Klein, NP Baxter, R Hutchins, K Gee, J Markowitz, L AF Surie, Diya Dunne, Eileen F. Naleway, Allison L. Weinmann, Sheila Klein, Nicola P. Baxter, Roger Hutchins, Kathleen Gee, Julianne Markowitz, Lauri TI Cervical Intraepithelial Neoplasia Grade 3 and Adenocarcinoma In Situ: Comparison of ICD-9 Codes and Pathology Results-Kaiser Permanente, United States, 2000-2005 SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID PAPILLOMAVIRUS; RECOMMENDATIONS; VACCINE; CANCER AB Background: Cervical intraepithelial neoplasia grade 3+ (CIN3+) and adenocarcinoma in situ incidence will be an important measure of HPV vaccine impact. Integrated healthcare delivery systems, such as Kaiser Permanente, could be used to monitor CIN3+ trends; however, limited evaluations of data from healthcare delivery systems for CIN3+ surveillance exist. Methods: We compared CIN3+ diagnoses by ICD-9 code with CIN3+ diagnoses by pathology results among 121,211 females aged 11 to 30 years who were continuously enrolled from 2000 to 2005 in either Kaiser Permanente Northern California or Kaiser Permanente Northwest. We calculated sensitivity and positive predictive value of diagnosis by ICD-9 codes using pathology CIN3+ diagnosis as the gold standard. Results: There were 1,090 women with at least one CIN3+ diagnosis by ICD-9 code 233.1 and 1,200 women with at least one CIN3+ diagnosis by pathology results. The sensitivity of the ICD-9 code for detecting a woman with at least one pathology diagnosis for CIN3+ was 62% (740/1,200); positive predictive value was 68% (740/1,090). Among women with at least one CIN3+ diagnosis by ICD-9 code, 679 (62%) had more than one visit with this code; whereas, among women with at least one CIN3+ diagnosis by pathology, 466 (39%) had more than one CIN3+ pathology result. Conclusions: ICD-9 codes may underestimate the number of women with at least one CIN3+ diagnosis. Impact: Pathology results, when available, may provide better estimates of CIN3+ incidence. (c) 2013 AACR. C1 [Surie, Diya; Dunne, Eileen F.; Hutchins, Kathleen; Markowitz, Lauri] CDC, Div STD Prevent, Atlanta, GA 30333 USA. [Surie, Diya] CDC Experience Appl Epidemiol Fellowship, Atlanta, GA 30333 USA. [Gee, Julianne] CDC, Immunizat Safety Off, Atlanta, GA 30333 USA. [Naleway, Allison L.; Weinmann, Sheila] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Klein, Nicola P.; Baxter, Roger] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA. RP Dunne, EF (reprint author), CDC, Div STD Prevent, 1600 Clifton Rd,MS E-02, Atlanta, GA 30333 USA. EM dde9@cdc.gov OI Naleway, Allison/0000-0001-5747-4643 FU External Medical Affairs, Pfizer Inc.; GlaxoSmithKline; Merck Co.; Merck; GSK; National Vaccine Program Office; Epidemiology and Surveillance Branch; Division of STD Prevention; NCHHSTP; CDC; American Health Insurance Plans (AHIP) [200-2002-00732] FX Diya Surie's work was made possible through The CDC Experience Applied Epidemiology Fellowship, a public/private partnership supported by a grant to the CDC Foundation from External Medical Affairs, Pfizer Inc. A.L. Naleway has a commercial research grant from GlaxoSmithKline. N.P. Klein has a commercial research grant from Merck & Co. and other commercial research support from GlaxoSmithKline. R. Baxter has a commercial research grant from Merck and GSK. No potential conflicts of interest were disclosed by the other authors.; This study was funded through a National Vaccine Program Office award received by the Epidemiology and Surveillance Branch, Division of STD Prevention, NCHHSTP, CDC, American Health Insurance Plans (AHIP) contract number: 200-2002-00732. NR 10 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JUN PY 2013 VL 22 IS 6 BP 1129 EP 1132 DI 10.1158/1055-9965.EPI-12-1413 PG 4 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 167PF UT WOS:000320643200016 PM 23563889 ER PT J AU Martin, D Dbouk, RH DeLeon-Carnes, M del Rio, C Guarner, J AF Martin, David Dbouk, Reema H. DeLeon-Carnes, Marlene del Rio, Carlos Guarner, Jeannette TI Haemophilus influenzae acute endometritis with bacteremia: case report and literature review SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Review DE Haemophilus influenzae; Endometritis; Pathology; Septicemia ID HEMOPHILUS-INFLUENZAE; INFECTIONS; FLORA AB Haemophilus influenzae rarely causes acute endometritis and the few published cases have always been associated with intrauterine devices (IUD). A 48-year-old female presented to the emergency department with a 3-day history of lower abdominal pain and fever. On physical examination she was tachycardic, hypotensive and had fundic tenderness to palpation. Imaging showed uterine leiomyomas and no IUD. Blood cultures grew a non-typable H. influenzae. Endometrial biopsy demonstrated acute endometritis. Tissue Gram stains and cervico-vaginal cultures were negative; however, polymerase chain reaction (PCR) determined presence of H. influenzae on the formalin-fixed, paraffin-embedded tissue biopsy. Evidence of H. influenzae in the endometrium demonstrates that the uterus can be the nidus for sepsis when invasive H. influenzae is found with no distinct usual primary focus. This case underscores the importance pathologic diagnosis and molecular testing. (C) 2013 Elsevier Inc. All rights reserved. C1 [Martin, David; Guarner, Jeannette] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Dbouk, Reema H.; del Rio, Carlos] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA. [DeLeon-Carnes, Marlene] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA. [del Rio, Carlos] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. RP Guarner, J (reprint author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. EM jguarne@emory.edu RI Guarner, Jeannette/B-8273-2013; del Rio, Carlos/B-3763-2012 OI del Rio, Carlos/0000-0002-0153-3517 NR 17 TC 2 Z9 2 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD JUN PY 2013 VL 76 IS 2 BP 235 EP 236 DI 10.1016/j.diagmicrobio2013.02.010 PG 2 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 155AJ UT WOS:000319717500021 PM 23537790 ER PT J AU Pasipanodya, JG Moonan, PK Vecino, E Miller, TL Fernandez, M Slocum, P Drewyer, G Weis, SE AF Pasipanodya, Jotam G. Moonan, Patrick K. Vecino, Edgar Miller, Thaddeus L. Fernandez, Michel Slocum, Philip Drewyer, Gerry Weis, Stephen E. TI Allopatric tuberculosis host-pathogen relationships are associated with greater pulmonary impairment SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE Tuberculosis; Pulmonary impairment; Genotypes; Race/ethnicity; Lineage ID MYCOBACTERIUM-TUBERCULOSIS; DRUG-RESISTANCE; GENETIC-VARIABILITY; STRAINS; EMERGENCE; SMOKING; POPULATIONS; VIRULENCE; THERAPY; COMPLEX AB Background: Host pathogen relationships can be classified as allopatric, when the pathogens originated from separate, non-overlapping geographic areas from the host; or sympatric, when host and pathogen shared a common ancestral geographic location. It remains unclear if host-pathogen relationships, as defined by phylogenetic lineage, influence clinical outcome. We sought to examine the association between allopatric and sympatric phylogenetic Mycobacterium tuberculosis lineages and pulmonary impairment after tuberculosis (FIAT). Methods: Pulmonary function tests were performed on patients 16 years of age and older who had received >= 20 weeks of treatment for culture-confirmed M. tuberculosis complex. Forced Expiratory Volume in 1 min (FEV1) >= 80%, Forced Vital Capacity (FVC) >= 80% and FEV1/FVC >70% of predicted were considered normal. Other results defined pulmonary impairment. Spoligotype and 12-locus mycobacterial interspersed repetitive units-variable number of tandem repeats (MIRU-VNTR) were used to assign phylogenetic lineage. PIAT severity was compared between host-pathogen relationships which were defined by geography and ethnic population. We used multivariate logistic regression modeling to calculate adjusted odds ratios (aOR) between phylogenetic lineage and FIAT. Results: Self-reported continental ancestry was correlated with Mycobacterium. tuberculosis lineage (p < 0.001). In multivariate analyses adjusting for phylogenetic lineage, age and smoking, the overall aOR for subjects with allopatric host-pathogen relationships and PIAT was 1.8 (95% confidence interval [CI]: 1.1, 2.9) compared to sympatric relationships. Smoking >30 pack-years was also associated with PIAT (aOR: 3.2; 95% CI: 1.5, 7.2) relative to smoking <1 pack-years. Conclusions: PIAT frequency and severity varies by host-pathogen relationship and heavy cigarette consumption, but not phylogenetic lineage alone. Patients who had disease resulting from allopatric-host-pathogen relationship were more likely to have PIAT than patients with disease from sympatric-host-pathogen relationship infection. Further study of this association may identify ways that treatment and preventive efforts can be tailored to specific lineages and racial/ethnic populations. (C) 2013 Elsevier B.V. All rights reserved. C1 [Pasipanodya, Jotam G.] UT Southwestern Med Ctr, Off Global Hlth, Dallas, TX USA. [Pasipanodya, Jotam G.; Moonan, Patrick K.; Vecino, Edgar; Miller, Thaddeus L.; Fernandez, Michel; Weis, Stephen E.] Univ N Texas, Texas Hlth Sci Ctr Ft Worth, Ft Worth, TX USA. [Moonan, Patrick K.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Fernandez, Michel; Drewyer, Gerry; Weis, Stephen E.] Tarrant Cty Publ Hlth, Div TB Eliminat, Ft Worth, TX USA. [Slocum, Philip] Touro Univ Vallejo, Calif Coll Osteopath Med, Vallejo, CA USA. RP Pasipanodya, JG (reprint author), Sch Publ Hlth, Dept Hlth Management & Policy, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA. EM jpasipanodya@hotmail.com RI Moonan, Patrick/F-4307-2014; OI Moonan, Patrick/0000-0002-3550-2065 FU Tuberculosis Epidemiologic Studies Consortium; Tuberculosis Trials Consortium of the CDC FX This work was made possible by the cooperation of the Tarrant County Public Health Department and the University of North Texas Health Science Center at Fort Worth, as well as both the U.S. Centers for Disease Control and Prevention. This research did not receive direct funding from these or other sources; however, the Tuberculosis Epidemiologic Studies Consortium and the Tuberculosis Trials Consortium of the CDC provided salary support for Drs. Fernandez, Miller, Pasipanodya, Vecino, and Weis, and Ms. Drewyer, although neither consortium directly funded this study nor had any role in study design, data collection, data analysis, data interpretation, nor writing this report. The authors have no significant conflicts of interest with any companies or organilations whose products or services may be discussed in this article. We thank Drs. Juliana Grant, Michael Iademarco, Phil LoBue, Eugene McCray, and Tom Navin for their thoughtful review and helpful comments to the manuscript. NR 51 TC 6 Z9 6 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD JUN PY 2013 VL 16 BP 433 EP 440 DI 10.1016/j.meegid.2013.02.015 PG 8 WC Infectious Diseases SC Infectious Diseases GA 166PM UT WOS:000320569500057 PM 23501297 ER PT J AU Harper, M Ashley, K AF Harper, Martin Ashley, Kevin TI Acid-Soluble Internal Capsules for Closed-Face Cassette Elemental Sampling and Analysis of Workplace Air SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE aerosol sampling; elemental analysis; internal capsule; occupational hygiene ID FILTER SAMPLES; WALL DEPOSITS; PERFORMANCE; METALS; SPECTROMETRY; DUSTS AB Airborne particles that are collected using closed-face filter cassettes (CFCs), which are used widely in the sampling of workplace aerosols, can deposit in places other than on the filter and thereby may not be included in the ensuing analysis. A technique for ensuring that internal non-filter deposits are included in the analysis is to collect airborne particles within an acid-soluble internal capsule that, following sampling, can be dissolved along with the filter for subsequent elemental analysis. An interlaboratory study (ILS) was carried out to evaluate the use of cellulosic CFC capsule inserts for their suitability in the determination of trace elements in airborne samples. The ILS was performed in accordance with an applicable ASTM International standard practice, ASTM E691, which describes statistical procedures for investigating interlaboratory precision. Performance evaluation materials consisted of prototype cellulose acetate capsules attached to mixed-cellulose ester filters. Batches of capsules were dosed with Pb-containing materials (standard aqueous solutions, and certified reference material soil and paint). Also, aerosol samples containing nine target analyte elements (As, Cd, Co, Cr, Cu, Fe, Pb, Mn, and Ni) were generated using a multiport sampler; various concentrations and sampling times were employed to yield samples fortified at desired loading levels. Triplicates of spiked capsules at three different loadings were conveyed to each volunteer laboratory; loading levels were unknown to the participants. The laboratories were asked to prepare the samples by acid dissolution and to analyze aliquots of extracted samples by atomic spectrometry in accordance with applicable ASTM International Standards. Participants were asked to report their results in units of g of each target element per sample. For the elements investigated, inter-laboratory precision and recovery estimates from the participating laboratories demonstrated the utility of the cellulosic capsule inserts for the measurement of sampled trace elements. C1 [Harper, Martin] NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA. [Ashley, Kevin] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. RP Harper, M (reprint author), NIOSH, Hlth Effects Lab Div, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM zzg7@cdc.gov FU CDC/NIOSH National Occupational Research Agenda (NORA) exposure assessment project FX We are extremely grateful to the volunteer laboratories for their participation in this study. The authors thank Ronnee Andrews (NIOSH), Owen Butler (HSL), and LeRoy Dobson (WOHL) for their technical assistance with preliminary experiments; David Bartley (Consultant) for his insights into the ASTM International ILS procedure; and Eli Smyrloglou (ES Consulting) for his work with and knowledge of filters. Finally, we would like to thank David Binstock (RTI International) and Yngvar Thomassen (STAMI) for their discussions and assistance in preparing the test samples. This work was carried out under the auspices of a CDC/NIOSH National Occupational Research Agenda (NORA) exposure assessment project. NR 29 TC 8 Z9 8 U1 1 U2 8 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD JUN 1 PY 2013 VL 10 IS 6 BP 297 EP 306 DI 10.1080/15459624.2013.777310 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 172DL UT WOS:000320980100005 PM 23548078 ER PT J AU Borse, NN Rudd, RA Dellinger, AM Sleet, DA AF Borse, Nagesh N. Rudd, Rose A. Dellinger, Ann M. Sleet, David A. TI Years of potential life lost from unintentional child and adolescent injuries - United States, 2000-2009 SO JOURNAL OF SAFETY RESEARCH LA English DT Article DE Childhood injuries; Unintentional Injuries; Burden of Disease AB Introduction: Quantifying years of potential life lost (YPLL) highlights childhood causes of mortality and provides a simple method to identify important causes of premature death. Methods: CDC analyzed data from the National Vital Statistics System multiple cause of death files for 2000-2009. Results: An average of 890 YPLL were lost each year due to unintentional injuries for every 100,000 persons aged 0-19 years. YPLL rates differed by sex, age group, race/ethnicity, injury mechanism and state. Conclusions: This report provides new information which can be used to prioritize interventions and identify subgroups of the population most at risk. (C) 2013 National Safety Council and Elsevier Ltd. All rights reserved. C1 [Borse, Nagesh N.] CDC, Ctr Global Hlth, Atlanta, GA 30333 USA. [Rudd, Rose A.; Dellinger, Ann M.; Sleet, David A.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Dellinger, AM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,MS F-62, Atlanta, GA 30341 USA. EM nborse@cdc.gov; adellinger@cdc.gov NR 10 TC 3 Z9 3 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 J9 J SAFETY RES JI J. Saf. Res. PD JUN PY 2013 VL 45 BP 127 EP 131 DI 10.1016/j.jsr.2013.02.001 PG 5 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 164SK UT WOS:000320429600015 PM 23708484 ER PT J AU Kapellusch, JM Garg, A Bao, SS Silverstein, BA Burt, SE Dale, AM Evanoff, BA Gerr, FE Harris-Adamson, C Hegmann, KT Merlino, LA Rempel, DM AF Kapellusch, Jay M. Garg, Arun Bao, Stephen S. Silverstein, Barbara A. Burt, Susan E. Dale, Ann Marie Evanoff, Bradley A. Gerr, Frederic E. Harris-Adamson, Carisa Hegmann, Kurt T. Merlino, Linda A. Rempel, David M. TI Pooling job physical exposure data from multiple independent studies in a consortium study of carpal tunnel syndrome SO ERGONOMICS LA English DT Article DE methods; ergonomics; NIOSH distal upper extremity consortium; physical exposure data pooling; physical exposure data compatibility; exposure data analysis ID HAND ACTIVITY LEVEL; EXTREMITY MUSCULOSKELETAL DISORDERS; UPPER-LIMB DISORDERS; RISK-FACTORS; POOLED ANALYSES; REPETITIVE MOVEMENTS; PROSPECTIVE COHORT; CLERICAL WORKERS; STRAIN INDEX; PREVALENCE AB Pooling data from different epidemiological studies of musculoskeletal disorders (MSDs) is necessary to improve statistical power and to more precisely quantify exposure-response relationships for MSDs. The pooling process is difficult and time-consuming, and small methodological differences could lead to different exposure-response relationships. A sub-committee of a six-study research consortium studying carpal tunnel syndrome: (i) visited each study site, (ii) documented methods used to collect physical exposure data and (iii) determined compatibility of exposure variables across studies. Certain measures of force, frequency of exertion and duty cycle were collected by all studies and were largely compatible. A portion of studies had detailed data to investigate simultaneous combinations of force, frequency and duration of exertions. Limited compatibility was found for hand/wrist posture. Only two studies could calculate compatible Strain Index scores, but Threshold Limit Value for Hand Activity Level could be determined for all studies. Challenges of pooling data, resources required and recommendations for future researchers are discussed. Practitioner Summary: There is a need for standardised measures and measurement protocols of physical exposure for the upper extremity. This study may provide guidance for those planning to conduct an epidemiological study on quantified job physical exposures, or planning to merge physical exposure data from similar studies with some methodologic differences. C1 [Kapellusch, Jay M.] Univ Wisconsin, Dept Occupat Sci & Technol, Milwaukee, WI 53201 USA. [Garg, Arun] Univ Wisconsin, Ctr Ergon, Milwaukee, WI 53201 USA. [Bao, Stephen S.; Silverstein, Barbara A.] Washington State Dept Labor & Ind, Safety & Hlth Assessment & Res Prevent SHARP Prog, Olympia, WA 98504 USA. [Burt, Susan E.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Dale, Ann Marie; Evanoff, Bradley A.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA. [Gerr, Frederic E.; Merlino, Linda A.] Univ Iowa, Coll Publ Hlth, Dept Occupat & Environm Hlth, Iowa City, IA USA. [Harris-Adamson, Carisa] Samuel Merritt Univ, Dept Phys Therapy, Oakland, CA USA. [Hegmann, Kurt T.] Univ Utah, RMCOEH, Salt Lake City, UT USA. [Rempel, David M.] Univ Calif San Francisco, Div Occupat & Environm Med, San Francisco, CA 94143 USA. RP Kapellusch, JM (reprint author), Univ Wisconsin, Dept Occupat Sci & Technol, Milwaukee, WI 53201 USA. EM kap@uwm.edu RI Dale, Ann Marie/P-1382-2014; OI Dale, Ann Marie/0000-0002-5624-8967; Burt, Susan/0000-0002-4353-9773; Evanoff, Bradley A./0000-0003-0085-333X FU NIOSH [R01 OH009712] FX This research was funded in part by Grant Number R01 OH009712 from the NIOSH. NR 67 TC 11 Z9 11 U1 0 U2 14 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0014-0139 J9 ERGONOMICS JI Ergonomics PD JUN 1 PY 2013 VL 56 IS 6 BP 1021 EP 1037 DI 10.1080/00140139.2013.797112 PG 17 WC Engineering, Industrial; Ergonomics; Psychology, Applied; Psychology SC Engineering; Psychology GA 166UC UT WOS:000320582800011 PM 23697792 ER PT J AU Grigorescu, V Zhang, Y Kissin, D Sauber-Schatz, E Sunderam, M Kirby, R Diop, H McKane, P Jamieson, D AF Grigorescu, V. Zhang, Y. Kissin, D. Sauber-Schatz, E. Sunderam, M. Kirby, R. Diop, H. McKane, P. Jamieson, D. TI Maternal characteristics and pregnancy outcomes among women undergoing Assisted Reproductive Technology (ART) by infertility diagnosis: polycystic ovary syndrome versus tubal obstruction SO HUMAN REPRODUCTION LA English DT Meeting Abstract CT 29th Annual Meeting of the European-Society-of-Human-Reproduction-and-Embryology (ESHRE) CY JUL 07-10, 2013 CL London, ENGLAND SP European Soc Human Reprod & Embryol (ESHRE) C1 [Grigorescu, V.; Zhang, Y.; Kissin, D.; Sunderam, M.; Jamieson, D.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Sauber-Schatz, E.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Atlanta, GA USA. [Kirby, R.] Univ S Florida, Coll Publ Hlth, Dept Community & Family Hlth, Tampa, FL USA. [Diop, H.] Massachusetts Dept Publ Hlth, Bur Family Hlth & Nutr, Off Data Translat, Boston, MA USA. [McKane, P.] Michigan Dept Community Hlth, Bur Epidemiol, MCH Epidemiol Unit, Lansing, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 J9 HUM REPROD JI Hum. Reprod. PD JUN PY 2013 VL 28 SU 1 BP 8 EP 9 PG 2 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 165FD UT WOS:000320467700019 ER PT J AU Kawwass, JF Crawford, S Kissin, DM Session, DR Boulet, S Jamieson, DJ AF Kawwass, J. F. Crawford, S. Kissin, D. M. Session, D. R. Boulet, S. Jamieson, D. J. TI Tubal factor infertility and perinatal risk after assisted reproductive technology SO HUMAN REPRODUCTION LA English DT Meeting Abstract CT 29th Annual Meeting of the European-Society-of-Human-Reproduction-and-Embryology (ESHRE) CY JUL 07-10, 2013 CL London, ENGLAND SP European Soc Human Reprod & Embryol (ESHRE) C1 [Kawwass, J. F.] Emory Univ, Ctr Dis Control & Prevent, Gyn OB REI, Atlanta, GA 30322 USA. [Crawford, S.; Kissin, D. M.; Boulet, S.; Jamieson, D. J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Session, D. R.] Emory Univ, Gyn Ob REI, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 J9 HUM REPROD JI Hum. Reprod. PD JUN PY 2013 VL 28 SU 1 BP 290 EP 291 PG 2 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 165FD UT WOS:000320467700684 ER PT J AU Colborn, JM Smith, KA Townsend, J Damian, D Nasci, RS Mutebi, JP AF Colborn, James M. Smith, Kirk A. Townsend, John Damian, Dan Nasci, Roger S. Mutebi, John-Paul TI WEST NILE VIRUS OUTBREAK IN PHOENIX, ARIZONA-2010: ENTOMOLOGICAL OBSERVATIONS AND EPIDEMIOLOGICAL CORRELATIONS SO JOURNAL OF THE AMERICAN MOSQUITO CONTROL ASSOCIATION LA English DT Article DE West Nile virus; Phoenix; Arizona; vector index; infection rate; mosquito density ID AEDES-AEGYPTI; UNITED-STATES; RISK-FACTORS; CALIFORNIA; INFECTION; DISEASE; PREVALENCE; USA; SURVEILLANCE; TRANSMISSION AB In 2010, Arizona experienced an unusually early and severe outbreak of West Nile virus (WNV) centered in the southeast section of Maricopa County. Entomological data were collected before and during the outbreak, from May 25 through July 31, 2010, using the CO2-baited light trap monitoring system maintained by Maricopa County Vector Control. In the outbreak area, the most abundant species in the Town of Gilbert and in the area covered by the Roosevelt Water Conservation District was Culex quinquefasciatus, constituting 75.1% and 71.8% of the total number of mosquitoes collected, respectively. Vector index (VI) profiles showed that the abundance of infected Cx. quinquefasciatus peaked prior to human cases, suggesting that this species was involved in the initiation of the outbreak. In contrast, the VI profiles for Cx. tarsalis were consistently low, suggesting limited involvement in initiating and sustaining transmission. Taken together, the higher abundance and the VI profiles strongly suggest that Cx. quinquefasciatus was the primary vector for this outbreak. The VI profiles consistently showed that the abundance of infected mosquitoes peaked 1 to 2 wk before the peaks of human cases, suggesting that VI could have successfully been utilized to predict the WNV outbreak in Maricopa County, AZ, in 2010. C1 [Colborn, James M.] Ctr Dis Control & Prevent, Presidents Malaria Initiat, Malaria Branch, Ctr Global Hlth,Div Parasit Dis & Malaria, Atlanta, GA 30316 USA. [Smith, Kirk A.; Townsend, John] Maricopa Cty Environm Serv, Vector Control Div, Phoenix, AZ 85009 USA. [Damian, Dan] Maricopa Cty Reg Dev Serv Agcy, Phoenix, AZ 85009 USA. [Nasci, Roger S.; Mutebi, John-Paul] Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA. RP Mutebi, JP (reprint author), Ctr Dis Control & Prevent, 3150 Rampart Rd, Ft Collins, CO 80521 USA. NR 40 TC 8 Z9 8 U1 0 U2 13 PU AMER MOSQUITO CONTROL ASSOC PI MOUNT LAUREL PA 15000 COMMERCE PARKWAY, SUITE C, MOUNT LAUREL, NJ 08054 USA SN 8756-971X J9 J AM MOSQUITO CONTR JI J. Am. Mosq. Control Assoc. PD JUN PY 2013 VL 29 IS 2 BP 123 EP 132 DI 10.2987/13-6326r.1 PG 10 WC Entomology SC Entomology GA 161DI UT WOS:000320171500005 PM 23923326 ER PT J AU Sejvar, JJ Zegarra, JA Jackson, BR Lopez-Gatell, H Philen, R Fonseco-Ford, M Mahon, B Arzate, F Lopez, B Weiss, J Kamatsu, K Muley, S Lahda, S Talkington, D Waterman, S AF Sejvar, J. J. Zegarra, J. A. Jackson, B. R. Lopez-Gatell, H. Philen, R. Fonseco-Ford, M. Mahon, B. Arzate, F. Lopez, B. Weiss, J. Kamatsu, K. Muley, S. Lahda, S. Talkington, D. Waterman, S. CA GBS Outbreak Invest Team TI CLINICAL, EPIDEMIOLOGIC, AND LABORATORY FEATURES OF AN OUTBREAK OF CAMPYLOBACTER-ASSOCIATED GUILLAIN-BARRE SYNDROME ALONG THE UNITED STATES/MEXICO BORDER SO JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM LA English DT Meeting Abstract CT Meeting of the Peripheral-Nerve-Society CY JUN 29-JUL 03, 2013 CL Saint Malo, FRANCE SP Peripheral Nerve Soc C1 [Sejvar, J. J.; Jackson, B. R.; Philen, R.; Fonseco-Ford, M.; Mahon, B.; Talkington, D.; Waterman, S.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Zegarra, J. A.] Unidad Vigilancia Epidemiol, Hermosillo, Sonora, Mexico. [Lopez-Gatell, H.; Arzate, F.] Direcc Gen Epidemiol, Mexico City, DF, Mexico. [Lopez, B.] Yuma Cty Hlth Dept, Yuma, AZ USA. [Weiss, J.; Kamatsu, K.] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. [Muley, S.; Lahda, S.] Barrow Neurol Inst, Phoenix, AZ 85013 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1085-9489 J9 J PERIPHER NERV SYST JI J. Peripher. Nerv. Syst. PD JUN PY 2013 VL 18 SU 2 BP 104 EP 104 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 167GT UT WOS:000320620200266 ER PT J AU West, BA Naumann, RB AF West, Bethany A. Naumann, Rebecca B. TI Disparities in Motor Vehicle-Related Deaths Among Females-United States, 2005-2009 SO JOURNAL OF WOMENS HEALTH LA English DT Article ID BELT USE; INTERVENTIONS; REVIEWS; CRASHES; SEATS AB Background: In 2010, almost 11,000 females were killed in motor vehicle crashes, and racial/ethnic minorities were affected disproportionally. Methods: To assess disparities in motor vehicle-related death rates by race/ethnicity among females in the United States, the Centers for Disease Control and Prevention analyzed 2005-2009 data from the National Vital Statistics System. Death rates and corresponding 95% confidence intervals were calculated, and differences between 2005 and 2009 death rates were examined. Results: The motor vehicle-related death rate for females was 6.8 deaths per 100,000 population in 2009. American Indian/Alaska Native females had the highest motor vehicle-related death rates, followed by whites, blacks, Hispanics, and Asian/Pacific Islanders. The greatest decrease in death rates between 2005 and 2009 occurred among whites from a rate of 9.4 per 100,000 population (95% CI: 9.2-9.6) to 7.1 per 100,000 population (95% CI: 6.9-7.2; absolute rate change: -2.3; p < 0.001). Conclusion: Despite the recent declines in motor vehicle-related death rates noted in this article, the need remains for increased use of evidence-based strategies to reduce the burden of motor vehicle-related deaths among females overall and especially among American Indian/Alaska Natives. C1 [West, Bethany A.; Naumann, Rebecca B.] Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP West, BA (reprint author), Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, 4770 Buford Highway NE,MS F-62, Atlanta, GA 30341 USA. EM bwest2@cdc.gov NR 18 TC 1 Z9 1 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD JUN PY 2013 VL 22 IS 6 BP 471 EP 474 DI 10.1089/jwh.2013.4365 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 161BE UT WOS:000320164600001 PM 23751162 ER PT J AU Soucie, JM De Staercke, C Monahan, PE Recht, M Chitlur, MB Gruppo, R Hooper, WC Kessler, C Kulkarni, R Manco-Johnson, MJ Powell, J Pyle, M Riske, B Sabio, H Trimble, S AF Soucie, J. Michael De Staercke, Christine Monahan, Paul E. Recht, Michael Chitlur, Meera B. Gruppo, Ralph Hooper, W. Craig Kessler, Craig Kulkarni, Roshni Manco-Johnson, Marilyn J. Powell, Jerry Pyle, Meredith Riske, Brenda Sabio, Hernan Trimble, Sean CA US Hemophilia Treatment Ctr Networ TI Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening SO TRANSFUSION LA English DT Article ID RHEUMATOID-ARTHRITIS; DNA; INFECTION; INDIVIDUALS; ANTIBODIES; EXPOSURE; PROTEIN; RANGE AB BACKGROUND: Parvovirus B19 (B19V) is a small, nonenveloped virus that typically causes a benign flu-like illness that occurs most frequently in childhood. The virus is resistant to current viral inactivation steps used in the manufacture of antihemophilic factor concentrates and B19V transmission through these products has been documented. Since 2000, B19V nucleic acid test (NAT) screening of plasma pools has been implemented to further decrease the viral burden in these products, but no study has examined populations using these products to assess the impact of the screening on B19V transmission. STUDY DESIGN AND METHODS: Blood specimens obtained from participants of a surveillance system established in federally supported specialized bleeding disorders clinics were used in a B19V seroprevalence study. RESULTS: A total of 1643 specimens from 1043 participants age 2 to 7 years born after B19V NAT screening was implemented were tested. Age-specific prevalence rates were generally higher for subjects exposed to either plasma-derived products alone or in combination with other products compared to subjects with no exposure to antihemophilic products. Overall, compared to participants unexposed to blood or blood products, those exposed to plasma-derived products alone were 1.7 times more likely to have antibodies to B19V (p=0.002). CONCLUSION: These results are consistent with continued B19V transmission through plasma-derived factor concentrates. Effective viral inactivation and detection processes are needed to protect users of these products from infection with B19V or other new or emerging viruses. C1 Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. Univ N Carolina, Chapel Hill, NC USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Childrens Hosp Michigan, Detroit, MI 48201 USA. Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. Lombardi Canc Ctr, Washington, DC USA. Michigan State Univ, E Lansing, MI 48824 USA. Univ Colorado, Sch Med, Aurora, CO USA. Univ Calif Davis, Sacramento, CA 95817 USA. Wake Forest Univ, Winston Salem, NC 27109 USA. RP Soucie, JM (reprint author), Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, 1600 Clifton Rd,MS E64, Atlanta, GA 30333 USA. EM msoucie@cdc.gov RI Chitlur, Meera/G-2913-2015; Kerlin, Bryce/E-3369-2011 OI Kerlin, Bryce/0000-0002-1756-8271 FU Centers for Disease Control and Prevention; Hemophilia Treatment Center Network (HTCN) FX The Universal Data Collection (UDC) Project is funded by a cooperative agreement between the Centers for Disease Control and Prevention and the Hemophilia Treatment Center Network (HTCN) comprised of comprehensive care clinics located throughout the United States and its territories. The principal investigators are as follows: Doreen Brettler, MD, Worcester, MA; Regina Butler, RN, Philadelphia, PA; Patricia Dominic, Atlanta, GA; Ivan C. Harner, FACHE, Ypsilanti, MI; Marilyn Manco-Johnson, MD, Aurora, CO; Paul Monahan, Chapel Hill, NC; Diane Nugent, MD, Orange, CA; Michael Recht, MD, PhD, Portland, OR; Kathleen Roach, MPH, MBA, Milwaukee, WI; Christopher E. Walsh, MD, New York, NY; and Brian Wicklund, MD, Kansas City, MO. The authors also acknowledge the staff of the HTCN for patient recruitment and data collection, the patients for their participation in the study, and Meredith Oakley MPH, DVM, for UDC project coordination. NR 30 TC 19 Z9 19 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 J9 TRANSFUSION JI Transfusion PD JUN PY 2013 VL 53 IS 6 BP 1217 EP 1225 DI 10.1111/j.1537-2995.2012.03907.x PG 9 WC Hematology SC Hematology GA 161HI UT WOS:000320183000011 PM 22998193 ER PT J AU Gaiter, JL Johnson, WD Taylor, E Thadiparthi, S Duncan-Alexander, T Lemon, C Turner, A Hickman, D Brown, D Aponte, E Kimbrough, L Prather, C AF Gaiter, Juarlyn L. Johnson, Wayne D. Taylor, Eboni Thadiparthi, Sekhar Duncan-Alexander, Thalia Lemon, Carla Turner, Amana Hickman, Debra Brown, Donald Aponte, Expedito Kimbrough, Lisa Prather, Cynthia TI SISTERS EMPOWERED, SISTERS AWARE: THREE STRATEGIES TO RECRUIT AFRICAN AMERICAN WOMEN FOR HIV TESTING SO AIDS EDUCATION AND PREVENTION LA English DT Article ID 7 US CITIES; DEMONSTRATION PROJECT; INFECTION; PREVENTION; COMMUNITY; SETTINGS; NETWORKS; ORGANIZATIONS; PERSPECTIVES; DISPARITIES AB African American women account for 66% of new HIV infections among U.S. women, and many are not aware of their status. The authors compared three strategies (targeted outreach, alternate venues, and social networks) to recruit African American women for HIV testing in Houston, New York City, Baltimore, and Dayton. A quasi-experimental design (N = 4,942) was used to compare HIV-positivity rates and to identify risk factors for previously undiagnosed infection. A total of 2.1% of the women were newly diagnosed with HIV. The proportion newly identified as HIV-positive did not differ significantly among the three strategies (2.4% for social networks, 1.7% for both targeted outreach and alternate venues). However, the social networks strategy recruited women with greater risk behaviors and other characteristics associated with newly identified HIV infection and thus may be effective at reaching some high-risk women before they become infected. C1 [Gaiter, Juarlyn L.; Johnson, Wayne D.; Taylor, Eboni; Kimbrough, Lisa; Prather, Cynthia] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Thadiparthi, Sekhar] Emergint Technol Inc, Atlanta, GA USA. [Duncan-Alexander, Thalia; Lemon, Carla] Wright State Univ, Boonshoft Sch Med, Dayton, OH 45435 USA. [Turner, Amana] Change Happens Inc, Houston, TX USA. [Hickman, Debra] Sisters Together & Reaching Inc, Baltimore, MD USA. [Brown, Donald] Johns Hopkins Univ, Baltimore, MD USA. [Aponte, Expedito] Harlem United Inc, New York, NY USA. RP Johnson, WD (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Prevent Res Branch, 1600 Clifton Rd,Mailstop E-37, Atlanta, GA 30333 USA. EM WJohnson@cdc.gov FU NCHHSTP CDC HHS [5U62 PS000186-04, 5U62 PS000206-04, 5U62 PS000182-04, 5U62 PS000199-04]; PHS HHS [06-603] NR 31 TC 1 Z9 1 U1 3 U2 16 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0899-9546 J9 AIDS EDUC PREV JI Aids Educ. Prev. PD JUN PY 2013 VL 25 IS 3 BP 190 EP 202 PG 13 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA 158EX UT WOS:000319953400002 PM 23631714 ER PT J AU Fasula, AM Fogel, CI Gelaude, D Carry, M Gaiter, J Parker, S AF Fasula, Amy M. Fogel, Catherine I. Gelaude, Deborah Carry, Monique Gaiter, Juarlyn Parker, Sharon TI PROJECT POWER: ADAPTING AN EVIDENCE-BASED HIV/STI PREVENTION INTERVENTION FOR INCARCERATED WOMEN SO AIDS EDUCATION AND PREVENTION LA English DT Article ID RISK REDUCTION MODEL; BEHAVIORAL INTERVENTIONS; CONDOM USE; HIV/AIDS AB Incarcerated women are a critical population for targeted HIV/STI prevention programming; however, there is a dearth of evidence-based, gender-specific behavioral interventions for this population. Systematically adapting existing evidence-based interventions (EBIs) can help fill this gap. We illustrate the adaptation of the HIV/STI prevention EBI, Project Safe, for use among incarcerated women and delivery in prisons. Project POWER, the final adapted intervention, was developed using formative research with prison staff and administration, incarcerated and previously incarcerated women, and input of community advisory boards. Intervention delivery adaptations included: shorter, more frequent intervention sessions; booster sessions prior to and just after release; facilitator experience in prisons and counseling; and new videos. Intervention content adaptations addressed issues of empowerment, substance use, gender and power inequity in relationships, interpersonal violence, mental health, reentry, and social support. This illustration of the adaption process provides information to inform additional efforts to adapt EBIs for this underserved population. C1 [Fasula, Amy M.; Gelaude, Deborah; Carry, Monique; Gaiter, Juarlyn] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Fogel, Catherine I.] Univ N Carolina, Chapel Hill Sch Nursing, Chapel Hill, NC 27515 USA. [Parker, Sharon] Brown Univ, Miriam Hosp, Div Infect Dis, Providence, RI USA. [Parker, Sharon] Brown Univ, Warren Alpert Sch Med, Providence, RI USA. RP Fasula, AM (reprint author), Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-37, Atlanta, GA 30333 USA. EM afasula@cdc.gov FU NCHHSTP CDC HHS [UR6PS000670]; NIAID NIH HHS [P30 AI050410, P30AI042853]; NIDA NIH HHS [T32 DA013911]; NIMH NIH HHS [R25 MH083620] NR 16 TC 10 Z9 10 U1 2 U2 12 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0899-9546 J9 AIDS EDUC PREV JI Aids Educ. Prev. PD JUN PY 2013 VL 25 IS 3 BP 203 EP 215 PG 13 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA 158EX UT WOS:000319953400003 PM 23631715 ER PT J AU Brown, IJ Dyer, AR Chan, Q Cogswell, ME Ueshima, H Stamler, J Elliott, P AF Brown, Ian J. Dyer, Alan R. Chan, Queenie Cogswell, Mary E. Ueshima, Hirotsugu Stamler, Jeremiah Elliott, Paul CA INTERSALT Cooperative Res Grp TI Estimating 24-Hour Urinary Sodium Excretion From Casual Urinary Sodium Concentrations in Western Populations SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE nutrition assessment; population surveillance; sodium intake ID REDUCED DIETARY-SODIUM; BLOOD-PRESSURE; SALT INTAKE; ELECTROLYTE EXCRETION; METHODOLOGICAL PROBLEMS; CREATININE EXCRETION; POTASSIUM EXCRETION; INTERSALT; HYPERTENSION; METAANALYSIS AB High intakes of dietary sodium are associated with elevated blood pressure levels and an increased risk of cardiovascular disease. National and international guidelines recommend reduced sodium intake in the general population, which necessitates population-wide surveillance. We assessed the utility of casual (spot) urine specimens in estimating 24-hour urinary sodium excretion as a marker of sodium intake in the International Cooperative Study on Salt, Other Factors, and Blood Pressure. There were 5,693 participants recruited in 19841987 at the ages of 2059 years from 29 North American and European samples. Participants were randomly assigned to test or validation data sets. Equations derived from casual urinary sodium concentration and other variables in the test data were applied to the validation data set. Correlations between observed and estimated 24-hour sodium excretion were 0.50 for individual men and 0.51 for individual women; the values were 0.79 and 0.71, respectively, for population samples. Bias in mean values (observed minus estimated) was small; for men and women, the values were 1.6 mmol per 24 hours and 2.3 mmol per 24 hours, respectively, at the individual level and 1.8 mmol per 24 hours and 2.2 mmol per 24 hours, respectively, at the population level. Proportions of individuals with urinary 24-hour sodium excretion above the recommended levels were slightly overestimated by the models. Casual urine specimens may be a useful, low-burden, low-cost alternative to 24-hour urine collections for estimation of population sodium intakes; ongoing calibration with study-specific 24-hour urinary collections is recommended to increase validity. C1 [Brown, Ian J.; Chan, Queenie; Elliott, Paul] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, London W2 1PG, England. [Dyer, Alan R.; Stamler, Jeremiah] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. [Cogswell, Mary E.] Ctr Dis Control & Prevent, Epidemiol & Surveillance Branch, Natl Ctr Chron Dis & Hlth Promot, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. [Ueshima, Hirotsugu] Shiga Univ Med Sci, Dept Hlth Sci, Otsu, Shiga 52021, Japan. [Elliott, Paul] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Med Res Council Hlth Protect Agcy Ctr Environm &, London W2 1PG, England. RP Elliott, P (reprint author), Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, MRC HPA Ctr Environm & Hlth, St Marys Campus,Norfolk Pl, London W2 1PG, England. EM p.elliott@imperial.ac.uk RI Chan, Queenie/C-5017-2011 OI Chan, Queenie/0000-0001-9278-230X FU United States Centers for Disease Control and Prevention (Atlanta, Georgia) [200-2010-43842]; Council on Epidemiology and Prevention of the World Heart Federation (Geneva, Switzerland); World Health Organization (Geneva, Switzerland); International Society of Hypertension (Ware, United Kingdom); Wellcome Trust (London, United Kingdom); National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, Maryland); Heart and Stroke Foundation of Canada (Ottawa, Ontario); British Heart Foundation (London, Great Britain); Japan Heart Foundation (Tokyo, Japan); Netherlands Heart Foundation (Den Haag, Netherlands); Chicago Health Research Foundation (Chicago, Illinois); Belgian National Research Foundation (Brussels, Belgium); Parastatal Insurance Company (Brussels, Belgium); National Institute for Health Research (NIHR) Biomedical Research Centre at Imperial College Healthcare National Health Service (NHS) Trust; Imperial College FX This work was supported by United States Centers for Disease Control and Prevention contract number 200-2010-43842 (Atlanta, Georgia). The International Cooperative Study on Salt, Other Factors, and Blood Pressure (INTERSALT) was supported by the Council on Epidemiology and Prevention of the World Heart Federation (Geneva, Switzerland); the World Health Organization (Geneva, Switzerland); the International Society of Hypertension (Ware, United Kingdom); the Wellcome Trust (London, United Kingdom); the National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, Maryland); the Heart and Stroke Foundation of Canada (Ottawa, Ontario); the British Heart Foundation (London, Great Britain); the Japan Heart Foundation (Tokyo, Japan); Netherlands Heart Foundation (Den Haag, Netherlands); the Chicago Health Research Foundation (Chicago, Illinois); the Belgian National Research Foundation (Brussels, Belgium); Parastatal Insurance Company (Brussels, Belgium); and by many national agencies supporting local studies. P. E. acknowledges support from the National Institute for Health Research (NIHR) Biomedical Research Centre at Imperial College Healthcare National Health Service (NHS) Trust and Imperial College. P. E. is an NIHR senior investigator. NR 47 TC 45 Z9 46 U1 2 U2 19 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 1 PY 2013 VL 177 IS 11 BP 1180 EP 1192 DI 10.1093/aje/kwt066 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 155MM UT WOS:000319752400002 PM 23673246 ER PT J AU Elliott, P Brown, IJ Dyer, AR Chan, Q Ueshima, H Stamler, J AF Elliott, Paul Brown, Ian J. Dyer, Alan R. Chan, Queenie Ueshima, Hirotsugu Stamler, Jeremiah CA INTERSALT Cooperative Res Grp TI Elliott et al. Respond to Quantifying Urine Sodium Excretion SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Editorial Material ID BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; ELECTROLYTE EXCRETION; RISK; INTERSALT; EVENTS C1 [Elliott, Paul; Brown, Ian J.; Chan, Queenie] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, London W2 1PG, England. [Dyer, Alan R.; Stamler, Jeremiah] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA. Ctr Dis Control & Prevent, Epidemiol & Surveillance Branch, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis & Hlth Promot, Atlanta, GA USA. [Ueshima, Hirotsugu] Shiga Univ Med Sci, Dept Hlth Sci, Otsu, Shiga 52021, Japan. [Elliott, Paul] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Med Res Council Hlth Protect Agcy Ctr Environm &, London W2 1PG, England. RP Elliott, P (reprint author), Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, MRC HPA Ctr Environm & Hlth, St Marys Campus,Norfolk Pl, London W2 1PG, England. EM p.elliott@imperial.ac.uk RI Chan, Queenie/C-5017-2011 OI Chan, Queenie/0000-0001-9278-230X NR 11 TC 2 Z9 2 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 1 PY 2013 VL 177 IS 11 BP 1196 EP 1198 DI 10.1093/aje/kwt065 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 155MM UT WOS:000319752400004 ER PT J AU Tinker, SC Gibbs, C Strickland, MJ Devine, OJ Crider, KS Werler, MM Anderka, MT Reefhuis, J AF Tinker, Sarah C. Gibbs, Cassandra Strickland, Matthew J. Devine, Owen J. Crider, Krista S. Werler, Martha M. Anderka, Marlene T. Reefhuis, Jennita CA Natl Birth Defects Prevention TI Impact of Time to Maternal Interview on Interview Responses in the National Birth Defects Prevention Study SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE bias (epidemiology); case-control studies; interviews as topic ID UNITED-STATES; PREGNANCY; RECALL; ACCURACY; MOTHERS; EVENTS; WEIGHT AB Prenatal exposures often are assessed using retrospective interviews. Time from exposure to interview may influence data accuracy. We investigated the association of time to interview (TTI) with aspects of interview responses in the National Birth Defects Prevention Study, a population-based case-control study of birth defects in 10 US states. Mothers completed a computer-assisted telephone interview 1.524 months after their estimated date of delivery. Proxy metrics for interview quality were whether certain exposures were reported, whether the start month of reported medication use or illness was reported, or whether responses were missing. Interaction by case status was assessed. Interviews were completed with 30,542 mothers (22,366 cases and 8,176 controls) who gave birth between 1997 and 2007. Mothers of cases were interviewed later than were mothers of controls (11.7 months vs. 9.5 months, respectively). In adjusted analyses, having a TTI that was greater than 6 months was associated with only a few aspects of interview responses (e.g., start month of pseudoephedrine use). Interaction by case-control status was observed for some exposures; mothers of controls had a greater reduction in interview quality with increased TTI in these instances (e.g., report of morning sickness, start month of acetaminophen use and ibuprofen use). The results suggest that TTI might impact interview responses; however, the impact may be minimal and specific to the type of exposure. C1 [Tinker, Sarah C.; Devine, Owen J.; Crider, Krista S.; Reefhuis, Jennita] US Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Gibbs, Cassandra] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Strickland, Matthew J.] Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30322 USA. [Werler, Martha M.] Boston Univ, Sch Publ Hlth, Slone Epidemiol Ctr, Boston, MA USA. [Anderka, Marlene T.] Massachusetts Dept Publ Hlth, Boston, MA USA. RP Tinker, SC (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop E86, Atlanta, GA 30333 USA. EM zzu9@cdc.gov OI Werler, Martha/0000-0003-3392-6814 FU Centers for Disease Control and Prevention [96043, 02081, DD09-001] FX This work was supported through cooperative agreements under Program Announcement 96043, Program Announcement 02081, and Funding Opportunity Announcement DD09-001 from the Centers for Disease Control and Prevention to the Centers for Birth Defects Research and Prevention that participated in the National Birth Defects Prevention Study. Coding of drug information in the National Birth Defects Prevention Study used the Slone Drug Dictionary, under license from the Slone Epidemiology Center at Boston University, Boston, Massachusetts. NR 16 TC 9 Z9 9 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 1 PY 2013 VL 177 IS 11 BP 1225 EP 1235 DI 10.1093/aje/kws352 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 155MM UT WOS:000319752400008 PM 23645625 ER PT J AU Rha, B AF Rha, Brian TI Update: Severe Respiratory Illness Associated With a Novel CoronavirusWorldwide, 2012-2013 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Editorial Material C1 CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, EIS, Atlanta, GA 30333 USA. RP Rha, B (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, EIS, Atlanta, GA 30333 USA. EM wif8@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2013 VL 13 IS 6 BP 1606 EP 1607 DI 10.1111/ajt.12320 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA 154WM UT WOS:000319706900029 ER PT J AU Fischer, PU Curtis, KC Folk, SM Wilkins, PP Marcos, LA Weil, GJ AF Fischer, Peter U. Curtis, Kurt C. Folk, Scott M. Wilkins, Patricia P. Marcos, Luis A. Weil, Gary J. TI Serological Diagnosis of North American Paragonimiasis by Western Blot Using Paragonimus kellicotti Adult Worm Antigen SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID MISSOURI; IMMUNODIAGNOSIS; IDENTIFICATION; COMPONENTS; CRAYFISH; CLONING; RAW AB We studied the value of an IgG Western blot (WB) with Paragonimus kellicotti (Pk) antigen for diagnosis of North American paragonimiasis. The test was evaluated with sera from patients with Pk and Paragonimus westermani infections, with control sera from patients with other helminth infections, and sera from healthy Americans. All 11 proven Pk infection sera and two samples from suspected cases that were negative by P. westermani WB at the Centers for Disease Control and Prevention (CDC) contained antibodies to antigens at 34 kDa and at 21/23 kDa. Seven of 7 P. westermani sera contained antibodies to the 34 kDa antigen, but only 2 recognized the 21/23 kDa doublet. No control samples were reactive with these antigens. Antibody reactivity declined after praziquantel treatment. Thus, the P. kellicotti WB appears to be superior to P. westermani WB for diagnosing Pk infections, and it may be useful for assessing responses to treatment. C1 [Fischer, Peter U.] Washington Univ, Sch Med, Dept Internal Med, Div Infect Dis, St Louis, MO 63110 USA. Heartland Reg Med Ctr, St Joseph, MO USA. Ctr Dis Control & Prevent, Atlanta, GA USA. RP Fischer, PU (reprint author), Washington Univ, Sch Med, Dept Internal Med, Div Infect Dis, 660 S Euclid Ave, St Louis, MO 63110 USA. EM Pufische@DOM.Wustl.edu FU Barnes Jewish Hospital Foundation FX This study was supported by a grant from the Barnes Jewish Hospital Foundation. NR 20 TC 7 Z9 7 U1 0 U2 6 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUN PY 2013 VL 88 IS 6 BP 1035 EP 1040 DI 10.4269/ajtmh.12-0720 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 158GO UT WOS:000319957700005 PM 23589531 ER PT J AU Papadi, B Boudreaux, C Tucker, JA Mathison, B Bishop, H Eberhard, ME AF Papadi, Bhavesh Boudreaux, Carole Tucker, J. Allan Mathison, Blaine Bishop, Henry Eberhard, Mark E. TI Case Report: Halicephalobus gingivalis: A Rare Cause of Fatal Meningoencephalomyelitis in Humans SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID OF-THE-LITERATURE; INFECTION; HORSE; MICRONEMA; DELETRIX AB The genus Halicephalobus consists of eight species of free-living nematodes. Only one species (H. gingivalis) has been reported to infect vertebrates. Human infection is extremely rare, and only four cases have been reported in the literature. These nematodes seem to exhibit neurotropism, but their life cycle, mode of infection, and risk factors are poorly understood. Neurohelminthiases are not commonly recognized in the United States and when they do occur, pose great diagnostic challenges because of lack of appropriate non-invasive screening and/or confirmatory tests. We report a challenging case of meningoencephalomyelitis caused by a Halicephalobus sp., in which the patient had a rapidly deteriorating clinical course. The case did not raise any clinical suspicion of neurohelminthiases, although increased eosinophils were present in the cerebrospinal fluid. This case presents an opportunity to highlight the importance of considering parasitic infection in meningoencephalitis or meningoencephalomyelitis presenting atypically. C1 Univ S Alabama, Med Ctr, Mobile, AL USA. [Mathison, Blaine; Bishop, Henry; Eberhard, Mark E.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA USA. [Papadi, Bhavesh] NCI, NIH, Bethesda, MD 20892 USA. [Boudreaux, Carole; Tucker, J. Allan] Univ S Alabama, Med Ctr, Dept Pathol, Mobile, AL USA. RP Papadi, B (reprint author), NCI, NIH, 10 Ctr Dr,Room 2A19, Bethesda, MD 20892 USA. EM bhavesh2papadi@yahoo.com; cboudrea@usouthal.edu; atucker@usouthal.edu; gqa4@cdc.gov; hsb2@cdc.gov; mle1@cdc.gov FU University of South Alabama Medical Center FX We thank the laboratory of University of South Alabama Medical Center for support. The American Committee on Clinical Tropical Medicine and Travelers' Health (ACCTMTH) assisted with publication expenses. NR 13 TC 4 Z9 4 U1 1 U2 8 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUN PY 2013 VL 88 IS 6 BP 1062 EP 1064 DI 10.4269/ajtmh.12-0730 PG 3 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 158GO UT WOS:000319957700009 PM 23509120 ER PT J AU Nofchissey, RA Deardorff, ER Blevins, TM Anishchenko, M Bosco-Lauth, A Berl, E Lubelczyk, C Mutebi, JP Brault, AC Ebel, GD Magnarelli, LA AF Nofchissey, Robert A. Deardorff, Eleanor R. Blevins, Tia M. Anishchenko, Michael Bosco-Lauth, Angela Berl, Erica Lubelczyk, Charles Mutebi, John-Paul Brault, Aaron C. Ebel, Gregory D. Magnarelli, Louis A. TI Seroprevalence of Powassan Virus in New England Deer, 1979-2010 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID WHITE-TAILED DEER; UNITED-STATES; TICK VIRUS; BORRELIA-BURGDORFERI; ANAPLASMA-PHAGOCYTOPHILUM; RECOMBINANT ANTIGENS; ENCEPHALITIS; TRANSMISSION; MAINE; ANTIBODIES AB Powassan virus and its subtype, deer tick virus, are closely related tick-borne flaviviruses that circulate in North America. The incidence of human infection by these agents appears to have increased in recent years. To define exposure patterns among white-tailed deer, potentially useful sentinels that are frequently parasitized by ticks, we screened serum samples collected during 1979-2010 in Connecticut, Maine, and Vermont for neutralizing antibody by using a novel recombinant deer tick virus-West Nile virus chimeric virus. Evidence of exposure was detected in all three states. Overall our results demonstrate that seroprevalence is variable in time and space, suggesting that risk of exposure to Powassan virus is similarly variable. C1 Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA. Connecticut Agr Expt Stn, Ctr Vector Biol & Zoonot Dis, New Haven, CT 06504 USA. [Anishchenko, Michael; Bosco-Lauth, Angela; Mutebi, John-Paul; Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. Vermont Dept Publ Hlth, Burlington, VT USA. [Lubelczyk, Charles] Maine Med Ctr Res Inst, Vector Borne Dis Lab, South Portland, ME USA. [Nofchissey, Robert A.] Univ New Mexico, Dept Med, Albuquerque, NM 87131 USA. [Deardorff, Eleanor R.] Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA. [Deardorff, Eleanor R.] Univ Texas Med Branch, Dept Expt Pathol, Galveston, TX 77555 USA. [Blevins, Tia M.; Magnarelli, Louis A.] Connecticut Agr Expt Stn, Dept Entomol, New Haven, CT 06504 USA. [Berl, Erica] Vermont Dept Hlth, Dept Infect Dis Epidemiol, Burlington, VT 05402 USA. [Magnarelli, Louis A.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. RP Ebel, GD (reprint author), Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Microbiol Immunol & Pathol, 1690 Campus Delivery, Ft Collins, CO 80523 USA. EM rnofchissey@salud.unm.edu; edeardorff@salud.unm.edu; tia.blevins@ct.gov; iot5@cdc.gov; mopargal@rams.colostate.edu; erica.berl@state.vt.us; lubelc@mmc.org; john-paul.mutebi@cdc.hhs.gov; acbrault1@mac.com; gregory.ebel@colostate.edu; louis.magnarelli@ct.gov RI Ebel, Gregory/D-8324-2017 FU National Institute of Allergy and Infectious Disease, National Institutes of Health [AI067380]; National Institute of General Medical Sciences under the University of New Mexico Academic Science Education and Research Training fellowship [K12GM088021] FX This study was supported in part by funds from the National Institute of Allergy and Infectious Disease, National Institutes of Health, under grant AI067380. Eleanor R. Deardorff was supported by Institutional Research and Academic Career Development Award K12GM088021 from the National Institute of General Medical Sciences under the University of New Mexico Academic Science Education and Research Training fellowship. NR 21 TC 4 Z9 4 U1 0 U2 7 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUN PY 2013 VL 88 IS 6 BP 1159 EP 1162 DI 10.4269/ajtmh.12-0586 PG 4 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 158GO UT WOS:000319957700023 PM 23568288 ER PT J AU Kuhn, JH Bao, YM Bavari, S Becker, S Bradfute, S Brister, JR Bukreyev, AA Cai, YY Chandran, K Davey, RA Dolnik, O Dye, JM Enterlein, S Gonzalez, JP Formenty, P Freiberg, AN Hensley, LE Honko, AN Ignatyev, GM Jahrling, PB Johnson, KM Klenk, HD Kobinger, G Lackemeyer, MG Leroy, EM Lever, MS Lofts, LL Muhlberger, E Netesov, SV Olinger, GG Palacios, G Patterson, JL Paweska, JT Pitt, L Radoshitzky, SR Ryabchikova, EI Saphire, EO Shestopalov, AM Smither, SJ Sullivan, NJ Swanepoel, R Takada, A Towner, JS van der Groen, G Volchkov, VE Wahl-Jensen, V Warren, TK Warfield, KL Weidmann, M Nichol, ST AF Kuhn, Jens H. Bao, Yiming Bavari, Sina Becker, Stephan Bradfute, Steven Brister, J. Rodney Bukreyev, Alexander A. Cai, Yingyun Chandran, Kartik Davey, Robert A. Dolnik, Olga Dye, John M. Enterlein, Sven Gonzalez, Jean-Paul Formenty, Pierre Freiberg, Alexander N. Hensley, Lisa E. Honko, Anna N. Ignatyev, Georgy M. Jahrling, Peter B. Johnson, Karl M. Klenk, Hans-Dieter Kobinger, Gary Lackemeyer, Matthew G. Leroy, Eric M. Lever, Mark S. Lofts, Loreen L. Muehlberger, Elke Netesov, Sergey V. Olinger, Gene G. Palacios, Gustavo Patterson, Jean L. Paweska, Janusz T. Pitt, Louise Radoshitzky, Sheli R. Ryabchikova, Elena I. Saphire, Erica Ollmann Shestopalov, Aleksandr M. Smither, Sophie J. Sullivan, Nancy J. Swanepoel, Robert Takada, Ayato Towner, Jonathan S. van der Groen, Guido Volchkov, Viktor E. Wahl-Jensen, Victoria Warren, Travis K. Warfield, Kelly L. Weidmann, Manfred Nichol, Stuart T. TI Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae SO ARCHIVES OF VIROLOGY LA English DT Article ID VERVET MONKEY DISEASE; MARBURG VIRUS; EBOLA-VIRUS; RHABDOVIRUS-SIMIAE; HEMORRHAGIC-FEVER; MOUSE MODEL; GUINEA-PIGS; VERO CELLS; INFECTION; AGENT AB The International Committee on Taxonomy of Viruses (ICTV) organizes the classification of viruses into taxa, but is not responsible for the nomenclature for taxa members. International experts groups, such as the ICTV Study Groups, recommend the classification and naming of viruses and their strains, variants, and isolates. The ICTV Filoviridae Study Group has recently introduced an updated classification and nomenclature for filoviruses. Subsequently, and together with numerous other filovirus experts, a consistent nomenclature for their natural genetic variants and isolates was developed that aims at simplifying the retrieval of sequence data from electronic databases. This is a first important step toward a viral genome annotation standard as sought by the US National Center for Biotechnology Information (NCBI). Here, this work is extended to include filoviruses obtained in the laboratory by artificial selection through passage in laboratory hosts. The previously developed template for natural filovirus genetic variant naming (< virus name > < isolation host-suffix >/< country of sampling >/< year of sampling >/< genetic variant designation >-< isolate designation >) is retained, but it is proposed to adapt the type of information added to each field for laboratory animal-adapted variants. For instance, the full-length designation of an Ebola virus Mayinga variant adapted at the State Research Center for Virology and Biotechnology "Vector" to cause disease in guinea pigs after seven passages would be akin to "Ebola virus VECTOR/C.porcellus-lab/COD/1976/Mayinga-GPA-P7". As was proposed for the names of natural filovirus variants, we suggest using the full-length designation in databases, as well as in the method section of publications. Shortened designations (such as "EBOV VECTOR/C.por/COD/76/May-GPA-P7") and abbreviations (such as "EBOV/May-GPA-P7") could be used in the remainder of the text depending on how critical it is to convey information contained in the full-length name. "EBOV" would suffice if only one EBOV strain/variant/isolate is addressed. C1 [Kuhn, Jens H.; Cai, Yingyun; Jahrling, Peter B.; Lackemeyer, Matthew G.; Wahl-Jensen, Victoria] NIAID, Integrated Res Facil Ft Detrick IRF Frederick, DCR, NIH, Frederick, MD 21702 USA. [Bao, Yiming; Brister, J. Rodney] Natl Lib Med, Informat Engn Branch, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA. [Bavari, Sina; Dye, John M.; Honko, Anna N.; Lofts, Loreen L.; Olinger, Gene G.; Palacios, Gustavo; Pitt, Louise; Radoshitzky, Sheli R.; Warren, Travis K.] USA, Med Res Inst Infect Dis, Frederick, MD USA. [Becker, Stephan; Dolnik, Olga; Klenk, Hans-Dieter] Univ Marburg, Inst Virol, D-35032 Marburg, Germany. [Bradfute, Steven] Univ New Mexico, Albuquerque, NM 87131 USA. [Bukreyev, Alexander A.; Freiberg, Alexander N.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA. [Bukreyev, Alexander A.; Freiberg, Alexander N.] Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77555 USA. [Chandran, Kartik] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA. [Davey, Robert A.; Patterson, Jean L.] Texas Biomed Res Inst, Dept Virol & Immunol, San Antonio, TX USA. [Enterlein, Sven; Warfield, Kelly L.] Integrated BioTherapeut Inc, Gaithersburg, MD USA. [Gonzalez, Jean-Paul] Inst Rech Dev, Dept Hlth, Marseille, France. [Gonzalez, Jean-Paul] Metabiota Inc, San Francisco, CA USA. [Formenty, Pierre] World Hlth Org, Geneva, Switzerland. [Hensley, Lisa E.] US FDA, Med Countermeasure Initiat, Silver Spring, MD USA. [Ignatyev, Georgy M.] Fed State Unitary Co Microgen Sci Ind Co Immunobi, Minist Hlth & Social Dept Russian Federat, Moscow, Russia. [Kobinger, Gary] Publ Hlth Agcy Canada, Special Pathogens Program, Natl Microbiol Lab, Winnipeg, MB, Canada. [Leroy, Eric M.] Ctr Int Rech Med Franceville, Franceville, Gabon. [Lever, Mark S.; Smither, Sophie J.] Dstl, Dept Biomed Sci, Salisbury, Wilts, England. [Muehlberger, Elke] Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA. [Muehlberger, Elke] Boston Univ, Sch Med, Natl Emerging Infect Dis Lab, Boston, MA 02118 USA. [Netesov, Sergey V.; Shestopalov, Aleksandr M.] Novosibirsk State Univ, Novosibirsk, Novosibirsk Obl, Russia. [Paweska, Janusz T.] Natl Hlth Lab Serv, Ctr Emerging & Zoonot Dis, Natl Inst Communicable Dis, Sandringham Johannesburg, Gauteng, South Africa. [Ryabchikova, Elena I.] Russian Acad Sci, Inst Chem Biol & Fundamental Med, Siberian Branch, Novosibirsk, Novosibirsk Obl, Russia. [Saphire, Erica Ollmann] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA. [Saphire, Erica Ollmann] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA. [Shestopalov, Aleksandr M.] State Res Ctr Virol & Biotechnol Vector, Koltsov, Novosibirsk Obl, Russia. [Sullivan, Nancy J.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. [Swanepoel, Robert] Univ Pretoria, Zoonoses Res Unit, ZA-0002 Pretoria, South Africa. [Takada, Ayato] Hokkaido Univ, Div Global Epidemiol, Res Ctr Zoonosis Control, Sapporo, Hokkaido, Japan. [Towner, Jonathan S.; Nichol, Stuart T.] Ctr Dis Control & Prevent CDC, VSPB, DHCPP, NCEZID, Atlanta, GA 30333 USA. [van der Groen, Guido] Prins Leopold Inst Trop Geneeskunde, Antwerp, Belgium. [Volchkov, Viktor E.] Univ Lyon, Lab Filovirus, Inserm U758, UCB Lyon 1,Ecole Normale Super Lyon, Lyon, France. [Weidmann, Manfred] Univ Med Gottingen, Abt Virol, Gottingen, Germany. RP Kuhn, JH (reprint author), NIAID, Integrated Res Facil Ft Detrick IRF Frederick, DCR, NIH, B-8200 Res Plaza, Frederick, MD 21702 USA. EM kuhnjens@mail.nih.gov; stn1@cdc.gov RI LEROY, Eric/I-4347-2016; Ryabchikova, Elena /G-3089-2013; Netesov, Sergey/A-3751-2013; Volchkov, Viktor/M-7846-2014; Kuhn, Jens H./B-7615-2011; Becker, Stephan/A-1065-2010; Palacios, Gustavo/I-7773-2015; Weidmann, Manfred/G-1817-2015; OI Gonzalez, Jean-Paul/0000-0003-3063-1770; Muhlberger, Elke/0000-0003-3547-9376; Honko, Anna/0000-0001-9165-148X; LEROY, Eric/0000-0003-0022-0890; Ryabchikova, Elena /0000-0003-4714-1524; Netesov, Sergey/0000-0002-7786-2464; Volchkov, Viktor/0000-0001-7896-8706; Kuhn, Jens H./0000-0002-7800-6045; Becker, Stephan/0000-0002-2794-5659; Palacios, Gustavo/0000-0001-5062-1938; Weidmann, Manfred/0000-0002-7063-7491; Shestopalov, Alexander/0000-0002-9734-0620; Olinger, Gene/0000-0001-7338-0292 FU Joint Science and Technology Office for Chem Bio Defense [TMTI0048_09_RD_T]; NIAID [HHSN272200200016I]; Intramural Research Program of the NIH, National Library of Medicine FX The content of this publication does not necessarily reflect the views or policies of the US Department of the Army, the US Department of Defense or the US Department of Health and Human Services or of the institutions and companies affiliated with the authors. This work was funded in part by the Joint Science and Technology Office for Chem Bio Defense (proposal #TMTI0048_09_RD_T to SB). YC, JHK, and VWJ performed this work as employees of Tunnell Consulting, Inc., and MGL as an employee of Lovelace Respiratory Research Institute, both subcontractors to Battelle Memorial Institute under its prime contract with NIAID, under Contract No. HHSN272200200016I. This research was also supported in part by the Intramural Research Program of the NIH, National Library of Medicine (YB and JRB). NR 42 TC 21 Z9 22 U1 1 U2 24 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0304-8608 EI 1432-8798 J9 ARCH VIROL JI Arch. Virol. PD JUN PY 2013 VL 158 IS 6 BP 1425 EP 1432 DI 10.1007/s00705-012-1594-2 PG 8 WC Virology SC Virology GA 155QK UT WOS:000319762800035 PM 23358612 ER PT J AU Kopec, JA Sayre, EC Schwartz, TA Renner, JB Helmick, CG Badley, EM Cibere, J Callahan, LF Jordan, JM AF Kopec, Jacek A. Sayre, Eric C. Schwartz, Todd A. Renner, Jordan B. Helmick, Charles G. Badley, Elizabeth M. Cibere, Jolanda Callahan, Leigh F. Jordan, Joanne M. TI Occurrence of Radiographic Osteoarthritis of the Knee and Hip Among African Americans and Whites: A Population-Based Prospective Cohort Study SO ARTHRITIS CARE & RESEARCH LA English DT Article ID 1ST NATIONAL-HEALTH; UNITED-STATES; RISK-FACTORS; PREVALENCE; ARTHRITIS; PROGRESSION; SYMPTOMS; LIMITATIONS; CAUCASIANS; OVERWEIGHT AB Objective To compare the incidence and progression of radiographic osteoarthritis (OA) in the knee and hip among African Americans and whites. Methods Using the joint as the unit of analysis, we analyzed data from the Johnston County Osteoarthritis Project, a population-based prospective cohort study in rural North Carolina. Baseline and followup assessments were 3-13 years apart. Assessments included standard knee and hip radiographs read for Kellgren/Lawrence (K/L) radiographic grade. Weighted analyses controlled for age, sex, body mass index, level of education, and baseline K/L grade; bootstrap methods adjusted for lack of independence between left and right joints. Time-to-event analysis was used to analyze the data. Results For radiographic knee OA, being African American had no association with incidence (adjusted hazard ratio [HRadj] 0.80, 95% confidence interval [95% CI] 0.53-1.22), but had a positive association with progression (HRadj 1.67, 95% CI 1.05-2.67). For radiographic hip OA, African Americans had a significantly lower incidence (HRadj 0.44, 95% CI 0.27-0.71), whereas the association with progression was positive but nonsignificant (HRadj 1.46, 95% CI 0.53-4.01). In sensitivity analyses, the association with hip OA incidence was robust to a wide range of assumptions. Conclusion African Americans are protected against incident hip OA, but may be more susceptible to progressive knee OA. C1 [Kopec, Jacek A.; Cibere, Jolanda] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Kopec, Jacek A.; Sayre, Eric C.; Cibere, Jolanda] Arthrit Res Ctr Canada, Richmond, BC, Canada. [Schwartz, Todd A.; Renner, Jordan B.; Callahan, Leigh F.; Jordan, Joanne M.] Univ N Carolina, Chapel Hill, NC USA. [Helmick, Charles G.] CDC, Atlanta, GA 30333 USA. [Badley, Elizabeth M.] Univ Toronto, Toronto, ON, Canada. RP Kopec, JA (reprint author), Univ British Columbia, Sch Populat & Publ Hlth, Milan Ilich Arthrit Res Ctr, 5591 3 Rd, Richmond, BC V6X 2C7, Canada. EM jkopec@arthritisresearch.ca RI Schwartz, Todd/D-4995-2012 OI Schwartz, Todd/0000-0002-0232-2543 FU CDC/Association of Schools of Public Health [S043, S3486]; Multipurpose Arthritis and Musculoskeletal Diseases Center [5-P60-AR-30701]; Multidisciplinary Clinical Research Center (National Institute of Arthritis and Musculoskeletal and Skin Diseases) [5-P60-AR49465] FX Supported by the CDC/Association of Schools of Public Health (grants S043 and S3486), the Multipurpose Arthritis and Musculoskeletal Diseases Center (grant 5-P60-AR-30701), and the Multidisciplinary Clinical Research Center (grant 5-P60-AR49465 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases). NR 25 TC 10 Z9 10 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD JUN PY 2013 VL 65 IS 6 BP 928 EP 935 DI 10.1002/acr.21924 PG 8 WC Rheumatology SC Rheumatology GA 155OY UT WOS:000319758900013 PM 23281251 ER PT J AU Ostchega, Y Hughes, JP Zhang, GY Nwankwo, T Chiappa, MM AF Ostchega, Yechiam Hughes, Jeffery P. Zhang, Guangyu Nwankwo, Tatiana Chiappa, Michele M. TI Mean mid-arm circumference and blood pressure cuff sizes for US adults: National Health and Nutrition Examination Survey, 1999-2010 SO BLOOD PRESSURE MONITORING LA English DT Article DE blood pressure cuff sizes; mid-arm circumference; National Health and Nutrition Examination Survey ID TRENDS; WIDTH AB Background Accurately measuring blood pressure (BP) requires choosing an appropriate BP cuff size. Objectives This study examined trends in mid-arm circumference (mid-AC) and distribution of BP cuff sizes using 1999-2002, 2003-2006, and 2007-2010 National Health and Nutrition Examination Survey (NHANES) data. Methods NHANES uses a complex multistage probability sample design to select participants who are representative of the entire civilian, noninstitutionalized US population. The analytic sample consisted of 28 233 participants aged 20 years or older. Mid-AC and BP cuff sizes were analyzed across survey years by sex, age, race/ethnicity, hypertension, and diabetic status. Results Data from NHANES 2007-2010 show that the mean mid-AC for men was 34.2 cm and for women was 31.9 cm. Men showed a significant trend in mid-AC (from 33.9 cm in 1999-2002 to 34.2 cm in 2007-2010; P < 0.05 for trend). In addition, 42.9% of men and 25.3% of women needed a large adult BP cuff and 1.9% of men and 2.8% of women needed thigh cuffs to be appropriately cuffed. Moreover, 52% of hypertensive men, 38% of hypertensive women, 59.1% of diabetic men, and 53.6% of diabetic women required the use of BP cuffs with sizes different from those of standard adult-sized BP cuffs for accurate BP measurement. Conclusion There was an overall significant trend in the mean mid-AC in cm for men but not for women. On the basis of NHANES 2007-2010 data, similar to 45% of adult men and similar to 28% of adult women required the use of BP cuffs with sizes different from those of standard adult-sized BP cuffs for accurate BP measurement. (c) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Ostchega, Yechiam; Hughes, Jeffery P.; Nwankwo, Tatiana; Chiappa, Michele M.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Hlth & Nutr Examinat Stat, Hyattsville, MD 20782 USA. [Zhang, Guangyu] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Off Res & Methodol, Hyattsville, MD 20782 USA. RP Ostchega, Y (reprint author), Natl Ctr Hlth Stat, NHANES Program, 3311 Toledo Rd,Room 4319, Hyattsville, MD 20782 USA. EM yxo1@cdc.gov NR 20 TC 3 Z9 3 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1359-5237 J9 BLOOD PRESS MONIT JI Blood Press. Monit. PD JUN PY 2013 VL 18 IS 3 BP 138 EP 143 DI 10.1097/MBP.0b013e3283617606 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 154RW UT WOS:000319694600003 PM 23604196 ER PT J AU Lindblade, KA Steinhardt, L Samuels, A Kachur, SP Slutsker, L AF Lindblade, Kim A. Steinhardt, Laura Samuels, Aaron Kachur, S. Patrick Slutsker, Laurence TI The silent threat: asymptomatic parasitemia and malaria transmission SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY LA English DT Review DE antimalarial; asymptomatic; elimination; infection; interventions; malaria; parasite ID PLASMODIUM-FALCIPARUM INFECTIONS; POLYMERASE-CHAIN-REACTION; RAPID DIAGNOSTIC-TESTS; NORTH-EASTERN TANZANIA; ACTIVE CASE DETECTION; NEW-GUINEAN CHILDREN; REAL-TIME PCR; GAMETOCYTE CARRIAGE; WESTERN KENYA; HIGH PREVALENCE AB Scale-up of malaria control interventions has resulted in a substantial decline in global malaria morbidity and mortality. Despite this achievement, there is evidence that current interventions alone will not lead to malaria elimination in most malaria-endemic areas and additional strategies need to be considered. Use of antimalarial drugs to target the reservoir of malaria infection is an option to reduce the transmission of malaria between humans and mosquito vectors. However, a large proportion of human malaria infections are asymptomatic, requiring treatment that is not triggered by care-seeking for clinical illness. This article reviews the evidence that asymptomatic malaria infection plays an important role in malaria transmission and that interventions to target this parasite reservoir may be needed to achieve malaria elimination in both low- and high-transmission areas. C1 [Lindblade, Kim A.; Steinhardt, Laura; Samuels, Aaron; Kachur, S. Patrick; Slutsker, Laurence] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. RP Lindblade, KA (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, 1600 Clifton Rd NE,MS A-06, Atlanta, GA 30333 USA. EM kil2@cdc.gov NR 130 TC 65 Z9 66 U1 2 U2 17 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1478-7210 J9 EXPERT REV ANTI-INFE JI Expert Rev. Anti-Infect. Ther. PD JUN PY 2013 VL 11 IS 6 BP 623 EP 639 DI 10.1586/ERI.13.45 PG 17 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 161BK UT WOS:000320165400015 PM 23750733 ER PT J AU Lansky, A Prejean, J Hall, I AF Lansky, Amy Prejean, Joseph Hall, Irene TI Challenges in identifying and estimating undiagnosed HIV infection SO FUTURE VIROLOGY LA English DT Editorial Material DE HIV; surveillance; testing; undiagnosed ID ANTIRETROVIRAL THERAPY; UNITED-STATES; TRANSMISSION; CARE; PREVALENCE; UNAWARE; AWARE C1 [Lansky, Amy; Prejean, Joseph; Hall, Irene] Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Lansky, A (reprint author), Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Mailstop D-21,1600 Clifton Rd, Atlanta, GA 30333 USA. EM all0@cdc.gov NR 20 TC 1 Z9 1 U1 0 U2 7 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1746-0794 J9 FUTURE VIROL JI Future Virol. PD JUN PY 2013 VL 8 IS 6 BP 523 EP 526 DI 10.2217/FVL.13.35 PG 4 WC Virology SC Virology GA 156BX UT WOS:000319796500001 ER PT J AU Khoury, MJ Janssens, ACJW Ransohoff, DF AF Khoury, Muin J. Janssens, A. Cecile J. W. Ransohoff, David F. TI How can polygenic inheritance be used in population screening for common diseases? SO GENETICS IN MEDICINE LA English DT Article DE evidence-based medicine; genetics; genomics; polygenic model; public health; risk assessment; screening ID SERVICES TASK-FORCE; PERSONALIZED MEDICINE HOPE; EGAPP WORKING GROUP; BREAST-CANCER RISK; 5 GENETIC-VARIANTS; COLORECTAL-CANCER; PROSTATE-CANCER; RECOMMENDATION STATEMENT; FAMILY-HISTORY; COMPLEX DISEASES AB Advances in genomics have near-term impact on diagnosis and management of monogenic disorders. For common complex diseases, the use of genomic information from multiple loci (polygenic model) is generally not useful for diagnosis and individual prediction. In principle, the polygenic model could be used along with other risk factors in stratified population screening to target interventions. For example, compared to age-based criterion for breast, colorectal, and prostate cancer screening, adding polygenic risk and family history holds promise for more efficient screening with earlier start and/or increased frequency of screening for segments of the population at higher absolute risk than an established screening threshold; and later start and/or decreased frequency of screening for segments of the population at lower risks. This approach, while promising, faces formidable challenges for building its evidence base and for its implementation in practice. Currently, it is unclear whether or not polygenic risk can contribute enough discrimination to make stratified screening worthwhile. Empirical data are lacking on population-based age-specific absolute risks combining genetic and non-genetic factors, on impact of polygenic risk genes on disease natural history, as well as information on comparative balance of benefits and harms of stratified interventions. Implementation challenges include difficulties in integration of this information in the current health-care system in the United States, the setting of appropriate risk thresholds, and ethical, legal, and social issues. In an era of direct-to-consumer availability of personal genomic information, the public health and health-care systems need to prepare for an evidence-based integration of this information into population screening. C1 [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA. [Khoury, Muin J.] NCI, Epidemiol & Genom Res Program, Bethesda, MD 20892 USA. [Janssens, A. Cecile J. W.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Ransohoff, David F.] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Ransohoff, David F.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. RP Khoury, MJ (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA. EM mkhoury@cdc.gov OI Janssens, A Cecile/0000-0002-6153-4976 FU Intramural CDC HHS [CC999999] NR 57 TC 15 Z9 15 U1 0 U2 16 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD JUN PY 2013 VL 15 IS 6 BP 437 EP 443 DI 10.1038/gim.2012.182 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA 158NV UT WOS:000319979800005 PM 23412608 ER PT J AU Scheuner, MT Edelen, MO Hilborne, LH Lubin, IM AF Scheuner, Maren T. Edelen, Maria Orlando Hilborne, Lee H. Lubin, Ira M. CA RAND Mol Genetic Test Report Advis TI Effective communication of molecular genetic test results to primary care providers SO GENETICS IN MEDICINE LA English DT Article DE communication; genetic testing; molecular genetics; standardized reporting ID CYSTIC-FIBROSIS DELTA-F508; FACTOR-V-LEIDEN; CLINICAL LABORATORIES; RISK; PHYSICIANS; MEDICINE; DISEASE; ERRORS; HEALTH; SCORE AB Purpose: We evaluated a template for molecular genetic test reports that was developed as a strategy to reduce communication errors between the laboratory and ordering clinician. Methods: We surveyed 1,600 primary care physicians to assess satisfaction, ease of use, and effectiveness of genetic test reports developed using our template and reports developed by clinical laboratories. Mean score differences of responses between the reports were compared using t-tests. Two-way analysis of variance evaluated the effect of template versus standard reports and the influence of physician characteristics. Results: There were 396 (24%) respondents. Template reports had higher scores than the standard reports for each survey item. The gender and specialty of the physician did not influence scores; however, younger physicians gave higher scores regardless of report type. There was significant interaction between report type and whether physicians ordered or reviewed any genetic tests (none versus at least one) in the past year, P = 0.005. Conclusion: For each survey item assessing satisfaction, ease of use, and effectiveness, physicians gave higher ratings to genetic test reports developed with the template than standard reports used by clinical laboratories. Physicians least familiar with genetic test reports, and possibly having the greatest need for better communication, were best served by the template reports. C1 [Scheuner, Maren T.; Edelen, Maria Orlando; Hilborne, Lee H.] RAND Corp, Santa Monica, CA 90406 USA. [Scheuner, Maren T.] Greater Los Angeles Healthcare Syst, Dept Vet Affairs, Los Angeles, CA USA. [Scheuner, Maren T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Hilborne, Lee H.] Quest Diagnost, West Hills, CA USA. [Hilborne, Lee H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Lubin, Ira M.] Ctr Dis Control & Prevent, Div Lab Sci & Stand, Atlanta, GA USA. RP Scheuner, MT (reprint author), RAND Corp, Santa Monica, CA 90406 USA. EM maren.scheuner@va.gov FU Centers for Disease Control and Prevention FX This work was supported by a cooperative agreement from the Centers for Disease Control and Prevention. The authors thank the RAND staff who supported this project, including Suzanne Benedict, Kristin Leuschner, PhD, Chau Pham, MS, Julie Brown, and Diane Schoeff. The authors thank the members of the RAND Molecular Genetic Test Report Advisory Board: Jean Amos Wilson, PhD, Joanne Armstrong, MD, Sylvia Au, MS, CGC, Dave Dotson, PhD, Laurel Estabrooks, PhD, Hawazin Faruki, DrPH, W. Andrew Faucett, MS, CGC, W. Gregory Feero, MD, PhD, Wayne Grody, MD, PhD, Mark Hoffman, PhD, Katherine A Johansen, PhD, Jeffrey A. Kant, MD, PhD, Howard Levy, MD, PhD, Elaine Lyon, PhD, Joseph D. McInerny, MA, MS, Harvey J. Murff, MD, MPH, Roberta A. Pagon, MD, Kate Reed, MS, CGC, Sue Richards, PhD, Wes Schreiber, MD, Iris Schriever, PhD, Tracy L. Trotter, MD, Bonnie Van, PhD, Neil S. Wenger, MD, MPH, Vicky Whittemore, PhD, Marc Williams, MD, Suzanne Ziemnik. NR 27 TC 6 Z9 6 U1 4 U2 13 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD JUN PY 2013 VL 15 IS 6 BP 444 EP 449 DI 10.1038/gim.2012.151 PG 6 WC Genetics & Heredity SC Genetics & Heredity GA 158NV UT WOS:000319979800006 PM 23222660 ER PT J AU Roehler, DR Sann, S Kim, P Bachani, AM Campostrini, S Florian, M Sidik, M Blanchard, C Sleet, DA Hyder, AA Ballesteros, MF AF Roehler, Douglas R. Sann, Socheata Kim, Pagna Bachani, Abdulgafoor M. Campostrini, Stefano Florian, Michael Sidik, Mirjam Blanchard, Claire Sleet, David A. Hyder, Adnan A. Ballesteros, Michael F. TI Motorcycle helmet attitudes, behaviours and beliefs among Cambodians SO INTERNATIONAL JOURNAL OF INJURY CONTROL AND SAFETY PROMOTION LA English DT Article DE motorcycle; helmet; road safety; Cambodia AB Motorcycle fatalities are increasing at an alarming rate in many South-East Asian countries, including Cambodia. Through brief face-to-face roadside interviews in Phnom Penh and four other Cambodian provinces, this article assesses Cambodian motorcyclists' attitudes, behaviours and beliefs related to motorcycle helmets. Out of 1016 motorcyclists interviewed, 50% were drivers, 40% were older passengers and 10% were child passengers. More drivers (50%) reported consistently wearing helmets, compared with older passengers (14%). Saving their life in the event of a crash was the impetus for drivers and older passengers to wear a helmet (96% and 98%, respectively). The top barriers to helmet use were: (1) depends on where I drive,' (2) I forget' and (3) inconvenient' or uncomfortable'. These descriptive findings were instrumental in shaping the Cambodian Helmet Vaccine Initiative passenger campaign to reduce the motorcycle-related injuries and fatalities to support the United Nations Decade of Action for Road Safety. C1 [Roehler, Douglas R.] Columbus Technol & Serv, El Segundo, CA USA. [Roehler, Douglas R.; Sleet, David A.; Ballesteros, Michael F.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Sann, Socheata] Handicap Int Belgium, Phnom Penh, Cambodia. [Kim, Pagna] Asia Injury Prevent Fdn, Khan Chamcamorn, Phnom Penh, Cambodia. [Bachani, Abdulgafoor M.; Hyder, Adnan A.] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Int Injury Res Unit, Baltimore, MD USA. [Campostrini, Stefano; Blanchard, Claire] Int Union Hlth Promot & Educ, F-93203 St Denis, France. [Florian, Michael; Sidik, Mirjam] Asia Injury Prevent Fdn, Ho Chi Minh City, Vietnam. RP Roehler, DR (reprint author), Columbus Technol & Serv, El Segundo, CA USA. EM droehler@cdc.gov NR 19 TC 3 Z9 3 U1 0 U2 2 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1745-7300 EI 1745-7319 J9 INT J INJ CONTROL SA JI Int. J. Inj. Control Saf. Promot. PD JUN 1 PY 2013 VL 20 IS 2 BP 179 EP 183 DI 10.1080/17457300.2012.759594 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 150FQ UT WOS:000319376000010 PM 23324068 ER PT J AU Donald, PR Ahmed, A Burman, WJ Cotton, MF Graham, SM Mendel, C McIlleron, H Mac Kenzie, WR Nachman, S Schaaf, HS Starke, JR Wingfield, C Hesseling, AC AF Donald, P. R. Ahmed, A. Burman, W. J. Cotton, M. F. Graham, S. M. Mendel, C. McIlleron, H. Mac Kenzie, W. R. Nachman, S. Schaaf, H. S. Starke, J. R. Wingfield, C. Hesseling, A. C. TI Requirements for the clinical evaluation of new anti-tuberculosis agents in children SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE tuberculosis; drugs; children; evaluation; framework; requirements ID DRUG-METABOLIZING-ENZYMES; SHORT-COURSE CHEMOTHERAPY; DEVELOPMENTAL PHARMACOLOGY; INTRATHORACIC TUBERCULOSIS; RESPIRATORY TUBERCULOSIS; PULMONARY TUBERCULOSIS; CHILDHOOD TUBERCULOSIS; INFANTS; DIAGNOSTICS; EXPRESSION AB The ultimate goal of evidence-based drug treatment is to produce a desired pharmacological response in a predictable manner and also to minimise adverse effects. This goal requires not only an increased awareness of the need to provide specific dosing recommendations aimed at specific patient groups, but also the implementation of a consistent integrative approach to recognise all factors contributing to the within- and between-subject variability in drug disposition and response. The assessment of new anti-tuberculosis agents and regimens in children requires a specific programme of investigation, and should be included early in human drug evaluation programmes. Appreciation of this principle is an important step forward towards the full integration of children into the tuberculosis research agenda and control programmes. The development of anti-tuberculosis drug formulations and regimens tailored to the requirements of children needs to consider physiological age-related differences for pharmacokinetics and toxicity between adults and children. Research based on these principles will create an evidence base that will inform the appropriate treatment of children with novel agents and regimens and will also inform future research, including the use of chemoprophylaxis and treatment-shortening strategies in children. C1 [Donald, P. R.; Schaaf, H. S.; Hesseling, A. C.] Univ Stellenbosch, Desmond Tutu TB Ctr, Dept Paediat & Child Hlth, Fac Med & Hlth Sci, Cape Town, South Africa. [Ahmed, A.] Carolinas Med Ctr, Ctr Pediat Res, Charlotte, NC 28203 USA. [Ahmed, A.] Univ N Carolina, Chapel Hill, NC USA. [Burman, W. J.] Denver Hlth Hosp, Infect Dis Clin Denver Publ Hlth, Denver, CO USA. [Cotton, M. F.] Univ Stellenbosch, Fac Hlth Sci, Childrens Infect Dis Clin Res Unit, Dept Paediat & Child Hlth, Cape Town, South Africa. [Graham, S. M.] Univ Melbourne, Dept Paediat, Royal Childrens Hosp, Ctr Int Child Hlth, Parkville, Vic 3052, Australia. [Mendel, C.] Global Alliance TB Drug Dev, New York, NY USA. [McIlleron, H.] Univ Cape Town, Dept Med, Fac Hlth Sci, ZA-7925 Cape Town, South Africa. [Mac Kenzie, W. R.] Ctr Dis Control & Prevent, TB Trials Consortium, Clin Res Branch, Div TB Eliminat, Atlanta, GA USA. [Nachman, S.] SUNY Stony Brook, Dept Pediat, Hlth Sci Ctr, Stony Brook, NY 11794 USA. [Starke, J. R.] Baylor Coll Med, Houston, TX 77030 USA. [Wingfield, C.] Treatment Act Grp, TB HIV Project, New York, NY USA. RP Donald, PR (reprint author), Univ Stellenbosch, Desmond Tutu TB Ctr, Dept Paediat & Child Hlth, Fac Hlth Sci, Cape Town, South Africa. EM prd@sun.ac.za; annekeh@sun.ac.za RI Mac Kenzie, William /F-1528-2013; OI Mac Kenzie, William /0000-0001-7723-0339; McIlleron, Helen/0000-0002-0982-6226 FU TBTC; USPHS through the CDC; Tuberculosis Epidemiologic Studies Consortium; CDC; IMPAACT FX PRD, MDC, ACH and AA receive financial support from the TBTC, which is funded by the USPHS through the CDC. AA also receives financial support from the Tuberculosis Epidemiologic Studies Consortium, also funded through the CDC. MFC, SN and ACH also receive support from IMPAACT. WRM is a project officer with the Tuberculosis Trials Consortium, CDC, USPHS. NR 33 TC 12 Z9 12 U1 0 U2 3 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD JUN PY 2013 VL 17 IS 6 BP 794 EP 799 DI 10.5588/ijtld.12.0567 PG 6 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 156TB UT WOS:000319845700016 PM 23676164 ER PT J AU Glasgow, RE Doria-Rose, VP Khoury, MJ Elzarrad, M Brown, ML Stange, KC AF Glasgow, Russell E. Doria-Rose, V. Paul Khoury, Muin J. Elzarrad, Mohammed Brown, Martin L. Stange, Kurt C. TI Comparative Effectiveness Research in Cancer: What Has Been Funded and What Knowledge Gaps Remain? SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Editorial Material ID PRACTICAL CLINICAL-TRIALS; MULTIMETHOD RESEARCH; HEALTH-CARE; UNINTENDED CONSEQUENCES; PARTICIPATORY RESEARCH; MULTISITE MULTIMETHOD; POPULATION HEALTH; DECISION-MAKING; PUBLIC-HEALTH; MEDICINE C1 [Glasgow, Russell E.; Doria-Rose, V. Paul; Khoury, Muin J.; Elzarrad, Mohammed; Brown, Martin L.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Elzarrad, Mohammed] NCI, Canc Prevent Fellowship Program, Bethesda, MD 20892 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. [Elzarrad, Mohammed] US FDA, Interagency Oncol Task Force Joint Fellowship Pro, Silver Spring, MD USA. [Stange, Kurt C.] Case Western Reserve Univ, Cleveland Clin & Translat Sci Collaborat, Case Comprehens Canc Ctr, Dept Family Med & Community Hlth,Dept Epidemiol &, Cleveland, OH 44106 USA. [Stange, Kurt C.] Case Western Reserve Univ, Cleveland Clin & Translat Sci Collaborat, Case Comprehens Canc Ctr, Dept Sociol, Cleveland, OH 44106 USA. RP Glasgow, RE (reprint author), NCI, Div Canc Control & Populat Sci, NIH, 6130 Execut Blvd, Rockville, MD 20852 USA. EM glasgowre@mail.nih.gov OI Doria-Rose, Vincent/0000-0002-8802-5143 NR 64 TC 8 Z9 8 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 JNCI-J NATL CANCER I JI JNCI-. Natl. Cancer Inst. PD JUN PY 2013 VL 105 IS 11 BP 766 EP 773 DI 10.1093/jnci/djt066 PG 8 WC Oncology SC Oncology GA 160QK UT WOS:000320134100007 PM 23578853 ER PT J AU Garfein, RS Rondinelli, A Barnes, RFW Cuevas, J Metzner, M Velasquez, M Rodriguez, D Reilly, M Xing, J Teshale, EH AF Garfein, Richard S. Rondinelli, Amanda Barnes, Richard F. W. Cuevas, Jazmine Metzner, Mitcheal Velasquez, Michele Rodriguez, David Reilly, Meredith Xing, Jian Teshale, Eyasu H. TI HCV Infection Prevalence Lower Than Expected among 18-40-Year-Old Injection Drug Users in San Diego, CA SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Article DE Hepatitis C virus; Injection drug use; Risk behaviors; Prevalence; Human immunodeficiency virus; Border region ID HEPATITIS-C; VIRUS-INFECTION; VIRAL-INFECTIONS; RISK BEHAVIORS; HUMAN-IMMUNODEFICIENCY; HIDDEN POPULATIONS; SYRINGE EXCHANGE; NEEDLE EXCHANGE; PUBLIC-HEALTH; UNITED-STATES AB San Diego, California shares the world's busiest land border crossing with Tijuana, Mexico-a city where 95 % of injection drug users (IDUs) test hepatitis C virus (HCV) antibody-positive. Yet, little is known about the prevalence and risk behaviors for HCV among IDUs in San Diego. In 2009-2010, 18-40-year-old IDUs in San Diego County completed a risk assessment interview and serologic testing for HCV and HIV infection. Recruitment involved respondent-driven sampling, venue-based sampling at a syringe exchange program, and convenience sampling. Correlates of HCV infection were identified by multivariable logistic regression. Among 510 current IDUs, 26.9 % (95 % CI 23.0-30.7 %) and 4.2 % (95 % CI 2.4-5.9 %) had been infected with HCV and HIV, respectively. Overall, median age was 28 years; 74 % were male; 60 % white and 29 % Hispanic; and 96 % were born in the U.S. Median years of injecting was 6; 41 % injected daily; 60 % injected heroin most often; 49 % receptively shared syringes and 68 % shared other injection paraphernalia; and only 22 % reported always using new syringes in the past 3 months. Two thirds had ever traveled to Mexico and 19 % injected in Mexico. HCV infection was independently associated with sharing injection paraphernalia (adjusted odds ratio [AOR] = 1.69) and SEP use (AOR = 2.17) in the previous 3 months, lifetime history of drug overdose (AOR = 2.66), and increased years of injecting (AOR = 2.82, all P values < 0.05). Controlling for recruitment method did not alter results. HCV infection prevalence among IDUs in San Diego was modest compared to other US cities and much lower than Tijuana. Given that known individual-level HCV risk factors were common in San Diego, the city's lower HCV prevalence might be due to differences in social and structural factors between the cities. C1 [Garfein, Richard S.; Rondinelli, Amanda; Barnes, Richard F. W.; Cuevas, Jazmine; Metzner, Mitcheal; Velasquez, Michele; Rodriguez, David] Univ Calif San Diego, Sch Med, Div Global Publ Hlth, San Diego, CA 92103 USA. [Reilly, Meredith; Xing, Jian; Teshale, Eyasu H.] Ctr Dis Control & Prevent, Div Viral Hepatitis, NCHHSTP, Atlanta, GA USA. RP Garfein, RS (reprint author), Univ Calif San Diego, Sch Med, Div Global Publ Hlth, San Diego, CA 92103 USA. EM rgarfein@ucsd.edu FU Centers for Disease Control and Prevention [200-2007-21016]; National Institutes of Health [AI36214, AI074621, AI007384]; California HIV/AIDS Research Program [RN07-SD-702] FX The authors greatly appreciate the support of the University of California San Diego, Antiviral Research Center for the use of its clinical facilities and HIV/HCV NAT testing; research activities performed by Philippe Duhaime, Maureen Clark, Katherine Banares, Nicholas Aldridge, Carlos Vera, Amanpreet Sandhu, and Amelia Poquette; laboratory guidance provided by DeeDee Pacheco; and the participants who volunteered their time for the study. This study was funded through a contract (#200-2007-21016) from the Centers for Disease Control and Prevention. Support for additional HIV and HCV testing was provided by grants from the National Institutes of Health (AI36214, AI074621, and AI007384) and the California HIV/AIDS Research Program (RN07-SD-702). NR 40 TC 9 Z9 9 U1 2 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 J9 J URBAN HEALTH JI J. Urban Health PD JUN PY 2013 VL 90 IS 3 BP 516 EP 528 DI 10.1007/s11524-012-9728-0 PG 13 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 154NQ UT WOS:000319683100011 PM 22766605 ER PT J AU Coggon, D Ntani, G Palmer, KT Felli, VE Harari, R Barrero, LH Felknor, SA Gimeno, D Cattrell, A Serra, C Bonzini, M Solidaki, E Merisalu, E Habib, RR Sadeghian, F Kadir, MM Warnakulasuriya, SSP Matsudaira, K Nyantumbu, B Sim, MR Harcombe, H Cox, K Marziale, MH Sarquis, LM Harari, F Freire, R Harari, N Monroy, MV Quintana, LA Rojas, M Vega, EJS Harris, EC Vargas-Prada, S Martinez, JM Delclos, G Benavides, FG Carugno, M Ferrario, MM Pesatori, AC Chatzi, L Bitsios, P Kogevinas, M Oha, K Sirk, T Sadeghian, A Peiris-John, RJ Sathiakumar, N Wickremasinghe, AR Yoshimura, N Kelsall, HL Hoe, VCW Urquhart, DM Derrett, S McBride, D Herbison, P Gray, A AF Coggon, David Ntani, Georgia Palmer, Keith T. Felli, Vanda E. Harari, Raul Barrero, Lope H. Felknor, Sarah A. Gimeno, David Cattrell, Anna Serra, Consol Bonzini, Matteo Solidaki, Eleni Merisalu, Eda Habib, Rima R. Sadeghian, Farideh Kadir, M. Masood Warnakulasuriya, Sudath S. P. Matsudaira, Ko Nyantumbu, Busisiwe Sim, Malcolm R. Harcombe, Helen Cox, Ken Marziale, Maria H. Sarquis, Leila M. Harari, Florencia Freire, Rocio Harari, Natalia Monroy, Magda V. Quintana, Leonardo A. Rojas, Marianela Vega, Eduardo J. Salazar Harris, E. Clare Vargas-Prada, Sergio Martinez, J. Miguel Delclos, George Benavides, Fernando G. Carugno, Michele Ferrario, Marco M. Pesatori, Angela C. Chatzi, Leda Bitsios, Panos Kogevinas, Manolis Oha, Kristel Sirk, Tuuli Sadeghian, Ali Peiris-John, Roshini J. Sathiakumar, Nalini Wickremasinghe, A. Rajitha Yoshimura, Noriko Kelsall, Helen L. Hoe, Victor C. W. Urquhart, Donna M. Derrett, Sarah McBride, David Herbison, Peter Gray, Andrew TI Disabling musculoskeletal pain in working populations: Is it the job, the person, or the culture? SO PAIN LA English DT Article DE Low back; Forearm; Pain; International; Socioeconomic; Psychosocial ID PSYCHOSOCIAL RISK-FACTORS; NECK PAIN; DISORDERS; DISABILITY; WORKERS; NURSES; HEALTH; BACK AB To compare the prevalence of disabling low back pain (DLBP) and disabling wrist/hand pain (DWHP) among groups of workers carrying out similar physical activities in different cultural environments, and to explore explanations for observed differences, we conducted a cross-sectional survey in 18 countries. Standardised questionnaires were used to ascertain pain that interfered with everyday activities and exposure to possible risk factors in 12,426 participants from 47 occupational groups (mostly nurses and office workers). Associations with risk factors were assessed by Poisson regression. The 1-month prevalence of DLBP in nurses varied from 9.6% to 42.6%, and that of DWHP in office workers from 2.2% to 31.6%. Rates of disabling pain at the 2 anatomical sites covaried (r = 0.76), but DLBP tended to be relatively more common in nurses and DWHP in office workers. Established risk factors such as occupational physical activities, psychosocial aspects of work, and tendency to somatise were confirmed, and associations were found also with adverse health beliefs and group awareness of people outside work with musculoskeletal pain. However, after allowance for these risk factors, an up-to 8-fold difference in prevalence remained. Systems of compensation for work-related illness and financial support for health-related incapacity for work appeared to have little influence on the occurrence of symptoms. Our findings indicate large international variation in the prevalence of disabling forearm and back pain among occupational groups carrying out similar tasks, which is only partially explained by the personal and socioeconomic risk factors that were analysed. (C) 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. C1 [Coggon, David; Ntani, Georgia; Palmer, Keith T.; Cox, Ken; Harris, E. Clare] Southampton Gen Hosp, Med Res Council Lifecourse Epidemiol Unit, Southampton SO16 6YD, Hants, England. [Felli, Vanda E.] Univ Sao Paulo, Sch Nursing, Sao Paulo, Brazil. [Harari, Raul; Harari, Florencia; Freire, Rocio; Harari, Natalia; Delclos, George] Inst Dev Prod & Work Environm, Corp Desarrollo Prod & Medio Ambiente Laboral IFA, Quito, Ecuador. [Barrero, Lope H.; Monroy, Magda V.; Quintana, Leonardo A.] Pontificia Univ Javeriana, Sch Engn, Dept Ind Engn, Bogota, Colombia. [Felknor, Sarah A.; Gimeno, David; Vega, Eduardo J. Salazar] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Southwest Ctr Occupat & Environm Hlth, Houston, TX USA. [Felknor, Sarah A.] NIOSH, Ctr Dis Control & Prevent, Atlanta, GA USA. [Cattrell, Anna] Kings Coll London, MRC, Social Genet & Dev Psychiat Ctr, London WC2R 2LS, England. [Serra, Consol; Vargas-Prada, Sergio; Martinez, J. Miguel; Delclos, George; Benavides, Fernando G.] Univ Pompeu Fabra, Ctr Res Occupat Hlth CiSAL, Barcelona, Spain. [Serra, Consol; Martinez, J. Miguel; Delclos, George; Benavides, Fernando G.; Kogevinas, Manolis] CIBER Epidemiol & Publ Hlth, Barcelona, Spain. [Serra, Consol] Parc Salut MAR, Occupat Hlth Serv, Barcelona, Spain. [Bonzini, Matteo; Ferrario, Marco M.] Univ Insubria, Epidemiol & Prevent Med Res Ctr, Varese, Italy. [Solidaki, Eleni; Chatzi, Leda] Univ Crete, Sch Med, Dept Social Med, Iraklion, Greece. [Merisalu, Eda] Univ Tartu, Dept Publ Hlth, Tartu, Estonia. [Habib, Rima R.] Amer Univ Beirut, Fac Hlth Sci, Dept Environm Hlth, Beirut, Lebanon. [Sadeghian, Farideh] Shahroud Univ Med Sci, Fac Hlth, Dept Occupat Hlth, Shahroud, Iran. [Kadir, M. Masood] Aga Khan Univ, Dept Community Hlth Sci, Karachi, Pakistan. [Warnakulasuriya, Sudath S. P.] Univ Sri Jayewardenepura, Fac Med Sci, Dept Med Educ & Hlth Sci, Nugegoda, Sri Lanka. [Matsudaira, Ko] Kanto Rosai Hosp, Clin Res Ctr Occupat Musculoskeletal Disorders, Kawasaki, Kanagawa, Japan. [Nyantumbu, Busisiwe] Natl Inst Occupat Hlth, Natl Hlth Lab Serv, Johannesburg, South Africa. [Nyantumbu, Busisiwe] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa. [Sim, Malcolm R.; Kelsall, Helen L.; Hoe, Victor C. W.; Urquhart, Donna M.] Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia. [Harcombe, Helen; McBride, David; Herbison, Peter; Gray, Andrew] Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand. [Marziale, Maria H.] Univ Sao Paulo, Sch Nursing Ribeirao Preto, Sao Paulo, Brazil. [Sarquis, Leila M.] Univ Fed Parana, BR-80060000 Curitiba, PR, Brazil. [Rojas, Marianela] Natl Univ Costa Rica, Inst Studies Tox Subst IRET, Heredia, Costa Rica. [Carugno, Michele; Pesatori, Angela C.] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy. [Pesatori, Angela C.] Fdn Ca Granda Osped Maggiore Policlin, Milan, Italy. [Bitsios, Panos] Univ Crete, Sch Med, Dept Psychiat, Iraklion, Greece. [Kogevinas, Manolis] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain. [Kogevinas, Manolis] IMIM Hosp Mar Res Inst, Barcelona, Spain. [Kogevinas, Manolis] Natl Sch Publ Hlth, Athens, Greece. [Oha, Kristel] North Estonia Med Ctr, Tallinn, Estonia. [Sirk, Tuuli] Polva Hosp, Polva, Estonia. [Sadeghian, Ali] Klinikum Leverkusen, Leverkusen, Germany. [Peiris-John, Roshini J.] Univ Sri Jayewardenepura, Fac Med Sci, Dept Physiol, Nugegoda, Sri Lanka. [Peiris-John, Roshini J.] Univ Auckland, Fac Med & Hlth Sci, Sch Populat Hlth, Sect Epidemiol & Biostat, Auckland 1, New Zealand. [Sathiakumar, Nalini] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Wickremasinghe, A. Rajitha] Univ Kelaniya, Fac Med, Kelaniya, Sri Lanka. [Yoshimura, Noriko] Univ Tokyo, Dept Joint Dis Res, Tokyo, Japan. [Hoe, Victor C. W.] Univ Malaya, Dept Social & Prevent Med, Fac Med, Ctr Occupat & Environm Hlth, Kuala Lumpur, Malaysia. [Derrett, Sarah] Univ Otago, Dept Prevent & Social Med, Injury Prevent Res Unit, Dunedin, New Zealand. RP Coggon, D (reprint author), Southampton Gen Hosp, MRC Lifecourse Epidemiol Unit, Southampton SO16 6YD, Hants, England. EM dnc@mrc.soton.ac.uk RI Hoe, VICTOR/B-5190-2010; Bonzini, Matteo/K-7540-2016; FELLI, VANDA/H-5942-2012; Kogevinas, Manolis/C-3918-2017; McBride, David/F-9664-2010; Benavides, Fernando/A-5137-2008; Serra, C/E-6879-2014; harari, florencia/O-3786-2014; Vargas-Prada, S/I-3065-2014; Harari, Raul/E-1241-2015; Gray, Andrew/L-9161-2015; OI Hoe, VICTOR/0000-0002-8073-157X; Bonzini, Matteo/0000-0002-6405-7554; FELLI, VANDA/0000-0001-7250-4353; McBride, David/0000-0001-5531-7687; Benavides, Fernando/0000-0003-0747-2660; Serra, C/0000-0001-8337-8356; harari, florencia/0000-0002-0362-579X; Vargas-Prada, S/0000-0002-0713-5392; Harari, Raul/0000-0002-1829-5316; Gray, Andrew/0000-0003-4299-2194; Marziale, Maria Helena Palucci/0000-0003-2790-3333; Peiris-John, Roshini/0000-0001-7812-2268; Ferrario, Marco M/0000-0003-2741-7124; Monroy Silva, Magda Viviana/0000-0002-6185-5999; pesatori, angela/0000-0002-0261-3252; Kelsall, Helen/0000-0003-0664-3376 FU UK Medical Research Council; Brazil: Colt Foundation [CF/03/05]; Ecuador: Colt Foundation [CF/03/05]; Colombia: NIH [5D43 TW00 0644-13, 0005919J]; NIH [0005919J, 5D43 TW00 0644-15]; Pontificia Universidad Javeriana, Costa Rica: Colt Foundation [CF/03/05]; Nicaragua: Colt Foundation [CF/03/05]; UK: Colt Foundation [CF/03/05]; Spain: Spanish Health Research Fund [FIS 070422]; Epidemiology and Public Health CIBER; Carlos III Institute of Health; Ministry of Science and Innovation; Italy: Department of Experimental Medicine, University of Insubria, Varese, Italy; Greece: Colt Foundation [CF/03/05]; Estonia: Colt Foundation [CF/03/05]; Lebanon: Colt Foundation [CF/03/05]; Iran: Deputy for Training and Research; Shahroud University of Medical Sciences; Pakistan: Colt Foundation [CF/03/05]; Sri Lanka: International Training and Research in Environmental and Occupational Health (ITREOH) Program of the University of Alabama at Birmingham from the National Institutes of Health and the Fogarty International Center [NIH-FIC] [5 D43 TWO5750]; Japan: University of Tokyo; South Africa: Colt Foundation [CF/03/05]; Australia: Monash University Strategic Grant Scheme; Monash University Near Miss Grant for NHMRC projects; NHMRC; VCWH by the Ministry of Higher Education in Malaysia; New Zealand: Health Research Council of New Zealand (International Investment Opportunity Fund Grant); Southwest Center for Occupational and Environmental Health at the University of Texas Health Science Center; NIH Fogarty International Center FX We thank: Andrea Lepos Ferrari who assisted with data collection in Brazil; Pietro Munoz, Patricio Oyos, Gonzalo Albuja, Maria Belduma, and Francisco Lara for their assistance with data collection in Ecuador; Patrica Monge, Melania Chaverri, and Freddy Brenes, who helped with data collection in Costa Rica; Aurora Aragon, Alberto Berrios, Samaria Balladares, and Martha Martinez, who helped with data collection in Nicaragua; Alfredo Jose Jiron who assisted with data entry in Nicaragua; Catalina Torres for translation and piloting of the questionnaire in Spain; Ben and Marie Carmen Coggon for back-translation of the Spanish questionnaire; Cynthia Alcantara, Xavier Orpella, Josep Anton Gonzalez, Joan Bas, Pilar Pena, Elena Brunat, Vicente San Jose, Anna Sala March, Anna Marquez, Josefina Lorente, Cristina Oliva, Montse Vergara, and Eduard Gaynes for their assistance with data collection in Spain; Natale Battevi, Lorenzo Bordini, Marco Conti, and Luciano Riboldi, who carried out data collection in Italy; Paul Maurice Conway for back-translation of the Italian questionnaire; Tiina Freimann, who helped with data collection in Estonia; Asad Ali Khan for supervision of data collection and checking in Pakistan; Khalil Qureshi for training of field workers and supervision of data collection and checking in Pakistan; and Masami Hirai, Tatsuya Isomura, Norimasa Kikuchi, Akiko Ishizuka, and Takayuki Sawada for their help with data collection and management in Japan. We are particularly grateful to all of the organisations that allowed us to approach their employees; and all of the workers who kindly participated in the study. Funding for the central coordination of the CUPID study was provided by the UK Medical Research Council. In addition, support for data collection in individual countries was obtained from the following sources: Brazil: Colt Foundation (CF/03/05), Ecuador: Colt Foundation (CF/03/05), Colombia: NIH Grant 5D43 TW00 0644-13, sub-award 0005919J; NIH Grant 5D43 TW00 0644-15, sub-award 0005919J; and Pontificia Universidad Javeriana, Costa Rica: Colt Foundation (CF/03/05), Nicaragua: Colt Foundation (CF/03/05), UK: Colt Foundation (CF/03/05), Spain: Spanish Health Research Fund (FIS 070422), and Epidemiology and Public Health CIBER, Carlos III Institute of Health, Ministry of Science and Innovation, Italy: Department of Experimental Medicine, University of Insubria, Varese, Italy, Greece: Colt Foundation (CF/03/05), Estonia: Colt Foundation (CF/03/05), Lebanon: Colt Foundation (CF/03/05), Iran: Deputy for Training and Research, Shahroud University of Medical Sciences, Pakistan: Colt Foundation (CF/03/05), Sri Lanka: International Training and Research in Environmental and Occupational Health (ITREOH) Program of the University of Alabama at Birmingham (Grant No. 5 D43 TWO5750 from the National Institutes of Health and the Fogarty International Center [NIH-FIC]), Japan: University of Tokyo, South Africa: Colt Foundation (CF/03/05), Australia: Monash University Strategic Grant Scheme and Monash University Near Miss Grant for NHMRC projects in 2008. HKL and DMU were supported by fellowships from NHMRC, and VCWH by the Ministry of Higher Education in Malaysia, New Zealand: Health Research Council of New Zealand (International Investment Opportunity Fund Grant), Data collection in Central America and Colombia was also supported by the Southwest Center for Occupational and Environmental Health at the University of Texas Health Science Center research training grant from the NIH Fogarty International Center.; We are grateful to all of the funding agencies who supported the study. NR 19 TC 45 Z9 49 U1 5 U2 40 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD JUN PY 2013 VL 154 IS 6 BP 856 EP 863 DI 10.1016/j.pain.2013.02.008 PG 8 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 148QA UT WOS:000319259500014 PM 23688828 ER PT J AU Holtgrave, DR Wolitski, RJ Pals, SL Aidala, A Kidder, DP Vos, D Royal, S Iruka, N Briddell, K Stall, R Bendixen, AV AF Holtgrave, David R. Wolitski, Richard J. Pals, Sherri L. Aidala, Angela Kidder, Daniel P. Vos, David Royal, Scott Iruka, Nkemdiri Briddell, Kate Stall, Ron Bendixen, Arturo Valdivia TI Cost-Utility Analysis of the Housing and Health Intervention for Homeless and Unstably Housed Persons Living with HIV SO AIDS AND BEHAVIOR LA English DT Article DE HIV; Housing; Homelessness; Prevention; Cost-effectiveness ID ACTIVE ANTIRETROVIRAL THERAPY; CASE-MANAGEMENT PROGRAM; UNITED-STATES; PERCEIVED STRESS; SERVICE USE; INFECTION; CARE; ADULTS; REACH; LIFE AB We present a cost-utility analysis based on data from the Housing and Health (H&H) Study of rental assistance for homeless and unstably housed persons living with HIV in Baltimore, Chicago and Los Angeles. As-treated analyses found favorable associations of housing with HIV viral load, emergency room use, and perceived stress (an outcome that can be quantitatively linked to quality of life). We combined these outcome data with information on intervention costs to estimate the cost-per-quality-adjusted-life-year (QALY) saved. We estimate that the cost-per-QALY-saved by the HIV-related housing services is $62,493. These services compare favorably (in terms of cost-effectiveness) to other well-accepted medical and public health services. C1 [Holtgrave, David R.; Iruka, Nkemdiri] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD 21205 USA. [Wolitski, Richard J.; Pals, Sherri L.; Kidder, Daniel P.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Aidala, Angela] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. [Vos, David] Dept Housing & Urban Dev, Washington, DC USA. [Royal, Scott] ABT Associates Inc, Cambridge, MA 02138 USA. [Briddell, Kate] Mayors Off Human Serv City Baltimore, Homeless Serv Program, Baltimore, MD USA. [Stall, Ron] Univ Pittsburgh, Pittsburgh, PA USA. [Bendixen, Arturo Valdivia] AIDS Fdn Chicago, Chicago, IL USA. RP Holtgrave, DR (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, 624 N Broadway,Suite 280, Baltimore, MD 21205 USA. EM dholtgra@jhsph.edu NR 32 TC 11 Z9 11 U1 1 U2 13 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD JUN PY 2013 VL 17 IS 5 BP 1626 EP 1631 DI 10.1007/s10461-012-0204-3 PG 6 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 150SZ UT WOS:000319412800004 PM 22588529 ER PT J AU Hall, HI Holtgrave, DR Tang, T Rhodes, P AF Hall, H. Irene Holtgrave, David R. Tang, Tian Rhodes, Philip TI HIV Transmission in the United States: Considerations of Viral Load, Risk Behavior, and Health Disparities SO AIDS AND BEHAVIOR LA English DT Article DE HIV; HIV transmission; Men who have sex with men; Disparities; Race/ethnicity ID PREVENTION; CARE; SEX AB Ongoing HIV transmission is related to prevalence, risk behavior and viral load among persons with HIV. We assessed the contribution of these factors to HIV transmission with transmission rate models and data reported to National HIV Surveillance and published rates of risk behavior. We also estimated numbers of persons with risk behaviors and unsuppressed viral load among sexual risk groups. The transmission rate is higher considering risk behavior (18.5 infections per 100 people with HIV) than that attributed to unsuppressed viral load (4.6). Since persons without risk behavior or suppressed viral load presumably transmit HIV at very low rates, transmission can be attributed to a combination of these factors (28.9). Service needs are greatest for MSM; their number with unsuppressed viral load engaging in unprotected discordant sex was 8 times the number of male heterosexuals and more than twice the number of female heterosexuals with high-risk transmission potential. While all persons with HIV need optimal care, treatment as prevention is most relevant when risk behavior is present among persons with unsuppressed HIV viral load. C1 [Hall, H. Irene; Rhodes, Philip] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Holtgrave, David R.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA. [Tang, Tian] ICF Int, Atlanta, GA USA. RP Hall, HI (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS E-47, Atlanta, GA 30333 USA. EM ixh1@cdc.gov NR 25 TC 34 Z9 36 U1 0 U2 11 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD JUN PY 2013 VL 17 IS 5 BP 1632 EP 1636 DI 10.1007/s10461-013-0426-z PG 5 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 150SZ UT WOS:000319412800005 PM 23456577 ER PT J AU O'Leary, A Horvath, KJ Rosser, BRS AF O'Leary, Ann Horvath, Keith J. Rosser, B. R. Simon TI Associations Between Partner-Venue Specific Personal Responsibility Beliefs and Transmission Risk Behavior by HIV-Positive Men Who Have Sex with Men (MSM) SO AIDS AND BEHAVIOR LA English DT Article DE Personal responsibility; Altruism; Partner specificity; MSM; Transmission risk; HIV ID NEGOTIATION; DISCLOSURE; INTERNET AB Personal responsibility beliefs of HIV-positive individuals to protect sex partners are an important determinant of engagement in transmission risk behavior. However, the degree to which such beliefs vary across different partners is unknown. HIV-positive men who have sex with men (n = 248) completing an online survey rated their personal responsibility beliefs for partners met in up to four different ways: (a) in a bar; (b) through the internet; (c) in a public sex environment (PSE); or (d) through friends or family. For those reporting two or more partner-meeting venues in the prior 3 months (n = 98), about a third reported variation in responsibility ratings. Means among the venues were compared in pairwise fashion, with the strongest beliefs accruing to partners met through friends or family and the least with partners met in PSEs. These results provide further evidence that identifying ways to increase personal responsibility beliefs is an important goal, as well as is the application of Bandura's theory of moral agency to HIV transmission risk behavior. C1 [O'Leary, Ann] Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent, NCHHSTP, Atlanta, GA 30333 USA. [Horvath, Keith J.; Rosser, B. R. Simon] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA. RP O'Leary, A (reprint author), Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent, NCHHSTP, 1600 Clifton Rd,MSE 37, Atlanta, GA 30333 USA. EM aoleary@cdc.gov FU NIAAA NIH HHS [R01 AA016270, R01AA01627001] NR 10 TC 7 Z9 7 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD JUN PY 2013 VL 17 IS 5 BP 1855 EP 1861 DI 10.1007/s10461-012-0291-1 PG 7 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 150SZ UT WOS:000319412800029 PM 22983535 ER PT J AU Cashman, KD Kiely, M Kinsella, M Durazo-Arvizu, RA Tian, L Zhang, Y Lucey, A Flynn, A Gibney, MJ Vesper, HW Phinney, KW Coates, PM Picciano, MF Sempos, CT AF Cashman, Kevin D. Kiely, Mairead Kinsella, Michael Durazo-Arvizu, Ramon A. Tian, Lu Zhang, Yue Lucey, Alice Flynn, Albert Gibney, Michael J. Vesper, Hubert W. Phinney, Karen W. Coates, Paul M. Picciano, Mary F. Sempos, Christopher T. TI Evaluation of Vitamin D Standardization Program protocols for standardizing serum 25-hydroxyvitamin D data: a case study of the program's potential for national nutrition and health surveys SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID TANDEM MASS-SPECTROMETRY; CIRCULATING 25-HYDROXYVITAMIN-D; ASSAYS; ADULTS; ACCURATE; D-3 AB Background: The Vitamin D Standardization Program (VDSP) has developed protocols for standardizing procedures of 25-hydroxyvitamin D [25(OH)D] measurement in National Health/Nutrition Surveys to promote 25(OH)D measurements that are accurate and comparable over time, location, and laboratory procedure to improve public health practice. Objective: We applied VDSP protocols to existing ELISA-derived serum 25(OH)D data from the Irish National Adult Nutrition Survey (NANS) as a case-study survey and evaluated their effectiveness by comparison of the protocol-projected estimates with those from a reanalysis of survey serums by using liquid chromatography-tandem mass spectrometry (LC-tandem MS). Design: The VDSP reference system and protocols were applied to ELISA-based serum 25(OH)D data from the representative NANS sample (n = 1118). A reanalysis of 99 stored serums by using standardized LC-tandem MS and resulting regression equations yielded predicted standardized serum 25(OH)D values, which were then compared with LC-tandem MS reanalyzed values for all serums. Results: Year-round prevalence rates for serum 25(OH)D concentrations <30, <40, and <50 nmol/L were 6.5%, 21.9%, and 40.0%, respectively, via original ELISA measurements and 11.4%, 25.3%, and 43.7%, respectively, when VDSP protocols were applied. Differences in estimates at <30- and <40-nmol/L thresholds, but not at the <50-nmol/L threshold, were significant (P < 0.05). A reanalysis of all serums by using LC-tandem MS confirmed prevalence estimates as 11.2%, 27.2%, and 45.0%, respectively. Prevalences of serum 25(OH)D concentrations >125 nmol/L were 1.2%, 0.3%, and 0.6% by means of ELISA, VDSP protocols, and LC-tandem MS, respectively. Conclusion: VDSP protocols hold a major potential for national nutrition and health surveys in terms of the standardization of serum 25(OH)D data. C1 [Cashman, Kevin D.; Kiely, Mairead; Kinsella, Michael; Zhang, Yue; Lucey, Alice; Flynn, Albert] Natl Univ Ireland Univ Coll Cork, Sch Food & Nutr Sci, Cork, Ireland. [Cashman, Kevin D.] Natl Univ Ireland Univ Coll Cork, Dept Med, Cork, Ireland. [Durazo-Arvizu, Ramon A.] Loyola Univ, Stritch Sch Med, Dept Prevent Med & Epidemiol, Chicago, IL 60611 USA. [Tian, Lu] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Gibney, Michael J.] Univ Coll Dublin, Inst Food & Hlth, Dublin 2, Ireland. [Vesper, Hubert W.] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Phinney, Karen W.] NIST, Div Analyt Chem, Gaithersburg, MD 20899 USA. [Coates, Paul M.; Picciano, Mary F.; Sempos, Christopher T.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. RP Cashman, KD (reprint author), Natl Univ Ireland Univ Coll Cork, Sch Food & Nutr Sci, Cork, Ireland. EM k.cashman@ucc.ie OI Flynn, Albert/0000-0002-7072-4202 FU Irish Department of Agriculture, Food and the Marine and The Health Research Board under their joint Food for Health Research Initiative; Office of Dietary Supplements, NIB; Irish Department of Agriculture, Food and the Marine and The Health Research Board FX Supported in part by the Irish Department of Agriculture, Food and the Marine and The Health Research Board under their joint Food for Health Research Initiative (2007-2012) and the Office of Dietary Supplements, NIB. The Irish Department of Agriculture, Food and the Marine and The Health Research Board were funders of the Irish National Adult Nutrition Survey. The Vitamin D Standardization Program is coordinated by the Office of Dietary Supplements, NIH. NR 32 TC 45 Z9 45 U1 0 U2 15 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD JUN PY 2013 VL 97 IS 6 BP 1235 EP 1242 DI 10.3945/ajcn.112.057182 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 150DX UT WOS:000319371500012 PM 23615829 ER PT J AU Luckhaupt, SE Dahlhamer, JM Ward, BW Sweeney, MH Sestito, JP Calvert, GM AF Luckhaupt, Sara E. Dahlhamer, James M. Ward, Brian W. Sweeney, Marie H. Sestito, John P. Calvert, Geoffrey M. TI Prevalence and work-relatedness of carpal tunnel syndrome in the working population, United States, 2010 national health interview survey SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE industry; occupations; carpal tunnel syndrome; occupational diseases ID RISK-FACTORS; SUPPLEMENT DATA; SURVEILLANCE; OCCUPATION; DISORDERS; INJURY AB Background Patterns of prevalence and work-relatedness of carpal tunnel syndrome (CTS) among workers offer clues about risk factors and targets for prevention. Methods Data from an occupational health supplement to the 2010 National Health Interview Survey were used to estimate the prevalence of self-reported clinician-diagnosed CTS overall and by demographic characteristics. The proportion of these cases self-reported to have been attributed to work by clinicians was also examined overall and by demographic characteristics. In addition, the distribution of industry and occupation (I&O) categories to which work-related cases of CTS were attributed was compared to the distribution of I&O categories of employment among current/recent workers. Results Data were available for 27,157 adults, including 17,524 current/recent workers. The overall lifetime prevalence of clinician-diagnosed CTS among current/recent workers was 6.7%. The 12-month prevalence was 3.1%, representing approximately 4.8 million workers with current CTS; 67.1% of these cases were attributed to work by clinicians, with overrepresentation of certain I&O categories. Conclusions CTS affected almost 5 million U.S. workers in 2010, with prevalence varying by demographic characteristics and I&O. Am. J. Ind. Med. 56:615-624, 2013. (c) 2012 Wiley Periodicals, Inc. C1 [Luckhaupt, Sara E.; Sweeney, Marie H.; Sestito, John P.; Calvert, Geoffrey M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Dahlhamer, James M.; Ward, Brian W.] Ctr Dis Control & Prevent, Divison Hlth Interview Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Luckhaupt, SE (reprint author), NIOSH, 4676 Columbia Pkwy,R-17, Cincinnati, OH 45226 USA. EM sluckhaupt@cdc.gov FU U.S. Government FX The authors express their appreciation to the many other persons, both within and outside of NIOSH and NCHS, who contributed to study planning, questionnaire development, and/or review of previous drafts of this paper. These include, but are not limited to Toni Alterman and Aaron Sussell. All authors are federal government employees, and the NHIS and preparation of this manuscript were completely funded by the U.S. Government. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health, or the National Center for Health Statistics. NR 26 TC 17 Z9 18 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD JUN PY 2013 VL 56 IS 6 BP 615 EP 624 DI 10.1002/ajim.22048 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 152HT UT WOS:000319523300002 PM 22495886 ER PT J AU Luckhaupt, SE Dahlhamer, JM Ward, BW Sussell, AL Sweeney, MH Sestito, JP Calvert, GM AF Luckhaupt, Sara E. Dahlhamer, James M. Ward, Brian W. Sussell, Aaron L. Sweeney, Marie H. Sestito, John P. Calvert, Geoffrey M. TI Prevalence of dermatitis in the working population, United States, 2010 National Health Interview Survey SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE industry; occupations; dermatitis; occupational diseases ID OCCUPATIONAL SKIN DISEASES; CONTACT-DERMATITIS; SURVEILLANCE AB Background Prevalence patterns of dermatitis among workers offer clues about risk factors and targets for prevention, but population-based estimates of the burden of dermatitis among US workers are lacking. Methods Data from an occupational health supplement to the 2010 National Health Interview Survey (NHIS-OHS) were used to estimate the prevalence of dermatitis overall and by demographic characteristics and industry and occupation (I&O) of current/recent employment. Results Data were available for 27,157 adults, including 17,524 current/recent workers. The overall prevalence rate of dermatitis among current/recent workers was 9.8% (range among I&O groups: 5.5-15.4%), representing approximately 15.2 million workers with dermatitis. The highest prevalence rates were among I&O groups related to health care. Overall, 5.6% of dermatitis cases among workers (9.2% among healthcare workers) were attributed to work by health professionals. Conclusions Dermatitis affected over 15 million US workers in 2010, and its prevalence varied by demographic characteristics and industry and occupation of employment. The prevalence rate of work-related dermatitis based on the NHIS-OHS was approximately 100-fold higher than incidence rates based on the Bureau of Labor Statistics' Survey of Occupational Illness and Injury. Am. J. Ind. Med. 56:625-634, 2013. Published 2012. This article is a U.S. Government work and is in the public domain in the USA. C1 [Luckhaupt, Sara E.; Sussell, Aaron L.; Sweeney, Marie H.; Sestito, John P.; Calvert, Geoffrey M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Dahlhamer, James M.; Ward, Brian W.] Ctr Dis Control & Prevent, Divison Hlth Interview Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Luckhaupt, SE (reprint author), NIOSH, 4676 Columbia Pkwy,R-17, Cincinnati, OH 45226 USA. EM sluckhaupt@cdc.gov FU US Government FX The authors express their appreciation to the many other persons, both within and outside of NIOSH and NCHS, who contributed to study planning, questionnaire development, and/or review of previous drafts of this paper. All authors are federal government employees, and the NHIS and preparation of this manuscript were completely funded by the US Government. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health, or the National Center for Health Statistics. NR 25 TC 8 Z9 8 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD JUN PY 2013 VL 56 IS 6 BP 625 EP 634 DI 10.1002/ajim.22080 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 152HT UT WOS:000319523300003 PM 22674651 ER PT J AU Calvert, GM Luckhaupt, SE Sussell, A Dahlhamer, JM Ward, BW AF Calvert, Geoffrey M. Luckhaupt, Sara E. Sussell, Aaron Dahlhamer, James M. Ward, Brian W. TI The prevalence of selected potentially hazardous workplace exposures in the US: Findings from the 2010 National Health Interview Survey SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE occupational exposure; industry; occupations; dermatitis; tobacco smoke pollution; heat stress disorders ID UNITED-STATES; WORKERS; SURVEILLANCE; INFORMATION; MATRIX; NOISE AB Objective Assess the national prevalence of current workplace exposure to potential skin hazards, secondhand smoke (SHS), and outdoor work among various industry and occupation groups. Also, assess the national prevalence of chronic workplace exposure to vapors, gas, dust, and fumes (VGDF) among these groups. Methods Data were obtained from the 2010 National Health Interview Survey (NHIS). NHIS is a multistage probability sample survey of the civilian non-institutionalized population of the US. Prevalence rates and their variances were calculated using SUDAAN to account for the complex NHIS sample design. Results The data for 2010 were available for 17,524 adults who worked in the 12 months that preceded interview. The highest prevalence rates of hazardous workplace exposures were typically in agriculture, mining, and construction. The prevalence rate of frequent handling of or skin contact with chemicals, and of non-smokers frequently exposed to SHS at work was highest in mining and construction. Outdoor work was most common in agriculture (85%), construction (73%), and mining (65%). Finally, frequent occupational exposure to VGDF was most common among mining (67%), agriculture (53%), and construction workers (51%). Conclusion We identified industries and occupations with the highest prevalence of potentially hazardous workplace exposures, and provided targets for investigation and intervention activities. Am. J. Ind. Med. 56:635-646, 2013. (c) 2012 Wiley Periodicals, Inc. C1 [Calvert, Geoffrey M.; Luckhaupt, Sara E.; Sussell, Aaron] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Dahlhamer, James M.; Ward, Brian W.] Ctr Dis Control & Prevent, Div Hlth Interview Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Calvert, GM (reprint author), NIOSH, 4676 Columbia Pkwy,R-17, Cincinnati, OH 45226 USA. EM gcalvert@cdc.gov FU US Government FX The authors thank the following individuals for their review of earlier versions of this manuscript: Paul Blanc, Bill Halperin, John Sestito, and Marie Haring Sweeney. The authors also thank Jia Li for her invaluable statistical guidance. All authors are federal government employees, and the NHIS and preparation of this manuscript were completely funded by the US Government. NR 24 TC 12 Z9 12 U1 0 U2 27 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD JUN PY 2013 VL 56 IS 6 BP 635 EP 646 DI 10.1002/ajim.22089 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 152HT UT WOS:000319523300004 PM 22821700 ER PT J AU Alterman, T Luckhaupt, SE Dahlhamer, JM Ward, BW Calvert, GM AF Alterman, Toni Luckhaupt, Sara E. Dahlhamer, James M. Ward, Brian W. Calvert, Geoffrey M. TI Prevalence rates of work organization characteristics among workers in the US: Data from the 2010 National Health Interview Survey SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE work organization; job stress; surveillance; occupational health; national survey; long work hours; non-standard work arrangements; temporary work; shift work ID CORONARY HEART-DISEASE; O-ASTERISK-NET; UNITED-STATES; JOB CHARACTERISTICS; RESEARCH AGENDA; ASSOCIATIONS; STRAIN; RISK AB Background Surveillance is needed to capture work organization characteristics and to identify their trends. Methods Data from the 2010 National Health Interview Survey (NHIS) were used to calculate prevalence rates for four work organization characteristics (long work hours, non-standard work arrangements, temporary positions, and alternative shifts) overall, and by demographic characteristics, and industry and occupation of current/recent employment. Results Data were available for 27,157 adults, of which 65% were current/recent workers. Among adults who worked in the past 12 months, 18.7% worked 48hr or more per week, 7.2% worked 60hr or more per week, 18.7% had non-standard work arrangements, 7.2% were in temporary positions, and 28.7% worked an alternative shift. Conclusions Prevalence rates of work organization characteristics are provided. These national estimates can be used to help occupational health professionals and employers to identify emerging occupational safety and health risks, allow researchers to examine associations with health, and use the data for benchmarking. Am. J. Ind. Med. 56:647-659, 2013. (c) 2012 Wiley Periodicals, Inc. C1 [Alterman, Toni; Luckhaupt, Sara E.; Calvert, Geoffrey M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Dahlhamer, James M.; Ward, Brian W.] Ctr Dis Control & Prevent, Div Hlth Interview Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Alterman, T (reprint author), Natl Inst Occupat Safety & Hlth MS R17, 4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM talterman@cdc.gov OI Alterman, Toni/0000-0003-1512-4367 FU Intramural CDC HHS [CC999999] NR 21 TC 40 Z9 40 U1 2 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD JUN PY 2013 VL 56 IS 6 BP 647 EP 659 DI 10.1002/ajim.22108 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 152HT UT WOS:000319523300005 PM 22911666 ER PT J AU Alterman, T Luckhaupt, SE Dahlhamer, JM Ward, BW Calvert, GM AF Alterman, Toni Luckhaupt, Sara E. Dahlhamer, James M. Ward, Brian W. Calvert, Geoffrey M. TI Job insecurity, work-family imbalance, and hostile work environment: Prevalence data from the 2010 National Health Interview Survey SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE job stress; national survey; bullying; job insecurity; work-family imbalance ID O-ASTERISK-NET; CORONARY HEART-DISEASE; RISK-FACTORS; WORKPLACE; DIMENSIONS; US; ASSOCIATIONS; SYMPTOMS; STRAIN AB Background Little nationally representative information on job insecurity, work-family imbalance, and hostile work environments experienced by workers in the US is available. Methods Prevalence rates from the 2010 National Health Interview Survey (NHIS) were calculated for three workplace psychosocial factors (job insecurity, work-family imbalance, bullying/harassment) using SUDAAN to account for the complex NHIS sample design. Results Data were available for 17,524 adults who worked in the 12 months that preceded the interview. Overall prevalence rates were 31.7% for job insecurity, 16.3% for work-family imbalance, and 7.8% for hostile work environment (being bullied or harassed). The highest prevalence rate of job insecurity was found for construction and extraction occupations. Workers in legal occupations had the highest prevalence rate of work-family imbalance. Workers in protective service occupations had the highest prevalence rate of hostile work environment. Conclusions We identified demographic characteristics along with industries and occupations with the highest prevalence rates for three adverse workplace psychosocial factors. These data can be used for benchmarking and identification of targets for investigation and intervention activities. Am. J. Ind. Med. 56:660-669, 2013. (c) 2012 Wiley Periodicals, Inc. C1 [Alterman, Toni; Luckhaupt, Sara E.; Calvert, Geoffrey M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Dahlhamer, James M.; Ward, Brian W.] Ctr Dis Control & Prevent, Div Hlth Interview Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Alterman, T (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 4676 Columbia Pkwy,R-17, Cincinnati, OH 45226 USA. EM talterman@cdc.gov OI Alterman, Toni/0000-0003-1512-4367 FU NHIS; US Government FX Contract grant sponsor: NHIS.; Contract grant sponsor: US Government. NR 24 TC 15 Z9 15 U1 2 U2 32 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD JUN PY 2013 VL 56 IS 6 BP 660 EP 669 DI 10.1002/ajim.22123 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 152HT UT WOS:000319523300006 PM 23023603 ER PT J AU Masterson, EA Tak, S Themann, CL Wall, DK Groenewold, MR Deddens, JA Calvert, GM AF Masterson, Elizabeth A. Tak, SangWoo Themann, Christa L. Wall, David K. Groenewold, Matthew R. Deddens, James A. Calvert, Geoffrey M. TI Prevalence of hearing loss in the United States by industry SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE occupational hearing loss; hearing impairment; hazardous noise; noise-induced hearing loss; occupational noise exposure standard ID HEALTH INTERVIEW SURVEY; NORD-TRONDELAG; PRIMARY-CARE; NOISE; MANAGEMENT; THRESHOLD; RISK; SURVEILLANCE; OCCUPATION; DEVICES AB Background Twenty-two million workers are exposed to hazardous noise in the United States. The purpose of this study is to estimate the prevalence of hearing loss among U.S. industries. Methods We examined 2000-2008 audiograms for male and female workers ages 18-65, who had higher occupational noise exposures than the general population. Prevalence and adjusted prevalence ratios (PRs) for hearing loss were estimated and compared across industries. Results In our sample, 18% of workers had hearing loss. When compared with the Couriers and Messengers industry sub-sector, workers employed in Mining (PR=1.65, CI=1.57-1.73), Wood Product Manufacturing (PR=1.65, CL=1.61-1.70), Construction of Buildings (PR=1.52, CI=1.45-1.59), and Real Estate and Rental and Leasing (PR=1.59, CL=1.51-1.68) had higher risks for hearing loss. Conclusions Workers in the Mining, Manufacturing, and Construction industries need better engineering controls for noise and stronger hearing conservation strategies. More hearing loss research is also needed within traditional low-risk industries like Real Estate. Am. J. Ind. Med. 56:670-681, 2013. (c) 2012 Wiley Periodicals, Inc. C1 [Masterson, Elizabeth A.; Tak, SangWoo; Themann, Christa L.; Wall, David K.; Groenewold, Matthew R.; Deddens, James A.; Calvert, Geoffrey M.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Tak, SangWoo] Massachusetts Dept Publ Hlth, Boston, MA USA. RP Masterson, EA (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 4676 Columbia Pkwy,MS-R17, Cincinnati, OH 45226 USA. EM emasterson@cdc.gov NR 57 TC 20 Z9 20 U1 1 U2 27 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD JUN PY 2013 VL 56 IS 6 BP 670 EP 681 DI 10.1002/ajim.22082 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 152HT UT WOS:000319523300007 PM 22767358 ER PT J AU King, BA Peck, RM Babb, SD AF King, Brian A. Peck, Richard M. Babb, Stephen D. TI Cost Savings Associated with Prohibiting Smoking in US Subsidized Housing SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID SECONDHAND SMOKE; FREE POLICIES; UNITED-STATES; EXPOSURE; RESIDENTS; ATTITUDES AB Background: Tobacco smoking in multiunit housing can lead to secondhand-smoke (SHS) exposure among nonsmokers, increased maintenance costs for units where smoking is permitted, and fire risks. During 2009-2010, approximately 7.1 million individuals lived in subsidized housing in the U.S., a large proportion of which were children, elderly, or disabled. Purpose: This study calculated the annual economic costs to society that could be averted by prohibiting smoking in all U.S. subsidized housing. Methods: Estimated annual cost savings associated with SHS-related health care, renovation of units that permit smoking, and smoking-attributable fires in U.S. subsidized housing were calculated using residency estimates from the U.S. Department of Housing and Urban Development and previously reported national and state cost estimates for these indicators. When state estimates were used, a price deflator was applied to account for differential costs of living or pricing across states. Estimates were calculated overall and by cost type for all U.S. subsidized housing, as well as for public housing only. Data were obtained and analyzed between January and March 2011. Results: Prohibiting smoking in all U.S. subsidized housing would yield cost savings of approximately $521 million per year, including $341 million in SHS-related healthcare expenditures, $108 million in renovation expenses, and $72 million in smoking-attributable fire losses. Prohibiting smoking in U.S. public housing alone would yield cost savings of approximately $154 million per year. Conclusions: Efforts to prohibit smoking in all U.S. subsidized housing would protect health and generate substantial cost savings to society. C1 CDC, Off Smoking & Hlth, Epidem Intelligence Serv, Atlanta, GA 30333 USA. Univ Illinois, Dept Econ, Chicago, IL 60680 USA. RP King, BA (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS K-50, Atlanta, GA 30341 USA. EM baking@cdc.gov FU Intramural CDC HHS [CC999999] NR 31 TC 11 Z9 11 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JUN PY 2013 VL 44 IS 6 BP 631 EP 634 DI 10.1016/j.amepre.2013.01.024 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 150DI UT WOS:000319370000009 PM 23683981 ER PT J AU Holman, DM Fox, KA Glenn, JD Guy, GP Watson, M Baker, K Cokkinides, V Gottlieb, M Lazovich, D Perna, FM Sampson, BP Seidenberg, AB Sinclair, C Geller, AC AF Holman, Dawn M. Fox, Kathleen A. Glenn, Jeffrey D. Guy, Gery P., Jr. Watson, Meg Baker, Katie Cokkinides, Vilma Gottlieb, Mark Lazovich, DeAnn Perna, Frank M. Sampson, Blake P. Seidenberg, Andrew B. Sinclair, Craig Geller, Alan C. TI Strategies to Reduce Indoor Tanning Current Research Gaps and Future Opportunities for Prevention SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID APPEARANCE-FOCUSED INTERVENTION; NONMELANOMA SKIN-CANCER; SERVICES TASK-FORCE; UNITED-STATES; MELANOMA; ATTITUDES; PRODUCTS; RISK; ADOLESCENTS; POPULATION AB Exposure to ultraviolet radiation from indoor tanning device use is associated with an increased risk of skin cancer, including risk of malignant melanoma, and is an urgent public health problem. By reducing indoor tanning, future cases of skin cancer could be prevented, along with the associated morbidity, mortality, and healthcare costs. On August 20, 2012, the CDC hosted a meeting to discuss the current body of evidence on strategies to reduce indoor tanning as well as research gaps. Using the Action Model to Achieve Healthy People 2020 Overarching Goals as a framework, the current paper provides highlights on the topics that were discussed, including (1) the state of the evidence on strategies to reduce indoor tanning; (2) the tools necessary to effectively assess, monitor, and evaluate the short- and long-term impact of interventions designed to reduce indoor tanning; and (3) strategies to align efforts at the national, state, and local levels through transdisciplinary collaboration and coordination across multiple sectors. Although many challenges and barriers exist, a coordinated, multilevel, transdisciplinary approach has the potential to reduce indoor tanning and prevent future cases of skin cancer. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Holman, Dawn M.; Fox, Kathleen A.; Glenn, Jeffrey D.; Guy, Gery P., Jr.; Watson, Meg] CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA. [Fox, Kathleen A.] CDC, Off Chief Staff, Atlanta, GA 30333 USA. [Cokkinides, Vilma] Amer Canc Soc, Dept Surveillance Res, Atlanta, GA 30329 USA. [Baker, Katie] E Tennessee State Univ, Skin Canc Prevent Lab, Coll Publ Hlth, Johnson City, TN 37614 USA. [Gottlieb, Mark] Northeastern Univ, Publ Hlth Advocacy Inst, Sch Law, Boston, MA 02115 USA. [Seidenberg, Andrew B.; Geller, Alan C.] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA. [Lazovich, DeAnn] Univ Minnesota, Div Epidemiol & Community Hlth, Masonic Canc Ctr, Minneapolis, MN USA. [Perna, Frank M.] NCI, Div Canc Control & Populat Sci, Behav Res Program, Rockville, MD USA. [Sampson, Blake P.] Univ Washington, Sch Med, Spokane, WA USA. [Sinclair, Craig] Canc Council Victoria, Canc Prevent Ctr, Carlton, Vic, Australia. RP Holman, DM (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy,MS-K55, Atlanta, GA 30341 USA. EM dholman@cdc.gov OI Gottlieb, Mark/0000-0001-8679-307X FU Intramural CDC HHS [CC999999] NR 89 TC 18 Z9 18 U1 0 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JUN PY 2013 VL 44 IS 6 BP 672 EP 681 DI 10.1016/j.amepre.2013.02.014 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 150DI UT WOS:000319370000014 PM 23683986 ER PT J AU Watson, M Holman, DM Fox, KA Guy, GP Seidenberg, AB Sampson, BP Sinclair, C Lazovich, D AF Watson, Meg Holman, Dawn M. Fox, Kathleen A. Guy, Gery P., Jr. Seidenberg, Andrew B. Sampson, Blake P. Sinclair, Craig Lazovich, DeAnn TI Preventing Skin Cancer Through Reduction of Indoor Tanning Current Evidence SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID HIGH-SCHOOL-STUDENTS; OF-THE-LITERATURE; UNITED-STATES; SUN EXPOSURE; ULTRAVIOLET-RADIATION; CUTANEOUS MELANOMA; YOUTH ACCESS; BED USE; ADOLESCENTS; RISK AB Exposure to ultraviolet radiation from indoor tanning devices (tanning beds, booths, and sun lamps) or from the sun contributes to the risk of skin cancer, including melanoma, which is the type of skin cancer responsible for most deaths. Indoor tanning is common among certain groups, especially among older adolescents and young adults, adolescent girls and young women, and non-Hispanic whites. Increased understanding of the health risks associated with indoor tanning has led to many efforts to reduce use. Most environmental and systems efforts in the U.S. (e.g., age limits or requiring parental consent/accompaniment) have occurred at the state level. At the national level, the U.S. Food and Drug Administration and the Federal Trade Commission regulate indoor tanning devices and advertising, respectively. The current paper provides a brief review of (1) the evidence on indoor tanning as a risk factor for skin cancer; (2) factors that may influence use of indoor tanning devices at the population level; and (3) various environmental and systems options available for consideration when developing strategies to reduce indoor tanning. This information provides the context and background for the companion paper in this issue of the American Journal of Preventive Medicine, which summarizes highlights from an informal expert meeting convened by the CDC in August 2012 to identify opportunities to prevent skin cancer by reducing use of indoor tanning devices. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Watson, Meg; Holman, Dawn M.; Fox, Kathleen A.; Guy, Gery P., Jr.] CDC, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Fox, Kathleen A.] CDC, Off Chief Staff, Atlanta, GA 30341 USA. [Seidenberg, Andrew B.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Sampson, Blake P.] Univ Washington, Sch Med, Spokane, WA USA. [Sinclair, Craig] Canc Council Victoria, Canc Prevent Ctr, Carlton, Vic, Australia. [Lazovich, DeAnn] Univ Minnesota, Div Epidemiol & Community Hlth, Masonic Canc Ctr, Minneapolis, MN USA. RP Watson, M (reprint author), CDC, Div Canc Prevent & Control, 4770 Buford Hwy,MS-K55, Atlanta, GA 30341 USA. EM EZE5@cdc.gov FU Intramural CDC HHS [CC999999] NR 79 TC 14 Z9 14 U1 2 U2 61 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JUN PY 2013 VL 44 IS 6 BP 682 EP 689 DI 10.1016/j.amepre.2013.02.015 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 150DI UT WOS:000319370000015 PM 23683987 ER PT J AU Gallo, MF Snead, MC Black, CM Brown, TM Kourtis, AP Jamieson, DJ Carter, M Penman-Aguilar, A Macaluso, M AF Gallo, Maria F. Snead, Margaret C. Black, Carolyn M. Brown, Teresa M. Kourtis, Athena P. Jamieson, Denise J. Carter, Marion Penman-Aguilar, Ana Macaluso, Maurizio TI Optimal methods for collecting and storing vaginal specimens for prostate-specific antigen testing in research studies SO CONTRACEPTION LA English DT Article DE Biomarker; In vitro experiment; Prostate-specific antigen ID SEXUALLY-TRANSMITTED-DISEASE; CHAIN-REACTION DETECTION; Y-CHROMOSOME SEQUENCES; MALE LATEX CONDOM; CLINICAL-TRIALS; POTENTIAL BIOMARKER; SEMEN; FLUID; FEMALE; PSA AB Background: Prostate-specific antigen (PSA) detected in vaginal fluid can be used in studies of HIV/sexually transmitted infection (STI) and pregnancy prevention as an alternative to relying on participant reports of exposure to semen. Optimal methods for collecting and storing specimens for this testing have not been determined. Study Design: We conducted a controlled, in vitro experiment of 550 specimens spiked with semen to determine the effects of swab type (five types), storage conditions of the swabs (room temperature with or without desiccant or at -80 degrees C without desiccant) and time from collection to testing (seven intervals over the course of 12 months) on the identification of PSA. We performed factorial analysis of variance to identify factors influencing PSA detection. Results: Concentrations of PSA detected in the swabs declined with time of storage over the 1-year experiment (p<.01). The 1-mL, rayon-tipped swab stored immediately at -80 degrees C following collection performed best. Conclusions: If immediate testing or freezer storage is not feasible, investigators should use a swab with 1-mL capacity with processing and testing as soon as possible after specimen collection. Published by Elsevier Inc. C1 [Gallo, Maria F.; Snead, Margaret C.; Kourtis, Athena P.; Jamieson, Denise J.; Carter, Marion; Penman-Aguilar, Ana] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Black, Carolyn M.; Brown, Teresa M.] Ctr Dis Control & Prevent, Div Sci Resources, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30341 USA. [Macaluso, Maurizio] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA. RP Gallo, MF (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,Mail Stop K-34, Atlanta, GA 30341 USA. EM mgallo@cdc.gov RI SADI, SHIVA/F-1774-2013; Macaluso, Maurizio/J-2076-2015 OI Macaluso, Maurizio/0000-0002-2977-9690 FU Intramural CDC HHS [CC999999] NR 26 TC 6 Z9 6 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD JUN PY 2013 VL 87 IS 6 BP 830 EP 835 DI 10.1016/j.contraception.2012.09.033 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 152RZ UT WOS:000319550100018 PM 23121826 ER PT J AU Leichliter, JS Haderxhanaj, LT Chesson, HW Aral, SO AF Leichliter, Jami S. Haderxhanaj, Laura T. Chesson, Harrell W. Aral, Sevgi O. TI Temporal Trends in Sexual Behavior Among Men Who Have Sex With Men in the United States, 2002 to 2006-2010 SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE trends; national probability sample; sexual behavior; MSM ID HIV-INFECTION; SECONDARY SYPHILIS; RISK BEHAVIORS; BLACK-MEN; YOUNG MEN; PREVALENCE; OPPORTUNITIES; DISPARITIES; PREVENTION; MSM AB Little is known about national trends in sexual behavior among MSM in the US. Data from the 2002 and 2006-2010 National Survey of Family Growth were used to compare sexual behaviors of sexually active MSM. Mean number of recent male partners significantly decreased from 2.9 in 2002 to 2.1 in 2006-2010 (P = 0.027), particularly among young MSM. Other sexual risk behaviors did not change or decrease over time. Our findings that sexual risk decreased as HIV and syphilis increased among MSM suggest that factors in addition to individual-level sexual risk should also be examined in relation to recent disease increases. C1 [Leichliter, Jami S.; Haderxhanaj, Laura T.; Chesson, Harrell W.; Aral, Sevgi O.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. RP Leichliter, JS (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd MS E-44, Atlanta, GA 30333 USA. EM jleichliter@cdc.gov FU Centers for Disease Control and Prevention (CDC); US Department of Energy FX This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention (CDC) administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and CDC. NR 26 TC 11 Z9 11 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JUN 1 PY 2013 VL 63 IS 2 BP 254 EP 258 DI 10.1097/QAI.0b013e31828e0cfc PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 146SY UT WOS:000319112500029 PM 23466645 ER PT J AU Oman, RF Vesely, SK Aspy, CB Tolma, EL Gavin, L Bensyl, DM Mueller, T Fluhr, JD AF Oman, Roy F. Vesely, Sara K. Aspy, Cheryl B. Tolma, Eleni L. Gavin, Lorrie Bensyl, Diana M. Mueller, Trisha Fluhr, Janene D. TI A Longitudinal Study of Youth Assets, Neighborhood Conditions, and Youth Sexual Behaviors SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Youth assets; Neighborhood environment; Broken windows; Teen pregnancy prevention; Youth risk behaviors ID ADOLESCENT HEALTH; RISK BEHAVIORS; FAMILY-STRUCTURE; PROGRAMS; POVERTY; RACE/ETHNICITY; ASSOCIATION; AGE AB Purpose: To prospectively determine whether individual, family, and community assets help youth to delay initiation of sexual intercourse (ISI); and for youth who do initiate intercourse, to use birth control and avoid pregnancy. The potential influence of neighborhood conditions was also investigated. Methods: The Youth Asset Study was a 4-year longitudinal study involving 1,089 youth (mean age = 14.2 years, standard deviation = 1.6; 53% female; 40% white, 28% Hispanic, 23% African American, 9% other race) and their parents. Participants were living in randomly selected census tracts. We accomplished recruitment via door-to-door canvassing. We interviewed one youth and one parent from each household annually. We assessed 17 youth assets (e.g., responsible choices, family communication) believed to influence behavior at multiple levels via in-person interviews methodology. Trained raters who conducted annual windshield tours assessed neighborhood conditions. Results: Cox proportional hazard or marginal logistic regression modeling indicated that 11 assets (e.g., family communication, school connectedness) were significantly associated with reduced risk for ISI; seven assets (e.g., educational aspirations for the future, responsible choices) were significantly associated with increased use of birth control at last sex; and 10 assets (e.g., family communication, school connectedness) were significantly associated with reduced risk for pregnancy. Total asset score was significantly associated with all three outcomes. Positive neighborhood conditions were significantly associated with increased birth control use, but not with ISI or pregnancy. Conclusions: Programming to strengthen youth assets may be a promising strategy for reducing youth sexual risk behaviors. (C) 2013 Society for Adolescent Health and Medicine. All rights reserved. C1 [Oman, Roy F.; Tolma, Eleni L.] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Dept Hlth Promot Sci, Oklahoma City, OK 73126 USA. [Vesely, Sara K.] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Dept Biostat & Epidemiol, Oklahoma City, OK 73126 USA. [Aspy, Cheryl B.] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Family & Prevent Med, Oklahoma City, OK 73126 USA. [Gavin, Lorrie; Mueller, Trisha] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Bensyl, Diana M.] Ctr Dis Control & Prevent, EIS Field Assignments Branch, Sci Educ & Profess Dev Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. [Fluhr, Janene D.] Oklahoma Inst Child Advocacy, Oklahoma City, OK USA. RP Oman, RF (reprint author), Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, POB 26901,Room 453, Oklahoma City, OK 73126 USA. EM Roy-Oman@ouhsc.edu OI Vesely, Sara/0000-0003-3448-0156 FU Centers for Disease Control and Prevention; Centers for Disease Control and Prevention (CDC) [5 U01 DP000132]; Inasmuch Foundation FX Drs. Oman, Vesely, Aspy, and Tolma and Ms. Fluhr received partial salary support from the Centers for Disease Control and Prevention for their participation in the study. Drs. Gavin and Bensyl and Ms. Mueller were employed by the Centers for Disease Control and Prevention during the study.; The Youth Asset Study was supported by Grant 5 U01 DP000132 from the Centers for Disease Control and Prevention (CDC) and funding from the Inasmuch Foundation. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or Inasmuch Foundation. NR 38 TC 10 Z9 10 U1 3 U2 32 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD JUN PY 2013 VL 52 IS 6 BP 779 EP 785 DI 10.1016/j.jadohealth.2012.12.005 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 151ZN UT WOS:000319499000018 PM 23402985 ER PT J AU Dallas, SD Mcgee, L Limbago, B Patel, JB McElmeel, ML Fulcher, LC Lonsway, DR Jorgensen, JH AF Dallas, Steven D. McGee, Lesley Limbago, Brandi Patel, Jean B. McElmeel, M. Leticia Fulcher, Letitia C. Lonsway, David R. Jorgensen, James H. TI Development of Doxycycline MIC and Disk Diffusion Interpretive Breakpoints and Revision of Tetracycline Breakpoints for Streptococcus pneumoniae SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article AB A study was performed to derive susceptibility testing interpretive breakpoints for doxycycline with Streptococcus pneumoniae and to reassess breakpoints for tetracycline using the requirements defined in Clinical and Laboratory Standards Institute (CLSI) document M23-A3. Tetracycline and doxycycline MICs and disk diffusion zone sizes were determined on 189 isolates selected from the 2009-2010 CDC Active Bacterial Core surveillance strain collection according to the testing methods described in CLSI documents M07-A8 and M02-A10. Tetracycline and doxycycline MICs and zones were compared to each other directly, and the reproducibility of MICs and zone diameters for both drugs was determined. Scatter-grams of tetracycline MICs versus corresponding zone diameters and doxycycline MICs versus zones were prepared, and analysis indicated that the present CLSI tetracycline MIC and disk breakpoints did not fit the susceptibility data for doxycycline. Doxycycline was 1 to 3 dilutions more potent than tetracycline, especially in strains harboring the tetM resistance determinant. tetM was detected in >= 90% of isolates having tetracycline MICs of >= 4 mu g/ml and in >= 90% with doxycycline MICs of >= 1. Limited pharmacokinetic/pharmacodynamic (PK/PD) data coupled with application of the error-rate bounded method of analysis suggested doxycycline-susceptible breakpoints of either <= 0.25 mu g/ml or <= 0.5 mu g/ml, with intermediate and resistant breakpoints 1 and 2 dilutions higher, respectively. The disk diffusion zone diameter correlates were susceptible at >= 28 mm, intermediate at 25 to 27 mm, and resistant at <= 24 mm. Revised lower tetracycline MIC breakpoints were suggested as susceptible at <= 1 mu g/ml, intermediate at 2 mu g/ml, and resistant at >= 4 mu g/ml. Suggested tetracycline disk diffusion zones were identical to those of doxycycline. C1 [Dallas, Steven D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Clin Lab Sci, San Antonio, TX 78229 USA. [Dallas, Steven D.; McElmeel, M. Leticia; Fulcher, Letitia C.; Jorgensen, James H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [McGee, Lesley] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA. [Limbago, Brandi; Lonsway, David R.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Patel, Jean B.] Ctr Dis Control & Prevent, Off Director, Atlanta, GA USA. RP Dallas, SD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Clin Lab Sci, San Antonio, TX 78229 USA. EM dallass@uthscsa.edu FU Meridian Biosciences Inc.; bioMerieux; Merck FX S.D.D. has received research support from Meridian Biosciences Inc. J.H.J. has consulted for Accelerate Diagnostics and Merck and received research support from bioMerieux and Merck. For all other authors, there are no conflicts to report. No outside funding was received to support this study. NR 12 TC 4 Z9 4 U1 0 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JUN PY 2013 VL 51 IS 6 BP 1798 EP 1802 DI 10.1128/JCM.00125-13 PG 5 WC Microbiology SC Microbiology GA 147VV UT WOS:000319197800023 PM 23554197 ER PT J AU Purfield, A Ahmad, N Park, BJ Kuhles, D St George, K Ginocchio, C Harris, JR AF Purfield, Anne Ahmad, Nina Park, Benjamin J. Kuhles, Daniel St George, Kirsten Ginocchio, Christine Harris, Julie R. TI Epidemiology of Commercial Rhesus Monkey Kidney Cells Contaminated with Coccidioides posadasii SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Letter C1 [Purfield, Anne; Park, Benjamin J.; Harris, Julie R.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA. [Purfield, Anne; Ahmad, Nina] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Ahmad, Nina; Kuhles, Daniel] New York State Dept Hlth, Bur Communicable Dis Control, Albany, NY USA. [St George, Kirsten] New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA. [Ginocchio, Christine] Hofstra North Shore LIJ Sch Med, Dept Pathol & Lab Med, Hempstead, NY USA. [Ginocchio, Christine] Hofstra North Shore LIJ Sch Med, Dept Mol Med, Hempstead, NY USA. [Ginocchio, Christine] North Shore LIJ Hlth Syst Labs, New York, NY USA. RP Purfield, A (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA. EM aip4@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JUN PY 2013 VL 51 IS 6 BP 2005 EP 2005 DI 10.1128/JCM.00697-13 PG 1 WC Microbiology SC Microbiology GA 147VV UT WOS:000319197800067 PM 23515550 ER PT J AU Forsythe, LP Kent, EE Weaver, KE Buchanan, N Hawkins, NA Rodriguez, JL Ryerson, AB Rowland, JH AF Forsythe, Laura P. Kent, Erin E. Weaver, Kathryn E. Buchanan, Natasha Hawkins, Nikki A. Rodriguez, Juan L. Ryerson, A. Blythe Rowland, Julia H. TI Receipt of Psychosocial Care Among Cancer Survivors in the United States SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID QUALITY-OF-LIFE; LONG-TERM SURVIVORS; SOCIAL SUPPORT; PATIENT; BREAST; COMMUNICATION; MORTALITY; DISTRESS; NEEDS; DEPRESSION AB Purpose Given the importance of psychosocial care for cancer survivors, this study used population-based data to characterize survivors who reported a discussion with health care provider(s) about the psychosocial effects of cancer and who reported using professional counseling or support groups (PCSG) and tested associations between receipt of psychosocial care and satisfaction with care. Patients and Methods We examined survivors of adult cancers from the 2010 National Health Interview Survey (N = 1,777). Multivariable logistic regression models examined factors associated with receipt of and satisfaction with psychosocial care. Results Most survivors (55.1%) reported neither provider discussions nor use of PCSG; 31.4% reported provider discussion only, 4.4% reported use of PCSG only, and 8.9% reported both. Non-Hispanic blacks (v non-Hispanic whites), married survivors, survivors of breast cancer (v prostate or less prevalent cancers), those treated with chemotherapy, and survivors reporting past research study/clinical trial participation were more likely to report provider discussion(s) (P < .01). Hispanics (v non-Hispanic whites), survivors age 40 to 49 years (v <= 39 years), survivors of breast cancer (v melanoma or less prevalent cancers), those diagnosed <= 1 year ago (v > 5 years ago), survivors treated with radiation, and past research participants were more likely to report use of PCSG (P < .05). Survivors reporting any psychosocial care were more likely to be "very satisfied" with how their needs were met (P < .001). Conclusion Many survivors do not report a discussion with providers about the psychosocial effects of cancer, which reflects a missed opportunity to connect survivors to psychosocial services. These data can benchmark the success of efforts to improve access to cancer-related psychosocial care. (c) 2013 by American Society of Clinical Oncology C1 [Forsythe, Laura P.; Kent, Erin E.; Rowland, Julia H.] NCI, NIH, Bethesda, MD 20892 USA. [Forsythe, Laura P.] Patient Centered Outcomes Res Inst, Washington, DC 20036 USA. [Weaver, Kathryn E.] Wake Forest Sch Med, Winston Salem, NC USA. [Buchanan, Natasha; Hawkins, Nikki A.; Rodriguez, Juan L.; Ryerson, A. Blythe] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Forsythe, LP (reprint author), Patient Centered Outcomes Res Inst, 1828 L St NW,Suite 900, Washington, DC 20036 USA. EM lforsythe@pcori.org FU National Cancer Institute, National Institutes of Health [HHSN 261201100189P]; Cancer Prevention Fellowship Program FX Supported by Contract No. HHSN 261201100189P from the National Cancer Institute, National Institutes of Health. Two authors were supported by the Cancer Prevention Fellowship Program (L.P.F. and E.E.K.). NR 59 TC 38 Z9 39 U1 2 U2 12 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JUN 1 PY 2013 VL 31 IS 16 BP 1961 EP + DI 10.1200/JCO.2012.46.2101 PG 10 WC Oncology SC Oncology GA 154FP UT WOS:000319657600016 PM 23610114 ER PT J AU Gahche, JJ Bailey, RL Mirel, LB Dwyer, JT AF Gahche, Jaime J. Bailey, Regan L. Mirel, Lisa B. Dwyer, Johanna T. TI The Prevalence of Using Iodine-Containing Supplements Is Low among Reproductive-Age Women, NHANES 1999-2006 SO JOURNAL OF NUTRITION LA English DT Article ID AMERICAN-THYROID-ASSOCIATION; UNITED-STATES; NATIONAL-HEALTH; NUTRITION; DEFICIENCY; PREGNANCY; RECOMMENDATIONS; TRENDS AB During pregnancy, the iodine requirement rises to meet demands for neurological development and fetal growth. If these requirements are not met, irreversible pathological cognitive and behavioral changes to the fetus may ensue. This study estimated the prevalence of iodine-containing dietary supplement (DS) use and intakes of iodine from DSs among pregnant women and nonpregnant women of reproductive age (15-39 y) who were interviewed and examined in NHANES 1999-2006 (n = 6404). Although 77.5% of pregnant women reported taking one or more DSs in the past 30 d, only 22.3% consumed an iodine-containing supplement. Most pregnant women reported using one DS and reported taking this product daily: The vast majority of iodine-containing DSs reported by pregnant women claimed an iodine content of 150 mu g iodine/serving on the label. Pregnant women using at least one DS containing iodine had a mean daily iodine intake of 122 mu g/d from supplements; the median value was 144 mu g/d. Median urinary iodine concentrations (UICs) were similar for pregnant and nonpregnant women in the population aged 15-39 y. The median UIC was 148 mu g/L for pregnant women and 133 mu g/L for nonpregnant women. The WHO has established a cutoff for insufficient iodine intake at <150 mu g/L for pregnant women and <100 mg/L for those who are not pregnant. This suggests that as a population, we may not be meeting adequate intakes of iodine for pregnant women. More research is needed on the iodine intakes of pregnant women and women of reproductive age on their total iodine intake from all sources, not just DSs. C1 [Gahche, Jaime J.; Mirel, Lisa B.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Natl Hlth & Nutr Examinat Surveys, Hyattsville, MD 20782 USA. [Bailey, Regan L.; Dwyer, Johanna T.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Dwyer, Johanna T.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA. [Dwyer, Johanna T.] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Dwyer, Johanna T.] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA. RP Gahche, JJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Natl Hlth & Nutr Examinat Surveys, Hyattsville, MD 20782 USA. EM dvt4@cdc.gov OI Dwyer, Johanna/0000-0002-0783-1769 NR 26 TC 11 Z9 13 U1 1 U2 3 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD JUN PY 2013 VL 143 IS 6 BP 872 EP 877 DI 10.3945/jn.112.169326 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 149GE UT WOS:000319306200016 PM 23616501 ER PT J AU Pfeiffer, CM Sternberg, MR Schleicher, RL Haynes, BMH Rybak, ME Pirkle, JL AF Pfeiffer, Christine M. Sternberg, Maya R. Schleicher, Rosemary L. Haynes, Bridgette M. H. Rybak, Michael E. Pirkle, James L. TI The CDC's Second National Report on Biochemical Indicators of Diet and Nutrition in the U.S. Population Is a Valuable Tool for Researchers and Policy Makers SO JOURNAL OF NUTRITION LA English DT Article ID TOTAL HOMOCYSTEINE CONCENTRATIONS; ASSAY-ADJUSTED DATA; METHYLMALONIC ACID; REPRODUCTIVE AGE; UNITED-STATES; FOLATE STATUS; SERUM; HEALTH; DEFICIENCY; WOMEN AB The CDC's National Report on Biochemical Indicators of Diet and Nutrition in the U.S. Population (Nutrition Report) is a serial publication that provides ongoing assessment of the population's nutritional status. The Nutrition Report presents data on blood and urine biomarker concentrations (selected water- and fat-soluble vitamins and nutrients, trace elements, dietary bioactive compounds) from a representative sample of the population participating in the NHANES. The Second Nutrition Report (released in 2012) contains reference information (means and percentiles) for 58 biomarkers measured during all or part of 2003-2006, stratified by age, sex, and race-ethnicity. Where available, we presented cutoff-based prevalence data during 2003-2006 and data on changes in biomarker concentrations or prevalence since 1999. Blood vitamin concentrations were generally higher in older (>= 60 y) than in younger (20-39 y) adults and lower in Mexican Americans and non-Hispanic blacks than in non-Hispanic whites. Nearly 80% of Americans (aged >= 6y) were not at risk of deficiencies in any of the 7 vitamins studied (vitamins A, B-6, B-12, C, D, and E and folate). Deficiency rates varied by age, sex, and race-ethnicity. Approximately 90% of women (aged 12-49 y) were not at risk of iron deficiency, but only 68% were not at risk of deficiencies in iron and all 7 vitamins. Young women (20-39 y) had median urine iodine concentrations bordering on insufficiency. First-time data are presented on plasma concentrations of 24 saturated and mono- and polyunsaturated fatty acids. Tabulation and graphical presentation of NHANES data in the Second Nutrition Report benefits those organizations involved in developing and evaluating nutrition policy. C1 [Pfeiffer, Christine M.; Sternberg, Maya R.; Schleicher, Rosemary L.; Haynes, Bridgette M. H.; Rybak, Michael E.; Pirkle, James L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Pfeiffer, CM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM cpfeiffer@cdc.gov OI Rybak, Michael/0000-0003-1650-8581 FU Intramural CDC HHS [CC999999] NR 32 TC 12 Z9 14 U1 0 U2 15 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD JUN PY 2013 VL 143 IS 6 BP 938S EP 947S DI 10.3945/jn.112.172858 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 149GE UT WOS:000319306200027 PM 23596164 ER PT J AU Sternberg, MR Schleicher, RL Pfeiffer, CM AF Sternberg, Maya R. Schleicher, Rosemary L. Pfeiffer, Christine M. TI Regression Modeling Plan for 29 Biochemical Indicators of Diet and Nutrition Measured in NHANES 2003-2006 SO JOURNAL OF NUTRITION LA English DT Article ID TESTS; INFERENCE; SELECTION AB The collection of articles in this supplement issue provides insight into the association of various covariates with concentrations of biochemical indicators of diet and nutrition (biomarkers), beyond age, race, and sex, using linear regression. We studied 10 specific sociodemographic and lifestyle covariates in combination with 29 biomarkers from NHANES 2003-2006 for persons aged >= 20y. The covariates were organized into 2 sets or "chunks": sociodemographic (age, sex, race-ethnicity, education, and income) and lifestyle (dietary supplement use, smoking, alcohol consumption, BM I, and physical activity) and fit in hierarchical fashion by using each category or set of related variables to determine how covariates, jointly, are related to biomarker concentrations. In contrast to many regression modeling applications, all variables were retained in a full regression model regardless of significance to preserve the interpretation of the statistical properties of beta coefficients, P values, and CIs and to keep the interpretation consistent across a set of biomarkers. The variables were preselected before data analysis, and the data analysis plan was designed at the outset to minimize the reporting of false-positive findings by limiting the amount of preliminary hypothesis testing. Although we generally found that demographic differences seen in biomarkers were over- or underestimated when ignoring other key covariates, the demographic differences generally remained significant after adjusting for sociodemographic and lifestyle variables. These articles are intended to provide a foundation to researchers to help them generate hypotheses for future studies or data analyses and/or develop predictive regression models using the wealth of NHANES data. C1 [Sternberg, Maya R.; Schleicher, Rosemary L.; Pfeiffer, Christine M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Pfeiffer, CM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM cpfeiffer@cdc.gov FU Intramural CDC HHS [CC999999] NR 28 TC 7 Z9 7 U1 0 U2 8 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD JUN PY 2013 VL 143 IS 6 BP 948S EP 956S DI 10.3945/jn.112.172957 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 149GE UT WOS:000319306200028 PM 23596165 ER PT J AU Pfeiffer, CM Sternberg, MR Schleicher, RL Rybak, ME AF Pfeiffer, Christine M. Sternberg, Maya R. Schleicher, Rosemary L. Rybak, Michael E. TI Dietary Supplement Use and Smoking Are Important Correlates of Biomarkers of Water-Soluble Vitamin Status after Adjusting for Sociodemographic and Lifestyle Variables in a Representative Sample of US Adults SO JOURNAL OF NUTRITION LA English DT Article ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; PLASMA TOTAL HOMOCYSTEINE; FOLIC-ACID FORTIFICATION; BODY-MASS INDEX; FOLATE STATUS; CHILDBEARING AGE; TOBACCO-SMOKE; NHANES-III; METHYLMALONIC ACID AB Biochemical indicators of water-soluble vitamin (WSV) status were measured in a nationally representative sample of the U.S. population in NHANES 2003-2006. To examine whether demographic differentials in nutritional status were related to and confounded by certain variables, we assessed the association of sociodemographic (age, sex, race-ethnicity, education, income) and lifestyle (dietary supplement use, smoking, alcohol consumption, BMI, physical activity) variables with biomarkers of WSV status in adults (aged >= 20 y): serum and RBC folate, serum pyridoxal-5'-phosphate (PLP), serum 4-pyridoxic acid, serum total cobalamin (vitamin B-12), plasma total homocysteine (tHcy), plasma methylmalonic acid (MMA), and serum ascorbic acid. Age (except for PLP) and smoking (except for M MA) were generally the strongest significant correlates of these biomarkers (vertical bar r vertical bar <= 0.43) and together with supplement use explained more of the variability compared with the other covariates in bivariate analysis. In multiple regression models, sociodemographic and lifestyle variables together explained from 7 (vitamin B-12) to 29% (tHcy) of the biomarker variability. We observed significant associations for most biomarkers (>= 6 of 8) with age, sex, race-ethnicity, supplement use, smoking, and BMI and for some biomarkers with FIR (5 of 8), education (1 of 8), alcohol consumption (4 of 8), and physical activity (5 of 8). We noted large estimated percentage changes in biomarker concentrations between race-ethnic groups (from -24 to 20%), between supplement users and nonusers (from -12 to 104%), and between smokers and nonsmokers (from -28 to 8%). In summary, age, sex, and race-ethnic differentials in biomarker concentrations remained significant after adjusting for sociodemographic and lifestyle variables. Supplement use and smoking were important correlates of biomarkers of WSV status. C1 [Pfeiffer, Christine M.; Sternberg, Maya R.; Schleicher, Rosemary L.; Rybak, Michael E.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Pfeiffer, CM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM cpfeiffer@cdc.gov OI Rybak, Michael/0000-0003-1650-8581 FU Intramural CDC HHS [CC999999] NR 50 TC 19 Z9 19 U1 1 U2 14 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 EI 1541-6100 J9 J NUTR JI J. Nutr. PD JUN PY 2013 VL 143 IS 6 BP 957S EP 965S DI 10.3945/jn.112.173021 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 149GE UT WOS:000319306200029 PM 23576641 ER PT J AU Schleicher, RL Sternberg, MR Pfeiffer, CM AF Schleicher, Rosemary L. Sternberg, Maya R. Pfeiffer, Christine M. TI Race-Ethnicity Is a Strong Correlate of Circulating Fat-Soluble Nutrient Concentrations in a Representative Sample of the US Population SO JOURNAL OF NUTRITION LA English DT Article ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; UNITED-STATES; ALPHA-TOCOPHEROL; ALCOHOL-CONSUMPTION; SERUM; ADULTS; BIOMARKERS; DIETARY; VARIABILITY AB Sociodemographic and lifestyle factors exert important influences on nutritional status; however, information on their association with biomarkers of fat-soluble nutrients is limited, particularly in a representative sample of adults. Serum or plasma concentrations of vitamin A, vitamin E, carotenes, xanthophylls, 25-hydroxyvitamin D [25(OH)D], SFAs, MUFAs, PUFAs, and total fatty acids (tFAs) were measured in adults (aged >= 20y) during all or part of NHANES 2003-2006. Simple and multiple linear regression models were used to assess 5 sociodemographic variables (age, sex, race-ethnicity, education, and income) and 5 lifestyle behaviors (smoking, alcohol consumption, BM I, physical activity, and supplement use) and their relation to biomarker concentrations. Adjustment for total serum cholesterol and lipid-altering drug use was added to the full regression model. Adjustment for latitude and season was added to the full model for 25(OH)D. Based on simple linear regression, race-ethnicity, BMI, and supplement use were significantly related to all fat-soluble biomarkers. Sociodemographic variables as a group explained 5-17% of biomarker variability, whereas together, sociodemographic and lifestyle variables explained 22-23% [25(OH)D, vitamin E, xanthophylls], 17% (vitamin A), 15% (MUFAs), 10-11% (SFAs, carotenes, tFAs), and 6% (PUFAs) of biomarker variability. Although lipid adjustment explained additional variability for all biomarkers except for 25(OH)D, it appeared to be largely independent of sociodemographic and lifestyle variables. After adjusting for sociodemographic, lifestyle, and lipid-related variables, major differences in biomarkers were associated with race-ethnicity (from -44 to 57%), smoking (up to -25%), supplement use (up to 21%), and BM I (up to -15%). Latitude and season attenuated some race-ethnicity differences. Of the sociodemographic and lifestyle variables examined, with or without lipid adjustment, most fat-soluble nutrient biomarkers were significantly associated with race-ethnicity. C1 [Schleicher, Rosemary L.; Sternberg, Maya R.; Pfeiffer, Christine M.] Ctr Dis Control & Prevent, Nutr Biomarkers Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Schleicher, RL (reprint author), Ctr Dis Control & Prevent, Nutr Biomarkers Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM rschleicher@cdc.gov FU Intramural CDC HHS [CC999999] NR 47 TC 9 Z9 9 U1 0 U2 7 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD JUN PY 2013 VL 143 IS 6 BP 966S EP 976S DI 10.3945/jn.112.172965 PG 11 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 149GE UT WOS:000319306200030 PM 23596163 ER PT J AU Pfeiffer, CM Sternberg, MR Caldwell, KL Pan, Y AF Pfeiffer, Christine M. Sternberg, Maya R. Caldwell, Kathleen L. Pan, Yi TI Race-Ethnicity Is Related to Biomarkers of Iron and Iodine Status after Adjusting for Sociodemographic and Lifestyle Variables in NHANES 2003-2006 SO JOURNAL OF NUTRITION LA English DT Article ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; US PRESCHOOL-CHILDREN; UNITED-STATES; CHILDBEARING AGE; ELDERLY POPULATION; MEXICAN-AMERICAN; PLASMA FERRITIN; DIETARY-INTAKE; WOMEN AB The NHANES 2003-2006 has assessed iron and iodine status, 2 trace element nutrients of continued public health interest, in the U.S. population. We investigated associations of sociodemographic (age, sex, race-ethnicity, education, income) and lifestyle (smoking, alcohol consumption, BM I, physical activity, dietary supplement use) variables with the iron status indicators serum ferritin, soluble transferrin receptor (sTfR), and body iron in women aged 20-49 y (n = 2539, 2513, and 2509, respectively) and with urine iodine, a biomarker of iodine intake, in adults aged y (n = 3066). Significant correlations between the study variables and biomarkers were weak (vertical bar r vertical bar <= 0.24). Urine creatinine (uCr) was Moderately significantly correlated with urine iodine (r= 0.52). The individual variables explained <= 5% of the variability in biomarker concentrations in bivariate analysis. In multiple regression models, sociodemographic and, lifestyle variables together explained 4-13% of the variability in iron indicators and 41% of the variability in urine iodine (uCr in the model). The adjusted estimated body iron was similar to 1 unit (mg/kg) lower in non-Hispanic black vs. non-Hispanic white women and similar to 1 unit higher in women who smoked vs. those who did not and in women consuming 1 vs. 0 alcoholic drinks/d. The adjusted estimated urine iodine concentration (uCr in the model) was 34% lower in non-Hispanic blacks vs. non-Hispanic whites, 22% higher in supplement users vs. nonusers, and 11% higher with every 10-y increase in age. In summary, after adjusting for sociodemographic and lifestyle variables (and uCr in the iodine model), race-ethnicity retained a strong association wilt sTfR, body iron, end urine iodine; smoking and alcohol consumption with iron biomarkers; and supplement use and age with urine iodine. C1 [Pfeiffer, Christine M.; Sternberg, Maya R.; Caldwell, Kathleen L.; Pan, Yi] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Pfeiffer, CM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. FU Intramural CDC HHS [CC999999] NR 51 TC 12 Z9 12 U1 1 U2 12 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 EI 1541-6100 J9 J NUTR JI J. Nutr. PD JUN PY 2013 VL 143 IS 6 BP 977S EP 985S DI 10.3945/jn.112.173039 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 149GE UT WOS:000319306200031 PM 23596169 ER PT J AU Rybak, ME Sternberg, MR Pfeiffer, CM AF Rybak, Michael E. Sternberg, Maya R. Pfeiffer, Christine M. TI Sociodemographic and Lifestyle Variables Are Compound- and Class-Specific Correlates of Urine Phytoestrogen Concentrations in the US Population SO JOURNAL OF NUTRITION LA English DT Article ID NUTRITION EXAMINATION SURVEY; CARDIOVASCULAR-DISEASE; PRODUCER PHENOTYPE; NATIONAL-HEALTH; DIETARY FACTORS; CANCER RISK; WOMEN; LIGNANS; ADULTS; METAANALYSIS AB Isoflavones and lignans are plant-derived dietary compounds generally believed to be beneficial to human health. We investigated the extent to which sociodemographic (age, sex, race-ethnicity, education, and income) and lifestyle variables (smoking, alcohol consumption, BMI, physical activity, and dietary supplement use) were correlates of spot urine concentration for daidzein, genistein, O-desmethylangolensin (DMA), equol, enterodiol, and enterolactone in the U.S. population aged >= 20 y (NHANES 2003-2006). We performed correlation analyses with continuous variables and calculated stratified unadjusted geometric means for each sociodemographic and lifestyle variable. We used bivariate significance testing and covariate adjustment by use of multiple regression models to identify influential variables and used beta coefficients to estimate relative effects. Urine creatinine was also included in our analyses because of its use in correcting for variable dilution in spot urine samples. We observed many significant (P < 0.05) associations with the sociodemographic and lifestyle variables that withstood covariate adjustment. Smoking was a significant correlate of urine DMA and enterolactone, with concentrations at least 25% lower in smokers vs. nonsmokers. Consumers of 1 daily alcoholic drink vs. none were estimated to have 18-21% lower urine equol and DMA concentrations. A 25% increase in BMI was associated with a 21% lower urine enterolactone concentration, and increasing physical activity was associated with a >6% higher urine enterolactone concentration. Dietary supplement use was not significantly associated with any of the urine phytoestrogens. Overall, we found that relationships between sociodemographic and lifestyle variables and urine phytoestrogen concentration were highly compound and class specific. C1 [Rybak, Michael E.; Sternberg, Maya R.; Pfeiffer, Christine M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Pfeiffer, CM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM cpfeiffer@cdc.gov OI Rybak, Michael/0000-0003-1650-8581 FU Intramural CDC HHS [CC999999] NR 48 TC 5 Z9 5 U1 1 U2 7 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 EI 1541-6100 J9 J NUTR JI J. Nutr. PD JUN PY 2013 VL 143 IS 6 BP 986S EP 994S DI 10.3945/jn.112.172981 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 149GE UT WOS:000319306200032 PM 23596167 ER PT J AU Vesper, HW Sternberg, MR Frame, T Pfeiffer, CM AF Vesper, Hubert W. Sternberg, Maya R. Frame, Tunde Pfeiffer, Christine M. TI Among 10 Sociodemographic and Lifestyle Variables, Smoking Is Strongly Associated with Biomarkers of Acrylamide Exposure in a Representative Sample of the US Population SO JOURNAL OF NUTRITION LA English DT Article ID NUTRITION EXAMINATION SURVEY; DNA ADDUCT FORMATION; HEMOGLOBIN ADDUCTS; DIETARY ACRYLAMIDE; MAILLARD REACTION; FISCHER-344 RATS; NATIONAL-HEALTH; GLYCIDAMIDE; CANCER; POLYMORPHISMS AB Hemoglobin adducts of acrylamide (HbAA) and glycidamide (HbGA) have been measured as biomarkers of acrylamide exposure and metabolism in a nationally representative sample of the U.S. population in the NHANES 2003-2004. We assessed the association of sociodemographic (age, sex, race-ethnicity, education, and income) and lifestyle (smoking, alcohol consumption, BMI, physical activity, and dietary supplement use) variables with these biomarkers in U.S. adults (aged >= 20 y). We used bivariate and multiple regression models and assessed the magnitude of an estimated change in biomarker concentration with change in a covariable for 2 biomarkers of acrylamide exposure. Smoking was strongly and significantly correlated with HbAA and HbGA concentrations (r(s) = 0.51 and 0.42, respectively), with biomarker concentrations being 126 and 101% higher in smokers compared with nonsmokers after adjusting for sociodemographic and lifestyle covariates. Age was moderately and significantly correlated with both biomarkers (r(s) = -0.21 and -0.22, respectively). BMI (r(s) = -0.11) and alcohol consumption (r(s) = 0.13) were weakly yet significantly correlated with HbAA concentrations only. The estimated percentage change in biomarker concentration was <= 20% for all variables other than smoking after adjusting for sociodemographic and lifestyle covariates. Using multiple regression models, the sociodemographic variables explained 9 and 7% whereas the sociodemographic and lifestyle variables together explained 46 and 25% of the variability in HbAA and HbGA, respectively, showing the importance of considering and adequately controlling for these variables in future studies. Our findings will be useful in the design and analysis of future studies that assess and evaluate exposure to acrylamide and its metabolism to glycidamide. C1 [Vesper, Hubert W.; Sternberg, Maya R.; Frame, Tunde; Pfeiffer, Christine M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Pfeiffer, CM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM cpfeiffer@cdc.gov FU Intramural CDC HHS [CC999999] NR 42 TC 2 Z9 2 U1 1 U2 9 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 EI 1541-6100 J9 J NUTR JI J. Nutr. PD JUN PY 2013 VL 143 IS 6 BP 995S EP 1000S DI 10.3945/jn.112.173013 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 149GE UT WOS:000319306200033 PM 23596166 ER PT J AU Haynes, BMH Pfeiffer, CM Sternberg, MR Schleicher, RL AF Haynes, Bridgette M. H. Pfeiffer, Christine M. Sternberg, Maya R. Schleicher, Rosemary L. TI Selected Physiologic Variables Are Weakly to Moderately Associated with 29 Biomarkers of Diet and Nutrition, NHANES 2003-2006 SO JOURNAL OF NUTRITION LA English DT Article ID PLASMA TOTAL HOMOCYSTEINE; 3RD NATIONAL-HEALTH; CHRONIC RENAL-INSUFFICIENCY; ACUTE-PHASE RESPONSE; WOMEN AGED 65; UNITED-STATES; METHYLMALONIC ACID; REPRESENTATIVE SAMPLE; COBALAMIN STATUS; REFERENCE RANGES AB The physiologic status of an individual may influence biomarkers of nutritional status. To help researchers with planning studies and interpreting data, we assessed the associations between common physiologic variables (fasting, inflammation, renal function, and pregnancy) and 29 biomarkers of diet and nutrition measured in blood or urine in a representative sample of the adult U.S. population (aged >= 20 y; pregnancy variable and iron indicators limited to women aged 20-49 y) participating in NHANES 2003-2006. We compared simple linear regression (model 1) with multiple linear regression [model 2, controlling for age, sex, race-ethnicity, smoking, supplement use, and the physiologic factors (and urine creatinine for urine biomarkers)] and report significant findings from model 2. Not being fasted was positively associated with most water-soluble vitamins (WSVs) and related metabolites (RMs). Some WSV, fat-soluble vitamin (FSV) and micronutrient (MN), and phytoestrogen concentrations were lower in the presence of inflammation (C-reactive protein >= 5 mg/L), whereas fatty acids and most iron indicators were higher. Most WSVs and RMs were higher when renal function was impaired [estimated glomerular filtration rate <60 mL/(min.1.73 m(2))]. Most WSV, FSV and MN, and fatty acid concentrations were higher in pregnant compared with nonpregnant women, but vitamins A and B-12 and most iron indicators were lower, The estimated changes in biomarker concentrations with different physiologic status were mostly small to moderate (<= 25%) and generally similar between models; renal function, however, showed several large differences for WSV and RM concentrations. This descriptive analysis of associations between physiologic variables and a large number of nutritional biomarkers showed that controlling for demographic variables, smoking, and supplement use generally did not change the interpretation of bivariate results. The analysis serves as a useful basis for more complex future research. C1 [Haynes, Bridgette M. H.; Pfeiffer, Christine M.; Sternberg, Maya R.; Schleicher, Rosemary L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Pfeiffer, CM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM cpfeiffer@cdc.gov FU Intramural CDC HHS [CC999999] NR 56 TC 11 Z9 11 U1 0 U2 6 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD JUN PY 2013 VL 143 IS 6 BP 1001S EP 1010S DI 10.3945/jn.112.172882 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 149GE UT WOS:000319306200034 PM 23596168 ER PT J AU Bjork, A Holman, RC Callinan, LS Hennessy, TW Cheek, JE McQuiston, JH AF Bjork, Adam Holman, Robert C. Callinan, Laura S. Hennessy, Thomas W. Cheek, James E. McQuiston, Jennifer H. TI Dog Bite Injuries among American Indian and Alaska Native Children SO JOURNAL OF PEDIATRICS LA English DT Article ID MOUNTAIN-SPOTTED-FEVER; UNITED-STATES; HOSPITALIZATIONS; ARIZONA; RESERVATION; OUTBREAK; EXPOSURE; ATTACKS; CARE AB Objective To examine dog bites among American Indian (AI) and Alaska Native (AN) children visiting Indian Health Service and tribal health facilities. Study design We retrospectively analyzed hospitalizations and outpatient visits with a diagnosis of dog bite between 2001 and 2008 in AI/AN children aged <20 years. Rates of dog bite hospitalizations and outpatient visits were estimated by age group, sex, region, and number and location of open wounds using Indian Health Service data. Analyses of hospitalizations for the general US population aged <20 years used the Nationwide Inpatient Sample. Results The average annual dog bite hospitalization rate was higher among AI/AN children in Alaska (6.1/100 000 population) and the Southwest region (5.3/100 000) compared with the general US child population (3.1/100 000; 95% CI, 2.9-3.3/100 000). The average annual outpatient visit rate in AI/AN children was highest in the Alaska (596.4/100 000), Southwest (540.0/100 000), and Northern Plains West (537.6/100 000) regions. The hospitalization rate was highest in both AI/AN and US males aged <5 years, and outpatient visit rates were highest in AI/AN males aged 5-9 years. Open wounds diagnoses weremost commonly seen on the head, neck, and face in hospitalized children (45.5% of open wounds in AI/AN children, 59.3% in US children; SE, 1.0%) and on the leg in AI/AN outpatients (35.6%). Conclusion Dog bites represent a significant public health threat in AI/AN children in the Alaska, the Southwest, and Northern PlainsWest regions of the US. Enhanced animal control and education efforts should reduce dog bite injuries and associated problems with pets and stray dogs, such as emerging infectious diseases. C1 [Bjork, Adam] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA. [Bjork, Adam; McQuiston, Jennifer H.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. [Holman, Robert C.; Callinan, Laura S.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. [Hennessy, Thomas W.] Ctr Dis Control & Prevent, Arctic Invest Program, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. [Cheek, James E.] Indian Hlth Serv, Off Publ Hlth Support, Div Epidemiol & Prevent, Albuquerque, NM USA. RP Bjork, A (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A-30, Atlanta, GA 30329 USA. EM abjork@cdc.gov OI Bjork, Adam/0000-0001-7544-2987 NR 39 TC 3 Z9 3 U1 0 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 J9 J PEDIATR-US JI J. Pediatr. PD JUN PY 2013 VL 162 IS 6 BP 1270 EP 1275 DI 10.1016/j.jpeds.2012.11.087 PG 6 WC Pediatrics SC Pediatrics GA 152AV UT WOS:000319502700037 PM 23332462 ER PT J AU Williams, SE Edwards, KM Baxter, RP LaRussa, PS Halsey, NA Dekker, CL Vellozzi, C Marchant, CD Donofrio, PD Reimschisel, TE Berger, M Gidudu, JF Klein, NP AF Williams, S. Elizabeth Edwards, Kathryn M. Baxter, Roger P. LaRussa, Philip S. Halsey, Neal A. Dekker, Cornelia L. Vellozzi, Claudia Marchant, Colin D. Donofrio, Peter D. Reimschisel, Tyler E. Berger, Melvin Gidudu, Jane F. Klein, Nicola P. TI Comprehensive Assessment of Serious Adverse Events Following Immunization by Health Care Providers SO JOURNAL OF PEDIATRICS LA English DT Editorial Material ID GUILLAIN-BARRE-SYNDROME; ACUTE DISSEMINATED ENCEPHALOMYELITIS; VACCINE-SAFETY; TRANSVERSE MYELITIS; CLINICAL-FEATURES; VARICELLA-VACCINE; CHILDREN; SEIZURES; TETANUS; RISK C1 [Williams, S. Elizabeth; Edwards, Kathryn M.; Donofrio, Peter D.; Reimschisel, Tyler E.] Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Res Program, Nashville, TN 37232 USA. [Baxter, Roger P.; Klein, Nicola P.] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA. [LaRussa, Philip S.] Columbia Univ, Div Pediat Infect Dis, New York, NY USA. [Halsey, Neal A.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Dis Prevent & Control Program, Baltimore, MD USA. [Dekker, Cornelia L.] Stanford Univ, Sch Med, Div Pediat Infect Dis, Stanford, CA 94305 USA. [Vellozzi, Claudia; Gidudu, Jane F.] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual & Promot, Natl Ctr Emerging & Zoonot Infect Dis,Off Infect, Atlanta, GA USA. [Marchant, Colin D.] Boston Med Ctr, Boston, MA USA. [Berger, Melvin] CSL Behring LLC, Immunol Res & Dev, King Of Prussia, PA USA. RP Williams, SE (reprint author), Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Res Program, 1161 21st Ave S,CCC 5326 MCN, Nashville, TN 37232 USA. EM elizabeth.williams@vanderbilt.edu FU NCIRD CDC HHS [U01 IP000488-02]; PHS HHS [HHSN272200800007C, 200-2012-50430] NR 64 TC 4 Z9 4 U1 0 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 J9 J PEDIATR-US JI J. Pediatr. PD JUN PY 2013 VL 162 IS 6 BP 1276 EP + DI 10.1016/j.jpeds.2013.01.028 PG 7 WC Pediatrics SC Pediatrics GA 152AV UT WOS:000319502700038 PM 23452584 ER PT J AU Dyer, JL Niezgoda, M Orciari, LA Yager, PA Ellison, JA Rupprecht, CE AF Dyer, Jessie L. Niezgoda, Michael Orciari, Lillian A. Yager, Pamela-A. Ellison, James A. Rupprecht, Charles E. TI Evaluation of an indirect rapid immunohistochemistry test for the differentiation of rabies virus variants SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Rabies; Immunohistochemistry; Rabies virus variants ID MONOCLONAL-ANTIBODIES; UNITED-STATES; DIAGNOSIS; COUNTRIES; STRAINS; STREET AB Cost effective diagnostic tests are needed in rabies virus (RABV) enzootic areas to study the prevalence, distribution, and transmission of rabies virus among reservoir hosts. To reduce the associated costs of acquiring and maintaining specialized laboratory equipment, an indirect rapid immunohistochemistry test (IRIT), for the detection and differentiation of RABV variants, was evaluated by traditional light microscopy. The IRIT utilizes fresh frozen brain touch impressions or cell culture monolayers fixed in buffered formalin, a panel of murine anti-nucleoprotein monoclonal antibodies (mAb-N) and commercially available biotin-labeled goat anti-mouse antibody. In this study, 96 RABV isolates, representing 20 RABV variants previously determined by antigenic typing using a panel of mAb-N and the indirect fluorescent antibody test (IFA), and genetic sequence analysis were characterized by IRIT and the results. compared. The IRIT results revealed distinct reactivity patterns associated with current and historical RABV reservoir hosts similar to IFA test and genetic sequence analysis. Evaluation of suspected RABV samples through IRIT does not require specialized equipment and is possible to perform in a field setting. Additionally, commercially available labeled secondary antibodies permit the use of a standard panel of unlabeled primary mAbs, without the need for fluorescence microscopy, and should augment existing attempts at antigenic characterization during canine rabies elimination campaigns in developed and developing countries. These results are useful in studying the epizootiology of rabies and inferring the source of infection when unknown. (C) 2013 Elsevier B.V. All rights reserved. C1 [Dyer, Jessie L.; Niezgoda, Michael; Orciari, Lillian A.; Yager, Pamela-A.; Ellison, James A.; Rupprecht, Charles E.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Poxvirus & Rabies Branch, Atlanta, GA 30329 USA. RP Dyer, JL (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Poxvirus & Rabies Branch, 1600 Clifton Rd NE,MS-G33, Atlanta, GA 30329 USA. EM JLDyer@cdc.gov OI Ellison, James/0000-0003-4492-4857 FU Emerging Infectious Diseases (EID) Fellowship Program; Association of Public Health Laboratories (APHL); CDC FX The authors thank several United States Departments of Health (AL, AZ, CA, CO, CT, NC, ND, NM, PA, SD, TX, VA) for providing samples as part of enhanced rabies surveillance efforts as well as Dillon Hightower, Modupe Osinubi and Andres Velasco-Villa of the Poxvirus and Rabies Branch, CDC. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. This research was supported in part by an appointment to the Emerging Infectious Diseases (EID) Fellowship Program administered by the Association of Public Health Laboratories (APHL) and funded by CDC. NR 29 TC 4 Z9 5 U1 0 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 J9 J VIROL METHODS JI J. Virol. Methods PD JUN PY 2013 VL 190 IS 1-2 BP 29 EP 33 DI 10.1016/j.jviromet.2013.03.009 PG 5 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 153XU UT WOS:000319636900006 PM 23541783 ER PT J AU Hamilton, BE Hoyert, DL Martin, JA Strobino, DM Guyer, B AF Hamilton, Brady E. Hoyert, Donna L. Martin, Joyce A. Strobino, Donna M. Guyer, Bernard TI Annual Summary of Vital Statistics: 2010-2011 EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material C1 [Hamilton, Brady E.; Hoyert, Donna L.; Martin, Joyce A.] Ctr Dis Control & Prevent, Div Vital Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Strobino, Donna M.; Guyer, Bernard] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat & Family Hlth Sci, Baltimore, MD USA. RP Hamilton, BE (reprint author), Ctr Dis Control & Prevent, Div Vital Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. NR 1 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD JUN PY 2013 VL 68 IS 6 BP 421 EP 422 DI 10.1097/01.ogx.0000431312.76961.4b PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 152VI UT WOS:000319559100007 ER PT J AU Parvez, F Katyal, M Alper, H Leibowitz, R Venters, H AF Parvez, Farah Katyal, Monica Alper, Howard Leibowitz, Ruth Venters, Homer TI Female sex workers incarcerated in New York City jails: prevalence of sexually transmitted infections and associated risk behaviors SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Article ID WOMEN AB Objectives Sexually transmitted infections (STIs) are an important cause of morbidity among incarcerated women and female sex workers (FSW). Little is known about FSW incarcerated in New York City (NYC) jails. We reviewed jail health records to identify the STI and HIV prevalence among newly incarcerated FSW in NYC jails. We also examined the relationship of demographics and self-reported clinical and risk behaviour history with FSW status and compared FSW with non-FSW incarcerated women to identify FSW predictors and, guide NYC jail programme planning and policy. Methods We retrospectively reviewed routinely collected jail health record data to identify the prevalence of chlamydia (Ct), gonorrhoea (Ng) and HIV infection among women newly incarcerated in NYC jails in 2009-2010 (study period) and studied the relationship of STIs, demographics and self-reported clinical and risk behaviour history with FSW status. Results During the study period, 10 828 women were newly incarcerated in NYC jails. Of these, 10 115 (93%) women were tested for Ct and Ng; positivity was 6.2% (95% CI 5.7% to 6.7%) and 1.7% (95% CI 1.4% to 1.9%), respectively. Nine percent had HIV infection. Seven hundred (6.5%) were defined as FSW. FSW were more likely to have Ct (adjusted OR (AOR): 1.55; 95% CI 1.17 to 2.05; p<0.0001) but not Ng or HIV. FSW were more likely to report age 20-24 years, reside in boroughs other than Manhattan, >= 6 prior incarcerations, >= 2 incarcerations during the study period, condom use with current sex partners, multiple sex partners and current drug use. Conclusions Women incarcerated in NYC jails had high rates of Ct, Ng, and HIV infection. FSW were at higher risk for Ct than non-FSW incarcerated women. These findings are being used to design targeted interventions to identify FSW, provide clinical and preventive services in jail and coordinate care with community partners. C1 [Parvez, Farah; Katyal, Monica; Alper, Howard; Venters, Homer] New York City Dept Hlth & Mental Hyg, Long Isl City, NY 11101 USA. [Parvez, Farah] Natl Ctr HIV AIDS, STD, Atlanta, GA USA. [Parvez, Farah] Ctr Dis Control & Prevent, TB Prevent, Atlanta, GA USA. [Leibowitz, Ruth] New York City Dept Hlth & Mental Hyg, Bur Correct Hlth Serv, Long Isl City, NY 11101 USA. RP Venters, H (reprint author), New York City Dept Hlth & Mental Hyg, Bur Correct Hlth Serv, 42-09 28th St,10th Floor,10-84,CN 52, Long Isl City, NY 11101 USA. EM hventer1@health.nyc.gov NR 10 TC 11 Z9 11 U1 1 U2 13 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUN PY 2013 VL 89 IS 4 BP 280 EP 284 DI 10.1136/sextrans-2012-050977 PG 5 WC Infectious Diseases SC Infectious Diseases GA 148OE UT WOS:000319253800003 PM 23687128 ER PT J AU Aral, SO Cates, W AF Aral, Sevgi O. Cates, Willard, Jr. TI Coverage, context and targeted prevention: optimising our impact SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; HIV PREVENTION; INFECTION; HEALTH; TRANSMISSION; STRATEGIES; EPIDEMICS; TRIALS AB Development of efficacious interventions is only the first step in achieving population level impact. Efficacious interventions impact infection levels in the population only if they are implemented at the right scale. Coverage must be prioritised across subpopulations based on the diversity and clustering of infections and risk in society, and expanded rapidly without delay. It is important to prioritise those who are most likely to transmit infection first. C1 [Aral, Sevgi O.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Cates, Willard, Jr.] FHI 360, Res Triangle Pk, NC USA. RP Aral, SO (reprint author), Ctr Dis Control & Prevent, CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, 1600 Clifton Rd,Mailstop E-02, Atlanta, GA 30333 USA. EM SAral@cdc.gov FU Preventive Technologies [GHO-A-00-09-00016-00]; HIV Prevention Trials Network Coordinating and Operations Center [1 U01 A1068619-01]; Microbicides Trials Network Operations Center [1 U01 A1068633-01] FX WC is funded by: Preventive Technologies Agreement, GHO-A-00-09-00016-00; HIV Prevention Trials Network Coordinating and Operations Center, 1 U01 A1068619-01; Microbicides Trials Network Operations Center, 1 U01 A1068633-01. NR 30 TC 12 Z9 12 U1 1 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUN PY 2013 VL 89 IS 4 BP 336 EP + DI 10.1136/sextrans-2012-050707 PG 5 WC Infectious Diseases SC Infectious Diseases GA 148OE UT WOS:000319253800019 PM 23270932 ER PT J AU Elliott, JC Aharonovich, E O'Leary, A Wainberg, M Hasin, D AF Elliott, J. C. Aharonovich, E. O'Leary, A. Wainberg, M. Hasin, D. TI ALCOHOL MOTIVES AND DRINKING BEHAVIORS IN HIV PRIMARY CARE PATIENTS SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 36th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 22-26, 2013 CL Orlando, FL SP Res Soc Alcoholism C1 [Elliott, J. C.; Aharonovich, E.; O'Leary, A.; Wainberg, M.; Hasin, D.] Columbia Univ, New York, NY 10032 USA. [Elliott, J. C.; Aharonovich, E.; O'Leary, A.; Wainberg, M.; Hasin, D.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2013 VL 37 SU 2 SI SI BP 155A EP 155A PG 1 WC Substance Abuse SC Substance Abuse GA 145EU UT WOS:000318998300578 ER PT J AU Dang, EP AF Dang, E. P. TI WOMEN'S PERCEPTION OF RISKS OF PRENATAL ALCOHOL EXPOSURE: FORMATIVE RESEARCH, MESSAGE TESTING, AND MATERIALS DEVELOPMENT SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 36th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 22-26, 2013 CL Orlando, FL SP Res Soc Alcoholism C1 [Dang, E. P.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2013 VL 37 SU 2 SI SI BP 303A EP 303A PG 1 WC Substance Abuse SC Substance Abuse GA 145EU UT WOS:000318998301351 ER PT J AU Mainous, AG Wright, RU Hulihan, MM Twal, WO McLaren, CE Diaz, VA McLaren, GD Argraves, WS Grant, AM AF Mainous, Arch G., III Wright, Robert U. Hulihan, Mary M. Twal, Waleed O. McLaren, Christine E. Diaz, Vanessa A. McLaren, Gordon D. Argraves, W. Scott Grant, Althea M. TI Telomere length and elevated iron: The influence of phenotype and HFE genotype SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Article ID HEREDITARY HEMOCHROMATOSIS; TRANSFERRIN SATURATION; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; GENE-MUTATIONS; OVERLOAD; POPULATION; RISK; CANCER; MORTALITY AB Elevated body iron stores are associated with morbidity and mortality due to oxidative stress. Hereditary hemochromatosis, a common condition caused by HFE gene mutations, can lead to excess iron storage and disease but clinical penetrance of HFE gene mutations is low and many people with elevated iron stores lack HFE mutations. We analyzed data from the Hemochromatosis and Iron Overload Screening Study to assess the relationship among HFE genotype (individuals with either homozygous or compound heterozygous status for C282Y and/or H63D HFE mutations were defined as genotype positive, or G+), elevated iron phenotype (individuals exceeding gender-specific transferrin saturation and serum ferritin threshold levels were considered phenotype positive, or P+), and leukocyte telomere length, a marker of biological aging and cumulative oxidative stress. In unadjusted analyses in comparison to individuals who were GP, G+P were not significantly different (OR 0.74; 95% CI 0.262.04), while the G+P+ (OR 2.03; 95% CI 1.153.56), and GP+ (OR 2.24; 95% CI 1.53.29) had increased risk of short telomeres (<=25th percentile) rather than long telomeres (>=75th percentile). In analyses adjusting for age, gender, and race/ethnicity, the effect of individuals with elevated iron phenotypes having short telomeres persisted with G+P+ individuals (OR 1.94; 95% CI 1.023.72), and GP+ individuals (OR 2.17; 95% CI 1.393.39) being significantly different from the GP group. In conclusion, elevated iron phenotype, but not HFE genotype, was associated with shortened telomeres. Further studies will be needed to determine whether telomere length provides a marker for morbidities specifically associated with iron overload. Am. J. Hematol. 88:492496, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Mainous, Arch G., III; Wright, Robert U.; Diaz, Vanessa A.] Med Univ S Carolina, Dept Family Med, Charleston, SC 29425 USA. [Hulihan, Mary M.; Grant, Althea M.] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA. [Twal, Waleed O.; Argraves, W. Scott] Med Univ S Carolina, Dept Regenerat Med, Charleston, SC 29425 USA. [McLaren, Christine E.] Univ Calif Irvine, Dept Epidemiol, Irvine, CA USA. [McLaren, Gordon D.] Long Beach Healthcare Syst, Dept Vet Affairs, Long Beach, CA USA. [McLaren, Gordon D.] Univ Calif Irvine, Dept Med, Div Hematol Oncol, Irvine, CA 92717 USA. RP Mainous, AG (reprint author), Med Univ S Carolina, Dept Family Med, Charleston Ctr 5, Suite 263, Charleston, SC 29425 USA. EM mainouag@musc.edu OI Mainous, Arch/0000-0002-2535-7685 FU Centers for Disease Control and Prevention (CDC) [1U01DD000754]; National Heart Lung and Blood Institute (NHLBI); NIH/NCRR South Carolina COBRE for Cardiovascular Disease [NIH/NCRR P20 RR016434]; South Carolina IDeA Networks of Biomedical Research Excellence (INBRE) [NIH/NCRR P20 RR16461] FX Contract grant sponsor: Centers for Disease Control and Prevention (CDC); Contract grant number: 1U01DD000754.; Contract grant sponsor: National Heart Lung and Blood Institute (NHLBI).; Contract grant sponsor: NIH/NCRR South Carolina COBRE for Cardiovascular Disease; Contract grant number: NIH/NCRR P20 RR016434.; Contract grant sponsor: South Carolina IDeA Networks of Biomedical Research Excellence (INBRE); Contract grant number: NIH/NCRR P20 RR16461. NR 54 TC 5 Z9 5 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 J9 AM J HEMATOL JI Am. J. Hematol. PD JUN PY 2013 VL 88 IS 6 BP 492 EP 496 DI 10.1002/ajh.23438 PG 5 WC Hematology SC Hematology GA 149BM UT WOS:000319293000008 PM 23512844 ER PT J AU Adetona, O Horton, K Sjodin, A Jones, R Hall, DB Aguillar-Villalobos, M Cassidy, BE Vena, JE Needham, LL Naeher, LP AF Adetona, Olorunfemi Horton, Kevin Sjodin, Andreas Jones, Richard Hall, Daniel B. Aguillar-Villalobos, Manuel Cassidy, Brandon E. Vena, John E. Needham, Larry L. Naeher, Luke P. TI Concentrations of select persistent organic pollutants across pregnancy trimesters in maternal and in cord serum in Trujillo, Peru SO CHEMOSPHERE LA English DT Article DE Persistent organic pollutants; Polychlorinated biphenyls; Organochlorine pesticides; Pregnancy; Trimesters ID POLYBROMINATED DIPHENYL ETHERS; ORGANOCHLORINE PESTICIDES; CRITICAL WINDOWS; WOMEN; NEURODEVELOPMENT; DETERMINANTS; POSTPARTUM; EXPOSURE; SPAIN; PCBS AB Although the production and use of some persistent organic pollutants (POPs) have been banned or highly restricted, human exposure remains a subject of investigation due to their environmental persistence. Physiological changes during pregnancy may affect the disposition of POPs in the mother's body, and thus fetal exposure. Changes in serum concentrations of organochlorine pesticides (OCP5) and polychlorinated biphenyls (PCBs) across pregnancy trimesters, and trans-placental transfer to the fetus were investigated. Seventy-nine pregnant women in Trujillo, Peru were recruited in the first trimester of pregnancy, and provided blood samples for the analysis of 35 PCB congeners, 9 OCPs, and 11 polybrominated biphenyl diethers (PBDEs). Subsequently, maternal blood samples were collected in the second (n = 64) and third trimesters (n = 59), and cord blood samples (n = 50) were collected at delivery. There were statistically significant changes across trimesters (p < 0.05) for both fresh weight (increase) and lipid adjusted concentrations (decrease) of hexachlorobenzene (HCB), 2,2-Bis(4-chlorophenyl)-1,1-dichloroethene (p,p'-DDE), PCB-74, 118, 138-158, 153, 170, 180 and 194. Fresh weight concentrations of these POPs increased from first to third trimester by 10-28%. On the other hand lipid adjusted concentrations decreased from first to third trimester by 16-28%. Serum lipids increased from first to third trimester by 53% indicating the dilution of the POPs in the lipids. Concentrations of 2,2-Bis(4-chlorophenyl)-1,1,1-trichloroethane (p,p'-DDT), its metabolite p,p'-DDE, PCB-118, 138-158, 153, 170 and 180 above their limits of detection were measured in >60% of cord serum samples. Intra-individual correlations in maternal serum concentrations were high for most of the POPs (rho = 0.62-0.99; p < 0.05) while correlations between maternal and cord serum concentrations were also high (rho = 0.68-0.99; p < 0.05). Results indicate that the disposition in the body and blood concentrations of POPs may change during pregnancy, and show trans-placental transfer of DDT, DDE and PCBs. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Adetona, Olorunfemi; Horton, Kevin; Cassidy, Brandon E.; Naeher, Luke P.] Univ Georgia, Coll Publ Hlth, Dept Environm Hlth Sci, Athens, GA 30602 USA. [Horton, Kevin] Agcy Tox Subst & Dis Registry, Atlanta, GA USA. [Sjodin, Andreas; Jones, Richard; Needham, Larry L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Hall, Daniel B.] Univ Georgia, Dept Stat, Franklin Coll Arts & Sci, Athens, GA 30602 USA. [Aguillar-Villalobos, Manuel] Asociac Aire Ambiental, Lima, Peru. [Vena, John E.] Univ Georgia, Coll Publ Hlth, Dept Epidemiol & Biostat, Athens, GA USA. RP Naeher, LP (reprint author), Univ Georgia, Coll Publ Hlth, Dept Environm Hlth Sci, Athens, GA 30602 USA. EM lnaeher@uga.edu RI Sjodin, Andreas/F-2464-2010 FU ISEA; ACC FX ISEA and ACC, the organizations that provided funding for this study had no role in its conduct; they had no role in the design of this study, collection and analysis of data, interpretation of data, manuscript writing or the decision to submit this manuscript. NR 33 TC 13 Z9 13 U1 5 U2 40 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0045-6535 J9 CHEMOSPHERE JI Chemosphere PD JUN PY 2013 VL 91 IS 10 BP 1426 EP 1433 DI 10.1016/j.chemosphere.2013.01.043 PG 8 WC Environmental Sciences SC Environmental Sciences & Ecology GA 146MC UT WOS:000319094200007 PM 23453434 ER PT J AU Kurbatova, EV Kaminski, DA Erokhin, VV Volchenkov, GV Andreevskaya, SN Chernousova, LN Demikhova, OV Ershova, JV Kaunetis, NV Kuznetsova, TA Larionova, EE Smirnova, TG Somova, TR Vasilieva, IA Vorobieva, AV Zolkina, SS Cegielski, JP AF Kurbatova, E. V. Kaminski, D. A. Erokhin, V. V. Volchenkov, G. V. Andreevskaya, S. N. Chernousova, L. N. Demikhova, O. V. Ershova, J. V. Kaunetis, N. V. Kuznetsova, T. A. Larionova, E. E. Smirnova, T. G. Somova, T. R. Vasilieva, I. A. Vorobieva, A. V. Zolkina, S. S. Cegielski, J. P. TI Performance of Cepheid(A (R)) Xpert MTB/RIFA (R) and TB-Biochip(A (R)) MDR in two regions of Russia with a high prevalence of drug-resistant tuberculosis SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES LA English DT Article ID NUCLEIC-ACID AMPLIFICATION; REAL-TIME PCR; MYCOBACTERIUM-TUBERCULOSIS; RIFAMPIN-RESISTANT; PULMONARY TUBERCULOSIS; QUALITY-CONTROL; DIAGNOSIS; ASSAY; IDENTIFICATION; HYBRIDIZATION AB The purpose of this study was to assess the performance of CepheidA (R) Xpert MTB/RIFA (R) ("Xpert") and TB-BiochipA (R) MDR ("TB-Biochip"). Sputum specimens from adults with presumptive tuberculosis (TB) were homogenized and split for: (1) direct Xpert and microscopy, and (2) concentration for Xpert, microscopy, culture [Lowenstein-Jensen (LJ) solid media and Mycobacteria Growth Indicator TubeA (R) (MGIT)], indirect drug susceptibility testing (DST) using the absolute concentration method and MGIT, and TB-Biochip. In total, 109 of 238 (45.8 %) specimens were culture-positive for Mycobacterium tuberculosis complex (MTBC), and, of these, 67 isolates were rifampicin resistant (RIF-R) by phenotypic DST and 64/67 (95.5 %) were isoniazid resistant (INH-R). Compared to culture of the same specimen, a single direct Xpert was more sensitive for detecting MTBC [95.3 %, 95 % confidence interval (CI), 90.0-98.3 %] than direct (59.6 %, 95 % CI, 50.2-68.5 %) or concentrated smear (85.3 %, 95 % CI, 77.7-91.1 %) or LJ culture (80.8 %, 95 % CI, 72.4-87.5 %); the specificity was 86.0 % (95 % CI, 78.9-91.3 %). Compared with MGIT DST, Xpert correctly identified 98.2 % (95 % CI, 91.5-99.9 %) of RIF-R and 95.5 % (95 % CI, 85.8-99.2 %) of RIF-susceptible (RIF-S) specimens. In a subset of 104 specimens, the sensitivity of TB-Biochip for MTBC detection compared to culture was 97.3 % (95 % CI, 91.0-99.5 %); the specificity was 78.1 % (95 % CI, 61.5-89.9 %). TB-Biochip correctly identified 100 % (95 % CI, 94.2-100 %) of RIF-R, 94.7 % (95 % CI, 76.7-99.7 %) of RIF-S, 98.2 % (95 % CI, 91.4-99.9 %) of INH-R, and 78.6 % (95 % CI, 52.1-94.2 %) of INH-S specimens compared to MGIT DST. Xpert and Biochip were similar in accuracy for detecting MTBC and RIF resistance compared to conventional culture methods. C1 [Kurbatova, E. V.; Kaminski, D. A.; Ershova, J. V.; Cegielski, J. P.] CDC, US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Erokhin, V. V.; Andreevskaya, S. N.; Chernousova, L. N.; Demikhova, O. V.; Larionova, E. E.; Smirnova, T. G.; Vasilieva, I. A.; Vorobieva, A. V.] Russian Acad Med Sci, Cent TB Res Inst, Moscow, Russia. [Volchenkov, G. V.; Kaunetis, N. V.; Kuznetsova, T. A.; Somova, T. R.; Zolkina, S. S.] Vladimir Oblast TB Dispensary, Vladimir, Russia. [Kaminski, D. A.] CDC, Global Lab Act, Div TB Eliminat, US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Kaminski, DA (reprint author), CDC, Global Lab Act, Div TB Eliminat, US Ctr Dis Control & Prevent, Mailstop F-08,1600 Clifton Rd,NE, Atlanta, GA 30333 USA. EM dkaminski@cdc.gov FU United States Agency for International Development (USAID) country mission in Russia FX This work was supported by the United States Agency for International Development (USAID) country mission in Russia. NR 27 TC 9 Z9 10 U1 2 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0934-9723 J9 EUR J CLIN MICROBIOL JI Eur. J. Clin. Microbiol. Infect. Dis. PD JUN PY 2013 VL 32 IS 6 BP 735 EP 743 DI 10.1007/s10096-012-1798-0 PG 9 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 149DO UT WOS:000319298400004 PM 23263819 ER PT J AU Alyousefi, NA Mahdy, MAK Xiao, LH Mahmud, R Lim, YAL AF Alyousefi, Naela A. Mahdy, Mohammed A. K. Xiao, Lihua Mahmud, Rohela Lim, Yvonne A. L. TI Molecular characterization of Giardia duodenalis in Yemen SO EXPERIMENTAL PARASITOLOGY LA English DT Article DE Giardia duodenalis; Genotyping; Yemen ID GENOTYPE; IDENTIFICATION; EPIDEMIOLOGY; INTESTINALIS; ASSEMBLAGE; DIARRHEA; EGYPT; HUMANS; LOCUS; ASSAY AB Giardia duodenalis is an important intestinal protozoan in Yemen with infection rates ranging from 18% to 27%. To date, there has been no genotyping study to provide a better understanding of the transmission dynamic. This study was conducted to genotype and subtype G. duodenalis in Yemen. Stool samples were collected from 503 Yemeni outpatients between I and 80 years old, including 219 males and 284 females. Giardia cysts were detected via microscopy after the formal-ether concentration. Genotyping of Giardia was carried out using PCR and sequence analysis of the 16s rRNA and b-giardin genes. Of the 89 microscopy-positive Giardia samples, 65 were successfully sequenced, of which 66% (43 of 65) were identified as G. duodenalis assemblage A and 34% (22 of 65) as assemblage B. Further subtyping analysis based on b-giardin gene identified the presence of subtypes A2 and A3, which belong to the anthroponotic sub-assemblage All. Data of the study suggest that anthroponotic transmission played a potential role in the transmission of giardiasis in the community. However, further genotyping and subtyping studies of specimens from humans and animals living in the same households are needed for a more definitive understanding of giardiasis transmission in Yemen. (C) 2013 Elsevier Inc. All rights reserved. C1 [Alyousefi, Naela A.; Mahdy, Mohammed A. K.; Mahmud, Rohela; Lim, Yvonne A. L.] Univ Malaya, Fac Med, Dept Parasitol, Kuala Lumpur, Malaysia. [Mahdy, Mohammed A. K.] Sanaa Univ, Fac Med, Dept Parasitol, Sanaa, Yemen. [Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Lim, YAL (reprint author), Univ Malaya, Fac Med, Dept Parasitol, Kuala Lumpur, Malaysia. EM limailian@um.edu.my RI MAHMUD, ROHELA/B-9593-2010; Xiao, Lihua/B-1704-2013; Alyousefi, Naelah/D-2006-2010; LIM, YVONNE /B-5276-2010; Mahdy, Mohammed/C-1187-2010 OI Xiao, Lihua/0000-0001-8532-2727; Alyousefi, Naelah/0000-0001-8871-1824; LIM, YVONNE /0000-0003-4050-6332; Mahdy, Mohammed/0000-0002-8340-5219 FU University of Malaya High Impact Research Grant [J-00000-73587]; University of Malaya Research Grant [PS204/2010A, RG302/11HTM] FX This research work was supported by the University of Malaya High Impact Research Grant (J-00000-73587) and University of Malaya Research Grants (PS204/2010A and RG302/11HTM). We thank staff members of the participating hospitals for their excellent assistance in the collection of samples and data. NR 32 TC 7 Z9 7 U1 0 U2 12 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4894 J9 EXP PARASITOL JI Exp. Parasitol. PD JUN PY 2013 VL 134 IS 2 BP 141 EP 147 DI 10.1016/j.exppara.2013.03.001 PG 7 WC Parasitology SC Parasitology GA 152PE UT WOS:000319542800003 PM 23523861 ER PT J AU Moreno, A Cabrera-Mora, M Garcia, A Orkin, J Strobert, E Barnwell, JW Galinski, MR AF Moreno, Alberto Cabrera-Mora, Monica Garcia, AnaPatricia Orkin, Jack Strobert, Elizabeth Barnwell, John W. Galinski, Mary R. TI Plasmodium coatneyi in Rhesus Macaques Replicates the Multisystemic Dysfunction of Severe Malaria in Humans SO INFECTION AND IMMUNITY LA English DT Article ID TUMOR-NECROSIS-FACTOR; SEVERE FALCIPARUM-MALARIA; HUMAN CEREBRAL MALARIA; PAPUA-NEW-GUINEA; MACACA-MULATTA; FACTOR-ALPHA; INTERFERON-GAMMA; PRIMATE MODEL; SERUM-LEVELS; RED-CELLS AB Severe malaria, a leading cause of mortality among children and nonimmune adults, is a multisystemic disorder characterized by complex clinical syndromes that are mechanistically poorly understood. The interplay of various parasite and host factors is critical in the pathophysiology of severe malaria. However, knowledge regarding the pathophysiological mechanisms and pathways leading to the multisystemic disorders of severe malaria in humans is limited. Here, we systematically investigate infections with Plasmodium coatneyi, a simian malaria parasite that closely mimics the biological characteristics of P. falciparum, and develop baseline data and protocols for studying erythrocyte turnover and severe malaria in greater depth. We show that rhesus macaques (Macaca mulatta) experimentally infected with P. coatneyi develop anemia, coagulopathy, and renal and metabolic dysfunction. The clinical course of acute infections required suppressive antimalaria chemotherapy, fluid support, and whole-blood transfusion, mimicking the standard of care for the management of severe malaria cases in humans. Subsequent infections in the same animals progressed with a mild illness in comparison, suggesting that immunity played a role in reducing the severity of the disease. Our results demonstrate that P. coatneyi infection in rhesus macaques can serve as a highly relevant model to investigate the physiological pathways and molecular mechanisms of malaria pathogenesis in naive and immune individuals. Together with high-throughput postgenomic technologies, such investigations hold promise for the identification of new clinical interventions and adjunctive therapies. C1 [Moreno, Alberto; Cabrera-Mora, Monica; Galinski, Mary R.] Emory Univ, Emory Vaccine Ctr, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA. [Moreno, Alberto; Galinski, Mary R.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA. [Garcia, AnaPatricia] Emory Univ, Div Pathol, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA. [Garcia, AnaPatricia] Emory Univ, Sch Med, Dept Pathol & Lab Med, Emory Univ Hosp, Atlanta, GA 30322 USA. [Orkin, Jack; Strobert, Elizabeth] Emory Univ, Div Anim Resources, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA. [Barnwell, John W.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Moreno, A (reprint author), Emory Univ, Emory Vaccine Ctr, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA. EM alberto.moreno@emory.edu FU NIH/NHLBI [1P01 HL078826]; NIH/NIAID [R01-AI064766, R01-AI024710]; National Center for Research Resources [P51RR000165]; Office of Research Infrastructure Programs/OD [P51OD011132]; NIAID [HHSN272201200031C] FX This research was supported by NIH/NHLBI grant number 1P01 HL078826 (original project 3 led by M.R.G. and A.M.) and NIH/NIAID grants R01-AI064766 and R01-AI024710. The Yerkes National Primate Research Center received support from the National Center for Research Resources P51RR000165, and it is currently supported by the Office of Research Infrastructure Programs/OD P51OD011132.; We also express our appreciation to NIAID and members of the Malaria Host-Pathogen Interaction Center (MaHPIC; NIAID contract number HHSN272201200031C) for ongoing discussions and the continued advancement of this project, developing NHP models to study malaria caused by various species. NR 131 TC 14 Z9 14 U1 1 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD JUN PY 2013 VL 81 IS 6 BP 1889 EP 1904 DI 10.1128/IAI.00027-13 PG 16 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 143GN UT WOS:000318855100004 PM 23509137 ER PT J AU Fresquez, MR Pappas, RS Watson, CH AF Fresquez, Mark R. Pappas, R. Steven Watson, Clifford H. TI Establishment of Toxic Metal Reference Range in Tobacco from US Cigarettes SO JOURNAL OF ANALYTICAL TOXICOLOGY LA English DT Article ID TOTAL CHROMIUM; CADMIUM; SMOKING; INFLAMMATION; PARTICLES; EXPOSURE; ALLERGY; CR(VI); NICKEL; SLUDGE AB Smoking remains the leading cause of preventable death in the United States. There are numerous harmful substances in tobacco and tobacco smoke. Among the more than 4,000 identified compounds in smoke, many metals contribute to the health risks associated with tobacco use. Specific metals found in tobacco and tobacco smoke have been classified as carcinogens by the International Agency for Research on Cancer. Exposure to toxic metals can cause outcomes including inflammation, sensitization and carcinogenesis. Metals in tobacco are transported in tobacco smoke proportionally with their concentrations in tobacco filler for a given cigarette design. To quantitatively examine the metal content in numerous tobacco products, high throughput methods are desired. This study developed a simple, rapid tobacco digestion method coupled with a sensitive analytical method using inductively coupled plasma-mass spectrometry. Because of known memory effects and volatility of mercury, quantitative determinations of mercury were made with a direct combustion analyzer. The methods were utilized to examine arsenic, beryllium, cadmium, chromium, cobalt, lead, manganese, mercury and nickel contents in cigarette tobacco and to establish a reference range for the metals in 50 varieties of cigarettes available in the US. These results are comparable to the limited data sets reported by others and with available standard reference material values. C1 [Fresquez, Mark R.] Battelle Atlanta, Atlanta, GA USA. [Pappas, R. Steven; Watson, Clifford H.] Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, Atlanta, GA 30333 USA. RP Pappas, RS (reprint author), Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, Atlanta, GA 30333 USA. EM RPappas@cdc.gov FU Intramural CDC HHS [CC999999] NR 41 TC 21 Z9 23 U1 2 U2 37 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0146-4760 J9 J ANAL TOXICOL JI J. Anal. Toxicol. PD JUN PY 2013 VL 37 IS 5 BP 298 EP 304 DI 10.1093/jat/bkt021 PG 7 WC Chemistry, Analytical; Toxicology SC Chemistry; Toxicology GA 151OR UT WOS:000319470400006 PM 23548667 ER PT J AU Oraka, E Iqbal, S Flanders, WD Brinker, K Garbe, P AF Oraka, Emeka Iqbal, Shahed Flanders, W. Dana Brinker, Kimberly Garbe, Paul TI Racial and Ethnic Disparities in Current Asthma and Emergency Department Visits: Findings from the National Health Interview Survey, 2001-2010 SO JOURNAL OF ASTHMA LA English DT Article DE Race; Ethnicity; Asthma; Health Status Disparities; Emergency Department ID SELF-MANAGEMENT; AFRICAN-AMERICAN; MEDICAL-CARE; CHILDREN; ORGANIZATION; METAANALYSIS; PERCEPTIONS; PREVALENCE; GUIDELINES; EDUCATION AB Objectives. Racial/ethnic disparities in current asthma prevalence and medical care are a major public health concern. We examined the differences in asthma prevalence and morbidity among major racial/ethnic populations in the US. Methods. We analyzed data from the 2001-2010 National Health Interview Survey for adults (>= 18 years) and children and adolescents (<18 years). Outcome variables were current asthma prevalence, at least one attack in the past 12 months, and at least one asthma-related emergency department/urgent care center (ED/UCC) visit in the past 12 months. We used multivariate logistic regression to calculate the model-adjusted prevalence and risk ratios (ARR). Results. In our study, 9.0% of the children and 7.2% of the adults had current asthma. Non-Hispanic black and Puerto Rican children were more likely to have current asthma (ARR 1.46, 1.66, respectively) and to visit the ED/UCC (ARR 1.61, 1.67, respectively) than non-Hispanic whites. American Indian/Alaskan Native children were more likely to have current asthma (ARR 1.76) than non-Hispanic whites. Mexican/Mexican American children and adults had lower prevalence of current asthma but higher ED/UCC use (adults only) than non-Hispanic whites. Among adults, Puerto Ricans and American Indian/Alaskan Natives were more likely to have current asthma (ARR 1.60, 1.39, respectively) than non-Hispanic whites, and all the studied racial/ethnic groups except Asians were more likely to have visited the ED/UCC than non-Hispanic whites. Adults and children who received emergency care for asthma in the past 12 months more frequently received multiple components of asthma management and control (e. g., taking long-term medication, having an asthma management plan) compared to those without emergency care. Conclusions. Racial/ethnic differences in current asthma prevalence, asthma attacks, and increased utilization of emergency room visits for asthma among minorities persist among children and adults. Appropriate and effective asthma management and education may lead to better asthma control and reduce emergency care utilization. C1 [Oraka, Emeka; Iqbal, Shahed; Garbe, Paul] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA. [Flanders, W. Dana] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA. [Flanders, W. Dana; Brinker, Kimberly] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Oraka, E (reprint author), Ctr Dis Control & Prevent CDC, ICF Int, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Mailstop E46, Atlanta, GA 30333 USA. EM eoraka@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX This work was supported by the Centers for Disease Control and Prevention (CDC). All authors attest that there are no conflicts of interest related to the submission of this manuscript. NR 43 TC 24 Z9 24 U1 0 U2 21 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0277-0903 J9 J ASTHMA JI J. Asthma PD JUN PY 2013 VL 50 IS 5 BP 488 EP 496 DI 10.3109/02770903.2013.790417 PG 9 WC Allergy; Respiratory System SC Allergy; Respiratory System GA 148FS UT WOS:000319229300007 PM 23544662 ER PT J AU Glenn, LM Lindsey, RL Folster, JP Pecic, G Boerlin, P Gilmour, MW Harbottle, H Zhao, SH McDermott, PF Fedorka-Cray, PJ Frye, JG AF Glenn, LaShanda M. Lindsey, Rebecca L. Folster, Jason P. Pecic, Gary Boerlin, Patrick Gilmour, Mathew W. Harbottle, Heather Zhao, Shaohua McDermott, Patrick F. Fedorka-Cray, Paula J. Frye, Jonathan G. TI Antimicrobial Resistance Genes in Multidrug-Resistant Salmonella enterica Isolated from Animals, Retail Meats, and Humans in the United States and Canada SO MICROBIAL DRUG RESISTANCE LA English DT Article ID PATHOGENIC ESCHERICHIA-COLI; SEROVAR TYPHIMURIUM; FOOD ANIMALS; PLASMIDS; MICROARRAY; STRAINS; SEQUENCE; IDENTIFICATION; POPULATIONS; HEIDELBERG AB Salmonella enterica is a prevalent foodborne pathogen that can carry multidrug resistance (MDR) and pose a threat to human health. Identifying the genetics associated with MDR in Salmonella isolated from animals, foods, and humans can help determine sources of MDR in food animals and their impact on humans. S. enterica serovars most frequently carrying MDR from healthy animals, retail meats, and human infections in the United States and Canada were identified and isolates resistant to the largest number of antimicrobials were chosen. Isolates were from U. S. slaughter (n = 12), retail (9), and humans (9), and Canadian slaughter (9), retail (9), and humans (8; total n = 56). These isolates were assayed by microarray for antimicrobial resistance and MDR plasmid genes. Genes detected encoded resistance to aminoglycosides (alleles of aac, aad, aph, strA/B); betalactams (blaTEM, blaCMY, blaPSE-1); chloramphenicol (cat, flo, cmlA); sulfamethoxazole (sulI); tetracycline (tet(A, B, C, D) and tetR); and trimethoprim (dfrA). Hybridization with IncA/C plasmid gene probes indicated that 27/56 isolates carried one of these plasmids; however, they differed in several variable regions. Cluster analysis based on genes detected separated most of the isolates into two groups, one with IncA/C plasmids and one without IncA/C plasmids. Other plasmid replicons were detected in all but one isolate, and included I1 (25/56), N (23/56), and FIB (10/56). The presence of different mobile elements along with similar resistance genes suggest that these genetic elements may acquire similar resistance cassettes, and serve as multiple sources for MDR in Salmonella from food animals, retail meats, and human infections. C1 [Glenn, LaShanda M.; Lindsey, Rebecca L.; Fedorka-Cray, Paula J.; Frye, Jonathan G.] USDA, Bacterial Epidemiol & Antimicrobial Resistance Re, Richard B Russell Res Ctr, ARS, Athens, GA 30605 USA. [Folster, Jason P.; Pecic, Gary] Ctr Dis Control & Prevent, Atlanta, GA USA. [Boerlin, Patrick] Ontario Vet Coll, Guelph, ON, Canada. [Gilmour, Mathew W.] Publ Hlth Agcy Canada, Winnipeg, MB, Canada. [Harbottle, Heather; Zhao, Shaohua; McDermott, Patrick F.] US FDA, Ctr Vet Med, Laurel, MD USA. RP Frye, JG (reprint author), USDA, Bacterial Epidemiol & Antimicrobial Resistance Re, Richard B Russell Res Ctr, ARS, 950 Coll Stn Rd, Athens, GA 30605 USA. EM jonathan.frye@ars.usda.gov RI Frye, Jonathan/I-6382-2013 OI Frye, Jonathan/0000-0002-8500-3395 FU USDA [6612-32000-006-00] FX The authors thank Jennifer Turpin, Georgina Hidalgo, Jovita Haro, Benny Barrett, and Takiyah Ball at USDA for technical assistance. From CDC we thank Jean Whichard for helpful conversations and editing the manuscript. From CIPARS we thank Lucie Dutil for isolate selection, and Laura Martin and Emily Weir for DNA isolation. We would also like to dedicate this article in memory of our colleague, Lucie Dutil, whom we had the privilege to know and work with through NARMS and CIPARS collaborations. This work was supported by USDA project number 6612-32000-006-00. NR 43 TC 14 Z9 14 U1 3 U2 25 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1076-6294 J9 MICROB DRUG RESIST JI Microb. Drug Resist. PD JUN PY 2013 VL 19 IS 3 BP 175 EP 184 DI 10.1089/mdr.2012.0177 PG 10 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 150OG UT WOS:000319399900004 PM 23350745 ER PT J AU Sjolund-Karlsson, M Howie, RL Blickenstaff, K Boerlin, P Ball, T Chalmers, G Duval, B Haro, J Rickert, R Zhao, SH Fedorka-Cray, PJ Whichard, JM AF Sjolund-Karlsson, Maria Howie, Rebecca L. Blickenstaff, Karen Boerlin, Patrick Ball, Takiyah Chalmers, Gabhan Duval, Brea Haro, Jovita Rickert, Regan Zhao, Shaohua Fedorka-Cray, Paula J. Whichard, Jean M. TI Occurrence of beta-Lactamase Genes Among Non-Typhi Salmonella enterica Isolated from Humans, Food Animals, and Retail Meats in the United States and Canada SO MICROBIAL DRUG RESISTANCE LA English DT Article ID CEFTRIAXONE-RESISTANT SALMONELLA; EXTENDED-SPECTRUM CEPHALOSPORINS; MULTIDRUG-RESISTANT; ESCHERICHIA-COLI; ANTIMICROBIAL RESISTANCE; SEROTYPE; CMY-2; PREVALENCE; EMERGENCE; INFECTION AB Non-Typhi Salmonella cause over 1.7 million cases of gastroenteritis in North America each year, and food-animal products are commonly implicated in human infections. For invasive infections, antimicrobial therapy is indicated. In North America, the antimicrobial susceptibility of Salmonella is monitored by the U. S. National Antimicrobial Resistance Monitoring System (NARMS) and The Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS). In this study, we determined the susceptibility to cephalosporins by broth microdilution among 5,041 non-Typhi Salmonella enterica isolated from food animals, retail meats, and humans. In the United States, 109 (4.6%) of isolates collected from humans, 77 (15.7%) from retail meat, and 140 (10.6%) from food animals displayed decreased susceptibility to cephalosporins (DSC). Among the Canadian retail meat and food animal isolates, 52 (13.0%) and 42 (9.4%) displayed DSC. All isolates displaying DSC were screened for beta-lactamase genes (bla(TEM), bla(SHV), bla(CMY), bla(CTX-M), and bla(OXA-1)) by polymerase chain reaction. At least one beta-lactamase gene was detected in 74/109 (67.9%) isolates collected from humans, and the blaCMY genes were most prevalent (69/109; 63.3%). Similarly, the blaCMY genes predominated among the beta-lactamase-producing isolates collected from retail meats and food animals. Three isolates from humans harbored a bla(CTX-M-15) gene. No animal or retail meat isolates harbored a bla(CTX-M) or bla(OXA-1) gene. A bla(TEM) gene was found in 5 human, 9 retail meat, and 17 animal isolates. Although serotype distributions varied among human, retail meat, and animal sources, overlap in bla(CMY)-positive serotypes across sample sources supports meat and food-animal sources as reservoirs for human infection. C1 [Sjolund-Karlsson, Maria; Rickert, Regan; Whichard, Jean M.] Ctr Dis Control & Prevent, Natl Antimicrobial Resistance Monitoring Syst, Atlanta, GA 30329 USA. [Howie, Rebecca L.] IHRC Inc, Atlanta, GA USA. [Blickenstaff, Karen; Zhao, Shaohua] US FDA, Laurel, MD USA. [Boerlin, Patrick; Chalmers, Gabhan] Ontario Vet Coll, Guelph, ON, Canada. [Ball, Takiyah; Duval, Brea; Haro, Jovita; Fedorka-Cray, Paula J.] USDA, Athens, GA USA. RP Sjolund-Karlsson, M (reprint author), Ctr Dis Control & Prevent, Natl Antimicrobial Resistance Monitoring Syst, OID NCEZID DFWED EDLB, 1600 Clifton Rd,Mail Stop G29, Atlanta, GA 30329 USA. EM fwt4@cdc.gov FU CDC; FDA-CVM; Laboratory for Foodborne Zoonoses, Public Health Agency of Canada, Guelph, Ontario, Canada FX We thank the NARMS-participating public health laboratories, the Retail Foods Survey Working Group, and the FSIS laboratories for submitting the isolates. We also thank the CO, MO, and NY Divisions of Public Health for providing patient interviews. This work was supported by an interagency agreement between CDC and FDA-CVM. Regarding CIPARS abattoir isolates, we thank the abattoir industry personnel and the Canadian Food Inspection Agency regional directors, inspection managers, and onsite staff for their extensive voluntary participation. The CIPARS farm surveillance component thanks all participating veterinarians and producers, the CIPARS Farm Swine Surveillance Advisory Committee as well as Agriculture and Agri-Food Canada, the provincial ministries of agriculture in BC, SK, AB, and QC, and the USDA, CAHFSE Program. The CIPARS retail component thanks the field technicians as well as the University of Prince Edward Island. Lastly, CIPARS thanks all laboratory technicians and data management staff for their contributions to the overall program. The molecular characterization of Canadian isolates was financially supported by the Laboratory for Foodborne Zoonoses, Public Health Agency of Canada, Guelph, Ontario, Canada. NR 52 TC 8 Z9 8 U1 0 U2 11 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1076-6294 J9 MICROB DRUG RESIST JI Microb. Drug Resist. PD JUN PY 2013 VL 19 IS 3 BP 191 EP 197 DI 10.1089/mdr.2012.0178 PG 7 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 150OG UT WOS:000319399900006 PM 23289438 ER PT J AU Kawwass, JF Crawford, S Kissin, DM Session, DR Boulet, S Jamieson, DJ AF Kawwass, Jennifer F. Crawford, Sara Kissin, Dmitry M. Session, Donna R. Boulet, Sheree Jamieson, Denise J. TI Tubal Factor Infertility and Perinatal Risk After Assisted Reproductive Technology SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID IN-VITRO FERTILIZATION; PREGNANCY RATES; EMBRYO TRANSFER; PRETERM BIRTH; OUTCOMES; HYDROSALPINGES; TRENDS; IMPLANTATION; METAANALYSIS; PREVALENCE AB OBJECTIVE: To assess trends of tubal factor infertility and to evaluate risk of miscarriage and delivery of preterm or low birth weight (LBW) neonates among women with tubal factor infertility using assisted reproductive technology (ART). METHODS: We assessed trends of tubal factor infertility among all fresh and frozen, donor, and nondonor ART cycles performed annually in the United States between 2000 and 2010 (N=1,418,774) using the National ART Surveillance System. The data set was then limited to fresh, nondonor in vitro fertilization cycles resulting in pregnancy to compare perinatal outcomes for cycles associated with tubal compared with male factor infertility. We performed bivariate and multivariable analyses controlling for maternal characteristics and calculated adjusted risk ratios (RRs) and 95% confidence intervals (CI). RESULTS: The percentage of ART cycles associated with tubal factor infertility diagnoses decreased from 2000 to 2010 (26.02-14.81%). Compared with male factor infertility, tubal factor portended an increased risk of miscarriage (14.0% compared with 12.7%, adjusted RR 1.08, 95% CI 1.04-1.12); risk was increased for both early and late miscarriage. Singleton neonates born to women with tubal factor infertility had an increased risk of preterm birth (15.8% compared with 11.6%, adjusted RR 1.27, 95% CI 1.20-1.34) and LBW (10.9% compared with 8.5%, adjusted RR 1.28, 95% CI 1.20-1.36). Significant increases in risk persisted for early and late preterm delivery and very low and moderately LBW delivery. A significantly elevated risk was also detected for twin, but not triplet, pregnancies. CONCLUSION: Tubal factor infertility, which is decreasing in prevalence in the United States, is associated with an increased risk of miscarriage, preterm birth, and LBW delivery as compared with couples with male factor infertility using ART. C1 Emory Univ, Dept Gynecol & Obstet, Sch Med, Div Reprod Endocrinol & Infertil, Atlanta, GA 30308 USA. Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Kawwass, JF (reprint author), Emory Univ, Dept Gynecol & Obstet, Sch Med, 550 Peachtree St,Suite 1800, Atlanta, GA 30308 USA. EM jennifer.kawwass@emory.edu FU Intramural CDC HHS [CC999999] NR 25 TC 17 Z9 18 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD JUN PY 2013 VL 121 IS 6 BP 1263 EP 1271 DI 10.1097/AOG.0b013e31829006d9 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 151BR UT WOS:000319436100018 PM 23812461 ER PT J AU Langley, GF McCracken, J Arvelo, W Estevez, A Villarruel, G Prill, M Iwane, M Gray, J Moscoso, F Reyes, L Moir, JC Ortiz, J Lindblade, K AF Langley, Gayle Fischer McCracken, John Arvelo, Wences Estevez, Alejandra Villarruel, Gissela Prill, Mila Iwane, Marika Gray, Jennifer Moscoso, Fabiola Reyes, Lissette Moir, Juan Carlos Ortiz, Jose Lindblade, Kim TI The Epidemiology and Clinical Characteristics of Young Children Hospitalized With Respiratory Syncytial Virus Infections in Guatemala (2007-2010) SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE respiratory syncytial virus; Guatemala; children; acute respiratory infections ID POPULATION-BASED SURVEILLANCE; REDUCES HOSPITALIZATION; TRACT INFECTIONS; RSV INFECTION; US CHILDREN; BRONCHIOLITIS; PNEUMONIA; INFLUENZA; INFANTS; DISEASE AB Background: There have been few population-based studies from Central America on respiratory syncytial virus (RSV) infections in young children. We report population-based incidence rates and describe epidemiological and clinical characteristics of children <5 years old hospitalized with RSV infections in Guatemala. Methods: Prospective, active hospital-based surveillance for acute respiratory infections in children <5 years old was conducted at 3 hospitals in Guatemala from November 2007 through July 2010. RSV hospitalization rates were calculated for areas where the catchment population could be defined. Comparisons were made between children who were RSV-positive and RSV-negative. Results: RSV was detected in 549 (25%) of enrolled children. Overall, annual rates of RSV hospitalizations ranged from 5.9 to 45.9 and 2.0 to 13.7 per 1000 children <1 year old and <5 years old, respectively, but varied by location and calendar year. Rates generally decreased with age-children <6 months had rates up to 30 times higher than older children, but children >12 months old still had rates up to 5.5 per 1000 per year and accounted for 42% of deaths. Children with RSV infections were more likely to have signs of respiratory distress (85% versus 63%, P < 0.001) compared with those without RSV infections, but case fatality ratios were similar (3-4%). Conclusions: The large burden and severity of RSV infections in young Guatemalan children is similar in magnitude and age distribution to RSV disease burdens found in other developing countries and suggests that this population would benefit from prevention strategies, including vaccines against RSV that are currently under development. C1 [Langley, Gayle Fischer; Villarruel, Gissela; Prill, Mila; Iwane, Marika] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [McCracken, John; Estevez, Alejandra; Gray, Jennifer; Moscoso, Fabiola] Grand Valley State Univ, Ctr Hlth Studies, Allendale, MI 49401 USA. [Arvelo, Wences; Lindblade, Kim] Ctr Dis Control & Prevent, Int Emerging Infect Program, Reg Off Cent Amer & Panama, Atlanta, GA 30333 USA. [Reyes, Lissette; Moir, Juan Carlos] Minist Publ Hlth & Welf, Nonthaburi, Thailand. [Ortiz, Jose] Guatemalan Inst Social Secur, Guatemala City, Guatemala. RP Langley, GF (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS C-25, Atlanta, GA 30333 USA. EM fez7@cdc.gov FU Centers for Disease Control and Prevention's Global Disease Detection, Emerging Infections [1U01GH000028-03] FX Funding for these activities was provided by the Centers for Disease Control and Prevention's Global Disease Detection, Emerging Infections appropriations through a grant to the Universidad del Valle de Guatemala, number 1U01GH000028-03. The Centers for Disease Control and Prevention participated in all aspects of study design, data collection, data analysis and article preparation. The authors have no other funding or conflicts of interest to disclose. NR 48 TC 7 Z9 8 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD JUN PY 2013 VL 32 IS 6 BP 629 EP 635 DI 10.1097/INF.0b013e318289e3bc PG 7 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 147ZR UT WOS:000319211700015 ER PT J AU Fisher, SC Kim, SY Sharma, AJ Rochat, R Morrow, B AF Fisher, S. C. Kim, S. Y. Sharma, A. J. Rochat, R. Morrow, B. TI Is obesity still increasing among pregnant women? Prepregnancy obesity trends in 20 states, 2003-2009 SO PREVENTIVE MEDICINE LA English DT Article DE PRAMS; Pregnancy; Body mass index; Obesity ID BODY-MASS INDEX; UNITED-STATES; MATERNAL OBESITY; HEALTH-CARE; RISK; METAANALYSIS; PREVALENCE; PREVENTION; WEIGHT; RECOMMENDATIONS AB Objective. To estimate trends in prepregnancy obesity prevalence among women who delivered live births in the US during 2003-2009, by state, age, and race-ethnicity. Methods. We used Pregnancy Risk Assessment Monitoring System (PRAMS) data from 2003, 2006, and 2009 to measure prepregnancy obesity (body mass index [BMI] >= 30 kg/m(2)) trends in 20 states. Trend analysis included 90,774 records from 20 US states with data for all 3 study years. We used a chi-square test for trend to determine the significance of actual and standardized trends, standardized to the age and race-ethnicity distribution of the 2003 sample. Results. Prepregnancy obesity prevalence increased by an average of 0.5 percentage points per year, from 17.6% in 2003 to 20.5% in 2009 (P < 0.001). Obesity increased among women aged 20-24 (P < 0.001), 30-34 (P = 0.001) and 35 years or older (P = 0.003), and among non-Hispanic white (P < .001), non-Hispanic black (P = 0.02), Hispanic (P = 0.01), and other women (P = 0.03). Conclusion. Overall, prepregnancy obesity prevalence continues to increase and varies by race-ethnicity and maternal age. These findings highlight the need to address obesity as a key component of preconception care, particularly among high-risk groups. Published by Elsevier Inc. C1 [Fisher, S. C.; Kim, S. Y.; Sharma, A. J.; Morrow, B.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30341 USA. [Fisher, S. C.; Rochat, R.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. [Sharma, A. J.] US Public Hlth Serv Commissioned Corps, Atlanta, GA 30341 USA. RP Kim, SY (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, 4770 Buford Hwy NE,MS K-23, Atlanta, GA 30341 USA. EM dgx5@cdc.gov OI Sharma, Andrea/0000-0003-0385-0011 FU Intramural CDC HHS [CC999999] NR 36 TC 60 Z9 65 U1 3 U2 16 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD JUN PY 2013 VL 56 IS 6 BP 372 EP 378 DI 10.1016/j.ypmed.2013.02.015 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 148HY UT WOS:000319236600003 PM 23454595 ER PT J AU Gallo, MF Steiner, MJ Hobbs, MM Warner, L Jamieson, DJ Macaluso, M AF Gallo, Maria F. Steiner, Markus J. Hobbs, Marcia M. Warner, Lee Jamieson, Denise J. Macaluso, Maurizio TI Biological Markers of Sexual Activity: Tools for Improving Measurement in HIV/Sexually Transmitted Infection Prevention Research SO SEXUALLY TRANSMITTED DISEASES LA English DT Editorial Material ID PROSTATE-SPECIFIC ANTIGEN; RANDOMIZED CONTROLLED-TRIAL; REPORTED CONDOM USE; VAGINAL FLUID; MICROBICIDE TRIAL; Y-CHROMOSOME; SEMEN; FEMALE; WOMEN; INTERCOURSE AB Research on interventions to prevent HIV and other sexually transmitted infections (STIs) is heavily influenced by participant reporting of sexual behavior, despite uncertainty about its validity. Exclusive reliance on participant self-report often is based, overtly or by implication, on 4 assumptions: (1) no feasible alternatives exist; (2) misreporting can be minimized to levels that can be disregarded; (3) misreporting tends to underreport sensitive behaviors; and (4) misreporting tends to be non-differential with respect to the groups being compared. The objective of this review are to evaluate these assumptions, including a review of studies using semen biomarkers to evaluate the validity of self-reported data, and to make recommendations for applying biological markers of semen exposure detectable in women to further strengthen research on HIV/STI prevention. Increasing evidence shows that semen biomarkers provide an important means of assessing and augmenting the validity of studies on HIV/STI prevention. Additional biomarkers are needed to assess male exposure to vaginal sex and both male and female exposure to anal sex. Methods and study designs that incorporate biomarkers into studies collecting self-reported behavioral data should be considered where possible. C1 [Gallo, Maria F.; Warner, Lee; Jamieson, Denise J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA USA. [Steiner, Markus J.] FHI 360, Res Triangle Pk, NC USA. [Hobbs, Marcia M.] Univ N Carolina, Dept Med & Microbiol & Immunol, Chapel Hill, NC USA. [Macaluso, Maurizio] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA. RP Gallo, MF (reprint author), Div Reprod Hlth, 4770 Buford Highway,Mail Stop K-34, Atlanta, GA 30341 USA. EM mgallo@cdc.gov RI Macaluso, Maurizio/J-2076-2015 OI Macaluso, Maurizio/0000-0002-2977-9690 FU NIAID NIH HHS [U19 AI031496] NR 34 TC 27 Z9 27 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD JUN PY 2013 VL 40 IS 6 BP 447 EP 452 DI 10.1097/OLQ.0b013e31828b2f77 PG 6 WC Infectious Diseases SC Infectious Diseases GA 147UH UT WOS:000319192500004 PM 23677018 ER PT J AU Stramer, L Boucher, B Foster, A Krysztof, E Winton, S Merced, L Miller, D Dickson, S Brodsky, P Munoz-Jordan, L Hunsperger, A Lanteri, C Anez, J Heisey, AR Rios, J Cory, E Innen, J AF Stramer, L. Boucher, B. Foster, A. Krysztof, E. Winton, S. Merced, L. Miller, D. Dickson, S. Brodsky, P. Munoz-Jordan, L. Hunsperger, A. Lanteri, C. Anez, J. Heisey, A. R. Rios, J. Cory, E. Innen, J. TI INVESTIGATIONAL DENGUE TESTING YIELDS HIGH RATES OF RNA-POSITIVE DONORS IN PUERTO RICO SO VOX SANGUINIS LA English DT Meeting Abstract C1 [Stramer, L.] Amer Red Cross, Gaithersburg, MD USA. [Boucher, B.; Foster, A.; Krysztof, E.; Winton, S.] Amer Red Cross, Sceintif Support Off, Gaithersburg, MD USA. [Merced, L.] Amer Red Cross Blood Serv, San Juan, PR USA. [Miller, D.] Amer Red Cross, Biomed Serv Testing Support, Charlotte, NC USA. [Dickson, S.] Amer Red Cross, Natl Testing Lab, Charlotte, NC USA. [Brodsky, P.] Quality Analyt Inc, Riverwoods, IL USA. [Munoz-Jordan, L.; Hunsperger, A.] Ctr Dis Control & Prevent, San Juan, PR USA. [Lanteri, C.] Blood Syst Res Inst, San Francisco, CA USA. [Anez, J.; Heisey, A. R.; Rios, J.] US FDA, DETTD, OBRR, CBER, Bethesda, MD 20014 USA. [Cory, E.; Innen, J.] Hologicgen Probe, San Diego, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0042-9007 J9 VOX SANG JI Vox Sang. PD JUN PY 2013 VL 105 SU 1 SI SI BP 195 EP 195 PG 1 WC Hematology SC Hematology GA 148FH UT WOS:000319228100514 ER PT J AU England, LJ Kim, SY Shapiro-Mendoza, CK Wilson, HG Kendrick, JS Satten, GA Lewis, CA Tucker, MJ Callaghan, WM AF England, Lucinda J. Kim, Shin Y. Shapiro-Mendoza, Carrie K. Wilson, Hoyt G. Kendrick, Juliette S. Satten, Glen A. Lewis, Claire A. Tucker, Myra J. Callaghan, William M. TI Effects of maternal smokeless tobacco use on selected pregnancy outcomes in Alaska Native women: a casecontrol study SO ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA LA English DT Article DE Abruption; cigarettes; pregnancy; pregnancy-associated hypertension; preterm delivery; smokeless tobacco ID CIGARETTE-SMOKING; SNUFF; RISK; PREECLAMPSIA; BIRTH; COHORT; MUMBAI; INDIA AB Objective To examine the potential effects of prenatal smokeless tobacco use on selected birth outcomes. Design A population-based, casecontrol study using a retrospective medical record review. Population Singleton deliveries 19972005 to Alaska Native women residing in western Alaska. Methods Hospital discharge codes were used to identify potential case deliveries and a random control sample. Data on tobacco use and confirmation of pregnancy outcomes were abstracted from medical records for 1123 deliveries. Logistic regression was used to examine associations between tobacco use and pregnancy outcomes. Adjusted odds ratios (OR), 95% confidence intervals (95% CI), and p-values were calculated. Main outcomes measures Preterm delivery, pregnancy-associated hypertension, and placental abruption. Results In unadjusted analysis, smokeless tobacco use was not significantly associated with preterm delivery (OR 1.44, 95% CI 0.972.15). After adjustment for parity, pre-pregnancy body mass index, and maternal age, the point estimate was attenuated and remained non-significant. No significant associations were observed between smokeless tobacco use and pregnancy-associated hypertension (adjusted OR 0.92, 95% CI 0.561.51) or placental abruption (adjusted OR 1.11, 95% CI 0.532.33). Conclusions Prenatal smokeless tobacco use does not appear to reduce risk of pregnancy-associated hypertension or to substantially increase risk of abruption. An association between smokeless tobacco and preterm delivery could not be ruled out. Components in tobacco other than nicotine likely play a major role in decreased pre-eclampsia risk in smokers. Nicotine adversely affects fetal neurodevelopment and our results should not be construed to mean that smokeless tobacco use is safe during pregnancy. C1 [England, Lucinda J.; Kim, Shin Y.; Shapiro-Mendoza, Carrie K.; Wilson, Hoyt G.; Kendrick, Juliette S.; Satten, Glen A.; Tucker, Myra J.; Callaghan, William M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30030 USA. [Lewis, Claire A.] Yukon Kuskokwim Hlth Corp, Bethel, AK USA. RP England, LJ (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, 4770 Buford Hwy NE,MS K-50, Atlanta, GA 30030 USA. EM lbe9@cdc.gov OI Satten, Glen/0000-0001-7275-5371 NR 16 TC 5 Z9 5 U1 2 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0001-6349 J9 ACTA OBSTET GYN SCAN JI Acta Obstet. Gynecol. Scand. PD JUN PY 2013 VL 92 IS 6 BP 648 EP 655 DI 10.1111/aogs.12124 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 146AH UT WOS:000319060700006 PM 23551054 ER PT J AU Shahinian, VB Hedgeman, E Gillespie, BW Young, EW Robinson, B Hsu, CY Plantinga, LC Burrows, NR Eggers, P Saydah, S Powe, NR Saran, R AF Shahinian, Vahakn B. Hedgeman, Elizabeth Gillespie, Brenda W. Young, Eric W. Robinson, Bruce Hsu, Chi-yuan Plantinga, Laura C. Burrows, Nilka Rios Eggers, Paul Saydah, Sharon Powe, Neil R. Saran, Rajiv CA CDC CKD Surveillance Syst TI Estimating Prevalence of CKD Stages 3-5 Using Health System Data SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Chronic kidney disease; surveillance; prevalence; epidemiology ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; UNITED-STATES; RISK; POPULATION; RECORD; DEATH; CARE AB Background: The feasibility of using health system data to estimate prevalence of chronic kidney disease (CKD) stages 3-5 was explored. Study Design: Cohort study. Setting & Participants: A 5% national random sample of patients from the Veterans Affairs (VA) health care system, enrollees in a managed care plan in Michigan (M-CARE), and participants from the 2005-2006 National Health and Nutrition Examination Survey (NHANES). Predictor: Observed CKD prevalence estimates in the health system population were calculated as patients with an available outpatient serum creatinine measurement with estimated glomerular filtration rate <60 mL/min/1.73 m(2), among those with at least one outpatient visit during the year. Outcomes & Measurements: A logistic regression model was fitted using data from the 2005-2006 NHANES to predict CKD prevalence in those untested for serum creatinine in the health system population, adjusted for demographics and comorbid conditions. Model results then were combined with the observed prevalence in tested patients to derive an overall predicted prevalence of CKD within the health systems. Results: Patients in the VA system were older, had more comorbid conditions, and were more likely to be tested for serum creatinine than those in the M-CARE system. Observed prevalences of CKD stages 3-5 were 15.6% and 0.9% in the VA and M-CARE systems, respectively. Using data from NHANES, the overall predicted prevalences of CKD were 20.4% and 1.6% in the VA and M-CARE systems, respectively. Limitations: Health system data quality was limited by missing data for laboratory results and race. A single estimated glomerular filtration rate value was used to define CKD, rather than persistence over 3 months. Conclusions: Estimation of CKD prevalence within health care systems is feasible, but discrepancies between observed and predicted prevalences suggest that this approach is dependent on data availability and quality of information for comorbid conditions, as well as the frequency of testing for CKD in the health care system. (c) 2013 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. C1 [Shahinian, Vahakn B.; Hedgeman, Elizabeth; Young, Eric W.; Saran, Rajiv] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Shahinian, Vahakn B.; Hedgeman, Elizabeth; Saran, Rajiv] Univ Michigan, Kidney Epidemiol & Cost Ctr, Ann Arbor, MI 48109 USA. [Gillespie, Brenda W.] Univ Michigan, Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA. [Gillespie, Brenda W.] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA. [Young, Eric W.] Vet Adm Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Robinson, Bruce] Arbor Res Collaborat Hlth, Ann Arbor, MI USA. [Hsu, Chi-yuan] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Plantinga, Laura C.; Powe, Neil R.] San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA. [Plantinga, Laura C.; Powe, Neil R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Burrows, Nilka Rios; Saydah, Sharon] Ctr Dis Control & Prevent, Atlanta, GA USA. [Saydah, Sharon] NIDDK, Bethesda, MD USA. RP Saran, R (reprint author), Univ Michigan, Kidney Epidemiol & Cost Ctr, Div Nephrol, Dept Internal Med, 1415 Washington Hts,Ste 3645, Ann Arbor, MI 48109 USA. EM rsaran@umich.edu FU Centers for Disease Control and Prevention (CDC) [1U58DP003836] FX This work is funded by the Centers for Disease Control and Prevention (CDC), grant 1U58DP003836 for the project titled "Establishing a Surveillance System for Chronic Kidney Disease." This material is the result of work partially supported with resources and the use of facilities at the VA Ann Arbor Healthcare System. Publication and report contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC, the VA, or the US Government. NR 18 TC 10 Z9 11 U1 0 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD JUN PY 2013 VL 61 IS 6 BP 930 EP 938 DI 10.1053/j.ajkd.2013.01.018 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 145FC UT WOS:000318999200014 PM 23489675 ER PT J AU Wise, ME Scott, RD Baggs, JM Edwards, JR Ellingson, KD Fridkin, SK McDonald, LC Jernigan, JA AF Wise, Matthew E. Scott, R. Douglas Baggs, James M. Edwards, Jonathan R. Ellingson, Katherine D. Fridkin, Scott K. McDonald, L. Clifford Jernigan, John A. TI National Estimates of Central Line-Associated Bloodstream Infections in Critical Care Patients SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID NETWORK NHSN REPORT; UNITED-STATES; INTERVENTION; PREVENTION; ADULTS; TRIAL AB OBJECTIVE. Recent studies have demonstrated that central line-associated bloodstream infections (CLABSIs) are preventable through implementation of evidence-based prevention practices. Hospitals have reported CLABSI data to the Centers for Disease Control and Prevention (CDC) since the 1970s, providing an opportunity to characterize the national impact of CLABSIs over time. Our objective was to describe changes in the annual number of CLABSIs in critical care patients in the United States. DESIGN. Monte Carlo simulation. SETTING. US acute care hospitals. PATIENTS. Nonneonatal critical care patients. METHODS. We obtained administrative data on patient-days for nearly all US hospitals and applied CLABSI rates from the National Nosocomial Infections Surveillance and the National Healthcare Safety Network systems to estimate the annual number of CLABSIs in critical care patients nationally during the period 1990-2010 and the number of CLABSIs prevented since 1990. RESULTS. We estimated that there were between 462,000 and 636,000 CLABSIs in nonneonatal critical care patients in the United States during 1990-2010. CLABSI rate reductions led to between 104,000 and 198,000 fewer CLABSIs than would have occurred if rates had remained unchanged since 1990. There were 15,000 hospital-onset CLABSIs in nonneonatal critical care patients in 2010; 70% occurred in medium and large teaching hospitals. CONCLUSIONS. Substantial progress has been made in reducing the occurrence of CLABSIs in US critical care patients over the past 2 decades. The concentration of critical care CLABSIs in medium and large teaching hospitals suggests that a targeted approach may be warranted to continue achieving reductions in critical care CLABSIs nationally. C1 [Wise, Matthew E.; Scott, R. Douglas; Baggs, James M.; Edwards, Jonathan R.; Ellingson, Katherine D.; Fridkin, Scott K.; McDonald, L. Clifford; Jernigan, John A.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP Wise, ME (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-38, Atlanta, GA 30333 USA. EM CXX4@cdc.gov OI Baggs, James/0000-0003-0757-4683 NR 24 TC 17 Z9 17 U1 0 U2 8 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JUN PY 2013 VL 34 IS 6 BP 547 EP 554 DI 10.1086/670629 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 142AB UT WOS:000318766800001 PM 23651883 ER PT J AU Tabak, YP Zilberberg, MD Johannes, RS Sun, XW McDonald, LC AF Tabak, Ying P. Zilberberg, Marya D. Johannes, Richard S. Sun, Xiaowu McDonald, L. Clifford TI Attributable Burden of Hospital-Onset Clostridium difficile Infection: A Propensity Score Matching Study SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID AUTOMATED CLINICAL-DATA; ACQUIRED INFECTION; RISK ADJUSTMENT; US HOSPITALS; DISEASE; MORTALITY; COSTS; DIARRHEA; EPIDEMIOLOGY; VALIDATION AB OBJECTIVE. To determine the attributable in-hospital mortality, length of stay (LOS), and cost of hospital-onset Clostridium difficile infection (HO-CDI). DESIGN. Propensity score matching. SETTING. Six Pennsylvania hospitals (2 academic centers, 1 community teaching facility, and 3 community nonteaching facilities) contributing data to a clinical research database. PATIENTS. Adult inpatients between 2007 and 2008. METHODS. We defined HO-CDI in adult inpatients as a positive C. difficile toxin assay result from a specimen collected more than 48 hours after admission and more than 8 weeks following any previous positive result. We developed an HO-CDI propensity model and matched cases with noncases by propensity score at a 1 : 3 ratio. We further restricted matching within the same hospital, within the same principal disease group, and within a similar length of lead time from admission to onset of HO-CDI. RESULTS. Among 77,257 discharges, 282 HO-CDI cases were identified. The propensity score-matched rate was 90%. Compared with matched noncases, HO-CDI patients had higher mortality (11.8% vs 7.3%; P < .05), longer LOS (median [interquartile range (IQR)], 12 [9-21] vs 11 [8-17] days; P < .01), and higher cost (median [IQR], $20,804 [$11,059-$38,429] vs $16,634 [$9,413-$30,319]; P < .01). The attributable effect of HO-CDI was 4.5% (95% confidence interval [CI], 0.2%-8.7%; P < .05) for mortality, 2.3 days (95% CI, 0.9-3.8; P < .01) for LOS, and $6,117 (95% CI, $1,659-$10,574; P < .01) for cost. CONCLUSIONS. Patients with HO-CDI incur additional attributable mortality, LOS, and cost burden compared with patients with similar primary clinical condition, exposure risk, lead time of hospitalization, and baseline characteristics. C1 [Tabak, Ying P.; Johannes, Richard S.; Sun, Xiaowu] CareFusion, Clin Res, San Diego, CA USA. [Zilberberg, Marya D.] Univ Massachusetts, Amherst, MA 01003 USA. [Zilberberg, Marya D.] EviMed Res Grp LLC, Williamsburg, VA USA. [Johannes, Richard S.] Brigham & Womens Hosp, Gastrointestinal Div, Boston, MA 02115 USA. [Johannes, Richard S.] Harvard Univ, Sch Med, Boston, MA USA. [McDonald, L. Clifford] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP McDonald, LC (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A07, Atlanta, GA 30333 USA. EM cmcdonald1@cdc.gov NR 29 TC 25 Z9 25 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JUN PY 2013 VL 34 IS 6 BP 588 EP 596 DI 10.1086/670621 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 142AB UT WOS:000318766800007 PM 23651889 ER PT J AU Abbo, L Lo, K Sinkowitz-Cochran, R Burke, AC Hopkins, RS Srinivasan, A Hooton, TM AF Abbo, Lilian Lo, Kaming Sinkowitz-Cochran, Ronda Burke, Anne Carol Hopkins, Richard S. Srinivasan, Arjun Hooton, Thomas M. TI Antimicrobial Stewardship Programs in Florida's Acute Care Facilities SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID INFECTIOUS-DISEASES SOCIETY; INSTITUTIONAL PROGRAM; AMERICA GUIDELINES; IMPLEMENTATION; EPIDEMIOLOGY; BARRIERS AB We surveyed acute care facilities in Florida to assess components of and barriers to sustained antimicrobial stewardship programs (ASPs). Most respondents with and without ASPs are doing some stewardship-related activities to improve antimicrobial use. Collaborative efforts between facilities and health departments are important to providing better resources for ASPs. C1 [Abbo, Lilian; Hooton, Thomas M.] Univ Miami, Miller Sch Med, Dept Med, Div Infect Dis, Miami, FL 33136 USA. [Lo, Kaming] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Div Biostat,Biostat Collaborat & Consulting Core, Miami, FL 33136 USA. [Sinkowitz-Cochran, Ronda; Srinivasan, Arjun] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Burke, Anne Carol; Hopkins, Richard S.] Florida Dept Hlth Bur Epidemiol, Tallahassee, FL USA. RP Abbo, L (reprint author), Univ Miami, Miller Sch Med, 1120 NW 14th St,Suite 851, Miami, FL 33136 USA. EM labbo@med.miami.edu FU Bureau of Epidemiology of the Florida Department of Health (Tallahassee, FL) FX This study was funded by the Bureau of Epidemiology of the Florida Department of Health (Tallahassee, FL) through American Recovery Reinvestment Act funding. NR 9 TC 7 Z9 7 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JUN PY 2013 VL 34 IS 6 BP 634 EP 637 DI 10.1086/670632 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 142AB UT WOS:000318766800015 PM 23651897 ER PT J AU Fanfair, RN Heslop, O Etienne, K Rainford, L Roy, M Gade, L Peterson, J O'Connell, H Noble-Wang, J Balajee, SA Brandt, ME Lindo, JF Park, BJ AF Fanfair, Robyn Neblett Heslop, Orville Etienne, Kizee Rainford, Lois Roy, Monika Gade, Lalitha Peterson, Joyce O'Connell, Heather Noble-Wang, Judith Balajee, S. Arunmozhi Brandt, Mary E. Lindo, John F. Park, Benjamin J. TI Trichosporon asahii among Intensive Care Unit Patients at a Medical Center in Jamaica SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID INFECTION AB We investigated an increase in Trichosporon asahii isolates among inpatients. We identified 63 cases; 4 involved disseminated disease. Trichosporon species was recovered from equipment cleaning rooms, washbasins, and fomites, which suggests transmission through washbasins. Patient washbasins should be single-patient use only; adherence to appropriate hospital disinfection guidelines was recommended. C1 [Fanfair, Robyn Neblett] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Fanfair, Robyn Neblett; Etienne, Kizee; Roy, Monika; Gade, Lalitha; Peterson, Joyce; Balajee, S. Arunmozhi; Brandt, Mary E.; Park, Benjamin J.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. [Heslop, Orville; Rainford, Lois; Lindo, John F.] Univ W Indies, Dept Microbiol, Kingston 7, Jamaica. [O'Connell, Heather; Noble-Wang, Judith] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Fanfair, RN (reprint author), 1600 Clifton Rd, Atlanta, GA 30333 USA. EM iyo5@cdc.gov FU Centers for Disease Control and Prevention, Center for Global Health FX Funding for this investigation was provided by the Centers for Disease Control and Prevention, Center for Global Health. NR 10 TC 4 Z9 5 U1 0 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JUN PY 2013 VL 34 IS 6 BP 638 EP 641 DI 10.1086/670633 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 142AB UT WOS:000318766800016 PM 23651898 ER PT J AU Magee, MJ Bloss, E Shin, SS Contreras, C Huaman, HA Ticona, JC Bayona, J Bonilla, C Yagui, M Jave, O Cegielski, JP AF Magee, M. J. Bloss, E. Shin, S. S. Contreras, C. Arbanil Huaman, H. Calderon Ticona, J. Bayona, J. Bonilla, C. Yagui, M. Jave, O. Cegielski, J. P. TI Clinical characteristics, drug resistance, and treatment outcomes among tuberculosis patients with diabetes in Peru SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Tuberculosis; Multi-drug resistance; Diabetes; Peru ID PULMONARY TUBERCULOSIS; MELLITUS; IMPACT; MANIFESTATIONS; RISK AB Objectives: Diabetes is a risk factor for active tuberculosis (TB). Data are limited regarding the association between diabetes and TB drug resistance and treatment outcomes. We examined characteristics of TB patients with and without diabetes in a Peruvian cohort at high risk for drug-resistant TB. Among TB patients with diabetes (TB-DM), we studied the association between diabetes clinical/management characteristics and TB drug resistance and treatment outcomes. Methods: During 2005-2008, adults with suspected TB with respiratory symptoms in Lima, Peru, who received rapid drug susceptibility testing (DST), were prospectively enrolled and followed during treatment. Bivariate and Kaplan-Meier analyses were used to examine the relationships of diabetes characteristics with drug-resistant TB and TB outcomes. Results: Of 1671 adult TB patients enrolled, 186 (11.1%) had diabetes. TB-DM patients were significantly more likely than TB patients without diabetes to be older, have had no previous TB treatment, and to have a body mass index (BMI) > 18.5 kg/m(2) (p < 0.05). In patients without and with previous TB treatment, the prevalence of multidrug-resistant TB was 23% and 26%, respectively, among patients without diabetes, and 12% and 28%, respectively, among TB-DM patients. Among 149 TB-DM patients with DST results, 104 (69.8%) had drug-susceptible TB and 45 (30.2%) had drug-resistant TB, of whom 29 had multidrug-resistant TB. There was no association between diabetes characteristics and drug-resistant TB. Of 136 TB-DM patients with outcome information, 107 (78.7%) had a favorable TB outcome; active diabetes management was associated with a favorable outcome. Conclusions: Diabetes was common in a cohort of TB patients at high risk for drug-resistant TB. Despite prevalent multidrug-resistant TB among TB-DM patients, the majority had a favorable TB treatment outcome. (C) 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. C1 [Magee, M. J.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Bloss, E.; Cegielski, J. P.] US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Shin, S. S.; Bayona, J.] Partners Hlth, Boston, MA USA. [Shin, S. S.; Contreras, C.; Bayona, J.] Socios Salud, Lima, Peru. [Arbanil Huaman, H.; Calderon Ticona, J.; Bonilla, C.; Jave, O.] Minist Salud Peru, Lima, Peru. [Yagui, M.] Univ Nacl Mayor San Marcos, Lima 14, Peru. RP Bloss, E (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E-10, Atlanta, GA 30333 USA. EM dpu2@cdc.gov FU NIAID [K23 AI054591-01A2]; Bill & Melinda Gates Foundation; Heiser Foundation; Infectious Diseases Society of America; US Centers for Disease Control and Prevention (US CDC) FX This work was supported by the US Centers for Disease Control and Prevention (US CDC), NIAID K23 AI054591-01A2, the Bill & Melinda Gates Foundation, Heiser Foundation, and the Infectious Diseases Society of America. Some of the authors of this publication are employed by the US CDC. NR 38 TC 8 Z9 10 U1 0 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD JUN PY 2013 VL 17 IS 6 BP E404 EP E412 DI 10.1016/j.ijid.2012.12.029 PG 9 WC Infectious Diseases SC Infectious Diseases GA 144XN UT WOS:000318975500008 PM 23434400 ER PT J AU Behrman, A Lopez, AS Chaves, SS Watson, BM Schmid, DS AF Behrman, Amy Lopez, Adriana S. Chaves, Sandra S. Watson, Barbara M. Schmid, D. Scott TI Varicella immunity in vaccinated healthcare workers SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Varicella; Chickenpox; Adult immunization; Healthcare workers; Cell-medicated immunity ID CELL-MEDIATED-IMMUNITY; ZOSTER-VIRUS; SOMATIC HYPERMUTATION; HERPES-ZOSTER; ADULTS; ANTIBODY; RESPONSES; VZV; COMPLICATIONS; EPIDEMIOLOGY AB Background: Nosocomial spread of varicella-zoster virus (VZV) infection can cause severe disease among vulnerable patient-populations and healthcare personnel (HCP). Limited data are available on duration of varicella vaccine-induced protection among adults and to what extent cell-mediated immunity (CMI) and antibody avidity contribute to protection. Objective: Evaluate humoral and cell-mediated immune responses of HCP who received a 2-dose regimen of varicella vaccine, and observe the responses to a 3rd vaccine dose among HCP who were seronegative after vaccination. Study design: A convenience sample of HCP with documented 2 doses of varicella vaccine was used to assess acquired VZV immune parameters (cytokine production, IgG avidity). HCP seronegative after 2 doses of vaccine were offered a third dose and evaluated further. Vaccine recipients' immune responses were compared with responses from persons with history of wild-type VZV infection. Results: The convenience sample consisted of 101 HCP with documented 2 doses of varicella vaccine; 12 (11.9%) were seronegative post-vaccination. 11.5% of 61 seropositive 2-dose recipients produced low avidity antibody, suggesting suboptimal response to vaccine. Seven 2-dose vaccinees who were VZV seronegative seroconverted after a third dose; however, 3/7 (42.9%) produced low avidity IgG. 142 persons with a history of varicella were all VZV IgG seropositive, and all had moderate to high avidity IgG. Conclusions: Measurements of serum IgG titers alone may not accurately reflect vaccine protection. Varicella vaccination of HCP remains important but further studies are needed to evaluate CMI and antibody avidity responses in HCP vaccinated with two doses of varicella vaccine. C1 [Behrman, Amy] Univ Penn, Hosp Univ Penn, Div Occupat Med, Philadelphia, PA 19104 USA. [Lopez, Adriana S.; Chaves, Sandra S.; Schmid, D. Scott] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. [Watson, Barbara M.] Philadelphia Dept Publ Hlth, Philadelphia, PA USA. RP Schmid, DS (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS G 18, Atlanta, GA 30333 USA. EM SSchmid@cdc.gov FU CDC grant [1U01 IP000019]; City of Philadelphia Public Health Department [544915]; CDC, Philadelphia Department of Public Health; Hospital of the University of Pennsylvania FX The study was partially funded through a CDC grant (Cooperative Agreement #1U01 IP000019 for Program Announcement 04116 - Varicella and Viral Vaccine Preventable Disease Surveillance) subcontracted from the City of Philadelphia Public Health Department, Fund #544915. The remainder was supported using core programmatic funds from CDC, Philadelphia Department of Public Health, and the Hospital of the University of Pennsylvania. NR 42 TC 7 Z9 7 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD JUN PY 2013 VL 57 IS 2 BP 109 EP 114 DI 10.1016/j.jcv.2013.01.015 PG 6 WC Virology SC Virology GA 139EH UT WOS:000318563900004 PM 23434396 ER PT J AU Deubelbeiss, AN Trachsel, C Bachli, EB Kuffer, A Budka, H Eniseyskiy, P Zimmermann, H Wallace, RM Farley, S Zanoni, RG AF Deubelbeiss, A. N. Trachsel, Ch. Bachli, E. B. Kuffer, A. Budka, H. Eniseyskiy, P. Zimmermann, H. Wallace, R. M. Farley, S. Zanoni, R. G. TI Imported human rabies in Switzerland, 2012: A diagnostic conundrum SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Rabies; Human; Clinical record; Diagnosis; Molecular Epidemiology ID POSTEXPOSURE PROPHYLAXIS; NEW-YORK; VIRUS; ENCEPHALITIS; BAT; ANTIBODIES; EXPOSURE; PATIENT; INFECTION; SCOTLAND AB Human rabies is rare in Western Europe. It is not easily recognized in the absence of a history of exposure. We describe the clinical course, diagnosis and follow-up of an imported human rabies case in Switzerland. The patient, a U. S. citizen, presented at an outpatient clinic in Iraq with pain in his right shoulder on July 5, 2012. On July 8 he was transferred to a hospital in the United Arab Emirates, where he exhibited progressive encephalitis with coma. On July 29, he was transferred to a hospital in Switzerland, where he died on July 31, 2012. The autopsy showed severe encephalitis. Rabies was diagnosed by the rapid fluorescent focus inhibition test (RFFIT) and confirmed by fluorescence antibody testing (FAT) in brain smears and immunohistochemistry on paraffin-embedded brain sections. The viral strain was characterized by RT-PCR followed by sequencing and phylogenetic analysis as an American bat rabies strain associated with Tadarida brasiliensis. Close contacts and exposed health care workers received postexposure prophylaxis (PEP). (C) 2013 Elsevier B.V. All rights reserved. C1 [Deubelbeiss, A. N.; Zanoni, R. G.] Inst Vet Virol, CH-3012 Bern, Switzerland. [Trachsel, Ch.; Bachli, E. B.] Uster Hosp, Clin Internal Med, CH-8610 Uster, Switzerland. [Kuffer, A.; Budka, H.] Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland. [Eniseyskiy, P.] Lukoil Overseas Balt Ltd, Dubai 115738, U Arab Emirates. [Zimmermann, H.] Swiss Fed Off Publ Hlth, CH-3003 Bern, Switzerland. [Wallace, R. M.] US Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Farley, S.] Contra Costa Hlth Serv, Martinez, CA USA. RP Zanoni, RG (reprint author), Inst Vet Virol, Laenggass Str 122, CH-3012 Bern, Switzerland. EM zanoni@vetsuisse.unibe.ch OI Budka, Herbert/0000-0002-1933-1577 FU Vetsuisse Faculty of the University of Berne; Swiss Federal Veterinary Office; Swiss Federal Office of Public Health; University Hospital of Zurich; Medical Faculty of the University of Zurich; Public Health Office of Zurich; Swiss Academy of Medical Sciences FX Vetsuisse Faculty of the University of Berne. Swiss Federal Veterinary Office. Swiss Federal Office of Public Health. University Hospital of Zurich. Medical Faculty of the University of Zurich.; The excellent technical assistance by Ms. D. Brugger, Ms. M. Zanoni (University of Berne), Ms. B. Piccapietra (University of Zurich) and Ms. K. Bihr and her team (Uster Hospital) is gratefully acknowledged. The unique support by the Public Health Office of Zurich is greatly acknowledged. AK is supported by a career development award of the Swiss Academy of Medical Sciences. This study was supported by the Vetsuisse Faculty of the University of Berne, the Swiss Federal Veterinary Office, the Swiss Federal Office of Public Health, the University Hospital of Zurich and the Medical Faculty of the University of Zurich. The authors declare no conflict of interest. NR 35 TC 0 Z9 0 U1 0 U2 17 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD JUN PY 2013 VL 57 IS 2 BP 178 EP 181 DI 10.1016/j.jcv.2013.02.001 PG 4 WC Virology SC Virology GA 139EH UT WOS:000318563900018 PM 23485347 ER PT J AU Fernandez, KH Bream, M Ali, MA Krogmann, T Zhao, H Li, Y Cohen, JI Damon, I Liu, V AF Fernandez, Kristen Heins Bream, Matthew Ali, Mir A. Krogmann, Tammy Zhao, Hui Li, Yu Cohen, Jeffrey I. Damon, Inger Liu, Vincent TI Investigation of molluscum contagiosum virus, orf and other parapoxviruses in lymphomatoid papulosis SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Letter ID T-CELL LYMPHOMA C1 [Fernandez, Kristen Heins] Univ Missouri, Dept Dermatol, Columbia, MO 65211 USA. [Bream, Matthew; Liu, Vincent] Univ Iowa, Dept Dermatol, Iowa City, IA USA. [Bream, Matthew; Liu, Vincent] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA. [Ali, Mir A.; Krogmann, Tammy; Cohen, Jeffrey I.] NIH, Infect Dis Lab, Bethesda, MD 20892 USA. [Ali, Mir A.; Krogmann, Tammy; Cohen, Jeffrey I.] NIH, Med Virol Sect, Bethesda, MD 20892 USA. [Zhao, Hui; Li, Yu; Damon, Inger] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. RP Fernandez, KH (reprint author), Univ Missouri, Dept Dermatol, Columbia, MO 65211 USA. EM Fernandezk@health.missouri.edu OI Fernandez, Kristen/0000-0002-3267-825X FU Intramural NIH HHS [Z01 AI000058-34] NR 5 TC 2 Z9 2 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD JUN PY 2013 VL 68 IS 6 BP 1046 EP 1047 DI 10.1016/j.jaad.2012.12.972 PG 3 WC Dermatology SC Dermatology GA 143ZW UT WOS:000318909600046 PM 23680202 ER PT J AU Dodd, KA McElroy, AK Jones, MEB Nichol, ST Spiropoulou, CF AF Dodd, Kimberly A. McElroy, Anita K. Jones, Megan E. B. Nichol, Stuart T. Spiropoulou, Christina F. TI Rift Valley Fever Virus Clearance and Protection from Neurologic Disease Are Dependent on CD4(+) T Cell and Virus-Specific Antibody Responses SO JOURNAL OF VIROLOGY LA English DT Article ID WEST-NILE-VIRUS; BLOOD-BRAIN-BARRIER; NSS PROTEIN; RHESUS MACAQUES; INFECTION; TRANSCRIPTION; LACKING; CHALLENGE; VIRULENCE; IMMUNITY AB Rift Valley fever virus (RVFV) causes outbreaks of severe disease in people and livestock throughout Africa and the Arabian Peninsula. Human RVFV infections generally manifest as a self-limiting febrile illness, but in some individuals, the disease can progress to a fatal encephalitis or hemorrhagic syndrome. Little is known about the host characteristics that predispose development of more severe disease. Early in infection, interferon-mediated antiviral responses are critical for controlling RVFV replication, but the roles of downstream adaptive immune responses in determining clinical outcome have not been examined. Here, using a C57BL/6 mouse disease model, we evaluated the roles of B cells and T cells in RVFV pathogenesis. Given the profound inhibition of the innate response by the viral NSs protein and rapid course of wild-type infection, we utilized an attenuated RVFV lacking NSs to examine host responses following primary infection. Experiments utilizing B-cell-deficient mice or targeted T cell depletions of wild-type mice demonstrated that B cells and CD4(+) T cells, but not CD8(+) T cells, were critical for mediating viral clearance, even in the presence of a functional innate response. One-third of CD4-depleted mice developed severe neurologic disease following infection, in contrast to virus-infected mock-depleted mice that showed no clinical signs. CD4(+) T cells were required for robust IgG and neutralizing antibody responses that correlated with RVFV clearance from peripheral tissues. Furthermore, CD4-depleted mice demonstrated significantly stronger proinflammatory responses relative to controls, suggesting CD4(+) T cells regulate immune responses to RVFV infection. Together, these results indicate CD4(+) T cells are critical determinants of RVFV pathogenesis and play an important role in preventing onset of neurologic disease. C1 [Dodd, Kimberly A.; McElroy, Anita K.; Jones, Megan E. B.; Nichol, Stuart T.; Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Viral Special Pathogens Branch, Atlanta, GA 30333 USA. [Dodd, Kimberly A.] Univ Calif Davis, Sch Vet Med, Davis, CA 95616 USA. [McElroy, Anita K.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. [Jones, Megan E. B.] Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30602 USA. RP Spiropoulou, CF (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Viral Special Pathogens Branch, Atlanta, GA 30333 USA. EM ccs8@cdc.gov NR 46 TC 8 Z9 10 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JUN PY 2013 VL 87 IS 11 BP 6161 EP 6171 DI 10.1128/JVI.00337-13 PG 11 WC Virology SC Virology GA 143ZF UT WOS:000318907500010 PM 23536675 ER PT J AU Weir, HK Johnson, CJ Thompson, TD AF Weir, Hannah K. Johnson, Christopher J. Thompson, Trevor D. TI The effect of multiple primary rules on population-based cancer survival SO CANCER CAUSES & CONTROL LA English DT Article DE Cancer survival; Multiple primary rules; SEER Program ID CONCORD AB Different rules for registering multiple primary (MP) cancers are used by cancer registries throughout the world, making international data comparisons difficult. This study evaluates the effect of Surveillance, Epidemiology, and End Results (SEER) and International Association of Cancer Registries (IACR) MP rules on population-based cancer survival estimates. Data from five US states and six metropolitan area cancer registries participating in the SEER Program were used to estimate age-standardized relative survival (RS%) for first cancers-only and all first cancers matching the selection criteria according to SEER and IACR MP rules for all cancer sites combined and for the top 25 cancer site groups among men and women. During 1995-2008, the percentage of MP cancers (all sites, both sexes) increased 25.4 % by using SEER rules (from 14.6 to 18.4 %) and 20.1 % by using IACR rules (from 13.2 to 15.8 %). More MP cancers were registered among females than among males, and SEER rules registered more MP cancers than IACR rules (15.8 vs. 14.4 % among males; 17.2 vs. 14.5 % among females). The top 3 cancer sites with the largest differences were melanoma (5.8 %), urinary bladder (3.5 %), and kidney and renal pelvis (2.9 %) among males, and breast (5.9 %), melanoma (3.9 %), and urinary bladder (3.4 %) among females. Five-year survival estimates (all sites combined) restricted to first primary cancers-only were higher than estimates by using first site-specific primaries (SEER or IACR rules), and for 11 of 21 sites among males and 11 of 23 sites among females. SEER estimates are comparable to IACR estimates for all site-specific cancers and marginally higher for all sites combined among females (RS 62.28 vs. 61.96 %). Survival after diagnosis has improved for many leading cancers. However, cancer patients remain at risk of subsequent cancers. Survival estimates based on first cancers-only exclude a large and increasing number of MP cancers. To produce clinically and epidemiologically relevant and less biased cancer survival estimates, data on all cancers should be included in the analysis. The multiple primary rules (SEER or IACR) used to identify primary cancers do not affect survival estimates if all first cancers matching the selection criteria are used to produce site-specific survival estimates. C1 [Weir, Hannah K.; Thompson, Trevor D.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Johnson, Christopher J.] Canc Data Registry Idaho, Boise, ID USA. RP Weir, HK (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy MS K55, Atlanta, GA 30341 USA. EM hbw4@cdc.gov FU Intramural CDC HHS [CC999999] NR 30 TC 9 Z9 11 U1 0 U2 6 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD JUN PY 2013 VL 24 IS 6 BP 1231 EP 1242 DI 10.1007/s10552-013-0203-3 PG 12 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 136OY UT WOS:000318372400018 PM 23558444 ER PT J AU Tierney, EF Thurman, DJ Beckles, GL Cadwell, BL AF Tierney, Edward F. Thurman, David J. Beckles, Gloria L. Cadwell, Betsy L. TI Association of statin use with peripheral neuropathy in the US population 40 years of age or older SO JOURNAL OF DIABETES LA English DT Article DE diabetes; peripheral neuropathy; statin use ID LIPID-LOWERING DRUGS; COA-REDUCTASE INHIBITORS; MYOCARDIAL-INFARCTION; DIABETIC-NEUROPATHY; HEART-DISEASE; TRENDS; THERAPY; RISK; PREVENTION; ADULTS AB Background: Peripheral neuropathy is a serious complication of diabetes and several conditions that may lead to the loss of lower extremity function and even amputations. Since the introduction of statins, their use has increased markedly. Recent reports suggest a role for statins in the development of peripheral neuropathy. The aims of the present study were to assess the association between statin use and peripheral neuropathy, and to determine whether this association varied by diabetes status. Methods: Data from the lower extremity examination supplement of the 1999-2004 National Health and Nutrition Examination Survey were used. Results: The overall prevalence of statin use was 15% and the prevalence of peripheral neuropathy was 14.9%. The prevalence of peripheral neuropathy was significantly higher among those who used statins compared with those who did not (23.5% vs 13.5%, respectively; P < 0.01). Multivariate logistic regression revealed that statin use (adjusted odds ratio 1.3; 95% confidence interval 1.1-1.6; Wald P = 0.04) was significantly associated with peripheral neuropathy, controlling for diabetes status, age, gender, race, height, weight, blood lead levels, poverty, glycohemoglobin, use of vitamin B-12, alcohol abuse, hypertension, and non-high-density lipoprotein cholesterol. Diabetes status, age, gender, height, weight, blood lead levels, poverty, and glycohemoglobin were also significantly associated with peripheral neuropathy. We found no effect modification between statin use and diabetes status, race, gender, age, vitamin B-12, blood lead levels, or alcohol abuse. Conclusions: In the present cross-sectional study, we found a modest association between peripheral neuropathy and statin use. Prospective studies are required to determine the causal direction. C1 [Tierney, Edward F.; Beckles, Gloria L.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA. [Thurman, David J.] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA 30341 USA. [Cadwell, Betsy L.] Ctr Dis Control & Prevent, Career Dev Div, Atlanta, GA 30341 USA. RP Tierney, EF (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, 4770 Buford Hwy,NE MailStop K10, Atlanta, GA 30341 USA. EM ext5@cdc.gov FU Centers for Disease Control and Prevention FX All authors were employed by the Centers for Disease Control and Prevention, which funded this study. NR 62 TC 16 Z9 17 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1753-0393 J9 J DIABETES JI J. Diabetes PD JUN PY 2013 VL 5 IS 2 BP 207 EP 215 DI 10.1111/1753-0407.12013 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 134VH UT WOS:000318243000016 PM 23121724 ER PT J AU Creek, DJ Bigira, V McCormack, S Arinaitwe, E Wanzira, H Kakuru, A Tappero, JW Sandison, TG Lindegardh, N Nosten, F Aweeka, FT Parikh, S AF Creek, Darren J. Bigira, Victor McCormack, Shelley Arinaitwe, Emmanuel Wanzira, Humphrey Kakuru, Abel Tappero, Jordan W. Sandison, Taylor G. Lindegardh, Niklas Nosten, Francois Aweeka, Francesca T. Parikh, Sunil TI Pharmacokinetic Predictors for Recurrent Malaria After Dihydroartemisinin-Piperaquine Treatment of Uncomplicated Malaria in Ugandan Infants SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE malaria; pharmacokinetics; piperaquine; artemisinin combination therapy; antimalarial ID PLASMODIUM-FALCIPARUM MALARIA; POPULATION PHARMACOKINETICS; ANTIMALARIAL PIPERAQUINE; ARTEMETHER-LUMEFANTRINE; TRANSMISSION INTENSITY; RURAL UGANDA; CHILDREN; EFFICACY; DRUG; TRIAL AB Background. Although dihydroartemisinin-piperaquine (DP) is used primarily in children, pharmacokinetic/pharmacodynamic (PK/PD) data on DP use in young children are lacking. Methods. We conducted a prospective PK/PD study of piperaquine in 107 young children in Uganda. Samples were collected up to 28 days after 218 episodes of malaria treatment, which occurred during follow-up periods of up to 5 months. Malaria follow-up was conducted actively to day 28 and passively to day 63. Results. The median capillary piperaquine concentration on day 7 after treatment was 41.9 ng/mL. Low piperaquine concentrations were associated with an increased risk of recurrent malaria for up to 42 days, primarily in those receiving trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis. In children not receiving TMP-SMX, low piperaquine concentrations were only modestly associated with an increased risk of recurrent malaria. However, for children receiving TMP-SMX, associations were strong and evident for all sampling days, with PQ concentrations of < 27.3 ng/mL on day 7 associated with a greatly increased risk of recurrent malaria. Notably, of 132 cases of recurrent malaria, 119 had detectable piperaquine concentrations at the time of presentation with recurrent malaria. Conclusions. These piperaquine PK/PD data represent the first in children < 2 years of age. Piperaquine exposure on day 7 correlated with an increased risk of recurrent malaria after DP treatment in children receiving TMP-SMX prophylaxis. Interestingly, despite strong associations, infants remained at risk for malaria, even if they had residual levels of piperaquine. C1 [Creek, Darren J.] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia. [Creek, Darren J.; McCormack, Shelley; Aweeka, Francesca T.; Parikh, Sunil] Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA 94143 USA. [Tappero, Jordan W.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sandison, Taylor G.] Univ Washington, Sch Med, Seattle, WA USA. [Parikh, Sunil] Yale Univ, Sch Publ Hlth & Med, New Haven, CT 06520 USA. [Bigira, Victor; Arinaitwe, Emmanuel; Wanzira, Humphrey; Kakuru, Abel] Makerere Univ, Sch Med, Kampala, Uganda. [Lindegardh, Niklas; Nosten, Francois] Mahidol Univ, Mahidol Oxford Trop Med Res Unit, Bangkok 10700, Thailand. [Nosten, Francois] Shoklo Malaria Res Unit, Mae Sot Tak, Thailand. [Nosten, Francois] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX1 2JD, England. RP Parikh, S (reprint author), Yale Univ, Sch Publ Hlth, 60 Coll St,Rm 444,Box 208322, New Haven, CT 06520 USA. EM sunil.parikh@yale.edu OI Nosten, Francois/0000-0002-7951-0745; Creek, Darren/0000-0001-7497-7082 FU Doris Duke Charitable Foundation [2007055]; Department of Health and Human Services/Centers for Disease Control and Prevention [U62P024421]; National Center for HIV, Viral Hepatitis, STD, and TB Prevention; Global AIDS Program FX This work was supported by the Doris Duke Charitable Foundation (Clinical Scientist Development Award 2007055 to S. P.) and the President's Emergency Plan for AIDS Relief, through the Department of Health and Human Services/Centers for Disease Control and Prevention (grant U62P024421). Subjects in this study were also enrolled in programs supported by the National Center for HIV, Viral Hepatitis, STD, and TB Prevention and the Global AIDS Program. NR 41 TC 14 Z9 14 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD JUN 1 PY 2013 VL 207 IS 11 BP 1646 EP 1654 DI 10.1093/infdis/jit078 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 139EA UT WOS:000318563200005 PM 23447696 ER PT J AU Gieraltowski, L Julian, E Pringle, J Macdonald, K Quilliam, D Marsden-Haug, N Saathoff-Huber, L Von Stein, D Kissler, B Parish, M Elder, D Howard-King, V Besser, J Sodha, S Loharikar, A Dalton, S Williams, I Behravesh, CB AF Gieraltowski, L. Julian, E. Pringle, J. Macdonald, K. Quilliam, D. Marsden-Haug, N. Saathoff-Huber, L. Von Stein, D. Kissler, B. Parish, M. Elder, D. Howard-King, V. Besser, J. Sodha, S. Loharikar, A. Dalton, S. Williams, I. Behravesh, C. Barton TI Nationwide outbreak of Salmonella Montevideo infections associated with contaminated imported black and red pepper: warehouse membership cards provide critical clues to identify the source SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Enteric bacteria; epidemiology; outbreaks; Salmonella ID TYPHIMURIUM; SEROTYPE; CANADA; SALAMI AB In November 2009, we initiated a multistate investigation of Salmonella Montevideo infections with pulsed-field gel electrophoresis pattern JIXX01.0011. We identified 272 cases in 44 states with illness onset dates ranging from 1 July 2009 to 14 April 2010. To help generate hypotheses, warehouse store membership card information was collected to identify products consumed by cases. These records identified 19 ill persons who purchased company A salami products before onset of illness. A case-control study was conducted. Ready-to-eat salami consumption was significantly associated with illness (matched odds ratio 8.5, 95% confidence interval 2.1-75.9). The outbreak strain was isolated from company A salami products from an environmental sample from one manufacturing plant, and sealed containers of black and red pepper at the facility. This outbreak illustrates the importance of using membership card information to assist in identifying suspect vehicles, the potential for spices to contaminate ready-to-eat products, and preventing raw ingredient contamination of these products. C1 [Gieraltowski, L.; Loharikar, A.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Epidem Intelligence Serv, Atlanta, GA USA. [Julian, E.; Quilliam, D.] Rhode Isl Dept Hlth, Providence, RI 02908 USA. [Pringle, J.; Besser, J.; Sodha, S.; Dalton, S.; Williams, I.; Behravesh, C. Barton] Ctr Dis Control & Prevent, Atlanta, GA USA. [Macdonald, K.; Marsden-Haug, N.] Washington State Dept Hlth, Olympia, WA USA. [Saathoff-Huber, L.] Illinois Dept Publ Hlth, Springfield, IL 62761 USA. [Von Stein, D.] Iowa Dept Hlth, De Moines, IA USA. [Kissler, B.] US Food Safety & Inspect Serv, USDA, Atlanta, GA USA. [Parish, M.; Elder, D.; Howard-King, V.] US FDA, Rockville, MD 20857 USA. RP Gieraltowski, L (reprint author), 1600 Clifton Rd NE,MS A38, Atlanta, GA 30329 USA. EM lax2@cdc.gov NR 23 TC 18 Z9 18 U1 1 U2 21 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD JUN PY 2013 VL 141 IS 6 BP 1244 EP 1252 DI 10.1017/S0950268812001859 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 135SS UT WOS:000318309400014 PM 23200262 ER PT J AU Abrams, JY Copeland, JR Tauxe, RV Date, KA Belay, ED Mody, RK Mintz, ED AF Abrams, J. Y. Copeland, J. R. Tauxe, R. V. Date, K. A. Belay, E. D. Mody, R. K. Mintz, E. D. TI Real-time modelling used for outbreak management during a cholera epidemic, Haiti, 2010-2011 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Cholera; epidemics; infectious disease control; modelling; Vibrio cholerae ID FIELD TRIAL; EL-TOR; TRANSMISSION; DISEASE; AFRICA; BANGLADESH; VACCINES; DYNAMICS; REGION; MALAWI AB The emergence of epidemic cholera in post-earthquake Haiti portended a public health disaster of uncertain magnitude. In order to coordinate relief efforts in an environment with limited healthcare infrastructure and stretched resources, timely and realistic projections of the extent of the cholera outbreak were crucial. Projections were shared with Government and partner organizations beginning 5 days after the first reported case and were updated using progressively more advanced methods as more surveillance data became available. The first projection estimated that 105 000 cholera cases would occur in the first year. Subsequent projections using different methods estimated up to 652 000 cases and 163 000-247 000 hospitalizations during the first year. Current surveillance data show these projections to have provided reasonable approximations of the observed epidemic. Providing the real-time projections allowed Haitian ministries and external aid organizations to better plan and implement response measures during the evolving epidemic. C1 [Abrams, J. Y.; Copeland, J. R.; Tauxe, R. V.; Date, K. A.; Belay, E. D.; Mody, R. K.; Mintz, E. D.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Abrams, JY (reprint author), Ctr Dis Control & Prevent, CDC Mailstop A30, Atlanta, GA 30333 USA. EM JAbrams@cdc.gov NR 39 TC 2 Z9 2 U1 5 U2 53 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD JUN PY 2013 VL 141 IS 6 BP 1276 EP 1285 DI 10.1017/S0950268812001793 PG 10 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 135SS UT WOS:000318309400017 PM 22935487 ER PT J AU Prejean, J Tang, T Hall, HI AF Prejean, Joseph Tang, Tian Hall, H. Irene TI HIV Diagnoses and Prevalence in the Southern Region of the United States, 2007-2010 SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE HIV; South; Southern region; US South ID US STATES; HIV/AIDS; REDISTRIBUTION; DISPARITIES; INFECTION AB On a number of leading health indicators, including HIV disease, individuals in the southern states of the United States fare worse than those in other regions. We analyzed data on adults and adolescents diagnosed with HIV infection through December 2010, and reported to the Centers for Disease Control and Prevention (CDC) through June 2011 from 46 states with confidential name-based HIV reporting since January 2007 to describe the impact of HIV in the South. In 2010 46.0 % of all new diagnoses of HIV infection occurred in the South. Compared to other regions, a higher percentage of diagnoses in the South were among women (23.8 %), blacks/African Americans (57.2 %), and among those in the heterosexual contact category (15.0 % for males; 88.5 % for females). From 2007 to 2010 the estimated number and rate of diagnoses of HIV infection decreased significantly in the South overall (estimated annual percentage change [EAPC] = -1.5 % [95 %CI -2.3 %, -0.7 %] and -2.1 % [95 % CI -4.0 %, -0.2 %], respectively) and among most groups of women, but there was no change in the number or rate of diagnoses of HIV infection among men overall. Significant decreases in men 30-39 and 40-49 years of age were offset by increases in young men 13-19 and 20-29 years of age. A continued focus on this area of high HIV burden is needed to yield success in the fight against HIV disease. C1 [Prejean, Joseph; Hall, H. Irene] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Tang, Tian] ICF Int, Atlanta, GA USA. RP Prejean, J (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS E-47, Atlanta, GA 30333 USA. EM jprejean@cdc.gov NR 28 TC 20 Z9 20 U1 2 U2 17 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 J9 J COMMUN HEALTH JI J. Community Health PD JUN PY 2013 VL 38 IS 3 BP 414 EP 426 DI 10.1007/s10900-012-9633-1 PG 13 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 136PJ UT WOS:000318373500002 PM 23179388 ER PT J AU Ortiz, AP Frias, O Perez, J Cabanillas, F Martinez, L Sanchez, C Capo-Ramos, DE Gonzalez-Keelan, C Mora, E Suarez, E AF Ortiz, Ana Patricia Frias, Orquidea Perez, Javier Cabanillas, Fernando Martinez, Lisa Sanchez, Carola Capo-Ramos, David E. Gonzalez-Keelan, Carmen Mora, Edna Suarez, Erick TI Breast cancer molecular subtypes and survival in a hospital-based sample in Puerto Rico SO CANCER MEDICINE LA English DT Article DE Breast cancer; Hispanic; Puerto Rico; subtypes; survival AB Information on the impact of hormone receptor status subtypes in breast cancer (BC) prognosis is still limited for Hispanics. We aimed to evaluate the association of BC molecular subtypes and other clinical factors with survival in a hospital-based female population of BC cases in Puerto Rico. We analyzed 663 cases of invasive BC diagnosed between 2002 and 2005. Information on HER-2/neu (HER-2) overexpression, estrogen (ER), and progesterone (PR) receptor status and clinical characteristics were retrieved from hospitals cancer registries and record review. Survival probabilities by covariates of interest were described using the Kaplan-Meier estimators. Cox proportional hazards models were employed to assess factors associated with risk of BC death. Overall, 17.3% of BC cases were triple-negative (TN), 61.8% were Luminal-A, 13.3% were Luminal-B, and 7.5% were HER-2 overexpressed. In the multivariate Cox model, among patients with localized stage, women with TN BC had higher risk of death (adjusted hazard ratio [HR]: 2.57, 95% confidence interval [CI]: 1.29-5.12) as compared to those with Luminal-A status, after adjusting for age at diagnosis. In addition, among women with regional/distant stage at diagnosis, those with TN BC (HR: 5.48, 95% CI: 2.63-11.47) and those HER-2+, including HER-2 overexpressed and Luminal-B, (HR: 2.73, 95% CI: 1.30-5.75) had a higher mortality. This is the most comprehensive epidemiological study to date on the impact of hormone receptor expression subtypes in BC survival in Puerto Rico. Consistent to results in other populations, the TN subtype and HER-2+ tumors were associated with decreased survival. C1 [Ortiz, Ana Patricia; Frias, Orquidea; Mora, Edna] Univ Puerto Rico, Ctr Comprehens Canc, Canc Control & Populat Sci Program, San Juan, PR 00927 USA. [Ortiz, Ana Patricia; Sanchez, Carola; Suarez, Erick] Univ Puerto Rico, Grad Sch Publ Hlth, Dept Biostat & Epidemiol, San Juan, PR 00927 USA. [Perez, Javier] Univ Puerto Rico, Ctr Comprehens Canc, Puerto Rico Cent Canc Registry, San Juan, PR 00927 USA. [Cabanillas, Fernando] Auxilio Mutuo Hosp, Ctr Canc, San Juan, PR 00919 USA. [Martinez, Lisa] Univ Puerto Rico, Sch Med, San Juan, PR 00927 USA. [Capo-Ramos, David E.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Bethesda, MD USA. [Gonzalez-Keelan, Carmen] Univ Puerto Rico, Sch Med, Dept Pathol, San Juan, PR 00927 USA. [Mora, Edna] Univ Puerto Rico, Sch Med, Dept Surg, San Juan, PR 00927 USA. RP Ortiz, AP (reprint author), Univ Puerto Rico, Ctr Comprehens Canc, PMB 711,89 Diego Ave Suite 105, San Juan, PR 00927 USA. FU Glaxo SmithKline; National Institute of Health: Training in Computational Genomic Epidemiology of Cancer (National Cancer Institute [NCI]) [5R25CA094186-08]; NCI [U54CA96297]; RCMI Program Grant from the University of Puerto Rico [G12RR03051] FX This study was supported by an unrestricted grant from Glaxo SmithKline with additional support from the following grants from the National Institute of Health: Training in Computational Genomic Epidemiology of Cancer (National Cancer Institute [NCI] 5R25CA094186-08), the NCI Grant U54CA96297 for the Puerto Rico Cancer Center/The University of Texas M. D. Anderson Cancer Center, Partners for Excellence in Cancer Research, and the RCMI Program Grant G12RR03051 from the University of Puerto Rico. NR 54 TC 3 Z9 6 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2045-7634 J9 CANCER MED-US JI Cancer Med. PD JUN PY 2013 VL 2 IS 3 BP 343 EP 350 DI 10.1002/cam4.78 PG 8 WC Oncology SC Oncology GA V36KJ UT WOS:000209210700009 PM 23930211 ER PT J AU Cherutich, P Bunnell, R Mermin, J AF Cherutich, Peter Bunnell, Rebecca Mermin, Jonathan TI HIV Testing: Current Practice and Future Directions SO CURRENT HIV/AIDS REPORTS LA English DT Article DE HIV; Global epidemic; HIV testing; Africa; International prevention; Antiretroviral therapy; Practice; Innovations ID EARLY ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; SUB-SAHARAN AFRICA; PARTNER NOTIFICATION; COST-EFFECTIVENESS; SEXUAL-BEHAVIOR; ANTIBODY TESTS; WESTERN KENYA; UNITED-STATES; SOUTH-AFRICA AB New approaches to expanding HIV testing and effective treatment and the wider availability of rapid testing technology have created new opportunities for achieving national and global HIV testing goals. In spite of HIV testing expansion in many settings, growing evidence of the prevention benefits of HIV testing, and the development of new, cost-effective approaches to HIV testing service provision, formidable obstacles to HIV testing expansion persist. Inequitable testing coverage exists within and across countries. While the proportion of people with HIV aware of their status is about 80 % in the U. S., the majority of HIVinfected persons in Africa are unaware of their status. Testing of most-at-risk populations, couples, children, and adolescents pose still unresolved policy and programmatic challenges. Future directions for HIV testing include rapid testing technology and detection of acute HIV infection, self-testing expansion, and partner notification. Expanded routine HIV screening and widespread testing is a public health imperative to reach national and international HIV prevention and treatment goals. C1 [Cherutich, Peter] Kenyatta Hosp Grounds, Minist Hlth, Natl AIDS STI Control Program, Nairobi, Kenya. [Bunnell, Rebecca] Ctr Dis Control & Prevent, NCCDPHP, Atlanta, GA USA. [Mermin, Jonathan] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Cherutich, P (reprint author), Kenyatta Hosp Grounds, Minist Hlth, Natl AIDS STI Control Program, Hosp Rd, Nairobi, Kenya. EM pcheru@nascop.or.ke NR 80 TC 15 Z9 15 U1 1 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1548-3568 EI 1548-3576 J9 CURR HIV-AIDS REP JI Curr. Hiv/Aids Rep. PD JUN PY 2013 VL 10 IS 2 BP 134 EP 141 DI 10.1007/s11904-013-0158-8 PG 8 WC Infectious Diseases SC Infectious Diseases GA AJ7TK UT WOS:000337900000004 PM 23526423 ER PT J AU Stauffer, W Cantey, PT Montgomery, S Fox, L Parise, ME Gorbacheva, O Weinberg, M Doney, A Rotz, L Cetron, MS AF Stauffer, WilliamM. Cantey, Paul T. Montgomery, Susan Fox, LeAnne Parise, Monica E. Gorbacheva, Olga Weinberg, Michelle Doney, Annelise Rotz, Lisa Cetron, Martin S. TI Presumptive Treatment and Medical Screening for Parasites in Refugees Resettling to the United States SO CURRENT INFECTIOUS DISEASE REPORTS LA English DT Article DE Intestinal parasites; Schistosomiasis; Refugees; Presumptive therapy; Screening; Strongyloidiasis ID TRANSMITTED HELMINTH INFECTIONS; STRONGYLOIDES-STERCORALIS; INTESTINAL PARASITES; COST-EFFECTIVENESS; SCHISTOSOMIASIS; IMMIGRANTS; IVERMECTIN; ALBENDAZOLE; CHILDREN; HYPERINFECTION AB More than 50,000 refugees are resettled to the United States annually, many from areas highly endemic for parasites. Some of these infections present little clinical consequence after migration, but others are responsible for morbidity and mortality. The Centers for Disease Control and Prevention has issued predeparture presumptive treatment and postarrival medical guidelines for the management of parasites. Although these guidelines are evidence based, there remain significant challenges to presumptive treatment programs in refugees. Gaps in the evidence continue; resettling populations are continually changing, thus altering the epidemiology; and there are logistical and cost barriers to fully implementing recommendations. This article will review the evolution and status of current guidelines, as well as identify gaps and challenges to full implementation. It is imperative for clinicians serving this population to be familiar with interventions received by refugees, since previous treatment will impact screening, diagnostic evaluation, and treatment decisions. C1 [Stauffer, WilliamM.] Univ Minnesota, Dept Med, Div Infect Dis & Int Med, Minneapolis, MN 55455 USA. [Cantey, Paul T.; Montgomery, Susan; Fox, LeAnne; Parise, Monica E.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Gorbacheva, Olga] Int Org Migrat, Geneva, Switzerland. [Gorbacheva, Olga] Int Org Migrat, Kathmandu, Nepal. [Stauffer, WilliamM.; Weinberg, Michelle; Doney, Annelise; Rotz, Lisa; Cetron, Martin S.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. RP Stauffer, W (reprint author), Univ Minnesota, Dept Med, Div Infect Dis & Int Med, 420 Delaware St SE,Mayo Bldg D407,MMC 250, Minneapolis, MN 55455 USA. EM Stauf005@umn.edu; pcantey@cdc.gov; zqu6@cdc.gov; lfox@cdc.gov; mparise@cdc.gov; ogorbacheva@iom.int; mpw5@cdc.gov; awc3@cdc.gov; ler8@cdc.gov; mzc4@CDC.GOV NR 34 TC 2 Z9 2 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3847 EI 1534-3146 J9 CURR INFECT DIS REP JI Curr. Infect. Dis. Rep. PD JUN PY 2013 VL 15 IS 3 BP 222 EP 231 DI 10.1007/s11908-013-0331-7 PG 10 WC Infectious Diseases SC Infectious Diseases GA AK2YQ UT WOS:000338286900005 PM 23686148 ER PT J AU Taylor, J Belay, B Park, S Onufrak, S Dietz, W AF Taylor, Jerome, Jr. Belay, Brook Park, Sohyun Onufrak, Stephen Dietz, William TI ASSOCIATION OF CHURCH-SPONSORED ACTIVITY PARTICIPATION AND PREVALENCE OF OVERWEIGHT AND OBESITY IN AFRICAN AMERICAN PROTESTANTS, NATIONAL SURVEY OF AMERICAN LIFE, 2001-2003 SO ETHNICITY & DISEASE LA English DT Article DE Religion; Obesity; Overweight; African Americans ID CARDIOVASCULAR RISK-FACTORS; BODY-MASS INDEX; UNITED-STATES; HEALTH-PROMOTION; SOCIAL NETWORK; MENTAL-HEALTH; RELIGION; INTERVENTION; NUTRITION; PROJECT AB Objective: This study examines the relationships between participation in the African American church and overweight/obesity (body mass index (BMI) >= 25 kg/m(2)). Design: This cross-sectional analysis was based on the National Survey of American Life 2001-2003 and included 2,689 African American Protestant (AAP) adults. Multivariate logistic regression was used to calculate adjusted odds ratios (aOR) and 95% confidence intervals (Cl) for overweight/obesity. Two practices were examined frequency of participation in church activities (excluding services) and frequency of church service attendance. Each practice was analyzed in separate models. Each model included the following covariates: age, marital status, education, poverty, smoking and region of country. We also adjusted models for sex. Results: After adjustment, African American Protestant men (AAPM) who participated in church activities at least weekly were more likely to be overweight/obese (aOR=2.17; 95% CI=1.25, 3.77) compared to AAPM who did not participate in church activities. There was no statistically significant association between overweight/obesity and participation in church activities for AAPW. There was no association between overweight/obesity and attendance of church services for AAP men and women combined. Conclusions: For AAPM, participation in church activities was significantly associated with overweight/obesity. Further studies are required to determine why this association occurs in AAPM but not AAPW. Studies looking at the wider application of the several successful health initiatives targeting the AAP community should also be considered. C1 [Taylor, Jerome, Jr.; Belay, Brook; Park, Sohyun; Onufrak, Stephen; Dietz, William] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, New Haven, CT USA. [Taylor, Jerome, Jr.] Yale Child Study Ctr, New Haven, CT USA. RP Taylor, J (reprint author), Yale Univ, Sch Med, Ctr Child Study, 230 South Frontage Rd, New Haven, CT 06519 USA. EM Jerome.Taylor@yale.edu FU External Medical Affairs, Pfizer Inc. FX We would like to thank Meredith Reynolds, PhD for her guidance and feedback during this project. Jerome Taylor's work was made possible through The CDC Experience Applied Epidemiology Fellowship, a public/private partnership supported by a grant to the CDC Foundation from External Medical Affairs, Pfizer Inc. Permission for publication of this manuscript has been obtained from authors and individuals listed in the acknowledgements. The findings and conclusions in this report are those of the authors and do not necessarily reflect the official position of the Centers for Disease Control and Prevention. NR 52 TC 0 Z9 0 U1 3 U2 7 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X EI 1945-0826 J9 ETHNIC DIS JI Ethn. Dis. PD SUM PY 2013 VL 23 IS 3 BP 322 EP 328 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AQ7QV UT WOS:000343015200009 PM 23914418 ER PT J AU Simon, AE Marsteller, JA Lin, SX AF Simon, Alan E. Marsteller, Jill A. Lin, Susan X. TI Physician-Patient Race Concordance from the Physician Perspective SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION LA English DT Article DE Concordance; Minority Workforce; Race; Ethnicity AB Background: The benefits of racial/ethnic physician-patient concordance have been cited to support increasing the number of minority pysicians. Few studies have examined the rates at which physicians of different race/ethnicity groups or specialties see concordant visits. We aim to determine wheather differences exist in rates at which physicians of different race/ethnicity groups and physician specialties see visits by patients of concordant race/ethnicity. Methods: We used data from the National Ambulatory Medical Care Survey, 2001-2006, a nationally representative survey of visits to private physician's offices. For physicians of each race/ethnicity group, the percentage of visits by patients in each race/ethnicity group was calculated. A concordant visit was defined as one in which a physician in a particular race/ethnicity group saw a patient of the same race/ethnicity group. Concordance rates were calculated overall, and for visits to primary care, medical specialties, and surgical specialties individually. Results: White physicians see a higher percentage of concordant visits than any other race/ethnicity of physician (84.3% p<0.001 vs. all others). followed by Hispanic physicians and non-Hispanic black physicians, who had statistically similar rates (50.0%, and 46.8%, p<0.05 for comparision). with non-Hispanic Asian physicians having the lowest rate of concordant visits (14.5%, p<0.001 vs. all others). Minority surgical and medical specialists have significantly lower rates of concordant visits (33.4% and 33.6% respectively) compared to minority primary care physicians (49.5%, p<0.001 for both comparisions). Conclusion: Concordance rates from the physician perspective differ by physician race/ethnicity and by physician specialty. C1 [Simon, Alan E.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Marsteller, Jill A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. [Lin, Susan X.] Columbia Univ, Med Ctr, Ctr Family & Community Med, New York, NY USA. RP Simon, AE (reprint author), Natl Ctr Hlth Stat, 3311 Toledo Rd,Rm 6122, Hyattsville, MD 20782 USA. EM fpa8@cdc.gov; jmarstel@jhsph.edu; xl8@columbia.edu NR 16 TC 2 Z9 2 U1 0 U2 1 PU NATL MED ASSOC PI WASHINGON PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA SN 0027-9684 J9 J NATL MED ASSOC JI J. Natl. Med. Assoc. PD SUM PY 2013 VL 105 IS 2 BP 150 EP 156 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA V36EJ UT WOS:000209195700005 PM 24079215 ER PT J AU Chatfield, J Milleson, M Stoddard, R Galloway, R AF Chatfield, Jenifer Milleson, Michael Stoddard, Robyn Galloway, Renee TI SEROSURVEY OF LEPTOSPIROSIS IN FERAL HOGS (SUS SCROFA) IN FLORIDA SO JOURNAL OF ZOO AND WILDLIFE MEDICINE LA English DT Article DE feral hog; Florida; leptospirosis; Sus scrofa; zoonosis ID EUROPEAN WILD HOGS; SEROLOGICAL SURVEY; POPULATION; SPP.; PREVALENCE; ANTIBODIES; CARNIVORES; PATHOGENS; EXPOSURE; BOARS AB Leptospira is a global pathogen of emerging public health importance in both developing and industrialized nations and can infect almost all mammalian species, including humans. As suburbanization and the popularity of outdoor recreational activities increases, so do human-wildlife and companion animal-wildlife interfaces. Florida offers a tropical climate favorable for outdoor activities and a semirural landscape that sustains an abundant feral hog population. Because no survey of leptospirosis in feral hogs (Sus scrofa) in Florida has been published to our knowledge, we sought to establish preliminary seroprevalence of leptospirosis exposure in feral hogs in Florida. Blood samples were collected opportunistically from 158 male and 166 female feral hogs taken at managed hunts and by permitted trappers in the northern, central, and southern regions of Florida. Samples were then analyzed using the microscopic agglutination test (MAT) for antibody titers to 20 Leptospira serovars representing 17 serogroups. A titer of >1:100 was considered positive; 33% (107/324 total samples) were positive to at least one serovar, and 46% of those were positive to multiple serovars. Antibodies to L. interrogans serovar Bratislava strain Jez Bratislava (serogroup Australis) was the most common, with 18% (58/324) testing positive for antibodies. These initial data indicate that there is a significant possibility of feral hogs having a larger role in the complex etiology of leptospirosis in Florida than historically estimated and that further investigation is warranted. C1 [Chatfield, Jenifer] Florida Dept Hlth, Zoonot & Vector Borne Dis Program, Tallahassee, FL 32399 USA. [Milleson, Michael] USDA, Natl Wildlife Dis Surveillance & Emergency Respon, Gainesville, FL 32641 USA. [Stoddard, Robyn; Galloway, Renee] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Atlanta, GA 30333 USA. RP Chatfield, J (reprint author), 4J Conservat Ctr, 38316 Mickler Rd, Dade City, FL 33523 USA. EM jen_chatfield@hotmail.com NR 24 TC 3 Z9 3 U1 1 U2 15 PU AMER ASSOC ZOO VETERINARIANS PI YULEE PA 581705 WHITE OAK ROAD, YULEE, FL 32097 USA SN 1042-7260 EI 1937-2825 J9 J ZOO WILDLIFE MED JI J. Zoo Wildl. Med. PD JUN PY 2013 VL 44 IS 2 BP 404 EP 407 DI 10.1638/2012-0258R2.1 PG 4 WC Veterinary Sciences SC Veterinary Sciences GA AM1PS UT WOS:000339620500020 PM 23805559 ER PT J AU Mittal, D Drummond, KL Blevins, D Curran, G Corrigan, P Sullivan, G AF Mittal, Dinesh Drummond, Karen L. Blevins, Dean Curran, Geoffrey Corrigan, Patrick Sullivan, Greer TI Stigma Associated With PTSD: Perceptions of Treatment Seeking Combat Veterans SO PSYCHIATRIC REHABILITATION JOURNAL LA English DT Article DE stigma; veterans; posttraumatic stress disorder; peer support AB Objective: Although stigma associated with serious mental illness, substance abuse disorders, and depression has been studied very little is known about stigma associated with Posttraumatic Stress Disorder (PTSD). This study explored stigma related to PTSD among treatment-seeking Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) combat veterans. Method: Sixteen treatment-seeking OEF/OIF veterans with combat-related PTSD participated in focus groups. We used qualitative methods to explore PTSD-related stigma. Results: Common perceived stereotypes of treatment-seeking veterans with PTSD included labels such as "dangerous/violent," or "crazy," and a belief that combat veterans are responsible for having PTSD. Most participants reported avoiding treatment early on to circumvent a label of mental illness. Participants initially reported experiencing some degree of self-stigma; however, following engagement in treatment they predominantly resisted these stereotypes. Although most participants considered combat-related PTSD as less stigmatizing than other mental illnesses, they reported difficulties with reintegration. Such challenges likely stem from both PTSD symptoms and veterans' perceptions of how the public views them. Most reported that fellow combat veterans best understood them. Conclusions and Implications for Practice: Awareness of public stereotypes impacts help seeking at least early in the course of illness. Peer-based outreach and therapy groups may help veterans engage in treatment early and resist stigma. C1 [Mittal, Dinesh] Ctr Mental Healthcare & Outcomes Res, North Little Rock, AR USA. [Mittal, Dinesh] VA South Cent Mental Illness Res Educ & Clin Ctr, Staff Psychiatrist, Cent Arkansas Vet Healthcare Syst, North Little Rock, AR USA. [Mittal, Dinesh; Curran, Geoffrey; Sullivan, Greer] Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA. [Drummond, Karen L.; Curran, Geoffrey; Sullivan, Greer] Cent Arkansas Vet Healthcare Syst, Ctr Mental Healthcare & Outcomes Res, VA Hlth Serv Res & Dev, North Little Rock, AR USA. [Drummond, Karen L.] Univ Arkansas Med Sci, Coll Med, Dept Psychiat, Div Hlth Serv Res, Little Rock, AR 72205 USA. [Blevins, Dean] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Sci Applicat Team, Capac Bldg Branch, Atlanta, GA USA. [Corrigan, Patrick] IIT, Coll Psychol, Chicago, IL 60616 USA. [Sullivan, Greer] VA South Cent Mental Illness Res Educ & Clin Ctr, North Little Rock, AR USA. RP Mittal, D (reprint author), Cent Arkansas Vet Healthcare Syst, Ctr Mental Healthcare & Outcomes Res, VA Hlth Serv Res & Dev HRS&D, 2200 Ft Roots Dr 152-NLR, North Little Rock, AR 72114 USA. EM Dinesh.Mittal@va.gov FU Department of Veterans Affairs, Office of Research & Development, Health Services Research and Development Service; VA Center for Mental Healthcare & Outcomes Research (CeMHOR); Understanding Self-Stigma Among OEF/OIF Veterans with PTSD [LIP 31-005] FX This research was supported by the Department of Veterans Affairs, Office of Research & Development, Health Services Research and Development Service; VA Center for Mental Healthcare & Outcomes Research (CeMHOR). The contents do not represent the views of the Department of Veterans Affairs or the United States Government. The authors acknowledge Mary Kate Bartnik, MA, Amanda Lunsford, MA, and Valorie Shue, BA, for help with literature search and editorial assistance. This work was conducted March 2010 August 2011. This research was supported by pilot grant funding (LIP 31-005: Understanding Self-Stigma Among OEF/OIF Veterans with PTSD). NR 30 TC 18 Z9 18 U1 2 U2 15 PU CENTER PSYCHIATRIC REHABILITATION PI BOSTON PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA SN 1095-158X EI 1559-3126 J9 PSYCHIATR REHABIL J JI Psychiatr. Rehabil. J. PD JUN PY 2013 VL 36 IS 2 BP 86 EP 92 DI 10.1037/h0094976 PG 7 WC Psychiatry; Rehabilitation SC Psychiatry; Rehabilitation GA V36ST UT WOS:000209231700005 PM 23750758 ER PT J AU Braun, KV Maenner, MJ Christensen, D Doernberg, NS Durkin, MS Kirby, RS Yeargin-Allsopp, M AF Braun, Kim Van Naarden Maenner, Matthew J. Christensen, Deborah Doernberg, Nancy S. Durkin, Maureen S. Kirby, Russell S. Yeargin-Allsopp, Marshalyn TI The role of migration and choice of denominator on the prevalence of cerebral palsy SO DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY LA English DT Article ID DEVELOPMENTAL-DISABILITIES; UNITED-STATES; US CHILDREN; EPIDEMIOLOGY; TRENDS; IMPACT AB Aim Differential migration and choice of denominator have been hypothesized to contribute to differences between period prevalence and birth prevalence of cerebral palsy (CP). The purpose of this study was to evaluate the effects of migration and choice of denominator on the prevalence of CP. Method Data from the Metropolitan Atlanta Developmental Disabilities Surveillance Program and census and birth certificate files were used to calculate various CP prevalence estimates for 2000. Results The overall CP period prevalence was 3.2 (95% confidence interval [CI] 2.73.8) per 1000 8-year-olds and was similar for those born in Atlanta who resided there at age 8years (3.3; 95% CI 2.74.1) and those born outside Atlanta who moved into Atlanta by age 8years (3.0; 95% CI 2.33.9). CP prevalence in these two migration strata was similar by sex and race/ethnicity. CP birth prevalence of 8-year-olds in Atlanta in 2000 was 2.0 (95% CI 1.62.5) per 1000 live births in 1992. Interpretation The authors found no evidence to support the hypothesis that differential in-migration explained higher period than birth prevalence of CP in Atlanta. Comparability of CP prevalence across geographic areas will be enhanced if future studies report both period and birth prevalence. C1 [Braun, Kim Van Naarden; Christensen, Deborah; Doernberg, Nancy S.; Yeargin-Allsopp, Marshalyn] Ctr Dis Control & Prevent, Dev Disabil Branch, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Maenner, Matthew J.; Durkin, Maureen S.] Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA. [Maenner, Matthew J.; Durkin, Maureen S.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA. [Kirby, Russell S.] Univ S Florida, Coll Publ Hlth, Dept Community & Family Hlth, Tampa, FL USA. RP Braun, KV (reprint author), 1600 Clifton Rd MS E-86, Atlanta, GA 30333 USA. EM kbn5@cdc.gov RI Durkin, Maureen/B-7834-2015 NR 18 TC 7 Z9 7 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0012-1622 J9 DEV MED CHILD NEUROL JI Dev. Med. Child Neurol. PD JUN PY 2013 VL 55 IS 6 BP 520 EP 526 DI 10.1111/dmcn.12095 PG 7 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA 134SW UT WOS:000318235800011 ER PT J AU Miernyk, K Bruden, D Zanis, C McMahon, B Sacco, F Hennessy, T Parkinson, A Bruce, M AF Miernyk, Karen Bruden, Dana Zanis, Carolyn McMahon, Brian Sacco, Frank Hennessy, Thomas Parkinson, Alan Bruce, Michael TI The Effect of Helicobacter pylori Infection on Iron Stores and Iron Deficiency in Urban Alaska Native Adults SO HELICOBACTER LA English DT Article DE Iron deficiency; serum ferritin; Alaska Native ID SERUM FERRITIN LEVELS; OPEN-LABEL TRIAL; CAUSAL RELATIONSHIP; ATROPHIC GASTRITIS; RURAL ALASKA; ANEMIA; CHILDREN; ERADICATION; METAANALYSIS; POPULATION AB Background Helicobacter pylori (H.pylori) infection has been correlated with low serum ferritin and iron deficiency. As a secondary analysis of a study of H.pylori reinfection, we investigated the association of H.pylori infection and the effect of its eradication on serum ferritin and iron deficiency. Methods Alaska Native adults undergoing esophagogastroduodenoscopy had sera collected and a 13C urea breath test (UBT) was performed. Those H.pylori positive were treated with an antibiotic regimen; those who tested negative 2months after treatment were evaluated at 4, 6, 12, and 24months by UBT and serum ferritin with an immunoradiometric assay. We excluded persons from further analysis if they were prescribed iron by their provider. Results We measured serum ferritin for 241 persons; 121/241 were H.pylori positive. The geometric mean ferritin (GMF) for persons with and without H.pylori infection was 37g/L and 50g/L, respectively (p=.04). At enrollment, 19/121 H.pylori-positive persons had iron deficiency compared with 8/120 H.pylori negative (p=.02). Among 66 persons tested at 24months, the GMF was higher at 24months (49.6g/L) versus enrollment (36.5g/L; p=.02). Six of 11 persons with iron deficiency at enrollment no longer had iron deficiency and had a higher GMF (p=.02) 24months after treatment. Conclusions H.pylori infection was correlated with lower serum ferritin and iron deficiency. After H.pylori eradication, serum ferritin increased and approximately half of persons resolved their iron deficiency. Testing for H.pylori infection and subsequent treatment of those positive could be considered in persons with unexplained iron deficiency. C1 [Miernyk, Karen; McMahon, Brian; Sacco, Frank] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. [Miernyk, Karen; Bruden, Dana; Zanis, Carolyn; McMahon, Brian; Hennessy, Thomas; Parkinson, Alan; Bruce, Michael] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. RP Miernyk, K (reprint author), Arctic Invest Program, 4055 Tudor Ctr Dr, Anchorage, AK 99517 USA. EM kmiernyk@cdc.gov FU Intramural CDC HHS [CC999999] NR 48 TC 3 Z9 3 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD JUN PY 2013 VL 18 IS 3 BP 222 EP 228 DI 10.1111/hel.12036 PG 7 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 134VB UT WOS:000318242300007 PM 23316928 ER PT J AU Ochomo, E Bayoh, MN Brogdon, WG Gimnig, JE Ouma, C Vulule, JM Walker, ED AF Ochomo, E. Bayoh, M. N. Brogdon, W. G. Gimnig, J. E. Ouma, C. Vulule, J. M. Walker, E. D. TI Pyrethroid resistance in Anopheles gambiae s.s. and Anopheles arabiensis in western Kenya: phenotypic, metabolic and target site characterizations of three populations SO MEDICAL AND VETERINARY ENTOMOLOGY LA English DT Article DE Anopheles arabiensis; Anopheles gambiae; insecticide resistance; metabolic detoxification; target site ID PERMETHRIN-IMPREGNATED NETS; TREATED BED NETS; INSECTICIDE RESISTANCE; MALARIA TRANSMISSION; NORTHERN CAMEROON; MICROPLATE ASSAY; TOLERANCE; COVERAGE; ALLELE; COTTON AB Field and laboratory investigations revealed phenotypic, target site and metabolic resistance to permethrin in an Anopheles gambiae s.s. (Diptera: Culicidae) population in Bungoma District, a region in western Kenya in which malaria is endemic and rates of ownership of insecticide-treated bednets are high. The sensitivity of individual An. gambiae s.l. females as indicated in assays using World Health Organization (WHO) test kits demonstrated reduced mortality in response to permethrin, deltamethrin and bendiocarb. Estimated time to knock-down of 50% (KDT50) of the test population in Centers for Disease Control (CDC) bottle bioassays was significantly lengthened for the three insecticides compared with that in a susceptible control strain. Anopheles arabiensis from all three sites showed higher mortality to all three insecticides in the WHO susceptibility assays compared with the CDC bottle assays, in which they showed less sensitivity and longer KDT50 than the reference strain for permethrin and deltamethrin. Microplate assays revealed elevated activity of -esterases and oxidases, but not glutathione-S-transferase, in An. gambiae s.s. survivors exposed to permethrin in bottle bioassays compared with knocked down and unexposed individuals. No An. arabiensis showed elevated enzyme activity. The 1014S kdr allele was fixed in the Bungoma An. gambiae s.s. population and absent from An. arabiensis, whereas the 1014F kdr allele was absent from all samples of both species. Insecticide resistance could compromise vector control in Bungoma and could spread to other areas as coverage with longlasting insecticide-treated bednets increases. C1 [Ochomo, E.; Ouma, C.] Maseno Univ, Sch Publ Hlth & Community Dev, Dept Biomed Sci & Technol, Maseno, Kenya. [Ochomo, E.; Bayoh, M. N.; Vulule, J. M.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Ctr Dis Control & Prevent, Kisumu 40100, Kenya. [Brogdon, W. G.; Gimnig, J. E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Walker, E. D.] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA. RP Ochomo, E (reprint author), Kenya Govt Med Res Ctr, Ctr Global Hlth Res, POB 1578, Kisumu 40100, Kenya. EM ericochomo@yahoo.com FU National Science Foundation [EF-072377]; National Institutes of Health [AI058542] FX We thank Claudia Corredor-Medina for training in the enzyme assays, Richard Amito for mosquito rearing, Joseph Nduati for expert laboratory assistance, and staff of the Entomology Section, Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya, for assistance with field collections. This study was funded by National Science Foundation grant EF-072377 and National Institutes of Health grant AI058542. NR 46 TC 15 Z9 15 U1 1 U2 33 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-283X J9 MED VET ENTOMOL JI Med. Vet. Entomol. PD JUN PY 2013 VL 27 IS 2 BP 156 EP 164 DI 10.1111/j.1365-2915.2012.01039.x PG 9 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA 133CF UT WOS:000318114300003 PM 22861380 ER PT J AU Odom, EC Vernon-Feagans, L Crouter, AC AF Odom, Erika C. Vernon-Feagans, Lynne Crouter, Ann C. TI Nonstandard maternal work schedules: Implications for African American children's early language outcomes SO EARLY CHILDHOOD RESEARCH QUARTERLY LA English DT Article DE Maternal nonstandard work; African American families; Parenting; Work-family spillover; Early child language ID LOW-INCOME FAMILIES; SHIFT WORK; BEHAVIORAL OUTCOMES; LABOR-FORCE; MOTHERS; LIFE; HOME; ASSOCIATIONS; ENVIRONMENT; PREDICTORS AB In this study, observed maternal positive engagement and perception of work-family spillover were examined as mediators of the association between maternal nonstandard work schedules and children's expressive language outcomes in 231 African American families living in rural households. Mothers reported their work schedules when their child was 24 months of age and children's expressive language development was assessed during a picture book task at 24 months and with a standardized assessment at 36 months. After controlling for family demographics, child, and maternal characteristics, maternal employment in nonstandard schedules at the 24-month timepoint was associated with lower expressive language ability among African American children concurrently and at 36 months of age. Importantly, the negative association between nonstandard schedules and children's expressive language ability at 24 months of age was mediated by maternal positive engagement and negative work-family spillover, while at 36 months of age, the association was mediated only by negative work-family spillover. These findings suggest complex links between mothers' work environments and African American children's developmental outcomes. Published by Elsevier Inc. C1 [Odom, Erika C.; Vernon-Feagans, Lynne] Univ N Carolina, Chapel Hill, NC USA. [Crouter, Ann C.] Penn State Univ, Family Life Project Key Investigators, University Pk, PA 16802 USA. RP Odom, EC (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE,MS K-25, Atlanta, GA 30341 USA. EM ecodom@cdc.gov FU NICHD NIH HHS [T32 HD007376, P01 HD039667] NR 60 TC 6 Z9 6 U1 5 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-2006 J9 EARLY CHILD RES Q JI Early Childhood Res. Q. PD JUN PY 2013 VL 28 IS 2 BP 379 EP 387 DI 10.1016/j.ecresq.2012.10.001 PG 9 WC Education & Educational Research; Psychology, Developmental SC Education & Educational Research; Psychology GA 113ZC UT WOS:000316707700017 PM 23459591 ER PT J AU Coulliette, AD Enger, KS Weir, MH Rose, JB AF Coulliette, Angela D. Enger, Kyle S. Weir, Mark H. Rose, Joan B. TI Risk reduction assessment of waterborne Salmonella and Vibrio by a chlorine contact disinfectant point-of-use device SO INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH LA English DT Article DE Salmonella; Vibrio; Risk assessment; Household water treatment; Water quality ID SAFE DRINKING-WATER; DEVELOPING-COUNTRIES; TYPHOID-FEVER; N-HALAMINE; EFFICACY; CHOLERA; DISEASE; BEADS AB Unsafe drinking water continues to burden developing countries despite improvements in clean water delivery and sanitation, in response to Millennium Development Goal 7. Salmonella serotype Typhi and Vibrio cholerae bacteria can contaminate drinking water, causing waterborne typhoid fever and cholera, respectively. Household water treatment (HWT) systems are widely promoted to consumers in developing countries but it is difficult to establish their benefits to the population for specific disease reduction. This research uses a laboratory assessment of halogenated chlorine beads treating contaminated water to inform a quantitative microbial risk assessment (QMRA) of S. Typhi and V. cholerae disease in a developing country community of 1000 people. Laboratory challenges using seeded well water resulted in logo reductions of 5.44 (+/- 0.98 standard error (SE)) and 6.07 (+/- 0.09 SE) for Salmonella serotype Typhimurium and V. cholerae, respectively. In well water with 10% sewage and seeded bacteria, the logo reductions were 6.06 (+/- 0.62 SE) and 7.78 (+/- 0.11 SE) for S. Typhimurium and V. cholerae, respectively. When one infected individual was contributing to the water contamination through fecal material leaking into the water source, the risk of disease associated with drinking untreated water was high according to a Monte Carlo analysis: a median of 0.20 (interquartile range [IQR] 0.017-0.54) for typhoid fever and a median of 0.11 (IQR 0.039-0.20) for cholera. If water was treated, risk greatly decreased, to a median of 4.1 x 10(-7) (IQR 1.6 x 10(-8) to 1.1 x 10(-5)) for typhoid fever and a median of 3.5 x 10(-9) (IQR 8.0 x 10(-10) to 1.3 x 10(-8)) for cholera. Insights on risk management policies and strategies for public health workers were gained using a simple QMRA scenario informed by laboratory assessment of HWT. (C) 2012 Elsevier GmbH. All rights reserved. C1 [Coulliette, Angela D.; Enger, Kyle S.; Weir, Mark H.; Rose, Joan B.] Michigan State Univ, Dept Fisheries & Wildlife, E Lansing, MI 48824 USA. RP Coulliette, AD (reprint author), Ctr Dis Control & Prevent, Clin & Environm Microbiol Branch, Div Healthcare Qual Promot & Epidemiol, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE,Bldg 17 Rm 4227,Mail Stop C16, Atlanta, GA 30329 USA. EM ACoulliette@cdc.gov FU HaloSource Inc. (Bothell, WA, USA); Center for Advancing Microbial Risk Assessment (CAMRA) (EPA) [RD832262]; Michigan State University's Provost Office for Post-Doctoral Diversity FX This study was supported by HaloSource Inc. (Bothell, WA, USA), the Center for Advancing Microbial Risk Assessment (CAMRA) (EPA grant# RD832262), and Michigan State University's Provost Office for Post-Doctoral Diversity. The authors thank Lauren Peterson for laboratory assistance. NR 41 TC 5 Z9 5 U1 2 U2 37 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 1438-4639 J9 INT J HYG ENVIR HEAL JI Int. J. Hyg. Environ. Health. PD JUN PY 2013 VL 216 IS 3 BP 355 EP 361 DI 10.1016/j.ijheh.2012.08.007 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 129WC UT WOS:000317873700019 PM 23041054 ER PT J AU Sutton, MY Parks, CP AF Sutton, Madeline Y. Parks, Carolyn P. TI HIV/AIDS Prevention, Faith, and Spirituality among Black/African American and Latino Communities in the United States: Strengthening Scientific Faith-Based Efforts to Shift the Course of the Epidemic and Reduce HIV-Related Health Disparities SO JOURNAL OF RELIGION & HEALTH LA English DT Article DE HIV; AIDS; Faith; Communities of color; Disparities ID BLACK CHURCHES; MEN; EXPECTATIONS; PROJECT; STIGMA; AIDS; GAY AB Black/African American and Latino communities are disproportionately affected by the domestic HIV/AIDS epidemic. Blacks/African Americans and Latinos are also more likely to report a formal, religious, or faith affiliation when compared with non-Hispanic whites. As such, faith leaders and their institutions have been identified in the National HIV/AIDS Strategy as having a vital role to serve in reducing: (1) HIV-related health disparities and (2) the number of new HIV infections by promoting non-judgmental support for persons living with and at risk for HIV/AIDS and by serving as trusted information resources for their congregants and communities. We describe faith doctrines and faith-science partnerships that are increasing in support of faith-based HIV prevention and service delivery activities and discuss the vital role of these faith-based efforts in highly affected black/African American and Latino communities. C1 [Sutton, Madeline Y.; Parks, Carolyn P.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Sutton, MY (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd NE MS E-45, Atlanta, GA 30333 USA. EM msutton@cdc.gov; cparksbani@cdc.gov NR 72 TC 20 Z9 20 U1 3 U2 28 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0022-4197 J9 J RELIG HEALTH JI J. Relig. Health PD JUN PY 2013 VL 52 IS 2 BP 514 EP 530 DI 10.1007/s10943-011-9499-z PG 17 WC Public, Environmental & Occupational Health; Religion SC Public, Environmental & Occupational Health; Religion GA 126NV UT WOS:000317625500015 PM 21626244 ER PT J AU Hernandez-Diaz, S Su, YC Mitchell, AA Kelley, KE Calafat, AM Hauser, R AF Hernandez-Diaz, Sonia Su, Yung-Cheng Mitchell, Allen A. Kelley, Katherine E. Calafat, Antonia M. Hauser, Russ TI Medications as a potential source of exposure to phthalates among women of childbearing age SO REPRODUCTIVE TOXICOLOGY LA English DT Article DE Phthalate; Toxicology; Medications; Mesalamine; Male reproductive system ID N-BUTYL PHTHALATE; SEXUAL-DIFFERENTIATION; ANOGENITAL DISTANCE; MALE INFANTS; HUMAN URINE; MALE-RAT; METABOLITES; POPULATION AB Objective: To evaluate the association between the use of medications potentially containing phthalates and urinary concentrations of specific phthalate metabolites around conception. Methods: Women enrolled in the Environment and Reproductive Health project from 2006 to 2009 completed questionnaires about the use of medications and provided multiple urine samples before and after conception. We compared the mean urinary concentration of phthalate metabolites between users of phthalate containing medications and a matched unexposed control group. Results: One woman used Asacol (R) (mesalamine), which utilizes dibutyl phthalate (DBP) as a delayed release coating material, and had a mean urinary concentration of the main DBP metabolite 200 times higher than the controls (8176 mu g/L vs. 37.5 mu g/L). The three users of stool softeners had a higher concentration of the main diethyl phthalate (DEP) metabolite (8636 mu g/L vs. 714.2 mu g/L). Neither the three additional Prilosec (R) (omeprazole) users nor one cyclobenzaprine user had higher urinary concentration than controls. Conclusion: Selected medications may be important sources of DBP and DEP exposures around conception. (C) 2013 Elsevier Inc. All rights reserved. C1 [Hernandez-Diaz, Sonia; Su, Yung-Cheng; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Su, Yung-Cheng] Buddhist Tzu Chi Dalin Gen Hosp, Emergency Dept, Dalin Township 622, Chiayi County, Taiwan. [Mitchell, Allen A.; Kelley, Katherine E.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Hauser, Russ] Harvard Univ, Sch Publ Hlth HSPH, Dept Environm Hlth Occupat & Environm Med, Boston, MA 02115 USA. [Hauser, Russ] Harvard Univ, Sch Publ Hlth HSPH, Program Epidemiol, Boston, MA 02115 USA. [Hauser, Russ] Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol Serv, Boston, MA 02114 USA. RP Su, YC (reprint author), Buddhist Tzu Chi Dalin Gen Hosp, Emergency Dept, 2 Minsheng Rd, Dalin Township 622, Chiayi County, Taiwan. EM drsu119@gmail.com OI Mitchell, Allen/0000-0003-0950-6799 FU National Institute of Environmental Health Sciences (NIEHS) [ES009718, ES00002]; National Institute of Child Health and Human Development [RO1HD059861]; Pfizer; ASISA FX National Institute of Environmental Health Sciences (NIEHS) (grant numbers: ES009718 and ES00002) and by the National Institute of Child Health and Human Development (grant number RO1HD059861); The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the U.S. Centers for Disease Control and Prevention. The Pharmacoepidemiology Program at the Harvard School of Public Health is supported by training grants from Pfizer and ASISA. The Slone Epidemiology Center receives unrelated research support from various pharmaceutical manufacturers, some of which may market products containing phthalates. NR 19 TC 19 Z9 20 U1 1 U2 29 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0890-6238 J9 REPROD TOXICOL JI Reprod. Toxicol. PD JUN PY 2013 VL 37 BP 1 EP 5 DI 10.1016/j.reprotox.2013.01.001 PG 5 WC Reproductive Biology; Toxicology SC Reproductive Biology; Toxicology GA 121OM UT WOS:000317254100001 PM 23333816 ER PT J AU Xu, F Town, M Balluz, LS Bartoli, WP Murphy, W Chowdhury, PP Garvin, WS Pierannunzi, C Zhong, YN Salandy, SW Jones, CK Crawford, CA AF Xu, Fang Town, Machell Balluz, Lina S. Bartoli, William P. Murphy, Wilmon Chowdhury, Pranesh P. Garvin, William S. Pierannunzi, Carol Zhong, Yuna Salandy, Simone W. Jones, Candace K. Crawford, Carol A. TI Surveillance for Certain Health Behaviors Among States and Selected Local Areas - United States, 2010 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID SELF-RATED HEALTH; HEART-DISEASE; PNEUMOCOCCAL DISEASE; ALCOHOL-CONSUMPTION; INTERVIEW SURVEY; NATIONAL-HEALTH; ECONOMIC COSTS; US ADULTS; PREVALENCE; MORTALITY AB Problem: Chronic diseases (e. g., heart disease, stroke, cancer, and diabetes) are the leading causes of morbidity and mortality in the United States. Engaging in healthy behaviors (e. g., quitting smoking and tobacco use, being more physically active, and eating a nutritious diet) and accessing preventive health-care services (e. g., routine physical checkups, screening for cancer, checking blood pressure, testing blood cholesterol, and receiving recommended vaccinations) can reduce morbidity and mortality from chronic and infectious disease and lower medical costs. Monitoring and evaluating health-risk behaviors and the use of health services is essential to developing intervention programs, promotion strategies, and health policies that address public health at multiple levels, including state, territory, metropolitan and micropolitan statistical area (MMSA), and county. Reporting Period: January-December 2010. Description of the System: The Behavioral Risk Factor Surveillance System (BRFSS) is an ongoing, state-based, random-digit-dialed telephone survey of noninstitutionalized adults aged >= 18 years residing in the United States. BRFSS collects data on health-risk behaviors, chronic diseases and conditions, access to health care, and use of preventive health services and practices related to the leading causes of death and disabilities in the United States. This report presents results for 2010 for all 50 states, the District of Columbia, the Commonwealth of Puerto Rico, Guam, the U. S. Virgin Islands, 192 MMSAs, and 302 counties. Results: In 2010, the estimated prevalence of high-risk health behaviors, chronic diseases and conditions, access to health care, and use of preventive health services varied substantially by state and territory, MMSA, and county. In the following summary of results, each set of proportions refers to the range of estimated prevalence for the disease, condition, or behaviors, as reported by survey respondents. Adults reporting good or better health: 67.9%-89.3% for states and territories, 72.2%-92.1% for MMSAs, and 72.8%-95.8% for counties. Adults with health-care coverage: 69.4%-95.7% for states and territories, 45.7%-97.0% for MMSAs, and 45.7%-97.2% for counties. Adults who had a dental visit in the past year: 57.2%-81.7% for states and territories, 47.1%-83.5% for MMSAs, and 47.1%-88.2% for counties. Adults aged >= 65 years having had all their natural teeth extracted (edentulism): 7.4%-36.0% for states and territories, 4.8%-34.8% for MMSAs, and 2.4%-39.3% for counties. A routine physical checkup during the preceding 12 months: 53.8%-80.0% for states and territories, 49.5%-82.6% for MMSAs, and 49.5%-85.3% for counties. Influenza vaccination received during the preceding 12 months among adults aged >= 65 years: 26.9%-73.4% for states and territories, 51.7%-77.1% for MMSAs, and 49.3%-87.8% for counties. Pneumococcal vaccination ever received among adults aged >= 65 years: 24.7%-74.0% for states and territories, 48.6%-79.9% for MMSAs, and 47.6%-83.1% for counties. Sigmoidoscopy or colonoscopy ever received among adults aged >= 50 years: 37.8%-75.7% for states and territories, 37.3%-79.9% for MMSAs, and 37.3%-82.5% for counties. Blood stool test received during the preceding 2 years among adults aged >= 50 years: 8.5%-27.0% for states and territories, 6.7%-51.3% for MMSAs, and 6.8%-57.2% for counties. Women who reported having had a Papanicolaou test during the preceding 3 years: 67.8%-88.9% for states and territories, 63.3%-91.2% for MMSAs, and 63.2%-95.7% for counties. Women aged >= 40 years who had a mammogram during the preceding 2 years: 63.8%-83.6% for states and territories, 60.3%-86.2% for MMSAs, and 59.3%-89.7% for counties. Current cigarette smokers: 5.8%-26.8% for states and territories, 5.8%-28.5% for MMSAs, and 5.9%-29.8% for counties. Binge drinking during the preceding month: 6.6%-21.6% for states and territories, 3.6%-23.0% for MMSAs, and 3.8%-24.0% for counties. Heavy drinking during the preceding month: 2.0%-7.2% for states and territories, 1.0%-10.0% for MMSAs, and 1.0%-14.2% for counties. Adults reporting no leisure-time physical activity: 17.5%-42.3% for states and territories, 13.1%-37.6% for MMSAs, and 8.5%-39.0% for counties. Adults who were overweight: 32.6%-40.7% for states and territories, 28.5%-42.5% for MMSAs, and 27.2%-46.4% for counties. Adults aged >= 20 years who were obese: 22.1%-35.0% for states and territories, 17.1%-42.1% for MMSAs, and 13.3%-42.1% for counties. Adults with current asthma: 5.2%-11.1% for states and territories, 3.4%-14.5% for MMSAs, and 3.3%-14.6% for counties. Adults with diagnosed diabetes: 5.3%-13.2% for states and territories, 4.6%-15.4% for MMSAs, and 2.6%-18.8% for counties. Adults with limited activities because of physical, mental or emotional problems: 10.8%-28.2% for states and territories, 13.5%-38.3% for MMSAs, and 11.7%-32.0% for counties. Adults using special equipment because of any health problem: 2.8%-10.6% for states and territories, 4.5%-15.5% for MMSAs, and 1.3%-15.5% for counties. Adults aged >= 45 years who have had coronary heart disease: 5.3%-16. 7% for states and territories, 6.5%-19.6% for MMSAs, and 4.9%-19.6% for counties. Adults aged >= 45 years who have had a stroke: 2.4%-7.1% for states and territories, 2.3%-8.8% for MSMAs, and 1.7%-8.8% for counties. Interpretation: The findings in this report indicate substantial variations in the health-risk behaviors, chronic diseases and conditions, access to health-care services, and the use of the preventive health services among U. S. adults at the state and territory, MMSA, and county levels. Healthy People 2010 ( HP 2010) objectives were established to monitor health behaviors, conditions, and the use of preventive health services for the first decade of the 2000s. The findings in this report indicate that many of the HP 2010 objectives were not achieved by 2010. The findings underscore the continued need for surveillance of health-risk behaviors, chronic diseases, and conditions and of the use of preventive health-care services. Public Health Action: Local and state health departments and federal agencies use BRFSS data to identify populations at high risk for certain health-risk behaviors, chronic diseases, and conditions and to evaluate the use of preventive health-care services. BRFSS data also are used to direct, implement, monitor, and evaluate public health programs and policies that can lead to a reduction in morbidity and mortality from chronic conditions and corresponding health-risk behaviors. C1 [Xu, Fang; Town, Machell; Balluz, Lina S.; Bartoli, William P.; Murphy, Wilmon; Chowdhury, Pranesh P.; Garvin, William S.; Pierannunzi, Carol; Zhong, Yuna; Salandy, Simone W.; Jones, Candace K.; Crawford, Carol A.] CDC, Div Behav Surveillance, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Xu, Fang; Bartoli, William P.; Murphy, Wilmon; Zhong, Yuna; Salandy, Simone W.; Jones, Candace K.] Northrop Grumman Corp, Atlanta, GA USA. RP Crawford, CA (reprint author), CDC, Div Behav Surveillance, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. EM cdg7@cdc.gov NR 112 TC 30 Z9 30 U1 1 U2 22 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD MAY 31 PY 2013 VL 62 IS 1 BP 1 EP 247 PG 247 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 199DD UT WOS:000322973800001 PM 23718989 ER PT J AU Caixeta, RB Sinha, DN Khoury, RN Rarick, J Fouad, H d'Espaignet, ET Bettcher, D Andes, LJ Palipudi, K Asma, S AF Caixeta, Roberta B. Sinha, Dhirendra N. Khoury, Rula N. Rarick, James Fouad, Heba d'Espaignet, Edouard Tursan Bettcher, Doug Andes, Linda J. Palipudi, Krishna Asma, Samira TI Antismoking Messages and Intention to Quit-17 Countries, 2008-2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID SMOKING-CESSATION C1 [d'Espaignet, Edouard Tursan; Bettcher, Doug] WHO, Geneva, Switzerland. [Andes, Linda J.; Palipudi, Krishna; Asma, Samira] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Andes, LJ (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM landes@cdc.gov NR 10 TC 5 Z9 5 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 31 PY 2013 VL 62 IS 21 BP 417 EP 422 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GI UT WOS:000322180300002 ER PT J AU Birkhead, G Hamilton, TE Kossover, R Perz, J Gangadharan, D Iskander, J AF Birkhead, Guthrie Hamilton, Thomas E. Kossover, Rachel Perz, Joseph Gangadharan, Denise Iskander, John TI CDC Grand Rounds: Preventing Unsafe Injection Practices in the US Health-Care System SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Birkhead, Guthrie] New York State Dept Hlth, Off Publ Hlth, Albany, NY 12237 USA. [Kossover, Rachel; Perz, Joseph] CDC, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Gangadharan, Denise; Iskander, John] CDC, Atlanta, GA 30333 USA. RP Perz, J (reprint author), CDC, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. EM jperz@cdc.gov NR 10 TC 4 Z9 4 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 31 PY 2013 VL 62 IS 21 BP 423 EP 425 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GI UT WOS:000322180300003 ER PT J AU Sniadack, DH Orenstein, WA AF Sniadack, David H. Orenstein, Walter A. TI A measles eradication goal is upon us; can rubella and congenital rubella syndrome be far behind? SO VACCINE LA English DT Editorial Material ID COST-EFFECTIVENESS; SUPPLEMENTARY IMMUNIZATION; ECONOMIC-EVALUATION; CHILDREN C1 [Sniadack, David H.] Ctr Dis Control & Prevent, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA. [Orenstein, Walter A.] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA. RP Sniadack, DH (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA. EM dhs0@cdc.gov NR 18 TC 1 Z9 1 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD MAY 31 PY 2013 VL 31 IS 24 BP 2659 EP 2660 DI 10.1016/j.vaccine.2013.04.019 PG 2 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 167MB UT WOS:000320635000001 PM 23602539 ER PT J AU McNeil, MM Li, RX Pickering, S Real, TM Smith, PJ Pemberton, MR AF McNeil, Michael M. Li, Rongxia Pickering, Susanne Real, Theresa M. Smith, Philip J. Pemberton, Michael R. TI Who is unlikely to report adverse events after vaccinations to the Vaccine Adverse Event Reporting System (VAERS)? SO VACCINE LA English DT Article DE Surveillance; Vaccine adverse events; Healthcare providers survey ID SAFETY AB Background: Healthcare provider (HCP) reporting to the Vaccine Adverse Event Reporting System (VAERS) is important to assuring the safety of U.S. licensed vaccines. HCP awareness of and practices regarding reporting of adverse events following immunization (AEFI) is understudied. Methods: A large, nationally representative sample of U.S. office-based HCP across three occupational groups (physicians, mid-level providers [physician assistants, advanced practice nurses] and nurses) and three primary care practice areas (pediatrics, family medicine, internal medicine) were surveyed utilizing standardized methodology. We assessed HCP familiarity with VAERS, the situations under which they were likely to report an AEFI, and the methods they used and preferred for reporting. We used logistic regression to determine factors associated with HCP not reporting AEFI to VAERS. Results: Our survey response rate was 54.9%. The percentage of HCP aware of VAERS (71%) varied by occupation and primary care practice area. About 37% of HCP had identified at least one AEFI with only 17% of these indicating that they had ever reported to VAERS. More serious events were more likely to be reported. Factors associated with HCP not reporting AEFI included: HCP not familiar versus very familiar with filing a paper VAERS report (OR=12.84; p < 0.0001), primary care practice area of internal medicine versus pediatrics (OR=4.22; p = 0.0005), and HCP not familiar versus very familiar with when it was required to file a VAERS report (OR=5.52; p = 0.0013). Conclusions: Specific educational interventions targeted to HCP likely to see AEFI but not currently reporting may improve vaccine safety reporting practices. Published by Elsevier Ltd. C1 [McNeil, Michael M.; Li, Rongxia; Pickering, Susanne; Real, Theresa M.] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Smith, Philip J.] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Pemberton, Michael R.] RTI Int, Res Triangle Pk, NC 27709 USA. RP McNeil, MM (reprint author), CDC, 1600 Clifton Rd NE,MS D-26, Atlanta, GA 30333 USA. EM mmm2@cdc.gov FU CDC FX Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use of trade names and commercial sources is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention, or the U.S. Public Health Service or the U.S. Department of Health and Human Services. The protocol for this study was determined to be non-research and therefore did not require review by the Institutional Review Board (IRB) of CDC or RTI International. Funding source:All phases of this study were supported by CDC. No external funding was secured for this study. Financial disclosure: The authors have no financial relationships relevant to this article to disclose. Conflict of interest: The authors have no conflicts of interest to disclose. NR 8 TC 7 Z9 7 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD MAY 31 PY 2013 VL 31 IS 24 BP 2673 EP 2679 DI 10.1016/j.vaccine.2013.04.009 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 167MB UT WOS:000320635000004 PM 23597717 ER PT J AU Donauer, S Payne, DC Edwards, KM Szilagyi, PG Hornung, RW Weinberg, GA Chappell, J Hall, CB Parashar, UD Staat, MA AF Donauer, Stephanie Payne, Daniel C. Edwards, Kathryn M. Szilagyi, Peter G. Hornung, Richard W. Weinberg, Geoffrey A. Chappell, James Hall, Caroline B. Parashar, Umesh D. Staat, Mary Allen TI Determining the effectiveness of the pentavalent rotavirus vaccine against rotavirus hospitalizations and emergency department visits using two study designs SO VACCINE LA English DT Article DE Case-control studies; Case-cohort studies; Immunization; Rotavirus; Rotavirus vaccines; Vaccination ID IMMUNIZATION INFORMATION-SYSTEM; POPULATION-BASED SURVEILLANCE; POLYMERASE-CHAIN-REACTION; INFLUENZAE TYPE-B; UNITED-STATES; CHILDREN 6; CONJUGATE VACCINE; YOUNG-CHILDREN; DISEASE; AGE AB The objective of this study is to determine the vaccine effectiveness (VE) of the pentavalent rotavirus vaccine (RV5) for preventing rotavirus-related hospitalizations and emergency department (ED) visits during the 2006-07 and 2007-08 rotavirus seasons using two study designs. Active, prospective population-based surveillance was conducted to identify cases of laboratory-confirmed rotavirus-related hospitalizations and ED visits to be used in case-cohort and case-control designs. VE was calculated using one comparison group for the case-cohort method and two comparison groups for the case-control method. The VE estimates produced by the three analyses were similar. Three doses of RV5 were effective for preventing rotavirus-related hospitalizations and ED visits in each analysis, with VE estimated as 92% in all three analyses. Two doses of RV5 were also effective, with VE ranging from 79% to 83%. A single dose was effective in the case-cohort analysis, but was not significant in either of the case-control analyses. The case-cohort and the case-control study designs produced the same VE point estimates for completion of the three dose series. Two and three doses of RV5 were effective in preventing rotavirus-related hospitalizations and ED visits. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Donauer, Stephanie] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45221 USA. [Staat, Mary Allen] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [Hornung, Richard W.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH USA. [Payne, Daniel C.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Epidemiol Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Edwards, Kathryn M.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA. [Chappell, James] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA. [Szilagyi, Peter G.; Weinberg, Geoffrey A.; Hall, Caroline B.] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA. RP Donauer, S (reprint author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45221 USA. EM stephanie.donauer@cchmc.org FU Intramural CDC HHS [CC999999] NR 51 TC 8 Z9 8 U1 0 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAY 31 PY 2013 VL 31 IS 24 BP 2692 EP 2697 DI 10.1016/j.vaccine.2013.03.072 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 167MB UT WOS:000320635000007 PM 23583814 ER PT J AU Prager, KC Greig, DJ Alt, DP Galloway, RL Hornsby, RL Palmer, LJ Soper, J Wu, QZ Zuerner, RL Gulland, FMD Lloyd-Smith, JO AF Prager, K. C. Greig, Denise J. Alt, David P. Galloway, Renee L. Hornsby, Richard L. Palmer, Lauren J. Soper, Jennifer Wu, Qingzhong Zuerner, Richard L. Gulland, Frances M. D. Lloyd-Smith, James O. TI Asymptomatic and chronic carriage of Leptospira interrogans serovar Pomona in California sea lions (Zalophus californianus) SO VETERINARY MICROBIOLOGY LA English DT Article DE Sea lion; Leptospira; Disease ecology; Persistence; Asymptomatic/subclinical carrier; Maintenance host ID IDENTIFICATION; INFECTION AB Since 1970, periodic outbreaks of leptospirosis, caused by pathogenic spirochetes in the genus Leptospira, have caused morbidity and mortality of California sea lions (Zalophus californianus) along the Pacific coast of North America. Yearly seasonal epizootics of varying magnitude occur between the months of July and December, with major epizootics occurring every 3-5 years. Genetic and serological data suggest that Leptospira interrogans serovar Pomona is the infecting serovar and is enzootic in the California sea lion population, although the mechanism of persistence is unknown. We report asymptomatic carriage of Leptospira in 39% (33/85) of wild, free-ranging sea lions sampled during the epizootic season, and asymptomatic seroconversion with chronic asymptomatic carriage in a rehabilitated sea lion. This is the first report of asymptomatic carriage in wild, free-ranging California sea lions and the first example of seroconversion and asymptomatic chronic carriage in a sea lion. Detection of asymptomatic chronic carriage of Leptospira in California sea lions, a species known to suffer significant disease and mortality from the same Leptospira strain, goes against widely-held notions regarding leptospirosis in accidental versus maintenance host species. Further, chronic carriage could provide a mechanism for persistent circulation of Leptospira in the California sea lion population, particularly if these animals shed infectious leptospires for months to years. (C) 2013 Elsevier B.V. All rights reserved. C1 [Prager, K. C.; Lloyd-Smith, James O.] Univ Calif Los Angeles, Dept Ecol & Evolutionary Biol, Los Angeles, CA 90095 USA. [Prager, K. C.; Lloyd-Smith, James O.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Prager, K. C.; Greig, Denise J.; Soper, Jennifer; Gulland, Frances M. D.] Marine Mammal Ctr, Sausalito, CA 94965 USA. [Alt, David P.; Hornsby, Richard L.; Zuerner, Richard L.] Natl Anim Dis Ctr, Infect Bacterial Dis Res Unit, Ames, IA 50010 USA. [Galloway, Renee L.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Palmer, Lauren J.] Marine Mammal Care Ctr, San Pedro, CA 90731 USA. [Wu, Qingzhong] Natl Ocean Serv, Hollings Marine Lab, Charleston, SC 29412 USA. [Zuerner, Richard L.] Swedish Univ Agr Sci, Dept Biomed Sci & Vet Publ Hlth, S-75007 Uppsala, Sweden. RP Prager, KC (reprint author), Univ Calif Los Angeles, Dept Ecol & Evolutionary Biol, 610 Charles E Young Dr South,Box 723905, Los Angeles, CA 90095 USA. EM kcprager@ucla.edu RI Lloyd-Smith, James/K-4080-2012 OI Lloyd-Smith, James/0000-0001-7941-502X FU John H. Prescott Marine Mammal Rescue Assistance Grant Program; Hellman Family Foundation; De Logi Chair in Biological Sciences FX We would like to thank the volunteers and staff from TMMC and MMCC/FM who helped in sample collection from stranded and wild-caught sea lions. We would also like to thank the John H. Prescott Marine Mammal Rescue Assistance Grant Program, the Hellman Family Foundation and the De Logi Chair in Biological Sciences for their financial support. This work was performed in part at the University of California Natural Reserve System Ano Nuevo Island Reserve. We would like to thank Ano Nuevo State Park rangers for their logistical support. NR 26 TC 5 Z9 5 U1 1 U2 28 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-1135 J9 VET MICROBIOL JI Vet. Microbiol. PD MAY 31 PY 2013 VL 164 IS 1-2 BP 177 EP 183 DI 10.1016/j.vetmic.2013.01.032 PG 7 WC Microbiology; Veterinary Sciences SC Microbiology; Veterinary Sciences GA 133IF UT WOS:000318131400023 PM 23419822 ER PT J AU Strle, F Wormser, GP Mead, P Dhaduvai, K Longo, MV Adenikinju, O Soman, S Tefera, Y Maraspin, V Lotric-Furlan, S Ogrinc, K Cimperman, J Ruzic-Sabljic, E Stupica, D AF Strle, Franc Wormser, Gary P. Mead, Paul Dhaduvai, Kanthi Longo, Michael V. Adenikinju, Omosalewa Soman, Sandeep Tefera, Yodit Maraspin, Vera Lotric-Furlan, Stanka Ogrinc, Katarina Cimperman, Joze Ruzic-Sabljic, Eva Stupica, Dasa TI Gender Disparity between Cutaneous and Non-Cutaneous Manifestations of Lyme Borreliosis SO PLOS ONE LA English DT Article ID ACRODERMATITIS CHRONICA ATROPHICANS; ERYTHEMA MIGRANS; CEREBROSPINAL-FLUID; EPIDEMIOLOGIC FEATURES; SEROLOGICAL DIAGNOSIS; ORAL DOXYCYCLINE; SOUTHERN SWEDEN; IMMUNE-RESPONSE; ENDEMIC AREA; FOLLOW-UP AB Cutaneous manifestations of Lyme borreliosis in Europe include erythema migrans (EM) and acrodermatitis chronica atrophicans (ACA); the most common non-cutaneous manifestations are Lyme neuroborreliosis (LNB) and Lyme arthritis. The purpose of this study was to evaluate the gender distribution of patients with these clinical manifestations of Lyme borreliosis. Data on gender were obtained from the clinical records of patients with Lyme borreliosis aged >= 15 years who had been evaluated at the University Medical Center Ljubljana, Ljubljana, Slovenia. Among 10,539 patients diagnosed with EM, 6,245 (59.3%) were female and among 506 ACA patients 347 (68.6%) were female. In contrast, among the 60 patients with Lyme arthritis only 15 (25%) were female (p<0.0001 for the comparison of gender with EM or ACA) and among the 130 patients with LNB only 51 (39.2%) were females (p<0.0001for the comparison of gender with EM or ACA). Although the proportion that was female in the LNB group was greater than that of patients with Lyme arthritis, this difference did not reach statistical significance (p = 0.10). Although older individuals are more likely to be female in the general Slovenian population, the age of patients with cutaneous versus non-cutaneous manifestations was not the explanation for the observed differences in gender. In conclusion, patients with cutaneous manifestations of Lyme borreliosis were predominantly female, whereas those with non-cutaneous manifestations were predominantly male. This provocative finding is unexplained but may have direct relevance to the pathogenesis of Lyme borreliosis. C1 [Strle, Franc; Maraspin, Vera; Lotric-Furlan, Stanka; Ogrinc, Katarina; Cimperman, Joze; Stupica, Dasa] Univ Med Ctr Ljubljana, Dept Infect Dis, Ljubljana, Slovenia. [Wormser, Gary P.; Dhaduvai, Kanthi; Longo, Michael V.; Adenikinju, Omosalewa; Soman, Sandeep; Tefera, Yodit] New York Med Coll, Div Infect Dis, Valhalla, NY 10595 USA. [Mead, Paul] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO USA. [Ruzic-Sabljic, Eva] Univ Ljubljana Fac Med, Inst Microbiol & Immunol, Ljubljana, Slovenia. RP Wormser, GP (reprint author), New York Med Coll, Div Infect Dis, Valhalla, NY 10595 USA. EM gary_wormser@nymc.edu FU Slovenian Research Agency [J3-3636, P3-0296]; Centers for Disease Control and Prevention; National Institutes of Health; Immunetics, Inc.; BioRad; DiaSorin, Inc.; BioMerieux FX This study was supported by research grants from Slovenian Research Agency (J3-3636, P3-0296) to FS and research grants from the Centers for Disease Control and Prevention, National Institutes of Health, Immunetics, Inc., BioRad, DiaSorin, Inc., and BioMerieux to GPW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 13 Z9 13 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 30 PY 2013 VL 8 IS 5 AR e64110 DI 10.1371/journal.pone.0064110 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 177SC UT WOS:000321394700032 PM 23737968 ER PT J AU Thomas, R Thomas, RS Auerbach, SS Portier, CJ AF Thomas, Reuben Thomas, Russell S. Auerbach, Scott S. Portier, Christopher J. TI Biological Networks for Predicting Chemical Hepatocarcinogenicity Using Gene Expression Data from Treated Mice and Relevance across Human and Rat Species SO PLOS ONE LA English DT Article ID RENAL TUBULAR TOXICITY; HEPATOCELLULAR-CARCINOMA; UNITED-STATES; N-ACETYLGLUCOSAMINYLTRANSFERASE; LIVER-CANCER; RISK-FACTORS; CARCINOGENICITY; PROFILES; KEGG; STEATOHEPATITIS AB Background: Several groups have employed genomic data from subchronic chemical toxicity studies in rodents (90 days) to derive gene-centric predictors of chronic toxicity and carcinogenicity. Genes are annotated to belong to biological processes or molecular pathways that are mechanistically well understood and are described in public databases. Objectives: To develop a molecular pathway-based prediction model of long term hepatocarcinogenicity using 90-day gene expression data and to evaluate the performance of this model with respect to both intra-species, dose-dependent and cross-species predictions. Methods: Genome-wide hepatic mRNA expression was retrospectively measured in B6C3F1 mice following subchronic exposure to twenty-six (26) chemicals (10 were positive, 2 equivocal and 14 negative for liver tumors) previously studied by the US National Toxicology Program. Using these data, a pathway-based predictor model for long-term liver cancer risk was derived using random forests. The prediction model was independently validated on test sets associated with liver cancer risk obtained from mice, rats and humans. Results: Using 5-fold cross validation, the developed prediction model had reasonable predictive performance with the area under receiver-operator curve (AUC) equal to 0.66. The developed prediction model was then used to extrapolate the results to data associated with rat and human liver cancer. The extrapolated model worked well for both extrapolated species (AUC value of 0.74 for rats and 0.91 for humans). The prediction models implied a balanced interplay between all pathway responses leading to carcinogenicity predictions. Conclusions: Pathway-based prediction models estimated from sub-chronic data hold promise for predicting long-term carcinogenicity and also for its ability to extrapolate results across multiple species. C1 [Thomas, Reuben] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA. [Thomas, Russell S.] Hamner Inst Hlth Sci, Res Triangle Pk, NC USA. [Auerbach, Scott S.] Natl Inst Environm Hlth Sci, Natl Toxicol Program, Biomol Screening Branch, Res Triangle Pk, NC USA. [Portier, Christopher J.] US Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30329 USA. [Portier, Christopher J.] US Ctr Dis Control & Prevent, Agcy Tox Subst & Dis Registry, Atlanta, GA USA. RP Portier, CJ (reprint author), US Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30329 USA. EM cip7@cdc.gov RI Portier, Christopher/A-3160-2010; OI Portier, Christopher/0000-0002-0954-0279; Thomas, Russell/0000-0002-2340-0301 FU Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences; Hamner Institutes from the American Chemistry Council's Long-Range Research Initiative FX This research was supported [in part] by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences. The mouse studies and associated microarray analyses were supported by a grant to The Hamner Institutes from the American Chemistry Council's Long-Range Research Initiative. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 57 TC 7 Z9 7 U1 2 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 30 PY 2013 VL 8 IS 5 AR e63308 DI 10.1371/journal.pone.0063308 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 177SC UT WOS:000321394700007 PM 23737943 ER PT J AU Hey, SP Heilig, CM Weijer, C AF Hey, Spencer Phillips Heilig, Charles M. Weijer, Charles TI Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program SO TRIALS LA English DT Article DE Translational medicine; Research efficiency; Graph-theoretic model; Robustness; Moxifloxacin; Tuberculosis; Research coordination; Research planning; Decision-making ID EARLY BACTERICIDAL ACTIVITY; PULMONARY TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; PHASE-II; MURINE TUBERCULOSIS; IN-VITRO; MOXIFLOXACIN; GATIFLOXACIN; TORCETRAPIB; FAILURE AB Background: Maximizing efficiency in drug development is important for drug developers, policymakers, and human subjects. Limited funds and the ethical imperative of risk minimization demand that researchers maximize the knowledge gained per patient-subject enrolled. Yet, despite a common perception that the current system of drug development is beset by inefficiencies, there remain few approaches for systematically representing, analyzing, and communicating the efficiency and coordination of the research enterprise. In this paper, we present the first steps toward developing such an approach: a graph-theoretic tool for representing the Accumulating Evidence and Research Organization (AERO) across a translational trajectory. Methods: This initial version of the AERO model focuses on elucidating two dimensions of robustness: (1) the consistency of results among studies with an identical or similar outcome metric; and (2) the concordance of results among studies with qualitatively different outcome metrics. The visual structure of the model is a directed acyclic graph, designed to capture these two dimensions of robustness and their relationship to three basic questions that underlie the planning of a translational research program: What is the accumulating state of total evidence? What has been the translational trajectory? What studies should be done next? Results: We demonstrate the utility of the AERO model with an application to a case study involving the antibacterial agent, moxifloxacin, for the treatment of drug-susceptible tuberculosis. We then consider some possible elaborations for the AERO model and propose a number of ways in which the tool could be used to enhance the planning, reporting, and analysis of clinical trials. Conclusion: The AERO model provides an immediate visual representation of the number of studies done at any stage of research, depicting both the robustness of evidence and the relationship of each study to the larger translational trajectory. In so doing, it makes some of the invisible or inchoate properties of the research system explicit - helping to elucidate judgments about the accumulating state of evidence and supporting decision-making for future research. C1 [Hey, Spencer Phillips] McGill Univ, Biomed Eth Unit, Studies Translat Eth & Med STREAM, Montreal, PQ H3A 1X1, Canada. [Heilig, Charles M.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Weijer, Charles] Western Univ, Rotman Inst Philosophy, Dept Philosophy, London, ON N6A 5B8, Canada. RP Hey, SP (reprint author), McGill Univ, Biomed Eth Unit, Studies Translat Eth & Med STREAM, Montreal, PQ H3A 1X1, Canada. EM spencer.hey@mcgill.ca RI Heilig, Charles/C-2753-2008 OI Heilig, Charles/0000-0003-1075-1310 NR 33 TC 7 Z9 7 U1 0 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1745-6215 J9 TRIALS JI Trials PD MAY 30 PY 2013 VL 14 AR 159 DI 10.1186/1745-6215-14-159 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 157GD UT WOS:000319883100001 PM 23721523 ER PT J AU Medina, RA Stertz, S Manicassamy, B Zimmermann, P Sun, XJ Albrecht, RA Uusi-Kerttula, H Zagordi, O Belshe, RB Frey, SE Tumpey, TM Garcia-Sastre, A AF Medina, Rafael A. Stertz, Silke Manicassamy, Balaji Zimmermann, Petra Sun, Xiangjie Albrecht, Randy A. Uusi-Kerttula, Hanni Zagordi, Osvaldo Belshe, Robert B. Frey, Sharon E. Tumpey, Terrence M. Garcia-Sastre, Adolfo TI Glycosylations in the Globular Head of the Hemagglutinin Protein Modulate the Virulence and Antigenic Properties of the H1N1 Influenza Viruses SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Article ID N-LINKED GLYCOSYLATION; SWINE-ORIGIN 2009; TRANSMISSION; PATHOGENESIS; IMMUNITY; RECOGNITION; INFECTION; FERRETS; SITES; MICE AB With the global spread of the 2009 pandemic H1N1 (pH1N1) influenza virus, there are increasing worries about evolution through antigenic drift. One way previous seasonal H1N1 and H3N2 influenza strains have evolved over time is by acquiring additional glycosylations in the globular head of their hemagglutinin (HA) proteins; these glycosylations have been believed to shield antigenically relevant regions from antibody immune responses. We added additional HA glycosylation sites to influenza A/Netherlands/602/2009 recombinant (rpH1N1) viruses, reflecting their temporal appearance in previous seasonal H1N1 viruses. Additional glycosylations resulted in substantially attenuated infection in mice and ferrets, whereas deleting HA glycosylation sites from a pre-pandemic virus resulted in increased pathogenicity in mice. We then more directly investigated the interactions of HA glycosylations and antibody responses through mutational analysis. We found that the polyclonal antibody response elicited by wild-type rpH1N1 HA was likely directed against an immunodominant region, which could be shielded by glycosylation at position 144. However, rpH1N1 HA glycosylated at position 144 elicited a broader polyclonal response able to cross-neutralize all wild-type and glycosylation mutant pH1N1 viruses. Moreover, mice infected with a recent seasonal virus in which glycosylation sites were removed elicited antibodies that protected against challenge with the antigenically distant pH1N1 virus. Thus, acquisition of glycosylation sites in the HA of H1N1 human influenza viruses affected not only their pathogenicity and ability to escape from polyclonal antibodies elicited by previous influenza virus strains but also their ability to induce cross-reactive antibodies against drifted antigenic variants. C1 [Medina, Rafael A.; Stertz, Silke; Manicassamy, Balaji; Albrecht, Randy A.; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA. [Medina, Rafael A.; Manicassamy, Balaji; Albrecht, Randy A.; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA. [Medina, Rafael A.; Uusi-Kerttula, Hanni] Pontificia Univ Catolica Chile, Mol Virol Lab, Millennium Inst Immunol & Immunotherapy, Ctr Invest Med, Santiago 8330024, Chile. [Medina, Rafael A.; Uusi-Kerttula, Hanni] Pontificia Univ Catolica Chile, Div Pediat, Escuela Med, Santiago 8330024, Chile. [Stertz, Silke; Zimmermann, Petra; Zagordi, Osvaldo] Univ Zurich, Inst Med Virol, CH-8057 Zurich, Switzerland. [Manicassamy, Balaji] Univ Chicago, Dept Microbiol, Chicago, IL 60637 USA. [Sun, Xiangjie; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Belshe, Robert B.; Frey, Sharon E.] St Louis Univ, Sch Med, St Louis, MO 63104 USA. [Garcia-Sastre, Adolfo] Mt Sinai Sch Med, Dept Med, Div Infect Dis, New York, NY 10029 USA. RP Medina, RA (reprint author), Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA. EM rmedinas@med.puc.cl; Adolfo.Garcia-Sastre@mssm.edu RI Stertz, Silke/D-5254-2015; OI Albrecht, Randy/0000-0003-4008-503X; Garcia-Sastre, Adolfo/0000-0002-6551-1827; Zagordi, Osvaldo/0000-0002-9082-8607 FU NIAID [P01AI058113, K99/R00, 1K99AI095320-01]; CRIP; NIAID-funded Center for Research on Influenza Pathogenesis contract [HHSN266200700010C]; NIH; CONICYT [79100014]; Fondecyt [1121172]; Program Iniciativa Cientifica Milenio from the Chilean Ministry of Economy, Development and Tourism FX These studies were partially supported by a NIAID Program Project grant (P01AI058113) and by CRIP, an NIAID-funded Center for Research on Influenza Pathogenesis contract (HHSN266200700010C, CEIRS program), to A.G.-S., and a contract (HHSN272200800003C) to R.B.B., all from the NIH. R.A.M. is supported by CONICYT through an Insertion of Human Capital to the Academy grant (79100014), and a Fondecyt grant (1121172) and by the Program Iniciativa Cientifica Milenio from the Chilean Ministry of Economy, Development and Tourism. B. M. is supported by NIAID K99/R00 Pathway to Independence award (1K99AI095320-01). NR 32 TC 14 Z9 14 U1 0 U2 11 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 J9 SCI TRANSL MED JI Sci. Transl. Med. PD MAY 29 PY 2013 VL 5 IS 187 AR 187ra70 DI 10.1126/scitranslmed.3005996 PG 12 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 152XU UT WOS:000319566200005 PM 23720581 ER PT J AU Bentsi-Enchill, AD Schmitz, J Edelman, R Durbin, A Roehrig, JT Smith, PG Hombach, J Farrar, J AF Bentsi-Enchill, Adwoa D. Schmitz, Julia Edelman, Robert Durbin, Anna Roehrig, John T. Smith, Peter G. Hombach, Joachim Farrar, Jeremy CA Live Dengue Vaccines Tech TI Long-term safety assessment of live attenuated tetravalent dengue vaccines: Deliberations from a WHO technical consultation SO VACCINE LA English DT Article DE Dengue vaccine; Vaccine safety; Post-licensure monitoring ID FLAVIVIRUS-NAIVE ADULTS; HEMORRHAGIC-FEVER; SHOCK SYNDROME; 4 SEROTYPES; INFECTION; CHILDREN; VIRUS; ANTIBODY; TRIAL; ENHANCEMENT AB Dengue is a rapidly growing public health threat with approximately 2.5 billion people estimated to be at risk. Several vaccine candidates are at various stages of pre-clinical and clinical development. Thus far, live dengue vaccine candidates have been administered to several thousands of volunteers and were well-tolerated, with minimal short-term safety effects reported in Phase I and Phase II clinical trials. Based on the natural history of dengue, a theoretical possibility of an increased risk of severe dengue as a consequence of vaccination has been hypothesized but not yet observed. In October 2011, the World Health Organization (WHO) convened a consultation of experts in dengue, vaccine regulation and vaccine safety to review the current scientific evidence regarding safety concerns associated with live attenuated dengue vaccines and, in particular, to consider methodological approaches for their long-term evaluation. In this paper we summarize the scientific background and methodological considerations relevant to the safety assessment of these vaccines. Careful planning and a coordinated approach to safety assessment are recommended to ensure adequate long-term evaluation of dengue vaccines that will support their introduction and continued use. (c) 2013 World Health Organization. Published by Elsevier Ltd. All rights reserved. C1 [Bentsi-Enchill, Adwoa D.; Schmitz, Julia; Hombach, Joachim] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva 27, Switzerland. [Edelman, Robert] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA. [Durbin, Anna] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Roehrig, John T.] Ctr Dis Control & Prevent, Arboviral Dis Branch, Ft Collins, CO USA. [Smith, Peter G.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1, England. [Farrar, Jeremy] Univ Oxford, Clin Res Unit, Hosp Trop Dis, Ho Chi Minh City, Vietnam. RP Bentsi-Enchill, AD (reprint author), WHO, Dept Immunizat Vaccines & Biol, Initiat Vaccine Res, 20 Ave Appia, CH-1211 Geneva 27, Switzerland. EM bentsienchilla@who.int OI Roehrig, John/0000-0001-7581-0479; Farrar, Jeremy/0000-0002-2700-623X FU US National Institutes of Health FX AB-E, RE, JF, JH, JTR and JS declare no conflicts of interest. AD has served as a speaker in scientific consultations on dengue vaccines and works through her institution on ongoing dengue vaccine trials sponsored by the US National Institutes of Health. PGS serves on the Independent Data and Monitoring Committee for ongoing dengue vaccine trials being conducted by Sanofi Pasteur. NR 48 TC 15 Z9 16 U1 2 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAY 28 PY 2013 VL 31 IS 23 BP 2603 EP 2609 DI 10.1016/j.vaccine.2013.03.038 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 172CE UT WOS:000320976800004 ER PT J AU Berkowitz, Z Saraiya, M Sawaya, GF AF Berkowitz, Zahava Saraiya, Mona Sawaya, George F. TI Cervical Cancer Screening Intervals, 2006 to 2009: Moving Beyond Annual Testing SO JAMA INTERNAL MEDICINE LA English DT Letter ID HUMAN-PAPILLOMAVIRUS; SOCIETY C1 [Berkowitz, Zahava; Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Sawaya, George F.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA. [Sawaya, George F.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Berkowitz, Z (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,Mail Stop K-55, Atlanta, GA 30341 USA. EM Zab3@cdc.gov NR 9 TC 17 Z9 17 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAY 27 PY 2013 VL 173 IS 10 BP 922 EP 924 DI 10.1001/jamainternmed.2013.368 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 159KR UT WOS:000320044800022 PM 23568334 ER PT J AU Hicks, LA Hersh, AL Fairlie, T AF Hicks, Lauri A. Hersh, Adam L. Fairlie, Tarayn TI Internists: Who Are We-And Where Are We Going? reply SO JAMA INTERNAL MEDICINE LA English DT Letter ID ADULTS; RHINOSINUSITIS; SINUSITIS C1 [Hicks, Lauri A.; Fairlie, Tarayn] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Resp Dis Branch, Atlanta, GA 30329 USA. [Hersh, Adam L.] Univ Utah, Div Pediat Infect Dis, Salt Lake City, UT USA. RP Hicks, LA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop C-25, Atlanta, GA 30329 USA. EM lhicks@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAY 27 PY 2013 VL 173 IS 10 BP 933 EP 934 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 159KR UT WOS:000320044800031 PM 23712408 ER PT J AU Casey-Lockyer, M Heick, RJ Mertzlufft, CE Yard, EE Wolkin, AF Noe, RS Murti, M AF Casey-Lockyer, Mary Heick, Rebecca J. Mertzlufft, Caitlin E. Yard, Ellen E. Wolkin, Amy F. Noe, Rebecca S. Murti, Michelle TI Deaths Associated with Hurricane Sandy - October-November 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Murti, Michelle] CDC, Atlanta, GA 30333 USA. RP Murti, M (reprint author), CDC, Atlanta, GA 30333 USA. EM mmurti@cdc.gov NR 10 TC 22 Z9 22 U1 0 U2 20 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 24 PY 2013 VL 62 IS 20 BP 393 EP 397 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GG UT WOS:000322180100001 ER PT J AU Warkentin, J Flood, J True, L Kanouse, J Shah, N Mase, SR Cronin, A Chorba, T AF Warkentin, Jon Flood, Jennifer True, Lisa Kanouse, Jennifer Shah, Neha Mase, Sundari R. Cronin, Ann Chorba, Terence TI Impact of a Shortage of First-Line Antituberculosis Medication on Tuberculosis Control - United States, 2012-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Kanouse, Jennifer; Shah, Neha; Mase, Sundari R.; Cronin, Ann; Chorba, Terence] CDC, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. RP Shah, N (reprint author), CDC, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. EM nshah6@cdc.gov NR 6 TC 10 Z9 10 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 24 PY 2013 VL 62 IS 20 BP 398 EP 400 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GG UT WOS:000322180100002 ER PT J AU Eberhard, M AF Eberhard, Mark TI Progress Toward Elimination of Onchocerciasis in the Americas-1993-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Eberhard, Mark] Carter Ctr, Onchocerciasis Eliminat Program Amer, Guatemala City, Guatemala. [Eberhard, Mark] CDC, Ctr Global Hlth, Div Parasit Dis & Malaria, Pan Amer Hlth Org, Atlanta, GA 30333 USA. RP Eberhard, M (reprint author), Carter Ctr, Onchocerciasis Eliminat Program Amer, Guatemala City, Guatemala. EM mle1@cdc.gov NR 7 TC 18 Z9 18 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 24 PY 2013 VL 62 IS 20 BP 405 EP 408 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GG UT WOS:000322180100004 ER PT J AU Serhan, F AF Serhan, Fatima TI Building Laboratory Capacity to Support the Global Rotavirus Surveillance Network SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 CDC, WHO, Div Viral Dis,Div Ctr Global Hlth, Natl Ctr Immunizat & Resp Dis & Global Immunizat, Atlanta, GA 30333 USA. RP Serhan, F (reprint author), CDC, WHO, Div Viral Dis,Div Ctr Global Hlth, Natl Ctr Immunizat & Resp Dis & Global Immunizat, Atlanta, GA 30333 USA. EM serhanfa@who.int NR 10 TC 2 Z9 2 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 24 PY 2013 VL 62 IS 20 BP 409 EP 412 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GG UT WOS:000322180100005 ER PT J AU Colby, K Sears, S McEvoy, E Hoenig, D Mathison, B de Almeida, M da Silva, AJ Bishop, H Montgomery, SP Manning, S Miller, LA AF Colby, Kate Sears, Stephen McEvoy, Elizabeth Hoenig, Don Mathison, Blaine de Almeida, Marcos da Silva, Alexandre J. Bishop, Henry Montgomery, Susan P. Manning, Susan Miller, Leigh Ann TI Ascariasis Associated with Pig Farming - Maine, 2010-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Colby, Kate] Univ So Maine, Portland, ME 04103 USA. [Manning, Susan; Miller, Leigh Ann] CDC, Atlanta, GA 30333 USA. RP Miller, LA (reprint author), CDC, Atlanta, GA 30333 USA. EM lamiller@cdc.gov NR 2 TC 1 Z9 1 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 24 PY 2013 VL 62 IS 20 BP 413 EP 413 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GG UT WOS:000322180100006 ER PT J AU Ding, Y Yeh, SH Mink, CAM Zangwill, KM Allred, N Hay, JW AF Ding, Yao Yeh, Sylvia H. Mink, Chris Anna M. Zangwill, Kenneth M. Allred, Normal Hay, Joel W. TI Cost-benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) SO VACCINE LA English DT Article DE Cost-benefit analysis; Postpartum; Tdap vaccine; Expected net benefit ID UNITED-STATES; BORDETELLA-PERTUSSIS; ADULT FORMULATION; ADOLESCENTS; INFANTS; POPULATION; IMMUNIZATION; TRANSMISSION; STRATEGIES; IMMUNITY AB Objective: To assess the economic benefits associated with hospital-based postpartum Tdap (combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccination. Methods: A decision tree model was constructed to calculate the potential cost-benefit of this strategy from both a health care system and a societal perspective. Probabilities and costs were derived from published literature, data reported to Centers for Disease Control and Prevention, and recommendations from expert panels. The maternal vaccination protection period for infants was defined as 7 months, and 10 years of waning immunity following Tdap for birth mothers was estimated in the model. All cost estimates were inflated to year 2012 US dollars and discounted at a 3% annual discount rate. Results: In the base case from a societal perspective, the expected costs per vaccinated and unvaccinated mother were estimated at $129.27 and $187.97, respectively, suggesting an expected net benefit of $58.70 per vaccinated mother. The overall societal benefits in the cohort of 3.6 million U.S. birth mothers ranged from $52.8-126.8 million, depending on the vaccination coverage level. If including direct medical costs only, the strategy would not generate net savings from a health care system perspective. Annual incidence of pertussis in birth mothers and Tdap efficacy exhibited substantial impact on the model as shown in one-way and two-way sensitivity analyses. Conclusions: Although postpartum Tdap vaccination is not cost-beneficial from a health care system perspective in the base case, this strategy is likely to generate net benefits from a societal perspective. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Ding, Yao; Hay, Joel W.] Univ So Calif, Leonard Schaeffer Ctr Hlth Policy & Econ, Dept Clin Pharm & Pharmaceut Econ & Policy, Sch Pharm, Los Angeles, CA 90089 USA. [Yeh, Sylvia H.; Mink, Chris Anna M.; Zangwill, Kenneth M.] Los Angeles Biomed Res Inst Harbor UCLA, UCLA Ctr Vaccine Res, Torrance, CA USA. [Allred, Normal] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Hay, JW (reprint author), Univ So Calif, Leonard Schaeffer Ctr Hlth Policy & Econ, UGW Unit A, Univ Pk Campus, Los Angeles, CA 90089 USA. EM jhay@usc.edu FU Centers for Disease Control and Prevention, U.S. Dept. of Health and Human Services [1U01IP000192] FX The authors would like to thank our project sponsor Centers for Disease Control and Prevention, U.S. Dept. of Health and Human Services, Award # 1U01IP000192. We also wish to thank Dr.Mark Messonnier and Dr.Garrett Beeler Asay for their helpful comments.Conflict of interest statement: None of the authors have a conflict of interest. Funding: Centers for Disease Control and Prevention, U.S. Dept. of Health and Human Services, Award # 1U01IP000192. NR 32 TC 2 Z9 2 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD MAY 24 PY 2013 VL 31 IS 22 BP 2558 EP 2564 DI 10.1016/j.vaccine.2013.03.053 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 165PE UT WOS:000320495000004 PM 23583811 ER PT J AU Link-Gelles, R Taylor, T Moore, MR AF Link-Gelles, Ruth Taylor, Thomas Moore, Matthew R. CA Active Bacterial Core Surveillance TI Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020 SO VACCINE LA English DT Article DE PCV13; Streptococcus pneumoniae; Pneumococcal conjugate vaccine; Serotype replacement; Invasive pneumococcal disease; Prevnar 13 ID PNEUMONIAE SEROTYPE 19A; AGED 19-35 MONTHS; STREPTOCOCCUS-PNEUMONIAE; CHILDREN; COVERAGE; ERA; EPIDEMIOLOGY; POPULATION; INFECTIONS; PREVENTION AB Introduction: Pneumococcal vaccines are highly effective at preventing invasive pneumococcal disease (IPD), a leading cause of global morbidity. Because pneumococcal vaccines can be expensive, it is useful to estimate what impact might be expected from their introduction. Our objective was to develop a statistical model that could predict rates of IPD following introduction of 13-valent pneumococcal conjugate vaccine (PCV13) in the U.S. Methods: We used active surveillance data to design and validate a Poisson model forecasting the reductions in IPD observed after U.S. introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in 2000. We used this model to forecast rates of IPD from 2010 to 2020 in the presence of PCV13. Because increases in non-PCV7-type IPD were evident following PCV7 introduction, we evaluated varying levels of increase in non-PCV13-type IPD ("serotype replacement") by sensitivity analyses. Results: A total of 43,507 cases of IPD were identified during 1998-2009; cases from this period were used to develop the model, which accurately predicted indirect effects of PCV7 in adults, as well as serotype replacement. Assuming that PCV13 provides similar protection against PCV13 serotypes as PCV7 did against PCV7 serotypes, the base-case model predicted approximately 168,000 cases of IPD prevented from 2011 to 2020. When serotype replacement was varied in sensitivity analyses from 0 to levels comparable to that seen with serotype 19A (the most common replacement serotype since PCV7 was introduced), the model predicted 167,000-170,000 cases prevented. The base-case model predicted rates of IPD in children under five years of age decreasing from 21.9 to 9.3 cases per 100,000 population. Conclusions: This model provides a "benchmark" for assessing progress in the prevention of IPD in the years after PCV13 introduction. The amount of serotype replacement is unlikely to greatly affect the overall number of cases prevented by PCV13. Published by Elsevier Ltd. C1 [Link-Gelles, Ruth; Taylor, Thomas; Moore, Matthew R.; Active Bacterial Core Surveillance] Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Link-Gelles, R (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop C-25, Atlanta, GA 30333 USA. EM HZT7@cdc.gov NR 28 TC 14 Z9 14 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD MAY 24 PY 2013 VL 31 IS 22 BP 2572 EP 2577 DI 10.1016/j.vaccine.2013.03.049 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 165PE UT WOS:000320495000006 PM 23583813 ER PT J AU Tseng, HF Sy, LS Liu, ILA Qian, L Marcy, SM Weintraub, E Yih, K Baxter, R Glanz, JM Donahue, J Naleway, A Nordin, J Jacobsen, SJ AF Tseng, Hung Fu Sy, Lina S. Liu, In-Lu Amy Qian, Lei Marcy, S. Michael Weintraub, Eric Yih, Katherine Baxter, Roger Glanz, Jason M. Donahue, James Naleway, Allison Nordin, James Jacobsen, Steven J. TI Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children SO VACCINE LA English DT Article DE Pneumococcal conjugate vaccine; Vaccine safety; Surveillance; Group sequential analysis ID SAFETY DATALINK PROJECT; KAWASAKI-DISEASE; IMMUNIZATION; ASSOCIATION; SEROTYPE-1; COMMITTEE; LICENSURE; OUTBREAK; INFANTS AB Although no increased risk was detected for serious adverse events in the prelicensure trials for the 13-valent pneumococcal vaccine, Prevnar 13 (R) (PCV13), continued monitoring of rare but serious adverse events is necessary. A surveillance system using cohort study design was set up to monitor safety of PCV13 immediately after it was included in the childhood immunization program in the United States. The exposed population included children of 1 month to 2 years old who received PCV13 from April, 2010 to January, 2012 from the eight managed care organizations participating in the Vaccine Safety Datalink Project in the United States. The historical unexposed population was children of the same age who received the 7-valent pneumococcal conjugate vaccine Prevnar 7 (R) (PCV7) in 2007 (or 2005 depending on the outcome of interest) to 2009. The risk of pre-specified adverse events in the risk window following PCV13 was repeatedly compared to that in the historical comparison group. The number of doses included in the study was 599,229. No increased risk was found for febrile seizures, urticaria or angioneurotic edema, asthma, thrombocytopenia, or anaphylaxis. An increased risk for encephalopathy was not confirmed following the medical record review. The relative risk for Kawasaki disease in 0-28 days following vaccination was 1.94 (95% confidence interval: 0.79-4.86), comparing PCV13 to PCV7. Comparing to PCV7 vaccine, we identified no significant increased risk of pre-specified adverse events in the Vaccine Safety Datalink study cohort. The possible association between PCV13 and Kawasaki disease may deserve further investigation. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Tseng, Hung Fu; Sy, Lina S.; Liu, In-Lu Amy; Qian, Lei; Marcy, S. Michael; Jacobsen, Steven J.] Kaiser Permanente, Pasadena, CA 91101 USA. [Weintraub, Eric] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. [Yih, Katherine] Harvard Univ, Sch Med, Boston, MA USA. [Yih, Katherine] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Baxter, Roger] Kaiser Permanente, Oakland, CA USA. [Glanz, Jason M.] Kaiser Permanente, Denver, CO USA. [Donahue, James] Marshfield Clin Res Fdn, Marshfield, WI USA. [Naleway, Allison] Kaiser Permanente, Portland, OR USA. [Nordin, James] Hlth Partners Res Fdn, Minneapolis, MN USA. RP Tseng, HF (reprint author), Kaiser Permanente, So Calif Permanente Med Grp, Dept Res & Evaluat, 100 S Los Robles Ave,2nd Floor, Pasadena, CA 91101 USA. EM Hung-Fu.x.Tseng@kp.org; Lina.s.Sy@Kp.org OI Naleway, Allison/0000-0001-5747-4643; Jacobsen, Steven/0000-0002-8174-8533 FU America's Health Insurance Plans (AHIP) from the Centers for Disease Control and Prevention (CDC) [200-2002-00732] FX This study was funded through a subcontract with America's Health Insurance Plans (AHIP) under contract 200-2002-00732 from the Centers for Disease Control and Prevention (CDC). NR 21 TC 16 Z9 16 U1 0 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD MAY 24 PY 2013 VL 31 IS 22 BP 2578 EP 2583 DI 10.1016/j.vaccine.2013.03.040 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 165PE UT WOS:000320495000007 PM 23579258 ER PT J AU McLellan-Lemal, E Toledo, L O'Daniels, C Villar-Loubet, O Simpson, C Adimora, AA Marks, G AF McLellan-Lemal, Eleanor Toledo, Lauren O'Daniels, Christine Villar-Loubet, Olga Simpson, Cathy Adimora, Ada A. Marks, Gary TI "A man's gonna do what a man wants to do": African American and Hispanic women's perceptions about heterosexual relationships: a qualitative study SO BMC WOMENS HEALTH LA English DT Article DE Heterosexual women; Relationship schemas and scripts; HIV risk perceptions ID RISK-REDUCTION INTERVENTION; SEXUAL SCRIPTS; CONDOM USE; ADOLESCENT GIRLS; HIV PREVENTION; GENDER-ROLES; OLDER WOMEN; BEHAVIOR; PARTNERS; POWER AB Background: HIV prevention efforts have given limited attention to the relational schemas and scripts of adult heterosexual women. These broader schemas and scripts of romantic and other sexual liaisons, partner selection, relationship dynamics, and power negotiations may help to better understand facilitators and barriers to HIV risk-reduction practices. Methods: We conducted exploratory qualitative interviews with 60 HIV-uninfected heterosexual African-American women from rural counties in North Carolina and Alabama, and Hispanic women from an urban county in southern Florida. Data were collected for relationship expectations; relationship experiences, and relationship power and decision-making. Interview transcripts underwent computer-assisted thematic analysis. Results: Participants had a median age of 34 years (range 18-59), 34% were married or living as married, 39% earned an annual income of $12,000 or less, 12% held less than a high school education, and 54% were employed. Among the Hispanic women, 95% were foreign born. We identified two overarching relationship themes: contradictions between relationship expectations and desires and life circumstances that negated such ideals, and relationship challenges. Within the contradictions theme, we discovered six subthemes: a good man is hard to find; sex can be currency used to secure desired outcomes; compromises and allowances for cheating, irresponsible, and disrespectful behavior; redefining dating; sex just happens; needing relationship validation. The challenges theme centered on two subthemes: uncertainties and miscommunication, and relationship power negotiation. Gender differences in relationship intentions and desires as well as communication styles, the importance of emotional and financial support, and the potential for relationships to provide disappointment were present in all subthemes. In examining HIV risk perceptions, participants largely held that risk for HIV-infection and the need to take precautions were problems of women who differed from them (i.e., abuse drugs, are promiscuous, exchange sex). Conclusion: Underlying women's relational schemas was a belief that relationship priorities differed for men and women. Consequently, expectations and allowances for partner infidelity and negligent behaviors were incorporated into their scripts. Moreover, scripts endorsed women's use of sex as currency in relationship formation and endurance, and did not emphasize HIV risk. Both couple-and gender-specific group-level interventions are needed to deconstruct (breakdown) and reconstruct (rewrite) relationship scripts. C1 [McLellan-Lemal, Eleanor; Toledo, Lauren; O'Daniels, Christine; Marks, Gary] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Toledo, Lauren] ICF Int, Atlanta, GA USA. [O'Daniels, Christine] Carter Consulting Inc, Atlanta, GA USA. [Villar-Loubet, Olga] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [Simpson, Cathy] Univ Alabama Birmingham, Birmingham, AL USA. [Adimora, Ada A.] Univ N Carolina, Chapel Hill, NC USA. RP McLellan-Lemal, E (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM egm4@cdc.gov OI McLellan-Lemal, Eleanor/0000-0002-1884-9315 NR 83 TC 2 Z9 2 U1 6 U2 23 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6874 J9 BMC WOMENS HEALTH JI BMC Womens Health PD MAY 24 PY 2013 VL 13 AR UNSP 27 DI 10.1186/1472-6874-13-27 PG 14 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology SC Public, Environmental & Occupational Health; Obstetrics & Gynecology GA 155DL UT WOS:000319725800001 PM 23705954 ER PT J AU Jiang, JL Barnwell, JW Meyer, EVS Galinski, MR AF Jiang, Jianlin Barnwell, John W. Meyer, Esmeralda V. S. Galinski, Mary R. TI Plasmodium vivax Merozoite Surface Protein-3 (PvMSP3): Expression of an 11 Member Multigene Family in Blood-Stage Parasites SO PLOS ONE LA English DT Article ID HUMAN MALARIA PARASITE; NATURALLY ACQUIRED ANTIBODIES; BINDING-LIKE PROTEINS; ERYTHROCYTE INVASION; GENETIC DIVERSITY; FALCIPARUM MEROZOITES; VACCINE; IDENTIFICATION; KNOWLESI; AMAZON AB Background: Three members of the Plasmodium vivax merozoite surface protein-3 (PvMSP3) family (PvMSP3-alpha, PvMSP3-beta and PvMSP3-gamma) were initially characterized and later shown to be part of a larger highly diverse family, encoded by a cluster of genes arranged head-to-tail in chromosome 10. PvMSP3-alpha and PvMSP3-beta have become genetic markers in epidemiological studies, and are being evaluated as vaccine candidates. This research investigates the gene and protein expression of the entire family and pertinent implications. Methodology/Principal Findings: A 60 kb multigene locus from chromosome 10 in P. vivax (Salvador 1 strain) was studied to classify the number of pvmsp3 genes present, and compare their transcription, translation and protein localization patterns during blood-stage development. Eleven pvmsp3 paralogs encode an N-terminal NLRNG signature motif, a central domain containing repeated variable heptad sequences, and conserved hydrophilic C-terminal features. One additional ORF in the locus lacks these features and was excluded as a member of the family. Transcripts representing all eleven pvmsp3 genes were detected in trophozoite- and schizont-stage RNA. Quantitative immunoblots using schizont-stage extracts and antibodies specific for each PvMSP3 protein demonstrated that all but PvMSP3.11 could be detected. Homologs were also detected by immunoblot in the closely related simian species, P. cynomolgi and P. knowlesi. Immunofluorescence assays confirmed that eight of the PvMSP3s are present in mature schizonts. Uniquely, PvMSP3.7 was expressed exclusively at the apical end of merozoites. Conclusion/Significance: Specific proteins were detected representing the expression of 10 out of 11 genes confirmed as members of the pvmsp3 family. Eight PvMSP3s were visualized surrounding merozoites. In contrast, PvMSP3.7 was detected at the apical end of the merozoites. Pvmsp3.11 transcripts were present, though no corresponding protein was detected. PvMSP3 functions remain unknown. The ten expressed PvMSP3s are predicted to have unique and complementary functions in merozoite biology. C1 [Jiang, Jianlin; Meyer, Esmeralda V. S.; Galinski, Mary R.] Emory Univ, Emory Vaccine Ctr, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA. [Barnwell, John W.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA USA. [Galinski, Mary R.] Emory Univ, Dept Med, Div Infect Dis, Sch Med, Atlanta, GA 30322 USA. RP Galinski, MR (reprint author), Emory Univ, Dept Med, Div Infect Dis, Sch Med, Atlanta, GA 30322 USA. EM mary.galinski@emory.edu FU National Institutes of Health, National Institute for Allergy and Infectious Diseases [1R01AI24710, R21AI094449]; National Center for Research Resources [P51RR000165]; Office of Research Infrastructure Programs/OD [P51OD011132] FX This research was funded by the National Institutes of Health, National Institute for Allergy and Infectious Diseases to MRG (1R01AI24710 and R21AI094449). The Yerkes National Primate Research Center received support from the National Center for Research Resources P51RR000165, and it is currently supported by the Office of Research Infrastructure Programs/OD P51OD011132. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 65 TC 10 Z9 10 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 23 PY 2013 VL 8 IS 5 AR e63888 DI 10.1371/journal.pone.0063888 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 151BM UT WOS:000319435600035 PM 23717506 ER PT J AU Curtis, KA Hanson, DL Kennedy, MS Owen, SM AF Curtis, Kelly A. Hanson, Debra L. Kennedy, M. Susan Owen, S. Michele TI Evaluation of a Multiplex Assay for Estimation of HIV-1 Incidence SO PLOS ONE LA English DT Article ID BED-ENZYME IMMUNOASSAY; HOMOSEXUAL MEN; PERFORMANCE-CHARACTERISTICS; LYMPHADENOPATHY SYNDROME; ANTIRETROVIRAL THERAPY; TYPE-1 SEROCONVERSION; VACCINE PREPAREDNESS; CONTINUING RISK; INFECTION; AVIDITY AB Objectives: Accurate methods of estimating HIV-1 incidence are critical for monitoring the status of the epidemic and the impact of prevention strategies. Although several laboratory-based tests have been developed strictly for this purpose, several limitations exist and improved methods or technologies are needed. We sought to further optimize a previously described bead-based, HIV-1-specific multiplex assay with the capability of measuring multiple immune responses for determining recent infection. Methods: We refined the customized HIV-1 Bio-Plex assay by determining cutoffs and mean durations of recency (MDR), based on the reactivity to longitudinal seroconversion specimens (n = 1347) from 311 ART-naive, HIV-1-infected subjects. False-recent rates (FRRs) were calculated for various long-term cohorts, including AIDS patients, individuals on ART, and subtype C specimens. Incidence was estimated for each individual assay analyte from a simulated population with a known incidence of 1%. For improved incidence estimates, multi-analyte algorithms based on combinations of 3 to 6 analytes were evaluated and compared to the performance of each individual analyte. Results: The MDR for the six analytes varied from 164.2 to 279.4 days, while the multi-analyte algorithm MDRs were less variable with a minimum and maximum value of 228.4 and 277.9 days, respectively. The FRRs for the 7 multi-analyte algorithms evaluated in this study varied from 0.3% to 3.1%, in a population of ART-naive, long-term individuals. All algorithms yielded improved incidence estimates as compared to the individual analytes, predicting an incidence of 0.95% to 1.02%. Conclusions: The HIV-specific multiplex assay described here measures several distinct immune responses in a single assay, allowing for the consideration of multi-analyte algorithms for improved HIV incidence estimates. C1 [Curtis, Kelly A.; Hanson, Debra L.; Kennedy, M. Susan; Owen, S. Michele] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Atlanta, GA 30329 USA. RP Curtis, KA (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Atlanta, GA 30329 USA. EM czv2@cdc.gov FU Centers for Disease Control and Prevention FX This study was supported with intramural funding from the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the official view of the Centers for Disease Control and Prevention. NR 43 TC 9 Z9 10 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 22 PY 2013 VL 8 IS 5 AR e64201 DI 10.1371/journal.pone.0064201 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 163UP UT WOS:000320362700118 PM 23717568 ER PT J AU Ford, ES Capewell, S AF Ford, Earl S. Capewell, Simon TI Trends in Total and Low-Density Lipoprotein Cholesterol among US Adults: Contributions of Changes in Dietary Fat Intake and Use of Cholesterol-Lowering Medications SO PLOS ONE LA English DT Article ID CARDIOVASCULAR RISK-FACTORS; SERUM-CHOLESTEROL; UNITED-STATES; NORTHERN SWEDEN; METAANALYSIS; FINLAND; PLASMA; LIPIDS; ADHERENCE; THERAPY AB Objective: Our aim was to examine the relative contributions of changes in dietary fat intake and use of cholesterol-lowering medications to changes in concentrations of total cholesterol among adults in the United States from 1988-1994 to 2007-2008. Method: We used data from adults aged 20-74 years who participated in National Health and Nutrition Examination Surveys from 1988-1994 to 2007-2008. The effect of change in dietary fat intake on concentrations of total cholesterol was estimated by the use of equations developed by Keys, Hegsted, and successors. Results: Age-adjusted mean concentrations of total cholesterol were 5.60 mmol/L (216 mg/dl) during 1988-1994 falling to 5.09 mmol/L (197 mg/dl) in 2007-2008 (P<0.001). No significant changes in the intake of total fat, saturated fat, polyunsaturated fat, and dietary cholesterol were observed from 1988-1994 to 2007-2008. However, the age-adjusted use of cholesterol-lowering medications increased from 1.6% to 12.5% (P<0.001). The various equations suggested that changes in dietary fat made minimal contributions to the observed trend in mean concentrations of total cholesterol. The increased use of cholesterol-lowering medications was estimated to account for approximately 46% of the change. Discussion: Mean concentrations of total cholesterol among adults in the United States have declined by similar to 4% since 1988-1994. The increased use of cholesterol-lowering medications has apparently accounted for about half of this small fall. Further substantial decreases in cholesterol might be potentially achievable by implementing effective and feasible public health interventions to promote the consumption of a more healthful diet by US adults. Disclaimer: The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. C1 [Ford, Earl S.] Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Ctr Dis Control & Prevent, Atlanta, GA USA. [Capewell, Simon] Univ Liverpool, Dept Publ Hlth, Liverpool L69 3BX, Merseyside, England. RP Ford, ES (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Ctr Dis Control & Prevent, Atlanta, GA USA. EM eford@cdc.gov NR 37 TC 16 Z9 17 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 22 PY 2013 VL 8 IS 5 AR UNSP e65228 DI 10.1371/journal.pone.0065228 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 163UP UT WOS:000320362700192 PM 23717695 ER PT J AU Hwang, J Alemayehu, BH Reithinger, R Tekleyohannes, SG Teshi, T Birhanu, SG Demeke, L Hoos, D Melaku, Z Kassa, M Jima, D Malone, JL Nettey, H Green, M Poe, A Akinyi, S Udhayakumar, V Kachur, SP Filler, S AF Hwang, Jimee Alemayehu, Bereket Hailegiorgis Reithinger, Richard Tekleyohannes, Samuel Girma Teshi, Takele Birhanu, Sintayehu Gebresillasie Demeke, Leykun Hoos, David Melaku, Zenebe Kassa, Moges Jima, Daddi Malone, Joseph L. Nettey, Henry Green, Michael Poe, Amanda Akinyi, Sheila Udhayakumar, Venkatachalam Kachur, S. Patrick Filler, Scott TI In Vivo Efficacy of Artemether-Lumefantrine and Chloroquine against Plasmodium vivax: A Randomized Open Label Trial in Central Ethiopia SO PLOS ONE LA English DT Article ID PAPUA-NEW-GUINEA; SOUTH-WEST ETHIOPIA; FALCIPARUM-MALARIA; RESISTANT FALCIPARUM; THERAPEUTIC RESPONSE; ARTEMISININ; INDONESIA; POPULATION; CHILDREN; FAILURE AB In Background: In vivo efficacy assessments of antimalarials are essential for ensuring effective case management. In Ethiopia, chloroquine (CQ) without primaquine is the first-line treatment for Plasmodium vivax in malarious areas, but artemether-lumefantrine (AL) is also commonly used. Methods and Findings: In 2009, we conducted a 42-day efficacy study of AL or CQ for P. vivax in Oromia Regional State, Ethiopia. Individuals with P. vivax monoinfection were enrolled. Primary endpoint was day 28 cure rate. In patients with recurrent parasitemia, drug level and genotyping using microsatellite markers were assessed. Using survival analysis, uncorrected patient cure rates at day 28 were 75.7% (95% confidence interval (CI) 66.8-82.5) for AL and 90.8% (95% CI 83.6-94.9) for CQ. During the 42 days of follow-up, 41.6% (47/113) of patients in the AL arm and 31.8% (34/107) in the CQ arm presented with recurrent P. vivax infection, with the median number of days to recurrence of 28 compared to 35 days in the AL and CQ arm, respectively. Using microsatellite markers to reclassify recurrent parasitemias with a different genotype as non-treatment failures, day 28 cure rates were genotype adjusted to 91.1% (95% CI 84.1-95.1) for AL and to 97.2% (91.6-99.1) for CQ. Three patients (2.8%) with recurrent parasitemia by day 28 in the CQ arm were noted to have drug levels above 100 ng/ml. Conclusions: In the short term, both AL and CQ were effective and well-tolerated for P. vivax malaria, but high rates of recurrent parasitemia were noted with both drugs. CQ provided longer post-treatment prophylaxis than AL, resulting in delayed recurrence of parasitemia. Although the current policy of species-specific treatment can be maintained for Ethiopia, the co-administration of primaquine for treatment of P. vivax malaria needs to be urgently considered to prevent relapse infections. C1 [Hwang, Jimee; Malone, Joseph L.; Nettey, Henry; Green, Michael; Akinyi, Sheila; Udhayakumar, Venkatachalam; Kachur, S. Patrick; Filler, Scott] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA 30329 USA. [Hwang, Jimee] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA. [Alemayehu, Bereket Hailegiorgis; Hoos, David] ICAP Columbia Univ, New York, NY USA. [Reithinger, Richard] US Agcy Int Dev, Addis Ababa, Ethiopia. [Reithinger, Richard] Res Triangle Inst, Washington, DC USA. [Tekleyohannes, Samuel Girma; Teshi, Takele; Birhanu, Sintayehu Gebresillasie; Demeke, Leykun; Melaku, Zenebe] ICAP Columbia Univ, Addis Ababa, Ethiopia. [Kassa, Moges; Jima, Daddi] Ethiopian Hlth & Nutr Res Inst, Addis Ababa, Ethiopia. [Jima, Daddi] Fed Minist Hlth, Addis Ababa, Ethiopia. [Nettey, Henry] Univ Ghana, Sch Pharm, Legon, Ghana. [Poe, Amanda] Atlanta Res & Educ Fdn, Decatur, GA USA. [Filler, Scott] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland. RP Hwang, J (reprint author), Ctr Dis Control & Prevent, Malaria Branch, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA 30329 USA. EM jhwang@cdc.gov OI Malone, Joseph/0000-0002-5515-6171 FU President's Malaria Initiative via the Office of Health, Infectious Diseases, and Nutrition, Bureau for Global Health, U.S. Agency for International Development (USAID); Centers for Disease Control and Prevention (CDC) FX This research was made possible through support provided by the President's Malaria Initiative via the Office of Health, Infectious Diseases, and Nutrition, Bureau for Global Health, U.S. Agency for International Development (USAID), under the terms of an Interagency Agreement with the Centers for Disease Control and Prevention (CDC). The opinions expressed herein are those of the author(s) and do not necessarily reflect the views of the CDC or the USAID. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 57 TC 11 Z9 11 U1 1 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 22 PY 2013 VL 8 IS 5 AR e63433 DI 10.1371/journal.pone.0063433 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 163UP UT WOS:000320362700021 PM 23717423 ER PT J AU Guy, GP Gillespie, TW Goodman, M Richardson, LC Ward, KC Lipscomb, J AF Guy, Gery P. Gillespie, Theresa Wicklin Goodman, Michael Richardson, Lisa Carolyn Ward, Kevin C. Lipscomb, Joseph TI Influence of guideline-concordant adjuvant therapy on all-cause and disease-specific survival among breast cancer patients in rural Georgia SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 31-JUN 04, 2013 CL Chicago, IL SP Amer Soc Clin Oncol C1 Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. Emory Univ, Dept Surg & Hematol, Atlanta, GA 30322 USA. Emory Univ, Dept Med Oncol, Atlanta, GA 30322 USA. Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2013 VL 31 IS 15 SU S MA 1130 PG 1 WC Oncology SC Oncology GA AG4VY UT WOS:000335419600557 ER PT J AU Halpern, MT Romaire, MA Haber, SG Tangka, FK Sabatino, SA Howard, DH AF Halpern, Michael T. Romaire, Melissa A. Haber, Susan G. Tangka, Florence K. Sabatino, Susan A. Howard, David H. TI Impact of Medicaid reimbursement and eligibility policies on receipt of cancer screening SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 31-JUN 04, 2013 CL Chicago, IL SP Amer Soc Clin Oncol C1 RTI Int, Washington, DC USA. RTI Int, Res Triangle Pk, NC USA. RTI Int, Waltham, MA USA. Ctr Dis Control & Prevent, DCPC EARB, Atlanta, GA USA. Emory Univ, Dept Hlth Policy & Management, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2013 VL 31 IS 15 SU S MA 6514 PG 1 WC Oncology SC Oncology GA AG4VY UT WOS:000335419602233 ER PT J AU Lynch, JA Fiore, L Kelley, MJ Borzecki, A Lathan, CS Hassett, M Rugo, HS Khoury, MJ Freedman, AN AF Lynch, Julie Ann Fiore, Louis Kelley, Michael J. Borzecki, Ann Lathan, Christopher S. Hassett, Michael Rugo, Hope S. Khoury, Muin J. Freedman, Andrew N. TI Current status of the implementation of gene expression testing in breast cancer management in the United States SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 31-JUN 04, 2013 CL Chicago, IL SP Amer Soc Clin Oncol C1 Vet Hlth Adm, Bedford, MA USA. Vet Hlth Adm, Boston, MA USA. Vet Hlth Adm, Durham, NC USA. Dana Farber Canc Inst, Boston, MA 02115 USA. UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. NCI, Epidemiol & Genom Res Program, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2013 VL 31 IS 15 SU S MA 6562 PG 1 WC Oncology SC Oncology GA AG4VY UT WOS:000335419602278 ER PT J AU Sabatino, SA Thompson, T Wu, XC Kimmick, GG Fleming, S Trentham-Dietz, A Cress, R Anderson, RT AF Sabatino, Susan A. Thompson, Trevor Wu, Xiao-cheng Kimmick, Gretchen Genevieve Fleming, Steven Trentham-Dietz, Amy Cress, Rosemary Anderson, Roger T. TI The influence of diabetes severity on guideline-concordant treatment for stage I-III breast cancer in the National Program of Cancer Registries (NPCR) patterns of care for breast and prostate cancer study (POCBP) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 31-JUN 04, 2013 CL Chicago, IL SP Amer Soc Clin Oncol C1 Ctr Dis Control & Prevent, DCPC EARB, Atlanta, GA USA. Ctr Dis Control, Atlanta, GA 30333 USA. Louisiana State Univ, Baton Rouge, LA 70803 USA. Duke Canc Inst, Durham, NC USA. Univ Kentucky, Lexington, KY USA. Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. Univ Calif Davis, Sch Med, Davis, CA 95616 USA. Penn State Coll Med, Hershey, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2013 VL 31 IS 15 SU S MA 6606 PG 2 WC Oncology SC Oncology GA AG4VY UT WOS:000335419602322 ER PT J AU Finks, J Collins, J Miller, C Fiedler, J Johnson, S Coyle, JR Brennan, BM Malani, AN Moudgal, V Vandenberg, D Speirs, KM Martin, D Tichendelean, C Sula, D Ledtke, C Heyding, RA MacCannell, T Chiller, T McFadden, J McFadden, J Dantes, R Nyaku, MK AF Finks, Jennie Collins, Jim Miller, Corinne Fiedler, Jay Johnson, Shannon Coyle, Joseph R. Brennan, Brenda M. Malani, Anurag N. Moudgal, Varsha Vandenberg, David Speirs, Karen M. Martin, David Tichendelean, Carmen Sula, Dennis Ledtke, Christopher Heyding, Robert A. MacCannell, Taranisia Chiller, Tom McFadden, Jevon McFadden, Jevon Dantes, Raymund Nyaku, Mawuli K. TI Spinal and Paraspinal Infections Associated with Contaminated Methylprednisolone Acetate Injections - Michigan, 2012-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES; OUTBREAK C1 [Malani, Anurag N.; Moudgal, Varsha; Vandenberg, David] St Joseph Mercy Hosp, Ann Arbor, MI 48104 USA. [Speirs, Karen M.; Martin, David; Tichendelean, Carmen; Sula, Dennis; Ledtke, Christopher] Munson Med Ctr, Traverse City, MI USA. [Heyding, Robert A.] Univ Michigan, Ann Arbor, MI 48109 USA. [Dantes, Raymund; Nyaku, Mawuli K.] CDC, Atlanta, GA 30333 USA. RP Nyaku, MK (reprint author), CDC, Atlanta, GA 30333 USA. EM mnyaku@cdc.gov NR 6 TC 9 Z9 9 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 17 PY 2013 VL 62 IS 19 BP 377 EP 381 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GD UT WOS:000322179800001 ER PT J AU Thoroughman, D Poe, J Sloan, T Sugg, TJ Humbaugh, K Blanton, J Russell, ES Wallace, RM AF Thoroughman, Douglas Poe, John Sloan, Thursa Sugg, T. J. Humbaugh, Kraig Blanton, Jesse Russell, Elizabeth S. Wallace, Ryan M. TI Assessment of Risk for Exposure to Bats in Sleeping Quarters Before and During Remediation - Kentucky, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES; RABIES C1 [Russell, Elizabeth S.; Wallace, Ryan M.] CDC, Atlanta, GA 30333 USA. RP Russell, ES (reprint author), CDC, Atlanta, GA 30333 USA. EM esrussell@cdc.gov NR 6 TC 1 Z9 1 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 17 PY 2013 VL 62 IS 19 BP 382 EP 384 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GD UT WOS:000322179800002 ER PT J AU Rossheim, B Goodman, S Bryant, N Winters-Callender, M Achter, A Kurkjian, K White-Comstock, MB Kamili, S Moorman, A Collier, M AF Rossheim, Brooke Goodman, Stephanie Bryant, Nancy Winters-Callender, Michele Achter, April Kurkjian, Katie White-Comstock, Mary Beth Kamili, Saleem Moorman, Anne Collier, Melissa TI Transmission of HBV Among Assisted-Living-Facility Residents - Virginia, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID OUTBREAKS C1 [Kamili, Saleem; Moorman, Anne; Collier, Melissa] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Collier, M (reprint author), CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM mgcollier@cdc.gov NR 5 TC 3 Z9 3 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 17 PY 2013 VL 62 IS 19 BP 389 EP 389 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GD UT WOS:000322179800004 ER PT J AU Schillie, SF Murphy, TV AF Schillie, Sarah F. Murphy, Trudy V. TI Seroprotection after recombinant hepatitis B vaccination among newborn infants: A review SO VACCINE LA English DT Review DE Hepatitis B; Vaccine; Immunization; Neonate; Infant; Seroprotection ID HBSAG POSITIVE MOTHERS; BIRTH-WEIGHT INFANTS; 2 DOSING SCHEDULES; PRETERM INFANTS; PROTECTIVE EFFICACY; VIRUS-INFECTION; PERINATAL TRANSMISSION; CARRIER MOTHERS; PRE-S2 ANTIGENS; IMMUNE GLOBULIN AB Introduction: Hepatitis B vaccination starting at birth provides a safety net for infants exposed to hepatitis B virus (HBV) during delivery or in early life. Hepatitis B vaccine is recommended in the United States for infants prior to birthing facility discharge, and within the first 12 h of life for infants born to hepatitis B surface antigen (HBsAg)-positive mothers. We performed a literature review and summarized the response to recombinant hepatitis B vaccine among infants. Methods: Studies published between 1987 and 2011 assessing seroprotection from recombinant hepatitis B vaccine starting within the first 30 days of life were eligible. Seroprotection was defined using an antibody to hepatitis B surface antigen (anti-HBs) threshold of 10 mIU/mL at series completion. Infant seroprotection was compared in trial arms varying by maternal hepatitis B antigen status (e antigen [HBeAg], HBsAg), hepatitis B immune globulin (HBIG) administration, birth weight, vaccine dosage, schedule, and age at first dose. Results: Forty-three studies were included. The median seroprotection proportion overall was 98% (range 52%, 100%). The final median seroprotection proportions did not vary appreciably by maternal HBsAg status, HBIG administration, or schedule. Higher compared to lower dosage resulted in earlier increases in anti-HBs but not in final seroprotection proportions. Infants with birth weights <2000 g compared to >= 2000 g had lower median seroprotection proportions (93% and 98%, respectively). Median seroprotection proportions were also lower when infants with birth weights <2000 g were vaccinated at 0-3 days of age compared to 1 month of age or older (68% versus 95%, respectively). Conclusion: High levels of protection from recombinant hepatitis B vaccine are achieved in term infants vaccinated at birth, effectively preventing transmission of HBV and resultant morbidity and mortality. Implications, if any, for long-term protection are unknown for differences in responses among infants vaccinated at birth compared to ages older than I month. Published by Elsevier Ltd. C1 [Schillie, Sarah F.; Murphy, Trudy V.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Vaccine Res & Policy Team, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. RP Schillie, SF (reprint author), 1600 Clifton Rd,MS G-37, Atlanta, GA 30333 USA. EM sschillie@cdc.gov NR 75 TC 22 Z9 23 U1 0 U2 21 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD MAY 17 PY 2013 VL 31 IS 21 SI SI BP 2506 EP 2516 DI 10.1016/j.vaccine.2012.12.012 PG 11 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 160TK UT WOS:000320143200005 PM 23257713 ER PT J AU Perou, R Bitsko, RH Blumberg, SJ Pastor, P Ghandour, RM Gfroerer, JC Hedden, SL Crosby, AE Visser, SN Schieve, LA Parks, SE Hall, JE Brody, D Simile, CM Thompson, WW Baio, J Avenevoli, S Kogan, MD Huang, LN AF Perou, Ruth Bitsko, Rebecca H. Blumberg, Stephen J. Pastor, Patricia Ghandour, Reem M. Gfroerer, Joseph C. Hedden, Sarra L. Crosby, Alex E. Visser, Susanna N. Schieve, Laura A. Parks, Sharyn E. Hall, Jeffrey E. Brody, Debra Simile, Catherine M. Thompson, William W. Baio, Jon Avenevoli, Shelli Kogan, Michael D. Huang, Larke N. TI Mental Health Surveillance Among Children - United States, 2005-2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article AB Mental disorders among children are described as "serious deviations from expected cognitive, social, and emotional development" (US Department of Health and Human Services Health Resources and Services Administration, Maternal and Child Health Bureau. Mental health: A report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, and National Institutes of Health, National Institute of Mental Health; 1999). These disorders are an important public health issue in the United States because of their prevalence, early onset, and impact on the child, family, and community, with an estimated total annual cost of $247 billion. A total of 13%-20% of children living in the United States experience a mental disorder in a given year, and surveillance during 1994-2011 has shown the prevalence of these conditions to be increasing. Suicide, which can result from the interaction of mental disorders and other factors, was the second leading cause of death among children aged 12-17 years in 2010. Surveillance efforts are critical for documenting the impact of mental disorders and for informing policy, prevention, and resource allocation. This report summarizes information about ongoing federal surveillance systems that can provide estimates of the prevalence of mental disorders and indicators of mental health among children living in the United States, presents estimates of childhood mental disorders and indicators from these systems during 2005-2011, explains limitations, and identifies gaps in information while presenting strategies to bridge those gaps. Attention-deficit/hyperactivity disorder (6.8%) was the most prevalent parent-reported current diagnosis among children aged 3-17 years, followed by behavioral or conduct problems (3.5%), anxiety (3.0%), depression (2.1%), autism spectrum disorders (1.1%), and Tourette syndrome (0.2% among children aged 6-17 years). An estimated 4.7% of adolescents aged 12-17 years reported an illicit drug use disorder in the past year, 4.2% had an alcohol abuse disorder in the past year, and 2.8% had cigarette dependence in the past month. The overall suicide rate for persons aged 10-19 years was 4.5 suicides per 100,000 persons in 2010. Approximately 8% of adolescents aged 12-17 years reported >= 14 mentally unhealthy days in the past month. Future surveillance of mental disorders among children should include standard case definitions of mental disorders to ensure comparability and reliability of estimates across surveillance systems, better document the prevalence of mental disorders among preschool-age children, and include additional conditions such as specific anxiety disorders and bipolar disorder. Standard surveillance case definitions are needed to reliably categorize and count mental disorders among surveillance systems, which will provide a more complete picture of the prevalence of mental disorders among children. More comprehensive surveillance is needed to develop a public health approach that will both help prevent mental disorders and promote mental health among children. C1 [Perou, Ruth; Bitsko, Rebecca H.; Visser, Susanna N.] CDC, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Blumberg, Stephen J.; Simile, Catherine M.] CDC, Div Hlth Interview Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Pastor, Patricia] CDC, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Ghandour, Reem M.; Kogan, Michael D.] US Hlth Resources & Serv Adm, Off Epidemiol & Res, Maternal & Child Hlth Bur, Rockville, MD 20857 USA. [Gfroerer, Joseph C.; Hedden, Sarra L.] Subst Abuse & Mental Hlth Serv Adm, Ctr Behav Hlth Stat & Qual, Rockville, MD USA. [Crosby, Alex E.; Parks, Sharyn E.; Hall, Jeffrey E.] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Schieve, Laura A.; Baio, Jon] CDC, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Brody, Debra] CDC, Div Hlth Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Thompson, William W.] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Avenevoli, Shelli] NIMH, Bethesda, MD 20892 USA. [Huang, Larke N.] Subst Abuse & Mental Hlth Serv Adm, Off Policy Planning & Innovat, Rockville, MD USA. EM rperou@cdc.gov NR 0 TC 108 Z9 111 U1 5 U2 17 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 17 PY 2013 VL 62 IS 2 SU S BP 1 EP 35 PG 35 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V40JZ UT WOS:000209476200001 PM 23677130 ER PT J AU Frieden, TR AF Frieden, Thomas R. TI Government's Role in Protecting Health and Safety SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID NEW-YORK-CITY C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Frieden, TR (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 5 TC 19 Z9 19 U1 2 U2 9 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 16 PY 2013 VL 368 IS 20 BP 1857 EP 1859 DI 10.1056/NEJMp1303819 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 143VK UT WOS:000318896200002 PM 23593978 ER PT J AU Holmberg, SD Spradling, PR Moorman, AC Denniston, MM AF Holmberg, Scott D. Spradling, Philip R. Moorman, Anne C. Denniston, Maxine M. TI Hepatitis C in the United States SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID VIRUS-INFECTION; PREVALENCE; CARE C1 [Holmberg, Scott D.; Spradling, Philip R.; Moorman, Anne C.; Denniston, Maxine M.] Ctr Dis Control & Prevent, Epidemiol & Surveillance Branch, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Holmberg, SD (reprint author), Ctr Dis Control & Prevent, Epidemiol & Surveillance Branch, Div Viral Hepatitis, Atlanta, GA 30333 USA. NR 6 TC 149 Z9 150 U1 0 U2 11 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 16 PY 2013 VL 368 IS 20 BP 1859 EP 1861 DI 10.1056/NEJMp1302973 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 143VK UT WOS:000318896200003 PM 23675657 ER PT J AU Uyeki, TM Cox, NJ AF Uyeki, Timothy M. Cox, Nancy J. TI Global Concerns Regarding Novel Influenza A (H7N9) Virus Infections SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID TRANSMISSION; FERRETS C1 [Uyeki, Timothy M.; Cox, Nancy J.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Uyeki, TM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. NR 5 TC 135 Z9 150 U1 0 U2 44 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 16 PY 2013 VL 368 IS 20 BP 1862 EP 1864 DI 10.1056/NEJMp1304661 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 143VK UT WOS:000318896200004 PM 23577629 ER PT J AU Chadha, MS Hirve, S Dawood, FS Lele, P Deoshatwar, A Sambhudas, S Juvekar, S LaFond, KE Mott, JA Lal, RB Mishra, AC AF Chadha, Mandeep S. Hirve, Siddhivinayak Dawood, Fatimah S. Lele, Pallavi Deoshatwar, Avinash Sambhudas, Somnath Juvekar, Sanjay LaFond, Kathryn E. Mott, Joshua A. Lal, Renu B. Mishra, Akhilesh C. TI Burden of Seasonal and Pandemic Influenza-Associated Hospitalization during and after 2009 A(H1N1)pdm09 Pandemic in a Rural Community in India SO PLOS ONE LA English DT Article ID HONG-KONG; UNITED-STATES; PNEUMONIA; CHILDREN; MORTALITY; EPIDEMIOLOGY; IMPACT AB Background: Influenza is vaccine-preventable; however, the burden of severe influenza in India remains unknown. We conducted a population-based study to estimate the incidence of laboratory confirmed influenza-associated hospitalizations in a rural community in western India. Methods: We conducted active surveillance for hospitalized patients with acute medical illnesses or acute chronic disease exacerbations in Pune during pandemic and post pandemic periods (May 2009-April 2011). Nasal and throat swabs were tested for influenza viruses. A community health utilization survey estimated the proportion of residents hospitalized with respiratory illness at non-study facilities and was used to adjust incidence estimates from facility-based surveillance. Results: Among 9,426 hospitalizations, 3,391 (36%) patients were enrolled; 665 of 3,179 (20.9%) tested positive for influenza. Of 665 influenza positives, 340 (51%) were pandemic A(H1N1)pdm09 and 327 (49%) were seasonal, including A/H3 (16%), A/H1 (3%) and influenza B (30%). The proportion of patients with influenza peaked during August 2009 (39%) and 2010 (42%). The adjusted annual incidence of influenza hospitalizations was 46.8/10,000 during pandemic and 40.5/10,000 during post-pandemic period with comparable incidence of A(H1N1) pdm09 during both periods (18.8 and 20.3, respectively). The incidence of both pH1N1 and seasonal hospitalized influenza disease was highest in the 5-29 year olds. Conclusions: We document the previously unrecognized burden of influenza hospitalization in a rural community following the emergence of influenza A(H1N1)pdm09 viruses in India. During peak periods of influenza activity circulation i.e during the monsoon period, 20% of all hospital admissions in the community had influenza positivity. These findings can inform development of influenza prevention and control strategies in India. C1 [Chadha, Mandeep S.; Deoshatwar, Avinash; Mishra, Akhilesh C.] Indian Council Med Res, Natl Inst Virol, Pune, Maharashtra, India. [Hirve, Siddhivinayak; Lele, Pallavi; Deoshatwar, Avinash; Sambhudas, Somnath; Juvekar, Sanjay] King Edward Mem Hosp Res Ctr, Vadu Rural Hlth Program, Pune, Maharashtra, India. [Dawood, Fatimah S.; LaFond, Kathryn E.; Mott, Joshua A.; Lal, Renu B.] Natl Ctr Immunizat & Resp Dis, Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Chadha, MS (reprint author), Indian Council Med Res, Natl Inst Virol, Pune, Maharashtra, India. EM acm1750@rediffmail.com; mscniv@hotmail.com FU Centers for Disease Control and Prevention [1U01IP000206] FX The Influenza Disease Burden, India Study was supported by a Centers for Disease Control and Prevention co-operative agreement # 1U01IP000206. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 7 Z9 7 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 15 PY 2013 VL 8 IS 5 AR e55918 DI 10.1371/journal.pone.0055918 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 145XK UT WOS:000319052700001 PM 23690913 ER PT J AU Ohmit, SE Petrie, JG Malosh, RE Cowling, BJ Thompson, MG Shay, DK Monto, AS AF Ohmit, Suzanne E. Petrie, Joshua G. Malosh, Ryan E. Cowling, Benjamin J. Thompson, Mark G. Shay, David K. Monto, Arnold S. TI Influenza Vaccine Effectiveness in the Community and the Household SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE influenza; vaccine effectiveness; households with children ID PANDEMIC INFLUENZA; UNITED-STATES; HONG-KONG; EFFICACY; IMMUNIZATION; PREVENTION AB Background. There is a recognized need to determine influenza vaccine effectiveness on an annual basis and a long history of studying respiratory illnesses in households. Methods. We recruited 328 households with 1441 members, including 839 children, and followed them during the 2010-2011 influenza season. Specimens were collected from subjects with reported acute respiratory illnesses and tested by real-time reverse transcriptase polymerase chain reaction. Receipt of influenza vaccine was defined based on documented evidence of vaccination in medical records or an immunization registry. The effectiveness of 2010-2011 influenza vaccination in preventing laboratory-confirmed influenza was estimated using Cox proportional hazards models adjusted for age and presence of high-risk condition, and stratified by prior season (2009-2010) vaccination status. Results. Influenza was identified in 78 (24%) households and 125 (9%) individuals; the infection risk was 8.5% in the vaccinated and 8.9% in the unvaccinated (P = .83). Adjusted vaccine effectiveness in preventing community-acquired influenza was 31% (95% confidence interval [CI], -7% to 55%). In vaccinated subjects with no evidence of prior season vaccination, significant protection (62% [95% CI, 17%-82%]) against community-acquired influenza was demonstrated. Substantially lower effectiveness was noted among subjects who were vaccinated in both the current and prior season. There was no evidence that vaccination prevented household transmission once influenza was introduced; adults were at particular risk despite vaccination. Conclusions. Vaccine effectiveness estimates were lower than those demonstrated in other observational studies carried out during the same season. The unexpected findings of lower effectiveness with repeated vaccination and no protection given household exposure require further study. C1 [Ohmit, Suzanne E.; Petrie, Joshua G.; Malosh, Ryan E.; Monto, Arnold S.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Cowling, Benjamin J.] Univ Hong Kong, Sch Publ Hlth, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China. [Thompson, Mark G.; Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Ohmit, SE (reprint author), Univ Michigan, Sch Publ Hlth, 1415 Washington Hts, Ann Arbor, MI 48109 USA. EM sohmit@umich.edu RI Cowling, Benjamin/C-4263-2009; OI Cowling, Benjamin/0000-0002-6297-7154; Shay, David/0000-0001-9619-4820 FU Centers for Disease Control and Prevention; University of Michigan [U01 IP000170] FX This work was supported by the Centers for Disease Control and Prevention through a cooperative agreement with the University of Michigan (U01 IP000170). NR 23 TC 62 Z9 63 U1 0 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 15 PY 2013 VL 56 IS 10 BP 1363 EP 1369 DI 10.1093/cid/cit060 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 140EF UT WOS:000318636500004 PM 23413420 ER PT J AU Garg, S Taylor, LE Grasso, C Mayer, KH AF Garg, Shikha Taylor, Lynn E. Grasso, Chris Mayer, Kenneth H. TI Prevalent and Incident Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men Engaged in Primary Care in a Boston Community Health Center SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE HIV; hepatitis C virus; men who have sex with men; screening; incidence ID SEXUALLY-TRANSMITTED-DISEASES; HUMAN-IMMUNODEFICIENCY-VIRUS; POSITIVE MEN; RISK-FACTORS; EPIDEMIC; COHORT; MSM; PREDICTORS; GUIDELINES; RIBAVIRIN AB Background. Sexually transmitted hepatitis C virus (HCV) infection is an emerging epidemic among human immunodeficiency virus (HIV)-infected men who have sex with men (MSM). HCV may be underrecognized in this population, historically thought to be at low risk. Methods. We determined the prevalence and incidence of HCV among HIV-infected men at Fenway Health between 1997 and 2009. We describe characteristics associated with HCV. Results. Of 1171 HIV-infected men, of whom 96% identify as MSM, 1068 (91%) were screened for HCV and 64 (6%) had a positive HCV antibody (Ab) result at initial screening. Among the 995 men whose initial HCV Ab result was negative, 62% received no further HCV Ab testing. Among the 377 men who had >= 1 additional HCV Ab test, 23 (6%) seroconverted over 1408 person-years, for an annualized incidence of 1.63 per 100 person-years (95% confidence interval, .97-2.30). Among the 87 HIV-infected MSM diagnosed with prevalent or incident HCV, 33% reported history of injection drug use, 46% noninjection drug use (NIDU), and 70% sexually transmitted infections (STIs). Sixty-four (74%) of HCV-infected MSM developed chronic HCV; 22 (34%) initiated HCV treatment and 13 (59%) of treated persons achieved a sustained virologic response (SVR). Conclusions. Prevalent and incident HCV, primarily acquired through nonparenteral means, was common in this HIV-infected population despite engagement in care. STIs and NIDU were common among HIV/HCV-coinfected MSM. SVR rates were high among those who underwent HCV treatment. All sexually active and/or substance-using HIV-infected MSM should receive routine and repeated HCV screening to allow for early diagnosis and treatment of HCV. C1 [Garg, Shikha] Tufts Med Ctr, Boston, MA USA. [Garg, Shikha; Taylor, Lynn E.] Brown Univ, Providence, RI 02912 USA. [Grasso, Chris; Mayer, Kenneth H.] Fenway Inst, Boston, MA USA. [Mayer, Kenneth H.] Harvard Univ, Sch Med, Boston, MA USA. [Mayer, Kenneth H.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Garg, S (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd,MS A32, Atlanta, GA 30333 USA. EM shikhagarg75@yahoo.com FU National Institute of Allergy and Infectious Diseases [5T32AI007438-17, P30AI042853]; National Institute on Drug Abuse [K23DA020383] FX This work was supported by the National Institute of Allergy and Infectious Diseases (5T32AI007438-17 to S. G.; P30AI042853) to support the Lifespan/Tufts/Brown Center for AIDS Research, and the National Institute on Drug Abuse (K23DA020383 to L. E. T.). NR 43 TC 23 Z9 23 U1 1 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 15 PY 2013 VL 56 IS 10 BP 1480 EP 1487 DI 10.1093/cid/cit054 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 140EF UT WOS:000318636500022 PM 23386630 ER PT J AU Kirkcaldy, RD Bolan, GA Wasserheit, JN AF Kirkcaldy, Robert D. Bolan, Gail A. Wasserheit, Judith N. TI Cephalosporin Resistance in Neisseria gonorrhoeae Infections Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID FLUOROQUINOLONE RESISTANCE; IMPACT C1 [Kirkcaldy, Robert D.; Bolan, Gail A.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Wasserheit, Judith N.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. RP Kirkcaldy, RD (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. EM rkirkcaldy@cdc.gov NR 6 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 15 PY 2013 VL 309 IS 19 BP 1990 EP 1991 DI 10.1001/jama.2013.4084 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 143GQ UT WOS:000318855500013 PM 23677305 ER PT J AU Perrone, LA Belser, JA Wadford, DA Katz, JM Tumpey, TM AF Perrone, Lucy A. Belser, Jessica A. Wadford, Debra A. Katz, Jacqueline M. Tumpey, Terrence M. TI Inducible Nitric Oxide Contributes to Viral Pathogenesis Following Highly Pathogenic Influenza Virus Infection in Mice SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE nitric oxide; H5N1; 1918; influenza ID A H5N1 VIRUS; RESPIRATORY-DISTRESS-SYNDROME; 1918 PANDEMIC VIRUS; ACUTE LUNG INJURY; AVIAN INFLUENZA; HUMAN-NEUTROPHILS; OXYGEN RADICALS; HUMAN-DISEASE; SYNTHASE; PATHOLOGY AB Highly pathogenic influenza A viruses, including avian H5N1 viruses and the 1918 pandemic virus, cause severe respiratory disease in humans and animals. Virus infection is followed by intense pulmonary congestion due to an extensive influx of macrophages and neutrophils, which can release large quantities of reactive oxygen species potentially contributing to the pathogenesis of lung disease. Here, the role of nitric oxide (NO), a potent signaling molecule in inflammation, was evaluated following highly pathogenic influenza virus challenge in mice. We observed higher levels of NO in mice infected with H5N1 and 1918 viruses as compared to a seasonal H1N1 virus. Mice deficient in inducible NO synthase (NOS2(-/-)) exhibited reduced morbidity, reduced mortality, and diminished cytokine production in lung tissue following H5N1 and 1918-virus challenge, compared with wild-type control mice. Furthermore, systemic treatment of mice with the NOS inhibitor NG-monomethyl-l-arginine delayed weight loss and death among 1918 virus infected mice compared to untreated control animals. This study demonstrates that NO contributes to the pathogenic outcome of H5N1 and 1918 viral infections in the mouse model. C1 [Perrone, Lucy A.; Belser, Jessica A.; Wadford, Debra A.; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Tumpey, TM (reprint author), Influenza Div, MS G-16,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM tft9@cdc.gov FU Centers for Disease Control and Prevention (CDC); American Society for Microbiology/US National Center for Immunization and Respiratory Diseases, CDC; Oak Ridge Institute for Science and Education, US Department of Energy FX This work was supported by the Centers for Disease Control and Prevention (CDC); the American Society for Microbiology/US National Center for Immunization and Respiratory Diseases, CDC (fellowship to L. A. P.); and the Oak Ridge Institute for Science and Education, US Department of Energy (support to L. A. P. and D. A. W.). NR 50 TC 17 Z9 17 U1 1 U2 28 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 15 PY 2013 VL 207 IS 10 BP 1576 EP 1584 DI 10.1093/infdis/jit062 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 132ZG UT WOS:000318106600013 PM 23420903 ER PT J AU Curlin, ME Leelawiwat, W Dunne, EF Chonwattana, W Mock, PA Mueanpai, F Thep-Amnuay, S Whitehead, SJ McNicholl, JM AF Curlin, Marcel E. Leelawiwat, Wanna Dunne, Eileen F. Chonwattana, Wannee Mock, Philip A. Mueanpai, Famui Thep-Amnuay, Sukhon Whitehead, Sara J. McNicholl, Janet M. TI Cyclic Changes in HIV Shedding From the Female Genital Tract During the Menstrual Cycle SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE HIV; mucosal; shedding; female; genital tract; menstrual cycle; transmission; Thailand ID HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTED WOMEN; CHIANG-RAI; SECRETIONS; PLASMA; RNA; THAILAND AB Factors increasing genital human immunodeficiency virus (HIV) shedding may increase female-to-male HIV transmission risk. We examined HIV shedding in 67 women with HIV type 1 and herpes simplex virus type 2 coinfection, during 2 menstrual cycles. Shedding occurred in 60%, 48%, and 54% of samples during the follicular, periovulatory, and luteal phases, respectively (P = .01). Shedding declined after menses until ovulation, with a slope -0.054 log(10) copies/swab/day (P < .001), corresponding to a change of approximately 0.74 log(10) copies between peak and nadir levels. Shedding increased during the luteal phase only among women with CD4 counts of < 350 cells/mu L. In reproductive-aged women, shedding frequency and magnitude are greatest immediately following menses and lowest at ovulation. C1 [Curlin, Marcel E.; Dunne, Eileen F.; Whitehead, Sara J.; McNicholl, Janet M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Curlin, Marcel E.; Leelawiwat, Wanna; Chonwattana, Wannee; Mock, Philip A.; Mueanpai, Famui; Whitehead, Sara J.] Thai Minist Publ Hlth US CDC Collaborat, Nonthaburi, Thailand. RP Curlin, ME (reprint author), CDC Box 68, APO, AP 96546 USA. EM mcurlin@th.cdc.gov FU US Centers for Disease Control and Prevention FX This work was supported by the US Centers for Disease Control and Prevention. NR 15 TC 6 Z9 6 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 15 PY 2013 VL 207 IS 10 BP 1616 EP 1620 DI 10.1093/infdis/jit063 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 132ZG UT WOS:000318106600018 PM 23417658 ER PT J AU Melin, B Dahlin, AM Andersson, U Wang, ZM Henriksson, R Hallmans, G Bondy, ML Johansen, C Feychting, M Ahlbom, A Kitahara, CM Wang, SS Ruder, AM Carreon, T Butler, MA Inskip, PD Purdue, M Hsing, AW Mechanic, L Gillanders, E Yeager, M Linet, M Chanock, SJ Hartge, P Rajaraman, P AF Melin, Beatrice Dahlin, Anna M. Andersson, Ulrika Wang, Zhaoming Henriksson, Roger Hallmans, Goran Bondy, Melissa L. Johansen, Christoffer Feychting, Maria Ahlbom, Anders Kitahara, Cari M. Wang, Sophia S. Ruder, Avima M. Carreon, Tania Butler, Mary Ann Inskip, Peter D. Purdue, Mark Hsing, Ann W. Mechanic, Leah Gillanders, Elizabeth Yeager, Meredith Linet, Martha Chanock, Stephen J. Hartge, Patricia Rajaraman, Preetha TI Known glioma risk loci are associated with glioma with a family history of brain tumours - A case-control gene association study SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE Glioma; brain tumours; genome-wide association study; single nucleotide polymorphism ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; CONSORTIUM; EPIDEMIOLOGY; GLIOGENE; DESIGN; RTEL1 AB Familial cancer can be used to leverage genetic association studies. Recent genome-wide association studies have reported independent associations between seven single nucleotide polymorphisms (SNPs) and risk of glioma. The aim of this study was to investigate whether glioma cases with a positive family history of brain tumours, defined as having at least one first- or second-degree relative with a history of brain tumour, are associated with known glioma risk loci. One thousand four hundred and thirty-one glioma cases and 2,868 cancer-free controls were identified from four casecontrol studies and two prospective cohorts from USA, Sweden and Denmark and genotyped for seven SNPs previously reported to be associated with glioma risk in casecontrol designed studies. Odds ratios were calculated by unconditional logistic regression. In analyses including glioma cases with a family history of brain tumours (n = 104) and control subjects free of glioma at baseline, three of seven SNPs were associated with glioma risk: rs2736100 (5p15.33, TERT), rs4977756 (9p21.3, CDKN2A-CDKN2B) and rs6010620 (20q13.33, RTEL1). After Bonferroni correction for multiple comparisons, only one marker was statistically significantly associated with glioma risk, rs6010620 (ORtrend for the minor (A) allele, 0.39; 95% CI: 0.250.61; Bonferroni adjusted ptrend, 1.7 x 104). In conclusion, as previously shown for glioma regardless of family history of brain tumours, rs6010620 (RTEL1) was associated with an increased risk of glioma when restricting to cases with family history of brain tumours. These findings require confirmation in further studies with a larger number of glioma cases with a family history of brain tumours. C1 [Melin, Beatrice; Dahlin, Anna M.; Andersson, Ulrika; Henriksson, Roger] Umea Univ, Dept Radiat Sci, S-90187 Umea, Sweden. [Wang, Zhaoming; Yeager, Meredith; Chanock, Stephen J.] Natl Canc Inst, Div Canc Epidemiol & Genet, Core Genotyping Facil, Gaithersburg, MD USA. [Hallmans, Goran] Umea Univ, Dept Publ Hlth & Clin Med, S-90187 Umea, Sweden. [Bondy, Melissa L.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA. [Johansen, Christoffer] Danish Canc Soc, Res Ctr, Copenhagen, Denmark. [Feychting, Maria; Ahlbom, Anders] Karolinska Inst, Inst Environm Med, Div Epidemiol, S-10401 Stockholm, Sweden. [Kitahara, Cari M.; Inskip, Peter D.; Purdue, Mark; Hsing, Ann W.; Linet, Martha; Hartge, Patricia; Rajaraman, Preetha] NCI, Div Canc Epidemiol & Genet, NIH, DHHS, Rockville, MD USA. [Wang, Sophia S.] City Hope Natl Med Ctr, Dept Populat Sci, Div Canc Etiol, Duarte, CA USA. [Wang, Sophia S.] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA. [Ruder, Avima M.; Carreon, Tania] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Butler, Mary Ann] NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Mechanic, Leah; Gillanders, Elizabeth] NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, Rockville, MD USA. RP Melin, B (reprint author), Umea Univ, Dept Radiat Sci, S-90187 Umea, Sweden. EM beatrice.melin@onkologi.umu.se RI Kitahara, Cari/R-8267-2016 FU National Institutes of Health, National Cancer Institute (Intramural Research Program); Royal Swedish Academy of Science (Acta Oncologica); Swedish Cancer Foundation; Northern Sweden Cancer Society; Swedish Research Council; Umea University Hospital (Cutting Edge); Umea University (Young Investigator Award); NIH [NIH 5R01 CA119215]; NIOSH Initiative for Cancer Control Projects for Farmers; CDC/NIOSH operating funds; Acta Oncologica through the Royal Swedish Academy of Science FX Grant sponsor: National Institutes of Health, National Cancer Institute (Intramural Research Program); Grant sponsors: Royal Swedish Academy of Science (Acta Oncologica), the Swedish Cancer Foundation, Northern Sweden Cancer Society, Swedish Research Council, Umea University Hospital (Cutting Edge), Umea University (Young Investigator Award); Grant sponsors: NIH; Grant number: NIH 5R01 CA119215; Grant sponsors: NIOSH Initiative for Cancer Control Projects for Farmers and CDC/NIOSH operating funds; Peter Hui from Integrated Management Systems is acknowledged for statistical support. The study was supported by Acta Oncologica through the Royal Swedish Academy of Science (B.M. salary). NR 21 TC 15 Z9 15 U1 0 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD MAY 15 PY 2013 VL 132 IS 10 BP 2464 EP 2468 DI 10.1002/ijc.27922 PG 5 WC Oncology SC Oncology GA 097ZO UT WOS:000315512300024 PM 23115063 ER PT J AU Quan, PL Firth, C Conte, JM Williams, SH Zambrana-Torrelio, CM Anthony, SJ Ellison, JA Gilbert, AT Kuzmin, IV Niezgoda, M Osinubi, MOV Recuenco, S Markotter, W Breiman, RF Kalemba, L Malekani, J Lindblade, KA Rostal, MK Ojeda-Flores, R Suzan, G Davis, LB Blau, DM Ogunkoya, AB Castillo, DAA Moran, D Ngam, S Akaibe, D Agwanda, B Briese, T Epstein, JH Daszak, P Rupprecht, CE Holmes, EC Lipkin, WI AF Quan, Phenix-Lan Firth, Cadhla Conte, Juliette M. Williams, Simon H. Zambrana-Torrelio, Carlos M. Anthony, Simon J. Ellison, James A. Gilbert, Amy T. Kuzmin, Ivan V. Niezgoda, Michael Osinubi, Modupe O. V. Recuenco, Sergio Markotter, Wanda Breiman, Robert F. Kalemba, Lems Malekani, Jean Lindblade, Kim A. Rostal, Melinda K. Ojeda-Flores, Rafael Suzan, Gerardo Davis, Lora B. Blau, Dianna M. Ogunkoya, Albert B. Alvarez Castillo, Danilo A. Moran, David Ngam, Sali Akaibe, Dudu Agwanda, Bernard Briese, Thomas Epstein, Jonathan H. Daszak, Peter Rupprecht, Charles E. Holmes, Edward C. Lipkin, W. Ian TI Bats are a major natural reservoir for hepaciviruses and pegiviruses SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID HEPATITIS-C VIRUS; RESPIRATORY SYNDROME CORONAVIRUS; READING FRAME; NIPAH VIRUS; PROTEIN; HOST; EVOLUTION; PRODUCTS; DISEASES; GENOME AB Although there are over 1,150 bat species worldwide, the diversity of viruses harbored by bats has only recently come into focus as a result of expanded wildlife surveillance. Such surveys are of importance in determining the potential for novel viruses to emerge in humans, and for optimal management of bats and their habitats. To enhance our knowledge of the viral diversity present in bats, we initially surveyed 415 sera from African and Central American bats. Unbiased high-throughput sequencing revealed the presence of a highly diverse group of bat-derived viruses related to hepaciviruses and pegiviruses within the family Flaviridae. Subsequent PCR screening of 1,258 bat specimens collected worldwide indicated the presence of these viruses also in North America and Asia. A total of 83 bat-derived viruses were identified, representing an infection rate of nearly 5%. Evolutionary analyses revealed that all known hepaciviruses and pegiviruses, including those previously documented in humans and other primates, fall within the phylogenetic diversity of the bat-derived viruses described here. The prevalence, unprecedented viral biodiversity, phylogenetic divergence, and worldwide distribution of the bat-derived viruses suggest that bats are a major and ancient natural reservoir for both hepaciviruses and pegiviruses and provide insights into the evolutionary history of hepatitis C virus and the human GB viruses. C1 [Quan, Phenix-Lan; Firth, Cadhla; Conte, Juliette M.; Williams, Simon H.; Anthony, Simon J.; Briese, Thomas; Lipkin, W. Ian] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10032 USA. [Zambrana-Torrelio, Carlos M.; Anthony, Simon J.; Rostal, Melinda K.; Epstein, Jonathan H.; Daszak, Peter] EcoHlth Alliance, New York, NY 10001 USA. [Ellison, James A.; Gilbert, Amy T.; Kuzmin, Ivan V.; Niezgoda, Michael; Osinubi, Modupe O. V.; Recuenco, Sergio; Rupprecht, Charles E.] Ctr Dis Control & Prevent, Natl Ctr Emerging Zoonot Infect Dis, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Markotter, Wanda] Univ Pretoria, Dept Microbiol & Plant Pathol, ZA-0002 Pretoria, South Africa. [Breiman, Robert F.] Ctr Dis Control & Prevent Kenya, Nairobi, Kenya. [Kalemba, Lems; Malekani, Jean] Univ Kinshasa, Kinshasa 11, Zaire. [Lindblade, Kim A.] Ctr Dis Control & Prevent Guatemala, Guatemala City 01015, Guatemala. [Ojeda-Flores, Rafael; Suzan, Gerardo] Univ Nacl Autonoma Mexico, Fac Med Vet & Zootecnia, Mexico City 04510, DF, Mexico. [Davis, Lora B.] Ctr Dis Control & Prevent Nigeria, Abuja, Nigeria. [Blau, Dianna M.] Ctr Dis Control & Prevent, Natl Ctr Emerging Zoonot Infect Dis, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Ogunkoya, Albert B.] Ahmadu Bello Univ, Dept Vet Med, Zaria, Kaduna State, Nigeria. [Alvarez Castillo, Danilo A.; Moran, David] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City 01015, Guatemala. [Ngam, Sali] Natl Vet Lab, Garoua, Cameroon. [Akaibe, Dudu] Univ Kisangani, Ctr Surveillance Biodiversite, Kisangani, Zaire. [Agwanda, Bernard] Natl Museums Kenya, Mammal Sect, Nairobi 00100, Kenya. [Holmes, Edward C.] Univ Sydney, Sch Biol Sci, Sydney Emerging Infect & Biosecur Inst, Sydney, NSW 2006, Australia. [Holmes, Edward C.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia. RP Quan, PL (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10032 USA. EM pq2106@columbia.edu OI Markotter, Wanda/0000-0002-7550-0080; Ellison, James/0000-0003-4492-4857; Holmes, Edward/0000-0001-9596-3552; Recuenco-Cabrera, Sergio/0000-0002-8446-7411 FU National Institutes of Health [AI051292, AI57158]; National Institute of Allergy and Infectious Diseases [5R01AI079231-02]; US Agency for International Development PREDICT Grant [GHNA 0009 0001 000]; US Department of Defense; Emerging Pandemic Threats Program of the US Agency for International Development; National Center for Emerging and Zoonotic Infectious Diseases; Centers for Disease Control and Prevention (Atlanta, GA); Global Disease Detection Program of the Centers for Disease Control and Prevention (Atlanta, GA) FX We thank the King and Chiefs of the Idanre community, Ondo State, Nigeria; the Federal Ministry of Health, Abuja, Nigeria; S. Wuyah, M. Lawal, M. Ari, A. Mohammed, I. Onaja, and G. Kia; the Faculty of Veterinary Medicine, Ahmadu Bello University (ABU), Zaria, Nigeria; and the Vice Chancellor and Management of ABU. We thank Luis Escobar, Alejandra Estevez, Maria Renee Lopez, Ramon Medrano, Maria E. Morales, and Maria Luisa Muller (Center for Health Studies, Universidad del Valle de Guatemala) and Julio Martinez (Guatemala Ministry of Agriculture-Animal Health Department). We thank Sophronia Yu, Edwin Danga, Evelyne Mulama, Solomon Gikundi, Leonard Nderitu, and Eric Ogola (Centers for Disease Control-Kenya), Rafael Ciraiz (Guatemala Ministry of Public Health and Social Assistance), and Arif Islam (from Bangladesh) for excellent technical assistance and logistics. This work was supported by National Institutes of Health Grants AI051292 and AI57158 (Northeast Biodefense Center) (to W. I. L.), National Institute of Allergy and Infectious Diseases Grant 5R01AI079231-02, US Agency for International Development PREDICT Grant GHNA 0009 0001 000, and an award from the US Department of Defense. This study was also supported by the Emerging Pandemic Threats Program of the US Agency for International Development, the National Center for Emerging and Zoonotic Infectious Diseases, the Centers for Disease Control and Prevention (Atlanta, GA), and Technical Support Corps funds from the Global Disease Detection Program of the Centers for Disease Control and Prevention (Atlanta, GA). NR 44 TC 92 Z9 95 U1 4 U2 44 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAY 14 PY 2013 VL 110 IS 20 BP 8194 EP 8199 DI 10.1073/pnas.1303037110 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 156EH UT WOS:000319803500050 PM 23610427 ER PT J AU Keitel, W Grohskopf, L Bresee, J Cox, N Sokolow, L AF Keitel, Wendy Grohskopf, Lisa Bresee, Joseph Cox, Nancy Sokolow, Leslie TI Prevention and Control of Influenza with Vaccines: Interim Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Keitel, Wendy] Baylor Coll Med, Houston, TX 77030 USA. [Grohskopf, Lisa; Bresee, Joseph; Cox, Nancy; Sokolow, Leslie] CDC, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. RP Grohskopf, L (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. EM lgrohskopf@cdc.gov NR 0 TC 12 Z9 12 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 10 PY 2013 VL 62 IS 18 BP 356 EP 356 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GC UT WOS:000322179700003 ER PT J AU Bornschlegel, K Holtzman, D Klevens, RM Ward, JW AF Bornschlegel, Katherine Holtzman, Deborah Klevens, R. Monina Ward, John W. TI Vital Signs: Evaluation of Hepatitis C Virus Infection Testing and Reporting - Eight US Sites, 2005-2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES; VIRAL-HEPATITIS; MORTALITY; BURDEN; CARE AB Background: Hepatitis C virus (HCV) infection is a serious public health problem. New infections continue to occur, and morbidity and mortality are increasing among an estimated 2.7-3.9 million persons in the United States living with HCV infection. Most persons are unaware of their infection status. Existing CDC guidelines for laboratory testing and reporting of antibody to HCV do not distinguish between past infection that has resolved and current infection that requires care and evaluation for treatment. To identify current infection, a test for HCV RNA is needed. Methods: Surveillance data reported to CDC from eight U.S. sites during 2005-2011 were analyzed to determine the proportion of persons newly reported on the basis of a positive test result for HCV infection. Persons reported with a positive result from an HCV antibody test only were compared with persons reported with a positive result for HCV RNA and examined by birth cohort (1945-1965 compared with all other years), surveillance site, and number of reported deaths. Annual rates of persons newly reported with HCV infection in 2011 also were calculated for each site. Results: Of 217,755 persons newly reported, 107,209 (49.2%) were HCV antibody positive only, and 110,546 (50.8%) were reported with a positive HCV RNA result that confirmed current HCV infection. In both groups, persons were most likely to have been born during 1945-1965 (58.5% of those who were HCV antibody positive only; 67.2% of those who were HCV RNA positive). Among all persons newly reported for whom death data were available, 6,734 (3.4%) were known to have died; deaths were most likely among persons aged 50-59 years. In 2011, across all sites, the annual rate of persons newly reported with HCV infection (positive HCV antibody only and HCV RNA positive) was 84.7 per 100,000 population. Conclusions: Hepatitis C is a commonly reported disease predominantly affecting persons born during 1945-1965, with deaths more frequent among persons of relatively young age. The lack of an HCV RNA test for approximately one half of persons newly reported suggests that testing and reporting must improve to detect all persons with current infection. Implications for Public Health: In an era of continued HCV transmission and expanding options for curative antiviral therapies, surveillance that identifies current HCV infection can help assess the need for services and link persons with infection to appropriate care and treatment. C1 [Bornschlegel, Katherine] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Holtzman, Deborah; Klevens, R. Monina; Ward, John W.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Holtzman, D (reprint author), CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM dholtzman@cdc.gov NR 18 TC 14 Z9 14 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 10 PY 2013 VL 62 IS 18 BP 357 EP 361 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GC UT WOS:000322179700004 ER PT J AU Getchell, JP Wroblewski, KE DeMaria, A Bean, CL Parker, MM Pandori, M Dufour, DR Busch, MP Brecher, ME Meyer, WA Pesano, RL Teo, CG Beckett, GA Araujo, AC Branson, BM Drobeniuc, J Hatia, R Holmberg, SD Kamili, S Ward, JW AF Getchell, Jane P. Wroblewski, Kelly E. DeMaria, Alfred, Jr. Bean, Christine L. Parker, Monica M. Pandori, Mark Dufour, D. Robert Busch, Michael P. Brecher, Mark E. Meyer, William A. Pesano, Rick L. Teo, Chong-Gee Beckett, Geoffrey A. Araujo, Aufra C. Branson, Bernard M. Drobeniuc, Jan Hatia, Rikita Holmberg, Scott D. Kamili, Saleem Ward, John W. TI Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID HEPATITIS-C; METAANALYSIS C1 [DeMaria, Alfred, Jr.] Massachusetts Dept Publ Hlth, Boston, MA 02111 USA. [Parker, Monica M.] New York State Dept Hlth, Albany, NY 12237 USA. [Pandori, Mark] San Francisco Dept Publ Health, San Francisco, CA USA. [Dufour, D. Robert] VA Med Ctr, Washington, DC USA. [Teo, Chong-Gee; Beckett, Geoffrey A.; Araujo, Aufra C.; Branson, Bernard M.; Drobeniuc, Jan; Hatia, Rikita; Holmberg, Scott D.; Kamili, Saleem; Ward, John W.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Teo, CG (reprint author), CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM cteo@cdc.gov NR 16 TC 76 Z9 76 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 10 PY 2013 VL 62 IS 18 BP 362 EP 365 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188GC UT WOS:000322179700005 ER PT J AU Tartof, S Cohn, A Tarbangdo, F Djingarey, MH Messonnier, N Clark, TA Kambou, JL Novak, R Diomande, FVK Medah, I Jackson, ML AF Tartof, Sara Cohn, Amanda Tarbangdo, Felix Djingarey, Mamoudou H. Messonnier, Nancy Clark, Thomas A. Kambou, Jean Ludovic Novak, Ryan Diomande, Fabien V. K. Medah, Isaie Jackson, Michael L. TI Identifying Optimal Vaccination Strategies for Serogroup A Neisseria meningitidis Conjugate Vaccine in the African Meningitis Belt SO PLOS ONE LA English DT Article ID SUB-SAHARAN AFRICA; MENINGOCOCCAL CARRIAGE; UNITED-KINGDOM; ANTIBODY PERSISTENCE; EPIDEMIC MENINGITIS; DISEASE; IMPACT; MODEL; IMMUNOGENICITY; TRANSMISSION AB Objective: The optimal long-term vaccination strategies to provide population-level protection against serogroup A Neisseria meningitidis (MenA) are unknown. We developed an age-structured mathematical model of MenA transmission, colonization, and disease in the African meningitis belt, and used this model to explore the impact of various vaccination strategies. Methods: The model stratifies the simulated population into groups based on age, infection status, and MenA antibody levels. We defined the model parameters (such as birth and death rates, age-specific incidence rates, and age-specific duration of protection) using published data and maximum likelihood estimation. We assessed the validity of the model by comparing simulated incidence of invasive MenA and prevalence of MenA carriage to observed incidence and carriage data. Results: The model fit well to observed age-and season-specific prevalence of carriage (mean pseudo-R2 0.84) and incidence of invasive disease (mean R2 0.89). The model is able to reproduce the observed dynamics of MenA epidemics in the African meningitis belt, including seasonal increases in incidence, with large epidemics occurring every eight to twelve years. Following a mass vaccination campaign of all persons 1-29 years of age, the most effective modeled vaccination strategy is to conduct mass vaccination campaigns every 5 years for children 1-5 years of age. Less frequent campaigns covering broader age groups would also be effective, although somewhat less so. Introducing conjugate MenA vaccine into the EPI vaccination schedule at 9 months of age results in higher predicted incidence than periodic mass campaigns. Discussion: We have developed the first mathematical model of MenA in Africa to incorporate age structures and progressively waning protection over time. Our model accurately reproduces key features of MenA epidemiology in the African meningitis belt. This model can help policy makers consider vaccine program effectiveness when determining the feasibility and benefits of MenA vaccination strategies. C1 [Tartof, Sara; Cohn, Amanda; Messonnier, Nancy; Clark, Thomas A.; Novak, Ryan; Diomande, Fabien V. K.] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Atlanta, GA 30333 USA. [Tarbangdo, Felix; Kambou, Jean Ludovic; Medah, Isaie] Minist Sante, Direct Lutte Malad, Ouagadougou, Burkina Faso. [Djingarey, Mamoudou H.; Diomande, Fabien V. K.] WHO, Intercountry Support Team West Africa, Ouagadougou, Burkina Faso. [Jackson, Michael L.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. RP Tartof, S (reprint author), Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Atlanta, GA 30333 USA. EM startof@gmail.com FU Centers for Disease Control and Prevention [797VE0001]; Modeling Vaccination Strategies for Serogroup A Meningococcal Disease in Africa FX This work was funded by the Centers for Disease Control and Prevention under contract #797VE0001, Modeling Vaccination Strategies for Serogroup A Meningococcal Disease in Africa. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 9 Z9 9 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 9 PY 2013 VL 8 IS 5 AR e63605 DI 10.1371/journal.pone.0063605 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 155HD UT WOS:000319737700054 PM 23671685 ER PT J AU Boon-Yasidhi, V Chokephaibulkit, K McConnell, MS Vanprapar, N Leowsrisook, P Prasitsurbsai, W Durier, Y Klumthanom, K Patel, A Sukwicha, W Naiwatanakul, T Chotpitayasunond, T AF Boon-yasidhi, Vitharon Chokephaibulkit, Kulkanya McConnell, Michelle S. Vanprapar, Nirun Leowsrisook, Pimsiri Prasitsurbsai, Wasana Durier, Yuitiang Klumthanom, Kanyarat Patel, Alpa Sukwicha, Wichuda Naiwatanakul, Thananda Chotpitayasunond, Tawee TI Development of a diagnosis disclosure model for perinatally HIV-infected children in Thailand SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV; diagnosis; disclosure; model; children ID HUMAN-IMMUNODEFICIENCY-VIRUS; ADOLESCENTS; HIV/AIDS AB While disclosure of HIV status to perinatally HIV-infected children has become an increasingly important clinical issue, specific disclosure guidelines are lacking. We developed a pediatric HIV diagnosis disclosure model to support caretakers. All HIV-infected children greater than 7-years-old at two participating hospitals in Bangkok, Thailand, and their caretakers, were offered disclosure according to the 4-step protocol: (1) screening; (2) readiness assessment; (3) disclosure; and (4) follow-up. Disclosure occurred after agreement of both providers and caretakers. Among 438 children who were screened, 398 (89%) were eligible. Readiness assessment was completed for 353 (91%) of eligible children and 216 (61%) were determined ready. Disclosure was done for 186 children. The mean age at eligibility screening was 10.5 years (range: 6.8-15.8 years); the mean age at disclosure was 11.7 years (range: 7.6-17.7 years). The mean duration between eligibility screening and disclosure was 15.2 months. There were no significant negative behavioral or emotional outcomes reported in children following disclosure. This HIV diagnosis disclosure model was feasible to implement and had no negative outcomes. As the time for preparation process was over 1 year for most cases, the disclosure process can be initiated as early as age 7 to allow enough time for disclosure to be completed by the age of adolescence. C1 [Boon-yasidhi, Vitharon; Chokephaibulkit, Kulkanya; Vanprapar, Nirun; Prasitsurbsai, Wasana; Durier, Yuitiang] Mahidol Univ, Fac Med, Dept Pediat, Siriraj Hosp, Bangkok 10700, Thailand. [McConnell, Michelle S.; Patel, Alpa] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Leowsrisook, Pimsiri; Chotpitayasunond, Tawee] Minist Publ Hlth, Dept Pediat, QSNICH, Bangkok, Thailand. [Klumthanom, Kanyarat; Sukwicha, Wichuda; Naiwatanakul, Thananda] GAP, Thailand MOPH US CDC Collaborat TUC, Bangkok, Thailand. RP Boon-Yasidhi, V (reprint author), Mahidol Univ, Fac Med, Dept Pediat, Siriraj Hosp, Bangkok 10700, Thailand. EM vitharon.boo@mahidol.ac.th OI Boon-yasidhi, Vitharon/0000-0002-6573-8044 FU CGH CDC HHS [5U19GH000004-05] NR 12 TC 8 Z9 8 U1 2 U2 7 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PD MAY 8 PY 2013 VL 25 IS 6 BP 756 EP 762 DI 10.1080/09540121.2012.749331 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 184JJ UT WOS:000321885600017 PM 23252607 ER PT J AU Medley, A Baggaley, R Bachanas, P Cohen, M Shaffer, N Lo, YR AF Medley, Amy Baggaley, Rachel Bachanas, Pamela Cohen, Myron Shaffer, Nathan Lo, Ying-Ru TI Maximizing the impact of HIV prevention efforts: Interventions for couples SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV; AIDS; HIV serodiscordant couples; couples HIV testing and counseling; HIV prevention; sub-Saharan Africa ID ACTIVE ANTIRETROVIRAL THERAPY; SUB-SAHARAN AFRICA; IMMUNODEFICIENCY-VIRUS TYPE-1; HORMONAL CONTRACEPTIVE USE; CONSISTENT CONDOM USE; DISCORDANT COUPLES; SOUTH-AFRICA; ALCOHOL-USE; BEHAVIORAL INTERVENTIONS; ADHERENCE INTERVENTION AB Despite efforts to increase access to HIV testing and counseling services, population coverage remains low. As a result, many people in sub-Saharan Africa do not know their own HIV status or the status of their sex partner(s). Recent evidence, however, indicates that as many as half of HIV-positive individuals in ongoing sexual relationships have an HIV-negative partner and that a significant proportion of new HIV infections in generalized epidemics occur within serodiscordant couples. Integrating couples HIV testing and counseling (CHTC) into routine clinic- and community-based services can significantly increase the number of couples where the status of both partners is known. Offering couples a set of evidence-based interventions once their HIV status has been determined can significantly reduce HIV incidence within couples and if implemented with sufficient scale and coverage, potentially reduce population-level HIV incidence as well. This article describes these interventions and their potential benefits. C1 [Medley, Amy; Bachanas, Pamela] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA 30329 USA. [Baggaley, Rachel; Shaffer, Nathan; Lo, Ying-Ru] World Hlth Org, Dept HIV AIDS, Geneva, Switzerland. [Cohen, Myron] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA. RP Medley, A (reprint author), US Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA 30329 USA. EM amedley@cdc.gov FU Intramural CDC HHS [CC999999] NR 86 TC 14 Z9 14 U1 1 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 EI 1360-0451 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PD MAY 7 PY 2013 VL 25 IS 12 BP 1569 EP 1580 DI 10.1080/09540121.2013.793269 PG 12 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 250QT UT WOS:000326868700014 PM 23656251 ER PT J AU Smith, BD Holtzman, D Ward, JW AF Smith, Bryce D. Holtzman, Deborah Ward, John W. TI Hepatitis C Virus Testing of Persons Born During 1945-1965 RESPONSE SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID INFECTION C1 [Smith, Bryce D.; Holtzman, Deborah; Ward, John W.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Smith, BD (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 7 TC 0 Z9 0 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 7 PY 2013 VL 158 IS 9 BP 705 EP 705 DI 10.7326/0003-4819-158-9-201305070-00016 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 146WV UT WOS:000319126900012 PM 23648954 ER PT J AU Ma, HY Lu, YN Malone, KE Marchbanks, PA Deapen, DM Spirtas, R Burkman, RT Strom, BL McDonald, JA Folger, SG Simon, MS Sullivan-Halley, J Press, MF Bernstein, L AF Ma, Huiyan Lu, Yani Malone, Kathleen E. Marchbanks, Polly A. Deapen, Dennis M. Spirtas, Robert Burkman, Ronald T. Strom, Brian L. McDonald, Jill A. Folger, Suzanne G. Simon, Michael S. Sullivan-Halley, Jane Press, Michael F. Bernstein, Leslie TI Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status SO BMC CANCER LA English DT Article DE Breast cancer; Mortality; Racial disparity; Triple negative; Luminal A; ER; PR; HER2; p53 ID REPRODUCTIVE EXPERIENCES; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; TUMOR SUBTYPES; SURVIVAL; RACE; MUTATIONS; EXPRESSION; GENE; OVEREXPRESSION AB Background: Black women are more likely than white women to have an aggressive subtype of breast cancer that is associated with higher mortality and this may contribute to the observed black-white difference in mortality. However, few studies have investigated the black-white disparity in mortality risk stratified by breast cancer subtype, defined by estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Furthermore, it is not known whether additional consideration of p53 protein status influences black-white differences in mortality risk observed when considering subtypes defined by ER, PR and HER2 status. Methods: Four biomarkers were assessed by immunohistochemistry in paraffin-embedded breast tumor tissue from 1,204 (523 black, 681 white) women with invasive breast cancer, aged 35-64 years at diagnosis, who accrued a median of 10 years' follow-up. Multivariable Cox proportional hazards regression models were fit to assess subtype-specific black-white differences in mortality risk. Results: No black-white differences in mortality risk were observed for women with triple negative (ER-negative [ER-], PR-, and HER2-) subtype. However, older (50-64 years) black women had greater overall mortality risk than older white women if they had been diagnosed with luminal A (ER-positive [ER+] or PR+ plus HER2-) breast cancer (all-cause hazard ratio, HR, 1.88; 95% confidence interval, CI, 1.18 to 2.99; breast cancer-specific HR, 1.51; 95% CI, 0.83 to 2.74). This black-white difference among older women was further confined to those with luminal A/p53-tumors (all-cause HR, 2.22; 95% CI, 1.30 to 3.79; breast cancer-specific HR, 1.89; 95% CI, 0.93 to 3.86). Tests for homogeneity of race-specific HRs comparing luminal A to triple negative subtype and luminal A/p53- to luminal A/p53+ subtype did not achieve statistical significance, although statistical power was limited. Conclusions: Our findings suggest that the subtype-specific black-white difference in mortality risk occurs mainly among older women diagnosed with luminal A/p53-breast cancer, which is most likely treatable. These results further suggest that factors other than subtype may be relatively more important in explaining the increased mortality risk seen in older black women. C1 [Ma, Huiyan; Lu, Yani; Sullivan-Halley, Jane; Bernstein, Leslie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Div Canc Etiol, Duarte, CA 91010 USA. [Malone, Kathleen E.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. [Marchbanks, Polly A.; McDonald, Jill A.; Folger, Suzanne G.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. [Deapen, Dennis M.] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90033 USA. [Press, Michael F.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Spirtas, Robert] Natl Inst Child Hlth & Dev, Formerly Contracept & Reprod Hlth Branch, Populat Res Ctr, Bethesda, MD 20892 USA. [Burkman, Ronald T.] Baystate Med Ctr, Dept Obstet & Gynecol, Springfield, MA 01199 USA. [Strom, Brian L.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Simon, Michael S.] Wayne State Univ, Dept Oncol, Karmanos Canc Inst, Detroit, MI 48201 USA. RP Ma, HY (reprint author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Div Canc Etiol, Duarte, CA 91010 USA. EM hma@coh.org FU National Institute for Child Health and Human Development [NO1-HD-3-3175]; National Cancer Institute [K05-CA136967]; National Cancer Institute, NIH; Emory University [N01-HD-3-3168]; Fred Hutchinson Cancer Research Center [N01-HD-2-3166]; Karmanos Cancer Institute at Wayne State University [N01-HD-3-3174]; University of Pennsylvania [NO1-HD-3-3276]; University of Southern California [N01-HD-3-3175]; Interagency Agreement with Centers for Disease Control and Prevention [Y01-HD-7022]; California Department of Health Services; Breast Cancer Research Foundation; [N01-CN-65064]; [N01-PC-67010] FX This work was supported by National Institute for Child Health and Human Development grant NO1-HD-3-3175 and National Cancer Institute grant K05-CA136967. Data collection for the Women's CARE Study was supported by the National Institute of Child Health and Human Development and National Cancer Institute, NIH, through contracts with Emory University (N01-HD-3-3168), Fred Hutchinson Cancer Research Center (N01-HD-2-3166), Karmanos Cancer Institute at Wayne State University (N01-HD-3-3174), University of Pennsylvania (NO1-HD-3-3276), and University of Southern California (N01-HD-3-3175) and Interagency Agreement with Centers for Disease Control and Prevention (Y01-HD-7022). Collection of cancer incidence data in LA County by University of Southern California was supported by California Department of Health Services as part of statewide cancer reporting program mandated by California Health and Safety Code, Section 103885. Support for use of SEER cancer registries through contracts N01-CN-65064 (Detroit) and N01-PC-67010 (LA). Biomarker determination and analyses were supported by a contract from the National Institute of Child Health and Human Development (NO1-HD-3-3175) and a grant from the Breast Cancer Research Foundation (MFPress). NR 59 TC 12 Z9 12 U1 0 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2407 J9 BMC CANCER JI BMC Cancer PD MAY 4 PY 2013 VL 13 AR 225 DI 10.1186/1471-2407-13-225 PG 11 WC Oncology SC Oncology GA 140TQ UT WOS:000318678600001 PM 23642215 ER PT J AU Harris, CD Watson, KB Carlson, SA Fulton, JE Dorn, JM Elam-Evans, L AF Harris, Carmen D. Watson, Kathleen B. Carlson, Susan A. Fulton, Janet E. Dorn, Joan M. Elam-Evans, Laurie TI Adult Participation in Aerobic and Muscle-Strengthening Physical Activities - United States, 2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID FACTOR SURVEILLANCE SYSTEM; PREVALENCE C1 CDC, Publ Hlth Surveillance & Informat Program Off, Off Surveillance, Epidemiol & Lab Serv, Atlanta, GA 30333 USA. EM charris2@cdc.gov NR 10 TC 69 Z9 69 U1 1 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 3 PY 2013 VL 62 IS 17 BP 326 EP 330 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FU UT WOS:000322178800002 ER PT J AU Hootman, JM Barbour, KE Watson, KB Fulton, JE AF Hootman, Jennifer M. Barbour, Kamil E. Watson, Kathleen B. Fulton, Janet E. TI State-Specific Prevalence of Walking Among Adults with Arthritis - United States, 2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PHYSICAL-ACTIVITY; PREFERENCES C1 [Hootman, Jennifer M.; Barbour, Kamil E.] CDC, Div Populat Hlth, Atlanta, GA 30333 USA. [Watson, Kathleen B.; Fulton, Janet E.] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Hootman, JM (reprint author), CDC, Div Populat Hlth, Atlanta, GA 30333 USA. EM jhootman@cdc.gov NR 9 TC 4 Z9 4 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 3 PY 2013 VL 62 IS 17 BP 331 EP 334 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FU UT WOS:000322178800003 ER PT J AU Lowther, SA AF Lowther, Sara A. TI Progress Toward Eradication of Polio - Worldwide, January 2011-March 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID POLIOMYELITIS ERADICATION C1 [Lowther, Sara A.] World Hlth Org, Polio Eradicat Dept, Geneva, Switzerland. CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Global Immunizat Div,Ctr Global Hlth, Atlanta, GA 30333 USA. RP Lowther, SA (reprint author), World Hlth Org, Polio Eradicat Dept, Geneva, Switzerland. EM slowther@cdc.gov NR 10 TC 18 Z9 18 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 3 PY 2013 VL 62 IS 17 BP 335 EP 338 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FU UT WOS:000322178800004 ER PT J AU Sullivan, EM Annest, JL Luo, F Simon, TR Dahlberg, LL AF Sullivan, Erin M. Annest, Joseph L. Luo, Feijun Simon, Thomas R. Dahlberg, Linda L. TI Suicide Among Adults Aged 35-64 Years - United States, 1999-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID US; RATES; INCREASE C1 [Sullivan, Erin M.; Annest, Joseph L.; Luo, Feijun] CDC, Div Anal Res & Practice Integrat, Atlanta, GA 30333 USA. [Simon, Thomas R.; Dahlberg, Linda L.] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Annest, JL (reprint author), CDC, Div Anal Res & Practice Integrat, Atlanta, GA 30333 USA. EM lannest@cdc.gov NR 10 TC 0 Z9 0 U1 1 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 3 PY 2013 VL 62 IS 17 BP CP1 EP 325 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FU UT WOS:000322178800001 ER PT J AU Nichols, EK Talley, LE Birungi, N McClelland, A Madraa, E Chandia, AB Nivet, J Flores-Ayala, R Serdula, MK AF Nichols, Erin K. Talley, Leisel E. Birungi, Nelly McClelland, Amanda Madraa, Elizabeth Chandia, Agnes B. Nivet, Jacqueline Flores-Ayala, Rafael Serdula, Mary K. TI Suspected Outbreak of Riboflavin Deficiency among Populations Reliant on Food Assistance: A Case Study of Drought-Stricken Karamoja, Uganda, 2009-2010 SO PLOS ONE LA English DT Article ID MICRONUTRIENT DEFICIENCIES; IRON AB Background: In 2009, a humanitarian response was launched to address a food security and livelihoods crisis in Karamoja, Uganda. During a polio immunization campaign in mid-August 2009, health workers in Nakapiripit District reported a concern about an increase in mouth sores, or angular stomatitis (AS) and gum ulcerations, among children in one village, and an investigation was launched. Objective: This article describes the investigation, lessons learned, and provides guidance for monitoring micronutrient deficiencies among populations receiving food assistance. Design: An investigation into a suspected outbreak of riboflavin (vitamin B2) deficiency was initiated, including a rapid assessment, mass screening, a convenience sample collection of blood specimens (n = 58 symptomatic cases and n = 18 asymptomatic individuals), and analysis of the general food ration (70% ration). Results: Findings showed signs of AS in only 399 (0.2%) of 179,172 screened individuals, including adults and children. Biochemical analysis confirmed riboflavin deficiency in 84.5% of specimens from symptomatic individuals and 94.4% of specimens from asymptomatic individuals. Ration distribution data showed that 55% of distributions provided less than half the riboflavin RDA. Conclusion: Evidence was insufficient to confirm an actual outbreak of riboflavin deficiency, though the present investigation adds further documentation that micronutrient deficiencies continue to persist among populations in emergency settings. This article describes challenges, lessons learned, and guidance for monitoring micronutrient deficiencies among food assistance recipients, including: ongoing nutrition monitoring and surveillance; training and sensitization about micronutrient deficiencies, sensitization of the population about locally-available food, and identifying ways to improve micronutrient interventions. C1 [Nichols, Erin K.] US PHS, Epidem Intelligence Serv Assigned, Div Nutr Phys Act & Obes, Ctr Dis Control & Prevent,Commissioned Corps, Atlanta, GA USA. [Talley, Leisel E.] Ctr Dis Control & Prevent, Int Emergency & Refugee Hlth, Atlanta, GA USA. [Birungi, Nelly] UNICEF Uganda Country Off, Kampala, Uganda. [McClelland, Amanda] Concern Worldwide Emergency Response Team, Kampala, Uganda. [Madraa, Elizabeth; Chandia, Agnes B.] Minist Hlth Uganda, Nutr Unit, Kampala, Uganda. [Nivet, Jacqueline] United Nations World Food Programme, Off Country Director, Kampala, Uganda. [Flores-Ayala, Rafael; Serdula, Mary K.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Int Micronutrient Malnutr Prevent & Control Tea, Atlanta, GA USA. RP Nichols, EK (reprint author), US PHS, Epidem Intelligence Serv Assigned, Div Nutr Phys Act & Obes, Ctr Dis Control & Prevent,Commissioned Corps, Atlanta, GA USA. EM EKNichols@cdc.gov FU Concern Worldwide, UNICEF; U.S. Centers for Disease Control and Prevention (CDC); World Food Programme (WFP); World Health Organization (WHO) FX Funding and technical assistance for this investigation were provided by Concern Worldwide, UNICEF, the U.S. Centers for Disease Control and Prevention (CDC), World Food Programme (WFP), and World Health Organization (WHO). The funders had a role in design, data collection, data review, data analysis, and biological testing. NR 14 TC 4 Z9 4 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 2 PY 2013 VL 8 IS 5 AR e62976 DI 10.1371/journal.pone.0062976 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 175AF UT WOS:000321200500047 PM 23658790 ER PT J AU Owusu-Edusei, K Chesson, HW Leichliter, JS Kent, CK Aral, SO AF Owusu-Edusei, Kwame, Jr. Chesson, Harrell W. Leichliter, Jami S. Kent, Charlotte K. Aral, Sevgi O. TI The Association Between Racial Disparity in Income and Reported Sexually Transmitted Infections SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID UNITED-STATES; RATES; SYPHILIS; GONORRHEA; EPIDEMIOLOGY; DISEASE; RACE; HIV AB Objectives. We examined the association between racial disparity in income and reported race-specific county-level bacterial sexually transmitted infections (STIs) in the United States focusing on disparities between Blacks and Whites. Methods. Data are from the US 2000 decennial census. We defined 2 race-income county groups (high and low race-income disparity) on the basis of the difference between Black and White median household incomes. We used 2 approaches to examine disparities in STI rates across the groups. In the first approach, we computed and compared race-specific STI rates for the groups. In the second approach, we used spatial regression analyses to control for potential confounders. Results. Consistent with the STI literature, chlamydia, gonorrhea, and syphilis rates for Blacks were substantially higher than were those for Whites. We also found that racial disparities in income were associated with racial disparities in chlamydia and gonorrhea rates and, to a lesser degree, syphilis rates. Conclusions. Racial disparities in household income may be a more important determinant of racial disparities in reported STI morbidity than are absolute levels of household income. C1 [Owusu-Edusei, Kwame, Jr.; Chesson, Harrell W.; Leichliter, Jami S.; Kent, Charlotte K.; Aral, Sevgi O.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. RP Owusu-Edusei, K (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd MS E-80, Atlanta, GA 30333 USA. EM Kowusuedusei@cdc.gov NR 29 TC 6 Z9 6 U1 0 U2 9 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAY PY 2013 VL 103 IS 5 BP 910 EP 916 DI 10.2105/AJPH.2012.301015 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA2UJ UT WOS:000330949300039 PM 23488482 ER PT J AU Lee, LM Wright, B Semaan, S AF Lee, Lisa M. Wright, Brandy Semaan, Salaam TI Expected Ethical Competencies of Public Health Professionals and Graduate Curricula in Accredited Schools of Public Health in North America SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article AB Objectives. We assessed expected ethics competencies of public health professionals in codes and competencies, reviewed ethics instruction at schools of public health, and recommended ways to bridge the gap between them. Methods. We reviewed the code of ethics and 3 sets of competencies, separating ethics-related competencies into 3 domains: professional, research, and public health. We reviewed ethics course requirements in 2010-2011 on the Internet sites of 46 graduate schools of public health and categorized courses as required, not required, or undetermined. Results. Half of schools (n = 23) required an ethics course for graduation (master's or doctoral level), 21 did not, and 2 had no information. Sixteen of 23 required courses were 3-credit courses. Course content varied from 1 ethics topic to many topics addressing multiple ethics domains. Conclusions. Consistent ethics education and competency evaluation can be accomplished through a combination of a required course addressing the 3 domains, integration of ethics topics in other courses, and "booster" trainings. Enhancing ethics competence of public health professionals is important to address the ethical questions that arise in public health research, surveillance, practice, and policy. C1 [Lee, Lisa M.; Wright, Brandy] Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. [Semaan, Salaam] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. RP Lee, LM (reprint author), Presidential Commiss Study Bioeth Issues, 1425 New York Ave NW,C-100, Washington, DC 20005 USA. EM Lisa.Lee@bioethics.gov NR 24 TC 8 Z9 8 U1 2 U2 6 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAY PY 2013 VL 103 IS 5 BP 938 EP 942 DI 10.2105/AJPH.2012.300680 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA2UJ UT WOS:000330949300043 PM 22994177 ER PT J AU Brown, DR Carroll, DD Carlson, SA Workman, LM Brown, DW AF Brown, David R. Carroll, Dianna D. Carlson, Susan A. Workman, Lauren M. Brown, David W. TI Physical Activity And Quality Of Life Among Us Adults With Limitations, BRFSS 2009 SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract CT 60th Annual Meeting of the American-College-of-Sports-Medicine CY MAY 28-JUN 01, 2013 CL Indianapolis, IN SP Amer Coll Sports Med C1 [Brown, David R.; Carroll, Dianna D.; Carlson, Susan A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Workman, Lauren M.] Univ S Carolina, Columbia, SC 29208 USA. [Brown, David W.] Brown Consulting Grp, Charlotte, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 EI 1530-0315 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2013 VL 45 IS 5 SU 1 MA 1151 BP 258 EP 258 PG 1 WC Sport Sciences SC Sport Sciences GA 300ND UT WOS:000330469702101 ER PT J AU Harris, CD AF Harris, Carmen D. TI Access To Parks Among School-age Youth Living In Rural And Urban Areas SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract CT 60th Annual Meeting of the American-College-of-Sports-Medicine CY MAY 28-JUN 01, 2013 CL Indianapolis, IN SP Amer Coll Sports Med C1 [Harris, Carmen D.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 EI 1530-0315 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2013 VL 45 IS 5 SU 1 MA 1184 BP 268 EP 268 PG 1 WC Sport Sciences SC Sport Sciences GA 300ND UT WOS:000330469702134 ER PT J AU Watson, KB Carlson, S Carroll, D Fulton, J AF Watson, Kathleen B. Carlson, Susan Carroll, Dianna Fulton, Janet TI Comparison of Accelerometer Cut Points to Estimate Physical Activity in US Adults SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract CT 60th Annual Meeting of the American-College-of-Sports-Medicine CY MAY 28-JUN 01, 2013 CL Indianapolis, IN SP Amer Coll Sports Med C1 [Watson, Kathleen B.; Carlson, Susan; Carroll, Dianna; Fulton, Janet] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 EI 1530-0315 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2013 VL 45 IS 5 SU 1 MA 1383 BP 313 EP 313 PG 1 WC Sport Sciences SC Sport Sciences GA 300ND UT WOS:000330469702286 ER PT J AU de Quevedo, IG Duperly, J Lobelo, F AF de Quevedo, Isabel Garcia Duperly, John Lobelo, Felipe TI Physical Activity Habits and Related Counseling Practices Among Health Care Providers: A Literature Review SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract CT 60th Annual Meeting of the American-College-of-Sports-Medicine CY MAY 28-JUN 01, 2013 CL Indianapolis, IN SP Amer Coll Sports Med C1 [de Quevedo, Isabel Garcia; Lobelo, Felipe] Ctr Dis Control & Prevent, Atlanta, GA USA. [Duperly, John] Univ Los Andes, Bogota, Colombia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 EI 1530-0315 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2013 VL 45 IS 5 SU 1 MA 1482 BP 342 EP 342 PG 1 WC Sport Sciences SC Sport Sciences GA 300ND UT WOS:000330469702376 ER PT J AU Powell, JB Kim, JH Coca, A Roberge, R AF Powell, Jeffrey B. Kim, Jung-Hyun Coca, Aitor Roberge, Raymond TI Effects Of Different Ambient Conditions On Thermo-physiological Responses To Wearing CBRN Ensemble SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract CT 60th Annual Meeting of the American-College-of-Sports-Medicine CY MAY 28-JUN 01, 2013 CL Indianapolis, IN SP Amer Coll Sports Med C1 [Powell, Jeffrey B.; Kim, Jung-Hyun; Coca, Aitor; Roberge, Raymond] NIOSH, CDC, NPPTL, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 EI 1530-0315 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2013 VL 45 IS 5 SU 1 MA 1497 BP 347 EP 347 PG 1 WC Sport Sciences SC Sport Sciences GA 300ND UT WOS:000330469702391 ER PT J AU Wilcox, S McClenaghan, B Sharpe, PA Leith, K Hootman, JM Baruth, M Wingard, E Ortaglia, A AF Wilcox, Sara McClenaghan, Bruce Sharpe, Patricia A. Leith, Katherine Hootman, Jennifer M. Baruth, Meghan Wingard, Ellen Ortaglia, Andrew TI Effects Of A Self-Directed, Multicomponent Exercise Program For Adults With Arthritis SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract CT 60th Annual Meeting of the American-College-of-Sports-Medicine CY MAY 28-JUN 01, 2013 CL Indianapolis, IN SP Amer Coll Sports Med C1 [Wilcox, Sara; McClenaghan, Bruce; Sharpe, Patricia A.; Leith, Katherine; Baruth, Meghan; Wingard, Ellen; Ortaglia, Andrew] Univ S Carolina, Columbia, SC 29208 USA. [Hootman, Jennifer M.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 EI 1530-0315 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2013 VL 45 IS 5 SU 1 MA 1590 BP 373 EP 374 PG 2 WC Sport Sciences SC Sport Sciences GA 300ND UT WOS:000330469703066 ER PT J AU Song, M Carroll, DD Lee, SM Fulton, JE AF Song, MinKyoung Carroll, Dianna D. Lee, Sarah M. Fulton, Janet E. TI Variety Of Physical Activity And Meeting The 2008 Guidelines Among US Youth SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract CT 60th Annual Meeting of the American-College-of-Sports-Medicine CY MAY 28-JUN 01, 2013 CL Indianapolis, IN SP Amer Coll Sports Med C1 [Song, MinKyoung] Univ Michigan, Ann Arbor, MI 48109 USA. [Carroll, Dianna D.; Lee, Sarah M.; Fulton, Janet E.] US Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 EI 1530-0315 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2013 VL 45 IS 5 SU 1 MA 1645 BP 389 EP 389 PG 1 WC Sport Sciences SC Sport Sciences GA 300ND UT WOS:000330469703121 ER PT J AU Carroll, DD Carlson, SA Eaton, DK Brown, DR AF Carroll, Dianna D. Carlson, Susan A. Eaton, Danice K. Brown, David R. TI Disability And Physical Activity In Older Adults, Brfss, 2009 SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract CT 60th Annual Meeting of the American-College-of-Sports-Medicine CY MAY 28-JUN 01, 2013 CL Indianapolis, IN SP Amer Coll Sports Med C1 [Carroll, Dianna D.; Carlson, Susan A.; Eaton, Danice K.; Brown, David R.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 EI 1530-0315 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2013 VL 45 IS 5 SU 1 MA 1651 BP 391 EP 391 PG 1 WC Sport Sciences SC Sport Sciences GA 300ND UT WOS:000330469703127 ER PT J AU Paul, P Carlson, SA Carroll, DD Fulton, JE AF Paul, Prabasaj Carlson, Susan A. Carroll, Dianna D. Fulton, Janet E. TI Changes in Walking for Transportation Among US Adults 2005-2010, National Health Interview Survey SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract CT 60th Annual Meeting of the American-College-of-Sports-Medicine CY MAY 28-JUN 01, 2013 CL Indianapolis, IN SP Amer Coll Sports Med C1 [Paul, Prabasaj; Carlson, Susan A.; Carroll, Dianna D.; Fulton, Janet E.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 EI 1530-0315 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2013 VL 45 IS 5 SU 1 MA 1655 BP 392 EP 392 PG 1 WC Sport Sciences SC Sport Sciences GA 300ND UT WOS:000330469703131 ER PT J AU Alsultan, A Dooley, KE Weiner, M Whitworth, W Mac Kenzie, WR Peloquin, CA AF Alsultan, Abdullah Dooley, Kelly E. Weiner, Marc Whitworth, William Mac Kenzie, William R. Peloquin, Charles A. CA TB Trials Consortium TI Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis SO JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS LA English DT Meeting Abstract C1 [Alsultan, Abdullah; Peloquin, Charles A.] Univ Florida, Gainesville, FL USA. [Dooley, Kelly E.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Weiner, Marc] San Antonio VA Med Ctr, San Antonio, TX USA. [Whitworth, William; Mac Kenzie, William R.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 2 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1567-567X EI 1573-8744 J9 J PHARMACOKINET PHAR JI J. Pharmacokinet. Pharmacodyn. PD MAY PY 2013 VL 40 SU 1 BP S46 EP S47 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 295OS UT WOS:000330126000043 ER PT J AU Gonzalez, D Mase, S Jereb, J Martin, F Daley, C Fred, D Briand, K Loeffler, A Chorba, T Peloquin, C AF Gonzalez, Daniel Mase, Sundari Jereb, John Martin, Fatma Daley, Charles Fred, Dorina Briand, Kennar Loeffler, Ann Chorba, Terence Peloquin, Charles TI Population Pharmacokinetics of Levofloxacin in Children Treated for, or Exposed to, Multidrug Resistant Tuberculosis in the Federated States of Micronesia and Republic of Marshall Islands SO JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS LA English DT Meeting Abstract ID PULMONARY TUBERCULOSIS; MOXIFLOXACIN; GATIFLOXACIN C1 [Gonzalez, Daniel; Peloquin, Charles] Univ Florida, Gainesville, FL USA. [Gonzalez, Daniel] Univ N Carolina, Chapel Hill, NC USA. [Gonzalez, Daniel] Duke Clin Res Inst, Durham, NC USA. [Mase, Sundari; Jereb, John; Chorba, Terence] Ctr Dis Control & Prevent, Atlanta, GA USA. [Martin, Fatma] North Bay Pediat, Vallejo, CA USA. [Daley, Charles] Natl Jewish Hlth, Denver, CO USA. [Fred, Dorina] TB Leprosy Program, Chuuk, Micronesia. [Briand, Kennar] TB Leprosy Program, Ebeye, Marshall Island. [Loeffler, Ann] Francis J Curry Natl TB Ctr, San Francisco, CA USA. NR 7 TC 1 Z9 1 U1 4 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1567-567X EI 1573-8744 J9 J PHARMACOKINET PHAR JI J. Pharmacokinet. Pharmacodyn. PD MAY PY 2013 VL 40 SU 1 BP S47 EP S48 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 295OS UT WOS:000330126000044 ER PT J AU Pan, Y Rose, CE Haber, M Ma, Y Carrasco, JL Stewart, B Keitel, WA Keyserling, H Jacobson, RM Poland, G McNeil, MM AF Pan, Yi Rose, Charles E. Haber, Michael Ma, Yan Carrasco, Josep L. Stewart, Brock Keitel, Wendy A. Keyserling, Harry Jacobson, Robert M. Poland, Gregory McNeil, Michael M. TI Assessing Agreement of Repeated Binary Measurements with an Application to the CDC's Anthrax Vaccine Clinical Trial SO INTERNATIONAL JOURNAL OF BIOSTATISTICS LA English DT Article DE agreement; binary; kappa; longitudinal; adverse event; anthrax vaccine ID CONCORDANCE CORRELATION-COEFFICIENT; INTRACLASS CORRELATION-COEFFICIENTS; CATEGORICAL-DATA; RELIABILITY; INTERRATER AB Cohen's kappa coefficient, which was introduced in 1960, serves as the most widely employed coefficient to assess inter-observer agreement for categorical outcomes. However, the original kappa can only be applied to cross-sectional binary measurements and, therefore, cannot be applied in the practical situation when the observers evaluate the same subjects at repeated time intervals. This study summarizes six methods of assessing agreement of repeated binary outcomes under different assumptions and discusses under which condition we should use the most appropriate method in practice. These approaches are illustrated using data from the CDC anthrax vaccine adsorbed (AVA) human clinical trial comparing the agreement for two solicited adverse events after AVA between the 1-3 day in-clinic medical record and the patient's diary on the same day. We hope this article can inspire researchers to choose the most appropriate method to assess agreement for their own study with longitudinal binary data. C1 [Pan, Yi; Stewart, Brock; McNeil, Michael M.] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [McNeil, Michael M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Pan, Yi] Logist Hlth Inc, La Crosse, WI USA. [Rose, Charles E.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Haber, Michael] Emory Univ, Dept Biostat & Bioinformat, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Ma, Yan] Cornell Univ, Dept Publ Hlth, Hosp Special Surg, Weill Med Coll, New York, NY 10021 USA. [Carrasco, Josep L.] Univ Barcelona, Barcelona, Spain. [Keitel, Wendy A.] Baylor Coll Med, Houston, TX 77030 USA. [Keyserling, Harry] Emory Univ, Sch Med, Atlanta, GA USA. [Jacobson, Robert M.] Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN USA. [Poland, Gregory] Mayo Clin, Rochester, MN USA. RP McNeil, MM (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM jun5@cdc.gov; cvr7@cdc.gov; mhaber@emory.edu; yam2007@med.cornell.edu; jlcarrasco@ub.edu; jnn6@cdc.gov; wkeitel@bcm.edu; hkeyser@emory.edu; jacobson.robert@mayo.edu; poland.gregory@mayo.edu; mmm2@cdc.gov RI Carrasco, Josep/D-3660-2011; OI Carrasco, Josep/0000-0003-1184-0753; Jacobson, Robert/0000-0002-6355-8752 NR 27 TC 0 Z9 0 U1 0 U2 4 PU WALTER DE GRUYTER GMBH PI BERLIN PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY SN 2194-573X EI 1557-4679 J9 INT J BIOSTAT JI Int. J. Biostat. PD MAY PY 2013 VL 9 IS 1 BP 19 EP 32 DI 10.1515/ijb-2012-0001 PG 14 WC Mathematical & Computational Biology; Statistics & Probability SC Mathematical & Computational Biology; Mathematics GA 285ZG UT WOS:000329433300002 ER PT J AU Al-Samarrai, T Madsen, A Zimmerman, R Maduro, G Li, WH Greene, C Begier, E AF Al-Samarrai, Teeb Madsen, Ann Zimmerman, Regina Maduro, Gil Li, Wenhui Greene, Carolyn Begier, Elizabeth TI Impact of a Hospital-Level Intervention to Reduce Heart Disease Overreporting on Leading Causes of Death SO PREVENTING CHRONIC DISEASE LA English DT Article ID NEW-YORK-CITY; CERTIFICATE COMPLETION; RISK-FACTORS; MORTALITY; ACCURACY AB Introduction The quality of cause-of-death reporting on death certificates affects the usefulness of vital statistics for public health action. Heart disease deaths are overreported in the United States. We evaluated the impact of an intervention to reduce heart disease overreporting on other leading causes of death. Methods A multicomponent intervention comprising training and communication with hospital staff was implemented during July through December 2009 at 8 New York City hospitals reporting excessive heart disease deaths. We compared crude, age-adjusted, and race/ethnicity-adjusted proportions of leading, underlying causes of death reported during death certification by intervention and nonintervention hospitals during preintervention (January-June 2009) and postintervention (January-June 2010) periods. We also examined trends in leading causes of death for 2000 through 2010. Results At intervention hospitals, heart disease deaths declined by 54% postintervention; other leading causes of death (ie, malignant neoplasms, influenza and pneumonia, cerebrovascular disease, and chronic lower respiratory diseases) increased by 48% to 232%. Leading causes of death at nonintervention hospitals changed by 6% or less. In the preintervention period, differences in leading causes of death between intervention and nonintervention hospitals persisted after controlling for race/ethnicity and age; in the postintervention period, age accounted for most differences observed between intervention and nonintervention hospitals. Postintervention, malignant neoplasms became the leading cause of premature death (ie, deaths among patients aged 35-74 y) at intervention hospitals. Conclusion A hospital-level intervention to reduce heart disease overreporting led to substantial changes to other leading causes of death, changing the leading cause of premature death. Heart disease overreporting is likely obscuring the true levels of cause-specific mortality. The Government are very keen on amassing statistics. They collect them, add them, raise them to the nth power, take the cube root and prepare wonderful diagrams. But what you must never forget is that every one of those figures comes in the first instance from the chowky dar (village watchman) who just puts down what he damn pleases. Stamp (1) C1 [Al-Samarrai, Teeb] Santa Clara Cty Dept Publ Hlth, San Jose, CA 95126 USA. [Al-Samarrai, Teeb] Ctr Dis Control & Prevent, Atlanta, GA USA. [Al-Samarrai, Teeb] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Madsen, Ann; Zimmerman, Regina; Maduro, Gil; Li, Wenhui; Begier, Elizabeth] New York City Dept Hlth & Mental Hyg, Bur Vital Stat, New York, NY USA. [Greene, Carolyn] New York City Dept Hlth & Mental Hyg, Div Epidemiol, New York, NY USA. RP Al-Samarrai, T (reprint author), Santa Clara Cty Dept Publ Hlth, 976 Lenzen St,Ste 1700, San Jose, CA 95126 USA. EM teeb.al-samarrai@phd.sccgov.org NR 33 TC 5 Z9 5 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD MAY PY 2013 VL 10 AR UNSP 120210 DI 10.5888/pcd10.120210 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285JX UT WOS:000329391200011 ER PT J AU King, BA Dube, SR Homa, DM AF King, Brian A. Dube, Shanta R. Homa, David M. TI Smoke-Free Rules and Secondhand Smoke Exposure in Homes and Vehicles Among US Adults, 2009-2010 SO PREVENTING CHRONIC DISEASE LA English DT Article ID CURRENT CIGARETTE-SMOKING; 4 COUNTRY SURVEY; UNITED-STATES; NONSMOKERS; IMPLEMENTATION; LEGISLATION; SUPPORT; LAWS AB Introduction An increasing number of US states and localities have implemented comprehensive policies prohibiting tobacco smoking in all indoor areas of public places and worksites. However, private settings such as homes and vehicles remain a major source of exposure to secondhand smoke (SHS) for many people. This study assessed the prevalence and correlates of voluntary smoke-free rules and SHS exposure in homes and vehicles among US adults. Methods We obtained data from the 2009-2010 National Adult Tobacco Survey, a landline and cellular-telephone survey of adults aged 18 years or older residing in the 50 US states or the District of Columbia. We calculated national and state estimates of smoke-free rules and past-7-day SHS exposure in homes and vehicles and examined national estimates by sex, age, race/ethnicity, and education. Results The national prevalence of voluntary smoke-free home rules was 81.1% (state range, 67.9%-92.9%), and the prevalence of household smoke-free vehicle rules was 73.6% (state range, 58.6%-85.8%). Among nonsmokers, the prevalence of SHS exposure was 6.0% in homes (state range, 2.4%-13.0%) and 9.2% in vehicles (state range, 4.8%-13.7%). SHS exposure among nonsmokers was greatest among men, younger adults, non-Hispanic blacks, and those with a lower level of education. Conclusion Most US adults report having voluntary smoke-free home and vehicle rules; however, millions of people remain exposed to SHS in these environments. Disparities in exposure also exist among certain states and subpopulations. Efforts are needed to warn about the dangers of SHS and to promote voluntary smoke-free home and vehicle rules. C1 [King, Brian A.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Dube, Shanta R.; Homa, David M.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP King, BA (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop K-50, Atlanta, GA 30341 USA. EM baking@cdc.gov NR 30 TC 19 Z9 19 U1 2 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD MAY PY 2013 VL 10 AR UNSP 120218 DI 10.5888/pcd10.120218 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285JX UT WOS:000329391200013 ER PT J AU Leadbetter, S Hawkins, NA Scholl, LE McCarty, FA Rodriguez, JL Freedner-Maguire, N Alford, SH Bellcross, CA Peipins, LA AF Leadbetter, Steven Hawkins, Nikki A. Scholl, Lawrence E. McCarty, Frances A. Rodriguez, Juan L. Freedner-Maguire, Naomi Alford, Sharon Hensley Bellcross, Cecelia A. Peipins, Lucy A. TI Recruiting Women for a Study on Perceived Risk of Cancer: Influence of Survey Topic Salience and Early Versus Late Response SO PREVENTING CHRONIC DISEASE LA English DT Article ID NONRESPONSE BIAS; FAMILY-HISTORY; HEALTH; PARTICIPATION; POPULATION AB Introduction Understanding the characteristics of early and late survey responders has implications for recruitment efforts and for informing potential response bias. The main objective of this analysis was to examine survey responder status (ie, early vs late response) by sociodemographic characteristics and by salience of study variables among respondents. Methods We analyzed data from a survey on family cancer history and perceived cancer risk among women at a large managed health-care organization. For baseline and 12-month follow-up surveys, we defined early versus late responder status according to the 95th percentile of the number of days it took to obtain completed interviews. Results We found no significant associations between responder status and sociodemographic characteristics at baseline or follow-up. At baseline, early responders were significantly more likely than late responders to have a personal history of breast cancer (5.2% vs 3.4%, P = .04) and to have been referred for genetic counseling (4.6% vs 2.0%, P = .004). The association between personal history of breast cancer and responder status persisted at follow-up; only 3.5% of late responders at baseline were also late responders at follow-up. Follow-up survey nonresponse rates did not vary by baseline responder status. Conclusion Survey topic salience is associated with early response and is important for recruitment. However, once recruited, late responders do not remain late responders at follow-up, suggesting that extra efforts made to recruit late responders are worthwhile. Health-related agencies that conduct surveys should consider survey salience in survey administration and recruitment strategies. C1 [Leadbetter, Steven] Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Hawkins, Nikki A.; Rodriguez, Juan L.; Peipins, Lucy A.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Scholl, Lawrence E.; Freedner-Maguire, Naomi] ICF Int, Fairfax, VA USA. [McCarty, Frances A.; Bellcross, Cecelia A.] Emory Univ, Atlanta, GA 30322 USA. [Alford, Sharon Hensley] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA. RP Leadbetter, S (reprint author), Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, 4770 Buford Hwy NE,Mailstop K-55, Atlanta, GA 30341 USA. EM sleadbetter@cdc.gov FU CDC [200-2002-00574, 0015] FX We thank the women from the HFHS who responded to our detailed questionnaires. We also thank Nicola Dawkins, Robert Pels, Ye Xu, and Susan Zaro (ICF International) for project development assistance and oversight. We gratefully acknowledge Judith Lee Smith and Mary C. White at CDC for their careful review of the manuscript. Funding support was provided by CDC (contract no. 200-2002-00574, task order 0015). NR 22 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD MAY PY 2013 VL 10 AR UNSP 120293 DI 10.5888/pcd10.120293 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285JX UT WOS:000329391200009 ER PT J AU Zhang, XY Onufrak, S Holt, JB Croft, JB AF Zhang, Xingyou Onufrak, Stephen Holt, James B. Croft, Janet B. TI A Multilevel Approach to Estimating Small Area Childhood Obesity Prevalence at the Census Block-Group Level SO PREVENTING CHRONIC DISEASE LA English DT Article ID UNITED-STATES; PRIORITIZING COMMUNITIES; OVERWEIGHT PREVALENCE; HEALTH; MODEL; US; MASSACHUSETTS; STRATEGIES; CHILDREN; DISEASE AB Introduction Traditional survey methods for obtaining nationwide small-area estimates (SAEs) of childhood obesity are costly. This study applied a geocoded national health survey in a multilevel modeling framework to estimate prevalence of childhood obesity at the census block-group level. Methods We constructed a multilevel logistic regression model to evaluate the influence of individual demographic characteristics, zip code, county, and state on the childhood obesity measures from the 2007 National Survey of Children's Health. The obesity risk for a child in each census block group was then estimated on the basis of this multilevel model. We compared direct survey and model-based SAEs to evaluate the model specification. Results Multilevel models in this study explained about 60% of state-level variances associated with childhood obesity, 82.8% to 86.5% of county-level, and 93.1% of zip code-level. The 95% confidence intervals of block-group level SAEs have a wide range (0.795-20.0), a low median of 2.02, and a mean of 2.12. The model-based SAEs of childhood obesity prevalence ranged from 2.3% to 54.7% with a median of 16.0% at the block-group level. Conclusion The geographic variances among census block groups, counties, and states demonstrate that locale may be as significant as individual characteristics such as race/ethnicity in the development of the childhood obesity epidemic. Our estimates provide data to identify priority areas for local health programs and to establish feasible local intervention goals. Model-based SAEs of population health outcomes could be a tool of public health assessment and surveillance. C1 [Zhang, Xingyou; Onufrak, Stephen; Holt, James B.; Croft, Janet B.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Zhang, XY (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,NE,MS K67, Atlanta, GA 30341 USA. EM gyx8@cdc.gov NR 29 TC 4 Z9 4 U1 0 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD MAY PY 2013 VL 10 AR UNSP 120252 DI 10.5888/pcd10.120252 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285JX UT WOS:000329391200002 ER PT J AU Turabelidze, G Gee, JE Hoffmaster, AR Manian, F Butler, C Byrd, D Schildknecht, S Hauser, LC Duncan, M Ferrett, R Evans, D Talley, C AF Turabelidze, George Gee, Jay E. Hoffmaster, Alex R. Manian, Farrin Butler, Cindy Byrd, David Schildknecht, Stephanie Hauser, Lina Chavez Duncan, Mary Ferrett, Rhonda Evans, Dana Talley, Crystal TI Contaminated Ventilator Air Flow Sensor Linked to Bacillus cereus Colonization of Newborns SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INTENSIVE-CARE-UNIT; INFECTIONS; OUTBREAK; DISSEMINATION; ANTHRACIS; STRAINS; NEONATE AB We investigated Bacillus cereus positive tracheal aspirates from infants on ventilators in a neonatal intensive care unit. Multi locus sequence typing determined a genetic match between strains isolated from samples from a case-patient and from the air flow sensor in the ventilator. Changing the sterilization method for sensors to steam autoclaving stopped transmission. C1 [Turabelidze, George; Butler, Cindy; Byrd, David; Schildknecht, Stephanie; Hauser, Lina Chavez; Talley, Crystal] Missouri Dept Hlth & Senior Serv, Jefferson City, MO USA. [Gee, Jay E.; Hoffmaster, Alex R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Manian, Farrin; Duncan, Mary; Ferrett, Rhonda; Evans, Dana] Mercy Hosp, St Louis, MO USA. RP Turabelidze, G (reprint author), Eastern Dist Off, Missouri Dept Hlth & Senior Serv, 220 S Jefferson St, St Louis, MO 63103 USA. EM George.Turabelidze@health.mo.gov FU Wellcome Trust FX This study made use of the Bacillus cereus Multi Locus Sequence Typing website (http://pubmlst.org/bcereus/) developed by Keith Jolley and sited at the University of Oxford. The development of that site was funded by the Wellcome Trust. NR 15 TC 2 Z9 3 U1 1 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2013 VL 19 IS 5 BP 781 EP 783 DI 10.3201/eid1905.120239 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LX UT WOS:000328173400014 PM 23647973 ER PT J AU Blau, DM Clark, SC Nolte, KB AF Blau, Dianna M. Clark, Steven C. Nolte, Kurt B. CA Natl Assoc Med Examiners Ad-hoc Co TI Infectious Disease Surveillance by Medical Examiners and Coroners SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID MED-X; BIOTERRORISM; MODEL C1 [Blau, Dianna M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Clark, Steven C.] Occupat Res & Assessment, Big Rapids, MI USA. [Nolte, Kurt B.] New Mexico Off Med Investigator, Albuquerque, NM USA. RP Blau, DM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G32, Atlanta, GA 30333 USA. EM dblau@cdc.gov NR 7 TC 3 Z9 3 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2013 VL 19 IS 5 BP 821 EP 822 DI 10.3201/eid1905.121661 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LX UT WOS:000328173400028 PM 23697772 ER PT J AU Mahy, BWJ AF Mahy, Brian W. J. TI In Memoriam: Alexander I. Klimov (1943-2013) SO EMERGING INFECTIOUS DISEASES LA English DT Biographical-Item RP Mahy, BWJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop D61, Atlanta, GA 30333 USA. EM bwjmahy@gmail.com NR 1 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2013 VL 19 IS 5 BP 842 EP 842 DI 10.3201/eid1905.IM0266 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LX UT WOS:000328173400040 PM 23697331 ER PT J AU Potter, P AF Potter, Polyxeni TI Imagining Sisyphus Happy SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM pmp1@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2013 VL 19 IS 5 BP 846 EP 847 DI 10.3201/eid1905.AC1905 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LX UT WOS:000328173400042 PM 23648124 ER PT J AU Langlois, PH Hoyt, AT Lupo, PJ Lawson, CC Waters, MA Desrosiers, TA Shaw, GM Romitti, PA Lammer, EJ AF Langlois, Peter H. Hoyt, Adrienne T. Lupo, Philip J. Lawson, Christina C. Waters, Martha A. Desrosiers, Tania A. Shaw, Gary M. Romitti, Paul A. Lammer, Edward J. TI Maternal Occupational Exposure to Polycyclic Aromatic Hydrocarbons and Risk of Oral Cleft-Affected Pregnancies SO CLEFT PALATE-CRANIOFACIAL JOURNAL LA English DT Article DE malformations; occupation; oral clefts; PAHs; polycyclic aromatic hydrocarbons ID GENE-ENVIRONMENT INTERACTION; BIRTH-DEFECTS PREVENTION; NEURAL-TUBE DEFECTS; CIGARETTE-SMOKING; OROFACIAL CLEFTS; ALCOHOL-CONSUMPTION; TOBACCO-SMOKE; DNA-ADDUCTS; VARIANTS; LIP AB Objective: To evaluate whether there is an association between maternal occupational exposure to polycyclic aromatic hydrocarbons and oral clefts in offspring. This is the first human study of polycyclic aromatic hydrocarbons and clefts of which the authors are aware. Design: Case-control study. Setting, Participants: Data for 1997 to 2002 from the National Birth Defects Prevention Study, a large population-based case-control study in the United States, were analyzed. Maternal telephone interviews yielded information on jobs held in the month before through 3 months after conception. Two industrial hygienists independently assessed occupational exposure to polycyclic aromatic hydrocarbons; all jobs rated as exposed or with rating difficulty were reviewed with a third industrial hygienist to reach consensus on all exposure parameters. Logistic regression estimated crude and adjusted odds ratios with 95% confidence intervals for cleft lip with or without cleft palate and cleft palate alone. Results: There were 2989 controls (3.5% exposed), 805 cases of cleft lip with or without cleft palate (5.8% exposed), and 439 cases of cleft palate alone (4.6% exposed). The odds of maternal occupational exposure to polycyclic aromatic hydrocarbons (any versus none) during pregnancy was increased for cleft lip with or without cleft palate cases as compared with controls (odds ratio, 1.69; 95% confidence interval, 1.18 to 2.40); the odds ratio was 1.47 (95% confidence interval 1.02 to 2.12) when adjusted for maternal education. There was a statistically significant adjusted exposure-response relationship for cleft lip with or without cleft palate (P-trend=.02). Odd ratios for cleft palate alone were not statistically significant. Conclusions: Maternal occupational exposure to polycyclic aromatic hydrocarbons was associated with increased risk of cleft lip with or without cleft palate in offspring. C1 [Langlois, Peter H.; Hoyt, Adrienne T.] Texas Ctr Birth Defects Res & Prevent, Birth Defects Epidemiol & Surveillance Branch, Texas Dept State Hlth Serv, Austin, TX 78714 USA. [Lupo, Philip J.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Lawson, Christina C.] NIOSH, Ctr Dis Control, Cincinnati, OH 45226 USA. [Lawson, Christina C.] NIOSH, Ctr Prevent, Cincinnati, OH 45226 USA. [Desrosiers, Tania A.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, North Carolina Ctr Birth Defects Res & Prevent, Chapel Hill, NC USA. [Shaw, Gary M.] Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94304 USA. [Romitti, Paul A.] Univ Iowa, Dept Epidemiol, Iowa City, IA USA. [Lammer, Edward J.] Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA. RP Langlois, PH (reprint author), Texas Ctr Birth Defects Res & Prevent, Dept State Hlth Serv, POB 149347,MC 1964, Austin, TX 78714 USA. EM peter.langlois@dshs.state.tx.us OI Lupo, Philip/0000-0003-0978-5863 FU NCBDD CDC HHS [U01 DD000494]; NIDCR NIH HHS [L40 DE023736, R03 DE021739]; NIEHS NIH HHS [P30 ES005605] NR 59 TC 6 Z9 7 U1 2 U2 11 PU ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS PI LAWRENCE PA 810 EAST 10TH STREET, LAWRENCE, KS 66044 USA SN 1545-1569 EI 1055-6656 J9 CLEFT PALATE-CRAN J JI Cleft Palate-Craniofac. J. PD MAY PY 2013 VL 50 IS 3 BP 337 EP 346 DI 10.1597/12-104 PG 10 WC Dentistry, Oral Surgery & Medicine; Surgery SC Dentistry, Oral Surgery & Medicine; Surgery GA 259OA UT WOS:000327535000012 PM 23136939 ER PT J AU Henneberger, PK Liang, XM Lemiere, C AF Henneberger, Paul K. Liang, Xiaoming Lemiere, Catherine TI A comparison of work-exacerbated asthma cases from clinical and epidemiological settings SO CANADIAN RESPIRATORY JOURNAL LA English DT Article DE Asthma; Asthma exacerbation; Case criteria; Work-related asthma ID THORACIC-SOCIETY STATEMENT; OCCUPATIONAL ASTHMA; WORKPLACE EXACERBATION; POPULATION; PREVALENCE; SYMPTOMS; ADULTS; HEALTH; FREQUENCY; SAMPLE AB BACKGROUND: Clinical and epidemiological studies commonly use different case definitions in different settings when investigating work-exacerbated asthma (WEA). These differences are likely to impact characteristics of the resulting WEA cases. OBJECTIVES: To investigate this issue by comparing two groups of WEA cases, one identified using an intensive clinical evaluation and another that fulfilled epidemiological criteria. METHODS: A total of 53 clinical WEA cases had been referred for suspected work-related asthma to two tertiary clinics in Canada, where patients completed tests that confirmed asthma and ruled out asthma caused by work. Forty-seven epidemiological WEA cases were employed asthma patients treated at a health maintenance organization in the United States who completed a questionnaire and spirometry, and fulfilled criteria for WEA based on self-reported, work-related worsening of asthma and relevant workplace exposures as judged by an expert panel. RESULTS: Using different case criteria in different settings resulted in case groups that had a mix of similarities and differences. The clinical WEA cases were more likely to have visited a doctor's office >= 3 times for asthma in the past year (75% versus 11%; P<0.0001), but did not seek more asthma-related emergency or in-patient care, or have lower spirometry values. The two groups differed substantially according to the industries and occupations where the cases worked. CONCLUSIONS: Findings from both types of studies should be considered when measuring the contribution of work to asthma exacerbations, identifying putative agents, and selecting industries and occupations in which to implement screening and surveillance programs. C1 [Henneberger, Paul K.; Liang, Xiaoming] Ctr Dis Control & Prevent, Div Resp Dis Studies, Natl Inst Occupat Safety & Hlth, Morgantown, WV USA. [Lemiere, Catherine] Univ Montreal, Hop Sacre Coeur, Montreal, PQ, Canada. RP Lemiere, C (reprint author), Hop Sacre Coeur, Dept Chest Med, 5400 Gouin Ouest, Montreal, PQ H4J 1C5, Canada. EM catherine.lemiere@umontreal.ca FU Centers for Disease Control and Prevention (United States) [R01 OH008391] FX The recruitment of study subjects in Quebec was funded by Cooperative Agreement number R01 OH008391 from the Centers for Disease Control and Prevention (United States). NR 30 TC 4 Z9 4 U1 0 U2 0 PU PULSUS GROUP INC PI OAKVILLE PA 2902 S SHERIDAN WAY, OAKVILLE, ONTARIO L6J 7L6, CANADA SN 1198-2241 J9 CAN RESPIR J JI Can. Respir. J. PD MAY-JUN PY 2013 VL 20 IS 3 BP 159 EP 164 PG 6 WC Respiratory System SC Respiratory System GA 207JM UT WOS:000323594700009 PM 23762884 ER PT J AU Satarug, S Swaddiwudhipong, W Ruangyuttikarn, W Nishijo, M Ruiz, P AF Satarug, Soisungwan Swaddiwudhipong, Witaya Ruangyuttikarn, Werawan Nishijo, Muneko Ruiz, Patricia TI Modeling Cadmium Exposures in Low- and High-Exposure Areas in Thailand SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE cadmium; computerized predictive model; diet; exposure source; food; health risk assessment; smoking; tolerable intake; toxicokinetics-based model; urinary threshold ID NUTRITION EXAMINATION SURVEY; RENAL TUBULAR FUNCTION; MAE SOT DISTRICT; NATIONAL-HEALTH; URINARY CADMIUM; ENVIRONMENTAL-POLLUTANTS; GENERAL-POPULATION; CIGARETTE-SMOKING; DIETARY EXPOSURE; TAK PROVINCE AB BACKGROUND: Previous U. S. population modeling studies have reported that urinary cadmium (Cd) excretion patterns differ with age, sex, and dietary exposure; associations between Cd exposures and health outcomes also have differed by age and sex. Therefore, it is important to test models used to estimate Cd exposures across an expanded Cd-exposure range. OBJECTIVES: We estimated relative Cd exposures from both diet and smoking in low- and high-exposure scenarios to provide data for improving risk assessment calculations. METHODS: We used a Cd toxicokinetic-based model to estimate Cd exposures based on urinary Cd levels measured for 399 persons in a low-exposure area (Bangkok) and 6,747 persons in a high-exposure area (Mae Sot) in Thailand. RESULTS: In Bangkok, we estimated dietary Cd exposures of 50-56 mu g/day for males and 21-27 mu g/day for females 20-59 years of age who never smoked. In Mae Sot, we estimated dietary Cd exposures of 188-224 mu g/day for males and 99-113 mu g/day for females 20-59 years of age who never smoked. In Bangkok, we estimated Cd exposures from smoking to be 5.5-20.4 mu g/day for male smokers 20-59 years of age. In Mae Sot, we estimated Cd exposures from smoking to be 9.8-26 mu g/day for male heavy smokers and 26 mu g/day for female heavy smokers. CONCLUSION: This study provides estimates of Cd exposures from diet and smoking in low-and high-exposure scenarios. Our findings suggest a relatively small safety margin between the established tolerable Cd reference exposure of 62 mu g/day and exposure levels previously associated with evidence of kidney and bone effects in Mae Sot residents, where dietary Cd exposures among women were only 1.6-2.1 times the reference value. C1 [Satarug, Soisungwan] Univ Queensland, Sch Med, Princess Alexandra Hosp, Ctr Kidney Dis Res, Brisbane, Qld 4102, Australia. [Ruangyuttikarn, Werawan] Chiang Mai Univ, Div Toxicol, Dept Forens Med, Chiang Mai, Thailand. [Nishijo, Muneko] Kanazawa Med Univ, Dept Publ Hlth, Kanazawa, Ishikawa, Japan. [Ruiz, Patricia] Ctr Dis Control & Prevent, Computat Toxicol & Methods Dev Lab, Div Toxicol & Human Hlth Sci, Agcy Tox Subst & Dis Registry, Atlanta, GA USA. RP Satarug, S (reprint author), Univ Queensland, Sch Med, Princess Alexandra Hosp, Ctr Kidney Dis Res, Brisbane, Qld 4102, Australia. EM sj.satarug@yahoo.com.au NR 51 TC 8 Z9 8 U1 0 U2 15 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD MAY PY 2013 VL 121 IS 5 BP 531 EP 536 DI 10.1289/ehp.1104769 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 208UX UT WOS:000323707300014 PM 23434727 ER PT J AU Warner, M Schall, RA Harley, KG Bradman, A Barr, D Eskenazi, B AF Warner, Marcella Schall, Raul Aguilar Harley, Kim G. Bradman, Asa Barr, Dana Eskenazi, Brenda TI In Utero DDT and DDE Exposure and Obesity Status of 7-Year-Old Mexican-American Children in the CHAMACOS Cohort SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE mass index; children; dichlorodiphenyltrichloroethane; dichlorodiphenyldichloroethylene; obesity; prenatal exposure ID BODY-MASS INDEX; POLYCHLORINATED-BIPHENYLS; ORGANOCHLORINE PESTICIDES; LACTATIONAL EXPOSURE; HUMAN-SERUM; GROWTH; OVERWEIGHT; PREGNANCY; EPIDEMIC; WEIGHT AB BACKGROUND: In utero exposure to endocrine disrupting compounds including dichlorodiphenyltrichloroethane (DDT) and dichlorodiphenyldichloroethylene (DDE) has been hypothesized to increase risk of obesity later in life. OBJECTIVES: The Center for the Health Assessment of Mothers and Children of Salinas (CHAMACOS) study is a longitudinal birth cohort of low-income Latinas living in a California agricultural community. We examined the relation of in utero DDT and DDE exposure to child obesity at 7 years of age. We also examined the trend with age (2, 3.5, 5, and 7 years) in the exposure-obesity relation. METHODS: We included 270 children with o,p'-DDT, p,p'-DDT, and p,p'-DDE concentrations measured in maternal serum during pregnancy (nanograms per gram lipid) and complete 7-year follow-up data including weight (kilograms) and height (centimeters). Body mass index (BMI; kilograms per meter squared) was calculated and obesity was defined as >= 95th percentile on the sex-specific BMI-for-age Centers for Disease Control and Prevention 2000 growth charts. RESULTS: At 7 years, 96 (35.6%) children were obese. A 10-fold increase in o,p'-DDT, p,p'-DDT, or p,p'-DDE, was nonsignificantly associated with increased odds (OR) of obesity [o,p'-DDT adjusted (adj-) OR = 1.17, 95% CI: 0.75, 1.82; p,p'-DDT adj-OR = 1.19, 95% CI: 0.81, 1.74; p,p'-DDE adj-OR = 1.22, 95% CI: 0.72, 2.06]. With increasing age at follow-up, we observed a significant trend toward a positive association between DDT and DDE exposure and odds of obesity. CONCLUSION: We did not find a significant positive relation between in utero DDT and DDE exposure and obesity status of 7-year-old children. However, given the observed trend with age, continued follow-up will be informative. C1 [Warner, Marcella; Schall, Raul Aguilar; Harley, Kim G.; Bradman, Asa; Eskenazi, Brenda] Univ Calif Berkeley, Sch Publ Hlth, Ctr Environm Res & Childrens Hlth, Berkeley, CA 94720 USA. [Barr, Dana] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA. [Barr, Dana] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Warner, M (reprint author), Univ Calif Berkeley, Sch Publ Hlth, Ctr Environm Res & Childrens Hlth, 1995 Univ Ave,Suite 265, Berkeley, CA 94720 USA. EM mwarner@berkeley.edu FU U.S. Environmental Protection Agency (EPA) [RD 83171001]; National Institute of Environmental Health Sciences (NIEHS) [PO1 ES009605] FX This research was made possible by grant numbers RD 83171001 from the U.S. Environmental Protection Agency (EPA) and PO1 ES009605 from the National Institute of Environmental Health Sciences (NIEHS). NR 34 TC 19 Z9 19 U1 1 U2 28 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD MAY PY 2013 VL 121 IS 5 BP 631 EP 636 DI 10.1289/ehp.1205656 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 208UX UT WOS:000323707300029 PM 23512307 ER PT J AU Eko, F He, Q Black, C Igietseme, J AF Eko, Francis He, Qing Black, Carolyn Igietseme, Joseph TI A VCG-based chlamydial vaccine engenders broad-based protective immunity SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting of the American-Association-of-Immunologists CY MAY 03-07, 2013 CL Honolulu, HI SP Amer Assoc Immunologists C1 [Eko, Francis; He, Qing; Igietseme, Joseph] Morehouse Sch Med, Atlanta, GA 30310 USA. [Black, Carolyn; Igietseme, Joseph] Ctr Dis Control & Prevent, NCEZID, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2013 VL 190 MA P4391 PG 1 WC Immunology SC Immunology GA 199ID UT WOS:000322987105205 ER PT J AU Gangappa, S De La Cruz, J Ganesh, T Diebold, B Cao, WP Smith, S Taylor, A Singh, N Hofstetter, A Kumar, A Katz, J Sambhara, S Lambeth, JD AF Gangappa, Shivaprakash De La Cruz, Juan Ganesh, Thota Diebold, Becky Cao, Weiping Smith, Susan Taylor, Andrew Singh, Neetu Hofstetter, Amelia Kumar, Amrita Katz, Jacqueline Sambhara, Suryaprakash Lambeth, J. David TI A novel quinazolin-derived reactive oxygen species-inhibitor suppresses influenza A virus-induced inflammatory mediators and leads to enhanced survival in mice SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting of the American-Association-of-Immunologists CY MAY 03-07, 2013 CL Honolulu, HI SP Amer Assoc Immunologists C1 [Gangappa, Shivaprakash; De La Cruz, Juan; Cao, Weiping; Taylor, Andrew; Singh, Neetu; Hofstetter, Amelia; Kumar, Amrita; Katz, Jacqueline; Sambhara, Suryaprakash] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Ganesh, Thota; Diebold, Becky; Smith, Susan; Lambeth, J. David] Emory Univ, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2013 VL 190 MA P4214 PG 1 WC Immunology SC Immunology GA 199ID UT WOS:000322987105031 ER PT J AU Hofstetter, A De La Cruz, J Patel, J McCoy, J Cao, WP Kim, J Diebold, B Belser, J Tumpey, T Katz, J Sambhara, S Lambeth, J Gangappa, S AF Hofstetter, Amelia De La Cruz, Juan Patel, Jenish McCoy, James Cao, Weiping Kim, Jin Diebold, Becky Belser, Jessica Tumpey, Terrence Katz, Jacqueline Sambhara, Suryaprakash Lambeth, J. Gangappa, Shivaprakash TI Adverse role of influenza A virus-induced Nox1 in neutralizing antibody responses and survival against lethal viral challenge in mice. SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting of the American-Association-of-Immunologists CY MAY 03-07, 2013 CL Honolulu, HI SP Amer Assoc Immunologists C1 [Hofstetter, Amelia; McCoy, James; Diebold, Becky; Lambeth, J.; Gangappa, Shivaprakash] Emory Univ, Sch Med, Atlanta, GA USA. [Hofstetter, Amelia; De La Cruz, Juan; Patel, Jenish; Cao, Weiping; Kim, Jin; Belser, Jessica; Tumpey, Terrence; Katz, Jacqueline; Sambhara, Suryaprakash; Gangappa, Shivaprakash] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2013 VL 190 MA P1407 PG 1 WC Immunology SC Immunology GA 199ID UT WOS:000322987101153 ER PT J AU Kim, JH Reber, A Biber, R Cao, WP Chirkova, T Katz, J Sambhara, S AF Kim, Jin Hyang Reber, Adrian Biber, Renata Cao, Weiping Chirkova, Tatiana Katz, Jacqueline Sambhara, Suryaprakash TI Role of human IgM memory B cells in influenza vaccine response SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting of the American-Association-of-Immunologists CY MAY 03-07, 2013 CL Honolulu, HI SP Amer Assoc Immunologists C1 [Kim, Jin Hyang; Reber, Adrian; Biber, Renata; Cao, Weiping; Chirkova, Tatiana; Katz, Jacqueline; Sambhara, Suryaprakash] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2013 VL 190 MA P4401 PG 1 WC Immunology SC Immunology GA 199ID UT WOS:000322987105215 ER PT J AU Swaims, A Haaland, R Lupo, D Evans-Strickfaden, T Kohlmeier, J Haddad, L Hart, C AF Swaims, Alison Haaland, Richard Lupo, Davis Evans-Strickfaden, Tammy Kohlmeier, Jacob Haddad, Lisa Hart, Clyde TI Intra-epithelial T lymphocytes from the cervical-vaginal mucosa of healthy women contain a majority population of CD4+cells and express high levels of the HIV-1 co-receptor CCR5. SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting of the American-Association-of-Immunologists CY MAY 03-07, 2013 CL Honolulu, HI SP Amer Assoc Immunologists C1 [Swaims, Alison; Haaland, Richard; Lupo, Davis; Evans-Strickfaden, Tammy; Hart, Clyde] Ctr Dis Control & Prevent, Branch Lab, Div HIV & AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA. [Kohlmeier, Jacob; Haddad, Lisa] Emory Univ, Sch Med, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2013 VL 190 MA P3341 PG 1 WC Immunology SC Immunology GA 199ID UT WOS:000322987104016 ER PT J AU Tripp, R Choi, Y Powell, T Boyd, J Palath, N Haynes, L Anderson, L Jorquera, P AF Tripp, Ralph Choi, Youngjoo Powell, Thomas Boyd, James Palath, Naveen Haynes, Lia Anderson, Larry Jorquera, Patricia TI Nanoparticle vaccines comprising the respiratory syncytial virus G Protein CX3C chemokine motif induce robust immunity protecting from challenge and disease SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting of the American-Association-of-Immunologists CY MAY 03-07, 2013 CL Honolulu, HI SP Amer Assoc Immunologists C1 [Tripp, Ralph; Choi, Youngjoo; Jorquera, Patricia] Univ Georgia, Athens, GA 30602 USA. [Powell, Thomas; Boyd, James; Palath, Naveen] Artificial Cell Technol, New Haven, CT USA. [Haynes, Lia] CDC, NCIRD, Atlanta, GA 30333 USA. [Anderson, Larry] Emory Univ, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2013 VL 190 MA 17919 PG 1 WC Immunology SC Immunology GA 199ID UT WOS:000322987106075 ER PT J AU Ellen, JM McCree, DH Muvva, R Chung, SE Miazad, RM Arrington-Sanders, R Jones, K Burnett, P Fichtenberg, C AF Ellen, J. M. McCree, D. H. Muvva, R. Chung, S-E Miazad, R. M. Arrington-Sanders, R. Jones, K. Burnett, P. Fichtenberg, C. TI Recruitment approaches to identifying newly diagnosed HIV infection among African American men who have sex with men SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE HIV; men who have sex with men; MSM; African American; diagnosis; alternate venue testing; social network strategy; provider referral; undiagnosed; case finding ID NEW-YORK-CITY; BLACK-MEN; RISK; SURVEILLANCE; TRANSMISSION; CLIENTS AB To determine effectiveness of alternate venue testing (AVT), social network strategy (SNS) and provider referral (PR) for identifying previously undiagnosed HIV-infected 18-64-year-old African American men who have sex with men (AA MSM) by a health department. For AVT, staff used a mobile clinic to conduct HIV testing. For PR, staff solicited contact information from HIV-infected AA MSM, located contacts and offered HIV testing. For SNS, HIV-positive AA MSM recruited network associates for HIV testing. Two hundred and eighteen self-identified AA MSM were tested through AVT (25.2% HIV positivity) of whom 20 were newly identified HIV-positive. Fourteen HIV-positive men participated in SNS; 22 AA MSM contacts were recruited through SNS, eight (36.4%) were HIV positive and none were new positives. Two HIV-infected men participated in the PR strategy, yielding two AA MSM sex partners (one previously positive). The results suggest the need for health departments to consider using several complimentary strategies for identifying previously undiagnosed HIV infections in AA MSM in urban environments such as Baltimore. C1 [Ellen, J. M.] Johns Hopkins Sch Med, Dept Pediat, Div Gen Pediat & Adolescent Med, Baltimore, MD USA. [McCree, D. H.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. [Muvva, R.; Miazad, R. M.; Burnett, P.] Baltimore City Dept Hlth, Bur STD HIV Prevent, Baltimore, MD USA. [Chung, S-E] Johns Hopkins Univ, Div Gen Pediat & Adolescent Med, Dept Pediat, Johns Hopkins Sch Med, Baltimore, MD 21218 USA. [Chung, S-E] Johns Hopkins Univ, Ctr Child & Community Hlth Res CCHR, Baltimore, MD 21218 USA. [Arrington-Sanders, R.; Jones, K.] Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Baltimore, MD USA. RP Ellen, JM (reprint author), Ctr Tower,5200 Eastern Ave,Ste 4200, Baltimore, MD 21224 USA. EM jellen@jhmi.edu NR 19 TC 2 Z9 2 U1 0 U2 6 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 0956-4624 J9 INT J STD AIDS JI Int. J. STD AIDS PD MAY PY 2013 VL 24 IS 5 BP 335 EP 339 DI 10.1177/0956462412472459 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 198EF UT WOS:000322904200001 PM 23615485 ER PT J AU Taylor, MM Reilley, B Yellowman, M Anderson, L de Ravello, L Tulloch, S AF Taylor, M. M. Reilley, B. Yellowman, M. Anderson, L. de Ravello, L. Tulloch, S. TI Use of expedited partner therapy among chlamydia cases diagnosed at an urban Indian health centre, Arizona SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE chlamydia; sexually transmitted infection; STD; expedited partner therapy (EPT); women's health; screening; treatment; patient delivered partner therapy; American Indian/Alaska Native ID SEXUALLY-TRANSMITTED-DISEASES; AMERICAN-INDIANS; TRACHOMATIS; PROVIDERS AB Chlamydia cases diagnosed in the women's clinic were more likely to receive expedited partner therapy (EPT) and to be re-tested as compared with urgent and emergent care settings. Fewer re-infections occurred among patients who received EPT. Disproportionate rates of chlamydia occur among American Indian (AI) populations. To describe use of EPT among chlamydia cases diagnosed at an urban Indian Health Service (IHS) facility in Arizona, health records were used to extract confirmed cases of chlamydia diagnosed between January 2009 and August 2011. Medical records of 492 patients diagnosed with chlamydia were reviewed. Among the 472 cases who received treatment, 246 (52%) received EPT. Receipt of EPT was significantly associated with being female (odds ratio (OR) 2.1, 1.03-4.4, P < 0.001) and receipt of care in the women's clinic (OR 9.9, 95% CI 6.0-16.2) or in a primary care clinic (OR 2.4, 95% CI 1.1-5.1). Compared with those receiving care in the women's clinic, the odds of receipt of EPT were significantly less in those attending the urgent/express care clinic (OR 0.1, 95% CI 0.06-0.2), and the emergency department (OR 0.1, 95% CI 0.05-0.2). Among treated patients who underwent re-testing (N = 323, 68% total treated) re-infection was less common among those that received EPT (13% versus 27%; OR 0.5, 95% CI 0.3-0.9). In this IHS facility, EPT was protective in preventing chlamydia re-infection. Opportunities to expand the use of EPT were identified in urgent and emergent care settings. C1 [Taylor, M. M.; Tulloch, S.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Taylor, M. M.; de Ravello, L.; Tulloch, S.] Indian Hlth Serv, Natl STD Program, Albuquerque, NM USA. [Taylor, M. M.] Arizona Dept Hlth Serv, Phoenix, AZ 85006 USA. [Taylor, M. M.; Anderson, L.] Maricopa Cty Dept Publ Hlth, Phoenix, AZ USA. [Reilley, B.] Indian Hlth Serv, Div Epidemiol, Albuquerque, NM USA. [Yellowman, M.] Phoenix Indian Med Ctr, Phoenix, AZ USA. [de Ravello, L.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Taylor, MM (reprint author), Arizona Dept Hlth Serv, 1645 East Roosevelt, Phoenix, AZ 85006 USA. EM MDT7@CDC.GOV NR 22 TC 2 Z9 2 U1 1 U2 9 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 0956-4624 J9 INT J STD AIDS JI Int. J. STD AIDS PD MAY PY 2013 VL 24 IS 5 BP 371 EP 374 DI 10.1177/0956462412472825 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 198EF UT WOS:000322904200007 PM 23970704 ER PT J AU Abu Samra, N Jori, F Xiao, LH Rikhotso, O Thompson, PN AF Abu Samra, Nada Jori, Ferran Xiao, Lihua Rikhotso, Oupa Thompson, Peter N. TI Molecular characterization of Cryptosporidium species at the wildlife/livestock interface of the Kruger National Park, South Africa SO COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES LA English DT Article DE Cryptosporidium spp.; Wildlife; Cattle; Kruger National Park; 18s rRNA gene ID NEW-YORK; PUBLIC-HEALTH; WILDLIFE; PREVALENCE; GENOTYPES; CATTLE; LIVESTOCK; OOCYSTS; PARVUM AB Molecular characterization of Cyptosporidium spp. was done on isolates from African elephant (Loxodonta africana), African buffalo (Syncerus coffer), impala (Aepyceros melampus) and native domestic calves collected during May and June 2008 at the wildlife/livestock interface of the Kruger National Park (KNP), South Africa. A polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) analysis of the 18S rRNA gene was used in feces from 51 calves (3-12 months of age), 71 buffalo, 71 impala and 72 elephant, and sequencing of the 18S rRNA gene was done on PCR-RFLP-positive wildlife samples. Cryptosporidium spp. were detected in 8% (4/51) of the calves and identified as C. andersoni (2/4) and C. bovis (2/4). Four of the 214 wildlife samples were positive for Cryptosporidium with a prevalence of 2.8% each in impala and buffalo. Cryptosporidium ubiquitum was detected in two impala and one buffalo, and C. bovis in one buffalo. A concurrent questionnaire conducted among 120 farmers in the study area investigated contacts between wildlife species and livestock. Buffalo and impala had the highest probability of contact with cattle outside the KNP. Despite the fairly low prevalence found in wildlife and cattle, the circulation of zoonotic Cryptosporidium spp., such as C. ubiquitum, should be investigated further, particularly in areas of high HIV infection prevalence. Further studies should target younger animals in which the prevalence is likely to be higher. (C) 2012 Published by Elsevier Ltd. C1 [Abu Samra, Nada; Thompson, Peter N.] Univ Pretoria, Dept Prod Anim Studies, Epidemiol Sect, ZA-0110 Onderstepoort, South Africa. [Jori, Ferran] Univ Pretoria, Dept Zool & Entomol, Mammal Res Inst, CIRAD,UR AGIRs, ZA-0002 Pretoria, South Africa. [Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Rikhotso, Oupa] Vet Serv, Dept Agr Rural Dev & Land Adm, Thulamahashe, Mpumalanga, South Africa. RP Abu Samra, N (reprint author), Univ Pretoria, Dept Prod Anim Studies, Epidemiol Sect, Private Bag X04, ZA-0110 Onderstepoort, South Africa. EM nada.nada@gmx.de RI Thompson, Peter/J-2534-2013; Xiao, Lihua/B-1704-2013; OI Xiao, Lihua/0000-0001-8532-2727; Thompson, Peter/0000-0002-2268-9748 FU Faculty of Veterinary Science, University of Pretoria; French Embassy in Pretoria, South Africa FX We are very grateful to the Faculty of Veterinary Science, University of Pretoria, and the French Embassy in Pretoria, South Africa for providing funding for this research. We acknowledge the support provided by Theresa Dearen from the Molecular Epidemiology Laboratory, Division of Foodborne, Waterborne and Environmental Diseases, Centers for Disease Control (CDC), Atlanta, Georgia, the State Veterinarian and Veterinary Health Assistants of Bushbuckridge, Mpumalanga. NR 25 TC 7 Z9 10 U1 0 U2 19 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0147-9571 J9 COMP IMMUNOL MICROB JI Comp. Immunol. Microbiol. Infect. Dis. PD MAY PY 2013 VL 36 IS 3 SI SI BP 295 EP 302 DI 10.1016/j.cimid.2012.07.004 PG 8 WC Immunology; Microbiology; Veterinary Sciences SC Immunology; Microbiology; Veterinary Sciences GA 175KX UT WOS:000321230700009 PM 22975725 ER PT J AU Smythe, L Adler, B Hartskeerl, RA Galloway, RL Turenne, CY Levett, PN AF Smythe, L. Adler, B. Hartskeerl, R. A. Galloway, R. L. Turenne, C. Y. Levett, P. N. CA Int Comm Systematics Prokaryotes S TI Classification of Leptospira genomospecies 1, 3, 4 and 5 as Leptospira alstonii sp nov., Leptospira vanthielii sp nov., Leptospira terpstrae sp nov and Leptospira yanagawae sp nov., respectively SO INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY LA English DT Article ID DEOXYRIBONUCLEIC-ACID; FAMILY LEPTOSPIRACEAE; GENE; IDENTIFICATION; HYBRIDIZATION; RELATEDNESS; SEROGROUPS; SEROVARS AB The genus Leptospira currently comprises 16 named species. In addition, four unnamed hybridization groups were designated Leptospira genomospecies 1, 3, 4 and 5. These groups represent valid species-level taxa, but were not assigned names in the original description by Brenner et al. [Int J Syst Bacteriol 49, 839-858 (1999)]. To rectify this situation, it is proposed that Leptospira genomospecies 1, genomospecies 3, genomospecies 4 and genomospecies 5 should be classified as Leptospira alstonii sp. nov., Leptospira vanthielii sp. nov., Leptospira terpstrae sp. nov. and Leptospira yanagawae sp. nov., respectively, with strains L. alstonii 79601(T) (=ATCC BAA-2439(T)), L. vanthielii WaZ Holland(T) (=ATCC 700522(T)), L. terpstrae LT 11-33(T) (=ATCC 700639(T)) and L. yanagawae Sao Paulo(T) (=ATCC 700523(T)) as the type strains. The type strains are also available from the culture collections of the WHO Collaborating Centres in Amsterdam, The Netherlands, and Brisbane, Australia. C1 [Smythe, L.] Queensland Hlth, Hlth Support Serv Agcy, WHO FAO OIE Collaborating Ctr Reference & Res Lep, Brisbane, Qld, Australia. [Adler, B.] Monash Univ, Australian Res Council, Ctr Excellence Struct & Funct Microbial Genom, Clayton, Vic 3800, Australia. [Hartskeerl, R. A.] Royal Trop Inst, KIT Biomed Res, WHO FAO OIE, NL-1105 AZ Amsterdam, Netherlands. [Hartskeerl, R. A.] Royal Trop Inst, KIT Biomed Res, Natl Leptospirosis Reference Ctr, NL-1105 AZ Amsterdam, Netherlands. [Galloway, R. L.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Turenne, C. Y.; Levett, P. N.] Saskatchewan Dis Control Lab, Regina, SK, Canada. RP Levett, PN (reprint author), Saskatchewan Dis Control Lab, Regina, SK, Canada. EM plevett@health.gov.sk.ca NR 21 TC 12 Z9 12 U1 0 U2 5 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 1466-5026 J9 INT J SYST EVOL MICR JI Int. J. Syst. Evol. Microbiol. PD MAY PY 2013 VL 63 BP 1859 EP 1862 DI 10.1099/ijs.0.047324-0 PN 5 PG 4 WC Microbiology SC Microbiology GA 168XM UT WOS:000320741200045 PM 22984140 ER PT J AU Freedman, DS AF Freedman, David S. TI Determination of body size measures and blood pressure levels among children SO JORNAL DE PEDIATRIA LA English DT Editorial Material ID FAT DISTRIBUTION; RISK-FACTORS; CARDIOVASCULAR-DISEASE; MASS; ADOLESCENTS; PREDICTION; OBESITY C1 Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. RP Freedman, DS (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. EM dxf1@cdc.gov FU Intramural CDC HHS [CC999999] NR 24 TC 1 Z9 2 U1 0 U2 1 PU SOC BRASIL PEDIATRIA PI RIO DE JANEIRO, RJ PA RUA SANTA CLARA 292, RIO DE JANEIRO, RJ, CEP 22401-01, BRAZIL SN 0021-7557 J9 J PEDIAT-BRAZIL JI J. Pediatr. PD MAY-JUN PY 2013 VL 89 IS 3 BP 211 EP 214 DI 10.1016/j.jped.2013.03.018 PG 4 WC Pediatrics SC Pediatrics GA 178DD UT WOS:000321423400001 PM 23684455 ER PT J AU Burr, G Eisenberg, J Jang, S AF Burr, Gregory Eisenberg, Judith Jang, SeungHee TI Case Study: Evaluation of Metal and Carbon Monoxide Exposures During Steel Slab Cutting and Slitting SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article C1 [Burr, Gregory; Eisenberg, Judith; Jang, SeungHee] Natl Inst Occupat Safety & Hlth, S Dept Hlth & Human Serv, Centers Dis Control & Prevent, Cincinnati, OH USA. [Burr, Gregory; Eisenberg, Judith; Jang, SeungHee] NIOSH, US Dept Hlth & Human Serv, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Burr, G (reprint author), NIOSH, US Dept Hlth & Human Serv, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. NR 4 TC 0 Z9 0 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD MAY 1 PY 2013 VL 10 IS 5 BP D57 EP D61 DI 10.1080/15459624.2013.768932 PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 174QR UT WOS:000321171000001 PM 23509948 ER PT J AU Napier, BA Burd, EM Satola, SW Cagle, SM Ray, SM McGann, P Pohl, J Lesho, EP Weiss, DS AF Napier, Brooke A. Burd, Eileen M. Satola, Sarah W. Cagle, Stephanie M. Ray, Susan M. McGann, Patrick Pohl, Jan Lesho, Emil P. Weiss, David S. TI Clinical Use of Colistin Induces Cross-Resistance to Host Antimicrobials in Acinetobacter baumannii SO MBIO LA English DT Article ID PEPTIDE; POLYMYXIN; LYSOZYME; PATHOGEN AB The alarming rise in antibiotic resistance has led to an increase in patient mortality and health care costs. This problem is compounded by the absence of new antibiotics close to regulatory approval. Acinetobacter baumannii is a human pathogen that causes infections primarily in patients in intensive care units (ICUs) and is highly antibiotic resistant. Colistin is one of the last-line antibiotics for treating A. baumannii infections; however, colistin-resistant strains are becoming increasingly common. This cationic antibiotic attacks negatively charged bacterial membranes in a manner similar to that seen with cationic antimicrobials of the innate immune system. We therefore set out to determine if the increasing use of colistin, and emergence of colistin-resistant strains, is concomitant with the generation of cross-resistance to host cationic antimicrobials. We found that there is indeed a positive correlation between resistance to colistin and resistance to the host antimicrobials LL-37 and lysozyme among clinical isolates. Importantly, isolates obtained before and after treatment of individual patients demonstrated that colistin use correlated with increased resistance to cationic host antimicrobials. These data reveal the overlooked risk of inducing cross-resistance to host antimicrobials when treating patients with colistin as a last-line antibiotic. IMPORTANCE Increased use of the cationic antibiotic colistin to treat multidrug-resistant Acinetobacter baumannii has led to the development of colistin-resistant strains. Here we report that treatment of patients with colistin can induce not only increased resistance to colistin but also resistance to host cationic antimicrobials. This worrisome finding likely represents an example of a broader trend observed in other bacteria against which colistin is used therapeutically such as Pseudomonas aeruginosa and Klebsiella pneumoniae. Furthermore, these data suggest that the possible future use of an array of cationic antimicrobial peptides in development as therapeutics may have unintended negative consequences, eventually leading to the generation of hypervirulent strains that are resistant to innate host defenses. The potential for the induction of cross-resistance to innate immune antimicrobials should be considered during the development of new therapeutics. C1 [Napier, Brooke A.; Weiss, David S.] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA. [Napier, Brooke A.; Weiss, David S.] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA. [Burd, Eileen M.; Satola, Sarah W.; Cagle, Stephanie M.; Ray, Susan M.; Weiss, David S.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA. [Satola, Sarah W.] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Satola, Sarah W.; Cagle, Stephanie M.; Ray, Susan M.] Georgia Emerging Infect Program, Atlanta, GA USA. [Burd, Eileen M.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [McGann, Patrick; Lesho, Emil P.] Walter Reed Army Inst Res, Multidrug Resistant Organism Repository & Surveil, Silver Spring, MD USA. [Pohl, Jan] Ctr Dis Control & Prevent, Div Sci Resources, Biotechnol Core Facil Branch, Atlanta, GA USA. [Ray, Susan M.] Grady Mem Hosp, Atlanta, GA USA. RP Weiss, DS (reprint author), Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA. EM david.weiss@emory.edu RI Valle, Ruben/A-7512-2013 FU NIH [R21-AI098800] FX This work was supported by NIH grant R21-AI098800. Its contents are solely our responsibility and do not necessarily represent the official views of the NIH. NR 25 TC 15 Z9 15 U1 2 U2 16 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 2150-7511 J9 MBIO JI mBio PD MAY-JUN PY 2013 VL 4 IS 3 AR e00021-13 DI 10.1128/mBio.00021-13 PG 5 WC Microbiology SC Microbiology GA 174WK UT WOS:000321187400003 PM 23695834 ER PT J AU McCarthy, KS Guntapong, R Thattiyaphong, A Wangroongsarb, P Hall, AJ Olsen, SJ Holtz, TH AF McCarthy, Katie S. Guntapong, Ratigorn Thattiyaphong, Aree Wangroongsarb, Piyada Hall, Aron J. Olsen, Sonja J. Holtz, Timothy H. TI OUTBREAK OF NOROVIRUS GASTROENTERITIS INFECTION, THAILAND SO SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH LA English DT Article DE norovirus; foodborne disease; disease outbreaks; Thailand ID FOODBORNE-DISEASE OUTBREAKS; GENETIC DIVERSITY; UNITED-STATES; CHIANG-MAI; FOOD WORKERS; SAPOVIRUS; SURVEILLANCE; SPREAD AB Norovirus is a leading cause of gastrointestinal illness worldwide. We investigated an outbreak of gastrointestinal illness in Pattaya, Thailand, among participants of a course. We asked participants and family members to complete a questionnaire asking about symptoms, meals eaten, and foods consumed during the course. We collected stool samples from persons reporting illness and analyzed specimens for several viruses and enteropathogenic bacteria. We defined a case as a person having one or more episodes of diarrhea, with onset between 30 August and 1 September 2010, in a participant or family member who attended the course. Of 56 people who attended, 95% completed the questionnaire: nine met the case definition (attack rate, 17%). Common symptoms included abdominal cramps, nausea, fatigue, headache, and vomiting. Food items with elevated risk ratios included: crispy fish maw, dried squid, and cashew nut salad [risk ratio (RR) 5.1; 95% confidence interval (CI) 0.7-37]; assorted salad bar with dressing (RR 3.0; 95% CI 0.9-11); and seafood kebab (RR 5.8; 95% CI 0.8-43). Among ill persons, four (44%) provided stool samples and two (50%) were positive for norovirus. Our data suggest a foodborne outbreak of norovirus. Increased use of norovirus diagnostics as well as measures to prevent transmission may help identify additional outbreaks and improve control measures to limit the spread of outbreaks. C1 [McCarthy, Katie S.] ASPH CDC Allan Rosenfield Global Hlth Fellow, Bangkok, Thailand. [McCarthy, Katie S.; Olsen, Sonja J.; Holtz, Timothy H.] Thailand Minist Publ Hlth, US Ctr Dis Control & Prevent Collaborat, Nonthaburi, Thailand. [Guntapong, Ratigorn; Thattiyaphong, Aree; Wangroongsarb, Piyada] Thailand Minist Publ Hlth, Natl Inst Hlth, Nonthaburi, Thailand. [Hall, Aron J.; Olsen, Sonja J.; Holtz, Timothy H.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Holtz, TH (reprint author), Minist Publ Hlth, Thailand MOPH US CDC Collaborat, DDC7 Bldg,4th Floor, Nonthaburi 11000, Thailand. EM tkh3@cdc.gov FU Centers for Disease Control and Prevention (CDC) through the Association of Schools of Public Health (ASPH) [5U36CD300430] FX We would like to thank Wiwan Sanasuttipun, Ornanong Ratchachenchai, Anchalee Warapronmongkholkul, Tanyawarin Janthiraj, and Frits van Griensven for their assistance in this investigation. This investigation was supported in part by a cooperative agreement with the Centers for Disease Control and Prevention (CDC) through the Association of Schools of Public Health (ASPH) Grant Number 5U36CD300430. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or ASPH. NR 18 TC 4 Z9 4 U1 3 U2 9 PU SOUTHEAST ASIAN MINISTERS EDUC ORGANIZATION PI BANGKOK PA SEAMEO-TROPMED, 420-6 RAJVITHI RD,, BANGKOK 10400, THAILAND SN 0125-1562 J9 SE ASIAN J TROP MED JI Southeast Asian J. Trop. Med. Public Health PD MAY PY 2013 VL 44 IS 3 BP 409 EP 416 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases; Tropical Medicine SC Public, Environmental & Occupational Health; Infectious Diseases; Tropical Medicine GA 164PH UT WOS:000320421500007 PM 24050072 ER PT J AU Semprini, AE Macaluso, M Hollander, L Vucetich, A Duerr, A Mor, G Ravizza, M Jamieson, DJ AF Semprini, Augusto Enrico Macaluso, Maurizio Hollander, Lital Vucetich, Alessandra Duerr, Ann Mor, Gil Ravizza, Marina Jamieson, Denise J. TI Safe conception for HIV-discordant couples: insemination with processed semen from the HIV-infected partner SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE assisted reproduction; effectivenes; follow-up studies; human immunodeficiency virus transmission; safety ID PROVIDING FERTILITY CARE; SERODISCORDANT COUPLES; ANTIRETROVIRAL THERAPY; ASSISTED REPRODUCTION; SPERM; SPERMATOZOA; INTRAUTERINE; EXPERIENCE; EFFICACY; WOMEN AB OBJECTIVE: The objective of the study was to evaluate the safety of semen washing with intrauterine insemination (SW-IUI) for achieving pregnancy when the man is human immunodeficiency virus (HIV) infected and the woman is HIV negative. STUDY DESIGN: We conducted a retrospective analysis of 635 HIV-discordant couples enrolled in a SW-IUI program and followed up 367 Italian women. We computed pregnancy, live birth, and multiple delivery rates and assessed the women's postinsemination HIV status. RESULTS: The retrospective analysis included 635 couples (2113 SW-IUI cycles): 41% of the women (95% confidence interval [CI], 37-45%) had a live birth (per-cycle live birth rate 13%; 95% CI, 11-14%). HIV status after SW-IUI was negative when available but unknown for 26% of the women: missing HIV status was not associated with correlates of HIV risk. The follow-up study included 367 couples (1365 cycles): 47% of the women (95% CI, 42-52%) had a live birth (per-cycle rate 14%; 95% CI, 12-16%). Ascertainment of postinsemination HIV status was complete and confirmed no HIV transmission attributable to SW-IUI. The upper 95% confidence limit of the HIV transmission rate was 1.8 per 1000 cycles in the retrospective analysis and 2.7 per 1000 cycles in the follow-up study. CONCLUSION: SW-IUI appears to be a safe and effective method for achieving pregnancy in HIV-discordant couples in which the man is HIV infected. C1 [Semprini, Augusto Enrico; Hollander, Lital; Vucetich, Alessandra; Mor, Gil] Esman Med Consulting, Milan, Italy. [Ravizza, Marina] San Paolo Hosp, Dept Obstet & Gynecol, Milan, Italy. [Macaluso, Maurizio; Duerr, Ann; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Semprini, AE (reprint author), Esman Med Consulting, Milan, Italy. RI Macaluso, Maurizio/J-2076-2015; OI Macaluso, Maurizio/0000-0002-2977-9690; SEMPRINI, AUGUSTO ENRICO/0000-0002-1113-2012; Hollander, Lital/0000-0001-5990-5267 FU Contraceptive Research and Development, Eastern Virginia Medical School [CSA-01-388]; United States Agency for International Development [HRN-A-00-98-00020-00]; Division of Reproductive Health, Centers for Disase Control and Prevention FX This study was supported by Contraceptive Research and Development, Eastern Virginia Medical School, subproject (CSA-01-388) under a Cooperative Agreement with the United States Agency for International Development (grant HRN-A-00-98-00020-00), which in turn receives funds for AIDS research from an interagency agreement with the Division of Reproductive Health, Centers for Disase Control and Prevention. NR 32 TC 3 Z9 4 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD MAY PY 2013 VL 208 IS 5 AR 402.e1 DI 10.1016/j.ajog.2013.02.009 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 139WE UT WOS:000318614900025 PM 23395921 ER PT J AU Abney, CW Knaack, JLS Ali, AAI Johnson, RC AF Abney, Carter W. Knaack, Jennifer L. S. Ali, Ahmed A. I. Johnson, Rudolph C. TI Novel Dual-Mode Immunomagnetic Method for Studying Reactivation of Nerve Agent-Inhibited Butyrylcholinesterase SO CHEMICAL RESEARCH IN TOXICOLOGY LA English DT Article ID TANDEM MASS-SPECTROMETRY; ACETYLCHOLINESTERASE ACTIVITY; ORGANOPHOSPHORUS COMPOUNDS; RETROSPECTIVE DETECTION; KINETIC-ANALYSIS; AGING KINETICS; HUMAN-SERUM; SARIN; EXPOSURE; CHOLINESTERASES AB A novel immunomagnetic method has been developed for the simultaneous measurement of organophosphorus nerve agent (OPNA) adducts to butyrylcholinesterase (BuChE) and free OPNAs in serum. This new approach, deemed dual-mode immunomagnetic analysis (Dual-Mode IMA), combines immunomagnetic separation (IMS) and immunomagnetic scavenging (IMSc) and has been used to measure the effectiveness of cholinesterase reactivators on OPNA-inhibited BuChE in serum. BuChE inhibited by the nerve agent VX, uninhibited BuChE, and unbound VX were measured up to 1 h after the addition of oxime reactivators pralidoxime (2-PAM) and obidoxime. IMS experiments consisted of extracting BuChE and VX-BuChE serum adducts using antibutyrylcholinesterase monoclonal antibodies conjugated to protein-G ferromagnetic particles. In a parallel set of experiments using IMSc, BuChE-coated magnetic beads were used to extract free VX from protein-depleted serum. Adducts from both IMS and IMSc were analyzed using a published IMS liquid chromatography tandem mass spectrometry (IMS-LC-MS/MS) protocol, which has also been demonstrated with other OPNAs. By applying this Dual-Mode IMA approach, 2-PAM was observed to be more potent than obidoxime in reactivating VX-adducted BuChE. VX-BuChE peptide concentrations initially measured at 19.7 +/- 0.7 ng/mL decreased over 1 h to 10.6 +/- 0.6 ng/mL when reactivated with 2-PAM and 14.4 +/- 1.2 ng/mL when reactivated with obidoxime. These experiments also show that previously published IMS-LC-MS/MS analyses are compatible with serum treated with oximes. Dual-Mode IMA is the first immunoaffinity method developed for the simultaneous measurement of OPNA adducted BuChE, unadducted BuChE, and free nerve agent in serum and is a promising new tool for studying reactivator effectiveness on cholinesterases inhibited by nerve agents. C1 [Abney, Carter W.; Ali, Ahmed A. I.] Ctr Dis Control & Prevent, Oak Ridge Inst Sci & Educ Fellow, Atlanta, GA 30341 USA. [Knaack, Jennifer L. S.; Johnson, Rudolph C.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Johnson, RC (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway,MS F44, Atlanta, GA 30341 USA. EM RJohnson6@cdc.gov OI Abney, Carter/0000-0002-1809-9577 FU Centers for Disease Control and Prevention; Centers for Disease Control and Prevention by the Oak Ridge Institute for Science and Education FX This work was funded by the Centers for Disease Control and Prevention and in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the CDC. NR 41 TC 4 Z9 5 U1 2 U2 15 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0893-228X J9 CHEM RES TOXICOL JI Chem. Res. Toxicol. PD MAY PY 2013 VL 26 IS 5 BP 775 EP 782 DI 10.1021/tx4000717 PG 8 WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology SC Pharmacology & Pharmacy; Chemistry; Toxicology GA 155BN UT WOS:000319720500017 PM 23656164 ER PT J AU Kerr, J Sallis, JF Owen, N De Bourdeaudhuij, I Cerin, E Sugiyama, T Reis, R Sarmiento, O Fromel, K Mitas, J Troelsen, J Christiansen, LB Macfarlane, D Salvo, D Schofield, G Badland, H Guillen-Grima, F Aguinaga-Ontoso, I Davey, R Bauman, A Saelens, B Riddoch, C Ainsworth, B Pratt, M Schmidt, T Frank, L Adams, M Conway, T Cain, K Van Dyck, D Bracy, N AF Kerr, Jacqueline Sallis, James F. Owen, Neville De Bourdeaudhuij, Ilse Cerin, Ester Sugiyama, Takemi Reis, Rodrigo Sarmiento, Olga Froemel, Karel Mitas, Josef Troelsen, Jens Christiansen, Lars Breum Macfarlane, Duncan Salvo, Deborah Schofield, Grant Badland, Hannah Guillen-Grima, Francisco Aguinaga-Ontoso, Ines Davey, Rachel Bauman, Adrian Saelens, Brian Riddoch, Chris Ainsworth, Barbara Pratt, Michael Schmidt, Tom Frank, Lawrence Adams, Marc Conway, Terry Cain, Kelli Van Dyck, Delfien Bracy, Nicole TI Advancing Science and Policy Through a Coordinated International Study of Physical Activity and Built Environments: IPEN Adult Methods SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE walking; walkability; pooled analyses; global; urban ID PERCEIVED NEIGHBORHOOD ENVIRONMENT; ACTIVITY QUESTIONNAIRE; BELGIAN ADULTS; ACTIGRAPH ACCELEROMETERS; ECOLOGICAL APPROACH; AUSTRALIAN ADULTS; WALKABILITY SCALE; ACTIVITY BEHAVIOR; HEALTH OUTCOMES; UNITED-STATES AB Background: National and international strategies to increase physical activity emphasize environmental and policy changes that can have widespread and long-lasting impact. Evidence from multiple countries using comparable methods is required to strengthen the evidence base for such initiatives. Because some environment and policy changes could have generalizable effects and others may depend on each country's context, only international studies using comparable methods can identify the relevant differences. Methods: Currently 12 countries are participating in the International Physical Activity and the Environment Network (IPEN) study. The IPEN Adult study design involves recruiting adult participants from neighborhoods with wide variations in environmental walkability attributes and socioeconomic status (SES). Results: Eleven of twelve countries are providing accelerometer data and 11 are providing GIS data. Current projections indicate that 14,119 participants will provide survey data on built environments and physical activity and 7145 are likely to provide objective data on both the independent and dependent variables. Though studies are highly comparable, some adaptations are required based on the local context. Conclusions: This study was designed to inform evidencebased international and country-specific physical activity policies and interventions to help prevent obesity and other chronic diseases that are high in developed countries and growing rapidly in developing countries. C1 [Kerr, Jacqueline; Sallis, James F.; Conway, Terry; Cain, Kelli] Univ Calif San Diego, La Jolla, CA 92093 USA. [Sallis, James F.; Adams, Marc; Conway, Terry; Cain, Kelli; Bracy, Nicole] San Diego State Univ, San Diego, CA 92182 USA. [Ainsworth, Barbara; Adams, Marc] Arizona State Univ, Tempe, AZ 85287 USA. [Owen, Neville; Sugiyama, Takemi] Univ Queensland, Brisbane, Qld 4072, Australia. [Owen, Neville] Monash Univ, Clayton, Vic 3800, Australia. [Owen, Neville] Univ Melbourne, Melbourne, Vic 3010, Australia. [De Bourdeaudhuij, Ilse; Van Dyck, Delfien] Univ Ghent, B-9000 Ghent, Belgium. [Cerin, Ester; Macfarlane, Duncan] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. [Reis, Rodrigo] Pontificia Univ Catolica Parana, Maringa, Parana, Brazil. [Sarmiento, Olga] Univ Los Andes, Bogota, Colombia. [Froemel, Karel; Mitas, Josef] Palacky Univ, CR-77147 Olomouc, Czech Republic. [Troelsen, Jens; Christiansen, Lars Breum] Univ Southern Denmark, Odense, Denmark. [Salvo, Deborah] Emory Univ, Atlanta, GA 30322 USA. [Schofield, Grant] Auckland Univ Technol, Auckland, New Zealand. [Badland, Hannah] UCL, London WC1E 6BT, England. [Badland, Hannah] Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia. [Guillen-Grima, Francisco; Aguinaga-Ontoso, Ines] Univ Publ Navarra, Navarra, Spain. [Davey, Rachel] Univ Canberra, Canberra, ACT 2601, Australia. [Bauman, Adrian] Univ Sydney, Sydney, NSW 2006, Australia. [Saelens, Brian] Seattle Childrens Hosp, Seattle, WA USA. [Saelens, Brian] Univ Washington, Seattle, WA 98195 USA. [Riddoch, Chris] Univ Bath, Bath BA2 7AY, Avon, England. [Pratt, Michael; Schmidt, Tom] Ctr Dis Control & Prevent, Atlanta, GA USA. [Frank, Lawrence] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. RP Kerr, J (reprint author), Univ Calif San Diego, La Jolla, CA 92093 USA. RI Cerin, Ester/L-1271-2015; Reis, Rodrigo/F-7447-2012; Adams, Marc/C-3513-2013; OI Cerin, Ester/0000-0002-7599-165X; Reis, Rodrigo/0000-0002-9872-9865; Adams, Marc/0000-0001-6310-1472; Sugiyama, Takemi/0000-0002-8859-5269; Mitas, Josef/0000-0001-7219-931X; Owen, Neville/0000-0003-2784-4820; Sarmiento, Olga/0000-0002-9190-3568; DAVEY, RACHEL/0000-0002-6117-2872 FU NCI NIH HHS [R01 CA127296]; NHLBI NIH HHS [HL67350] NR 101 TC 54 Z9 56 U1 3 U2 38 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD MAY PY 2013 VL 10 IS 4 BP 581 EP 601 PG 21 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 163QI UT WOS:000320351600014 PM 22975776 ER PT J AU Zhang, XZ Bullard, KM Cotch, MF Wilson, MR Rovner, BW McGwin, G Owsley, C Barker, L Crews, JE Saaddine, JB AF Zhang, Xinzhi Bullard, Kai McKeever Cotch, Mary Frances Wilson, M. Roy Rovner, Barry W. McGwin, Gerald, Jr. Owsley, Cynthia Barker, Lawrence Crews, John E. Saaddine, Jinan B. TI Association Between Depression and Functional Vision Loss in Persons 20 Years of Age or Older in the United States, NHANES 2005-2008 SO JAMA OPHTHALMOLOGY LA English DT Article ID QUALITY-OF-LIFE; REPORTED VISUAL FUNCTION; DUAL SENSORY LOSS; MACULAR DEGENERATION; ELDERLY-PATIENTS; SELF-MANAGEMENT; MOOD DISORDERS; PRIME-MD; IMPAIRMENT; ADULTS AB Importance: This study provides further evidence from a national sample to generalize the relationship between depression and vision loss to adults across the age spectrum. Better recognition of depression among people reporting reduced ability to perform routine activities of daily living due to vision loss is warranted. Objectives: To estimate, in a national survey of US adults 20 years of age or older, the prevalence of depression among adults reporting visual function loss and among those with visual acuity impairment. The relationship between depression and vision loss has not been reported in a nationally representative sample of US adults. Previous studies have been limited to specific cohorts and predominantly focused on the older population. Design: The National Health and Nutrition Examination Survey (NHANES) 2005-2008. Setting: Across-sectional, nationally representative sample of adults, with prevalence estimates weighted to represent the civilian, noninstitutionalized US population. Participants: A total of 10 480 US adults 20 years of age or older. Main Outcome Measures: Depression, as measured by the 9-item Patient Health Questionnaire depression scale, and vision loss, as measured by visual function using a questionnaire and by visual acuity at examination. Results: In 2005-2008, the estimated crude prevalence of depression (9-item Patient Health Questionnaire score of >= 10) was 11.3% (95% CI, 9.7%-13.2%) among adults with self-reported visual function loss and 4.8% (95% CI, 4.0%-5.7%) among adults without. The estimated prevalence of depression was 10.7% (95% CI, 8.0%-14.3%) among adults with presenting visual acuity impairment (visual acuity worse than 20/40 in the better-seeing eye) compared with 6.8% (95% CI, 5.8%-7.8%) among adults with normal visual acuity. After controlling for age, sex, race/ethnicity, marital status, living alone or not, education, income, employment status, health insurance, body mass index, smoking, binge drinking, general health status, eyesight worry, and major chronic conditions, self-reported visual function loss remained significantly associated with depression (overall odds ratio, 1.9 [95% CI, 1.6-2.3]), whereas the association between presenting visual acuity impairment and depression was no longer statistically significant. Conclusions and Relevance: Self-reported visual function loss, rather than loss of visual acuity, is significantly associated with depression. Health professionals should be aware of the risk of depression among persons reporting visual function loss. C1 [Zhang, Xinzhi] Natl Inst Minor Hlth & Hlth Dispar, Div Data Management & Sci Reporting, NIH, Bethesda, MD 20892 USA. [Cotch, Mary Frances] NEI, NIH, Bethesda, MD 20892 USA. [Bullard, Kai McKeever; Barker, Lawrence; Crews, John E.; Saaddine, Jinan B.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Rovner, Barry W.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat, Philadelphia, PA 19107 USA. [Rovner, Barry W.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Neurol, Philadelphia, PA 19107 USA. [McGwin, Gerald, Jr.; Owsley, Cynthia] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL USA. RP Zhang, XZ (reprint author), Natl Inst Minor Hlth & Hlth Dispar, Div Data Management & Sci Reporting, NIH, 6707 Democracy Blvd,Ste 800, Bethesda, MD 20892 USA. EM xinzhi.zhang@nih.gov OI Cotch, Mary Frances/0000-0002-2046-4350 FU National Center for Health Statistics of the CDC; Division of Diabetes Translation of the CDC [05FED47304]; National Eye Institute/National Institutes of Health [ZIAEY000402] FX This study was supported by the National Center for Health Statistics of the CDC. Funding for the NHANES retinal component was provided by intra-agency agreement 05FED47304 from the Division of Diabetes Translation of the CDC. Funding for the vision component was provided by Intramural Research Program award ZIAEY000402 from the National Eye Institute/National Institutes of Health. NR 72 TC 31 Z9 32 U1 3 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6165 EI 2168-6173 J9 JAMA OPHTHALMOL JI JAMA Ophthalmol. PD MAY PY 2013 VL 131 IS 5 BP 573 EP 581 DI 10.1001/jamaophthalmol.2013.2597 PG 9 WC Ophthalmology SC Ophthalmology GA 163JY UT WOS:000320333300002 PM 23471505 ER PT J AU Gavidia, CM Verastegui, MR Garcia, HH Lopez-Urbina, T Tsang, VCW Pan, W Gilman, RH Gonzalez, AE AF Gavidia, Cesar M. Verastegui, Manuela R. Garcia, Hector H. Lopez-Urbina, Teresa Tsang, Victor C. W. Pan, William Gilman, Robert H. Gonzalez, Armando E. CA Cysticercosis Working Grp Peru TI Relationship between Serum Antibodies and Taenia solium Larvae Burden in Pigs Raised in Field Conditions SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID PORCINE CYSTICERCOSIS; SWINE CYSTICERCOSIS; INFECTION; PERU; NEUROCYSTICERCOSIS; DIAGNOSIS; ANTIGENS; ELISA; OXFENDAZOLE; PREVALENCE AB Background: Serological tests have been used for the diagnosis of Taenia solium infection in pigs. However, those serological results do not necessarily correlate with the actual infection burden after performing pig necropsy. This study aimed to evaluate the Electro Immuno Transfer Blot (EITB) seropositivity with infection burden in naturally infected pigs. Methodology/Principal Findings: In an endemic area of Peru, 476 pigs were sampled. Seroprevalence was 60.5 +/- 4.5% with a statistically higher proportion of positive older pigs (>8 months) than young pigs. The logistic model showed that pigs >8 month of age were 2.5 times more likely to be EITB-positive than <= 8 months. A subset of 84 seropositive pigs were necropsied, with 45.2% (38/84) positive to 1-2 bands, 46.4% (39/84) to 3 bands, and 8.3% (7/84) to 4+ bands. 41 out of 84 positive pigs were negative to necropsy (48.8%) and 43 (51%) had one or more cysts (positive predictive value). Older pigs showed more moderate and heavy infection burdens compared to younger pigs. In general, regardless of the age of the pig, the probability of having more cysts (parasite burden) increases proportionally with the number of EITB bands. Conclusions/Significance: The probability of being necropsy-positive increased with the number of bands, and age. Therefore, the EITB is a measure of exposure rather than a test to determine the real prevalence of cysticercosis infection. C1 [Gavidia, Cesar M.; Lopez-Urbina, Teresa; Gonzalez, Armando E.] Univ Nacl Mayor San Marcos, Sch Vet Med, Lima 14, Peru. [Verastegui, Manuela R.; Garcia, Hector H.] Univ Peruana Cayetano Heredia, Sch Sci, Dept Microbiol, Lima, Peru. [Tsang, Victor C. W.] Ctr Dis Control, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA. [Pan, William] Duke Univ, Duke Global Hlth Inst, Durham, NC USA. [Pan, William] Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA. [Gilman, Robert H.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Cysticercosis Working Grp Peru] Cysticercosis Working Grp Peru, Lima, Peru. RP Gavidia, CM (reprint author), Univ Nacl Mayor San Marcos, Sch Vet Med, Lima 14, Peru. EM cgavidia@jhsph.edu OI Jimenez Chunga, Juan Atilio/0000-0002-6431-8371; Gavidia, Cesar Miguel/0000-0003-3936-5077 FU National Institutes of Health [U01 AI35894]; Wellcome Trust, UK [USA 063109]; National Institutes of Health, USA [P01 AI51976, TW05562]; Food and Drug Administration [01107]; Bill and Melinda Gates Foundation, USA [23981] FX This project was supported by the National Institutes of Health grant number U01 AI35894. Other supporting research grants are USA 063109 from the Wellcome Trust, UK; P01 AI51976, and TW05562 from the National Institutes of Health, USA; 01107 from the Food and Drug Administration, and 23981 from the Bill and Melinda Gates Foundation, USA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 37 TC 10 Z9 11 U1 0 U2 15 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAY PY 2013 VL 7 IS 5 AR e2192 DI 10.1371/journal.pntd.0002192 PG 8 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 158SW UT WOS:000319994400007 PM 23658848 ER PT J AU Huang, CYH Kinney, RM Livengood, JA Bolling, B Arguello, JJ Luy, BE Silengo, SJ Boroughs, KL Stovall, JL Kalanidhi, AP Brault, AC Osorio, JE Stinchcomb, DT AF Huang, Claire Y. -H. Kinney, Richard M. Livengood, Jill A. Bolling, Bethany Arguello, John J. Luy, Betty E. Silengo, Shawn J. Boroughs, Karen L. Stovall, Janae L. Kalanidhi, Akundi P. Brault, Aaron C. Osorio, Jorge E. Stinchcomb, Dan T. TI Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax) SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID ATTENUATED FLAVIVIRUS VACCINES; AEDES-AEGYPTI; GROWTH-CHARACTERISTICS; CYNOMOLGUS MONKEYS; ORAL INFECTION; PDK-53 VIRUS; LIVE; NEUROVIRULENCE; MICE; FORMULATIONS AB Background: We have developed a manufacturing strategy that can improve the safety and genetic stability of recombinant live-attenuated chimeric dengue vaccine (DENVax) viruses. These viruses, containing the pre-membrane (prM) and envelope (E) genes of dengue serotypes 1-4 in the replicative background of the attenuated dengue-2 PDK-53 vaccine virus candidate, were manufactured under cGMP. Methodology/Principal Findings: After deriving vaccine viruses from RNA-transfected Vero cells, six plaque-purified viruses for each serotype were produced. The plaque-purified strains were then analyzed to select one stock for generation of the master seed. Full genetic and phenotypic characterizations of the master virus seeds were conducted to ensure these viruses retained the previously identified attenuating determinants and phenotypes of the vaccine viruses. We also assessed vector competence of the vaccine viruses in sympatric (Thai) Aedes aegypti mosquito vectors. Conclusion/Significance: All four serotypes of master vaccine seeds retained the previously defined safety features, including all three major genetic loci of attenuation, small plaques, temperature sensitivity in mammalian cells, reduced replication in mosquito cell cultures, and reduced neurovirulence in new-born mice. In addition, the candidate vaccine viruses demonstrated greatly reduced infection and dissemination in Aedes aegypti mosquitoes, and are not likely to be transmissible by these mosquitoes. This manufacturing strategy has successfully been used to produce the candidate tetravalent vaccine, which is currently being tested in human clinical trials in the United States, Central and South America, and Asia. C1 [Huang, Claire Y. -H.; Kinney, Richard M.; Bolling, Bethany; Arguello, John J.; Luy, Betty E.; Silengo, Shawn J.; Boroughs, Karen L.; Stovall, Janae L.; Brault, Aaron C.] Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Dis, Ft Collins, CO USA. [Livengood, Jill A.; Osorio, Jorge E.; Stinchcomb, Dan T.] Inviragen Inc, Ft Collins, CO USA. [Livengood, Jill A.; Osorio, Jorge E.; Stinchcomb, Dan T.] Inviragen Inc, Madison, WI USA. [Kalanidhi, Akundi P.] Shantha Biotech Ltd, Hyderabad, Andhra Pradesh, India. RP Huang, CYH (reprint author), Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Dis, Ft Collins, CO USA. EM chuang1@cdc.gov OI Stinchcomb, Dan/0000-0002-3634-7503 FU Centers for the Disease Control and Prevention; Inviragen; Dengue Vaccine Initiative of the International Vaccine Institute; National Institute of Allergy and Infectious Disease of the National Institutes of Health [1 U01AI070433] FX This study was supported primarily by the Centers for the Disease Control and Prevention, Inviragen, a grant from Dengue Vaccine Initiative (previously Pediatric Dengue Vaccine Initiative) of the International Vaccine Institute, and grant 1 U01AI070433 from the National Institute of Allergy and Infectious Disease of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 33 TC 18 Z9 19 U1 2 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAY PY 2013 VL 7 IS 5 AR e2243 DI 10.1371/journal.pntd.0002243 PG 11 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 158SW UT WOS:000319994400043 PM 23738026 ER PT J AU Krolewiecki, AJ Lammie, P Jacobson, J Gabrielli, AF Levecke, B Socias, E Arias, LM Sosa, N Abraham, D Cimino, R Echazu, A Crudo, F Vercruysse, J Albonico, M AF Krolewiecki, Alejandro J. Lammie, Patrick Jacobson, Julie Gabrielli, Albis-Francesco Levecke, Bruno Socias, Eugenia Arias, Luis M. Sosa, Nicanor Abraham, David Cimino, Ruben Echazu, Adriana Crudo, Favio Vercruysse, Jozef Albonico, Marco TI A Public Health Response against Strongyloides stercoralis : Time to Look at Soil-Transmitted Helminthiasis in Full SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Review ID IVERMECTIN; INFECTIONS; ALBENDAZOLE; DIAGNOSIS; CHILDREN; TRIAL; COMMUNITY; EFFICACY; ASSAY; THIABENDAZOLE AB Strongyloides stercoralis infections have a worldwide distribution with a global burden in terms of prevalence and morbidity that is largely ignored. A public health response against soil-transmitted helminth (STH) infections should broaden the strategy to include S. stercoralis and overcome the epidemiological, diagnostic, and therapeutic challenges that this parasite poses in comparison to Ascaris lumbricoides, Trichuris trichiura, and hookworms. The relatively poor sensitivity of single stool evaluations, which is further lowered when quantitative techniques aimed at detecting eggs are used, also complicates morbidity evaluations and adequate drug efficacy measurements, since S. stercoralis is eliminated in stools in a larval stage. Specific stool techniques for the detection of larvae of S. stercoralis, like Baermann's and Koga's agar plate, despite superiority over direct techniques are still suboptimal. New serologies using recombinant antigens and molecular-based techniques offer new hopes in those areas. The use of ivermectin rather than benzimidazoles for its treatment and the need to have curative regimens rather than lowering the parasite burden are also unique for S. stercoralis in comparison to the other STH due to its life cycle, which allows reproduction and amplification of the worm burden within the human host. The potential impact on STH of the benzimidazoles/ivermectin combinations, already used for control/elimination of lymphatic filariasis, should be further evaluated in public health settings. While waiting for more effective single-dose drug regimens and new sensitive diagnostics, the evidence and the tools already available warrant the planning of a common platform for STH and S. stercoralis control. C1 [Krolewiecki, Alejandro J.; Cimino, Ruben; Echazu, Adriana] Univ Nacl Salta, Inst Invest Enfermedades Trop, Oran, Argentina. [Krolewiecki, Alejandro J.] Inst Patol Expt CONICET, Salta, Argentina. [Lammie, Patrick] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Jacobson, Julie] Bill & Melinda Gates Fdn, Seattle, WA USA. [Gabrielli, Albis-Francesco] World Hlth Org, Dept Control Neglected Trop Dis, Geneva, Switzerland. [Levecke, Bruno; Vercruysse, Jozef] Univ Ghent, Fac Vet Med, Dept Virol Parasitol & Immunol, Merelbeke, Belgium. [Socias, Eugenia] Fdn Mundo Sano, Buenos Aires, DF, Argentina. [Arias, Luis M.; Sosa, Nicanor] Minist Salud Publ Prov Salta, Salta, Argentina. [Abraham, David] Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA. [Crudo, Favio] Municipalidad Zarate, Subsecretaria Salud, Zarate, Argentina. [Albonico, Marco] Sacro Cuore Hosp, Ctr Trop Dis, Negrar, Italy. [Albonico, Marco] Ivo de Carneri Fdn IdCF, Milan, Italy. RP Krolewiecki, AJ (reprint author), Univ Nacl Salta, Inst Invest Enfermedades Trop, Oran, Argentina. EM alekrol@hotmail.com OI ALBONICO, Marco/0000-0002-7805-2391 FU Bill & Melinda Gates Foundation; Ministry of Health of the Province of Salta, Argentina; Fundacion Mundo Sano, Oran, Salta, Argentina; EC [FP7-GA-261495]; WHO FX This paper was produced as a result of a Meeting on "Optimizing Therapeutic Options for STH", sponsored by the Bill & Melinda Gates Foundation, the Ministry of Health of the Province of Salta, Argentina and Fundacion Mundo Sano, held in Oran, Salta, Argentina; 16 and 17 August 2011. This paper reflects the personal views of the authors and should not be interpreted to represent official policies or positions of their respective institutions. The Bill & Melinda Gates Foundation supported the participation of most international experts. MA was co-funded by the EC within the 7th Framework Program under grant agreement no. FP7-GA-261495 (COHEMI network). AFG's participation was supported by WHO. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 47 TC 28 Z9 29 U1 3 U2 17 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAY PY 2013 VL 7 IS 5 AR e2165 DI 10.1371/journal.pntd.0002165 PG 7 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 158SW UT WOS:000319994400004 PM 23675541 ER PT J AU Li, R Bilik, D Brown, MB Zhang, P Ettner, SL Ackermann, RT Crosson, JC Herman, WH AF Li, Rui Bilik, Dori Brown, Morton B. Zhang, Ping Ettner, Susan L. Ackermann, Ronald T. Crosson, Jesse C. Herman, William H. TI Medical Costs Associated With Type 2 Diabetes Complications and Comorbidities SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID MANAGED-CARE; RESOURCE USE; POPULATION; PROJECTIONS; PREVALENCE; MELLITUS; US AB Objectives: To estimate the direct medical costs associated with type 2 diabetes, its complications, and its comorbidities among US managed care patients. Study Design: Data were from patient surveys, chart reviews, and health insurance claims for 7109 people with type 2 diabetes from 8 health plans participating in the Translating Research Into Action for Diabetes (TRIAD) study between 1999 and 2002. Methods: A generalized linear regression model was developed to estimate the association of patients' demographic characteristics, tobacco use status, treatments, related complications, and comorbidities with medical costs. Results: The mean annualized direct medical cost was $2465 for a white man with type 2 diabetes who had been diagnosed fewer than 15 years earlier, was treated with oral medication or diet alone, and had no complications or comorbidities. We found annualized medical costs to be 10% to 50% higher for women and for patients whose diabetes had been diagnosed 15 or more years earlier, who used tobacco, who were being treated with insulin, or who had several other complications. Coronary heart disease, congestive heart failure, hemiplegia, and amputation were each associated with 70% to 150% higher costs. Costs were approximately 300% higher for end-stage renal disease treated with dialysis and approximately 500% higher for end-stage renal disease with kidney transplantation. Conclusions: Most medical costs incurred by patients with type 2 diabetes are related to complications and comorbidities. Our cost estimates can help when determining the most cost-effective interventions to prevent complications and comorbidities. Am J Manag Care. 2013;19(5):421-430 C1 [Li, Rui; Zhang, Ping] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA. [Bilik, Dori; Herman, William H.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Brown, Morton B.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Ettner, Susan L.] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA USA. [Ackermann, Ronald T.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Crosson, Jesse C.] UMDNJ Robert Wood Johnson Med Sch, Dept Family Med & Community Hlth, New Brunswick, NJ USA. RP Li, R (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, 4770 Buford Hwy NE,MS K-10, Atlanta, GA 30341 USA. EM eok8@cdc.gov FU Centers for Disease Control and Prevention (Division of Diabetes Translation) [04005]; National Institute of Diabetes and Digestive and Kidney Diseases [04005]; Biostatistics and Economic Modeling Core of the Michigan Diabetes Research and Training Center from National Institute of Diabetes and Digestive and Kidney Diseases [P60DK020572] FX This study was jointly funded by Program Announcement number 04005 from the Centers for Disease Control and Prevention (Division of Diabetes Translation) and the National Institute of Diabetes and Digestive and Kidney Diseases. This analysis was also supported by the Biostatistics and Economic Modeling Core of the Michigan Diabetes Research and Training Center, Grant P60DK020572 from the National Institute of Diabetes and Digestive and Kidney Diseases. NR 18 TC 19 Z9 19 U1 1 U2 7 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD MAY PY 2013 VL 19 IS 5 BP 421 EP 430 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 162VH UT WOS:000320293600011 PM 23781894 ER PT J AU Broussard, CS AF Broussard, C. S. TI Anticipated Improvements to Human Data Content in the Proposed US FDA Pregnancy Label SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Broussard, C. S.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2013 VL 97 IS 5 SI SI BP 280 EP 280 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 171MB UT WOS:000320932100018 ER PT J AU Brousard, CS AF Brousard, C. S. TI Utility of Multidrug Disease-Based Pregnancy Registries to Inform Clinical Management Guidelines SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Brousard, C. S.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2013 VL 97 IS 5 SI SI BP 298 EP 298 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 171MB UT WOS:000320932100055 ER PT J AU Larocca, JL Binder, AM Carwile, JL Calafat, AM Michels, KB AF Larocca, J. L. Binder, A. M. Carwile, J. L. Calafat, A. M. Michels, K. B. TI Correlative and Predictive Values of First Trimester Urinary Phenol and Phthalate Concentrations from Two Boston-Based Prospective Birth Cohorts SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Larocca, J. L.] Harvard Univ, Ctr Environm, Cambridge, MA 02138 USA. [Binder, A. M.; Carwile, J. L.; Michels, K. B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Larocca, J. L.; Michels, K. B.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA. [Calafat, A. M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2013 VL 97 IS 5 SI SI BP 304 EP 304 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 171MB UT WOS:000320932100064 ER PT J AU Hanasen, JM Haris, C Gomez, RR Schuster, DZ Sant, KE Pohl, J Reed, M AF Hanasen, J. M. Haris, C. Gomez, R. R. Schuster, D. Z. Sant, K. E. Pohl, J. Reed, M. TI Inhibition of Glutathione Biosynthesis Alters Compartmental Redox Status and the Thiol Proteome in Organogenesis-Stage Rat Conceptuses SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Hanasen, J. M.] Emory Univ, Atlanta, GA 30322 USA. [Haris, C.; Gomez, R. R.; Schuster, D. Z.; Sant, K. E.] Univ Michigan, Ann Arbor, MI 48109 USA. [Pohl, J.; Reed, M.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2013 VL 97 IS 5 SI SI BP 306 EP 306 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 171MB UT WOS:000320932100068 ER PT J AU Ailes, E Peterson, C Riehle-Colarusso, T Oster, ME Olney, RS Cassell, CH Fixler, DE Carmichael, SL Shaw, GM Gilboa, SM AF Ailes, E. Peterson, C. Riehle-Colarusso, T. Oster, M. E. Olney, R. S. Cassell, C. H. Fixler, D. E. Carmichael, S. L. Shaw, G. M. Gilboa, S. M. TI Late-Detected Critical Congenital Heart Disease among US Newborns: Estimating the Potential Impact of Universal Screening SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Ailes, E.; Peterson, C.; Riehle-Colarusso, T.; Oster, M. E.; Olney, R. S.; Cassell, C. H.; Gilboa, S. M.] CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Ailes, E.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Oster, M. E.] Emory Univ, Sibley Heart Ctr, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA. [Fixler, D. E.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Carmichael, S. L.; Shaw, G. M.] Stanford Univ, Sch Med, Dept Pediat, Div Neonatal & Dev Med, Palo Alto, CA 94304 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2013 VL 97 IS 5 SI SI BP 319 EP 319 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 171MB UT WOS:000320932100093 ER PT J AU Carmichael, SL Ma, C Tinker, S Rasmussen, S Shaw, GM AF Carmichael, S. L. Ma, C. Tinker, S. Rasmussen, S. Shaw, G. M. TI Association of Maternal Stressors and Social Support with Risks of Birth Defects SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Carmichael, S. L.; Ma, C.; Shaw, G. M.] Stanford Univ, Stanford, CA 94305 USA. [Tinker, S.; Rasmussen, S.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2013 VL 97 IS 5 SI SI BP 320 EP 320 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 171MB UT WOS:000320932100095 ER PT J AU Peterson, SR Frey, MT Gilboa, SM Broussard, CS AF Peterson, S. R. Frey, M. T. Gilboa, S. M. Broussard, C. S. TI Public Perception of Risk Factors for Birth Defects: HealthStyles, 2010-2011 SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Peterson, S. R.] Emory Univ, Atlanta, GA 30322 USA. [Frey, M. T.; Gilboa, S. M.; Broussard, C. S.] CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Frey, M. T.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2013 VL 97 IS 5 SI SI BP 328 EP 328 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 171MB UT WOS:000320932100108 ER PT J AU Langlois, PH Hoyt, AT Lupo, PJ Lawson, CC Desrosiers, TA Shaw, GM Romitti, PA Symanski, E Reefhuis, J Malik, S AF Langlois, P. H. Hoyt, A. T. Lupo, P. J. Lawson, C. C. Desrosiers, T. A. Shaw, G. M. Romitti, P. A. Symanski, E. Reefhuis, J. Malik, S. TI Maternal Occupational Exposure to Polycyclic Aromatic Hydrocarbons and Risk of Selected Birth Defects SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Langlois, P. H.; Hoyt, A. T.] Texas Dept State Hlth Serv, Austin, TX USA. [Lupo, P. J.] Baylor Coll Med, Houston, TX 77030 USA. [Lawson, C. C.] NIOSH, Cincinnati, OH 45226 USA. [Desrosiers, T. A.] Univ N Carolina, Chapel Hill, NC USA. [Shaw, G. M.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Romitti, P. A.] Univ Iowa, Iowa City, IA USA. [Symanski, E.] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. [Reefhuis, J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Malik, S.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2013 VL 97 IS 5 SI SI BP 329 EP 329 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 171MB UT WOS:000320932100111 ER PT J AU Cragan, JD Jamieson, DJ Lavigne, SV Martinez, L Nichols, G Shealy, KR Wolfe, L AF Cragan, J. D. Jamieson, D. J. Lavigne, S., V Martinez, L. Nichols, G. Shealy, K. R. Wolfe, L. TI Evaluating the Quality of Data Collected by Teratology Information Services about Maternal and Infant Health Following Medication Use during Pregnancy and Lactation SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Cragan, J. D.; Jamieson, D. J.; Shealy, K. R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lavigne, S., V; Nichols, G.] Univ Connecticut, Ctr Hlth, Connecticut Pregnancy Exposure Informat Serv, Hartford, CT USA. [Martinez, L.] Utah Dept Hlth, Salt Lake City, UT 84116 USA. [Wolfe, L.] Univ N Texas, Texas Teratogen Informat Serv, Denton, TX 76203 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2013 VL 97 IS 5 SI SI BP 362 EP 362 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 171MB UT WOS:000320932100144 ER PT J AU Dere, R Yi, JH Lei, C Saad, OM Huang, C Li, YH Baudys, J Kaur, S AF Dere, Randall Yi, Joo-Hee Lei, Corinna Saad, Ola M. Huang, Catherine Li, Yanhong Baudys, Jakub Kaur, Surinder TI PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine SO BIOANALYSIS LA English DT Article ID METASTATIC BREAST-CANCER; IN-VIVO; MONOCLONAL-ANTIBODY; THERAPY; IMMUNOCONJUGATE; STABILITY; ONCOGENE; T-DM1 AB Background: Antibody drug conjugates (ADCs) combine the characteristics of large-molecule biologics and small-molecule drugs and are heterogeneous mixtures that can biotransform in vivo, resulting in additional complexity. ADC bioanalytical strategies require novel analytical methods, as well as existing large- and small-molecule methods. Because ADCs in late-stage clinical development are relatively new, regulatory guidelines and standard industry best practices for developing strategies for bioanalytical PK assays are still being established. Results: A PK assay strategy was developed that included comprehensive novel reagent and assay characterization approaches for the ADC ado-trastuzumab emtansine (T-DMI). Conclusion: The bioanalytical strategy was successfully applied to the drug development of T-DMI and ensured that key analytes were accurately measured in support of nonclinical and clinical development. C1 [Dere, Randall; Yi, Joo-Hee; Lei, Corinna; Saad, Ola M.; Huang, Catherine; Li, Yanhong; Kaur, Surinder] Genentech Inc, Dept Bioanalyt Sci, San Francisco, CA 94080 USA. [Baudys, Jakub] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Dere, R (reprint author), Genentech Inc, Dept Bioanalyt Sci, 1 DNA Way, San Francisco, CA 94080 USA. EM dere.randall@gene.com NR 29 TC 19 Z9 21 U1 1 U2 13 PU FUTURE SCI LTD PI LONDON PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND SN 1757-6180 J9 BIOANALYSIS JI Bioanalysis PD MAY PY 2013 VL 5 IS 9 BP 1025 EP 1040 DI 10.4155/BIO.13.72 PG 16 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 158FR UT WOS:000319955400011 PM 23641694 ER PT J AU Bardenheier, BH Elixhauser, A Imperatore, G Devlin, HM Kuklina, EV Geiss, LS Correa, A AF Bardenheier, Barbara H. Elixhauser, Anne Imperatore, Giuseppina Devlin, Heather M. Kuklina, Elena V. Geiss, Linda S. Correa, Adolfo TI Variation in Prevalence of Gestational Diabetes Mellitus Among Hospital Discharges for Obstetric Delivery Across 23 States in the United States SO DIABETES CARE LA English DT Article ID NEW-YORK-CITY; RACIAL/ETHNIC DISPARITIES; MATERNAL MORBIDITY; PREGNANT-WOMEN; OBESE WOMEN; TRENDS; POPULATION; RISK AB OBJECTIVE-To examine variability in diagnosed gestational diabetes mellitus (GDM) prevalence at delivery by race/ethnicity and state. RESEARCH DESIGN AND METHODS-We used data from the Healthcare Cost and Utilization Project State Inpatient Databases for 23 states of the United States with available race/ethnicity data for 2008 to examine age-adjusted and race-adjusted rates of GDM by state. We used multilevel analysis to examine factors that explain the variability in GDM between states. RESULTS-Age-adjusted and race-adjusted GDM rates (per 100 deliveries) varied widely between states, ranging from 3.47 in Utah to 7.15 in Rhode Island. Eighty-six percent of the variability in GDM between states was explained as follows: 14.7% by age; 11.8% by race/ethnicity; 5.9% by insurance; and 2.9% by interaction between race/ethnicity and insurance at the individual level; 17.6% by hospital level factors; 27.4% by the proportion of obese women in the state; 4.3% by the proportion of Hispanic women aged 15-44 years in the state; and 1.5% by the proportion of white non-Hispanic women aged 15-44 years in the state. CONCLUSIONS-Our results suggest that GDM rates differ by state, with this variation attributable to differences in obesity at the population level (or "at the state level"), age, race/ethnicity, hospital, and insurance. C1 [Bardenheier, Barbara H.; Imperatore, Giuseppina; Devlin, Heather M.; Geiss, Linda S.] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Elixhauser, Anne] Agcy Healthcare Res & Qual, Rockville, MD USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Kuklina, Elena V.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Bardenheier, BH (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM bfb7@cdc.gov NR 30 TC 25 Z9 25 U1 1 U2 7 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2013 VL 36 IS 5 BP 1209 EP 1214 DI 10.2337/dc12-0901 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 155WW UT WOS:000319782100024 PM 23248195 ER PT J AU Ruiz, P Myshkin, E Quigley, P Faroon, O Wheeler, JS Mumtaz, MM Brennan, RJ AF Ruiz, P. Myshkin, E. Quigley, P. Faroon, O. Wheeler, J. S. Mumtaz, M. M. Brennan, R. J. TI Assessment of hydroxylated metabolites of polychlorinated biphenyls as potential xenoestrogens: a QSAR comparative analysis SO SAR AND QSAR IN ENVIRONMENTAL RESEARCH LA English DT Article DE QSAR; OH-PCB; PCBs metabolites; estrogenicity; in silico metabolism ID ACTIVITY-RELATIONSHIP MODELS; RECEPTOR BINDING AFFINITIES; (Q)SAR APPLICATION TOOLBOX; IN-SILICO PREDICTION; TOXICITY END-POINTS; ESTROGEN-RECEPTOR; OH-PCBS; APPLICABILITY DOMAIN; VARIABLE SELECTION; DIVERSE CHEMICALS AB Alternative methods, including quantitative structure-activity relationships (QSAR), are being used increasingly when appropriate data for toxicity evaluation of chemicals are not available. Approximately 40 mono-hydroxylated polychlorinated biphenyls (OH-PCBs) have been identified in humans. They represent a health and environmental concern because some of them have been shown to have agonist or antagonist interactions with human hormone receptors. This could lead to modulation of steroid hormone receptor pathways and endocrine system disruption. We performed QSAR analyses using available estrogenic activity (human estrogen receptor ER alpha) data for 71 OH-PCBs. The modelling was performed using multiple molecular descriptors including electronic, molecular, constitutional, topological, and geometrical endpoints. Multiple linear regressions and recursive partitioning were used to best fit descriptors. The results show that the position of the hydroxyl substitution, polarizability, and meta adjacent un-substituted carbon pairs at the phenolic ring contribute towards greater estrogenic activity for these chemicals. These comparative QSAR models may be used for predictive toxicity, and identification of health consequences of PCB metabolites that lack empirical data. Such information will help prioritize such molecules for additional testing, guide future basic laboratory research studies, and help the health/risk assessment community understand the complex nature of chemical mixtures. C1 [Ruiz, P.; Faroon, O.; Wheeler, J. S.; Mumtaz, M. M.] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA USA. [Myshkin, E.; Brennan, R. J.] Thomson Reuters, Carlsbad, CA USA. RP Ruiz, P (reprint author), Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA USA. EM pruiz@cdc.gov NR 84 TC 7 Z9 7 U1 1 U2 31 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1062-936X J9 SAR QSAR ENVIRON RES JI SAR QSAR Environ. Res. PD MAY 1 PY 2013 VL 24 IS 5 SI SI BP 659 EP 682 DI 10.1080/1062936X.2013.781537 PG 24 WC Chemistry, Multidisciplinary; Computer Science, Interdisciplinary Applications; Environmental Sciences; Mathematical & Computational Biology; Toxicology SC Chemistry; Computer Science; Environmental Sciences & Ecology; Mathematical & Computational Biology; Toxicology GA 161II UT WOS:000320185900004 PM 23557136 ER PT J AU Tynan, MA Ribisl, KM Loomis, BR AF Tynan, Michael A. Ribisl, Kurt M. Loomis, Brett R. TI Impact of cigarette minimum price laws on the retail price of cigarettes in the USA SO TOBACCO CONTROL LA English DT Article ID COMPANY INCENTIVE PROGRAMS; TOBACCO; STORES; PROMOTIONS; SMOKING AB Introduction Cigarette price increases prevent youth initiation, reduce cigarette consumption and increase the number of smokers who quit. Cigarette minimum price laws (MPLs), which typically require cigarette wholesalers and retailers to charge a minimum percentage mark-up for cigarette sales, have been identified as an intervention that can potentially increase cigarette prices. 24 states and the District of Columbia have cigarette MPLs. Methods Using data extracted from SCANTRACK retail scanner data from the Nielsen company, average cigarette prices were calculated for designated market areas in states with and without MPLs in three retail channels: grocery stores, drug stores and convenience stores. Regression models were estimated using the average cigarette pack price in each designated market area and calendar quarter in 2009 as the outcome variable. Results The average difference in cigarette pack prices are 46 cents in the grocery channel, 29 cents in the drug channel and 13 cents in the convenience channel, with prices being lower in states with MPLs for all three channels. Conclusions The findings that MPLs do not raise cigarette prices could be the result of a lack of compliance and enforcement by the state or could be attributed to the minimum state mark-up being lower than the free-market mark-up for cigarettes. Rather than require a minimum mark-up, which can be nullified by promotional incentives and discounts, states and countries could strengthen MPLs by setting a simple 'floor price' that is the true minimum price for all cigarettes or could prohibit discounts to consumers and retailers. C1 [Tynan, Michael A.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Ribisl, Kurt M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Hlth Behav, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA. [Loomis, Brett R.] RTI Int, Publ Hlth Policy Res Program, Res Triangle Pk, NC USA. RP Tynan, MA (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS K-50, Atlanta, GA 30341 USA. EM mtynan@cdc.gov RI Ribisl, Kurt/C-4867-2015 OI Ribisl, Kurt/0000-0003-3318-8524 FU Centers for Disease Control and Prevention [200-2008-F-24376-CDC NCCDPHP] FX This work was supported by award number 200-2008-F-24376-CDC NCCDPHP from the Centers for Disease Control and Prevention. NR 21 TC 13 Z9 13 U1 1 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0964-4563 J9 TOB CONTROL JI Tob. Control PD MAY PY 2013 VL 22 IS E1 AR e78 DI 10.1136/tobaccocontrol-2012-050554 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 159CT UT WOS:000320022400014 PM 22863888 ER PT J AU Szilagyi, PG Albertin, C Humiston, SG Rand, CM Schaffer, S Brill, H Stankaitis, J Yoo, BK Blumkin, A Stokley, S AF Szilagyi, Peter G. Albertin, Christina Humiston, Sharon G. Rand, Cynthia M. Schaffer, Stanley Brill, Howard Stankaitis, Joseph Yoo, Byung-Kwang Blumkin, Aaron Stokley, Shannon TI A Randomized Trial of the Effect of Centralized Reminder/Recall on Immunizations and Preventive Care Visits for Adolescents SO ACADEMIC PEDIATRICS LA English DT Article DE adolescent immunization; outreach; reminder/recall ID HUMAN-PAPILLOMAVIRUS VACCINE; WELL-CHILD CARE; MEDICAID-MANAGED CARE; COST-EFFECTIVENESS; INFLUENZA VACCINATION; PUBLIC-HEALTH; UNITED-STATES; INNER-CITY; DISADVANTAGED POPULATION; QUALITY IMPROVEMENT AB OBJECTIVE: To assess the impact of a managed care-based patient reminder/recall system on immunization rates and preventive care visits among low-income adolescents. METHODS: We conducted a randomized controlled trial between December 2009 and December 2010 that assigned adolescents aged 11-17 years to one of three groups mailed letter, telephone reminders, or control. Publicly insured youths (n = 4115) were identified in 37 participating primary care practices. The main outcome measures were immunization rates for routine vaccines (meningococcus, pertussis, HPV) and preventive visit rates at study end. RESULTS: Intervention and control groups were similar at baseline for demographics, immunization rates, and preventive visits. Among adolescents who were behind at the start, immunization rates at study end increased by 21% for mailed (P < .01 vs control), 17% for telephone (P < .05), and 13% for control groups. The proportion of adolescents with a preventive visit (within 12 months) was: mailed (65%; P < .01), telephone (63%; P < .05), and controls (59%). The number needed to treat for an additional fully vaccinated adolescent was 14 for mailed and 25 for telephone reminders; for an additional preventive visit, it was 17 and 29. The intervention cost $18.78 (mailed) or $16.68 (phone) per adolescent per year to deliver. The cost per additional adolescent fully vaccinated was $463.99 for mailed and $714.98 for telephone; the cost per additional adolescent receiving a preventive visit was $324.75 and $487.03. CONCLUSIONS: Managed care-based mail or telephone reminder/recall improved adolescent immunizations and preventive visits, with modest costs and modest impact. C1 [Szilagyi, Peter G.; Albertin, Christina; Rand, Cynthia M.; Schaffer, Stanley; Blumkin, Aaron] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA. [Humiston, Sharon G.] Childrens Mercy Hosp & Clin, Dept Pediat, Div Emergency & Urgent Care, Kansas City, MO USA. [Brill, Howard; Stankaitis, Joseph] Monroe Plan Med Care, Rochester, NY USA. [Yoo, Byung-Kwang] Univ Calif Davis, Sch Med, Davis, CA USA. [Stokley, Shannon] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Szilagyi, PG (reprint author), Box 777,601 Elmwood Ave, Rochester, NY 14642 USA. EM peter_szilagyi@urmc.rochester.edu OI Schaffer, Stanley/0000-0001-7993-1374 FU Centers for Disease Control and Prevention [U01 IP000128] FX The study was funded by the Centers for Disease Control and Prevention (grant U01 IP000128). We appreciate the collaboration of the physicians and staff at the participating primary care practices. We also thank the manuscript reviewers for their thoughtful critiques. NR 58 TC 33 Z9 33 U1 3 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 J9 ACAD PEDIATR JI Acad. Pediatr. PD MAY-JUN PY 2013 VL 13 IS 3 BP 204 EP 213 PG 10 WC Pediatrics SC Pediatrics GA 148MW UT WOS:000319249700005 PM 23510607 ER PT J AU Grossman, CI Purcell, DW Rotheram-Borus, MJ Veniegas, R AF Grossman, Cynthia I. Purcell, David W. Rotheram-Borus, Mary Jane Veniegas, Rosemary TI Opportunities for HIV Combination Prevention to Reduce Racial and Ethnic Health Disparities SO AMERICAN PSYCHOLOGIST LA English DT Article DE HIV prevention; HIV care; HIV testing; health disparities ID US EMERGENCY-DEPARTMENTS; FOR-DISEASE-CONTROL; AFRICAN-AMERICAN; ANTIRETROVIRAL THERAPY; POSTEXPOSURE PROPHYLAXIS; MEDICATION ADHERENCE; CONSPIRACY BELIEFS; HIV/AIDS TREATMENT; LIMITED KNOWLEDGE; UNITED-STATES AB Despite advances in HIV prevention and care, African Americans and Latino Americans remain at much higher risk of acquiring HIV, are more likely to be unaware of their HIV-positive status, are less likely to be linked to and retained in care, and are less likely to have suppressed viral load than are Whites. The first National HIV/AIDS Strategy (NHAS) has reducing these disparities as one of its three goals by encouraging the implementation of combination high-impact HIV intervention strategies. Federal agencies have expanded their collaborations in order to decrease HIV-related disparities through better implementation of data-driven decision making; integration and consolidation of the continuum of HIV care; and the reorganization of relationships among public health agencies, researchers, community-based organizations, and HIV advocates. Combination prevention, the integration of evidence-based and impactful behavioral, biomedical, and structural intervention strategies to reduce HIV incidence, provides the tools to address the HIV epidemic. Unfortunately, health disparities exist at every step along the HIV testing-to-care continuum. This provides an opportunity and a challenge to everyone involved in HIV prevention and care to understand and address health disparities as an integral part of ending the HIV epidemic in the United States. To further reduce health disparities, successful implementation of NHAS and combination prevention strategies will require multidisciplinary teams, including psychologists with diverse cultural backgrounds and experiences, to successfully engage groups at highest risk for HIV and those already infected with HIV. In order to utilize the comprehensive care continuum, psychologists and behavioral scientists have a role to play in reconceptualizing the continuum of care, conducting research to address health disparities, and creating community mobilization strategies. C1 [Grossman, Cynthia I.] NIMH, Div AIDS Res, Bethesda, MD 20892 USA. [Purcell, David W.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Rotheram-Borus, Mary Jane] Univ Calif Los Angeles, Ctr Community Hlth, Los Angeles, CA 90024 USA. [Veniegas, Rosemary] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90024 USA. RP Rotheram-Borus, MJ (reprint author), Univ Calif Los Angeles, Ctr Community Hlth, 10920 Wilshire Blvd,Suite 350, Los Angeles, CA 90024 USA. EM cchpublications@mednet.ucla.edu OI Purcell, David/0000-0001-8125-5168 FU Intramural CDC HHS [CC999999]; NCATS NIH HHS [UL1 TR000124, UL1TR000124]; NIAID NIH HHS [5P30AI028697, P30 AI028697]; NIMH NIH HHS [MH58107, P30 MH058107] NR 77 TC 7 Z9 7 U1 2 U2 7 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0003-066X J9 AM PSYCHOL JI Am. Psychol. PD MAY-JUN PY 2013 VL 68 IS 4 SI SI BP 237 EP 246 DI 10.1037/a0032711 PG 10 WC Psychology, Multidisciplinary SC Psychology GA 146FS UT WOS:000319075900004 PM 23688091 ER PT J AU Halkitis, PN Wolitski, RJ Millett, GA AF Halkitis, Perry N. Wolitski, Richard J. Millett, Gregorio A. TI A Holistic Approach to Addressing HIV Infection Disparities in Gay, Bisexual, and Other Men Who Have Sex With Men SO AMERICAN PSYCHOLOGIST LA English DT Article DE HIV/AIDS; gay and bisexual men; syndemics; health disparity; biopsychosocial ID NEW-YORK-CITY; SEXUALLY-TRANSMITTED INFECTIONS; PSYCHOSOCIAL HEALTH-PROBLEMS; UNSAFE ANAL INTERCOURSE; UNITED-STATES; LATINO MEN; BLACK-MEN; ANTIRETROVIRAL THERAPY; SAN-FRANCISCO; HETEROSEXUAL MEN AB Gay, bisexual, and other men who have sex with men (MSM) have been disproportionately affected by HIV and AIDS since the beginning of the epidemic in the United States and in many other parts of the world. The HIV epidemic is inextricably tied to other health problems that disproportionately affect gay, bisexual, and other MSM including psychological comorbidities, substance use, sexual victimization, stigmatization, and multiple forms of discrimination. These interrelated health problems and social issues can be characterized as a syndemic of mutually reinforcing conditions or epidemics. Moreover, the syndemic is directed by biological, behavioral, psychosocial, and structural determinants. Addressing HIV within the context of a larger syndemic will require a more holistic approach to HIV prevention and treatment that recognizes the interplay between biological, behavioral, psychosocial, and structural factors that affect the health and well-being of sexual minority men. C1 [Halkitis, Perry N.] NYU, Ctr Hlth Ident Behav & Prevent Studies, Steinhardt Sch Culture Educ & Human Dev, New York, NY 10003 USA. [Halkitis, Perry N.] NYU, Dept Populat Hlth, Langone Med Ctr, New York, NY 10003 USA. [Wolitski, Richard J.; Millett, Gregorio A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Halkitis, PN (reprint author), NYU, 82 Washington Sq East, New York, NY 10003 USA. EM pnh1@nyu.edu NR 125 TC 32 Z9 32 U1 3 U2 12 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0003-066X J9 AM PSYCHOL JI Am. Psychol. PD MAY-JUN PY 2013 VL 68 IS 4 SI SI BP 261 EP 273 DI 10.1037/a0032746 PG 13 WC Psychology, Multidisciplinary SC Psychology GA 146FS UT WOS:000319075900006 PM 23688093 ER PT J AU Rhoden, E Liu, HM Wang-Chern, SW Oberste, MS AF Rhoden, Eric Liu, Hong-Mei Wang-Chern, Shur-wern Oberste, M. Steven TI Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds SO ANTIVIRAL RESEARCH LA English DT Article DE Poliovirus; Poliomyelitis; Global polio eradication initiative; Antiviral compounds; Protease inhibitors; Capsid inhibitors ID RHINOVIRUS 3C PROTEASE; ERADICATION; PLECONARIL; DESIGN; AG7088 AB The National Research Council has recommended that at least one, preferably two, polio antiviral drugs be developed as a supplement to the tools currently available for control of polio outbreaks post-eradication. The primary application of such drugs is expected to be the resolution of chronic poliovirus excretion in persons with primary immunodeficiency disorders. We have assessed the in vitro activity of AG-7404 (also known as "compound 1"), an inhibitor of picornaviral 3C protease, against a large panel of programmatically important poliovirus strains and its activity in combination with two poliovirus capsid inhibitors, V-073 and BTA798. AG-7404 was active against all viruses in this panel, with EC50 values ranging from 0.080 to 0.674 mu M. Similarly, BTA798 was active against all viruses in this panel, with EC50 values ranging from 0.003 to 0.591 mu M. By comparison, values for V-073 were 0.003-0.126 mu M. BTA798 was active against V-073-resistant variants with an alanine to valine change in VP3 at position 24. However, BTA798 was inactive against the V-073-resistant strains with amino acid substitutions at VP1 amino acids 194 (equivalent to 192 in type 3) and 236. As expected from its different mechanism of action, AG-7404 was fully active against all V-073-resistant variants, with EC50 values ranging from 0.218 to 0.819 mu M, compared to values of 0.202-0.407 mu M for the V-073-susceptible parental strains. In vitro drug combination experiments demonstrated synergy between AG-7404 and either V-073 or BTA798, whereas the combination of the two capsid inhibitors acted additively. Published by Elsevier B.V. C1 [Rhoden, Eric; Liu, Hong-Mei; Wang-Chern, Shur-wern; Oberste, M. Steven] Ctr Dis Control & Prevent, Polio & Picornavirus Lab Branch, Div Viral Dis, Atlanta, GA USA. RP Oberste, MS (reprint author), 1600 Clifton Rd NE,Mailstop G-17, Atlanta, GA 30333 USA. EM erhoden@cdc.gov; hliu@cdc.gov; schern@cdc.gov; soberste@cdc.gov NR 23 TC 13 Z9 13 U1 1 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 J9 ANTIVIR RES JI Antiviral Res. PD MAY PY 2013 VL 98 IS 2 BP 186 EP 191 DI 10.1016/j.antiviral.2013.03.003 PG 6 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA 154YF UT WOS:000319711900007 PM 23499651 ER PT J AU Khan, K Eckhardt, R Brownstein, JS Naqvi, R Hu, W Kossowsky, D Scales, D Arino, J MacDonald, M Wang, J Sears, J Cetron, MS AF Khan, Kamran Eckhardt, Rose Brownstein, John S. Naqvi, Raza Hu, Wei Kossowsky, David Scales, David Arino, Julien MacDonald, Michael Wang, Jun Sears, Jennifer Cetron, Martin S. TI Entry and exit screening of airline travellers during the A(H1N1) 2009 pandemic: a retrospective evaluation SO BULLETIN OF THE WORLD HEALTH ORGANIZATION LA English DT Article ID INFLUENZA-A H1N1; ACUTE RESPIRATORY SYNDROME; INFECTIOUS-DISEASES; INTERNATIONAL SPREAD; AIR-TRAVEL; TRANSPORTATION; RESTRICTIONS; QUARANTINE; EPIDEMICS; AIRPORTS AB Objective To evaluate the screening measures that would have been required to assess all travellers at risk of transporting A(H1N1)pdm09 out of Mexico by air at the start of the 2009 pandemic. Methods Data from flight itineraries for travellers who flew from Mexico were used to estimate the number of international airports where health screening measures would have been needed, and the number of travellers who would have had to be screened, to assess all air travellers who could have transported the H1N1 influenza virus out of Mexico during the initial stages of the 2009 A(H1N1) pandemic. Findings Exit screening at 36 airports in Mexico, or entry screening of travellers arriving on direct flights from Mexico at 82 airports in 26 other countries, would have resulted in the assessment of all air travellers at risk of transporting A(H1N1)pdm09 out of Mexico at the start of the pandemic. Entry screening of 116 travellers arriving from Mexico by direct or connecting flights would have been necessary for every one traveller at risk of transporting A(H1N1)pdm09. Screening at just eight airports would have resulted in the assessment of 90% of all air travellers at risk of transporting A(H1N1)pdm09 out of Mexico in the early stages of the pandemic. Conclusion During the earliest stages of the A(H1N1) pandemic, most public health benefits potentially attainable through the screening of air travellers could have been achieved by screening travellers at only eight airports. C1 [Khan, Kamran] St Michaels Hosp, Div Infect Dis, Dept Med, Toronto, ON M5B 1W8, Canada. [Eckhardt, Rose; Hu, Wei; Kossowsky, David; Wang, Jun; Sears, Jennifer] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada. [Brownstein, John S.] Harvard Univ, Sch Med, Boston Childrens Hosp, Childrens Hosp Informat Program, Boston, MA USA. [Naqvi, Raza] Univ Toronto, Dept Med, Toronto, ON, Canada. [Scales, David] Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA. [Arino, Julien] Univ Manitoba, Dept Math, Winnipeg, MB R3T 2N2, Canada. [MacDonald, Michael] Ryerson Univ, Dept Geog, Toronto, ON, Canada. [Cetron, Martin S.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. RP Khan, K (reprint author), St Michaels Hosp, Div Infect Dis, Dept Med, 30 Bond St, Toronto, ON M5B 1W8, Canada. EM khank@smh.ca RI Arino, Julien/G-1221-2014; Naqvi, Raza/I-5644-2015 OI Arino, Julien/0000-0001-6409-5027; FU Canadian Institutes of Health Research FX Funding was provided by the Canadian Institutes of Health Research. NR 31 TC 13 Z9 13 U1 2 U2 16 PU WORLD HEALTH ORGANIZATION PI GENEVA 27 PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND SN 0042-9686 J9 B WORLD HEALTH ORGAN JI Bull. World Health Organ. PD MAY PY 2013 VL 91 IS 5 BP 368 EP 376 DI 10.2471/BLT.12.114777 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 152QU UT WOS:000319547000015 PM 23678200 ER PT J AU Van Orden, KA Stone, DM Rowe, J McIntosh, WL Podgorski, C Conwell, Y AF Van Orden, Kimberly A. Stone, Deborah M. Rowe, Jody McIntosh, Wendy L. Podgorski, Carol Conwell, Yeates TI The Senior Connection: Design and rationale of a randomized trial of peer companionship to reduce suicide risk in later life SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Geriatrics; Elderly; Social connectedness; Suicide; Prevention ID SOCIAL INTEGRATION; COMPLETED SUICIDE; PHYSICAL ILLNESS; ELDERLY SUICIDES; OLDER-ADULTS; PRIMARY-CARE; LONELINESS; AGE; VALIDATION; PREVENTION AB There is a pressing public health need to find interventions that reduce suicide risk in later life. Psychiatric and physical illness, functional decline, and social factors place seniors at risk for suicide. Reflecting this body of evidence, the Centers for Disease Control and Prevention (CDC) has identified the promotion and strengthening of social connectedness, between and within the individual, family, community, and broader societal levels, as a key strategy for suicide prevention. The Senior Connection, a randomized trial of peer companionship for older adults, is described here, with an emphasis on the most novel features of the study design-grounding in a psychological theory of suicide and intervening at an early stage in the suicide risk trajectory by linking primary care patients with the Aging Services Provider Network. (c) 2013 Elsevier Inc. All rights reserved. C1 [Van Orden, Kimberly A.; Podgorski, Carol; Conwell, Yeates] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Stone, Deborah M.; McIntosh, Wendy L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rowe, Jody] Lifespan Greater Rochester Inc, Rochester, NY USA. RP Van Orden, KA (reprint author), Univ Rochester, Med Ctr, Dept Psychiat, 300 Crittenden Blvd,Box PSYCH, Rochester, NY 14642 USA. EM Kimberly_vanorden@urmc.rochester.edu OI Van Orden, Kimberly/0000-0001-9439-401X FU Centers for Disease Control and Prevention [1U01CE001942-01]; National Institute of Mental Health [T32MH20061, R24MH07610]; National Institutes of Health [2KL2RR024136-06, RR024160] FX This research was supported in part by Grants No. 1U01CE001942-01 from the Centers for Disease Control and Prevention, T32MH20061 and R24MH07610 from the National Institute of Mental Health, and 2KL2RR024136-06 and RR024160 from the National Institutes of Health. NR 52 TC 10 Z9 10 U1 5 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAY PY 2013 VL 35 IS 1 BP 117 EP 126 DI 10.1016/j.cct.2013.03.003 PG 10 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 153YD UT WOS:000319637800014 PM 23506973 ER PT J AU Goodson, JL Finkbeiner, T Davis, NL Lyimo, D Rwebembera, A Swartzendruber, AL Wallace, AS Kimambo, S Kimario, CJ Wiktor, SZ Luman, ET AF Goodson, James L. Finkbeiner, Thomas Davis, Nicole L. Lyimo, Dafrossa Rwebembera, Anath Swartzendruber, Andrea L. Wallace, Aaron S. Kimambo, Sajida Kimario, Chrispin J. Wiktor, Stefan Z. Luman, Elizabeth T. TI Evaluation of Using Routine Infant Immunization Visits to Identify and Follow-Up HIV-Exposed Infants and Their Mothers in Tanzania SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV; early infant diagnosis; routine immunizations; vaccination; integration ID PRIMARY-HEALTH-CARE; SCALE-UP; SERVICES; DIAGNOSIS; AFRICA; PREVENTION; MORTALITY; INFECTION; PROGRAMS; CLINICS AB Background: Without treatment, approximately half of HIV-infected infants die by age 2 years, and 80% die before age 5 years. Early identification of HIV-infected and HIV-exposed infants provides opportunities for life-saving interventions. We evaluated integration of HIV-related services with routine infant immunization in Tanzania. Methods: During April 2009 to March 2010, at 4 urban and 4 rural sites, mothers' HIV status was determined at first-month immunization using antenatal cards. HIV-exposed infants were offered HIV testing and follow-up care. Impact of integrated service delivery was assessed by comparing average monthly vaccine doses administered during the study period and a 2-year baseline period; acceptance was assessed by interviewing mothers and service providers. Findings: During 7569 visits, 308 HIV-exposed infants were identified and registered; of these, 290 (94%) were tested, 15 (5%) were HIV infected. At urban sites, first-month vaccine doses remained stable (+2% for pentavalent vaccine and -4% for polio vaccine), and vaccine doses given later in life (pentavalent, polio, and measles) increased 12%, 8%, and 11%, respectively. At rural sites, first-month vaccine doses decreased 33% and 35% and vaccine doses given later in life decreased 23%, 28%, and 28%. Mothers and service providers generally favored integrated services; however, HIV-related stigma and inadequate confidentiality controls of HIV testing were identified, particularly at rural sites. Interpretation: Integration of HIV-related services at immunization visits identified HIV-exposed infants, HIV-infected infants, and HIV-infected mothers; however, decreases in vaccine doses administered at rural sites were concerning. HIV-related service integration with immunization visits needs careful monitoring to ensure optimum vaccine delivery. C1 [Goodson, James L.; Wallace, Aaron S.; Luman, Elizabeth T.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. [Finkbeiner, Thomas; Kimambo, Sajida; Wiktor, Stefan Z.] Ctr Dis Control & Prevent, AIDS Program, Div Global HIV, Dar Es Salaam, Tanzania. [Davis, Nicole L.; Swartzendruber, Andrea L.] Ctr Dis Control & Prevent, AIDS Program, Div Global HIV, Atlanta, GA 30333 USA. [Lyimo, Dafrossa] Minist Hlth & Social Welf, Expanded Program Immunizat, Dar Es Salaam, Tanzania. [Rwebembera, Anath] Minist Hlth & Social Welf, Natl AIDS Control Program, Dar Es Salaam, Tanzania. [Kimario, Chrispin J.] Elizabeth Glaser Pediat AIDS Fdn, Dar Es Salaam, Tanzania. RP Goodson, JL (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS-E05, Atlanta, GA 30333 USA. EM jgoodson@cdc.gov FU US Centers for Disease Control and Prevention FX The US Centers for Disease Control and Prevention provided funding and participated in study design, data analysis, report writing, and decisions to submit the article for publication. NR 29 TC 12 Z9 12 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAY 1 PY 2013 VL 63 IS 1 BP E9 EP E15 DI 10.1097/QAI.0b013e31828a3e3f PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 146SW UT WOS:000319112200002 PM 23406977 ER PT J AU Sherman, AV Gubitz, AK Al-Chalabi, A Bedlack, R Berry, J Conwit, R Harris, BT Horton, DK Kaufmann, P Leitner, ML Miller, R Shefner, J Vonsattel, JP Mitsumoto, H AF Sherman, Alexander V. Gubitz, Amelie K. Al-Chalabi, Ammar Bedlack, Richard Berry, James Conwit, Robin Harris, Brent T. Horton, D. Kevin Kaufmann, Petra Leitner, Melanie L. Miller, Robert Shefner, Jeremy Vonsattel, Jean Paul Mitsumoto, Hiroshi TI Infrastructure resources for clinical research in amyotrophic lateral sclerosis SO AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION LA English DT Article DE Amyotrophic lateral sclerosis (ALS); motor neuron disease (MND); clinical research infrastructure; North America; Europe ID NEURON DISEASE; STEM-CELLS; ALS; EPIDEMIOLOGY AB Clinical trial networks, shared clinical databases, and human biospecimen repositories are examples of infrastructure resources aimed at enhancing and expediting clinical and/or patient oriented research to uncover the etiology and pathogenesis of amyotrophic lateral sclerosis (ALS), a rapidly progressive neurodegenerative disease that leads to the paralysis of voluntary muscles. The current status of such infrastructure resources, as well as opportunities and impediments, were discussed at the second Tarrytown ALS meeting held in September 2011. The discussion focused on resources developed and maintained by ALS clinics and centers in North America and Europe, various clinical trial networks, U. S. government federal agencies including the National Institutes of Health (NIH), the Agency for Toxic Substances and Disease Registry (ATSDR) and the Centers for Disease Control and Prevention (CDC), and several voluntary disease organizations that support ALS research activities. Key recommendations included 1) the establishment of shared databases among individual ALS clinics to enhance the coordination of resources and data analyses; 2) the expansion of quality-controlled human biospecimen banks; and 3) the adoption of uniform data standards, such as the recently developed Common Data Elements (CDEs) for ALS clinical research. The value of clinical trial networks such as the Northeast ALS (NEALS) Consortium and the Western ALS (WALS) Consortium was recognized, and strategies to further enhance and complement these networks and their research resources were discussed. C1 [Sherman, Alexander V.] Massachusetts Gen Hosp, NCRI, Boston, MA 02114 USA. [Gubitz, Amelie K.; Conwit, Robin; Kaufmann, Petra] NINDS, NIH, Bethesda, MD 20892 USA. [Al-Chalabi, Ammar] Kings Coll London, Inst Psychiat, Dept Clin Neurosci, London WC2R 2LS, England. [Bedlack, Richard] Duke Inst Brain Sci, Sch Med, Div Neurol, Durham, NC USA. [Berry, James] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Harris, Brent T.] Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA. [Horton, D. Kevin] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA USA. [Leitner, Melanie L.] Prize4Life, Cambridge, MA USA. [Miller, Robert] Calif Pacific Med Ctr, Forbes Norris MDA ALS Res Ctr, San Francisco, CA USA. [Shefner, Jeremy] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA. [Vonsattel, Jean Paul] Columbia Univ, New York Presbyterian Hosp, Med Ctr, Dept Pathol & Cell Biol, New York, NY USA. [Mitsumoto, Hiroshi] Columbia Univ, Dept Neurol, Med Ctr, Eleanor & Lou Gehrig MDA ALS Res Ctr, New York, NY USA. RP Sherman, AV (reprint author), Massachusetts Gen Hosp, 13th St,Bldg 149, Charlestown, MA 02129 USA. EM avsherman@partners.org RI Al-Chalabi, Ammar/E-5361-2010 OI Al-Chalabi, Ammar/0000-0002-4924-7712 NR 22 TC 7 Z9 7 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 2167-8421 EI 2167-9223 J9 AMYOTROPH LAT SCL FR JI Amyotroph. Lateral Scher. Frontotemp. Degenerat. PD MAY PY 2013 VL 14 SU 1 BP 53 EP 61 DI 10.3109/21678421.2013.779058 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 145KH UT WOS:000319014100006 PM 23678880 ER PT J AU Kosoy, M AF Kosoy, Michael TI Deepening the Conception of Functional Information in the Description of Zoonotic Infectious Diseases SO ENTROPY LA English DT Review DE bacterial species; complexity; diversity; functional information; immune system; infection; host of infection; pathogen; infectious disease ID HOST-PARASITE INTERACTIONS; EVOLUTIONARY ECOLOGY; MULTIPLE INFECTION; POPULATION BIOLOGY; NATURAL-HISTORY; GENE-EXPRESSION; HERD-IMMUNITY; LIFE-HISTORY; COMPLEXITY; DYNAMICS AB Infectious agents, their hosts, and relevant abiotic components are directly involved in the complex dynamic process of maintaining infectious diseases in Nature. The current tendency to focus on host-pathogen interactions at the molecular and organismal levels does not advance our knowledge about infectious diseases, as much as it potentially could, by ignoring the ecological context pivotal for understanding the biology of the diseases. A new model of investigation requires a dynamic shift of perspectives in the "simplicity-complexity" dimension: from virulence factors to multi-sided descriptions of the pathogens; from particular microbes to wide microbial communities; from clinical manifestations to a variety of infectious patterns; from findings of infectious agents to defining a natural focus of the infection as a self-regulated system; from single factors affecting host-parasite relations to the complex ecological context. Various aspects of interactions between hosts, vectors, pathogens, and environmental niches should be integrated at multiple spatiotemporal scales and at different levels of biological organization (molecular, genomic, organismal, population, and ecosystem). C1 Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA. RP Kosoy, M (reprint author), Ctr Dis Control & Prevent, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM mck3@cdc.gov NR 118 TC 2 Z9 2 U1 2 U2 19 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1099-4300 J9 ENTROPY-SWITZ JI Entropy PD MAY PY 2013 VL 15 IS 5 BP 1929 EP 1962 DI 10.3390/e15051929 PG 34 WC Physics, Multidisciplinary SC Physics GA 151EF UT WOS:000319442800023 ER PT J AU Tilea, A Hedgeman, E Steffick, D Rein-Weston, A Banerjee, T Powe, N Rios-Burrows, N Williams, D Saran, R AF Tilea, Anca Hedgeman, Elizabeth Steffick, Diane Rein-Weston, Annie Banerjee, Tanushree Powe, Neil Rios-Burrows, Nilka Williams, Desmond Saran, Rajiv TI PUBLIC HEALTH SURVEILLANCE OF CHRONIC KIDNEY DISEASE IN THE UNITED STATES SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Meeting Abstract CT 50th European-Renal-Association - European-Dialysis-and-Transplant-Association Congress CY MAY 18-21, 2013 CL Istanbul, TURKEY SP European Renal Assoc (ERA), European Dialysis & Transplant Assoc (EDTA) C1 [Tilea, Anca; Hedgeman, Elizabeth; Steffick, Diane; Saran, Rajiv] UM, Ann Arbor, MI USA. [Rios-Burrows, Nilka; Williams, Desmond] CDC, Atlanta, GA 30333 USA. [Rein-Weston, Annie; Banerjee, Tanushree; Powe, Neil] UCSF, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD MAY PY 2013 VL 28 SU 1 BP 143 EP 143 PG 1 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 151ZF UT WOS:000319498200386 ER PT J AU Gargis, AS Heath, LS Heath, HE LeBlanc, PA Gargis, SR Harris, TH Sloan, GL AF Gargis, Amy S. Heath, Lucie S. Heath, Harry E. LeBlanc, Paul A. Gargis, Shaw R. Harris, Travis H. Sloan, Gary L. TI Complete nucleotide sequences of plasmids pACK2 and pACK5 from Staphylococcus simulans biovar staphylolyticus SO PLASMID LA English DT Article DE Lysostaphin; Cadmium resistance; Biofilm; Staphylococcus simulans biovar staphylolyticus ID CADMIUM RESISTANCE DETERMINANTS; GENE; IDENTIFICATION; AUREUS AB Staphylococcus simulans biovar staphylolyticus contains five plasmids, designated pACK1-pACK5. Recently, the nucleotide sequences of three of these plasmids, pACK1, pACK3, and pACK4, were reported. In order to complete the characterization of these five plasmids, the nucleotide sequences of the two remaining plasmids, pACK2 (37683 bp) and pACK5 (3191 bp), were determined. pACK5 is comprised of two regions, one with 85% identity at the nucleotide level to a region of pWBG1773 and another region with an ORF that shares no significant similarity to sequences previously described in GenBank. pACK2 encodes proteins for cadmium resistance and enhanced biofilm formation. The similarities at the nucleotide level among regions of the plasmids of S. simulans by. staphylolyticus suggest that these plasmids have undergone multiple intermolecular rearrangements. (C) 2013 Elsevier Inc. All rights reserved. C1 [Gargis, Amy S.; Heath, Lucie S.; Heath, Harry E.; LeBlanc, Paul A.; Gargis, Shaw R.; Harris, Travis H.; Sloan, Gary L.] Univ Alabama, Dept Biol Sci, Tuscaloosa, AL 35487 USA. RP Gargis, AS (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G-23, Atlanta, GA 30329 USA. EM asgargis@gmail.com NR 22 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0147-619X J9 PLASMID JI Plasmid PD MAY PY 2013 VL 69 IS 3 BP 257 EP 262 DI 10.1016/j.plasmid.2013.01.008 PG 6 WC Genetics & Heredity; Microbiology SC Genetics & Heredity; Microbiology GA 150CT UT WOS:000319368500008 PM 23396145 ER PT J AU Turner, MM Boudewyns, V Kirby-Straker, R Telfer, J AF Turner, Monique Mitchell Boudewyns, Vanessa Kirby-Straker, Rowie Telfer, Jana TI A double dose of fear: A theory-based content analysis of news articles surrounding the 2006 cough syrup contamination crisis in Panama SO RISK MANAGEMENT-AN INTERNATIONAL JOURNAL LA English DT Article DE risk communication; crisis communication; fear appeals; health communication ID PARALLEL PROCESS MODEL; RISK COMMUNICATION; EPPM; PROTECTION; APPEALS; HEALTH AB This study applied the extended parallel process model (EPPM) to evaluate the crisis messages employed by the mainstream media and the government during the 2006 diethylene glycol (DEG) poisoning crisis in Panama. Messages were content analyzed for its use of tenets of the EPPM. Overall, the findings reveal that the news coverage clearly emphasized the threat of DEC poisoning over the efficacy of avoiding being poisoned. In addition, quantitative analyses showed that the information provided by Ministry of Health of Panama (MINSA) and the local news outlets were widely divergent. These data indicate that the majority (82 per cent) of MINSA press releases included a balance of both threat and efficacy elements, compared with only 29 per cent of Panama newspapers. Panama newspapers tended to emphasize threat alone. Risk Management (2013) 15, 79-99. doi:10.1057/rm.2012.13 C1 [Turner, Monique Mitchell] George Washington Univ, Sch Publ Hlth & Hlth Serv, Dept Prevent & Community Hlth, Washington, DC 20037 USA. [Boudewyns, Vanessa; Kirby-Straker, Rowie] Univ Maryland, Dept Commun, College Pk, MD 20742 USA. [Telfer, Jana] CDC, Agcy Tox Subst & Dis Registry, Atlanta, GA 30341 USA. RP Turner, MM (reprint author), George Washington Univ, Sch Publ Hlth & Hlth Serv, Dept Prevent & Community Hlth, 2175K St NW, Washington, DC 20037 USA. RI Boudewyns, Vanessa/G-5713-2013 OI Boudewyns, Vanessa/0000-0002-1777-290X NR 30 TC 2 Z9 2 U1 6 U2 28 PU PALGRAVE MACMILLAN LTD PI BASINGSTOKE PA BRUNEL RD BLDG, HOUNDMILLS, BASINGSTOKE RG21 6XS, HANTS, ENGLAND SN 1460-3799 J9 RISK MANAG-UK JI Risk Manag. PD MAY PY 2013 VL 15 IS 2 BP 79 EP 99 DI 10.1057/rm.2012.13 PG 21 WC Social Sciences, Interdisciplinary SC Social Sciences - Other Topics GA 147NP UT WOS:000319174600001 ER PT J AU McAlister, FA Robitaille, C Gillespie, C Yuan, KM Rao, DP Grover, S Dai, SL Johansen, H Joffres, M Loustalot, F Campbell, N AF McAlister, Finlay A. Robitaille, Cynthia Gillespie, Cathleen Yuan, Keming Rao, Deepa P. Grover, Steven Dai, Sulan Johansen, Helen Joffres, Michel Loustalot, Fleetwood Campbell, Norm TI The Impact of Cardiovascular Risk-Factor Profiles on Blood Pressure Control Rates in Adults From Canada and the United States SO CANADIAN JOURNAL OF CARDIOLOGY LA English DT Article ID US ADULTS; HYPERTENSION MANAGEMENT; NATIONAL-HEALTH; PRIMARY-CARE; 2 DECADES; PREVALENCE; MORTALITY; POPULATION; DISEASE; WOMEN AB Background: It is unclear whether blood pressure control varies across the spectrum of atherosclerotic risk. Methods: We used data from nonpregnant adults who had fasted laboratory samples drawn for the 2007-2009 cycle of the Canadian Health Measures Survey (CHMS) or the 2005-2008 US National Health and Nutrition Examination Survey (NHANES). Results: The 1692 CHMS subjects and 3541 NHANES participants were demographically similar (aged a mean of 45 years), although NHANES participants exhibited higher obesity rates (33.8% vs 22.2%, P < 0.001). Over 80% of CHMS and NHANES subjects with hypertension had at least 1 other cardiovascular risk factor. As the number of atherosclerotic risk factors increased, hypertension prevalence increased, but blood pressure control rates improved (from 48% among hypertensives with no other risk factors in CHMS to 77% among those with 3 or more risk factors, and from 35% to 53% in NHANES). However, the converse was not true: The distribution of Framingham risk scores for those subjects with "controlled hypertension" was nearly identical to the distribution among those adults with uncontrolled hypertension in both CHMS and NHANES and substantially higher than scores in normotensive subjects. Conclusions: Although control of blood pressure was better in patients with multiple atherosclerotic risk factors, hypertensives with controlled blood pressures exhibited risk-factor profiles similar to those of participants with uncontrolled blood pressures. This suggests the need, in educational messaging and therapy decision making, for an increased focus on total atherosclerotic risk rather than just blood pressure control. C1 [McAlister, Finlay A.] Univ Alberta, Div Gen Internal Med, Edmonton, AB, Canada. [Robitaille, Cynthia; Rao, Deepa P.; Dai, Sulan] Publ Hlth Agcy Canada, Chron Dis Surveillance & Monitoring Div, Ottawa, ON, Canada. [Gillespie, Cathleen; Yuan, Keming] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. [Grover, Steven] McGill Univ, Div Gen Internal Med, Montreal, PQ, Canada. [Johansen, Helen; Loustalot, Fleetwood] Univ Ottawa, Dept Community Med & Epidemiol, Ottawa, ON, Canada. [Joffres, Michel] Simon Fraser Univ, Vancouver, BC, Canada. [Campbell, Norm] Univ Calgary, Dept Med, Libin Cardiovasc Inst, Calgary, AB, Canada. [Campbell, Norm] Univ Calgary, Dept Community Hlth Sci, Libin Cardiovasc Inst, Calgary, AB, Canada. [Campbell, Norm] Univ Calgary, Dept Physiol & Pharmacol, Libin Cardiovasc Inst, Calgary, AB, Canada. RP McAlister, FA (reprint author), Univ Alberta Hosp, 2F1-21 WMC,8440 112 St, Edmonton, AB T6G 2R7, Canada. EM Finlay.McAlister@ualberta.ca OI Gillespie, Cathleen/0000-0003-1878-1055; Rao, Deepa/0000-0002-1657-7168 FU Alberta Innovates-Health Solutions Senior Health Scholar Award FX F.A.M. is supported by an Alberta Innovates-Health Solutions Senior Health Scholar Award. N.C. holds the Heart and Stroke Foundation of Canada Canadian Institutes of Health Research Chair in Hypertension Prevention and Control. NR 35 TC 12 Z9 12 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0828-282X J9 CAN J CARDIOL JI Can. J. Cardiol. PD MAY PY 2013 VL 29 IS 5 BP 598 EP 605 DI 10.1016/j.cjca.2012.12.004 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 144WJ UT WOS:000318972100013 PM 23454038 ER PT J AU Reber, A Katz, J AF Reber, Adrian Katz, Jacqueline TI Immunological assessment of influenza vaccines and immune correlates of protection SO EXPERT REVIEW OF VACCINES LA English DT Review DE immune correlates; influenza virus; protection; vaccines ID T-CELL RESPONSES; SINGLE-RADIAL-HEMOLYSIS; VIRUS-INFECTED-CELLS; HEMAGGLUTINATION-INHIBITING ANTIBODY; NEURAMINIDASE-SPECIFIC INFLUENZA; HUMAN MONOCLONAL-ANTIBODIES; LINKED IMMUNOSORBENT-ASSAY; HEPATITIS-B-VACCINE; A-VIRUS; IN-VITRO AB Influenza vaccines remain the primary public health tool in reducing the ever-present burden of influenza and its complications. In seeking more immunogenic, more effective and more broadly cross-protective influenza vaccines, the landscape of influenza vaccines is rapidly expanding, both in near-term advances and next-generation vaccine design. Although the first influenza vaccines were licensed over 60 years ago, the hemagglutination-inhibition antibody titer is currently the only universally accepted immune correlate of protection against influenza. However, hemagglutination-inhibition titers appear to be less effective at predicting protection in populations at high risk for severe influenza disease; older adults, young children and those with certain medical conditions. The lack of knowledge and validated methods to measure alternate immune markers of protection against influenza remain a substantial barrier to the development of more immunogenic, broadly cross-reactive and effective influenza vaccines. Here, the authors review the knowledge of immune effectors of protection against influenza and discuss assessment methods for a broader range of immunological parameters that could be considered in the evaluation of traditional or new-generation influenza vaccines. C1 [Reber, Adrian; Katz, Jacqueline] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. [Reber, Adrian] Battelle Mem Inst, Atlanta, GA 30329 USA. RP Katz, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM jmk9@cdc.gov FU GlaxoSmithKline; Nobilon; Merck Sharp and Dohme; Colby Pharmaceuticals FX J Katz has received research funding from GlaxoSmithKline, Nobilon, Merck Sharp and Dohme, and Juvaris, Inc. (now Colby Pharmaceuticals). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 207 TC 35 Z9 35 U1 2 U2 32 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1476-0584 J9 EXPERT REV VACCINES JI Expert Rev. Vaccines PD MAY PY 2013 VL 12 IS 5 BP 519 EP 536 DI 10.1586/ERV.13.35 PG 18 WC Immunology SC Immunology GA 143FP UT WOS:000318852500011 PM 23659300 ER PT J AU Grosse, SD Caughey, AB AF Grosse, Scott D. Caughey, Aaron B. TI Modeling uncertain outcomes of genetic testing: factor V Leiden mutation and pregnant women SO GENETICS IN MEDICINE LA English DT Editorial Material ID COLORECTAL-CANCER; LYNCH SYNDROME; THROMBOPROPHYLAXIS; THROMBOPHILIA; STRATEGIES C1 [Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, Atlanta, GA 30333 USA. [Caughey, Aaron B.] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA. RP Grosse, SD (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, Atlanta, GA 30333 USA. EM sgrosse@cdc.gov NR 16 TC 1 Z9 1 U1 2 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD MAY PY 2013 VL 15 IS 5 BP 335 EP 337 DI 10.1038/gim.2013.17 PG 3 WC Genetics & Heredity SC Genetics & Heredity GA 143SN UT WOS:000318888600003 PM 23448720 ER PT J AU Goodman, D Stampfel, C Creanga, AA Callaghan, WM Callahan, T Bonzon, E Berg, C Grigorescu, V AF Goodman, David Stampfel, Caroline Creanga, Andreea A. Callaghan, William M. Callahan, Tegan Bonzon, Erin Berg, Cynthia Grigorescu, Violanda TI Revival of a Core Public Health Function: State- and Urban-Based Maternal Death Review Processes SO JOURNAL OF WOMENS HEALTH LA English DT Review ID PREGNANCY-RELATED MORTALITY; UNITED-STATES; PREVENTABILITY AB This article reviews some of the current challenges for maternal death review in the United States, describes key findings from an assessment of U. S. capacity for conducting maternal death reviews, and introduces a new Maternal Mortality Initiative that aims to develop standardized guidelines for state- or city-based maternal deaths review processes. C1 [Goodman, David; Creanga, Andreea A.; Callaghan, William M.; Berg, Cynthia; Grigorescu, Violanda] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Stampfel, Caroline; Callahan, Tegan; Bonzon, Erin] Assoc Maternal & Child Hlth Programs, Washington, DC USA. RP Goodman, D (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS K-22, Atlanta, GA 30341 USA. EM dagoodman@cdc.gov NR 9 TC 6 Z9 6 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAY PY 2013 VL 22 IS 5 BP 395 EP 398 DI 10.1089/jwh.2013.4318 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 142FC UT WOS:000318781000001 PM 23600436 ER PT J AU Robbins, CL Dietz, PM Cox, S Kuklina, EV AF Robbins, Cheryl L. Dietz, Patricia M. Cox, Shanna Kuklina, Elena V. TI Cholesterol Screening for Women: Who Is "At-Risk"? SO JOURNAL OF WOMENS HEALTH LA English DT Article ID UNITED-STATES; CARDIOVASCULAR HEALTH; US ADULTS; PREVENTION; AFCAPS/TEXCAPS; PREVALENCE; LOVASTATIN; MORTALITY; DISEASE; RECALL AB Background: High cholesterol often precedes cardiovascular disease (CVD) and guidelines recommend cholesterol screening among at-risk women. Definitions of CVD risk vary and prevalence of dyslipidemia (abnormal total cholesterol, high-density lipoprotein (HDL-C), or non-HDL-C) among at-risk women may vary by age and definition of CVD risk. Methods: This study used 2007-2008 National Health and Nutrition Examination Survey data (n = 1,781), a representative sample of the U. S. civilian, non-institutionalized population, to estimate the proportion of women without previous dyslipidemia diagnosis who are U. S. Preventive Services Task Force (USPSTF) at-risk and American Heart Association (AHA) at-risk. We also report dyslipidemia prevalence stratified by age. Results: Over half (55.0%) of younger women (20-44 years) and 74.2% of older women (>= 45 years) were USPSTF at-risk, while nearly all younger and older women had at least one AHA risk factor (99.5% and 99.6%, respectively). Dyslipidemia prevalence among younger women was 47.3% (95% confidence interval [CI]: 42.2-52.5) for USPSTF-at-risk and 39.5% (95% CI: 35.7-43.4) for AHA at-risk. Among older women, it was 65.5% (95% CI: 60.8-69.9) for USPSTF at-risk and 63.3% (95% CI: 59.0-67.4) for AHA at-risk. Conclusions: The AHA risk definition identified 45% more young women and 25% more older women than the USPSTF risk definition; however, both definitions of at-risk identified similar prevalence estimates of dyslipidemia among women. Given a high prevalence of dyslipidemia among younger women, future research is needed to assess whether identification and treatment of young women with dyslipidemia will decrease CVD mortality among them later in life. C1 [Robbins, Cheryl L.; Dietz, Patricia M.; Cox, Shanna] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Kuklina, Elena V.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Robbins, CL (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway Northeast,Mailstop K-23, Atlanta, GA 30341 USA. EM ggf9@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 2 Z9 2 U1 3 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAY PY 2013 VL 22 IS 5 BP 404 EP 411 DI 10.1089/jwh.2012.4074 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 142FC UT WOS:000318781000004 PM 23621744 ER PT J AU Soucie, JM Monahan, PE Kulkarni, R De Staercke, C Recht, M Chitlur, MB Gruppo, R Hooper, WC Kessler, C Manco-Johnson, MJ Powell, J Pyle, M Riske, B Sabio, H Trimble, S AF Soucie, J. Michael Monahan, Paul E. Kulkarni, Roshni De Staercke, Christine Recht, Michael Chitlur, Meera B. Gruppo, Ralph Hooper, W. Craig Kessler, Craig Manco-Johnson, Marilyn J. Powell, Jerry Pyle, Meredith Riske, Brenda Sabio, Hernan Trimble, Sean TI Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates SO TRANSFUSION LA English DT Letter C1 [Soucie, J. Michael; De Staercke, Christine; Hooper, W. Craig; Pyle, Meredith; Trimble, Sean] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Monahan, Paul E.] Univ N Carolina, Chapel Hill, NC USA. [Kulkarni, Roshni] Michigan State Univ, E Lansing, MI 48824 USA. [Recht, Michael] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Chitlur, Meera B.] Childrens Hosp Michigan, Detroit, MI 48201 USA. [Gruppo, Ralph] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [Kessler, Craig] Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA. [Manco-Johnson, Marilyn J.; Riske, Brenda] Univ Colorado, Sch Med, Aurora, CO USA. [Powell, Jerry] Univ Calif Davis, Sacramento, CA 95817 USA. [Sabio, Hernan] Wake Forest Univ, Winston Salem, NC 27109 USA. RP Soucie, JM (reprint author), Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. EM msoucie@cdc.gov RI Chitlur, Meera/G-2913-2015 NR 5 TC 5 Z9 5 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 J9 TRANSFUSION JI Transfusion PD MAY PY 2013 VL 53 IS 5 BP 1143 EP 1144 DI 10.1111/trf.12153 PG 2 WC Hematology SC Hematology GA 140MC UT WOS:000318657200031 PM 23659532 ER PT J AU Bathija, S Walton, S Lau, D Galanter, WL Schumock, GT Nutescu, E AF Bathija, S. Walton, S. Lau, D. Galanter, W. L. Schumock, G. T. Nutescu, E. TI REFERRAL PATTERNS FOR PATIENTS TREATED WITH WARFARIN THROMBOPROPHYLAXIS AFTER HIP AND KNEE REPLACEMENT SURGERY SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Bathija, S.; Walton, S.; Schumock, G. T.; Nutescu, E.] Univ Illinois, Chicago, IL USA. [Lau, D.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Galanter, W. L.] Univ Illinois Hosp & Hlth Sci Syst, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY PY 2013 VL 16 IS 3 BP A201 EP A201 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 144CE UT WOS:000318916401540 ER PT J AU Buchacz, K Young, B Palella, FJ Armon, C Brooks, JT Dean, B AF Buchacz, K. Young, B. Palella, F. J. Armon, C. Brooks, J. T. Dean, B. TI TRENDS IN GENOTYPIC RESISTANCE TESTING USE AND RESULTS AMONG ANTIRETROVIRAL-NAIVE PATIENTS IN THE HIV OUTPATIENT STUDY (HOPS) SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Buchacz, K.; Brooks, J. T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Young, B.] Int Assoc Phys AIDS Care, Washington, DC USA. [Palella, F. J.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Armon, C.] Cerner Corp, Vienna, VA USA. [Dean, B.] Cerner Res, Culver City, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY PY 2013 VL 16 IS 3 BP A81 EP A81 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 144CE UT WOS:000318916400416 ER PT J AU Dean, B Debes, R Bozzette, S Buchacz, K Brooks, JT AF Dean, B. Debes, R. Bozzette, S. Buchacz, K. Brooks, J. T. TI HIV LABORATORY TESTS USED AS A PROXY FOR MEDICAL VISITS FOR DEFINING ENGAGEMENT IN CARE SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Dean, B.; Bozzette, S.] Cerner Res, Culver City, CA USA. [Debes, R.] Cerner Corp, North Kansas City, MO USA. [Bozzette, S.] Univ Calif San Diego, Culver City, CA USA. [Buchacz, K.; Brooks, J. T.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY PY 2013 VL 16 IS 3 BP A99 EP A99 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 144CE UT WOS:000318916401013 ER PT J AU Ekwueme, DU Howard, D Gelb, C Rim, SH Cooper, C AF Ekwueme, D. U. Howard, D. Gelb, C. Rim, S. H. Cooper, C. TI AN EXPLORATORY ANALYSIS OF THE BENEFITS AND COSTS OF A NATIONAL CAMPAIGN TO PROMOTE COLORECTAL CANCER SCREENING - CDC'S SCREEN FOR LIFE: NATIONAL COLORECTAL CANCER ACTION CAMPAIGN SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Ekwueme, D. U.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Howard, D.] Emory Univ, Atlanta, GA 30322 USA. [Gelb, C.; Rim, S. H.] CDC, Atlanta, GA 30333 USA. [Cooper, C.] Soltera Ctr Hlth Commun Res, Oro Valley, AZ USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY PY 2013 VL 16 IS 3 BP A142 EP A142 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 144CE UT WOS:000318916401235 ER PT J AU Guy, GP Lipscomb, J Gillespie, T Goodman, M Richardson, LC Ward, KC AF Guy, G. P., Jr. Lipscomb, J. Gillespie, T. Goodman, M. Richardson, L. C. Ward, K. C. TI FACTORS ASSOCIATED WITH GUIDELINE-CONCORDANT ADJUVANT THERAPY AMONG BREAST CANCER PATIENTS IN RURAL GEORGIA SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Guy, G. P., Jr.; Lipscomb, J.; Goodman, M.; Ward, K. C.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Gillespie, T.] Emory Univ, Sch Med, Atlanta, GA USA. [Richardson, L. C.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY PY 2013 VL 16 IS 3 BP A154 EP A154 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 144CE UT WOS:000318916401300 PM 23693470 ER PT J AU Guy, GP Ekwueme, DU Yabroff, KR Dowling, EC Li, C Rodriguez, J de Moor, JS Virgo, KS AF Guy, G. P., Jr. Ekwueme, D. U. Yabroff, K. R. Dowling, E. C. Li, C. Rodriguez, J. de Moor, J. S. Virgo, K. S. TI THE ECONOMIC BURDEN OF CANCER SURVIVORSHIP AMONG ADULTS IN THE UNITED STATES SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Guy, G. P., Jr.; Ekwueme, D. U.; Li, C.; Rodriguez, J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Yabroff, K. R.; de Moor, J. S.] NCI, Bethesda, MD 20892 USA. [Dowling, E. C.] Inst Technol Assessment, Boston, MA USA. [Virgo, K. S.] Emory Univ, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY PY 2013 VL 16 IS 3 BP A136 EP A137 PG 3 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 144CE UT WOS:000318916401207 ER PT J AU Lipscomb, J Guy, GP Gillespie, T Goodman, M Richardson, LC Ward, KC AF Lipscomb, J. Guy, G. P. Gillespie, T. Goodman, M. Richardson, L. C. Ward, K. C. TI BREAST CANCER PATIENTS RECEIVING GUIDELINE-CONCORDANT ADJUVANT THERAPY REGIMENS HAVE BETTER ALL-CAUSE AND DISEASE-SPECIFIC SURVIVAL: NEW FINDINGS FROM RURAL GEORGIA SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Lipscomb, J.; Goodman, M.; Ward, K. C.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Guy, G. P.; Richardson, L. C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gillespie, T.] Emory Univ, Sch Med, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY PY 2013 VL 16 IS 3 BP A1 EP A1 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 144CE UT WOS:000318916400002 PM 23693165 ER PT J AU Nurmagambetov, T Uzoebo, V Hayes, R AF Nurmagambetov, T. Uzoebo, V Hayes, R. TI MULTICOMPONENT HOME-BASED ENVIRONMENTAL INTERVENTIONS ARE EFFECTIVE IN REDUCING MORBIDITY OF CHILDREN WITH ASTHMA FROM LOW INCOME FAMILIES SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Nurmagambetov, T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Uzoebo, V; Hayes, R.] NYC Dept Hlth & Human Hyg, New York, NY USA. NR 0 TC 0 Z9 0 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY PY 2013 VL 16 IS 3 BP A240 EP A240 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 144CE UT WOS:000318916402199 ER PT J AU Palella, FJ Buchacz, K Debes, R Baker, R Armon, C Brooks, JT Dean, B AF Palella, F. J. Buchacz, K. Debes, R. Baker, R. Armon, C. Brooks, J. T. Dean, B. TI CONTINUED DECLINES IN MORTALITY ARE LARGELY DUE TO REDUCTIONS IN NON-AIDS RELATED DEATHS, AND MORTALITY REMAINS DISPROPORTIONATELY HIGHER AMONG BLACKS AND THE PUBLICLY INSURED IN THE HIV OUTPATIENT STUDY (HOPS), 1996-2009 SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Palella, F. J.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Buchacz, K.; Brooks, J. T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Debes, R.] Cerner Corp, North Kansas City, MO USA. [Baker, R.; Armon, C.] Cerner Corp, Vienna, VA USA. [Dean, B.] Cerner Res, Culver City, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY PY 2013 VL 16 IS 3 BP A83 EP A83 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 144CE UT WOS:000318916400430 PM 23694585 ER PT J AU Peasah, SK Meltzer, M AF Peasah, S. K. Meltzer, M. TI ECONOMIC EVALUATION OF INFLUENZA VACCINATION IN PREVENTING HOSPITALIZATION IN CARDIOVASCULAR DISEASE PATIENTS SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Peasah, S. K.] Ctr Dis & Prevent, Atlanta, GA USA. [Meltzer, M.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY PY 2013 VL 16 IS 3 BP A283 EP A283 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 144CE UT WOS:000318916402427 PM 23694195 ER PT J AU Zhuo, X Zhang, P AF Zhuo, X. Zhang, P. TI COST-EFFECTIVENESS OF LIFESTYLE INTERVENTION AMONG ADULTS AT A HIGH RISK FOR HYPERTENSION AND DIABETES: A HEALTH PLAN PERSPECTIVE SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Zhuo, X.; Zhang, P.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY PY 2013 VL 16 IS 3 BP A190 EP A191 PG 2 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 144CE UT WOS:000318916401486 ER PT J AU Koo, D Ikeda, R AF Koo, Denise Ikeda, Robin TI Stephen Brady Thacker, 1947-2013 Obituary SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Biographical-Item C1 [Koo, Denise] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. [Ikeda, Robin] Ctr Dis Control & Prevent, Off Noncommunicable Dis Injury & Environm Hlth, Atlanta, GA 30333 USA. RP Koo, D (reprint author), Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, 1600 Clifton Rd NE,MS E-92, Atlanta, GA 30333 USA. EM dkoo@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD MAY 1 PY 2013 VL 177 IS 9 BP 867 EP 869 DI 10.1093/aje/kwt070 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 139IR UT WOS:000318576300002 PM 24761450 ER PT J AU Talih, M AF Talih, Makram TI Invited Commentary: Can Changes in the Distributions of and Associations Between Education and Income Bias Estimates of Temporal Trends in Health Disparities? SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Editorial Material DE conditional independence; health literacy; undirected graphs AB Chen et al. (Am J Epidemiol. 2013; 177(9): 870-881) develop a simulation study for comparing various measures of socioeconomic health disparities when bias can arise from temporal changes in the bivariate distribution of education and income. In this commentary, I argue that, in relation to health, the "meaning" of education cannot be reduced to its socioeconomic value; improved health literacy, for instance, can result in important health benefits. Further, I suggest that unless there is a substantial prior understanding of the data-generating mechanism, directed acyclic graph models should be avoided because causal relationships cannot be inferred from regression. An alternative is to resort to conditional independence graphs, which use only undirected edges. Finally, although the slope index of inequality can, in some specific cases, be seen to reduce bias in temporal comparisons of socioeconomic health disparities, it was not designed for causal inference. The slope index of inequality simply describes the average change in the proportion in poor health when the population is ordered by socioeconomic status. C1 [Talih, Makram] Ctr Dis Control & Prevent, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Talih, M (reprint author), Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 6317, Hyattsville, MD 20782 USA. EM mtalih@cdc.gov FU Intramural CDC HHS [CC999999] NR 13 TC 3 Z9 3 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD MAY 1 PY 2013 VL 177 IS 9 BP 882 EP 884 DI 10.1093/aje/kwt042 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 139IR UT WOS:000318576300004 PM 23568596 ER PT J AU Morrison, S Shenassa, ED Mendola, P Wu, TT Schoendorf, K AF Morrison, Stephanie Shenassa, Edmond D. Mendola, Pauline Wu, Tongtong Schoendorf, Kenneth TI Allostatic load may not be associated with chronic stress in pregnant women, NHANES 1999-2006 SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Allostasis; Stress; Psychological; Pregnancy complications ID CUMULATIVE BIOLOGICAL RISK; NUTRITION EXAMINATION SURVEY; NATIONAL-HEALTH; UNITED-STATES; AGE; MACARTHUR; PATTERNS; BIRTH AB Purpose: Pregnant women are generally excluded from studies that measure allostatic load (AL) because there is concern that the changing levels of AL-related biomarkers during pregnancy do not reflect a woman's true AL The goal of this study was to determine whether AL can be measured in a meaningful way during pregnancy. Methods: The National Health and Nutrition Examination Survey (NHANES) is a nationally representative, cross-sectional survey of the U.S. civilian population. AL was based on the distributions of 10 biomarkers in pregnant (n = 1138) and nonpregnant (n = 4993) women aged 15 to 44 from NHANES (1999-2006). Results: The distribution of each AL-related biomarker differed significantly between pregnant and nonpregnant women (P < .01). Among nonpregnant women, high AL findings were consistent with previous studies (e.g., higher AL in women who are black, are older, and who have lower incomes). However, these associations were not seen in pregnant women. Conclusions: Our results suggest that the various biomarkers that comprise AL may reflect proximal factors in pregnancy more strongly than they represent exposure to chronic stress over a woman's lifetime. Therefore, our approach to measuring AL may not provide meaningful information about chronic stress in pregnant women without further consideration of pregnancy-related factors. (C) 2013 Elsevier Inc. All rights reserved. C1 [Morrison, Stephanie; Shenassa, Edmond D.; Wu, Tongtong] Univ Maryland, Sch Publ Hlth, Dept Epidemiol & Biostat, College Pk, MD 20742 USA. [Shenassa, Edmond D.] Univ Maryland, Sch Publ Hlth, Maternal & Child Hlth Program, College Pk, MD 20742 USA. [Mendola, Pauline] Eunice Kennedy Shriver Natl Inst Hlth & Human Dev, Epidemiol Branch, Div Epidemiol Stat & Prevent Res, Rockville, MD USA. [Schoendorf, Kenneth] Ctr Dis Control & Prevent, Infant Child & Womens Hlth Stat Branch, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Shenassa, ED (reprint author), 1142GG Sch Publ Hlth, Maternal & Child Hlth Program, College Pk, MD USA. EM Shenassa@UMD.edu OI Mendola, Pauline/0000-0001-5330-2844 FU Flight Attendants Medical Research Institute; Intramural Research Program of the NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development FX E. Shenassa was supported by Flight Attendants Medical Research Institute. P. Mendola: This research was supported in part by the Intramural Research Program of the NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development. The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the National Center for Health Statistics, Centers for Disease Control and Prevention. NR 20 TC 9 Z9 9 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD MAY PY 2013 VL 23 IS 5 BP 294 EP 297 DI 10.1016/j.annepidem.2013.03.006 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 140OL UT WOS:000318664700011 PM 23621995 ER PT J AU Ford, ES Mannino, DM Wheaton, AG Giles, WH Presley-Cantrell, L Croft, JB AF Ford, Earl S. Mannino, David M. Wheaton, Anne G. Giles, Wayne H. Presley-Cantrell, Letitia Croft, Janet B. TI Trends in the Prevalence of Obstructive and Restrictive Lung Function Among Adults in the United States Findings From the National Health and Nutrition Examination Surveys From 1988-1994 to 2007-2010 SO CHEST LA English DT Article ID AMERICAN THORACIC SOCIETY; SMOKING-CESSATION INTERVENTIONS; PULMONARY-DISEASE; SECONDHAND SMOKE; REFERENCE VALUES; US POPULATION; COPD; EXPOSURE; BRONCHODILATOR; METAANALYSIS AB Background: National spirometric surveillance data in the United States were last collected during 1988-1994. The objective of this study was to provide current estimates for obstructive and restrictive impairment of lung function and to examine changes since 1988-1994. Methods: We used data from 14,360 participants aged 20 to 79 years from the National Health and Nutrition Examination Survey (NHANES) III (1988-1994) and 9,024 participants from NHANES 2007-2010. Spirometry was conducted using the same spirometers and generally similar protocols. Results: During 2007-2010, 13.5% (SE, 0.6) of participants had evidence of airway obstruction (FEV1/FVC < 0.70): 79.9% of adults had normal lung function, 6.5% had a restrictive impairment, 7.5% had mild obstruction, 5.4% had moderate obstruction, and 0.7% had severe obstruction. Although the overall age-adjusted prevalence of any obstruction did not change significantly from 1988-1994 (14.6%) to 2007-2010 (13.5%) (P = .178), significant decreases were noted for participants aged 60 to 79 years and for Mexican Americans. The prevalence of current smoking remained high among participants with moderate (48.4%) and severe (37.9%) obstructive impairments. A significant decline in current smoking occurred only among those with normal lung function (P < .05). Conclusion: Spirometry revealed little change in the prevalence of any obstructive and restrictive impairment in lung function during 2007-2010, compared with 1988-1994. C1 [Ford, Earl S.; Wheaton, Anne G.; Giles, Wayne H.; Presley-Cantrell, Letitia; Croft, Janet B.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30341 USA. [Mannino, David M.] Univ Kentucky, Coll Publ Hlth, Dept Prevent Med & Environm Hlth, Lexington, KY USA. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,MS K67, Atlanta, GA 30341 USA. EM eford@cdc.gov OI Mannino, David/0000-0003-3646-7828 FU GlaxoSmithKline plc; Novartis AG; Pfizer, Inc; AstraZeneca; Forest Laboratories, Inc; Creative Educational Concepts, Inc. FX Dr Mannino has received honoraria/consulting fees and served on speaker bureaus for GlaxoSmithKline plc; Novartis AG; Pfizer, Inc; AstraZeneca; Forest Laboratories, Inc; and Creative Educational Concepts, Inc. Furthermore, he has received royalties from UpToDate. Drs Ford, Wheaton, Giles, Presley-Cantrell, and Croft have reported to CHEST that no potential conflicts of interest exist. NR 28 TC 48 Z9 49 U1 0 U2 2 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD MAY PY 2013 VL 143 IS 5 BP 1395 EP 1406 DI 10.1378/chest.12-1135 PG 12 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 137TS UT WOS:000318461700032 PM 23715520 ER PT J AU Curtis, KM Tepper, NK Jamieson, DJ Marchbanks, PA AF Curtis, Kathryn M. Tepper, Naomi K. Jamieson, Denise J. Marchbanks, Polly A. TI Adaptation of the World Health Organization's Selected Practice Recommendations for Contraceptive Use for the United States SO CONTRACEPTION LA English DT Editorial Material ID UNINTENDED PREGNANCY; DISPARITIES AB Background: The Centers for Disease Control and Prevention (CDC) recently adapted global guidance on contraceptive use from the World Health Organization (WHO) to create the US Selected Practice Recommendations for Contraceptive Use (US SPR). The WHO guidance includes evidence-based recommendations on common, yet sometimes complex, contraceptive management questions. Study Design: We determined the need and scope for the adaptation, conducted 30 systematic reviews of the scientific evidence and convened a meeting of health care professionals to discuss translation of the evidence into recommendations. Results: The US SPR provides recommendations on contraceptive management issues such as how to initiate contraceptive methods, what regular follow-up is needed, and how to address problems, including missed pills and side effects such as unscheduled bleeding. Conclusion: The US SPR is intended to serve as a source of clinical guidance for providers in assisting women and men to initiate and successfully use contraception to prevent unintended pregnancy. Published by Elsevier Inc. C1 [Curtis, Kathryn M.; Tepper, Naomi K.; Jamieson, Denise J.; Marchbanks, Polly A.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Curtis, KM (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. EM kmc6@cdc.gov NR 15 TC 4 Z9 4 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 513 EP 516 DI 10.1016/j.contraception.2012.08.024 PG 4 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500003 PM 23040134 ER PT J AU Folger, SG Jamieson, DJ Godfrey, EM Zapata, LB Curtis, KM AF Folger, Suzanne G. Jamieson, Denise J. Godfrey, Emily M. Zapata, Lauren B. Curtis, Kathryn M. TI Evidence-based guidance on selected practice recommendations for contraceptive use: identification of research gaps SO CONTRACEPTION LA English DT Editorial Material ID RANDOMIZED-CONTROLLED-TRIAL; TUBAL-STERILIZATION; UNITED-STATES; MEDROXYPROGESTERONE ACETATE; ORAL-CONTRACEPTIVES; ADHERENCE; WOMEN; DISCONTINUATION; RISK; MANAGEMENT C1 [Folger, Suzanne G.; Jamieson, Denise J.; Godfrey, Emily M.; Zapata, Lauren B.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Godfrey, Emily M.] Univ N Carolina, Dept Obstet & Gynecol, Chapel Hill, NC 27599 USA. RP Folger, SG (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, MS K-34,4770 Buford Highway NE, Atlanta, GA 30341 USA. EM sxg1@cdc.gov FU Intramural CDC HHS [CC999999] NR 50 TC 7 Z9 7 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 517 EP 523 DI 10.1016/j.contraception.2012.08.003 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500004 PM 23083526 ER PT J AU Brahmi, D Curtis, KM AF Brahmi, Dalia Curtis, Kathryn M. TI When can a woman start combined hormonal contraceptives (CHCs)?: a systematic review SO CONTRACEPTION LA English DT Review DE Contraception; Combined hormonal contraception; Initiation; Pills; Patch; Ring ID OVARIAN FOLLICULAR DEVELOPMENT; QUICK START; IMMEDIATE INITIATION; BLEEDING PATTERNS; CONTROLLED-TRIAL; VAGINAL RING; MICROGYNON AB Background: Conventional methods of initiating combined hormonal contraceptives (CHCs), specifically combined oral contraceptives (COCs), the contraceptive patch and the contraceptive ring, require that women delay starting CHCs until menses begin, during which time a woman may be at risk of unintended pregnancy. The objective of this systematic review is to examine the evidence on the risk of becoming pregnant after starting the method (contraceptive effectiveness including surrogate measures such as ovarian follicular development and hormone levels), risk of already being pregnant, side effects and continuation when starting CHCs on different days of the menstrual cycle. Study Design: We searched the MEDLINE database for all articles (in all languages) published in peer-reviewed journals from inception through March 2012 for evidence relevant to starting CHCs on different days of the menstrual cycle and the outcomes of contraceptive effectiveness (including ovarian follicular development and hormonal levels), side effects and continuation rates. Results: From 1635 reviewed articles, 18 studies met our inclusion criteria. Evidence from four studies suggests that neither the risk of inadvertently starting COCs in a woman who is pregnant nor the risk of pregnancy after COC initiation are affected by the cycle day on which COCs are started. While follicular activity increased as the cycle day on which COCs were initiated increased, no women ovulated when starting on Day 5. When starting on Day 7, there was no increase in ovulation for a 30-mcg pill but a significant increase in ovulation with a 20-mcg pill compared with starting on Day 1. Evidence from two small studies suggests that 7 days of pills leads to inhibition of ovulation. One small study suggests that only 3 days of ring use is needed to inhibit ovulation, but this was following one complete treatment cycle of ring use. Evidence also suggests that starting CHCs on any day of the cycle does not affect bleeding problems or other side effects for both COCs and the patch. While starting CHCs via Quick Start (starting on the day of the health care visit) may initially increase continuation compared with more conventional starting strategies, evidence suggests that this difference disappears over time. Conclusion: The body of evidence suggested that (a) pregnancy rates did not differ by the timing of CHC initiation; (b) the more follicular activity that occurred prior to starting COCs, the more likely ovulation was to occur; however, no ovulations were seen when COCs were started at a follicle diameter of 10 mm (mean cycle day=7.6) or when the ring was started at follicle diameter of 13 mm (median cycle day=11); (c) bleeding patterns and other side effects did not vary with the timing of CHC initiation and (d) continuation rates of CHCs were initially improved by Quick Start, but differences between groups disappeared over time. Published by Elsevier Inc. C1 [Brahmi, Dalia] Ipas, Chapel Hill, NC 27515 USA. [Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Curtis, KM (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. EM kmc6@cdc.gov NR 21 TC 9 Z9 9 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 524 EP 538 DI 10.1016/j.contraception.2012.09.010 PG 15 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500005 PM 23153903 ER PT J AU Cleary, TP Tepper, NK Cwiak, C Whiteman, MK Jamieson, DJ Marchbanks, PA Curtis, KM AF Cleary, Tara P. Tepper, Naomi K. Cwiak, Carrie Whiteman, Maura K. Jamieson, Denise J. Marchbanks, Polly A. Curtis, Kathryn M. TI Pregnancies after hysteroscopic sterilization: a systematic review SO CONTRACEPTION LA English DT Review DE Adiana; Essure; Hysteroscopic sterilization; Pregnancies; Systematic review ID PERMANENT BIRTH-CONTROL; TUBAL-STERILIZATION; FEMALE STERILIZATION; CONTROL DEVICE; ESSURE; EXPERIENCE; OFFICE; SATISFACTION; SAFETY; WOMEN AB Background: Female sterilization is the second most commonly used form of contraception in the United States. Newer approaches to female sterilization, including hysteroscopic methods, have been approved for use in the United States since 2002. Little is known about the occurrence and timing of pregnancies after these procedures. Study Design: The objective of this systematic review was to identify evidence that assesses when and how often pregnancies occur following hysteroscopic sterilization. The PubMed database was searched for all studies published from database inception through March 2012 that reported whether or not pregnancies occurred following hysteroscopic sterilization. Results: Twenty-four original research articles of fair quality met the inclusion criteria: 22 studies of women who underwent Essure (R) placement and 2 studies of women who underwent Adiana (R) placement. Eleven articles that documented bilateral tubal occlusion with hysterosalpingogram (HSG) or placement with X-ray or ultrasound following Essure (R) placement did not report any pregnancies with follow-up ranging from 7 months to 7 years. The remaining 11 articles identified 102 reported pregnancies. Eighteen of these pregnancies occurred prior to the 3-month period required before imaging for contraceptive reliability. Two articles did not report what follow-up imaging was performed among women after Essure (R) placement; one of these articles reported three pregnancies. Two reports from the same study of women who underwent Adiana (R) placement reported six pregnancies during the first year of follow-up, three pregnancies during the second year of follow-up and no pregnancies during the third year of follow-up. Conclusions: Fair-quality evidence suggests that among women who were followed beyond 3 months after hysteroscopic sterilization, pregnancies were rare and generally occurred among women who had no imaging follow-up or had inadequate confirmation of placement or occlusion. Few pregnancies occurred in women with documented bilateral tubal occlusion by HSG or correct placement at 3 months by ultrasound or X-ray. Only one study reported follow-up past 5 years. Further studies are needed to address the long-term effectiveness of hysteroscopic sterilization. Published by Elsevier Inc. C1 [Cleary, Tara P.; Cwiak, Carrie] Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA 30303 USA. [Tepper, Naomi K.; Whiteman, Maura K.; Jamieson, Denise J.; Marchbanks, Polly A.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Tepper, NK (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. EM ntepper@cdc.gov NR 32 TC 29 Z9 29 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 539 EP 548 DI 10.1016/j.contraception.2012.08.006 PG 10 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500006 PM 23040124 ER PT J AU Godfrey, EM Folger, SG Jeng, G Jamieson, DJ Curtis, KM AF Godfrey, Emily M. Folger, Suzanne G. Jeng, Gary Jamieson, Denise J. Curtis, Kathryn M. TI Treatment of bleeding irregularities in women with copper-containing IUDs: a systematic review SO CONTRACEPTION LA English DT Review DE Contraception; Intrauterine device; Intrauterine contraception; Abnormal bleeding; Treatment ID MENSTRUAL BLOOD-LOSS; INTRAUTERINE-CONTRACEPTIVE-DEVICES; IBUPROFEN; ACID; MENORRHAGIA; PREVENTION; INHIBITORS; DRUGS; USERS AB Background: Bleeding irregularities, such as intermenstrual spotting or heavy or prolonged menstrual bleeding, are common among copper-containing intrauterine device (Cu-IUD) users and are one of the leading reasons for method discontinuation. This review evaluates the evidence for effective therapeutic and preventive treatments for bleeding irregularities during Cu-IUD use. Study Design: We searched the PubMed database for peer-reviewed articles that were published in any language from inception of the database through March 2012 and were relevant to treatments for irregular bleeding during Cu-IUD use. We used standard abstract forms and grading systems to summarize and assess the quality of the evidence. Results: From 1470 articles, we identified 17 articles that met our inclusion criteria. Evidence from two studies of poor quality demonstrated that antifibrinolytic agents or nonsteroidal anti-inflammatory drugs (NSAIDs) have been used for intermenstrual bleeding or spotting among a small number of Cu-IUD users with mixed results. Evidence from 10 studies of fair to poor quality suggested that some NSAIDs may significantly reduce menstrual blood loss or bleeding duration among Cu-IUD users with heavy or prolonged menstrual bleeding. Antifibrinolytic drugs or antidiuretics may also help reduce blood loss. High-dose aspirin was shown to increase blood loss among those with baseline menorrhagia. Evidence from five studies of fair to poor quality suggested that bleeding irregularities among new Cu-IUD users may be prevented with NSAIDs, although one large study of good quality suggested that prophylactic treatment with ibuprofen does not affect continuation of Cu-IUD use. Evidence from two studies of fair to poor quality suggested that antifibrinolytic agents might be helpful in preventing heavy or prolonged menstrual bleeding among new Cu-IUD users. Conclusions: Limited evidence suggests that NSAIDs may be effective treatments for bleeding irregularities associated with Cu-IUD use; antifibrinolytic agents and antidiuretics have also been studied as possible treatments in a small number of subjects, but their safety has not been well documented. NSAIDs and antifibrinolytics may also prevent bleeding irregularities among new CU-IUD users. Preventive NSAID use, however, does not impact Cu-IUD continuation. (C) 2013 Elsevier Inc. All rights reserved. C1 [Godfrey, Emily M.; Folger, Suzanne G.; Jeng, Gary; Jamieson, Denise J.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Godfrey, Emily M.] Univ N Carolina, Dept Obstet & Gynecol, Chapel Hill, NC 27599 USA. RP Godfrey, EM (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, MS K-34 NE, Atlanta, GA 30341 USA. EM egodfrey414@gmail.com NR 36 TC 7 Z9 7 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 549 EP 566 DI 10.1016/j.contraception.2012.09.006 PG 18 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500007 PM 23199413 ER PT J AU Godfrey, EM Whiteman, MK Curtis, KM AF Godfrey, Emily M. Whiteman, Maura K. Curtis, Kathryn M. TI Treatment of unscheduled bleeding in women using extended- or continuous-use combined hormonal contraception: a systematic review SO CONTRACEPTION LA English DT Review DE Contraception; Combined hormonal contraception; Unscheduled bleeding; Extended contraception; Continuous contraception ID RANDOMIZED-CONTROLLED-TRIAL; ORAL-CONTRACEPTIVES; REGIMEN; DOXYCYCLINE; ESTRADIOL; PATTERNS; SUPPRESSION; MANAGEMENT; ESTROGEN; INTERVAL AB Background: Unscheduled uterine bleeding is common among women who choose extended or continuous combined hormonal contraception and may subsequently lead to method discontinuation. This systematic review evaluates the evidence on treatments for unscheduled bleeding for women using continuous or extended combined hormonal contraception. Study design: We searched the PubMed database for peer-reviewed articles that were published in any language from inception of the database through January 2012 and were relevant to therapeutic or prophylactic treatments for unscheduled uterine bleeding during extended or continuous combined hormonal contraception use. We used standard abstract forms and grading systems to summarize and assess the quality of the evidence. Results: Four articles met the inclusion criteria. Evidence from two randomized controlled trials, both of fair quality, suggested that a short hormone-free interval of 3 or 4 days improved a current unscheduled bleeding episode. Evidence from one randomized controlled trial of fair quality suggested that oral doxycycline (100 mg twice daily) did not improve a current unscheduled bleeding episode. One good quality randomized controlled trial suggested that prophylactic treatment with a daily low dose of oral doxycycline (40 mg) caused earlier onset of amenorrhea in new extended combined oral contraceptive users. Conclusions: Limited evidence suggests that introducing a short hormone-free interval when unscheduled bleeding occurs during continuous or extended hormonal contraceptive use may reduce unscheduled bleeding days; one study suggests that twice-daily oral doxycycline initiated at the time of unscheduled bleeding is an ineffective treatment. Limited data suggest that prophylactic low-dose daily oral doxycycline may induce earlier amenorrhea among new extended combined hormonal contraceptive users. (C) 2013 Elsevier Inc. All rights reserved. C1 [Godfrey, Emily M.; Whiteman, Maura K.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Godfrey, Emily M.] Univ N Carolina, Dept Obstet & Gynecol, Chapel Hill, NC 27599 USA. RP Godfrey, EM (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. NR 32 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 567 EP 575 DI 10.1016/j.contraception.2012.08.005 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500008 PM 23044386 ER PT J AU Rodriguez, MI Godfrey, EM Warden, M Curtis, KM AF Rodriguez, Maria I. Godfrey, Emily M. Warden, Meredith Curtis, Kathryn M. TI Prevention and management of nausea and vomiting with emergency contraception: a systematic review SO CONTRACEPTION LA English DT Review DE Nausea; Emesis; Emergency contraception; Postcoital contraception ID RANDOMIZED CONTROLLED-TRIAL; YUZPE REGIMEN; ULIPRISTAL ACETATE; LEVONORGESTREL AB Background: Nausea and vomiting are side effects of emergency contraception pill (ECP) use. Different ECP regimens and the use of antinausea drugs may prevent these side effects. Methods: We conducted two searches to identify data pertaining to the prevention of nausea and vomiting with ECP use and management of emesis with ECP use. Both searches queried the PubMed and Cochrane databases for peer-reviewed articles, in any language, published on January 1966 February 2012. Types of ECP included in our searches were levonorgestrel (LNG), Yuzpe regimens or ulipristal acetate (UA). Our search strategy for data on management of emesis with ECP use also included the gray literature. The gray literature includes materials such as reports, patent claims, prescribing information and package labels that are not published commercially. Results: Eleven articles met the inclusion criteria. Split dose or two doses of LNG caused less nausea than UA and standard two-dose Yuzpe regimen in one study. Four studies demonstrated no difference between split-dose versus single-dose LNG. In two trials, meclizine and metoclopramide, given before Yuzpe ECPs, reduced nausea, but only meclizine reduced vomiting. Conclusion: The evidence does not support routine use of antiemetics with ECP use. Data to guide management of emesis with ECP are limited to expert opinion and package labeling. (C) 2013 Elsevier Inc. All rights reserved. C1 [Rodriguez, Maria I.] World Hlth Org, Dept Reprod Hlth & Res, CH-1211 Geneva 27, Switzerland. [Godfrey, Emily M.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Warden, Meredith] Univ Calif San Francisco, Dept Obstet & Gynecol, San Francisco, CA 94110 USA. RP Rodriguez, MI (reprint author), World Hlth Org, Dept Reprod Hlth & Res, CH-1211 Geneva 27, Switzerland. EM rodriguezmar@who.int NR 18 TC 5 Z9 5 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 583 EP 589 DI 10.1016/j.contraception.2012.09.031 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500010 PM 23121827 ER PT J AU Rodriguez, MI Curtis, KM Gaffield, ML Jackson, E Kapp, N AF Rodriguez, Maria I. Curtis, Kathryn M. Gaffield, Mary Lyn Jackson, Emily Kapp, Nathalie TI Advance supply of emergency contraception: a systematic review SO CONTRACEPTION LA English DT Review DE Advance supply; Emergency contraception; Post coital contraception ID RANDOMIZED CONTROLLED-TRIAL; INCREASED ACCESS; UNINTENDED PREGNANCY; ADVANCED PROVISION; BEHAVIOR; PILLS; LEVONORGESTREL; INFORMATION; RATES; WOMEN AB Background: Emergency contraceptive pills (ECPs) are an underutilized means to reduce unintended pregnancy. Advance provision of ECPs may increase timely use, thereby decreasing risk of unintended pregnancy. Study Design: We searched MEDLINE and EMBASE through February 2012 for randomized, controlled trials (RCTs) pertaining to safety and efficacy of advance provision of ECP. The quality of each individual study was evaluated using the United States Preventive Services Task Force evidence grading system. Results: The search strategy identified 714 articles. Seventeen papers reported on safety or efficacy of advance ECPs in adult or adolescent women. Any use of ECPs was two to seven times greater among women who received an advanced supply of ECP. However, a summary estimate (RR 0.90, 95% CI 0.69-1.18) of four RCTs did not demonstrate a significant reduction in unintended pregnancy over 12 months when advance provision was compared with standard provision of ECPs. Patterns of contraceptive use, pregnancy rates and incidence of sexually transmitted infections did not vary between treatment and control groups in the majority of studies among either adults or adolescents. Conclusion: Available evidence supports the safety of advance provision of ECPs. Efficacy of advance provision compared with standard provision of ECPs in reducing unintended pregnancy rates at the population level has not been demonstrated. (C) 2013 Elsevier Inc. All rights reserved. C1 [Rodriguez, Maria I.; Gaffield, Mary Lyn; Kapp, Nathalie] World Hlth Org, Dept Reprod Hlth & Res, CH-1211 Geneva 27, Switzerland. [Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Jackson, Emily] Univ So Calif, Dept Family Med, Los Angeles, CA 90089 USA. RP Rodriguez, MI (reprint author), World Hlth Org, Dept Reprod Hlth & Res, CH-1211 Geneva 27, Switzerland. EM rodrigma@ohsu.edu NR 36 TC 20 Z9 20 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 590 EP 601 DI 10.1016/j.contraception.2012.09.011 PG 12 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500011 PM 23040139 ER PT J AU Salcedo, J Rodriguez, MI Curtis, KM Kapp, N AF Salcedo, Jennifer Rodriguez, Maria I. Curtis, Kathryn M. Kapp, Nathalie TI When can a woman resume or initiate contraception after taking emergency contraceptive pills? A systematic review SO CONTRACEPTION LA English DT Review DE Emergency contraception; ECP; Levonorgestrel; Ulipristal acetate; Yuzpe method AB Background: Hormonal emergency contraception can postpone ovulation, making a woman vulnerable to pregnancy later in the same cycle. However, concern exists as to whether concurrently administered emergency contraception pills (ECP) and other hormonal methods of contraception may affect the effectiveness of both medications. Study Design: A systematic review of the literature using PubMed and the Cochrane databases was performed to identify articles concerning the resumption or initiation of regular contraception within the same cycle as ECP use. We searched for articles in any language, published between 1980 and April 2012 and included all methods of emergency contraception pills available in the USA. Results: The search strategy identified 184 articles in the PubMed and Cochrane databases, of which none met inclusion criteria. Conclusion: The drug manufacturer advises continuation or initiation of routine contraception as soon as possible after use of ulipristal acetate, with concomitant use of a reliable barrier method until next menses. However, a theoretical concern exists that given ulipristal acetate's function as a selective progesterone receptor modulator, coadministration of a progestin could decrease its effectiveness as an emergency contraceptive. Initiation of hormonal contraception following levonorgestrel or the Yuzpe regimen for emergency contraception carries no similar concern for decreased method effectiveness. (C) 2013 Elsevier Inc. All rights reserved. C1 [Salcedo, Jennifer] Univ Calif Los Angeles, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA. [Rodriguez, Maria I.; Kapp, Nathalie] World Hlth Org, Dept Reprod Hlth & Res, CH-1211 Geneva 27, Switzerland. [Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Salcedo, J (reprint author), Univ Hawaii, Dept Obstet & Gynecol, Honolulu, HI 96826 USA. EM jsalcedo@ucera.org NR 14 TC 5 Z9 5 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 602 EP 604 DI 10.1016/j.contraception.2012.08.013 PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500012 PM 22995538 ER PT J AU Steenland, MW Rodriguez, MI Marchbanks, PA Curtis, KM AF Steenland, Maria W. Rodriguez, Maria-Isabel Marchbanks, Polly A. Curtis, Kathryn M. TI How does the number of oral contraceptive pill packs dispensed or prescribed affect continuation and other measures of consistent and correct use? A systematic review SO CONTRACEPTION LA English DT Review DE Contraception; Systematic review AB Background: The review was conducted to examine studies that assess whether the number of pill packs dispensed, or prescribed, affects method continuation and other measures of use. Study Design: PubMed database was searched from inception through March 2012 for all peer-reviewed articles, in any language, that examined the effect of the number of oral contraceptive pill packs dispensed on method continuation, and other measures of use. The quality of each study was assessed using the United States Preventive Services Task Force grading system. Results: Four studies met the inclusion criteria for this review. Studies that compared 1 vs. 12, 1 vs. 12-13, or 3 vs. 7 packs found increased method continuation. However, one study that examined the difference between providing one and then three packs versus providing four packs all at once did not find a difference in continuation. In addition to continuation, evidence from the individual studies included found that a greater number of pill packs was associated with fewer pregnancy tests, fewer pregnancies and less cost per client. A greater number of pill packs was, however, also associated with increased pill wastage. Conclusions: A small body of evidence suggests that dispensing a greater number of oral contraceptive pill packs may increase continuation of use. Published by Elsevier Inc. C1 [Steenland, Maria W.; Marchbanks, Polly A.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Rodriguez, Maria-Isabel] World Hlth Org, Dept Reprod Hlth & Res, CH-1211 Geneva 27, Switzerland. RP Steenland, MW (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. EM inu8@cdc.gov NR 7 TC 7 Z9 7 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 605 EP 610 DI 10.1016/j.contraception.2012.08.004 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500013 PM 23040121 ER PT J AU Steenland, MW Zapata, LB Brahmi, D Marchbanks, PA Curtis, KM AF Steenland, Maria W. Zapata, Lauren B. Brahmi, Dalia Marchbanks, Polly A. Curtis, Kathryn M. TI Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: a systematic review SO CONTRACEPTION LA English DT Review DE Contraception; Adverse event; Hypertension; Pelvic inflammatory disease; Weight gain ID DEPOT-MEDROXYPROGESTERONE ACETATE; PELVIC-INFLAMMATORY-DISEASE; 20 MCG/DAY DEVICES; LATER WEIGHT-GAIN; BLOOD-PRESSURE; INTRAUTERINE CONTRACEPTION; ORAL-CONTRACEPTIVES; TCU 380AG; COPPER; LEVONORGESTREL AB Background: After a woman initiates certain methods of contraception [e.g., hormonal methods, intrauterine devices (IUDs)], she is generally asked to return at some interval for a follow-up visit; however, is it unclear whether follow up is needed, what an appropriate follow-up schedule is and what should be done at follow-up visits. Methods: We conducted four separate searches in the PubMed database for all peer-reviewed articles in any language published from database inception through April 2012 that examined the following health outcomes for combined hormonal contraceptives (CHCs), IUDs or medroxyprogesterone acetate (DMPA): (a) incidence of hypertension among women who began using a CHC compared to women not using a CHC; (b) incidence of migraine among women who began using a CHC compared to women not using a CHC; (c) incidence of pelvic inflammatory disease (PID) among women who began using an IUD compared to women who started another form or used no method of contraception or examined incidence of PID at two or more time periods after IUD insertion and (d) whether initial weight gain predicts future weight gain among women who began using DMPA. The quality of each study was assessed using the United States Preventive Services Task Force grading system. Results: A total of 15 studies met our inclusion criteria: 5 examined hypertension and combined oral contraceptive (COC) use, 7 examined PID and IUD use and 3 examined weight gain after DMPA initiation. No studies that examined migraine after CHC initiation met our inclusion criteria. Few women developed hypertension after initiating COCs, and studies examining increases in blood pressure after COC initiation found mixed results (Level I, fair to II-2, fair). Among women who had a copper IUD inserted, there was little difference in incidence of PID, or IUD removal for PID, compared with women who initiated DMPA, a hormone-releasing IUD, or COCs (Level I, good to Level II-2, fair). Studies that examined when women were diagnosed with PID after IUD insertion found mixed results. The study with the largest sample size found a much greater incidence of PID in the first 20 days after insertion, with very low rates of PM up to 8 years postinsertion (Level I, good to Level II-3, poor). Studies that examined weight gain after DMPA initiation found that weight gain >5% of baseline weight at 6 months was associated with greater mean change in weight and greater mean change in body mass index at follow-up times ranging from 12 to 36 months (Level II-2, fair to Level II-3, fair). Conclusions: Evidence on select adverse events associated with initiation of contraceptive use is limited but does not suggest increased risk of hypertension among COC users or increased risk of PID among IUD users. DMPA users who gain >5% of baseline body weight may be at increased risk of future weight gain. Published by Elsevier Inc. C1 [Steenland, Maria W.; Zapata, Lauren B.; Marchbanks, Polly A.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Brahmi, Dalia] Ipas, Chapel Hill, NC 27515 USA. RP Steenland, MW (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. EM inu8@cdc.gov NR 25 TC 9 Z9 9 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 611 EP 624 DI 10.1016/j.contraception.2012.09.017 PG 14 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500014 PM 23177264 ER PT J AU Steenland, MW Zapata, LB Brahmi, D Marchbanks, PA Curtis, KM AF Steenland, Maria W. Zapata, Lauren B. Brahmi, Dalia Marchbanks, Polly A. Curtis, Kathryn M. TI The effect of follow-up visits or contacts after contraceptive initiation on method continuation and correct use SO CONTRACEPTION LA English DT Review DE Contraception; Continuation; Correct use; Follow-up; Service use ID SERVICES AB Background: We conducted a systematic review to assess whether follow-up visits or contacts after a woman begins using contraception improve method continuation and correct use. Study Design: We searched the PubMed database for all peer-reviewed articles in any language published from database inception through May 2012 that examined the effect of a structured follow-up schedule of visits or contacts on contraceptive use. We included studies that compared women who initiated a method of contraception with a certain follow-up schedule compared to women with a different follow-up schedule or no follow-up at all. To be included, studies must have compared groups on a measure of contraceptive use (e.g., pregnancy, correct use, consistent use, method discontinuation including expulsion). Though not ideally suited to answer our review question, studies in which women used a variety of contraceptive methods but results were not stratified by method type were included. Results: Four studies met our inclusion criteria (Level I, poor to II-2, poor). Two studies examined the effect of a specific follow-up visit schedule on intrauterine device (IUD) continuation: one examining frequency of visits and one examining the timing of the first follow-up visit. Women with more frequent follow-up visits did not have a statistically significant difference in proportion of removals for medical reasons compared with women who had fewer follow-up visits; among women who had their IUDs removed for medical reasons, those who had more frequent follow-up visits had a longer mean time of use prior to removal. The other study found more removals and shorter continuation among women with a follow-up visit at 1 week compared to women with a follow-up visit at 1 month after IUD insertion (no statistical tests reported). Two studies examined the effect of follow-up phone calls compared to no follow-up phone calls after an initial family planning visit among adolescents initiating a variety of contraceptive methods. Neither of the two studies found any differences in method continuation or correct use between study groups. Conclusions: It is difficult to determine what effect, if any, follow-up visits or contacts have on contraceptive method continuation or correct use. Few studies were identified, and those that were identified were mostly of poor quality, were not method specific and had either poor patient compliance with follow-up visits or poor phone contact completion rates. (C) 2013 Published by Elsevier Inc. C1 [Steenland, Maria W.; Zapata, Lauren B.; Marchbanks, Polly A.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Brahmi, Dalia] Ipas, Chapel Hill, NC 27515 USA. RP Steenland, MW (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. EM inu8@cdc.gov FU Intramural CDC HHS [CC999999] NR 6 TC 5 Z9 5 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 625 EP 630 DI 10.1016/j.contraception.2012.09.018 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500015 PM 23114736 ER PT J AU Tepper, NK Curtis, KM Steenland, MW Marchbanks, PA AF Tepper, Naomi K. Curtis, Kathryn M. Steenland, Maria W. Marchbanks, Polly A. TI Blood pressure measurement prior to initiating hormonal contraception: a systematic review SO CONTRACEPTION LA English DT Review DE Blood pressure; Hormonal contraception; Systematic review ID ACUTE MYOCARDIAL-INFARCTION; ORAL-CONTRACEPTIVES; YOUNG-WOMEN; THROMBOEMBOLIC STROKE; MULTICENTER; HEALTH; RISK; MICA AB Background: Women with hypertension who use hormonal methods of contraception may have an increased risk for cardiovascular events. This review was conducted to evaluate the evidence regarding whether blood pressure should be measured prior to initiating hormonal contraceptives. Study Design: The PubMed database was searched from database inception through March 2012 for all peer-reviewed articles in any language concerning blood pressure measurement prior to initiation of hormonal contraceptives. Articles were included if they reported on women with and without blood pressure measurement prior to current hormonal contraceptive usage and assessed cardiovascular outcomes. The quality of each study was assessed using the United States Preventive Services Task Force grading system. Results: Six fair-quality articles from three studies met inclusion criteria for this review. Three case-control studies showed that women who did not have blood pressure measurement prior to initiating combined oral contraceptives (COCs) had a higher risk for acute myocardial infarction (AMI) than women who did have blood pressure measurement. Two case-control studies showed that women who did not have blood pressure measurement prior to initiating COCs had a higher risk for ischemic stroke than women who did have blood pressure measurement. One case-control study showed no difference in the risk for hemorrhagic stroke among women who initiated COCs based on whether or not blood pressure was measured. Conclusions: Fair-quality evidence from five reports showed that women who did not have blood pressure measurement prior to COC initiation had a higher risk for AMI and ischemic stroke than women who did have blood pressure measurement. One fair-quality study showed no increased risk for hemorrhagic stroke based on whether or not blood pressure was measured. Studies that examined hormonal contraceptive methods other than COCs were not identified. Published by Elsevier Inc. C1 [Tepper, Naomi K.; Curtis, Kathryn M.; Steenland, Maria W.; Marchbanks, Polly A.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Tepper, NK (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. EM ntepper@cdc.gov NR 13 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 631 EP 638 DI 10.1016/j.contraception.2012.08.025 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500016 PM 23063336 ER PT J AU Tepper, NK Steenland, MW Marchbanks, PA Curtis, KM AF Tepper, Naomi K. Steenland, Maria W. Marchbanks, Polly A. Curtis, Kathryn M. TI Hemoglobin measurement prior to initiating copper intrauterine devices: a systematic review SO CONTRACEPTION LA English DT Review DE Hemoglobin; Anemia; Copper intrauterine device; Systematic review ID MENSTRUAL BLOOD-LOSS; IRON-DEFICIENCY ANEMIA; 20 MCG/DAY DEVICES; CONTRACEPTIVE-DEVICES; FERRITIN LEVELS; SERUM FERRITIN; SURFACE-AREA; TCU 380AG; WOMEN; IUDS AB Background: Women using copper intrauterine devices (IUDs) frequently experience bleeding abnormalities. This review was conducted to evaluate the evidence regarding whether hemoglobin levels should be measured prior to copper IUD insertion. Study Design: The PubMed database was searched from database inception through March 2012 for all peer-reviewed articles in any language concerning hemoglobin changes among women with anemia who have copper IUDs inserted. Articles were included if they reported changes in hemoglobin among anemic women over a specified period of time following copper IUD insertion. Articles were excluded in which there were no women with anemia at baseline or outcomes among women with anemia were not reported separately. For indirect evidence, articles were included which addressed hemoglobin changes among women without anemia who had copper IUDs inserted. The quality of each direct study was assessed using the US Preventive Services Task Force grading system. Results: Four level I to II-2 studies of fair quality met inclusion criteria as direct evidence. Evidence from one randomized trial and one prospective cohort study showed no statistically significant changes in hemoglobin among copper IUD users with anemia, while two prospective cohort studies showed a statistically significant, but clinically small, mean decrease in hemoglobin levels over 12 months of follow-up. We also identified 21 studies examining changes in hemoglobin among healthy women using copper IUDs as indirect evidence; this body of evidence was not graded. These studies generally showed no clinically significant changes in hemoglobin levels with up to 5 years of follow-up. Conclusions: Limited fair-quality evidence was mixed but generally showed no clinically significant changes in hemoglobin among women with anemia who used copper IUDs for up to 12 months. Indirect evidence among healthy women using copper IUDs did not show clinically significant changes in hemoglobin levels when followed for up to 5 years of use. Published by Elsevier Inc. C1 [Tepper, Naomi K.; Steenland, Maria W.; Marchbanks, Polly A.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Tepper, NK (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. EM ntepper@cdc.gov NR 31 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 639 EP 644 DI 10.1016/j.contraception.2012.08.008 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500017 PM 23040123 ER PT J AU Tepper, NK Steenland, MW Marchbanks, PA Curtis, KM AF Tepper, Naomi K. Steenland, Maria W. Marchbanks, Polly A. Curtis, Kathryn M. TI Laboratory screening prior to initiating contraception: a systematic review SO CONTRACEPTION LA English DT Review DE Glucose; Lipids; Liver enzymes; Cervical cytology; Sexually transmitted infections; HIV; Contraception ID UNITED-STATES; UNINTENDED PREGNANCY; INTRAUTERINE-DEVICES; ORAL-CONTRACEPTIVES; GLUCOSE-METABOLISM; SERUM-LIPIDS; WOMEN; RISK; INFECTION; CANCER AB Background: Certain contraceptive methods may increase the risk of adverse events for women with certain medical conditions, including some women with diabetes, hyperlipidemia, liver disease, cervical cancer, sexually transmitted infections (STIs) or human immunodeficiency virus (HIV). This review was conducted to evaluate the evidence regarding health outcomes among women with and without laboratory testing to identify certain medical conditions prior to initiating contraceptives. Study Design: The PubMed database was searched from database inception through April 2012 for all peer-reviewed articles in any language evaluating health outcomes among women who initiated certain contraceptive methods and who had or had not received glucose, lipid, liver enzyme, cervical cytology, STI or HIV screening. Results: The systematic review did not identify any relevant direct evidence. Conclusions: While certain methods of hormonal contraception may not be safe for use by some women with diabetes, hyperlipidemia or liver disease, there is little value in screening for these conditions in asymptomatic women prior to initiation of contraceptive methods due to the low prevalence of these conditions among women of reproductive age. Although intrauterine devices (IUDs) and cervical caps should not be initiated in women with cervical cancer, the high rates of cervical screening and low incidence of cervical cancer in the United States make this scenario unlikely. Although some women at risk for, or infected with, STIs or HIV should not undergo IUD insertion, if women have been screened for STIs or HIV according to guidelines, additional screening at the time of IUD insertion is not warranted. Requiring unnecessary laboratory screening prior to initiation of contraceptive methods may impose barriers to contraceptive access, and efforts to remove such barriers are critical in reducing unintended pregnancy. Published by Elsevier Inc. C1 [Tepper, Naomi K.; Steenland, Maria W.; Marchbanks, Polly A.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Tepper, NK (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. EM ntepper@cdc.gov NR 26 TC 5 Z9 5 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 645 EP 649 DI 10.1016/j.contraception.2012.08.009 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500018 PM 23040133 ER PT J AU Tepper, NK Curtis, KM Steenland, MW Marchbanks, PA AF Tepper, Naomi K. Curtis, Kathryn M. Steenland, Maria W. Marchbanks, Polly A. TI Physical examination prior to initiating hormonal contraception: a systematic review SO CONTRACEPTION LA English DT Review DE Physical examination; Clinical breast examination; Pelvic examination; Hormonal contraception; Systematic review ID PELVIC EXAMINATION; BREAST AB Background: Provision of contraception is often linked with physical examination, including clinical breast examination (CBE) and pelvic examination. This review was conducted to evaluate the evidence regarding outcomes among women with and without physical examination prior to initiating hormonal contraceptives. Study Design: The PubMed database was searched from database inception through March 2012 for all peer-reviewed articles in any language concerning CBE and pelvic examination prior to initiating hormonal contraceptives. The quality of each study was assessed using the United States Preventive Services Task Force grading system. Results: The search did not identify any evidence regarding outcomes among women screened versus not screened with CBE prior to initiation of hormonal contraceptives. The search identified two case control studies of fair quality which compared women who did or did not undergo pelvic examination prior to initiating oral contraceptives (OCs) or depot medroxyprogesterone acetate (DMPA). No differences in risk factors for cervical neoplasia, incidence of sexually transmitted infections, incidence of abnormal Pap smears or incidence of abnormal wet mount findings were observed. Conclusions: Although women with breast cancer should not use hormonal contraceptives, there is little utility in screening prior to initiation, due to the low incidence of breast cancer and uncertain value of CBE among women of reproductive age. Two fair quality studies demonstrated no differences between women who did or did not undergo pelvic examination prior to initiating OCs or DMPA with respect to risk factors or clinical outcomes. In addition, pelvic examination is not likely to detect any conditions for which hormonal contraceptives would be unsafe. Published by Elsevier Inc. C1 [Tepper, Naomi K.; Curtis, Kathryn M.; Steenland, Maria W.; Marchbanks, Polly A.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Tepper, NK (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. EM ntepper@cdc.gov NR 17 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 650 EP 654 DI 10.1016/j.contraception.2012.08.010 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500019 PM 23121820 ER PT J AU Tepper, NK Steenland, MW Gaffield, ME Marchbanks, PA Curtis, KM AF Tepper, Naomi K. Steenland, Maria W. Gaffield, Mary E. Marchbanks, Polly A. Curtis, Kathryn M. TI Retention of intrauterine devices in women who acquire pelvic inflammatory disease: a systematic review SO CONTRACEPTION LA English DT Review DE Intrauterine device; Pelvic inflammatory disease; Systematic review ID ACUTE SALPINGITIS; REMOVAL; TRIAL; AGE AB Background: Women using intrauterine devices (IUDs) are not protected against acquiring pelvic inflammatory disease (PID). If a woman has an IUD in place when she is diagnosed with PID, there is a theoretical concern that presence of an IUD might impact the course of treatment. This review was conducted to evaluate the evidence regarding whether an IUD should be retained or removed if a woman develops MD. Study Design: The PubMed database was searched from database inception through April 2012 for all peer-reviewed articles in any language concerning PID in women using IUDs. Articles were included if they examined women with IUDs who developed PID and compared the clinical course of women in whom the IUD was retained versus women in whom the IUD was removed. Articles were excluded if the infection was diagnosed before or at the time of IUD insertion. The quality of each study was assessed using the United States Preventive Services Task Force grading system. Results: Four fair-quality studies met inclusion criteria for this review. One randomized controlled trial showed that women with IUDs removed had longer hospitalizations than those with IUD retention (15% versus 4%, p<.01), although there were no differences in PID recurrences or subsequent pregnancies. Another randomized controlled trial showed no differences in laboratory parameters among women who retained the IUD when compared with women in whom the IUD was removed. One prospective cohort study showed that there were no differences in clinical or laboratory parameters during hospitalization; however, the IUD removal group had a higher proportion hospitalized for more than 2 weeks compared with the IUD retention group (33% versus 19%, p<.05). One randomized controlled trial showed that women who had the IUD removed experienced improved recovery in most clinical signs and symptoms compared with women who retained the IUD. Conclusions: Three fair-quality studies showed no difference in clinical or laboratory outcomes among women who retained IUDs when compared with women who had IUDs removed, and two of these studies showed that women who had IUDs removed had longer hospitalizations. In contrast, one fair quality study showed improved clinical signs and symptoms among women who had IUDs removed. Overall, women who retained their IUDs had similar or better outcomes than women who had their IUDs removed. Published by Elsevier Inc. C1 [Tepper, Naomi K.; Steenland, Maria W.; Marchbanks, Polly A.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Gaffield, Mary E.] World Hlth Org, Dept Reprod Hlth & Res, CH-1211 Geneva 27, Switzerland. RP Tepper, NK (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. EM ntepper@cdc.gov NR 16 TC 8 Z9 8 U1 2 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 655 EP 660 DI 10.1016/j.contraception.2012.08.011 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500020 PM 23040135 ER PT J AU Tepper, NK Marchbanks, PA Curtis, KM AF Tepper, Naomi K. Marchbanks, Polly A. Curtis, Kathryn M. TI Use of a checklist to rule out pregnancy: a systematic review SO CONTRACEPTION LA English DT Review DE Pregnancy checklist; Pregnancy test; Contraception; Systematic review ID FAMILY-PLANNING CLIENTS; JOB AID; CARE; TESTS AB Background: Safe initiation of contraceptive methods requires that pregnancy be excluded. The World Health Organization has developed a list of criteria to assess pregnancy status. This review was conducted to evaluate the evidence regarding these criteria in excluding pregnancy. Study Design: The PubMed database was searched from database inception through March 2012 for all peer-reviewed articles in any language concerning the performance of a pregnancy checklist compared to urine pregnancy tests. The quality of each study was assessed using the United States Preventive Services Task Force grading system. Results: Four analyses of data from three studies met inclusion criteria as direct evidence. All were diagnostic accuracy studies of fair quality that evaluated the performance of a pregnancy checklist compared with urine pregnancy test to rule out pregnancy. The performance of the checklist varied, with sensitivity ranging from 55-100% and specificity ranging from 39-89%. The negative predictive value was consistent across studies at 99-100%. Conclusion: All four analyses demonstrated high (99-100%) negative predictive value for the pregnancy checklist. Published by Elsevier Inc. C1 [Tepper, Naomi K.; Marchbanks, Polly A.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Tepper, NK (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. EM ntepper@cdc.gov NR 16 TC 7 Z9 7 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 661 EP 665 DI 10.1016/j.contraception.2012.08.007 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500021 PM 23040127 ER PT J AU Whiteman, MK Tyler, CP Folger, SG Gaffield, ME Curtis, KM AF Whiteman, Maura K. Tyler, Crystal P. Folger, Suzanne G. Gaffield, Mary E. Curtis, Kathryn M. TI When can a woman have an intrauterine device inserted? A systematic review SO CONTRACEPTION LA English DT Review DE Intrauterine devices; Insertion; Menstruation; Systematic review ID MENSTRUAL-CYCLE; IUD; EXPERIENCE; RATES AB Background: Intrauterine device (IUD) insertion during menses may be viewed as preferable by some providers, as it provides reassurance that the woman is not pregnant. However, this practice may result in unnecessary inconvenience and cost to women. The objective of this systematic review is to evaluate the evidence for the effect of inserting IUDs on different days of the menstrual cycle on contraceptive continuation, effectiveness and safety. Study Design: We searched the MEDLINE database for peer-reviewed articles published in any language from database inception through March 2012 concerning the effect of inserting copper IUDs (Cu-IUD) or levonorgestrel-releasing IUDs (LNG-IUDs) on different days of the menstrual cycle on contraceptive continuation, effectiveness, and safety. The quality of each individual piece of evidence was assessed using the United States Preventive Services Task Force grading system. Results: We identified eight articles that met the criteria for review. Each study examined the Cu-IUD; no studies were identified that examined the LNG-IUD. Overall, these studies suggest that timing of Cu-IUD insertion has little effect on longer term outcomes (rates of continuation, removal, expulsion, or pregnancy) or on shorter term outcomes (pain at insertion, bleeding at insertion, immediate expulsion). Specifically, there was no evidence to suggest that outcomes were better when Cu-IUD insertions were performed during menses. Limitations of the studies include small sample sizes for insertions performed during later days of the menstrual cycle and non-randomized assignment to timing of insertion. Conclusions: There is fair evidence (body of evidence grading: II-2, fair) indicating that timing of Cu-IUD insertion has little effect on contraceptive continuation, effectiveness or safety. Published by Elsevier Inc. C1 [Whiteman, Maura K.; Tyler, Crystal P.; Folger, Suzanne G.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Gaffield, Mary E.] World Hlth Org, Dept Reprod Hlth & Res, CH-1211 Geneva 27, Switzerland. RP Whiteman, MK (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. EM acq5@cdc.gov FU Intramural CDC HHS [CC999999] NR 15 TC 8 Z9 8 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 666 EP 673 DI 10.1016/j.contraception.2012.08.015 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500022 PM 22995537 ER PT J AU Zapata, LB Steenland, MW Brahmi, D Marchbanks, PA Curtis, KM AF Zapata, Lauren B. Steenland, Maria W. Brahmi, Dalia Marchbanks, Polly A. Curtis, Kathryn M. TI Patient understanding of oral contraceptive pill instructions related to missed pills: a systematic review SO CONTRACEPTION LA English DT Review DE Contraception; Missed pills; Patient compliance; Health education ID RANDOMIZED-CONTROLLED-TRIAL; PACKAGE INSERT; INFORMATION; KNOWLEDGE; CONSISTENCY; LEAFLETS; WOMEN AB Background: Instructions on what to do after pills are missed are critical to reducing unintended pregnancies resulting from patient non-adherence to oral contraceptive (OC) regimens. Missed pill instructions have previously been criticized for being too complex, lacking a definition of what is meant by "missed pills," and for being confusing to women who may not know the estrogen content of their formulation. To help inform the development of missed pill guidance to be included in the forthcoming US Selected Practice Recommendations, the objective of this systematic review was to evaluate the evidence on patient understanding of missed pill instructions. Study design: We searched the PubMed database for peer-reviewed articles that examined patient understanding of OC pill instructions that were published in any language from inception of the database through March 2012. We included studies that examined women's knowledge and understanding of missed pill instructions after exposure to some written material (e.g., patient package insert, brochure), as well as studies that compared different types of missed pill instructions on women's comprehension. We used standard abstract forms and grading systems to summarize and assess the quality of the evidence. Results: From 1620 articles, nine studies met our inclusion criteria. Evidence from one randomized controlled trial (RCT) and two descriptive studies found that more women knew what to do after missing 1 pill than after missing 2 or 3 pills (Level I, good, to Level II-3, poor), and two descriptive studies found that more women knew what to do after missing 2 pills than after missing 3 pills (Level II-3, fair). Data from two descriptive studies documented the difficulty women have understanding missed pill instructions contained in patient package inserts (Level II-3, poor), and evidence from two RCTs found that providing written brochures with information on missed pill instructions in addition to contraceptive counseling significantly improved knowledge of how to manage missed pills for up to three months compared to contraceptive counseling alone (Level I, fair). Evidence from one RCT found that graphic-based missed pill instructions were better than text-only instructions (Level I, good), and data from two RCTs found that less information resulted in improved comprehension (Level I, good to fair). Evidence from one descriptive study found that many women missing pills did not intend to follow recommended actions per missed pill instructions despite understanding the guidance (Level II-3, poor). Conclusions: There is wide variability in the percent of women having correct knowledge on what to do when pills are missed after exposure to written missed pills instructions, with more women knowing what to do after missing 1 pill than after missing 2 or 3 pills. Women have difficulty understanding missed pill instructions contained in patient package inserts. Providing written brochures with information on missed pill instructions in addition to contraceptive counseling may improve knowledge of how to manage missed pills. Graphic-based missed pill instructions and those containing less information may result in improved comprehension. Even with clear instructions, many women missing pills may choose not to follow the recommended actions. Published by Elsevier Inc. C1 [Zapata, Lauren B.; Steenland, Maria W.; Marchbanks, Polly A.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Brahmi, Dalia] Ipas, Chapel Hill, NC 27515 USA. RP Zapata, LB (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. EM lzapata@cdc.gov NR 29 TC 5 Z9 5 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 674 EP 684 DI 10.1016/j.contraception.2012.08.026 PG 11 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500023 PM 23040136 ER PT J AU Zapata, LB Steenland, MW Brahmi, D Marchbanks, PA Curtis, KM AF Zapata, Lauren B. Steenland, Maria W. Brahmi, Dalia Marchbanks, Polly A. Curtis, Kathryn M. TI Effect of missed combined hormonal contraceptives on contraceptive effectiveness: a systematic review SO CONTRACEPTION LA English DT Review DE Combined hormonal contraceptives; Missed pills; Dosing errors; Patient compliance; Contraceptive effectiveness; Pregnancy; Ovarian suppression ID VAGINAL RING; ETHINYL ESTRADIOL; ORAL-CONTRACEPTIVES; CYCLE CONTROL; FOLLICULAR DEVELOPMENT; DELIBERATE OMISSION; OVARIAN-FUNCTION; FREE INTERVAL; OVULATION; PILL AB Background: Combined hormonal contraceptives (CHCs) are popular methods of reversible contraception in the United States, but adherence remains an issue as reflected in their lower rates of typical use effectiveness. The objective of this systematic review was to evaluate evidence on the effect of missed CHCs on pregnancy rates as well as surrogate measures of contraceptive effectiveness (e.g., ovulation, follicular development, changes in hormone levels, cervical mucus quality). Study Design: We searched the PubMed database for peer-reviewed articles published in any language from database inception through April 2012. We included studies that examined measures of contraceptive effectiveness during cycles with extended hormone-free intervals or nonadherence (e.g., omission of pills, delayed patch replacement) on days not adjacent to the hormone-free interval. We used standard abstract forms and grading systems to summarize and assess the quality of the evidence. Results: The search strategy identified 1387 articles, of which 26 met our study selection criteria. There is wide variability in the amount of follicular development and risk of ovulation among women who extended the pill-free interval to 8-14 days; in general, the risk of ovulation was low, and among women who did ovulate, cycles were usually abnormal (i.e., low progesterone levels, small follicles and/or poor cervical mucus) (Level I, good, indirect to Level II-3, fair, indirect). Studies of women who missed one to four consecutive pills or 1-3 consecutive days of delay before patch replacement at times other than adjacent to the hormone-free interval reported little follicular activity and low risk of ovulation (Level I, fair, indirect to Level II-3, poor, indirect). Studies comparing 30 mcg versus 20 mcg mc ethinyl estradiol pills showed more follicular activity when 20 mcg ethinyl estradiol pills were missed (Level I, good, indirect). Conclusion: Most of the studies in this evidence base relied on surrogate measures of pregnancy risk and ranged in quality. For studies providing indirect evidence on the effects of missed CHCs, it is unclear how differences in surrogate measures correspond to pregnancy risk. Fewer studies examined the transdermal patch and vaginal ring than combined oral contraceptives. Published by Elsevier Inc. C1 [Zapata, Lauren B.; Steenland, Maria W.; Marchbanks, Polly A.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Brahmi, Dalia] Ipas, Chapel Hill, NC 27515 USA. RP Zapata, LB (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. EM lzapata@cdc.gov FU Intramural CDC HHS [CC999999] NR 38 TC 12 Z9 13 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD MAY PY 2013 VL 87 IS 5 BP 685 EP 700 DI 10.1016/j.contraception.2012.08.035 PG 16 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 137TQ UT WOS:000318461500024 PM 23083527 ER PT J AU Steinmaus, C Miller, MD Cushing, L Blount, BC Smith, AH AF Steinmaus, Craig Miller, Mark D. Cushing, Lara Blount, Benjamin C. Smith, Allan H. TI Combined effects of perchlorate, thiocyanate, and iodine on thyroid function in the National Health and Nutrition Examination Survey 2007-08 SO ENVIRONMENTAL RESEARCH LA English DT Article DE Perchlorate; Iodine; Thiocyanate; Thyroid hormone; National Health and Nutrition Examination; Survey ID DRINKING-WATER; EARLY-PREGNANCY; HORMONE LEVELS; UNITED-STATES; MATERNAL HYPOTHYROXINEMIA; REFERENCE RANGE; FREE-THYROXINE; LONG-TERM; EXPOSURE; NITRATE AB Perchlorate, thiocyanate, and low iodine intake can all decrease iodide intake into the thyroid gland. This can reduce thyroid hormone production since iodide is a key component of thyroid hormone. Previous research has suggested that each of these factors alone may decrease thyroid hormone levels, but effect sizes are small. We hypothesized that people who have all three factors at the same time have substantially lower thyroid hormone levels than people who do not, and the effect of this combined exposure is substantially larger than the effects seen in analyses focused on only one factor at a time. Using data from the 2007-2008 National Health and Nutrition Examination Survey, subjects were categorized into exposure groups based on their urinary perchlorate, iodine, and thiocyanate concentrations, and mean serum thyroxine concentrations were compared between groups. Subjects with high perchlorate (n=1939) had thyroxine concentrations that were 5.0% lower (mean difference-0.40 mu g/dl, 95% confidence interval-0.14-0.65) than subjects with low perchlorate (n=2084). The individual effects of iodine and thiocyanate were even smaller. Subjects with high perchlorate, high thiocyanate, and low iodine combined (n=62) had thyroxine concentrations 12.9% lower (mean difference=1.07 mu g/dl, 95% confidence interval=0.55-1.59) than subjects with low perchlorate, low thiocyanate, and adequate iodine (n=376). Potential confounders had little impact on results. Overall, these results suggest that concomitant exposure to perchlorate, thiocyanate, and low iodine markedly reduces thyroxine production. This highlights the potential importance of examining the combined effects of multiple agents when evaluating the toxicity of thyroid-disrupting agents. (C) 2013 Elsevier Inc. All rights reserved. C1 [Steinmaus, Craig; Miller, Mark D.] Calif Environm Protect Agcy, Off Environm Hlth Hazard Assessment, Oakland, CA 94612 USA. [Cushing, Lara] Univ Calif Berkeley, Energy & Resources Grp, Berkeley, CA 93720 USA. [Blount, Benjamin C.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA. [Smith, Allan H.] Univ Calif Berkeley, Arsen Hlth Effects Res Grp, Berkeley, CA 94704 USA. RP Steinmaus, C (reprint author), Calif Environm Protect Agcy, Off Environm Hlth Hazard Assessment, 1515 Clay St,16th Floor, Oakland, CA 94612 USA. EM craigs@berkeley.edu; ucsfpehsumiller@gmail.com; lara.cushing@berkeley.edu; bkb3@cdc.gov; ahsmith@berkeley.edu OI Miller, Mark/0000-0002-9301-0093 FU National Institute of Environmental Health Sciences [1R01ES020365-01]; University of California Center for Occupational and Environmental Health FX Funding for this project was provided by Grant 1R01ES020365-01 from the National Institute of Environmental Health Sciences and from the University of California Center for Occupational and Environmental Health. NR 49 TC 20 Z9 20 U1 7 U2 29 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 J9 ENVIRON RES JI Environ. Res. PD MAY PY 2013 VL 123 BP 17 EP 24 DI 10.1016/j.envres.2013.01.005 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 142XB UT WOS:000318829800003 PM 23473920 ER PT J AU Antao, VC AF Antao, Vinicius C. TI The World Trade Center disaster: a tragic source of medical advancement SO EUROPEAN RESPIRATORY JOURNAL LA English DT Editorial Material ID OBSTRUCTIVE PULMONARY-DISEASE; YORK-STATE PERSONNEL; CENTER DUST; CENTER SITE; HEALTH; EXPOSURE; SYMPTOMS; INFLAMMATION; BIOMARKERS; COLLAPSE C1 [Antao, Vinicius C.] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA 30341 USA. RP Antao, VC (reprint author), Agcy Tox Subst & Dis Registry, 4770 Buford Highway NE,MS F-57, Atlanta, GA 30341 USA. EM VAntao@cdc.gov NR 26 TC 1 Z9 1 U1 0 U2 2 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 J9 EUR RESPIR J JI Eur. Resp. J. PD MAY PY 2013 VL 41 IS 5 BP 999 EP 1001 DI 10.1183/09031936.00181112 PG 3 WC Respiratory System SC Respiratory System GA 141TV UT WOS:000318750300001 PM 23633605 ER PT J AU Checkley, W Robinson, CL Baumann, LM Romero, K Combe, JM Gilman, RH Wise, RA Hamilton, RG Gonzalvez, G Cama, V Hansel, NN AF Checkley, William Robinson, Colin L. Baumann, Lauren M. Romero, Karina Combe, Juan M. Gilman, Robert H. Wise, Robert A. Hamilton, Robert G. Gonzalvez, Guillermo Cama, Vitaliano Hansel, Nadia N. CA PURA Study Investigators TI Effect of urbanisation on the relationship between total serum IgE and asthma SO EUROPEAN RESPIRATORY JOURNAL LA English DT Article DE Asthma clinical/basic investigations; atopic asthma; epidemiology of asthma ID SKIN-TEST REACTIVITY; IMMUNOGLOBULIN-E; AIRWAY RESPONSIVENESS; ALLERGY; CHILDREN; INFLAMMATION; ASSOCIATION; MORBIDITY; EXPOSURE; ATOPY AB It is unclear if the relationship of total serum IgE with asthma varies with degree of urbanisation. We hypothesised that the relationship of total serum IgE to asthma is more pronounced in an urban versus a rural environment. We enrolled 1441 children aged 13-15 years in a pen-urban shanty town in Lima, Peru (n=725) and 23 villages in rural Tumbes, Peru (n=716). We asked participants about asthma and allergy symptoms, environmental exposures and sociodemographics; and performed spirometry, and exhaled nitric oxide and allergy skin testing. We obtained blood for total serum IgE in 1143 (79%) participants. Geometric means for total serum IgE were higher in Lima versus Tumbes (262 versus 192 kU.L-1; p<0.001). The odds of asthma increased by factors of 1.6 (95% CI 1.3-2.0) versus 1.4 (95% Cl 0.9-2.1) per log unit increase in total serum IgE in Lima versus Tumbes, respectively. Atopy was an effect modifier of the relationship of total serum IgE on asthma. Among atopics and non-atopics, the odds of asthma increased by a factor of 2.0 (95% CI 1.5-2.7) and 1.0 (95% CI 0.7-1.4) per log unit increase in total serum IgE, respectively. Total serum IgE was associated with atopic asthma but not with non-atopic asthma. Urbanisation did. not appear to be an effect modifier of this relationship. C1 [Checkley, William; Robinson, Colin L.; Baumann, Lauren M.; Wise, Robert A.; Hansel, Nadia N.] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care, Baltimore, MD 21205 USA. [Checkley, William; Gilman, Robert H.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Program Global Dis Epidemiol & Control, Dept Int Hlth, Baltimore, MD 21205 USA. [Hamilton, Robert G.] Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Baltimore, MD 21205 USA. [Cama, Vitaliano] Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA USA. [Hansel, Nadia N.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA. [Checkley, William; Gilman, Robert H.] Univ Peruana Cayetano Heredia, CRONICAS Ctr Excellence Chron Dis Res, Lima, Peru. [Romero, Karina; Combe, Juan M.; Gilman, Robert H.] Asociac Benef PRISMA, Lima, Peru. [Gonzalvez, Guillermo] Univ Peruana Cayetano Heredia, Dept Microbiol, Lima, Peru. RP Checkley, W (reprint author), Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care, 1800 Orleans St Suite 9121, Baltimore, MD 21205 USA. EM wcheckl1@jhmi.edu OI Wise, Robert/0000-0002-8353-2349 FU Johns Hopkins Center for Global Health; Fogarty International Center Training Grant [R24 TW007988]; Johns Hopkins University; National Heart, Lung and Blood Institute, National Institutes of Health [R00HL096955, HHSN268200900033C]; National Institutes of Environmental Health Sciences [R01ES018845]; Tufts University School of Medicine; NIH T35 Training Grant [T35AI065385] FX This study was supported by a Johns Hopkins Center for Global Health Award and the Fogarty International Center Training Grant (Grant R24 TW007988). W. Checkley was supported by a Clinician Scientist Award from the Johns Hopkins University, a K99/R00 Pathway to Independence Award (R00HL096955) from the National Heart, Lung and Blood Institute, National Institutes of Health and by a contract (HHSN268200900033C) with the National Heart, Lung and Blood Institute, National Institutes of Health. N. Hansel and W. Checkley were further supported by a R01 grant from the National Institutes of Environmental Health Sciences (R01ES018845). C.L. Robinson was a Fogarty International Clinical Research Scholar during the time of this work and was further supported by Tufts University School of Medicine. L.M. Baumann was supported by a pre-doctoral NIH T35 Training Grant (T35AI065385). NR 31 TC 3 Z9 3 U1 0 U2 6 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 J9 EUR RESPIR J JI Eur. Resp. J. PD MAY PY 2013 VL 41 IS 5 BP 1074 EP 1081 DI 10.1183/09031936.00025512 PG 8 WC Respiratory System SC Respiratory System GA 141TV UT WOS:000318750300015 PM 22835619 ER PT J AU Ganova-Raeva, LM Khudyakov, YE AF Ganova-Raeva, Lilia M. Khudyakov, Yury E. TI Application of mass spectrometry to molecular diagnostics of viral infections SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS LA English DT Review DE DNA sequencing; infectious disease; mass spectrometry; molecular diagnostics; molecular surveillance; viral infection ID HEPATITIS-C VIRUS; ASSISTED LASER-DESORPTION; BASE-SPECIFIC CLEAVAGE; IONIZATION-TIME; ELECTROSPRAY-IONIZATION; RESPIRATORY PATHOGENS; RAPID IDENTIFICATION; DNA ANALYSIS; HEPATOCELLULAR-CARCINOMA; CLINICAL MICROBIOLOGY AB Mass spectrometry (MS) has found numerous applications in life sciences. It has high accuracy, sensitivity and wide dynamic range in addition to medium- to high-throughput capabilities. These features make MS a superior platform for analysis of various biomolecules including proteins, lipids, nucleic acids and carbohydrates. Until recently, MS was applied for protein detection and characterization. During the last decade, however, MS has successfully been used for molecular diagnostics of microbial and viral infections with the most notable applications being identification of pathogens, genomic sequencing, mutation detection, DNA methylation analysis, tracking of transmissions, and characterization of genetic heterogeneity. These new developments vastly expand the MS application from experimental research to public health and clinical fields. Matching of molecular techniques with specific requirements of the major MS platforms has produced powerful technologies for molecular diagnostics, which will further benefit from coupling with computational tools for extracting clinical information from MS-derived data. C1 [Ganova-Raeva, Lilia M.; Khudyakov, Yury E.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30329 USA. RP Ganova-Raeva, LM (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE,MS A-33, Atlanta, GA 30329 USA. EM lkg7@cdc.gov NR 86 TC 4 Z9 4 U1 0 U2 23 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7159 EI 1744-8352 J9 EXPERT REV MOL DIAGN JI Expert Rev. Mol. Diagn. PD MAY PY 2013 VL 13 IS 4 BP 377 EP 388 DI 10.1586/ERM.13.24 PG 12 WC Pathology SC Pathology GA 139YJ UT WOS:000318620900013 PM 23638820 ER PT J AU Dube, SR Arrazola, RA Lee, J Engstrom, M Malarcher, A AF Dube, Shanta R. Arrazola, Rene A. Lee, Joann Engstrom, Martha Malarcher, Ann TI Pro-Tobacco Influences and Susceptibility to Smoking Cigarettes Among Middle and High School Students-United States, 2011 SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article ID ADOLESCENT SMOKING; PROMOTION; EXPOSURE; ADVERTISEMENTS; INDUSTRY; SMOKERS AB Purpose: Smoking is a leading cause of cancer, and most smokers begin during adolescence. We examined the proportion of adolescents exposed to pro-tobacco advertising and assessed the association between this exposure and susceptibility to smoking. Methods: Data from the 2011 National Youth Tobacco Survey were used to calculate the proportion of susceptible middle school (MS) and high school (HS) students exposed to pro-tobacco advertisements through stores, magazines, and the Internet. Following previous work, susceptibility to smoking cigarettes was defined as "never smoked but open to trying cigarettes." Results: In 2011, 81.5% of MS students and 86.9% of HS students were exposed to tobacco advertisements in stores; 48.2% of MS students and 54.0% of HS students were exposed to such advertising in magazines. Exposure to tobacco advertisements on the Internet was similar for MS (40.8%) and HS students (40.2%). Of those surveyed, 22.5% of MS students and 24.2% of HS students were susceptible to trying cigarettes. Exposure to magazine advertising declined from 71.8% in 2000 to 46.1% in 2009 among susceptible MS students; however, exposure increased to 55.4% in 2011. Tobacco advertising seen through the Internet among susceptible HS students increased from 25.9% in 2000 to 44.7% in 2011. Conclusions: Adolescents continue to be exposed to pro-tobacco advertisements. Adolescents susceptible to smoking are more likely to report exposure to pro-tobacco advertisements. In addition to continued monitoring, more effective interventions to eliminate youth exposure to pro-tobacco marketing are needed. Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Dube, Shanta R.; Arrazola, Rene A.; Lee, Joann; Engstrom, Martha; Malarcher, Ann] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Dube, SR (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS K-50, Atlanta, GA 30341 USA. EM skd7@cdc.gov FU Centers for Disease Control and Prevention; Centers for Disease Control and Prevention (CDC); U.S. Department of Energy FX Publication of this article was supported by the Centers for Disease Control and Prevention.; This project was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention (CDC) administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the CDC. NR 32 TC 17 Z9 17 U1 0 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD MAY PY 2013 VL 52 IS 5 SU S BP S45 EP S51 DI 10.1016/j.jadohealth.2012.07.007 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 140UQ UT WOS:000318681800008 PM 23601611 ER PT J AU Holman, DM Rodriguez, JL Peipins, L Watson, M White, MC AF Holman, Dawn M. Rodriguez, Juan L. Peipins, Lucy Watson, Meg White, Mary C. TI Highlights From a Workshop on Opportunities for Cancer Prevention During Preadolescence and Adolescence SO JOURNAL OF ADOLESCENT HEALTH LA English DT Editorial Material ID HIGH-SCHOOL-STUDENTS; UNITED-STATES; HEALTH INEQUALITIES; PUBLIC-HEALTH; RECENT TRENDS; DISPARITIES; CHILDHOOD; PROVIDERS; BEHAVIOR; SMOKING AB In an effort to explore opportunities for cancer prevention during preadolescence and adolescence, the Cancer Prevention Across the Lifespan workgroup within the Division of Cancer Prevention and Control at the Centers for Disease Control and Prevention (CDC) convened an informal panel of experts for a 2-day workshop August 9-10, 2011. In this report, we provide highlights from the workshop. A central theme of the workshop was that preadolescence and adolescence are times of unique susceptibility and vulnerability within the lifespan. Participants discussed the evidence linking exposures during adolescence (e.g., risky behaviors, chemicals, medical imaging procedures) and subsequent cancer risk during adulthood. Participants also discussed potential opportunities to intervene on risk factors for cancer at multiple levels during adolescence, the importance of more focused approaches to adequately address health disparities, and the ongoing need for transdisciplinary and translational prevention research. Future opportunities for the CDC include further leveraging surveillance data from sources such as the National Health and Nutrition Examination Survey, the Youth Risk Behavior Surveillance System, and the National Children's Study and continuing to build on collaborations with other federal agencies and with national, state, and local organizations. Many ideas and insights generated during the workshop will be put into action as CDC continues to explore opportunities for cancer prevention during youth and across the lifespan. Published by Elsevier Inc on behalf of Society for Adolescent Health and Medicine. C1 [Holman, Dawn M.; Rodriguez, Juan L.; Peipins, Lucy; Watson, Meg; White, Mary C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. RP Holman, DM (reprint author), Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, 4770 Buford Hwy MS-K55, Atlanta, GA 30341 USA. EM DHolman@cdc.gov RI White, Mary /C-9242-2012 OI White, Mary /0000-0002-9826-3962 FU Intramural CDC HHS [CC999999] NR 60 TC 8 Z9 9 U1 1 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD MAY PY 2013 VL 52 IS 5 SU S BP S8 EP S14 DI 10.1016/j.jadohealth.2013.02.018 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 140UQ UT WOS:000318681800002 PM 23601615 ER PT J AU Holman, DM Watson, M AF Holman, Dawn M. Watson, Meg TI Correlates of Intentional Tanning Among Adolescents in the United States: A Systematic Review of the Literature SO JOURNAL OF ADOLESCENT HEALTH LA English DT Review ID NONMELANOMA SKIN-CANCER; YOUNG-ADULTS; INDOOR TANNERS; SUN PROTECTION; US ADOLESCENTS; BED USE; RISK; MELANOMA; BEHAVIORS; PREVENTION AB Purpose: Exposure to ultraviolet radiation and a history of sunburn in childhood contribute to risk of skin cancer in adolescence and in adulthood, but many adolescents continue to seek a tan, either from the sun or from tanning beds (i.e., intentional tanning). To understand tanning behavior among adolescents, we conducted a systematic review of the literature to identify correlates of intentional tanning in the United States. Methods: We included articles on original research published in English between January 1, 2001, and October 31, 2011, that used self-reported data on intentional tanning by U. S. adolescents aged 8 to 18 years and examined potential correlates of tanning behaviors. Thirteen articles met our criteria; all used cross-sectional survey data and quantitative methods to assess correlates of intentional tanning. Results: Results indicate that multiple factors influence tanning among adolescents. Individual factors that correlated with intentional tanning include demographic factors (female sex, older age), attitudes (preferring tanned skin), and behaviors (participating in other risky or appearance-focused behaviors such as dieting). Social factors correlated with intentional tanning include parental influence (having a parent who tans or permits tanning) and peer influence (having friends who tan). Only four studies examined broad contextual factors such as indoor tanning laws and geographic characteristics; they found that proximity to tanning facilities and geographic characteristics (living in the Midwest or South, living in a low ultraviolet area, and attending a rural high school) are associated with intentional tanning. Conclusions: These findings inform future public health research and intervention efforts to reduce intentional tanning. Published by Elsevier Inc on behalf of Society for Adolescent Health and Medicine. C1 [Holman, Dawn M.; Watson, Meg] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. RP Holman, DM (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy MS-K55, Atlanta, GA 30341 USA. EM DHolman@cdc.gov FU Intramural CDC HHS [CC999999] NR 59 TC 17 Z9 17 U1 3 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD MAY PY 2013 VL 52 IS 5 SU S BP S52 EP S59 DI 10.1016/j.jadohealth.2012.09.021 PG 8 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 140UQ UT WOS:000318681800009 PM 23601612 ER PT J AU White, MC Peipins, LA Watson, M Trivers, KF Holman, DM Rodriguez, JL AF White, Mary C. Peipins, Lucy A. Watson, Meg Trivers, Katrina F. Holman, Dawn M. Rodriguez, Juan L. TI Cancer Prevention for the Next Generation SO JOURNAL OF ADOLESCENT HEALTH LA English DT Editorial Material ID UNITED-STATES; BREAST-CANCER; SOCIAL DETERMINANTS; PUBLIC-HEALTH; LUNG-CANCER; AVOIDABLE RISKS; PROSTATE-CANCER; TUMOR SUBTYPES; RECENT TRENDS; LIFE-STYLE AB Given the continued growth in the number of persons with cancer in the United States, the primary prevention of cancer remains an urgent public health priority. As the field of cancer prevention continues to mature and scientific knowledge evolves, it is imperative to challenge the status quo and embrace new approaches to cancer prevention. In this commentary, we summarize recent trends and some of the scientific advances that have been made over the past few decades regarding the complex process of cancer development and the interaction of individual and social risk factors. We examine some of the assumptions and terminology that have characterized cancer prevention approaches for more than a quarter century and the impact of these assumptions and our use of terminology. We propose that it is possible for today's youth to experience lower cancer incidence rates as adults compared with previous generations. To accomplish this goal, a more transdisciplinary and multifaceted approach is needed, adapted as appropriate for different populations and stages of life. The greatest improvements in cancer prevention may occur as a result of innovative, multilevel interventions that build on the expanding scientific evidence base. Published by Elsevier Inc on behalf of Society for Adolescent Health and Medicine. C1 [White, Mary C.; Peipins, Lucy A.; Watson, Meg; Trivers, Katrina F.; Holman, Dawn M.; Rodriguez, Juan L.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP White, MC (reprint author), CDC, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, 4770 Buford Highway NE,Mailstop K55, Atlanta, GA 30341 USA. EM mxw5@cdc.gov RI White, Mary /C-9242-2012 OI White, Mary /0000-0002-9826-3962 FU Intramural CDC HHS [CC999999] NR 98 TC 13 Z9 14 U1 0 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD MAY PY 2013 VL 52 IS 5 SU S BP S1 EP S7 DI 10.1016/j.jadohealth.2013.02.016 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 140UQ UT WOS:000318681800001 PM 23601606 ER PT J AU Loeppke, RR Schill, AL Chosewood, LC Grosch, JW Allweiss, P Burton, WN Barnes-Farrell, JL Goetzel, RZ Heinen, L Hudson, TW Hymel, P Merchant, J Edington, DW Konicki, DL Larson, PW AF Loeppke, Ronald R. Schill, Anita L. Chosewood, L. Casey Grosch, James W. Allweiss, Pamela Burton, Wayne N. Barnes-Farrell, Janet L. Goetzel, Ron Z. Heinen, LuAnn Hudson, T. Warner Hymel, Pamela Merchant, James Edington, Dee W. Konicki, Doris L. Larson, Paul W. TI Advancing Workplace Health Protection and Promotion for an Aging Workforce SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID DISEASE PREVALENCE; WORKERS; CARE AB Objective: To explore issues related to the aging workforce, including barriers to integrating health protection and promotion programs, and provide recommendations for best practices to maximize contributions by aging workers. Methods: Workgroups reviewed literature and case studies to develop consensus statements and recommendations for a national approach to issues related to older workers. Results: Consensus statements and actions steps were identified for each of the Summit goals and call-to-action statements were developed. Conclusions: A national dialogue to build awareness of integrated health protection and promotion for the aging workforce is needed. Workers will benefit from improved health and performance; employers will realize a more engaged and productive workforce; and the nation will gain a vital, competitive workforce. C1 [Loeppke, Ronald R.] US Prevent Med, Brentwood, TN 37027 USA. [Schill, Anita L.] NIOSH, Washington, DC USA. [Chosewood, L. Casey] NIOSH, Total Worker Hlth, Ctr Dis Control & Prevent, Atlanta, GA USA. [Grosch, James W.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Allweiss, Pamela] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Burton, Wayne N.] Amer Express Wellness Ctr, New York, NY USA. [Barnes-Farrell, Janet L.] Univ Connecticut, Dept Psychol, Storrs, CT USA. [Goetzel, Ron Z.] Emory Univ, Rollins Sch Publ Hlth, Inst Hlth & Prod Studies, Washington, DC USA. [Goetzel, Ron Z.] Truven Hlth Analyt, Analyt Consulting & Res Serv, Consulting & Appl Res, Bethesda, MD USA. [Heinen, LuAnn] Natl Business Grp Hlth, Inst Innovat Workforce Wellbeing, Washington, DC USA. [Heinen, LuAnn] Natl Business Grp Hlth, Inst Hlth Prod & Human Capital, Washington, DC USA. [Hudson, T. Warner] Univ Calif Los Angeles, Med Ctr, Occupat Hlth Facil, Los Angeles, CA 90024 USA. [Hymel, Pamela] Walt Disney Pk & Resorts, Burbank, CA USA. [Merchant, James] Univ Iowa, Dept Prevent Med & Environm Hlth, Iowa City, IA 52242 USA. [Edington, Dee W.] Univ Michigan, Hlth Management Res Ctr, Ann Arbor, MI 48109 USA. [Konicki, Doris L.] KDK Solut Ltd, Chicago, IL USA. [Larson, Paul W.] Paul Larson Commun, Evanston, IL USA. RP Loeppke, RR (reprint author), US Prevent Med, 5166 Remington Dr, Brentwood, TN 37027 USA. EM Rloeppke.md@uspm.com FU National Institute for Occupational Safety and Health FX The Invitational Summit was supported in part by a grant from National Institute for Occupational Safety and Health. NR 38 TC 19 Z9 19 U1 0 U2 26 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD MAY PY 2013 VL 55 IS 5 BP 500 EP 506 DI 10.1097/JOM.0b013e31829613a4 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 141UR UT WOS:000318752500006 PM 23657074 ER PT J AU Roemer, EC Kent, KB Samoly, DK Gaydos, LM Smith, KJ Agarwal, A Matson-Koffman, DM Goetzel, RZ AF Roemer, Enid Chung Kent, Karen B. Samoly, Daniel K. Gaydos, Laura M. Smith, Kristyn J. Agarwal, Amol Matson-Koffman, Dyann M. Goetzel, Ron Z. TI Reliability and Validity Testing of the CDC Worksite Health ScoreCard An Assessment Tool to Help Employers Prevent Heart Disease, Stroke, and Related Health Conditions SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID PHYSICAL-ACTIVITY INTERVENTIONS; LIFE-STYLE; PROMOTION; WOMEN; RISK AB Objective: To develop, evaluate, and improve the reliability and validity of the CDC Worksite Health ScoreCard (HSC). Methods: We tested interrater reliability by piloting the HSC at 93 worksites, examining question response concurrence between two representatives from each worksite. We conducted cognitive interviews and site visits to evaluate face validity of items and refined the instrument for general distribution. Results: The mean question concurrence rate was 77%. Respondents reported the tool to be useful, and on average 49% of all possible interventions were in place at the surveyed worksites. The interviews highlighted issues undermining reliability and validity, which were addressed in the final version of the instrument. Conclusions: The revised HSC is a reasonably valid and reliable tool for assessing worksite health promotion programs, policies, and environmental supports directed at preventing cardiovascular disease. C1 [Roemer, Enid Chung; Kent, Karen B.; Samoly, Daniel K.; Smith, Kristyn J.; Goetzel, Ron Z.] Emory Univ, Inst Hlth & Prod Studies, Washington, DC 20037 USA. [Gaydos, Laura M.; Agarwal, Amol] Emory Univ, Atlanta, GA 30322 USA. [Matson-Koffman, Dyann M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. [Goetzel, Ron Z.] Truven Hlth Analyt, Bethesda, MD USA. RP Roemer, EC (reprint author), Emory Univ, Rollins Sch Publ Hlth, Inst Hlth & Prod Studies, 1341 22nd St NW, Washington, DC 20037 USA. EM enid.c.roemer@emory.edu FU Centers for Disease Control and Prevention [5U48DP001909]; Emory University Prevention Research Center [5U48DP001909] FX Funding for this study was provided through a cooperative agreement between the Centers for Disease Control and Prevention and the Emory University Prevention Research Center; grant number 5U48DP001909. NR 17 TC 7 Z9 7 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD MAY PY 2013 VL 55 IS 5 BP 520 EP 526 DI 10.1097/JOM.0b013e31828349a7 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 141UR UT WOS:000318752500009 PM 23618885 ER PT J AU Simon, AE Lukacs, SL Mendola, P AF Simon, Alan E. Lukacs, Susan L. Mendola, Pauline TI National Trends in Emergency Department Use of Urinalysis, Complete Blood Count, and Blood Culture for Fever Without a Source Among Children Aged 2 to 24 Months in the Pneumococcal Conjugate Vaccine 7 Era SO PEDIATRIC EMERGENCY CARE LA English DT Article DE fever; PCV-7; testing ID URINARY-TRACT-INFECTION; PRIMARY-CARE PHYSICIANS; FEBRILE INFANTS; PRACTICE GUIDELINES; YOUNG-CHILDREN; OCCULT BACTEREMIA; INITIAL UTI; MANAGEMENT; DISEASE; PEDIATRICIANS AB Objectives: The epidemiology of serious bacterial infections in children has changed since the introduction of the pneumococcal conjugate vaccine (PCV-7) in 2000. Whether emergency department (ED) physicians have changed diagnostic approaches to fever without a source (FWS) in response is unknown. We examine trends in rates of complete blood count (CBC), urinalysis (UA), and blood cultures among 2- to 24-month-old children with FWS since the introduction of PCV-7. Methods: The National Hospital Ambulatory Medical Care Survey-Emergency Department, 2001-2009, was used to identify visits to the ED by 2- to 24-month-old children with FWS. Rates of CBC, UA, neither CBC nor UA, and blood culture were tracked across time. Trends were identified using Joinpoint regression and bivariate and multivariate logistic regressions with year as the independent variables and ordering of each test as the dependent variables. Results: In bivariate and multivariate analyses, CBC orders declined between 2004 and 2009 for visits by all children 2 to 24 months, children 2 to 11 months, and boys 2 to 24 months (adjusted odds ratio [aOR], 0.88 per year [P < 0.01]; aOR, 0.88 [P < 0.05]; and aOR, 0.83 [P < 0.01], respectively). Between 2004 and 2009, ordering neither CBC nor UA increased among all children 2 to 24 months (aOR, 1.10; P < 0.05) and among boys (aOR, 1.16; P < 0.05). Orders for blood cultures declined across the time period in bivariate analysis, but not in multivariate analysis. Conclusions: The rate of ordering a CBC for children in the 2- to 24-month age group presenting to the ED with FWS declined, a change coincident with the changing epidemiology of serious bacterial infection since the PCV-7 vaccine was introduced. C1 [Simon, Alan E.; Lukacs, Susan L.] Ctr Dis Control & Prevent, Infant Child & Womens Hlth Stat Branch, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Mendola, Pauline] Eunice Kennedy Shriver Natl Inst Child Hlth & Dev, Div Epidemiol Stat & Prevent Res, NIH, Rockville, MD USA. RP Simon, AE (reprint author), Natl Ctr Hlth Stat, 3311 Toledo Rd,Rm 6122, Hyattsville, MD 20782 USA. EM fpa8@cdc.gov OI Mendola, Pauline/0000-0001-5330-2844 FU Intramural Research Program of the NIH, Eunice Kennedy Shriver National Institute of Child Health and Human Development FX This research was supported in part by the Intramural Research Program of the NIH, Eunice Kennedy Shriver National Institute of Child Health and Human Development. NR 40 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0749-5161 J9 PEDIATR EMERG CARE JI Pediatr. Emerg. Care PD MAY PY 2013 VL 29 IS 5 BP 560 EP 567 DI 10.1097/PEC.0b013e31828e56e1 PG 8 WC Emergency Medicine; Pediatrics SC Emergency Medicine; Pediatrics GA 138YW UT WOS:000318549400002 PM 23603643 ER PT J AU Zhao, Z Smith, PJ AF Zhao, Zhen Smith, Philip J. TI Trends in vaccination coverage disparities among children, United States, 2001-2010 SO VACCINE LA English DT Article DE Disparities; Vaccination coverage; Children; Healthy people 2010 AB Introduction: One of two overarching goals of the Healthy People 2010 initiative was to eliminate health disparities. We evaluate trends in children vaccination coverage disparities by socio-demographic characteristics in the United States from 2001 through 2010. Methods: Disparities in vaccination coverage for the 4:3:1:3:3:1 vaccine series was assessed with National Immunization Survey (NIS) 2001-2010 data. The disparities between two categories of population were independently evaluated yearly from 2001 through 2010. Results: In 2001, 10 out of 12 disparities were significant (P-value <0.05). Six disparities were reduced from statistically significant in 2001 to not significant in 2010. Across 2001-2010,8 disparities narrowed significantly; the average change in disparities per year were negative and ranged from -0.30% to -0.64% (P-value <0.05). Conclusions: Significant success has been achieved in reducing disparities in vaccination coverage for young children among most of the major socio-demographic subpopulations in the United States by 2010. Published by Elsevier Ltd. C1 [Zhao, Zhen; Smith, Philip J.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Zhao, Z (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mail Stop A19, Atlanta, GA 30333 USA. EM zaz0@cdc.gov NR 6 TC 9 Z9 9 U1 0 U2 9 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD MAY 1 PY 2013 VL 31 IS 19 BP 2324 EP 2327 DI 10.1016/j.vaccine.2013.03.018 PG 4 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 136RL UT WOS:000318381000002 PM 23524025 ER PT J AU Lu, PJ Byrd, KK Murphy, TV AF Lu, Peng-jun Byrd, Kathy K. Murphy, Trudy V. TI Hepatitis A vaccination coverage among adults 18-49 years traveling to a country of high or intermediate endemicity, United States SO VACCINE LA English DT Article DE Hepatitis A; Hepatitis A vaccine; Vaccination; Coverage; Adults at risk; Travel status ID HIGH-RISK ADULTS; IMMUNIZATION PRACTICES; VIRUS-INFECTIONS; INFLUENZA; OLDER; ADOLESCENTS; PREVENTION AB Background: Since 1996, hepatitis A vaccine (HepA) has been recommended for adults at increased risk for infection including travelers to high or intermediate hepatitis A endemic countries. In 2009, travel outside the United States and Canada was the most common exposure nationally reported for persons with hepatitis A virus (HAV) infection. Objective: To assess HepA vaccination coverage among adults 18-49 years traveling to a country of high or intermediate endemicity in the United States. Methods: We analyzed data from the 2010 National Health Interview Survey (NHIS), to determine self-reported HepA vaccination coverage (>= 1 dose) and series completion (>= 2 dose) among persons 18-49 years who traveled, since 1995, to a country of high or intermediate HAV endemicity. Multivariable logistic regression and predictive marginal analyses were conducted to identify factors independently associated with HepA vaccine receipt. Results: In 2010, approximately 36.6% of adults 18-49 years reported traveling to high or intermediate hepatitis A endemic countries; among this group unadjusted HepA vaccination coverage was 26.6% compared to 12.7% among non-travelers (P-values < 0.001) and series completion were 16.9% and 7.6%, respectively (P-values < 0.001). On multivariable analysis among all respondents, travel status was an independent predictor of HepA coverage and series completion (both P-values < 0.001). Among travelers, HepA coverage and series completion (>= 2 doses) were higher for travelers 18-25 years (prevalence ratios 2.3, 2.8, respectively, P-values < 0.001) and for travelers 26-39 years (prevalence ratios 1.5, 1.5, respectively, P-value < 0.001, P-value = 0.002, respectively) compared to travelers 40-49 years. Other characteristics independently associated with a higher likelihood of HepA receipt among travelers included Asian race/ethnicity, male sex, never having been married, having a high school or higher education, living in the western United States, having greater number of physician contacts or receipt of influenza vaccination in the previous year. HepB vaccination was excluded from the model because of the significant correlation between receipt of HepA vaccination and HepB vaccination could distort the model. Conclusions: Although travel to a country of high or intermediate hepatitis A endemicity was associated with higher likelihood of HepA vaccination in 2010 among adults 18-49 years, self-reported HepA vaccination coverage was low among adult travelers to these areas. Healthcare providers should ask their patients' upcoming travel plans and recommend and offer travel related vaccinations to their patients. Published by Elsevier Ltd. C1 [Lu, Peng-jun] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Byrd, Kathy K.; Murphy, Trudy V.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Lu, PJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,NE,Mail Stop A19, Atlanta, GA 30333 USA. EM lhp8@cdc.gov NR 43 TC 7 Z9 7 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD MAY 1 PY 2013 VL 31 IS 19 BP 2348 EP 2357 DI 10.1016/j.vaccine.2013.03.011 PG 10 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 136RL UT WOS:000318381000006 PM 23523408 ER PT J AU Xu, X Pesko, MF Tynan, MA Gerzoff, RB Malarcher, AM Pechacek, TF AF Xu, Xin Pesko, Michael F. Tynan, Michael A. Gerzoff, Robert B. Malarcher, Ann M. Pechacek, Terry F. TI Cigarette Price-Minimization Strategies by U.S. Smokers SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID 4 COUNTRY SURVEY; BEHAVIORS AB Background: Smokers may react to cigarette excise tax increases by engaging in price-minimization strategies (i.e., finding ways to reduce the cost of cigarette smoking) rather than by quitting or reducing their cigarette use, thereby reducing the public health benefits of such tax increases. Purpose: To evaluate the state and national prevalence of five common cigarette price-minimization strategies and the size of price reductions obtained from these strategies. Methods: Using data from the 2009 2010 National Adult Tobacco Survey, the prevalence of five common price-minimization strategies by type of strategy and by smoker's cigarette consumption level were estimated. The price reductions associated with these price-minimization strategies also were evaluated. Analyses took place in November 2012. Results: Approximately 55.4% of U.S. adult smokers used at least one of five price-minimization strategies in the previous year, with an average reduction of $1.27 per pack (22.0%). Results varied widely by state. Conclusions: Cigarette price-minimization strategies are practiced widely among current smokers, and resulting price reductions are relatively large. Policies that decrease opportunities to effectively apply cigarette price-minimization strategies would increase the public health gains of cigarette excise tax increases. (Am J Prev Med 2013;44(5):472-476) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Xu, Xin; Tynan, Michael A.; Gerzoff, Robert B.; Malarcher, Ann M.; Pechacek, Terry F.] CDC, Off Smoking & Hlth, Atlanta, GA 30333 USA. [Pesko, Michael F.] Cornell Univ, Weill Cornell Med Coll, New York, NY 10021 USA. RP Xu, X (reprint author), CDC, Off Smoking & Hlth, Epidemiol Branch, 4770 Buford Highway,Mailstop K-50, Atlanta, GA 30341 USA. EM xinxu@cdc.gov FU Intramural CDC HHS [CC999999] NR 25 TC 16 Z9 16 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2013 VL 44 IS 5 BP 472 EP 476 DI 10.1016/j.amepre.2013.01.019 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 128XS UT WOS:000317803600007 PM 23597810 ER PT J AU Holub, CK Elder, JP Arredondo, EM Barquera, S Eisenberg, CM Romero, LMS Rivera, J Lobelo, F Simoes, EJ AF Holub, Christina K. Elder, John P. Arredondo, Elva M. Barquera, Simon Eisenberg, Christina M. Romero, Luz Maria Sanchez Rivera, Juan Lobelo, Felipe Simoes, Eduardo J. TI Obesity Control in Latin American and U.S. Latinos A Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID PHYSICAL-ACTIVITY INTERVENTIONS; LOW-INCOME MOTHERS; WEIGHT-LOSS; CHILDREN; PREVENTION; HEALTH; WOMEN; COMMUNICATION; OVERWEIGHT; NUTRITION AB Context: Latinos are the largest and fastest-growing ethnically diverse group in the U.S.; they are also the most overweight. Mexico is now second to the U.S. in experiencing the worst epidemic of obesity in the world. Objectives of this study were to (1) conduct a systematic review of obesity-related interventions targeting Latinos living in the U.S. and Latin America and (2) develop evidence-based recommendations to inform culturally relevant strategies targeting obesity. Evidence acquisition: Obesity-related interventions, published between 1965 and 2010, were identified through searches of major electronic databases in 2010-2011. Selection criteria included evaluation of obesity-related measures; intervention conducted in a community setting; and at least 50.0% Latino/Latin American participants, or with stratified results by race/ethnicity. Evidence synthesis: Body of evidence was based on the number of available studies, study design, execution, and effect size. Of 19,758 articles, 105 interventions met final inclusion criteria. Interventions promoting physical activity and/or healthy eating had strong or sufficient evidence for recommending (1) school-based interventions in the U.S. and Latin America; (2) interventions for overweight or obese children in the healthcare context in Latin America; (3) individual-based interventions for overweight or obese adults in the U.S.; (4) individual-based interventions for adults in Latin America; and (5) healthcare-based interventions for overweight or obese adults in Latin America. Conclusions: Most intervention approaches combined physical activity and healthy eating to address both sides of the energy-balance equation. Results can help guide comprehensive evidence-based efforts to tackle the obesity epidemic in the U.S. and Latin America. (Am J Prev Med 2013;44(5):529-537) (C) 2013 American Journal of Preventive Medicine C1 [Holub, Christina K.; Elder, John P.; Arredondo, Elva M.; Eisenberg, Christina M.] San Diego State Univ, Inst Behav & Community Hlth, San Diego, CA 92123 USA. [Barquera, Simon; Romero, Luz Maria Sanchez; Rivera, Juan] Natl Inst Publ Hlth, Nutr & Hlth Res Ctr, Cuernavaca, Morelos, Mexico. [Lobelo, Felipe] Natl Ctr Chron Dis Prevent & Hlth Promot, Global Hlth Promot Off, Atlanta, GA 30333 USA. [Simoes, Eduardo J.] Univ Missouri, Sch Med, Dept Hlth Management & Informat, Columbia, MO USA. RP Elder, JP (reprint author), San Diego State Univ, Inst Behav & Community Hlth, 9245 Sky Pk Court,Suite 221, San Diego, CA 92123 USA. EM jelder@projects.sdsu.edu OI Lobelo, Felipe/0000-0003-4185-7193; Simoes, Eduardo/0000-0003-4371-4305 FU CDC [1U48 DP001917] FX The present study was funded by the CDC, Grant Number 1U48 DP001917; publication of the article was supported through the same CDC grant. NR 53 TC 15 Z9 15 U1 1 U2 37 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2013 VL 44 IS 5 BP 529 EP 537 DI 10.1016/j.amepre.2013.01.023 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 128XS UT WOS:000317803600016 PM 23597819 ER PT J AU Torres, REM Banegas, EI Mendoza, M Diaz, C Bucheli, STM Fontecha, GA Alam, MT Goldman, I Udhayakumar, V Zambrano, JON AF Mejia Torres, Rosa Elena Ilich Banegas, Engels Mendoza, Meisy Diaz, Cesar Mancero Bucheli, Sandra Tamara Fontecha, Gustavo A. Alam, Md Tauqeer Goldman, Ira Udhayakumar, Venkatachalam Nicolas Zambrano, Jose Orlinder TI Efficacy of Chloroquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Honduras SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID DRUG-RESISTANCE; SULFADOXINE-PYRIMETHAMINE; CENTRAL-AMERICA; VENEZUELA; CHEMOTHERAPY; COMBINATION; MEFLOQUINE; ARTESUNATE; MUTATIONS; CHILDREN AB Chloroquine (CQ) is officially used for the primary treatment of Plasmodium falciparum malaria in Honduras. In this study, the therapeutic efficacy of CQ for the treatment of uncomplicated P. falciparum malaria in the municipality of Puerto Lempira, Gracias a Dios, Honduras was evaluated using the Pan American Health Organization World Health Organization protocol with a follow-up of 28 days. Sixty-eight patients from 6 months to 60 years of age microscopically diagnosed with uncomplicated P. falciparum malaria were included in the final analysis. All patients who were treated with CQ (25 mg/kg over 3 days) cleared parasitemia by day 3 and acquired no new P. falciparum infection within 28 days of follow-up. All the parasite samples sequenced for CQ resistance mutations (pfcrt) showed only the CQ-sensitive genotype (CVMNK). This finding shows that CO remains highly efficacious for the treatment of uncomplicated P. falciparum malaria in Gracias a Dios, Honduras. C1 UNAH, Dept Masters Infect Dis & Zoonoses MEIZ, Sch Microbiol, Tegucigalpa, Honduras. Atlanta Res & Educ Fdn, Decatur, GA USA. [Goldman, Ira; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Fontecha, Gustavo A.] UNAH, Dept Masters Infect Dis & Zoonoses, Sch Microbiol, Tegucigalpa, Honduras. [Alam, Md Tauqeer] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth,Atlanta Res & Educ Fdn, Decatur, GA USA. EM rosaelenamejiatorres@yahoo.com; engelsbanegas@yahoo.com; elimeis@hotmail.com; diazcortezert@gmail.com; mancerot@paho.org; gustavo.fontecha@unah.edu.hn; hsf1@cdc.gov; ifg1@cdc.gov; vxu0@cdc.gov; jnicolaszambrano@yahoo.es FU US Agency for International Development (USAID) under the USAID Pan American Health Organization [527A-00-08-00026-00]; Ministry of Health of Honduras FX This work was funded by the US Agency for International Development (USAID) under the USAID Pan American Health Organization agreement for the Amazon Malaria Initiative Network for Surveillance of Anti-Malarial Drug Resistance Project 527A-00-08-00026-00 and the Ministry of Health of Honduras. NR 32 TC 7 Z9 7 U1 0 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2013 VL 88 IS 5 BP 850 EP 854 DI 10.4269/ajtmh.12-0671 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 136WR UT WOS:000318394600007 ER PT J AU Steinhardt, LC Yeka, A Nasr, S Wiegand, RE Rubahika, D Sserwanga, A Wanzira, H Lavoy, G Kamya, M Dorsey, G Filler, S AF Steinhardt, Laura C. Yeka, Adoke Nasr, Sussann Wiegand, Ryan E. Rubahika, Denis Sserwanga, Asadu Wanzira, Humphrey Lavoy, Geoff Kamya, Moses Dorsey, Grant Filler, Scott TI The Effect of Indoor Residual Spraying on Malaria and Anemia in a High-Transmission Area of Northern Uganda SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID INSECTICIDE-TREATED NETS; COMBINATION; PREVALENCE; MORBIDITY; MORTALITY; INTENSE; IMPACT AB Indoor residual spraying (IRS) with insecticide is now recommended for malaria control in high-transmission settings. However, concerns about insecticide resistance have increased. We conducted a cross-sectional household survey in high-transmission northern Uganda in two districts previously sprayed with pyrethroids before documentation of pyrethroid resistance and at least one round of carbamates and in one contiguous district that was not sprayed. Parasitemia prevalence among children < 5 years of age was lower in the two IRS districts compared with the non-sprayed district: 37.0% and 16.7% versus 49.8%, P < 0.001. Anemia prevalence was also significantly lower in the two IRS districts: 38.8% and 36.8% versus 53.0%, P < 0.001. Multivariable Poisson regression models indicated that a child living in a sprayed district had a 46% and 32% lower risk of parasitemia and anemia, respectively, than a child in a non-sprayed district (P < 0.001). Carefully managed IRS can significantly reduce malaria burden in high-transmission settings. C1 Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA 30333 USA. Infect Dis Res Collaborat, Kampala, Uganda. Minist Hlth, Natl Malaria Control Programme, Kampala, Uganda. Makerere Univ, Kampala, Uganda. [Dorsey, Grant] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Filler, Scott] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland. [Steinhardt, Laura C.; Wiegand, Ryan E.] Ctr Dis Control & Prevent, CDC, Atlanta, GA 30333 USA. [Yeka, Adoke; Sserwanga, Asadu; Wanzira, Humphrey; Lavoy, Geoff; Kamya, Moses] UMSP, Kampala, Uganda. [Nasr, Sussann] Ctr Dis Control & Prevent Angola, Luanda, Angola. [Rubahika, Denis] Uganda Natl Malaria Control Programme, Kamapala, Uganda. RP Steinhardt, LC (reprint author), Ctr Dis Control & Prevent, CDC, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM LSteinhardt@cdc.gov; yadoke@muucsf.org; Snasr@usaid.gov; RWiegand@cdc.gov; drubahika@yahoo.com; asserwanga@muucsf.org; wanzirah@yahoo.com; glavoy@muucsf.org; mkamya@infocom.co.ug; gdorsey@medsfgh.ucsf.edu; Scott.Filler@theglobalfund.org FU President's Malaria Initiative (PMI) FX This study was funded by the President's Malaria Initiative (PMI). NR 31 TC 11 Z9 11 U1 2 U2 19 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2013 VL 88 IS 5 BP 855 EP 861 DI 10.4269/ajtmh.12-0747 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 136WR UT WOS:000318394600008 PM 23458956 ER PT J AU Luo, HM Dong, XQ Li, FR Xie, X Song, ZZ Shao, ZJ Li, ZJ Tong, ZH Wang, GF Zhang, HT Yang, TL He, G He, ZY Fontaine, RE Zeng, G AF Luo, Huiming Dong, Xingqi Li, Furong Xie, Xu Song, Zhizhong Shao, Zhujun Li, Zhongjie Tong, Zhaohui Wang, Guangfa Zhang, Hongtao Yang, Tielong He, Gao He, Zeyuan Fontaine, Robert E. Zeng, Guang TI A Cluster of Primary Pneumonic Plague Transmitted in a Truck Cab in a New Enzootic Focus in China SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID OUTBREAK AB We investigated a cluster of five cases of severe pneumonia from one village in Yunnan Province, China. We searched for severe pneumonia in the village and hospitals. We interviewed patients and family members about exposures. We tested acute and convalescent sera for antigen and antibody of severe acute respiratory syndrome, avian influenza, and plague. The only common exposure of the five patients was riding together in the enclosed cab of a truck for 1.5 hours while taking the first patient to the hospital. Seroconversion to plague F1 antigen confirmed plague in three survivors. Unfamiliarity of clinicians with plague and lack of sputum examination, blood culture, or postmortem examination delayed the diagnosis. No plague cases occurred among family and village contacts and health care workers. High infectivity in this cluster was limited to a crowded, poorly ventilated truck. C1 Chinese Field Epidemiol Training Program, Beijing 100050, Peoples R China. Yunnan Prov Endem Dis Prevent Inst, Dali, Peoples R China. [Shao, Zhujun; Li, Zhongjie] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China. [Tong, Zhaohui] Affiliated Beijing Chaoyang Hosp, Capital Med Coll, Beijing, Peoples R China. [Wang, Guangfa] Peking Univ, Hosp 1, Beijing 100871, Peoples R China. Lijiang Ctr Dis Control & Prevent, Beijing, Yunnan, Peoples R China. Yulong Ctr Dis Control & Prevent, Beijing, Yunnan, Peoples R China. US Ctr Dis Control & Prevent, Atlanta, GA USA. [Luo, Huiming; Li, Furong; Xie, Xu; Zeng, Guang] Chinese Field Epidemiol Training Program, Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China. [Dong, Xingqi; Song, Zhizhong] Yunnan Prov Endem Dis Prevent Inst Off, Dali, Peoples R China. [Zhang, Hongtao; Yang, Tielong] Lijiang Ctr Dis Control & Prevent, Dept Epidemiol, Beijing, Yunnan, Peoples R China. [He, Gao; He, Zeyuan] Yulong Ctr Dis Control & Prevent, Dept Epidemiol, Beijing, Yunnan, Peoples R China. [Fontaine, Robert E.] US Ctr Dis Control & Prevent, Div Publ Hlth Syst & Workforce Dev, Atlanta, GA USA. RP Zeng, G (reprint author), Off China CDC, China FETP, Beijing 100050, Peoples R China. EM hmluo@vip.sina.com; Dongxq99@vip.sina.com; lifurong2005@yahoo.com.cn; xiexv@hotmail.com; 13808766541@126.com; shaozhujun@126.com; lizhongjiecdc@163.com; tongzhh@hotmail.com; wangguangfa@hotmail.com; zhtaozr@126.com; ytl19531205@yahoo.com.cn; hg13308889009@yahoo.com.cn; ljlizhaoxiu@163.com; ref1@cdc.gov; zeng4605@vip.sina.com NR 16 TC 1 Z9 2 U1 0 U2 13 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2013 VL 88 IS 5 BP 923 EP 928 DI 10.4269/ajtmh.12-0163 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 136WR UT WOS:000318394600019 PM 23509116 ER PT J AU Jentes, ES Han, P Gershman, MD Rao, SR LaRocque, RC Staples, JE Ryan, ET AF Jentes, Emily S. Han, Pauline Gershman, Mark D. Rao, Sowmya R. LaRocque, Regina C. Staples, J. Erin Ryan, Edward T. CA Global TravEpiNet Consortium TI Travel Characteristics and Yellow Fever Vaccine Usage Among US Global TravEpiNet Travelers Visiting Countries with Risk of Yellow Fever Virus Transmission, 2009-2011 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID INTERNATIONAL-AIRPORT; RELATIVES ABROAD; FRIENDS; RECOMMENDATIONS; PREVENTION; IMMIGRANTS; KNOWLEDGE; ATTITUDES; DISEASES AB Yellow fever (YF) vaccine-associated serious adverse events and changing YF epidemiology have challenged healthcare providers to vaccinate only travelers whose risk of YF during travel is greater than their risk of adverse events. We describe the travel characteristics and YF vaccine use among US travelers visiting Global TravEpiNet clinics from January of 2009 to March of 2011. Of 16,660 travelers, 5,588 (34%) had itineraries to areas with risk of YF virus transmission. Of those travelers visiting one country with YF risk (N = 4,517), 71% were vaccinated at the visit, and 20% were presumed to be immune from prior vaccination. However, travelers visiting friends and relatives (odds ratio [OR] = 2.57,95% confidence interval [95% CI] = 1.27-5.22) or going to Nigeria (OR = 3.01,95% CI = 1.37-6.62) were significantly more likely to decline vaccination. To optimize YF vaccine use, clinicians should discuss an individual's risk benefit assessment of vaccination and close knowledge gaps regarding vaccine use among at-risk populations. C1 [Jentes, Emily S.; Han, Pauline; Gershman, Mark D.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. [Rao, Sowmya R.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA. [Rao, Sowmya R.] Bedford Vet Adm Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO USA. [LaRocque, Regina C.; Ryan, Edward T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Staples, J. Erin] Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Dis, Ft Collins, CO USA. RP Jentes, ES (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, 1600 Clifton Rd,MS E-03, Atlanta, GA 30333 USA. EM ejentes@cdc.gov; hfd7@cdc.gov; dvj8@cdc.gov; sowmya.rao@va.gov; rclarocque@partners.org; auv1@cdc.gov; etryan@partners.org FU US Centers for Disease Control and Prevention [U19CI000514, U01CK000175] FX This work was supported by Grants U19CI000514 and U01CK000175 from the US Centers for Disease Control and Prevention. NR 29 TC 2 Z9 2 U1 0 U2 5 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2013 VL 88 IS 5 BP 954 EP 961 DI 10.4269/ajtmh.12-0463 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 136WR UT WOS:000318394600025 PM 23458961 ER PT J AU Reynolds, MG Emerson, GL Pukuta, E Karhemere, S Muyembe, JJ Bikindou, A McCollum, AM Moses, C Wilkins, K Zhao, H Damon, IK Karem, KL Li, Y Carroll, DS Mombouli, JV AF Reynolds, Mary G. Emerson, Ginny L. Pukuta, Elisabeth Karhemere, Stomy Muyembe, Jean J. Bikindou, Alain McCollum, Andrea M. Moses, Cynthia Wilkins, Kimberly Zhao, Hui Damon, Inger K. Karem, Kevin L. Li, Yu Carroll, Darin S. Mombouli, Jean V. TI Short Report: Detection of Human Monkeypox in the Republic of the Congo Following Intensive Community Education SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID TIME PCR ASSAYS; VIRUS; SMALLPOX; BASIN AB Monkeypox is an acute viral infection with a clinical course resembling smallpox. It is endemic in northern and central Democratic Republic of the Congo (DRC), but it is reported only sporadically in neighboring Republic of the Congo (ROC). In October 2009, interethnic violence in northwestern DRC precipitated the movement of refugees across the Ubangi River into ROC. The influx of refugees into ROC heightened concerns about monkeypox in the area, because of the possibility that the virus could be imported, or that incidence could increase caused by food insecurity and over reliance on bush meat. As part of a broad-based campaign to improve health standards in refugee settlement areas, the United Nations International Children's Emergency Fund (UNICEF) sponsored a program of intensive community education that included modules on monkeypox recognition and prevention. In the 6 months immediately following the outreach, 10 suspected cases of monkeypox were reported to health authorities. Laboratory testing confirmed monkeypox virus infection in two individuals, one of whom was part of a cluster of four suspected cases identified retrospectively. Anecdotes collected at the time of case reporting suggest that the outreach campaign contributed to detection of suspected cases of monkeypox. C1 [Reynolds, Mary G.; Emerson, Ginny L.; McCollum, Andrea M.; Wilkins, Kimberly; Zhao, Hui; Damon, Inger K.; Karem, Kevin L.; Li, Yu] US Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA USA. Inst Natl Rech Biomed, Kinshasa, Zaire. Med Afrique, Brazzaville, Congo. Int Conservat & Educ Fund, Washington, DC USA. Delegat Gen Rech Sci & Tech, Brazzaville, Congo. [Pukuta, Elisabeth; Karhemere, Stomy; Muyembe, Jean J.] INRB Virol, Kinshasa, Zaire. [Bikindou, Alain] Med Afrique Med, Brazzaville, Congo. [Moses, Cynthia] INCEF, Washington, DC USA. [Carroll, Darin S.] Ctr Dis Control & Prevent, Coordinating Ctr Infect Dis, Atlanta, GA USA. [Mombouli, Jean V.] Natl Lab, Brazzaville, Congo. RP Reynolds, MG (reprint author), 1600 Clifton Rd NE,Mailstop G-18, Atlanta, GA 30333 USA. EM nzr6@cdc.gov; dtt4@cdc.gov; eliepukuta@yahoo.fr; stomy_karhem@yahoo.fr; jjmuyembe@yahoo.fr; abikindou@yahoo.fr; azv4@cdc.gov; cyn@incef.org; ibx4@cdc.gov; cgz9@cdc.gov; iad7@cdc.gov; kdk6@cdc.gov; lay4@cdc.gov; zuz4@cdc.gov; jvmombouli@hotmail.com NR 12 TC 5 Z9 5 U1 1 U2 6 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2013 VL 88 IS 5 BP 982 EP 985 DI 10.4269/ajtmh.12-0758 PG 4 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 136WR UT WOS:000318394600028 PM 23400570 ER PT J AU Godsey, MS King, RJ Burkhalter, K Delorey, M Colton, L Charnetzky, D Sutherland, G Ezenwa, VO Wilson, LA Coffey, M Milheim, LE Taylor, VG Palmisano, C Wesson, DM Guptill, SC AF Godsey, Marvin S., Jr. King, Raymond J. Burkhalter, Kristen Delorey, Mark Colton, Leah Charnetzky, Dawn Sutherland, Genevieve Ezenwa, Vanessa O. Wilson, Lawrence A. Coffey, Michelle Milheim, Lesley E. Taylor, Viki G. Palmisano, Charles Wesson, Dawn M. Guptill, Stephen C. TI Ecology of Potential West Nile Virus Vectors in Southeastern Louisiana: Enzootic Transmission in the Relative Absence of Culex quinquefasciatus SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID HOST-FEEDING PATTERNS; BATON-ROUGE PARISH; MOSQUITOS DIPTERA-CULICIDAE; NORTHEASTERN UNITED-STATES; FIELD-COLLECTED MOSQUITOS; EQUINE ENCEPHALITIS-VIRUS; DIFFERENT HABITAT TYPES; ST-TAMMANY-PARISH; TAMPA BAY AREA; NEW-YORK AB A study of West Nile virus (WNV) ecology was conducted in St. Tammany Parish, Louisiana, from 2002 to 2004. Mosquitoes were collected weekly throughout the year using Centers for Disease Control and Prevention (CDC) light traps placed at 1.5 and 6 m above the ground and gravid traps. A total of 379,466 mosquitoes was collected. WNV was identified in 32 pools of mosquitoes comprising four species; 23 positive pools were from Culex nigripalpus collected during 2003. Significantly more positive pools were obtained from Cx. nigripalpus collected in traps placed at 6 m than 1.5 m that year, but abundance did not differ by trap height. In contrast, Cx. nigripalpus abundance was significantly greater in traps placed at 6 m in 2002 and 2004. Annual temporal variation in Cx. nigripalpus peak seasonal abundance has important implications for WNV transmission in Louisiana. One WNV-positive pool, from Cx. erraticus, was collected during the winter of 2004, showing year-round transmission. The potential roles of additional mosquito species in WNV transmission in southeastern Louisiana are discussed. C1 Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA. Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA. [Ezenwa, Vanessa O.; Coffey, Michelle; Milheim, Lesley E.; Guptill, Stephen C.] US Geol Survey, Eastern Geog Sci Ctr, Reston, VA 22092 USA. [Wilson, Lawrence A.] Fernbank Sci Ctr, Atlanta, GA USA. [Taylor, Viki G.; Palmisano, Charles] St Tammany Parish Mosquito Abatement Dist, Slidell, LA USA. [Wesson, Dawn M.] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Trop Med, New Orleans, LA USA. [Godsey, Marvin S., Jr.; Burkhalter, Kristen; Delorey, Mark; Colton, Leah; Charnetzky, Dawn; Sutherland, Genevieve] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [King, Raymond J.] Ctr Dis Control & Prevent, Publ Hlth Informat & Technol Program Off, Atlanta, GA USA. RP Godsey, MS (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM mjg9@cdc.gov; rnk8@cdc.gov; ktb3@cdc.gov; esy7@cdc.gov; ant6@cdc.gov; dcharnetzky@yahoo.com; genevieve_sutherland@yahoo.com; vezenwa@uga.edu; larry.wilson@fernbank.edu; mcoffey@usgs.gov; lmilheim@usgs.gov; bugladyviki@yahoo.com; chuck_palmisano@yahoo.com; wesson@tulane.edu; sguptill@guptillgeoscience.com FU US Geological Survey; Centers for Disease Control and Prevention FX Funding for this study was provided by the US Geological Survey and the Centers for Disease Control and Prevention. NR 59 TC 1 Z9 1 U1 2 U2 13 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2013 VL 88 IS 5 BP 986 EP 996 DI 10.4269/ajtmh.12-0109 PG 11 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 136WR UT WOS:000318394600029 PM 23478575 ER PT J AU Torres-Aponte, JM Luce, RR Hunsperger, E Munoz-Jordan, JL Beltran, M Vergne, E Arguello, DF Garcia, EJ Sun, W Tomashek, KM AF Torres-Aponte, Jomil M. Luce, Richard R. Hunsperger, Elizabeth Munoz-Jordan, Jorge L. Beltran, Manuela Vergne, Edgardo Argueello, D. Fermin Garcia, Enid J. Sun, Wellington Tomashek, Kay M. TI Enhanced West Nile Virus Surveillance in a Dengue-Endemic Area-Puerto Rico, 2007 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID IMMUNOGLOBULIN-G ANTIBODIES; BLOOD-DONORS; NEW-YORK; ENCEPHALITIS; MANIFESTATIONS; HEMISPHERE; INFECTION; MOSQUITOS; EPIDEMIC; OUTBREAK AB In June of 2007, West Nile virus (WNV) was detected in sentinel chickens and blood donors in Puerto Rico, where dengue virus (DENV) is hyperendemic. Enhanced human surveillance for acute febrile illness (AFI) began in eastern Puerto Rico on July 1, 2007. Healthcare providers submitted specimens from AFI cases for WNV and DENV virology and serology testing. Over 6 months, 385 specimens were received from 282 cases; 115 (41%) specimens were DENV laboratory-positive, 86 (31%) specimens were laboratory-indeterminate, and 32 (11%) specimens were laboratory-negative for WNV and DENV. One WNV infection was detected by anti-WNV immunoglobulin M (IgM) antibody and confirmed by a plaque reduction neutralization test. DENV and WNV infections could not be differentiated in 27 cases (10%). During a period of active WNV transmission, enhanced human surveillance identified one case of symptomatic WNV infection. Improved diagnostic methods are needed to allow differentiation of WNV and DENV in dengue-endemic regions. C1 [Torres-Aponte, Jomil M.] Puerto Rico Dept Hlth, Epidemiol & Res Off, San Juan, PR 00920 USA. [Hunsperger, Elizabeth; Munoz-Jordan, Jorge L.; Beltran, Manuela; Vergne, Edgardo; Argueello, D. Fermin; Tomashek, Kay M.] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR USA. [Luce, Richard R.] Ctr Dis Control & Prevent, Ctr Global Hlth, Libreville, Gabon. [Garcia, Enid J.] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA. [Sun, Wellington] US FDA, Ctr Biol Evaluat & Res, Div Vaccines & Related Prod Applicat, Rockville, MD 20857 USA. RP Torres-Aponte, JM (reprint author), Puerto Rico Dept Hlth, Epidemiol & Res Off, 1324 Calle Canada, San Juan, PR 00920 USA. EM dzq9@cdc.gov; dwe5@cdc.gov; enh4@cdc.gov; ckq2@cdc.gov; mvb6@cdc.gov; edv1@cdc.gov; dla7@cdc.gov; enid.garcia3@upr.edu; wellington.sun@fda.hhs.gov; kct9@cdc.gov NR 30 TC 1 Z9 1 U1 0 U2 3 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2013 VL 88 IS 5 BP 997 EP 1002 DI 10.4269/ajtmh.12.0575 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 136WR UT WOS:000318394600030 PM 23478583 ER PT J AU Zapata, LB Kissin, DM Bogoliubova, O Yorick, RV Kraft, JM Jamieson, DJ Marchbanks, PA Hillis, SD AF Zapata, Lauren B. Kissin, Dmitry M. Bogoliubova, Olga Yorick, Roman V. Kraft, Joan Marie Jamieson, Denise J. Marchbanks, Polly A. Hillis, Susan D. TI Orphaned and abused youth are vulnerable to pregnancy and suicide risk SO CHILD ABUSE & NEGLECT LA English DT Article DE Orphans; Abuse; Pregnancy; Suicide ideation; Risk factors; Protective factors ID ADVERSE CHILDHOOD EXPERIENCES; EARLY ADULTHOOD; PHYSICAL ABUSE; HIV-INFECTION; MENTAL-HEALTH; CHILDREN; ADOLESCENTS; ZIMBABWE; EXPOSURE; VIOLENCE AB Objective: Little is known about the magnitude and consequences of violence against children for those living outside family care. We sought to estimate the frequency of childhood abuse and examine its association with lifetime pregnancy involvement (LPI) and past year suicide ideation among orphaned youth. Methods: We analyzed data collected via cross-sectional interviewer-administered surveys completed by 293 orphaned youth aged 16-23 years living outside of family care in St. Petersburg, Russia. We used multivariable logistic regression to estimate adjusted odds ratios (AORs) of LPI and past year suicide ideation associated with childhood physical and sexual abuse. Other risk factors were also examined (e.g., social vulnerability, sexual and substance use behaviors), and characteristics of orphaned youth with LPI and past year suicide ideation were described. Results: The prevalence of childhood abuse was higher among females than among males (23.3% versus 15.6% for physical abuse, and 20.3% versus 5.6% for sexual abuse), as was the prevalence of LPI and past year suicide ideation among those with histories of abuse. Experiences of childhood abuse were strong risk factors for both LPI and past year suicide ideation, with significant variation by gender. While both types of abuse were significantly associated with LPI and past year suicide ideation among females, physical abuse was significantly associated with LPI and sexual abuse was associated with suicide ideation for males. Of the other characteristics examined, strong modifiable risk factors included having no one to turn to for help and no involvement in activities outside of class. Among those with LPI (n=36), nearly 20% had been pregnant or gotten someone pregnant >= 2 times, most (61.8%) reported at least one induced abortion, and current use of effective contraception was nearly non-existent. Among those with past year suicide ideation (n=30), nearly half (44.8%) reported attempting suicide. Conclusions: There is an urgent need for interventions to prevent and mitigate the negative influence of childhood abuse experiences. Programs providing services to orphaned youth should increase access to sexual education, effective contraceptives, and mental health counseling. Published by Elsevier Ltd. C1 [Zapata, Lauren B.; Kissin, Dmitry M.; Kraft, Joan Marie; Jamieson, Denise J.; Marchbanks, Polly A.; Hillis, Susan D.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Bogoliubova, Olga] St Petersburg State Univ, Dept Psychol, St Petersburg 199034, Russia. [Yorick, Roman V.] HealthRight Int, St Petersburg 197376, Russia. RP Zapata, LB (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Hwy NE,Mailstop K34, Atlanta, GA 30341 USA. RI Bogolyubova, Olga/D-3691-2013 OI Bogolyubova, Olga/0000-0003-3159-1926 FU Intramural CDC HHS [CC999999] NR 39 TC 3 Z9 3 U1 3 U2 28 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0145-2134 J9 CHILD ABUSE NEGLECT JI Child Abuse Negl. PD MAY PY 2013 VL 37 IS 5 BP 310 EP 319 DI 10.1016/j.chiabu.2012.10.005 PG 10 WC Family Studies; Psychology, Social; Social Work SC Family Studies; Psychology; Social Work GA 137VV UT WOS:000318467200004 PM 23290621 ER PT J AU Ellingson, KD Patel, PR AF Ellingson, Katherine D. Patel, Priti R. TI Arteriovenous fistula infection as a cause of vascular access hemorrhage Reply SO KIDNEY INTERNATIONAL LA English DT Letter C1 [Ellingson, Katherine D.; Patel, Priti R.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP Ellingson, KD (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, MS-A31,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM kellingson@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD MAY PY 2013 VL 83 IS 5 BP 970 EP 970 DI 10.1038/ki.2013.32 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 136EI UT WOS:000318344000032 PM 23633059 ER PT J AU Gill, SK Broussard, C Devine, O Green, RF Rasmussen, SA Reefhuis, J AF Gill, Simerpal K. Broussard, Cheryl Devine, Owen Green, Ridgely Fisk Rasmussen, Sonja A. Reefhuis, Jennita CA Natl Birth Defects Prevention Stud TI Association Between Maternal Age and Birth Defects of Unknown Etiology-United States, 1997-2007 EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material C1 [Gill, Simerpal K.; Broussard, Cheryl; Devine, Owen; Green, Ridgely Fisk; Rasmussen, Sonja A.; Reefhuis, Jennita] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Gill, Simerpal K.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Gill, SK (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD MAY PY 2013 VL 68 IS 5 BP 346 EP 347 DI 10.1097/01.ogx.0000430381.52864.c3 PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 138BD UT WOS:000318482300009 ER PT J AU Oster, ME Lee, KA Honein, MA Riehle-Colarusso, T Shin, M Correa, A AF Oster, Matthew E. Lee, Kyung A. Honein, Margaret A. Riehle-Colarusso, Tiffany Shin, Mikyong Correa, Adolfo TI Temporal Trends in Survival Among Infants With Critical Congenital Heart Defects SO PEDIATRICS LA English DT Article DE epidemiology; congenital heart disease/defects; screening; neonatal; survival rate; pulse oximetry ID PULSE OXIMETRY; CARDIOVASCULAR MALFORMATIONS; METROPOLITAN ATLANTA; CARDIAC-SURGERY; GREAT-ARTERIES; DISEASE; MORTALITY; DIAGNOSIS; TRANSPOSITION; PREVALENCE AB OBJECTIVE: To evaluate the trends in survival for infants with critical congenital heart defects (CCHDs) and to examine the potential impact of timing of diagnosis and other prognostic factors on survival. METHODS: We performed a retrospective population-based cohort study in infants born with structural congenital heart defects (CHDs) between 1979 and 2005 and ascertained by the Metropolitan Atlanta Congenital Defects Program. We estimated Kaplan-Meier survival probabilities for 12 CCHD phenotypes by birth era and timing of diagnosis among infants without noncardiac defects or chromosomal disorders and used stratified Cox proportional hazards models to assess potential prognostic factors. RESULTS: Of 1 056 541 births, there were 6965 infants with CHDs (1830 with CCHDs). One-year survival was 75.2% for those with CCHDs (n = 1336) vs 97.1% for those with noncritical CHDs (n = 3530; P < .001). One-year survival for infants with CCHDs improved from 67.4% for the 1979-1993 birth era to 82.5% for the 1994-2005 era (P < .001). One-year survival was 71.7% for infants with CCHDs diagnosed at <= 1 day of age (n = 890) vs 82.5% for those with CCHDs diagnosed at >1 day of age (n = 405; P < .001). There was a significantly higher risk of 1-year mortality for infants with an earlier birth era, earlier diagnosis, and low birth weight and whose mothers were <30 years old. CONCLUSIONS: One-year survival for infants with CCHDs has been improving over time, yet mortality remains high. Later diagnosis is associated with improved 1-year survival. These benchmark data and identified prognostic factors may aid future evaluations of the impact of pulse oximetry screening on survival from CCHDs. C1 [Oster, Matthew E.; Lee, Kyung A.; Honein, Margaret A.; Riehle-Colarusso, Tiffany; Shin, Mikyong; Correa, Adolfo] Nat Ctr Birth Defects & Dev Disabil, Ctr Dis Control & Prevent, Atlanta, GA USA. [Oster, Matthew E.] Emory Univ, Sibley Heart Ctr, Atlanta, GA 30322 USA. [Lee, Kyung A.] Northrup Grumman Informat Syst, Atlanta, GA USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. RP Oster, ME (reprint author), Sibley Heart Ctr Cardiol, 2835 Brandywine Rd,Ste 300, Atlanta, GA 30341 USA. EM osterm@kidsheart.com FU Intramural CDC HHS [CC999999] NR 31 TC 59 Z9 59 U1 0 U2 10 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD MAY PY 2013 VL 131 IS 5 BP E1502 EP E1508 DI 10.1542/peds.2012-3435 PG 7 WC Pediatrics SC Pediatrics GA 135EO UT WOS:000318270700016 PM 23610203 ER PT J AU Herrin, J Wesolowski, LG Heffelfinger, JD Bostick, N Hall, HI Ethridge, SF Branson, BM AF Herrin, Jeph Wesolowski, Laura G. Heffelfinger, James D. Bostick, Nathan Hall, H. Irene Ethridge, Steven F. Branson, Bernard M. TI HIV Screening Practices and Hospital Characteristics in the US, 2009-2010 SO PUBLIC HEALTH REPORTS LA English DT Article ID ANTIRETROVIRAL THERAPY; UNITED-STATES; INFECTION; RECOMMENDATIONS; MORTALITY; AIDS; CARE AB Objectives. The Centers for Disease Control and Prevention recommends HIV screening in U.S. health-care settings unless providers document a yield of undiagnosed HIV infections of <1 per 1,000 population. However, implementation of this guidance has not been widespread and little is known of the characteristics of hospitals with screening practices in place. We assessed how screening practices vary with hospital characteristics. Methods. We used a national hospital survey of HIV testing practices, linked to HIV prevalence for the county, parish, borough, or city where the hospital was located, to assess HIV screening of some or all patients by hospitals. We used multivariate logistic regression analysis to assess the association between screening practices and hospital characteristics that were significantly associated with screening in bivariate analyses. Results. Of 376 hospitals in areas of prevalence >= 0.1%, only 25 (6.6%) reported screening all patients for HIV and 131 (34.8%) reported screening some or all patients. Among 638 hospitals included, screening some or all patients was significantly (p<0.05) more common at teaching hospitals, hospitals with higher numbers of annual admissions, and hospitals with a high proportion of Medicaid admissions. In multivariable analysis, screening some or all patients was independently associated with admitting more than 15% of Medicaid patients and receiving resources or reimbursement for screening tests. Conclusion. We found that few hospitals surveyed reported screening some or all patients, and failure to screen is common across all types of hospitals in all regions of the country. Expanded reimbursement for screening may increase compliance with the recommendations. C1 [Herrin, Jeph; Bostick, Nathan] Hlth Res & Educ Trust, Chicago, IL 60606 USA. [Herrin, Jeph] Yale Univ, Sch Med, New Haven, CT USA. [Wesolowski, Laura G.; Heffelfinger, James D.; Hall, H. Irene; Ethridge, Steven F.; Branson, Bernard M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Herrin, J (reprint author), Hlth Res & Educ Trust, 155 N Wacker,Ste 400, Chicago, IL 60606 USA. EM jherrin@aha.org NR 27 TC 9 Z9 9 U1 0 U2 2 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAY-JUN PY 2013 VL 128 IS 3 BP 161 EP 169 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 137UN UT WOS:000318463800006 PM 23633731 ER PT J AU Tong, VT Dietz, PM Farr, SL D'Angelo, DV England, LJ AF Tong, Van T. Dietz, Patricia M. Farr, Sherry L. D'Angelo, Denise V. England, Lucinda J. TI Estimates of Smoking Before and During Pregnancy, and Smoking Cessation During Pregnancy: Comparing Two Population-Based Data Sources SO PUBLIC HEALTH REPORTS LA English DT Article ID PRENATAL SMOKING; BIRTH CERTIFICATES; QUESTIONNAIRES AB Objectives. We compared three measures of maternal smoking status-prepregnancy, during pregnancy, and smoking cessation during pregnancy-between the Pregnancy Risk Assessment Monitoring System (PRAMS) questionnaire and the 2003 revised birth certificate (BC). Methods. We analyzed data from 10,485 women with live births in eight states from the 2008 PRAMS survey, a confidential, anonymous survey administered in the postpartum period that is linked to select BC variables. We calculated self-reported prepregnancy and prenatal smoking (last trimester only) prevalence based on the BC, the PRAMS survey, and the two data sources combined, and the percentage of smoking cessation during pregnancy based on the BC and PRAMS survey. We used two-sided t-tests to compare BC and PRAMS estimates. Results. Prepregnancy smoking prevalence estimates were 17.3% from the BC, 24.4% from PRAMS, and 25.4% on one or both data sources. Prenatal smoking prevalence estimates were 11.3% from the BC, 14.0% from PRAMS, and 15.2% on one or both data sources. The percentages of prepregnancy smokers who indicated that they quit smoking by the last trimester were 35.1% from the BC and 42.6% from PRAMS. The PRAMS estimates of prepregnancy and prenatal smoking, and smoking cessation during pregnancy were statistically higher than the corresponding BC estimates (t-tests, p<0.05). Conclusions. PRAMS captured more women who smoked before and during the last trimester than the revised BC. States implementing PRAMS and the revised BC should consider information from both sources when developing population-based estimates of smoking before pregnancy and during the last trimester of pregnancy. C1 [Tong, Van T.; Dietz, Patricia M.; Farr, Sherry L.; D'Angelo, Denise V.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30341 USA. [England, Lucinda J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30341 USA. RP Tong, VT (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, 4770 Buford Hwy NE,MS-K23, Atlanta, GA 30341 USA. EM vtong@cdc.gov NR 13 TC 30 Z9 30 U1 1 U2 8 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAY-JUN PY 2013 VL 128 IS 3 BP 179 EP 188 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 137UN UT WOS:000318463800008 PM 23633733 ER PT J AU Seib, K Gleason, C Richards, JL Chamberlain, A Andrews, T Watson, L Whitney, E Hinman, AR Omer, SB AF Seib, Katherine Gleason, Cindy Richards, Jennifer L. Chamberlain, Allison Andrews, Tracey Watson, Lin Whitney, Ellen Hinman, Alan R. Omer, Saad B. TI Partners in Immunization: 2010 Survey Examining Differences Among H1N1 Vaccine Providers in Washington State SO PUBLIC HEALTH REPORTS LA English DT Article ID EMERGENCY PREPAREDNESS; HEALTH AB Objectives. Emergency response involving mass vaccination requires the involvement of traditional vaccine providers as well as other health-care providers, including pharmacists, obstetricians, and health-care providers at correctional facilities. We explored differences in provider experiences administering pandemic vaccine during a public health emergency. Methods. We conducted a cross-sectional survey of H1N1 vaccine providers in Washington State, examining topics regarding pandemic vaccine administration, participation in preparedness activities, and communication with public health agencies. We also examined differences among provider types in responses received (n=619, 80.9% response rate). Results. Compared with other types of vaccine providers (e.g., family practitioners, obstetricians, and specialists), pharmacists reported higher patient volumes as well as higher patient-to-practitioner ratios, indicating a broad capacity for community reach. Pharmacists and correctional health-care providers reported lower staff coverage with seasonal and H1N1 vaccines. Compared with other vaccine providers, pharmacists were also more likely to report relying on public health information from federal sources. They were less likely to report relying on local health departments (LHDs) for pandemic-related information, but indicated a desire to be included in LHD communications and plans. While all provider types indicated a high willingness to respond to a public health emergency, pharmacists were less likely to have participated in training, actual emergency response, or surge capacity initiatives. No obstetricians reported participating in surge capacity initiatives. Conclusions. Results from this survey suggest that efforts to increase communication and interaction between public health agencies and pharmacy, obstetric, and correctional health-care vaccine providers may improve future preparedness and emergency response capability and reach. C1 [Seib, Katherine; Omer, Saad B.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. [Seib, Katherine; Richards, Jennifer L.; Chamberlain, Allison; Whitney, Ellen; Hinman, Alan R.; Omer, Saad B.] Emory Univ, Preparedness & Emergency Response Res Ctr, Atlanta, GA 30322 USA. [Gleason, Cindy] Washington State Dept Hlth, Emergency Preparedness Unit, Olympia, WA USA. [Andrews, Tracey; Watson, Lin] Ctr Dis Control & Prevent, Atlanta, GA USA. [Andrews, Tracey; Watson, Lin] Washington State Dept Hlth, Off Immunizat & Child Profile, Olympia, WA USA. [Hinman, Alan R.] Task Force Global Hlth, Decatur, GA USA. RP Seib, K (reprint author), Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, 1518 Clifton Rd,Ste 7020E, Atlanta, GA 30322 USA. EM kseib@emory.edu FU Centers for Disease Control and Prevention (CDC) [5P01TP000300] FX This study was supported by grant #5P01TP000300 from the Centers for Disease Control and Prevention (CDC) to the Emory University Preparedness and Emergency Response Research Center. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of CDC. NR 19 TC 2 Z9 2 U1 0 U2 6 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAY-JUN PY 2013 VL 128 IS 3 BP 198 EP 211 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 137UN UT WOS:000318463800010 PM 23633735 ER PT J AU Kancherla, V Braun, KV Yeargin-Allsopp, M AF Kancherla, Vijaya Braun, Kim Van Naarden Yeargin-Allsopp, Marshalyn TI Dental care among young adults with intellectual disability SO RESEARCH IN DEVELOPMENTAL DISABILITIES LA English DT Article DE Dental care; Dental care for disabled; Intellectual disability; Young adult ID DEVELOPMENTAL-DISABILITIES; MENTAL-RETARDATION; CHILDREN; HEALTH; MEDICAID; PEOPLE; ACCESS; PERSPECTIVES; EXPERIENCES; POPULATION AB Dental care among young adults with intellectual disability (ID) is poorly documented and largely unmet. By using population-based data from the Metropolitan Atlanta Developmental Disabilities Follow-Up Study, we assessed factors associated with at least one or two dental visits per year among young adults with and without ID. Significantly fewer young adults with ID (45%) visited a dentist at least once per year, compared with those without ID (58%). ID severity and the presence of co-occurring developmental disabilities predicted dental care use. Sociodemographics, daily functioning, societal participation, dental services, and dental health factors were examined as predictors of dental care frequency. Our findings can help focus efforts toward improving the frequency of dental care visits among young adults with ID. Published by Elsevier Ltd. C1 [Kancherla, Vijaya] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Braun, Kim Van Naarden; Yeargin-Allsopp, Marshalyn] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Braun, KV (reprint author), Ctr Dis Control & Prevent, Dev Disabil Branch, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd MS E-86, Atlanta, GA 30333 USA. EM kbn5@cdc.gov FU Intramural CDC HHS [CC999999] NR 44 TC 3 Z9 3 U1 1 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0891-4222 J9 RES DEV DISABIL JI Res. Dev. Disabil. PD MAY PY 2013 VL 34 IS 5 BP 1630 EP 1641 DI 10.1016/j.ridd.2013.02.006 PG 12 WC Education, Special; Rehabilitation SC Education & Educational Research; Rehabilitation GA 129WZ UT WOS:000317876000027 PM 23501584 ER PT J AU Kaprielian, VS Silberberg, M McDonald, MA Koo, D Hull, SK Murphy, G Tran, AN Sheline, BL Halstater, B Martinez-Bianchi, V Weigle, NJ de Oliveira, JS Sangvai, D Copeland, J Tilson, HH Scutchfield, FD Michener, JL AF Kaprielian, Victoria S. Silberberg, Mina McDonald, Mary Anne Koo, Denise Hull, Sharon K. Murphy, Gwen Tran, Anh N. Sheline, Barbara L. Halstater, Brian Martinez-Bianchi, Viviana Weigle, Nancy J. de Oliveira, Justine Strand Sangvai, Devdutta Copeland, Joyce Tilson, Hugh H. Scutchfield, F. Douglas Michener, J. Lloyd TI Teaching Population Health: A Competency Map Approach to Education SO ACADEMIC MEDICINE LA English DT Article ID ACADEMIC-MEDICAL-CENTER; PUBLIC-HEALTH; COMMUNITY; PERSPECTIVE AB A 2012 Institute of Medicine report is the latest in the growing number of calls to incorporate a population health approach in health professionals' training. Over the last decade, Duke University, particularly its Department of Community and Family Medicine, has been heavily involved with community partners in Durham, North Carolina, to improve the local community's health. On the basis of these initiatives, a group of interprofessional faculty began tackling the need to fill the curriculum gap to train future health professionals in public health practice, community engagement, critical thinking, and team skills to improve population health effectively in Durham and elsewhere. The Department of Community and Family Medicine has spent years in care delivery redesign and curriculum experimentation, design, and evaluation to distinguish the skills trainees and faculty need for population health improvement and to integrate them into educational programs. These clinical and educational experiences have led to a set of competencies that form an organizational framework for curricular planning and training. This framework delineates which learning objectives are appropriate and necessary for each learning level, from novice through expert, across multiple disciplines and domains. The resulting competency map has guided Duke's efforts to develop, implement, and assess training in population health for learners and faculty. In this article, the authors describe the competency map development process as well as examples of its application and evaluation at Duke and limitations to its use with the hope that other institutions will apply it in different settings. C1 [Kaprielian, Victoria S.; McDonald, Mary Anne; Murphy, Gwen; Weigle, Nancy J.; de Oliveira, Justine Strand; Sangvai, Devdutta; Michener, J. Lloyd] Duke Univ, Sch Med, Dept Community & Family Med, Durham, NC USA. [Silberberg, Mina; Tran, Anh N.] Duke Univ, Sch Med, Dept Community & Family Med, Div Community Hlth, Durham, NC USA. [Koo, Denise] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA USA. [Hull, Sharon K.] Northeast Ohio Med Univ, Rootstown, OH USA. [Hull, Sharon K.] Summa Hlth Syst NEOMED, Patient Ctr Outcomes Res Collaborat, Rootstown, OH USA. [Sheline, Barbara L.] Duke Univ, Sch Med, Durham, NC USA. [Halstater, Brian; Martinez-Bianchi, Viviana] Duke Univ, Sch Med, Family Med Residency Program, Durham, NC USA. [Sangvai, Devdutta] Duke Univ Hlth Syst, Durham, NC USA. [Copeland, Joyce] Duke Univ, Sch Med, Dept Community & Family Med, Med Student Programs, Durham, NC USA. [Tilson, Hugh H.] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Scutchfield, F. Douglas] Univ Kentucky, Dept Prevent Med & Environm Hlth, Coll Publ Hlth, Lexington, KY USA. RP Kaprielian, VS (reprint author), Campbell Univ, Sch Osteopath Med, POB 4280, Buies Creek, NC 27506 USA. EM kaprielianv@campbell.edu RI Scutchfield, F. Douglas/F-9959-2013; Timmers, Gabrielle/O-6505-2016 FU National Institutes of Health [5UL1-RR024128-05, 8U13-TR000184-03] FX Portions of this work were supported by grants from the National Institutes of Health (5UL1-RR024128-05 and 8U13-TR000184-03). NR 39 TC 12 Z9 12 U1 0 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD MAY PY 2013 VL 88 IS 5 BP 626 EP 637 DI 10.1097/ACM.0b013e31828acf27 PG 12 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 131VQ UT WOS:000318025600022 PM 23524919 ER PT J AU Higa, DH Crepaz, N Marshall, KJ Kay, L Vosburgh, HW Spikes, P Lyles, CM Purcell, DW AF Higa, Darrel H. Crepaz, Nicole Marshall, Khiya J. Kay, Linda Vosburgh, H. Waverly Spikes, Pilgrim Lyles, Cynthia M. Purcell, David W. TI A Systematic Review to Identify Challenges of Demonstrating Efficacy of HIV Behavioral Interventions for Gay, Bisexual, and Other Men Who Have Sex with Men (MSM) SO AIDS AND BEHAVIOR LA English DT Review DE HIV prevention; Men who have sex with men; Behavioral interventions; Systematic review ID RANDOMIZED CONTROLLED-TRIAL; RISK-REDUCTION INTERVENTIONS; PREVENTION INTERVENTION; SAFER-SEX; AFRICAN-AMERICAN; UNITED-STATES; METHAMPHETAMINE USE; STRESS-MANAGEMENT; FUTURE-DIRECTIONS; CLINICAL-TRIAL AB Gay, bisexual, and other men who have sex with men (MSM) are disproportionately affected by HIV but few MSM-specific evidence-based interventions (EBIs) have been identified for this vulnerable group. We conducted a systematic review to identify reasons for the small number of EBIs for MSM. We also compared study, intervention and sample characteristics of EBIs versus non-EBIs to better understand the challenges of demonstrating efficacy evidence. Thirty-three MSM-specific studies were evaluated: Nine (27 %) were considered EBIs while 24 (73 %) were non-EBIs. Non-EBIs had multiple methodological limitations; the most common was not finding a significant positive effect. Compared to EBIs, non-EBIs were less likely to use peer intervention deliverers, include sexual communication in their interventions, and intervene at the community level. Incorporating characteristics associated with EBIs may strengthen behavioral interventions for MSM. More EBIs are needed for substance-using MSM, MSM of color, MSM residing in the south and MSM in couples. C1 [Higa, Darrel H.; Crepaz, Nicole; Marshall, Khiya J.; Kay, Linda; Vosburgh, H. Waverly; Spikes, Pilgrim; Lyles, Cynthia M.; Purcell, David W.] US Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Higa, DH (reprint author), US Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM dhiga@cdc.gov OI Purcell, David/0000-0001-8125-5168 NR 93 TC 17 Z9 17 U1 6 U2 20 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD MAY PY 2013 VL 17 IS 4 BP 1231 EP 1244 DI 10.1007/s10461-013-0418-z PG 14 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 133WO UT WOS:000318171800003 PM 23397183 ER PT J AU Kim, EJ Creswell, J Guardado, ME Shah, N Kim, AA Nieto, AI Hernandez-Ayala, FD Monterroso, E Paz-Bailey, G AF Kim, Evelyn J. Creswell, Jacob Guardado, Maria Elena Shah, Neha Kim, Andrea A. Nieto, Ana Isabel de Maria Hernandez-Ayala, Flor Monterroso, Edgar Paz-Bailey, Gabriela TI Correlates of Bisexual Behaviors Among Men who have Sex with Men in El Salvador SO AIDS AND BEHAVIOR LA English DT Article DE Men who have sex with men; Bisexual; HIV; Sexually transmitted infection ID DRIVEN SAMPLING METHODOLOGY; MIDDLE-INCOME COUNTRIES; LATINO MEN; CONDOM USE; INTERNATIONAL SETTINGS; HIV-INFECTION; RISK BEHAVIOR; AMERICAN MEN; POPULATIONS; INTERVENTIONS AB Bisexual behaviors may increase transmission pathways of HIV and sexually transmitted infections (STIs) from a higher prevalence group to lower prevalence groups in El Salvador. In 2008, men who have sex with men (MSM) were recruited in San Salvador and San Miguel using respondent driven sampling. Participants were interviewed and tested for HIV and STIs. Sixteen seeds and 797 MSM participated; 34.9% in San Salvador and 58.8% in San Miguel reported bisexual behavior. Bisexual behavior was associated with drug use (adjusted odds ratio (AOR) = 2.57, 95% CI: 1.30-5.06) and insertive anal sex (AOR = 5.45, 95% CI: 3.01-9.87), and inversely associated with having a stable male partner (AOR = 0.47, 95% CI: 0.26-0.84) and disclosing MSM behavior to family (AOR = 0.41, 95% CI: 0.22-0.75). Bisexual behavior was associated with risk behaviors with male and female partners that may be associated with HIV and STI transmission. Bisexual men displayed a distinct identity calling for tailored interventions. C1 [Kim, Evelyn J.; Shah, Neha; Kim, Andrea A.; Monterroso, Edgar] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Creswell, Jacob; Paz-Bailey, Gabriela] Univ Valle Guatemala, Ctr Estudios Salud, Guatemala City, Guatemala. [Guardado, Maria Elena; de Maria Hernandez-Ayala, Flor; Paz-Bailey, Gabriela] Intervent Network, Training Program Epidemiol, Atlanta, GA USA. [Guardado, Maria Elena; de Maria Hernandez-Ayala, Flor; Paz-Bailey, Gabriela] Intervent Network, Training Program Publ Hlth, Atlanta, GA USA. [Nieto, Ana Isabel] Minist Hlth, Natl AIDS Program, San Salvador, El Salvador. RP Kim, EJ (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, 1600 Clifton Rd NE,MS E-30, Atlanta, GA 30333 USA. EM ejkim@cdc.gov NR 46 TC 10 Z9 10 U1 1 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD MAY PY 2013 VL 17 IS 4 BP 1279 EP 1287 DI 10.1007/s10461-012-0152-y PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 133WO UT WOS:000318171800007 PM 22361925 ER PT J AU Jeffries, WL Marks, G Lauby, J Murrill, CS Millett, GA AF Jeffries, William L. Marks, Gary Lauby, Jennifer Murrill, Christopher S. Millett, Gregorio A. TI Homophobia is Associated with Sexual Behavior that Increases Risk of Acquiring and Transmitting HIV Infection Among Black Men Who Have Sex with Men SO AIDS AND BEHAVIOR LA English DT Article DE Homophobia; Human immunodeficiency virus; Gay men; Men who have sex with men; Black Americans ID AFRICAN-AMERICAN GAY; UNITED-STATES; PREVENTION INTERVENTION; SOCIAL SUPPORT; BISEXUAL MEN; LATINO MEN; US CITIES; HEALTH; STRESS; DISCRIMINATION AB We investigated whether the experience of homophobic events increases the odds of engaging in unprotected anal intercourse (UAI) among black men who have sex with men (MSM) and whether social integration level buffered the association. Participants (N = 1,154) reported homophobic events experienced in the past 12 months. Social integration measures included social support, closeness with family members and friends, attachment to the black gay community, openness about sexuality within religious communities, and MSM social network size. Logistic regression analyses indicated that experiencing homophobia was associated with (1) UAI among men not previously diagnosed with HIV and (2) sexual HIV transmission risk behavior among men who knew they were HIV-infected. None of the social integration measures buffered these associations. Homophobia may promote acquisition and transmission of HIV infection among black MSM. Interventions are needed to reduce homophobia experienced by black MSM. C1 [Jeffries, William L.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Sci, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. [Jeffries, William L.; Marks, Gary; Millett, Gregorio A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Lauby, Jennifer] Publ Hlth Management Corp, Philadelphia, PA USA. [Murrill, Christopher S.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Millett, Gregorio A.] Off Natl AIDS Policy, Washington, DC USA. RP Jeffries, WL (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Sci, Sci Educ & Profess Dev Program Off, 1600 Clifton Rd MS E-37, Atlanta, GA 30333 USA. EM wjeffries@cdc.gov NR 45 TC 41 Z9 42 U1 3 U2 21 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD MAY PY 2013 VL 17 IS 4 BP 1442 EP 1453 DI 10.1007/s10461-012-0189-y PG 12 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 133WO UT WOS:000318171800025 PM 22569942 ER PT J AU Chen, A Ned, RM Donovan, A Andrews, NC AF Chen, Alan Ned, Renee M. Donovan, Adriana Andrews, Nancy C. TI INACTIVATION OF TRANSFERRIN RECEPTOR (TFR1) IN THE PANCREAS RESULTS IN PANCREATITIS AND DIABETES SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Meeting Abstract C1 [Chen, Alan; Andrews, Nancy C.] Duke Univ, Durham, NC 27706 USA. [Ned, Renee M.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 J9 AM J HEMATOL JI Am. J. Hematol. PD MAY PY 2013 VL 88 IS 5 BP E197 EP E197 PG 1 WC Hematology SC Hematology GA 132BT UT WOS:000318043500331 ER PT J AU Chen, A Ned, RM Donovan, A Andrews, NC AF Chen, Alan Ned, Renee M. Donovan, Adriana Andrews, Nancy C. TI TRANSFERRIN RECEPTOR 1 (TFR1) IS REQUIRED FOR MAINTENANCE OF THE INTESTINAL EPITHELIUM SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Meeting Abstract C1 [Chen, Alan; Andrews, Nancy C.] Duke Univ, Durham, NC 27706 USA. [Ned, Renee M.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 J9 AM J HEMATOL JI Am. J. Hematol. PD MAY PY 2013 VL 88 IS 5 BP E12 EP E13 PG 2 WC Hematology SC Hematology GA 132BT UT WOS:000318043500012 ER PT J AU Jones, B Unger, E Alam, G Yin, LN Lu, L Williams, R Miller, D O'Callaghan, J AF Jones, Byron Unger, Erica Alam, Gelareh Yin, Lina Lu, Lu Williams, Robert Miller, Diane O'Callaghan, James TI IRON: KEY TO INDIVIDUAL DIFFERENCES IN SUSCEPTIBILITY TO PESTICIDE NEUROTOXICITY? SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Meeting Abstract C1 [Jones, Byron; Unger, Erica; Alam, Gelareh; Yin, Lina] Penn State Univ, University Pk, PA 16802 USA. [Lu, Lu; Williams, Robert] U Tennessee Hlth Sci Ctr, Memphis, TN USA. [Miller, Diane] NIOSH, CDC, Washington, DC USA. [O'Callaghan, James] Natl Inst Occupat Hlth & Safety, CDC, Washington, DC USA. RI Miller, Diane/O-2927-2013 NR 0 TC 0 Z9 0 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 J9 AM J HEMATOL JI Am. J. Hematol. PD MAY PY 2013 VL 88 IS 5 BP E155 EP E155 PG 1 WC Hematology SC Hematology GA 132BT UT WOS:000318043500258 ER PT J AU Andrew, ME Li, SQ Wactawski-Wende, J Dorn, JP Mnatsakanova, A Charles, LE Fekedulegn, D Miller, DB Violanti, JM Burchfiel, CM Sharp, DS AF Andrew, Michael E. Li, Shengqiao Wactawski-Wende, Jean Dorn, Joan P. Mnatsakanova, Anna Charles, Luenda E. Fekedulegn, Desta Miller, Diane B. Violanti, John M. Burchfiel, Cecil M. Sharp, Dan S. TI Adiposity, muscle, and physical activity: Predictors of perturbations in heart rate variability SO AMERICAN JOURNAL OF HUMAN BIOLOGY LA English DT Article ID AUTONOMIC NERVOUS-SYSTEM; VISCERAL ADIPOSITY; INSULIN-RESISTANCE; POLYVAGAL THEORY; BODY-COMPOSITION; ASSOCIATION; OBESITY; TISSUE; RISK; PSYCHOPATHOLOGY AB Objectives This study examines cross-sectional associations of indices of adiposity, lean body mass, and physical activity, with heart rate variability (HRV), a marker for parasympathetic cardiac vagal control. Methods The study population consists of 360 officers from the Buffalo New York Police Department. Indices of adiposity include body mass index, waist circumference, and a fat-mass index taken from dual-energy X-ray absorptiometry (DEXA) measurements. Lean body mass indices were derived from DEXA measurements of trunk mass and extremity lean mass. Physical activity was measured using a 7-day self-report questionnaire. HRV was obtained from 5-min electrocardiogram measurements by means of parametric spectral analysis resulting in estimates for high-frequency (HF) and low-frequency (LF) HRV. Results Both HF and LF HRV were significantly associated with markers for adiposity, two components of lean mass and physical activity with all associations being in the expected direction except that for trunk lean mass. This unexpected result is explained by the possibility that trunk mass is a marker for visceral adiposity rather than lean mass. Body mass index did not explain any additional variance in HRV above and beyond waist circumference and the DEXA indices. Conclusions Higher levels of physical activity, lower levels of markers for central adiposity and higher lean mass in the extremities predict higher levels of HRV in this population of police officers. This association between modifiable risk factors and markers for autonomic function suggest possible interventions that may improve health and performance. Am. J. Hum. Biol. 25:370377, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Andrew, Michael E.; Mnatsakanova, Anna; Charles, Luenda E.; Fekedulegn, Desta; Miller, Diane B.; Burchfiel, Cecil M.; Sharp, Dan S.] NIOSH, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Li, Shengqiao] Univ Pittsburgh, Med Ctr, Med Ctr Hlth Plan, Pittsburgh, PA USA. [Wactawski-Wende, Jean; Dorn, Joan P.; Violanti, John M.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Social & Prevent Med, Buffalo, NY 14260 USA. RP Andrew, ME (reprint author), NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, 1095 Willowdale Rd MS4020, Morgantown, WV 26505 USA. EM MAndrew@CDC.GOV RI Miller, Diane/O-2927-2013 FU NIOSH [200-2003-01580]; National Occupational Research Agenda (NORA) program FX This work was supported by NIOSH contract no. 200-2003-01580 to SUNY Buffalo and the National Occupational Research Agenda (NORA) program. NR 45 TC 7 Z9 7 U1 0 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1042-0533 J9 AM J HUM BIOL JI Am. J. Hum. Biol. PD MAY-JUN PY 2013 VL 25 IS 3 BP 370 EP 377 DI 10.1002/ajhb.22379 PG 8 WC Anthropology; Biology SC Anthropology; Life Sciences & Biomedicine - Other Topics GA 132AS UT WOS:000318040700013 PM 23564378 ER PT J AU Bridges, CB Woods, L Coyne-Beasley, T AF Bridges, C. B. Woods, L. Coyne-Beasley, T. CA ACIP Adult Immunization Work Grp TI Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Adults Aged 19 Years and Older-United States, 2013 (Reprinted from MMWR, vol 62, pg 9, 2013) SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Reprint C1 [Bridges, C. B.; Woods, L.; ACIP Adult Immunization Work Grp] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Coyne-Beasley, T.] Univ N Carolina, Div Gen Pediat & Adolescent Med, Chapel Hill, NC USA. RP Bridges, CB (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM cbridges@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAY PY 2013 VL 13 IS 5 BP 1354 EP 1363 DI 10.1111/ajt.12279 PG 10 WC Surgery; Transplantation SC Surgery; Transplantation GA 135GR UT WOS:000318277100029 ER PT J AU Fazili, Z Whitehead, RD Paladugula, N Pfeiffer, CM AF Fazili, Zia Whitehead, Ralph D., Jr. Paladugula, Neelima Pfeiffer, Christine M. TI A high-throughput LC-MS/MS method suitable for population biomonitoring measures five serum folate vitamers and one oxidation product SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY LA English DT Article DE Automated solid phase extraction; MeFox; hmTHF; Method comparison; Microbiologic assay; Anticoagulant types ID TANDEM MASS-SPECTROMETRY; MICROBIOLOGIC ASSAY; ROUND-TABLE; PLASMA; QUANTIFICATION; CATABOLITES; BIOMARKERS; RADIOASSAY; NHANES AB Small specimen volume and high sample throughput are key features needed for routine methods used for population biomonitoring. We modified our routine eight-probe solid phase extraction (SPE) LC-MS/MS method for the measurement of five folate vitamers [5-methyltetrahydrofolate (5-methylTHF), folic acid (FA), plus three minor forms: THF, 5-formylTHF, 5,10-methenylTHF] and one oxidation product of 5-methylTHF (MeFox) to require less serum volume (150 mu L instead of 275 mu L) by using 96-well SPE plates with 50 mg instead of 100 mg phenyl sorbent and to provide faster throughput by using a 96-probe SPE system. Total imprecision (10 days, two replicates/day) for three serum quality control pools was 2.8-3.6 % for 5-methylTHF (19.5-51.1 nmol/L), 6.6-8.7 % for FA (0.72-11.4 nmol/L), and a parts per thousand currency sign11.4 % for the minor folate forms (< 1-5 nmol/L). The mean (+/- SE) recoveries of folates spiked into serum (3 days, four levels, two replicates/level) were: 5-methylTHF, 99.4 +/- 3.6 %; FA, 100 +/- 1.8 %; minor folates, 91.7-108 %. SPE extraction efficiencies were a parts per thousand yen85 %, except for THF (78 %). Limits of detection were a parts per thousand currency sign0.3 nmol/L. The new method correlated well with our routine method [n = 150, r = 0.99 for 5-methylTHF, FA, and total folate (tFOL, sum of folate forms)] and produced slightly higher tFOL (5.6 %) and 5-methylTHF (7.3 %) concentrations, likely due to the faster 96-probe SPE process (1 vs. 5 h), resulting in improved SPE efficiency and recovery compared to the eight-probe SPE method. With this improved LC-MS/MS method, 96 samples can be processed in similar to 2 h, and all relevant folate forms can be accurately measured using a small serum volume. C1 [Fazili, Zia; Whitehead, Ralph D., Jr.; Paladugula, Neelima; Pfeiffer, Christine M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Pfeiffer, CM (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Hwy NE,Mail Stop F55, Atlanta, GA 30341 USA. EM CPfeiffer@cdc.gov FU Intramural CDC HHS [CC999999] NR 23 TC 7 Z9 8 U1 1 U2 28 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1618-2642 J9 ANAL BIOANAL CHEM JI Anal. Bioanal. Chem. PD MAY PY 2013 VL 405 IS 13 BP 4549 EP 4560 DI 10.1007/s00216-013-6854-9 PG 12 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 131DK UT WOS:000317972200025 PM 23462981 ER PT J AU Nett, RJ Campana, D Custis, CL Helgerson, SD AF Nett, Randall J. Campana, David Custis, Cody L. Helgerson, Steven D. TI Office-Related Antibiotic Prescribing for Medicaid-Enrolled Children SO CLINICAL PEDIATRICS LA English DT Article DE antibacterial agents; prescriptions; respiratory tract infections; child; Medicaid; Montana ID RESPIRATORY-TRACT INFECTIONS; UNITED-STATES; PRIMARY-CARE; MANAGEMENT; RESISTANCE; PHARYNGITIS; PHYSICIANS; DIAGNOSIS; SINUSITIS; COLDS AB Background. Prudent antibiotic prescribing practices are essential to limiting antibiotic resistance. Objective. To assess the trend in percentage of office visits for acute respiratory infections (ARIs) linked with an antibiotic prescription. Methods. Retrospective analysis of Montana Medicaid billing claims data for each year, 1999 to 2010, was done. Participants included continuously enrolled children aged acurrency sign14 years. Primary outcomes were ARI-related office visits and filled antibiotic prescriptions within 10 days of the office visit. Results. Of the 873 244 office visits identified, 116 962 (13%) had an ARI as the primary diagnosis. Among ARI-related office visits, 64 250 (55%) were linked with an antibiotic prescription. From 1999 to 2010, the odds of ARI-related visits being linked with an antibiotic prescription did not change (odds ratio = 1.00; 95% confidence interval = 0.995-1.002). Conclusions. The percentage of ARI-related visits linked with an antibiotic prescription did not decrease from 1999 to 2010. Further efforts are needed to reduce antibiotic treatment for ARIs. C1 [Nett, Randall J.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Nett, Randall J.; Campana, David; Custis, Cody L.; Helgerson, Steven D.] Montana Dept Publ Hlth & Human Serv DPHHS, Helena, MT USA. RP Nett, RJ (reprint author), Montana Dept Publ Hlth & Human Serv, Cogswell Bldg,Room B-201,1400 Broadway, Helena, MT 59610 USA. EM ggE5@cdc.gov NR 26 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0009-9228 J9 CLIN PEDIATR JI Clin. Pediatr. PD MAY PY 2013 VL 52 IS 5 BP 403 EP 410 DI 10.1177/0009922813479158 PG 8 WC Pediatrics SC Pediatrics GA 134XN UT WOS:000318249200004 PM 23460649 ER PT J AU Thurtle, N Greig, J Cooney, L Amitai, Y Brown, MJ Janyau, MK Kosnett, MJ Moussally, K Shanks, L Dargan, PI AF Thurtle, Natalie Greig, Jane Cooney, Lauren Amitai, Yona Brown, Mary Jean Janyau, Muhammad K. Kosnett, Michael J. Moussally, Krystel Shanks, Lauren Dargan, Paul I. TI Description of 3924 courses of chelation with 2,3-dimercaptosuccinic acid in children with severe lead poisoning in Zamfara, northern Nigeria SO CLINICAL TOXICOLOGY LA English DT Meeting Abstract C1 [Thurtle, Natalie; Greig, Jane; Cooney, Lauren; Moussally, Krystel; Shanks, Lauren] Medecins Sans Frontieres Holland UK & Nigeria, Geneva, Switzerland. [Amitai, Yona] Minist Hlth, Dept Maternal Child & Adolescent Hlth, Jerusalem, Israel. [Brown, Mary Jean] Ctr Dis Control & Prevent, Atlanta, GA USA. [Janyau, Muhammad K.] Zamfara State Govt, Gusasu, Nigeria. [Kosnett, Michael J.] Univ Colorado, Hlth Sci Ctr, Div Clin Pharmacol & Toxicol, Denver, CO USA. [Dargan, Paul I.] Guys & St Thomas NHS Fdn Trust, London, England. NR 0 TC 0 Z9 0 U1 0 U2 2 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1556-3650 J9 CLIN TOXICOL JI Clin. Toxicol. PD MAY PY 2013 VL 51 IS 4 MA 3 BP 253 EP 254 PG 2 WC Toxicology SC Toxicology GA 130SD UT WOS:000317938600014 ER PT J AU Gade, L Scheel, CM Pham, CD Lindsley, MD Iqbal, N Cleveland, AA Whitney, AM Lockhart, SR Brandt, ME Litvintseva, AP AF Gade, Lalitha Scheel, Christina M. Pham, Cau D. Lindsley, Mark D. Iqbal, Naureen Cleveland, Angela Ahlquist Whitney, Anne M. Lockhart, Shawn R. Brandt, Mary E. Litvintseva, Anastasia P. TI Detection of Fungal DNA in Human Body Fluids and Tissues during a Multistate Outbreak of Fungal Meningitis and Other Infections SO EUKARYOTIC CELL LA English DT Article ID ASPERGILLUS-FUMIGATUS; PCR; EXSEROHILUM; IDENTIFICATION; BIPOLARIS; PATIENT; AGENTS; ASSAY AB Exserohilum rostratum was the major cause of an outbreak of fungal infections linked to injections of contaminated methylprednisolone acetate. Because almost 14,000 persons were exposed to product that was possibly contaminated with multiple fungal pathogens, there was unprecedented need for a rapid throughput diagnostic test that could detect both E. rostratum and other unusual agents of fungal infection. Here we report development of a novel PCR test that allowed for rapid and specific detection of fungal DNA in cerebrospinal fluid (CSF), other body fluids and tissues of infected individuals. The test relied on direct purification of free-circulating fungal DNA from fluids and subsequent PCR amplification and sequencing. Using this method, we detected Exserohilum rostratum DNA in 123 samples from 114 case-patients (28% of 413 case-patients for whom 627 samples were available), and Cladosporium DNA in one sample from one case-patient. PCR with novel Exserohilum-specific ITS-2 region primers detected 25 case-patients with samples that were negative using broad-range ITS primers. Compared to fungal culture, this molecular test was more sensitive: of 139 case-patients with an identical specimen tested by culture and PCR, E. rostratum was recovered in culture from 19 (14%), but detected by PCR in 41 (29%), showing a diagnostic sensitivity of 29% for PCR compared to 14% for culture in this patient group. The ability to rapidly confirm the etiologic role of E. rostratum in these infections provided an important contribution in the public health response to this outbreak. C1 [Gade, Lalitha; Scheel, Christina M.; Pham, Cau D.; Lindsley, Mark D.; Iqbal, Naureen; Cleveland, Angela Ahlquist; Lockhart, Shawn R.; Brandt, Mary E.; Litvintseva, Anastasia P.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Mycot Dis Branch, Atlanta, GA USA. [Whitney, Anne M.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Bacterial Special Pathogens Branch, Atlanta, GA USA. RP Litvintseva, AP (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Mycot Dis Branch, Atlanta, GA USA. EM frq8@cdc.gov NR 33 TC 28 Z9 28 U1 1 U2 12 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1535-9778 J9 EUKARYOT CELL JI Eukaryot. Cell PD MAY PY 2013 VL 12 IS 5 BP 677 EP 683 DI 10.1128/EC.00046-13 PG 7 WC Microbiology; Mycology SC Microbiology; Mycology GA 133OP UT WOS:000318148300005 PM 23457192 ER PT J AU Gould, LH Mody, RK Ong, KL Clogher, P Cronquist, AB Garman, KN Lathrop, S Medus, C Spina, NL Webb, TH White, PL Wymore, K Gierke, RE Mahon, BE Griffin, PM AF Gould, L. Hannah Mody, Rajal K. Ong, Kanyin L. Clogher, Paula Cronquist, Alicia B. Garman, Katie N. Lathrop, Sarah Medus, Carlota Spina, Nancy L. Webb, Tameka H. White, Patricia L. Wymore, Katie Gierke, Ruth E. Mahon, Barbara E. Griffin, Patricia M. CA Emerging Infect Program FoodNet TI Increased Recognition of Non-O157 Shiga Toxin-Producing Escherichia coli Infections in the United States During 2000-2010: Epidemiologic Features and Comparison with E. coli O157 Infections SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID HEMOLYTIC-UREMIC SYNDROME; DIARRHEA; CHILDREN; SURVEILLANCE; CONNECTICUT; ARGENTINA; MEXICO AB Background: Shiga toxin-producing Escherichia coli (STEC) are an important cause of diarrhea and the major cause of postdiarrheal hemolytic uremic syndrome. Non-O157 STEC infections are being recognized with greater frequency because of changing laboratory practices. Methods: Foodborne Diseases Active Surveillance Network (FoodNet) site staff conducted active, population-based surveillance for laboratory-confirmed STEC infections. We assessed frequency and incidence of STEC infections by serogroup and examined and compared demographic factors, clinical characteristics, and frequency of international travel among patients. Results: During 2000-2010, FoodNet sites reported 2006 cases of non-O157 STEC infection and 5688 cases of O157 STEC infections. The number of reported non-O157 STEC infections increased from an incidence of 0.12 per 100,000 population in 2000 to 0.95 per 100,000 in 2010; while the rate of O157 STEC infections decreased from 2.17 to 0.95 per 100,000. Among non-O157 STEC, six serogroups were most commonly reported: O26 (26%), O103 (22%), O111 (19%), O121 (6%), O45 (5%), and O145 (4%). Non-O157 STEC infections were more common among Hispanics, and infections were less severe than those caused by O157 STEC, but this varied by serogroup. Fewer non-O157 STEC infections were associated with outbreaks (7% versus 20% for O157), while more were associated with international travel (14% versus 3% for O157). Conclusions: Improved understanding of the epidemiologic features of non-O157 STEC infections can inform food safety and other prevention efforts. To detect both O157 and non-O157 STEC infections, clinical laboratories should routinely and simultaneously test all stool specimens submitted for diagnosis of acute community-acquired diarrhea for O157 STEC and for Shiga toxin and ensure that isolates are sent to a public health laboratory for serotyping and subtyping. C1 [Gould, L. Hannah; Mody, Rajal K.; Ong, Kanyin L.; Gierke, Ruth E.; Mahon, Barbara E.; Griffin, Patricia M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Clogher, Paula] Connecticut Emerging Infect Program, New Haven, CT USA. [Cronquist, Alicia B.] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Garman, Katie N.] Tennessee Dept Hlth, Nashville, TN USA. [Lathrop, Sarah] New Mexico Emerging Infect Program, Albuquerque, NM USA. [Medus, Carlota] Minnesota Dept Hlth, St Paul, MN USA. [Spina, Nancy L.] New York State Emerging Infect Program, Albany, NY USA. [Webb, Tameka H.] Georgia Dept Community Hlth, Div Publ Hlth, Atlanta, GA USA. [White, Patricia L.] US Food Safety & Inspect Serv, USDA, Omaha, NE USA. [Wymore, Katie] Calif Emerging Infect Program, Oakland, CA USA. RP Gould, LH (reprint author), Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, 1600 Clifton Rd NE,MS A38, Atlanta, GA 30333 USA. EM lgould@cdc.gov FU Centers for Disease Control and Prevention; United States Department of Agriculture; United States Food and Drug Administration FX We thank the Emerging Infections Program surveillance officers and the participating local and state health departments and laboratories. Mike Hoekstra provided valuable input on the statistical analyses. Funding for this report was provided by the Centers for Disease Control and Prevention, the United States Department of Agriculture, and the United States Food and Drug Administration. NR 24 TC 86 Z9 86 U1 0 U2 28 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD MAY PY 2013 VL 10 IS 5 BP 453 EP 460 DI 10.1089/fpd.2012.1401 PG 8 WC Food Science & Technology SC Food Science & Technology GA 134OW UT WOS:000318223100008 PM 23560425 ER PT J AU Kelly, D Zhang, QC Soucie, JM Manco-Johnson, M Dimichele, D AF Kelly, D. Zhang, Q. C. Soucie, J. M. Manco-Johnson, M. Dimichele, D. CA Coordinating Comm Universal TI Prevalence of clinical hip abnormalities in haemophilia A and B: an analysis of the UDC database SO HAEMOPHILIA LA English DT Article DE arthropathy; haemophilia; hip joint; joint disease; target joint ID FACTOR-VIII; ARTHROPATHY; CHILDREN; OBESITY; DISEASE AB Clinical hip abnormalities, secondary to recurrent joint and/or muscle bleeding in persons with haemophilia, have not been well characterized and have the potential for significant morbidity. We aimed to examine the prevalence of clinical hip abnormalities in the US haemophilia population and to explore associations between these findings and putative risk factors. We conducted a study of hip abnormalities of 8192 subjects aged 269years with haemophilia A and haemophilia B (54% of haemophilia A and haemophilia B are severe) currently enrolled in the Universal Data Collection (UDC) database. Associations between hip abnormality and type/severity of haemophilia A/B, current age, history of high-titre (5BU) inhibitor (HTinh), concomitant ankle (AA) and knee arthropathy (KA), overweight and obesity and prophylaxis were examined using logistic regression. Overall prevalence of hip abnormality at the last recorded UDC visit for all subjects was 16.7%. Haemophilia A (aOR=1.3, 1.01.4), severe haemophilia (aOR=1.3, 1.01.5), a history of HTinh (aOR=1.4, 1.11.7), and concomitant AA (aOR=1.7, 1.41.9) were each independently associated with hip abnormality. Older age (4569years) was significantly associated with hip abnormality prevalence only in subjects with KA (aOR=3.4, 1.95.9). The presence of overweight (aOR=1.4, 1.11.8) and obesity (aOR=2.1, 1.62.8) was associated with hip abnormality only among subjects without KA. Hip abnormality prevalence was not influenced by prophylaxis (aOR=0.9, 0.81.1). These data suggest that hip abnormalities in US patients with haemophilia are associated with haemophilia severity and type, HTinh, concomitant AA and, depending on the presence or absence of KA, advancing age and obesity. C1 [Kelly, D.; Dimichele, D.] Weill Cornell Med Coll, New York, NY USA. [Zhang, Q. C.; Soucie, J. M.] CDC, Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, Atlanta, GA 30333 USA. [Manco-Johnson, M.] Univ Colorado, Mt States Reg Hemophilia & Thrombosis Ctr, Denver, CO 80202 USA. [Manco-Johnson, M.] Childrens Hosp, Aurora, CO USA. RP Kelly, D (reprint author), Boston Childrens Hosp, Dept Anesthesia Perioperat & Pain Med, Div Crit Care Med, 300 Longwood Ave,Bader 620, Boston, MA 02115 USA. EM daniel.kelly@childrens.harvard.edu RI Kerlin, Bryce/E-3369-2011 OI Kerlin, Bryce/0000-0002-1756-8271 FU Intramural CDC HHS [CC999999] NR 22 TC 3 Z9 3 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 J9 HAEMOPHILIA JI Haemophilia PD MAY PY 2013 VL 19 IS 3 BP 426 EP 431 DI 10.1111/hae.12073 PG 6 WC Hematology SC Hematology GA 132OM UT WOS:000318078400035 PM 23252621 ER PT J AU Buckner, T Ma, A Nielsen, B Miller, C Key, N AF Buckner, T. Ma, A. Nielsen, B. Miller, C. Key, N. TI Development of an Inhibitory Antibody in a Patient with Combined Factor V and Factor VIII Deficiency SO HAEMOPHILIA LA English DT Meeting Abstract C1 [Buckner, T.; Ma, A.; Nielsen, B.; Key, N.] Univ N Carolina, Chapel Hill, NC USA. [Miller, C.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 J9 HAEMOPHILIA JI Haemophilia PD MAY PY 2013 VL 19 IS 3 BP 458 EP 458 PG 1 WC Hematology SC Hematology GA 132OM UT WOS:000318078400044 ER PT J AU Carpenter, S Soucie, J Presley, R Ragni, M Wicklund, B Silvey, M Davidson, H AF Carpenter, S. Soucie, J. Presley, R. Ragni, M. Wicklund, B. Silvey, M. Davidson, H. TI Hepatitis B vaccination equally effective by subcutaneous route in children with bleeding disorders: a UDC database analysis SO HAEMOPHILIA LA English DT Meeting Abstract C1 [Carpenter, S.; Wicklund, B.; Silvey, M.] Childrens Mercy Hosp, Kansas City, MO 64108 USA. [Soucie, J.; Presley, R.] Ctr Dis Control, Div Blood Disorders, Atlanta, GA 30333 USA. [Ragni, M.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Davidson, H.] Phoenix Childrens Hosp, Phoenix, AZ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 J9 HAEMOPHILIA JI Haemophilia PD MAY PY 2013 VL 19 IS 3 BP 465 EP 466 PG 2 WC Hematology SC Hematology GA 132OM UT WOS:000318078400063 ER PT J AU Kerlin, B Smoyer, W Tsai, J Boulet, S AF Kerlin, B. Smoyer, W. Tsai, J. Boulet, S. TI Venous thromboembolism dramatically increases healthcare utilization and mortality in childhood chronic kidney disease SO HAEMOPHILIA LA English DT Meeting Abstract C1 [Kerlin, B.; Smoyer, W.] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA. [Tsai, J.; Boulet, S.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 J9 HAEMOPHILIA JI Haemophilia PD MAY PY 2013 VL 19 IS 3 BP 467 EP 468 PG 2 WC Hematology SC Hematology GA 132OM UT WOS:000318078400071 ER PT J AU Walsh, C Soucie, M Miller, C AF Walsh, C. Soucie, M. Miller, C. TI Increased mortality risk in US Hemophilia A inhibitor patients SO HAEMOPHILIA LA English DT Meeting Abstract C1 [Walsh, C.] Mt Sinai Sch Med, New York, NY USA. [Soucie, M.; Miller, C.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 J9 HAEMOPHILIA JI Haemophilia PD MAY PY 2013 VL 19 IS 3 BP 470 EP 471 PG 2 WC Hematology SC Hematology GA 132OM UT WOS:000318078400084 ER PT J AU Eby, JC Gray, MC Warfel, JM Paddock, CD Jones, TF Day, SR Bowden, J Poulter, MD Donato, GM Merkel, TJ Hewlett, EL AF Eby, Joshua C. Gray, Mary C. Warfel, Jason M. Paddock, Christopher D. Jones, Tara F. Day, Shandra R. Bowden, James Poulter, Melinda D. Donato, Gina M. Merkel, Tod J. Hewlett, Erik L. TI Quantification of the Adenylate Cyclase Toxin of Bordetella pertussis In Vitro and during Respiratory Infection SO INFECTION AND IMMUNITY LA English DT Article ID POLYMERASE-CHAIN-REACTION; VIRULENCE FACTORS; EPITHELIAL-CELLS; LETHAL FACTOR; HEMOLYTIC ACTIVITIES; BACILLUS-ANTHRACIS; INSERTION-SEQUENCE; HUMAN NEUTROPHILS; ESCHERICHIA-COLI; CR3 CD11B/CD18 AB Whooping cough results from infection of the respiratory tract with Bordetella pertussis, and the secreted adenylate cyclase toxin (ACT) is essential for the bacterium to establish infection. Despite extensive study of the mechanism of ACT cytotoxicity and its effects over a range of concentrations in vitro, ACT has not been observed or quantified in vivo, and thus the concentration of ACT at the site of infection is unknown. The recently developed baboon model of infection mimics the prolonged cough and transmissibility of pertussis, and we hypothesized that measurement of ACT in nasopharyngeal washes (NPW) from baboons, combined with human and in vitro data, would provide an estimate of the ACT concentration in the airway during infection. NPW contained up to similar to 10(8) CFU/ml B. pertussis and 1 to 5 ng/ml ACT at the peak of infection. Nasal aspirate specimens from two human infants with pertussis contained bacterial concentrations similar to those in the baboons, with 12 to 20 ng/ml ACT. When similar to 10(8) CFU/ml of a laboratory strain of B. pertussis was cultured in vitro, ACT production was detected in 60 min and reached a plateau of similar to 60 ng/ml in 6 h. Furthermore, when bacteria were brought into close proximity to target cells by centrifugation, intoxication was increased 4-fold. Collectively, these data suggest that at the bacterium-target cell interface during infection of the respiratory tract, the concentration of ACT can exceed 100 ng/ml, providing a reference point for future studies of ACT and pertussis pathogenesis. C1 [Eby, Joshua C.; Gray, Mary C.; Day, Shandra R.; Donato, Gina M.; Hewlett, Erik L.] Univ Virginia, Sch Med, Dept Med, Div Infect Dis & Int Hlth, Charlottesville, VA 22908 USA. [Warfel, Jason M.; Merkel, Tod J.] US FDA, Div Bacterial Parasit & Allergen Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA. [Paddock, Christopher D.; Jones, Tara F.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA. [Poulter, Melinda D.] Univ Virginia, Dept Pathol, Med Ctr, Charlottesville, VA 22903 USA. RP Hewlett, EL (reprint author), Univ Virginia, Sch Med, Dept Med, Div Infect Dis & Int Hlth, Charlottesville, VA 22908 USA. EM eh2v@virginia.edu FU NIH, NIAID [5 RO1 AI1018000, 1K08AI081900-01, 2T32AI007046-36]; Food and Drug Administration; NIH/NIAID [Y1-AI-1727-01]; NIH National Center for Research Resources [P40RR012317, 5R24RR016556-10] FX This work was supported by funding from the NIH, NIAID (grants 5 RO1 AI1018000 [E.L.H.] and 1K08AI081900-01 [J.C.E.]), Food and Drug Administration and NIH/NIAID interagency agreement Y1-AI-1727-01 (T.J.M.), the NIH National Center for Research Resources (grants P40RR012317 and 5R24RR016556-10 [T.J.M.]), and an Infectious Diseases Training Grant from the NIH, NIAID (grant 2T32AI007046-36 [S.R.D.]). NR 72 TC 22 Z9 22 U1 0 U2 14 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD MAY PY 2013 VL 81 IS 5 BP 1390 EP 1398 DI 10.1128/IAI.00110-13 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 126AE UT WOS:000317582700002 PM 23429530 ER PT J AU Lustig, G Ryan, CM Secor, WE Johnson, PJ AF Lustig, Gila Ryan, Christopher M. Secor, W. Evan Johnson, Patricia J. TI Trichomonas vaginalis Contact-Dependent Cytolysis of Epithelial Cells SO INFECTION AND IMMUNITY LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; PROSTATE-CANCER; CLINICAL PRESENTATION; SURFACE SACCHARIDES; DRUG SUSCEPTIBILITY; SUBSEQUENT RISK; INFECTION; METRONIDAZOLE; STRAINS; PROTEINS AB Trichomonas vaginalis is an extracellular protozoan parasite that binds to the epithelium of the human urogenital tract during infection. In this study, we examined the propensities of 26 T. vaginalis strains to bind to and lyse prostate (BPH-1) and ectocervical (Ect1) epithelium and to lyse red blood cells (RBCs). We found that only three of the strains had a statistically significant preference for either BPH-1 (MSA1103) or Ect1 (LA1 and MSA1123). Overall, we observed that levels of adherence are highly variable among strains, with a 12-fold range of adherence on Ect1 cells and a 45-fold range on BPH-1 cells. Cytolysis levels displayed even greater variability, from no detectable cytolysis to 80% or 90% cytolysis of Ect1 and BPH-1, respectively. Levels of adherence and cytolysis correlate for weakly adherent/cytolytic strains, and a threshold of attachment was found to be necessary to trigger cytolysis; however, this threshold can be reached without inducing cytolysis. Furthermore, cytolysis was completely blocked when we prevented attachment of the parasites to host cells while allowing soluble factors complete access. We demonstrate that hemolysis was a rare trait, with only 4 of the 26 strains capable of lysing>20% RBCs with a 1:30 parasite/RBC ratio. Hemolysis also did not correlate with adherence to or cytolysis of either male (BPH-1)-or female (Ect1)-derived epithelial cell lines. Our results reveal that despite a broad range of pathogenic properties among different T. vaginalis strains, all strains show strict contact-dependent cytolysis. C1 [Lustig, Gila; Ryan, Christopher M.; Johnson, Patricia J.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. [Secor, W. Evan] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Johnson, PJ (reprint author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. EM johnsonp@ucla.edu FU National Institutes of Health [R01AI069058]; American Cancer Society FX This work was supported by National Institutes of Health grant R01AI069058 (to P.J.J.) and by a postdoctoral fellowship from the American Cancer Society (to C.M.R.). NR 76 TC 16 Z9 17 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD MAY PY 2013 VL 81 IS 5 BP 1411 EP 1419 DI 10.1128/IAI.01244-12 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 126AE UT WOS:000317582700004 PM 23429535 ER PT J AU Roth, S Whitehead, S Thamthitiwat, S Chittaganpitch, M Maloney, SA Baggett, HC Olsen, SJ AF Roth, Serena Whitehead, Sara Thamthitiwat, Somsak Chittaganpitch, Malinee Maloney, Susan A. Baggett, Henry C. Olsen, Sonja J. TI Concurrent influenza virus infection and tuberculosis in patients hospitalized with respiratory illness in Thailand SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Influenza; pneumonia; respiratory diseases; surveillance; Thailand; tuberculosis ID PNEUMONIA; MORTALITY AB Thailand, where influenza viruses circulate year-round, is one of 22 WHO-designated high-burden countries for tuberculosis (TB). Surveillance for hospitalized respiratory illness between 2003 and 2011 revealed 23 (<1% of 7180 tested) with concurrent influenza and TB. Only two persons were previously known to have TB suggesting that acute respiratory illness may bring patients to medical attention and lead to TB diagnosis. Influenza/TB was not associated with higher disease severity or mortality. C1 [Roth, Serena; Whitehead, Sara; Thamthitiwat, Somsak; Maloney, Susan A.; Baggett, Henry C.; Olsen, Sonja J.] Thailand MOPH US CDC Collaborat, Nonthaburi, Thailand. [Whitehead, Sara] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Chittaganpitch, Malinee] Minist Publ Hlth, Natl Inst Hlth, Nonthaburi, Thailand. [Maloney, Susan A.; Baggett, Henry C.] Ctr Dis Control & Prevent, Div Global Dis Detect & Emergency Response, Atlanta, GA USA. [Olsen, Sonja J.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Olsen, SJ (reprint author), Amer Embassy, CDC Box 68, APO, AP 96546 USA. EM sco2@cdc.gov FU CDC [5U19GH000004] FX This work was supported by a cooperative agreement from CDC (#5U19GH000004). NR 13 TC 2 Z9 2 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAY PY 2013 VL 7 IS 3 BP 244 EP 248 DI 10.1111/j.1750-2659.2012.00413.x PG 5 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 131XX UT WOS:000318033100006 PM 22817684 ER PT J AU Morgan, OW Chittaganpitch, M Clague, B Chantra, S Sanasuttipun, W Prapasiri, P Naorat, S Laosirithavorn, Y Peret, TCT Erdman, DD Baggett, HC Olsen, SJ Fry, AM AF Morgan, Oliver W. Chittaganpitch, Malinee Clague, Birgit Chantra, Somrak Sanasuttipun, Wichai Prapasiri, Prabda Naorat, Sathapana Laosirithavorn, Yongjua Peret, Teresa C. T. Erdman, Dean D. Baggett, Henry C. Olsen, Sonja J. Fry, Alicia M. TI Hospitalization due to human parainfluenza virusassociated lower respiratory tract illness in rural Thailand SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Human parainfluenza viruses; pneumonia; surveillance; Thailand ID POLYMERASE-CHAIN-REACTION; SEASONAL TRENDS; PNEUMONIA; INFECTIONS; VIRUS; CHILDREN; INFLUENZA AB Background Human parainfluenza viruses (HPIVs) are an important cause of acute respiratory illness in young children but little is known about their epidemiology in the tropics. Methods From 20032007, we conducted surveillance for hospitalized respiratory illness in rural Thailand. We performed reverse-transcriptase polymerase chain reaction on nasopharyngeal specimens and enzyme immunoassay on paired sera Results Of 10,097 patients enrolled, 573 (5%) of all ages and 370 (9%) of children <5 years of age had evidence of HPIV infection (HPIV1=189, HPIV2=54, HPIV3=305, untyped=27). Average adjusted annual incidence of HPIV-associated hospitalized respiratory illness was greatest in children aged <1 year (485 per 100,000 person years). Conclusions In Thailand, HPIV caused substantial illnesses requiring hospitalization in young children. C1 [Morgan, Oliver W.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Atlanta, GA 30333 USA. [Chittaganpitch, Malinee] Minist Publ Hlth, Thailand Natl Inst Hlth, Nonthaburi, Thailand. [Clague, Birgit; Prapasiri, Prabda; Naorat, Sathapana; Baggett, Henry C.; Olsen, Sonja J.] Thailand MOPH US CDC Collaborat, Int Emerging Infect Program, Nonthaburi, Thailand. [Chantra, Somrak] Sa Kaeo Prov Hlth Off, Sa Kaeo, Thailand. [Sanasuttipun, Wichai] Nakhon Phanom Prov Hlth Off, Nakhon Phanom, Thailand. [Laosirithavorn, Yongjua] Minist Publ Hlth, Bur Epidemiol, Nonthaburi, Thailand. [Peret, Teresa C. T.; Erdman, Dean D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Olsen, Sonja J.; Fry, Alicia M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Fry, AM (reprint author), Ctr Dis Control & Prevent, MS-A-32,1600 Clifton Rd, Atlanta, GA 30333 USA. EM afry@cdc.gov FU Center for Disease Control and Prevention FX We thank Dr Ryan Dare (CDC) for his assistance. This study was funded by the Center for Disease Control and Prevention. NR 25 TC 6 Z9 6 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAY PY 2013 VL 7 IS 3 BP 280 EP 285 DI 10.1111/j.1750-2659.2012.00393.x PG 6 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 131XX UT WOS:000318033100011 PM 22716273 ER PT J AU Kosasih, H Roselinda Nurhayati Klimov, A Xu, XY Lindstrom, S Mahoney, F Beckett, C Burgess, TH Blair, PJ Uyeki, TM Sedyaningsih, ER AF Kosasih, Herman Roselinda Nurhayati Klimov, Alexander Xu Xiyan Lindstrom, Stephen Mahoney, Frank Beckett, Charmagne Burgess, Timothy H. Blair, Patrick J. Uyeki, Timothy M. Sedyaningsih, Endang R. TI Surveillance of Influenza in Indonesia, 20032007 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Indonesia; influenza; surveillance ID VIRUS; EPIDEMIOLOGY; H5N1; INFECTION; THAILAND AB Background Longitudinal data are limited about the circulating strains of influenza viruses and their public health impact in Indonesia. We conducted influenza surveillance among outpatients and hospitalized patients with influenza-like illness (ILI) across the Indonesian archipelago from 2003 through 2007. Methodology Demographic, clinical data, and respiratory specimens were collected for 4236 ILI patients tested for influenza virus infection by RT-PCR and viral culture. Principal Findings Influenza A and B viruses co-circulated year-round with seasonal peaks in influenza A virus activity during the rainy season (DecemberJanuary). During 20032007, influenza viruses were identified in 20 center dot 1% (4236/21030) of ILI patients, including 20 center dot 1% (4015/20012) of outpatients, and 21 center dot 7% (221/1018) of inpatients. One H5N1 case was identified retrospectively in an outpatient with ILI. Antigenic drift in circulating influenza A and B virus strains was detected during the surveillance period in Indonesia. In a few instances, antigenically drifted viruses similar to the World Health Organization (WHO) vaccine strains were detected earlier than the date of their designation by WHO. Conclusions Influenza A and B virus infections are an important cause of influenza-like illness among outpatients and hospitalized patients in Indonesia. While year-round circulation of influenza viruses occurs, prevention and control strategies should be focused upon the seasonal peak during rainy season months. Ongoing virologic surveillance and influenza disease burden studies in Indonesia are important priorities to better understand the public health impact of influenza in South-East Asia and the implications of influenza viral evolution and global spread. C1 [Kosasih, Herman; Roselinda; Sedyaningsih, Endang R.] Minist Hlth, Jakarta, Indonesia. [Kosasih, Herman; Nurhayati; Blair, Patrick J.] US Naval Med Res Unit NAMRU, Jakarta, Indonesia. [Klimov, Alexander; Xu Xiyan; Lindstrom, Stephen; Uyeki, Timothy M.] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Mahoney, Frank] US Ctr Dis Control & Prevent, Jakarta, Indonesia. [Beckett, Charmagne] USN, Med Res Ctr, Silver Spring, MD USA. [Burgess, Timothy H.] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA. RP Uyeki, TM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Mailstop A-20,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM tuyeki@cdc.gov FU U.S. Department of Defense Armed Forces Health Surveillance Center, Division of Global Emerging Infections Surveillance (AFHSC/GEIS); U.S. Centers for Disease Control and Prevention (CDC) FX The author(s) declare that they have no conflict of interest. This work was funded in part by grants from the U.S. Department of Defense Armed Forces Health Surveillance Center, Division of Global Emerging Infections Surveillance (AFHSC/GEIS) and the U.S. Centers for Disease Control and Prevention (CDC). The views expressed are those of the authors and do not necessarily represent the official policies of the CDC, the U.S. Department of Defense or the Department of the Navy. NR 29 TC 10 Z9 10 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAY PY 2013 VL 7 IS 3 BP 312 EP 320 DI 10.1111/j.1750-2659.2012.00403.x PG 9 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 131XX UT WOS:000318033100015 PM 22804910 ER PT J AU Gupta, V Dawood, FS Rai, SK Broor, S Wigh, R Mishra, AC Lafond, K Mott, JA Widdowson, MA Lal, RB Krishnan, A AF Gupta, Vivek Dawood, Fatimah S. Rai, Sanjay K. Broor, Shobha Wigh, Rajan Mishra, Akhilesh C. Lafond, Kathryn Mott, Joshua A. Widdowson, Marc-Alain Lal, Renu B. Krishnan, Anand TI Validity of clinical case definitions for influenza surveillance among hospitalized patients: results from a rural community in North India SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Case definitions; epidemiology; FARI; ILI; India; influenza; inpatients; SARI; surveillance; validity ID INFECTION; SYMPTOMS AB Objective: Clinical case definitions used for influenza surveillance among hospitalized patients vary and need systematic evaluation. Design, setting and sample: During July 2009August 2011, we collected clinical data and specimens (nasal and throat swabs) from rural patients hospitalized for acute medical illnesses. Specimens were tested by rRT-PCR for influenza viruses. Main outcome measures: Case definitions evaluated the following: influenza-like illness (ILI: measured fever plus cough or sore throat); severe acute respiratory illness (SARI: ILI with difficulty breathing in 5years, Integrated Management of Childhood Illnessdefined pneumonia or severe pneumonia, or physician diagnosed lower respiratory infection in <5years); acute respiratory infection (ARI: 1 of cough, nasal discharge, difficulty breathing or sore throat); febrile acute respiratory illness (FARI: fever plus either cough, sore throat, runny nose, difficulty breathing, or earache). Variants that included reported fever and additional signsymptom combinations were also evaluated. Results: We enrolled 1043 hospitalized patients, including 257 children <5years of age (range 1day86years). Seventy-four patients tested influenza virus positive (including 28 A(H1N1)pdm09). Sensitivity(95% CI) and specificity (95% CI) for influenza infection were 78% (6787) and 60% (5763) for ILI (measured/reported fever); 37% (2649) and 78% (7580) for SARI (measured/reported fever); 82% (7290) and 57% (5460) for FARI (measured/reported fever); 88% (7894) and 45% (4249) for ARI; and 74% (6384) and 61% (5864) for measured/reported fever plus cough. Case definitions including only measured fever had lower sensitivity. Conclusion: ILI and FARI with measured/reported fever provided good balance between sensitivity and specificity among hospitalized patients. The simpler case definition of measured/reported fever plus cough is suited for field surveillance. C1 [Gupta, Vivek] INCLEN Trust Int, AIIMS INCLEN Collaborat Influenza Projects, New Delhi, India. [Dawood, Fatimah S.; Lafond, Kathryn; Mott, Joshua A.; Widdowson, Marc-Alain; Lal, Renu B.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Rai, Sanjay K.; Broor, Shobha; Wigh, Rajan; Krishnan, Anand] All India Inst Med Sci, New Delhi 110029, India. [Mishra, Akhilesh C.] Natl Inst Virol, Pune, Maharashtra, India. RP Krishnan, A (reprint author), All India Inst Med Sci, Ctr Community Med, New Delhi 110029, India. EM anand.drk@gmail.com OI Widdowson, Marc-Alain/0000-0002-0682-6933; Gupta, Vivek/0000-0002-6157-3705; Krishnan, Anand/0000-0002-9173-7811 FU Centers for Disease Control and Prevention, Atlanta, USA [U01 IP000206] FX The authors wish to thank Dr. Anthony Mounts, Dr Mandeep Chadha, Dr Timothy Uyeki, Dr Dipanjan Sujit Roy and Dr Meenakshi Nagarkar for their support during the study. The study was supported by cooperative agreements U01 IP000206 from the Centers for Disease Control and Prevention, Atlanta, USA. NR 23 TC 5 Z9 5 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAY PY 2013 VL 7 IS 3 BP 321 EP 329 DI 10.1111/j.1750-2659.2012.00401.x PG 9 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 131XX UT WOS:000318033100016 PM 22804843 ER PT J AU Katz, J Villanueva, J Moen, A Cox, N AF Katz, Jacqueline Villanueva, Julie Moen, Ann Cox, Nancy TI Alexander (Sasha) I. Klimov, PhD, ScD (1943-2013) Obituary SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Biographical-Item C1 [Katz, Jacqueline; Villanueva, Julie; Moen, Ann; Cox, Nancy] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. RP Katz, J (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAY PY 2013 VL 7 IS 3 BP 356 EP 357 DI 10.1111/irv.12110 PG 2 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 131XX UT WOS:000318033100020 PM 23594214 ER PT J AU Santibanez, TA Singleton, JA Santibanez, SS Wortley, P Bell, BP AF Santibanez, Tammy A. Singleton, James A. Santibanez, Scott S. Wortley, Pascale Bell, Beth P. TI Socio-demographic differences in opinions about 2009 pandemic influenza A (H1N1) and seasonal influenza vaccination and disease among adults during the 20092010 influenza season SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Influenza; vaccination; adults ID 2009-JANUARY 2010; UNITED-STATES; COVERAGE; INTERVENTIONS AB Background In April 2009, a novel influenza A virus emerged in the United States. By the end of July, influenza A (H1N1) 2009 monovalent (2009 H1N1) vaccine had been developed, licensed, and recommended by the Advisory Committee on Immunization Practices. Initial target groups for vaccination were identified and the first vaccine was publicly available in early October 2009. Objective This study examines socio-demographic differences in opinions about 2009 pandemic influenza A (H1N1) (pH1N1) and seasonal influenza disease and vaccines and the association with receipt of influenza vaccinations during the 20092010 influenza season. Changes in opinions over the course of the pH1N1 pandemic were also examined. Methods Data from the 2009 National H1N1 Flu Survey (NHFS) were analyzed. The NHFS was a CDC-sponsored telephone survey initiated in response to the 2009 pH1N1 pandemic to obtain weekly within-season estimates of vaccination coverage, opinions, and other information. Results Opinions about influenza vaccine and disease varied significantly by race/ethnicity, income, and education level. In multivariable logistic regression analysis, adjusted 2009 H1N1 vaccination coverage was most strongly associated with opinions about the effectiveness of the vaccine and personal risk of disease, varying from 7 to 11% among adults who believed the vaccine to have low effectiveness and themselves at low risk of influenza, to 5053% among those who thought vaccine effectiveness to be high and themselves at high risk of influenza. Conclusion Improving communication about personal risk and the effectiveness of influenza vaccines may improve vaccination coverage. The findings of difference in opinions could be used to target communication. C1 [Santibanez, Tammy A.; Singleton, James A.; Santibanez, Scott S.; Wortley, Pascale; Bell, Beth P.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Santibanez, TA (reprint author), Ctr Dis Control & Prevent CDC, 1600 Clifton Rd NE,Mailstop A-19, Atlanta, GA 30333 USA. EM afz5@cdc.gov NR 24 TC 7 Z9 8 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAY PY 2013 VL 7 IS 3 BP 383 EP 392 DI 10.1111/j.1750-2659.2012.00374.x PG 10 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 131XX UT WOS:000318033100024 PM 22568588 ER PT J AU Looker, AC AF Looker, Anne C. TI Serum 25-Hydroxyvitamin D and Risk of Major Osteoporotic Fractures in Older U.S. Adults SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE EPIDEMIOLOGY; POPULATION STUDY; VITAMIN D; OSTEOPOROSIS; FRACTURE ID VITAMIN-D DEFICIENCY; VERTEBRAL FRACTURES; HIP FRACTURE; NONSPINE FRACTURES; US POPULATION; ELDERLY-MEN; WOMEN; HEALTH; IDENTIFICATION; ASSOCIATION AB Results from previous prospective studies linking serum 25-hydroxyvitamin D (25OHD) with fracture risk have been inconsistent. The present study examined the relationship between serum 25OHD and risk of incident major osteoporotic fracture (hip, spine, radius, and humerus) in older U.S. adults. The study used a pooled cohort of 4749 men and women ages 65 years and older from the third National Health and Nutrition Examination Survey (NHANES III, 19881994) and NHANES 20002004. Incident fractures were identified using linked mortality and Medicare records that were obtained for participants from both surveys. Serum 25OHD values were measured by radioimmunoassay in both surveys. Cox proportional hazards models were used to estimate the relative risk (RR) of fracture by serum 25OHD level. There were 525 incident major osteoporotic fractures (287 hip fractures) in the sample. Serum 25OHD was a significant linear predictor of major osteoporotic fracture and significant quadratic predictor of hip fracture in the total sample and among those with less than 10 years of follow-up, but it was not related to risk of either fracture type among those with 10 years of follow-up. Major osteoporotic fracture risk was increased by 26% to 27% for each SD decrease in serum 25OHD among those with less than 10 years of follow-up. Serum 25OHD was significantly related to risk of major osteoporotic fractures as a group and to hip fracture alone in this cohort of older U.S. adults from NHANES III and NHANES 20002004. However, the predictive utility of serum 25OHD diminished after 10 years. In addition, the relationship appeared to be linear when major osteoporotic fracture risk was considered but quadratic when hip fracture risk was assessed. (c) 2013 American Society for Bone and Mineral Research. C1 [Looker, Anne C.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Looker, AC (reprint author), Natl Ctr Hlth Stat, Room 4310,3311 Toledo Rd, Hyattsville, MD 20782 USA. EM alooker@cdc.gov NR 50 TC 22 Z9 26 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD MAY PY 2013 VL 28 IS 5 BP 997 EP 1006 DI 10.1002/jbmr.1828 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 131VF UT WOS:000318024300005 PM 23184640 ER PT J AU Weiss, LM Cushion, MT Didier, E Xiao, LH Marciano-Cabral, F Sinai, AP Matos, O Calderon, EJ Kaneshiro, ES AF Weiss, Louis M. Cushion, Melanie T. Didier, Elizabeth Xiao, Lihua Marciano-Cabral, Francine Sinai, Anthony P. Matos, Olga Calderon, Enrique J. Kaneshiro, Edna S. TI The 12th International Workshops on Opportunistic Protists (IWOP-12) SO JOURNAL OF EUKARYOTIC MICROBIOLOGY LA English DT Article DE Acanthamoeba; Blastocystis; Cryptosporidium; Giardia; Microsporidia; Pneumocystis; Toxoplasma ID CRYPTOSPORIDIUM-PARVUM; GENOME AB The 12th International Workshops on Opportunistic Protists (IWOP-12) was held in August 2012 in Tarrytown, New York. The objectives of the IWOP meetings are to: (1) serve as a forum for exchange of new information among active researchers concerning the basic biology, molecular genetics, immunology, biochemistry, pathogenesis, drug development, therapy, and epidemiology of these immunodeficiency-associated pathogenic eukaryotic microorganisms that are seen in patients with AIDS and (2) foster the entry of new and young investigators into these underserved research areas. The IWOP meeting focuses on opportunistic protists, e.g. the free-living amoebae, Pneumocystis, Cryptosporidium, Toxoplasma, the Microsporidia, and kinetoplastid flagellates. This conference represents the major conference that brings together research groups working on these opportunistic pathogens. Slow but steady progress is being achieved on understanding the biology of these pathogenic organisms, their involvement in disease causation in both immune-deficient and immune-competent hosts, and is providing critical insights into these emerging and reemerging pathogens. This IWOP meeting demonstrated the importance of newly developed genomic level information for many of these pathogens and how analysis of such large data sets is providing key insights into the basic biology of these organisms. A great concern is the loss of scientific expertise and diversity in the research community due to the ongoing decline in research funding. This loss of researchers is due to the small size of many of these research communities and a lack of appreciation by the larger scientific community concerning the state of art and challenges faced by researchers working on these organisms. C1 [Weiss, Louis M.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA. [Weiss, Louis M.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA. [Cushion, Melanie T.] Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH USA. [Cushion, Melanie T.] Vet Adm Med Ctr, Cincinnati, OH 45220 USA. [Didier, Elizabeth] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Trop Med, New Orleans, LA USA. [Xiao, Lihua] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Marciano-Cabral, Francine] Virginia Commonwealth Univ, Med Coll Virginia, Dept Microbiol & Immunol, Richmond, VA 23298 USA. [Sinai, Anthony P.] Univ Kentucky, Dept Microbiol Immunol & Mol Genet, Lexington, KY USA. [Matos, Olga] Univ Nova Lisboa, Inst Hyg & Trop Med, CMDT, Dept Med Parasitol, Lisbon, Portugal. [Calderon, Enrique J.] Virgen del Rocio Univ Hosp, Ctr Biomed Res Network Epidemiol & Publ Hlth, Dept Internal Med, Seville, Spain. [Kaneshiro, Edna S.] Univ Cincinnati, Dept Biol Sci, Cincinnati, OH 45221 USA. RP Weiss, LM (reprint author), Albert Einstein Coll Med, Dept Med, 1300 Morris Pk Ave,Room 504 Forchheimer Bldg, Bronx, NY 10461 USA. EM louis.weiss@einstein.yu.edu RI Xiao, Lihua/B-1704-2013; IBIS, EPIDEMIOLOGIA/O-8791-2015; OI Xiao, Lihua/0000-0001-8532-2727; MATOS, OLGA/0000-0001-5793-7716; Calderon, Enrique/0000-0002-3166-5086 FU National Institutes of Health [R13 AI098295-01A1]; Burroughs Welcome Fund; ATCC; Associates of Cape Cod, Inc.; Phthisis Diagnostics; Waterborne, Inc. FX IWOP-12 was supported by grants from the National Institutes of Health (R13 AI098295-01A1), Burroughs Welcome Fund, ATCC, Associates of Cape Cod, Inc., Phthisis Diagnostics, and Waterborne, Inc. We thank members of our laboratory groups for reading this manuscript. NR 7 TC 2 Z9 3 U1 0 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5234 J9 J EUKARYOT MICROBIOL JI J. Eukaryot. Microbiol. PD MAY-JUN PY 2013 VL 60 IS 3 BP 298 EP 308 DI 10.1111/jeu.12034 PG 11 WC Microbiology SC Microbiology GA 134WG UT WOS:000318245900008 PM 23560871 ER PT J AU Flax, VL Bentley, ME Chasela, CS Kayira, D Hudgens, MG Kacheche, KZ Chavula, C Kourtis, AP Jamieson, DJ van der Horst, CM Adair, LS AF Flax, Valerie L. Bentley, Margaret E. Chasela, Charles S. Kayira, Dumbani Hudgens, Michael G. Kacheche, Kopekani Z. Chavula, Charity Kourtis, Athena P. Jamieson, Denise J. van der Horst, Charles M. Adair, Linda S. TI Lipid-Based Nutrient Supplements Are Feasible As a Breastmilk Replacement for HIV-Exposed Infants from 24 to 48 Weeks of Age SO JOURNAL OF NUTRITION LA English DT Article ID UNINFECTED CHILDREN BORN; CATCH-UP GROWTH; INFECTED MOTHERS; NUTRITIONAL-STATUS; ANTIRETROVIRAL DRUGS; MALAWIAN CHILDREN; RURAL MALAWI; COTE-DIVOIRE; TRANSMISSION; PREDICTORS AB The Breastfeeding, Antiretrovirals, and Nutrition (BAN) Study randomized HIV-infected mothers and their infants to receive either maternal lipid-based nutrient supplements (LNS) during lactation or no LNS and then to 1 of 3 antiretroviral drug (ARV) arms (maternal, infant, or no drugs). Assigned interventions were provided from 0 to 28 wk and all infants (n = 16191 were given LNS during (24-28 wk) and following (28-48 wk) weaning. This paper assesses the feasibility of infant LNS as a breastmilk replacement and uses longitudinal random effects models to examine associations of interventions, morbidity, and season with weight-for-age (WAZ), length-for-age (LAZ), and BMI-for-age (BMIZ) Z-scores from 24 to 48 wk. Infant LNS adherence was high (94.1% ate it daily). From 24 to 48 wk, mean WAZ (-0.42 to 0.76 SD; P< 0.001) and LAZ (-0.93 to -1.56 SD; P < 0.001) steadily declined, whereas BM IZ remained >0 throughout. A higher LAZ was associated with assignment to the maternal LNS arm (beta=0.19; P < 0.05). Lower WAZ and BM IZ were associated with seasonal food insecurity (beta=-0.08 and 0.09, respectively; both P < 0.001), fever (beta=-0.07 and 0.13; both P < 0.001), diarrhea (beta=-0.19 and 0.23; both P < 0.001), and assignment to the infant ARV arm (beta=-0.17 and 0.17; both P< 0.05). The magnitude of the season and morbidity effects was small and BAN infants had higher weights and lengths than their counterparts in the general population. High LNS adherence and the modest impact of morbidity on growth indicate that LNS is a feasible breastmilk replacement for HIV-exposed infants weaned early, but controlled trials are needed tdguantify the effects of LNS on growth in this population. J. Nutr. 143: 701-707, 2013. C1 [Flax, Valerie L.; Bentley, Margaret E.; Adair, Linda S.] Univ N Carolina, Carolina Populat Ctr, Sch Med, Chapel Hill, NC 27515 USA. [Flax, Valerie L.; Bentley, Margaret E.; Adair, Linda S.] Univ N Carolina, Sch Med, Dept Nutr, Chapel Hill, NC USA. [Hudgens, Michael G.] Univ N Carolina, Dept Biostat, Sch Med, Chapel Hill, NC USA. [van der Horst, Charles M.] Univ N Carolina, Div Infect Dis, Sch Med, Chapel Hill, NC USA. [Chasela, Charles S.; Kayira, Dumbani; Kacheche, Kopekani Z.; Chavula, Charity] UNC Project, Lilongwe, Malawi. [Chasela, Charles S.] Univ Witwatersrand, Div Epidemiol & Biostat, Sch Publ Hlth, Parktown, South Africa. [Kourtis, Athena P.; Jamieson, Denise J.] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Flax, VL (reprint author), Univ N Carolina, Carolina Populat Ctr, Sch Med, Chapel Hill, NC 27515 USA. EM flax@unc.edu OI Flax, Valerie/0000-0003-0200-3355 FU Prevention Research Centers Special Interest Project of the CDC [SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, 22-09 U48-DP001944-011]; Bill and Melinda Gates Foundation [0PP53107]; National Institute of Allergy and Infectious Diseases; University of North Carolina Center for AIDS Research [P30-A150410]; NIH Fogarty AIDS International Training and Research Program [DHHS/NIH/FIC 2-D43 Tw01039-06, R24 Tw00798] FX The Breastfeeding, Antretrovirals, and Nutrition Study was supported by grants from the Prevention Research Centers Special Interest Project of the CDC (SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, and SIP 22-09 U48-DP001944-011, the Bill and Melinda Gates Foundation (0PP53107), the National Institute of Allergy and Infectious Diseases, the University of North Carolina Center for AIDS Research (P30-A150410), and the NIH Fogarty AIDS International Training and Research Program (DHHS/NIH/FIC 2-D43 Tw01039-06 and R24 Tw00798; the American Recovery and Reinvestment Act) The antiretrovirals used in the BAN study were donated by Abbott Laboratories, GlaxoSmithKline, Boehringeringelheim, Roche Pharmaceuticals, and Bristol-Myers Squibb. The Call to Action PMTCT program was supported by the Elizabeth Glaser Pediatric AIDS Foundation, UNICEF, the World Food Program, the Malawi Ministry of Health and Population, Johnson and Johnson, and the U.S. Agency for International Development. NR 49 TC 2 Z9 2 U1 0 U2 6 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD MAY PY 2013 VL 143 IS 5 BP 701 EP 707 DI 10.3945/jn.112.168245 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 132GU UT WOS:000318056700020 PM 23468553 ER PT J AU LeBouf, RF Slaven, JE Coffey, CC AF LeBouf, Ryan F. Slaven, James E. Coffey, Christopher C. TI Effect of calibration environment on the performance of direct-reading organic vapor monitors SO JOURNAL OF THE AIR & WASTE MANAGEMENT ASSOCIATION LA English DT Article ID PHOTOIONIZATION DETECTORS; EXPOSURE AB The performance of two direct-reading organic vapor monitors (monitors) when calibrated at different environmental conditions was compared with charcoal tube results. Three MIRAN SapphIRe portable ambient air analyzers (SAP) and three Century portable toxic vapor analyzers (TVAs) were evaluated. Prior to sampling, the monitors were calibrated per the manufacturer's instructions using methane for the TVA flame ionization detector (FID) and isobutylene for the photoionization detector (PID), whereas the SapphIRe instruments were zeroed and the instrument's manufacturer-supplied library was used. For the first series of tests (Part 1Same condition), the monitors were calibrated under the same environmental conditions as those present during sampling. They were then challenged with four cyclohexane concentrations (30, 150, 300, and 475 ppm) under two extreme environmental conditions: 5 degrees C and 30% relative humidity (RH) (same/cold) and 38 degrees C and 90% RH (same/hot). For the second series of tests (Part 2Different condition), the monitors were calibrated at approximately normal indoor environmental conditions (21 degrees C and 50% RH) and sampled at extreme environmental conditions (different/cold and different/hot). The monitor readings from the two methods were compared with the actual cyclohexane concentration determined from charcoal tubes using ratios and root mean square errors. A number of monitor failures, both below detection limit values in the presence of a known challenge concentration and erroneously high measurements, occurred in each part: same condition 20.7% (149/720) and different condition 42.4% (305/720), with a majority of the failures (>78%) during the hot and humid conditions. All monitors performed best at the same/cold, followed by the same/hot, in terms of closeness to the reference standard method and low within-monitor variability. The ranked choice of monitors for same/cold is PID > SAP > FID; for different/cold FID > PID > SAP; for same/hot SAP > PID > FID; and for different/hot PID > SAP (FID not included due to 100% failure rate). Implications: Direct-reading organic vapor monitors are used for assessing the concentrations of volatile organic compounds in the air at varying environmental conditions. Typical calibration is performed at laboratory temperature and pressure. The monitors may be used in atmospheres that differ from that during calibration. An understanding of the effect of calibration environment on monitor performance may provide valuable information on the reliability and appropriateness of certain monitor types for industrial hygienists, emergency responders, and exposure assessment practitioners. Results of the study indicate monitor calibration should be performed at the same environmental conditions as sampling. C1 [LeBouf, Ryan F.; Coffey, Christopher C.] NIOSH, Dept Hlth & Human Serv, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Slaven, James E.] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN USA. [Coffey, Christopher C.] NIOSH, Off Director, Natl Personal Protect Technol Lab, Morgantown, WV 26505 USA. RP LeBouf, RF (reprint author), NIOSH, Dept Hlth & Human Serv, Ctr Dis Control & Prevent, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM rlebouf@cdc.gov FU National Institute for Occupational Safety and Health FX This work was supported by the National Institute for Occupational Safety and Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. Mention of commercial product or trade name does not constitute endorsement by the Centers for Disease Control and Prevention/National Institute for Occupational Safety and Health. NR 12 TC 1 Z9 1 U1 2 U2 14 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1096-2247 J9 J AIR WASTE MANAGE JI J. Air Waste Manage. Assoc. PD MAY 1 PY 2013 VL 63 IS 5 BP 528 EP 533 DI 10.1080/10962247.2013.772926 PG 6 WC Engineering, Environmental; Environmental Sciences; Meteorology & Atmospheric Sciences SC Engineering; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences GA 133OU UT WOS:000318148900004 PM 23786144 ER PT J AU Belser, JA Davis, CT Balish, A Edwards, LE Zeng, H Maines, TR Gustin, KM Martinez, IL Fasce, R Cox, NJ Katz, JM Tumpey, TM AF Belser, Jessica A. Davis, C. Todd Balish, Amanda Edwards, Lindsay E. Zeng, Hui Maines, Taronna R. Gustin, Kortney M. Lopez Martinez, Irma Fasce, Rodrigo Cox, Nancy J. Katz, Jacqueline M. Tumpey, Terrence M. TI Pathogenesis, Transmissibility, and Ocular Tropism of a Highly Pathogenic Avian Influenza A (H7N3) Virus Associated with Human Conjunctivitis SO JOURNAL OF VIROLOGY LA English DT Article ID H5N1 VIRUSES; BRITISH-COLUMBIA; MOUSE MODEL; RECEPTOR SPECIFICITY; HEMAGGLUTININ GENE; LETHAL INFECTION; HOST RESPONSES; FERRETS; MICE; VACCINE AB H7 subtype influenza A viruses, responsible for numerous outbreaks in land-based poultry in Europe and the Americas, have caused over 100 cases of confirmed or presumed human infection over the last decade. The emergence of a highly pathogenic avian influenza H7N3 virus in poultry throughout the state of Jalisco, Mexico, resulting in two cases of human infection, prompted us to examine the virulence of this virus (A/Mexico/InDRE7218/2012 [MX/7218]) and related avian H7 subtype viruses in mouse and ferret models. Several high- and low-pathogenicity H7N3 and H7N9 viruses replicated efficiently in the respiratory tract of mice without prior adaptation following intranasal inoculation, but only MX/7218 virus caused lethal disease in this species. H7N3 and H7N9 viruses were also detected in the mouse eye following ocular inoculation. Virus from both H7N3 and H7N9 subtypes replicated efficiently in the upper and lower respiratory tracts of ferrets; however, only MX/7218 virus infection caused clinical signs and symptoms and was capable of transmission to naive ferrets in a direct-contact model. Similar to other highly pathogenic H7 viruses, MX/7218 replicated to high titers in human bronchial epithelial cells, yet it downregulated numerous genes related to NF-kappa B-mediated signaling transduction. These findings indicate that the recently isolated North American lineage H7 subtype virus associated with human conjunctivitis is capable of causing severe disease in mice and spreading to naive-contact ferrets, while concurrently retaining the ability to replicate within ocular tissue and allowing the eye to serve as a portal of entry. C1 [Belser, Jessica A.; Davis, C. Todd; Balish, Amanda; Edwards, Lindsay E.; Zeng, Hui; Maines, Taronna R.; Gustin, Kortney M.; Cox, Nancy J.; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. [Lopez Martinez, Irma] Inst Diagnost & Referencia Epidemiol, Mexico City, DF, Mexico. [Fasce, Rodrigo] Inst Salud Publ Chile, Secc Virus Resp & Exantemat, Santiago, Chile. RP Tumpey, TM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. EM tft9@cdc.gov NR 57 TC 35 Z9 38 U1 0 U2 25 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD MAY PY 2013 VL 87 IS 10 BP 5746 EP 5754 DI 10.1128/JVI.00154-13 PG 9 WC Virology SC Virology GA 133QT UT WOS:000318155000037 PM 23487452 ER PT J AU Shankar, RK Pihoker, C Dolan, LM Standiford, D Badaru, A Dabelea, D Rodriguez, B Black, MH Imperatore, G Hattersley, A Ellard, S Gilliam, LK AF Shankar, Roopa Kanakatti Pihoker, Catherine Dolan, Lawrence M. Standiford, Debra Badaru, Angela Dabelea, Dana Rodriguez, Beatriz Black, Mary Helen Imperatore, Giuseppina Hattersley, Andrew Ellard, Sian Gilliam, Lisa K. CA Search Diabet Youth Study Grp TI Permanent neonatal diabetes mellitus: prevalence and genetic diagnosis in the SEARCH for Diabetes in Youth Study SO PEDIATRIC DIABETES LA English DT Article DE ABCC8; infant; INS; KCNJ11; neonatal diabetes ID K-ATP CHANNEL; ACTIVATING MUTATIONS; SULFONYLUREA THERAPY; DEVELOPMENTAL DELAY; ORAL SULFONYLUREAS; KIR6.2 KCNJ11; UNITED-STATES; COMMON-CAUSE; INSULIN; ABCC8 AB Background Neonatal diabetes mellitus (NDM) is defined as diabetes with onset before 6months of age. Nearly half of individuals with NDM are affected by permanent neonatal diabetes mellitus (PNDM). Mutations in KATP channel genes (KCNJ11, ABCC8) and the insulin gene (INS) are the most common causes of PNDM. Objective To estimate the prevalence of PNDM among SEARCH for Diabetes in Youth (SEARCH) study participants (20012008) and to identify the genetic mutations causing PNDM. Methods SEARCH is a multicenter population-based study of diabetes in youth <20yr of age. Participants diagnosed with diabetes before 6months of age were invited for genetic testing for mutations in the KCNJ11, ABCC8, and INS genes. Results Of the 15,829 SEARCH participants with diabetes, 39 were diagnosed before 6months of age. Thirty-five of them had PNDM (0.22% of all diabetes cases in SEARCH), 3 had transient neonatal diabetes that had remitted by 18months and 1 was unknown. The majority of them (66.7%) had a clinical diagnosis of type1 diabetes by their health care provider. Population prevalence of PNDM in youth <20yr was estimated at 1 in 252000. Seven participants underwent genetic testing; mutations causing PNDM were identified in five (71%), (two KCNJ11, three INS). Conclusions We report the first population-based frequency of PNDM in the US based on the frequency of PNDM in SEARCH. Patients with NDM are often misclassified as having type1 diabetes. Widespread education is essential to encourage appropriate genetic testing and treatment of NDM. C1 [Shankar, Roopa Kanakatti; Dolan, Lawrence M.; Standiford, Debra] Cincinnati Childrens Hosp Med Ctr, Div Endocrinol, Cincinnati, OH 45229 USA. [Pihoker, Catherine; Badaru, Angela] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Dabelea, Dana] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Denver, CO 80202 USA. [Rodriguez, Beatriz] Kuakini Med Ctr, Honolulu, HI USA. [Black, Mary Helen] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA. [Imperatore, Giuseppina] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Hattersley, Andrew; Ellard, Sian] Univ Exeter, Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter, Devon, England. [Gilliam, Lisa K.] Univ Washington, Dept Med, Seattle, WA USA. RP Shankar, RK (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Endocrinol, MLC 7012,3333 Burnet Ave, Cincinnati, OH 45229 USA. EM roopakshankar@gmail.com OI Hattersley, Andrew/0000-0001-5620-473X FU Centers for Disease Control and Prevention [00097, DP-05-069, DP-10-001]; National Institute of Diabetes and Digestive and Kidney Diseases; Juvenile Diabetes Research Foundation [JDRF 9-2007-1700]; European Union from FP7 integrated project CEED3; European Union from Madam Curie initial funding network BOLD; Peninsula NIHR Clinical Research Facility; Kaiser Permanente Southern California [U48/CCU919219, U01 DP000246, U18DP002714]; University of Colorado, Denver [U48/CCU819241-3, U01 DP000247, U18DP000247-06A1]; Kuakini Medical Center [U58CCU919256, U01 DP000245]; Children's Hospital Medical Center Cincinnati [U48/CCU519239, U01 DP000248, 1U18DP002709]; University of North Carolina at Chapel Hill [U48/CCU419249, U01 DP000254, U18DP002708-01]; University of Washington School of Medicine [U58/CCU019235-4, U01 DP000244, U18DP002710-01]; Wake Forest University School of Medicine [U48/CCU919219, U01 DP000250, 200-2010-35171]; NIH/NCRR [UL1RR029882]; Children's Hospital and Regional Medical Center [M01RR00037]; Colorado Pediatric General Clinical Research Center [M01 RR00069]; Barbara Davis Center at the University of Colorado at Denver [DERC NIH P30 DK57516]; Institutional Clinical and Translational Science Award (CTSA), NIH/NCRR at the University of Cincinnati [1UL1RR026314-01] FX Grant Support: SEARCH for Diabetes in Youth is funded by the Centers for Disease Control and Prevention (PA numbers 00097, DP-05-069, and DP-10-001) and supported by the National Institute of Diabetes and Digestive and Kidney Diseases. The Monogenic Diabetes ancillary study was supported by funding from the Juvenile Diabetes Research Foundation (JDRF 9-2007-1700). Staff in Exeter were funded by the European Union funding from FP7 integrated project CEED3 and Madam Curie initial funding network BOLD and the Peninsula NIHR Clinical Research Facility.; Site Contract Numbers: Kaiser Permanente Southern California (U48/CCU919219, U01 DP000246, and U18DP002714), University of Colorado, Denver (U48/CCU819241-3, U01 DP000247, and U18DP000247-06A1), Kuakini Medical Center (U58CCU919256 and U01 DP000245), Children's Hospital Medical Center Cincinnati, (U48/CCU519239, U01 DP000248, and 1U18DP002709), University of North Carolina at Chapel Hill (U48/CCU419249, U01 DP000254, and U18DP002708-01), University of Washington School of Medicine (U58/CCU019235-4, U01 DP000244, and U18DP002710-01), Wake Forest University School of Medicine (U48/CCU919219, U01 DP000250, and 200-2010-35171).; The authors wish to acknowledge the involvement of General Clinical Research Centers (GCRC) at the South Carolina Clinical & Translational Research (SCTR) Institute, at the Medical University of South Carolina (NIH/NCRR Grant number UL1RR029882); Children's Hospital and Regional Medical Center (Grant Number M01RR00037); Colorado Pediatric General Clinical Research Center (Grant Number M01 RR00069) and the Barbara Davis Center at the University of Colorado at Denver (DERC NIH P30 DK57516); and the Institutional Clinical and Translational Science Award (CTSA), NIH/NCRR at the University of Cincinnati (Grant Number 1UL1RR026314-01). NR 27 TC 17 Z9 17 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1399-543X J9 PEDIATR DIABETES JI Pediatr. Diabetes PD MAY PY 2013 VL 14 IS 3 BP 174 EP 180 DI 10.1111/pedi.12003 PG 7 WC Endocrinology & Metabolism; Pediatrics SC Endocrinology & Metabolism; Pediatrics GA 133DY UT WOS:000318118800004 ER PT J AU Knoeller, GE Mazurek, JM Moorman, JE AF Knoeller, Gretchen E. Mazurek, Jacek M. Moorman, Jeanne E. TI Health-related quality of life among adults with work-related asthma in the United States SO QUALITY OF LIFE RESEARCH LA English DT Article DE Occupational asthma; Quality of life; Occupational health; Behavioral Risk Factor Surveillance System; Asthma ID FACTOR SURVEILLANCE SYSTEM; SELF-RATED HEALTH; CALL-BACK-SURVEY; CARE UTILIZATION; OCCUPATIONAL ASTHMA; RISK-FACTORS; MORTALITY; RELIABILITY; PREVALENCE; SEVERITY AB The objective of this study was to examine health-related quality of life among adults with work-related asthma. We analyzed 2006-2009 Behavioral Risk Factor Surveillance System Asthma Call-back Survey data for ever-employed adults with current asthma from 38 states and District of Columbia. Individuals with work-related asthma had been told by a doctor or other health professional that their asthma was related to any job they ever had. Health-related quality of life indicators included poor self-rated health, impaired physical health, impaired mental health, and activity limitation. We calculated prevalence ratios (PRs) adjusted for age, sex, race/ethnicity, education, income, employment, and health insurance. Of ever-employed adults with current asthma, an estimated 9.0 % had work-related asthma, 26.9 % had poor self-rated health, 20.6 % had impaired physical health, 18.2 % had impaired mental health, and 10.2 % had activity limitation. Individuals with work-related asthma were significantly more likely than those with non-work-related asthma to have poor self-rated health [PR, 1.45; 95 % confidence interval (CI), 1.31-1.60], impaired physical health (PR, 1.60; 95 % CI, 1.42-1.80), impaired mental health (PR, 1.55; 95 % CI, 1.34-1.80), and activity limitation (PR, 2.16; 95 % CI, 1.81-2.56). Future research should examine opportunities to improve health-related quality of life among individuals with work-related asthma. C1 [Knoeller, Gretchen E.; Mazurek, Jacek M.] Ctr Dis Control & Prevent CDC, Natl Inst Occupat Safety & Hlth, Morgantown, WV 26505 USA. [Moorman, Jeanne E.] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Knoeller, GE (reprint author), Ctr Dis Control & Prevent CDC, Natl Inst Occupat Safety & Hlth, 1095 Willowdale Rd,MS HG 900, Morgantown, WV 26505 USA. EM ipb8@cdc.gov FU Intramural CDC HHS [CC999999] NR 48 TC 11 Z9 11 U1 1 U2 7 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 J9 QUAL LIFE RES JI Qual. Life Res. PD MAY PY 2013 VL 22 IS 4 BP 771 EP 780 DI 10.1007/s11136-012-0206-7 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 135TI UT WOS:000318311000009 PM 22661107 ER PT J AU Steiner, AZ Long, DL Herring, AH Kesner, JS Meadows, JW Baird, DD AF Steiner, Anne Z. Long, D. Leann Herring, Amy H. Kesner, James S. Meadows, Juliana W. Baird, Donna D. TI Urinary Follicle-Stimulating Hormone as a Measure of Natural Fertility in a Community Cohort SO REPRODUCTIVE SCIENCES LA English DT Article DE fecundability; fertility; follicle-stimulating hormone; ovarian reserve; urine ID IN-VITRO FERTILIZATION; MENSTRUAL-CYCLE; OVARIAN RESERVE; LUTEINIZING-HORMONE; OVULATORY WOMEN; BASAL; TIME; CONCEPTION; PREGNANCY; FSH AB High serum follicle-stimulating hormone (FSH) levels have been associated with diminished ovarian reserve; however, the association between high urinary FSH and reduced natural fertility has yet to be established. We sought to characterize the relationship between a single or multiple measurements of early follicular phase urinary FSH and fertility. Women (n = 209), 30 to 44 years old with no history of infertility, who had been trying to conceive for less than 3 months, provided early follicular phase urine. Participants subsequently kept a diary to record bleeding and intercourse and conducted standardized pregnancy testing for up to 6 months. A subset of women (N = 95) collected urine on cycle day 3 for up to 6 cycles. Urine was analyzed for FSH and creatinine (cr) corrected. Proportional hazard models were used to calculate fecundability ratios (FRs). Urinary FSH levels across cycles from the same woman were highly correlated (adjusted intraclass correlation - .77); within-woman variance was 3-fold lower than variance among women. Women with an initial urinary FSH level <7 mIU/mg cr exhibited a nonsignificant reduction in the probability of pregnancy (adjusted FR 0.71, 95% confidence interval [CI]: 0.45-1.13), as did women with elevated urinary FSH (>= 12 mIU/mg cr; adjusted FR 0.78, 95% CI: 0.46-1.32). Using the most recent or maximum urinary FSH value did not strengthen the association. In the general population, urinary FSH levels appear to be nonlinearly associated with fertility; however, broad CIs indicate a lack of statistical significance. Repetitive testing appears to be of little benefit. C1 [Steiner, Anne Z.] Univ N Carolina, Dept Obstet & Gynecol, Chapel Hill, NC 27599 USA. [Long, D. Leann; Herring, Amy H.] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA. [Herring, Amy H.] Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC 27599 USA. [Kesner, James S.; Meadows, Juliana W.] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. [Baird, Donna D.] NIEHS, Epidemiol Branch, NIH, Res Triangle Pk, NC 27709 USA. RP Steiner, AZ (reprint author), Univ N Carolina, Dept Obstet & Gynecol, CB 7570,4001 Old Clin Bldg, Chapel Hill, NC 27599 USA. EM asteiner@med.unc.edu RI Baird, Donna/D-5214-2017 OI Baird, Donna/0000-0002-5544-2653 FU NIH, National Institute of Environmental Health Sciences; NICHD/NIH [R21HD060229, K12HD050113]; NIEHS/NIH [T32ES007018] FX Drs Allen Wilcox and Carmen Williams provided helpful comments on an earlier draft of this manuscript. This research was supported in part by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (ie, support for coauthor D.B.).; The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the NICHD/NIH (grant number R21HD060229 and K12HD050113 [UNC WRHR]) and NIEHS/NIH (grant number T32ES007018). NR 37 TC 4 Z9 4 U1 0 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1933-7191 EI 1933-7205 J9 REPROD SCI JI Reprod. Sci. PD MAY PY 2013 VL 20 IS 5 BP 549 EP 556 DI 10.1177/1933719112459226 PG 8 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 131KF UT WOS:000317991200007 PM 23171685 ER PT J AU Kington, RS AF Kington, Raynard S. TI On Being an "African American Scientist" SO SCIENTIST LA English DT Editorial Material C1 [Kington, Raynard S.] Grinnell Coll, Grinnell, IA 50112 USA. [Kington, Raynard S.] Natl Inst Hlth, Bethesda, MD 20892 USA. [Kington, Raynard S.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Kington, RS (reprint author), Grinnell Coll, Grinnell, IA 50112 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SCIENTIST INC PI PHILADELPHIA PA 400 MARKET ST, STE 1250, PHILADELPHIA, PA 19106 USA SN 0890-3670 J9 SCIENTIST JI Scientist PD MAY PY 2013 VL 27 IS 5 BP 28 EP 28 PG 1 WC Information Science & Library Science; Multidisciplinary Sciences SC Information Science & Library Science; Science & Technology - Other Topics GA 135VO UT WOS:000318319000007 ER PT J AU Elliott, I Jerome, A Angwafor, SA Smith, ML Takougang, I Noh, J Tsang, V Wilkins, P Cockburn, L Keystone, J Njamnshi, AK Snead, OC AF Elliott, Irene Jerome, Ambanibe Angwafor, Samuel A. Smith, Mary Lou Takougang, Innocent Noh, John Tsang, Victor Wilkins, Patricia Cockburn, Lynn Keystone, Jay Njamnshi, Alfred K. Snead, O. Carter, III TI Epilepsy and cysticercosis in North-West Cameroon: A serological study SO SEIZURE-EUROPEAN JOURNAL OF EPILEPSY LA English DT Article DE Taenia solium; Seropositivity; Seizures; Epilepsy; Cysticercosis; Case-control; Africa; Cameroon ID SOLIUM CYSTICERCOSIS; TAENIA-SOLIUM; NEUROCYSTICERCOSIS; TOXOCARIASIS; SEIZURES; BURUNDI; AFRICA AB Purpose: The prevalence of epilepsy in Cameroon is higher than that of the industrialized world and other developing countries. Neurocysticercosis due to Taenia solium infestation has been reported as a major cause of epilepsy in some parts of Cameroon although there are some conflicting data. The prevalence of epilepsy is especially high in the Momo division of the North-West Province of Cameroon. We hypothesized that individuals with epilepsy in this region have a higher percentage of seropositivity to T. solium than matched controls. Methods: We conducted a case-control study in the Momo subdivision of Ngie. Individuals with epilepsy were recruited from the health centers in Ngie. Control subjects were selected from 19 Ngie villages. Potential cases of people with epilepsy (PWE) were identified through a questionnaire applied by trained field workers, using history of epileptic seizures as a key indicator. Blood samples were taken from all consenting individuals by finger prick, stored in StabilZyme Select, and assayed for antibodies to T. solium in an Atlanta based reference laboratory. Results: We accrued 249 patients with epilepsy, of whom 237 met the inclusion criteria, and 245 age-matched controls. There was no significant difference in seropositivity to T. solium between those individuals with epilepsy (5%) and controls (4.9%). Conclusions: Our data do not support the hypothesis that epilepsy is associated with seropositivity to T. solium. It is highly unlikely that cysticercosis plays a causative role in the high prevalence of epilepsy in this region of Cameroon. (C) 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. C1 [Elliott, Irene; Smith, Mary Lou; Snead, O. Carter, III] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Jerome, Ambanibe] Assoc Orphans & Disabled, Teze, Cameroon. [Angwafor, Samuel A.] Cent Hosp Yaounde, Batibo, Cameroon. [Angwafor, Samuel A.] Batibo Dist Hosp, Batibo, Cameroon. [Smith, Mary Lou; Cockburn, Lynn; Keystone, Jay; Snead, O. Carter, III] Univ Toronto, Toronto, ON, Canada. [Takougang, Innocent] Dept Publ Hlth, Yaounde, Cameroon. [Noh, John; Tsang, Victor; Wilkins, Patricia] Ctr Dis Control & Prevent, Atlanta, GA USA. [Njamnshi, Alfred K.] Minist Publ Hlth, Yaounde, Cameroon. RP Snead, OC (reprint author), Hosp Sick Children, Div Neurol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada. EM carter.snead@sickkids.ca FU The Bloorview Children's Hospital Foundation, Toronto, Ontario, Canada FX This study was supported by funding from The Bloorview Children's Hospital Foundation, Toronto, Ontario, Canada. None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. NR 22 TC 4 Z9 5 U1 0 U2 7 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1059-1311 J9 SEIZURE-EUR J EPILEP JI Seizure PD MAY PY 2013 VL 22 IS 4 BP 283 EP 286 DI 10.1016/j.seizure.2013.01.012 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 132GX UT WOS:000318057000006 PM 23428421 ER PT J AU Avila-Tang, E Al-Delaimy, WK Ashley, DL Benowitz, N Bernert, JT Kim, S Samet, JM Hecht, SS AF Avila-Tang, Erika Al-Delaimy, Wael K. Ashley, David L. Benowitz, Neal Bernert, John T. Kim, Sungroul Samet, Jonathan M. Hecht, Stephen S. TI Assessing secondhand smoke using biological markers SO TOBACCO CONTROL LA English DT Review ID ENVIRONMENTAL TOBACCO-SMOKE; CORONARY-HEART-DISEASE; LUNG CARCINOGEN 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; TANDEM MASS-SPECTROMETRY; TOENAIL NICOTINE LEVELS; PASSIVE SMOKING; LIQUID-CHROMATOGRAPHY; NONSMOKING WOMEN; SERUM COTININE; CIGARETTE SMOKERS AB Secondhand smoke exposure (SHSe) is a known cause of many adverse health effects in adults and children. Increasingly, SHSe assessment is an element of tobacco control research and implementation worldwide. In spite of decades of development of approaches to assess SHSe, there are still unresolved methodological issues; therefore, a multidisciplinary expert meeting was held to catalogue the approaches to assess SHSe and with the goal of providing a set of uniform methods for future use by investigators and thereby facilitate comparisons of findings across studies. The meeting, held at Johns Hopkins, in Baltimore, Maryland, USA, was supported by the Flight Attendant Medical Research Institute (FAMRI). A series of articles were developed to summarise what is known about self-reported, environmental and biological SHSe measurements. Non-smokers inhale toxicants in SHS, which are mainly products of combustion of organic materials and are not specific to tobacco smoke exposure. Biomarkers specific to SHSe are nicotine and its metabolites (eg, cotinine), and metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Cotinine is the preferred blood, saliva and urine biomarker for SHSe. Cotinine and nicotine can also be measured in hair and toenails. NNAL (4-[methylnitrosamino]-1-[3-pyridyl]-1-butanol), a metabolite of NNK, can be determined in the urine of SHS-exposed non-smokers. The selection of a particular biomarker of SHSe and the analytic biological medium depends on the scientific or public health question of interest, study design and setting, subjects, and funding. This manuscript summarises the scientific evidence on the use of biomarkers to measure SHSe, analytical methods, biological matrices and their interpretation. C1 [Avila-Tang, Erika] Johns Hopkins Bloomberg Sch Publ Hlth, Inst Global Tobacco Control, Dept Epidemiol, Baltimore, MD 21205 USA. [Al-Delaimy, Wael K.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. [Ashley, David L.; Bernert, John T.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Benowitz, Neal] Univ Calif San Francisco, Dept Med, Div Clin Pharmacol, San Francisco, CA USA. [Benowitz, Neal] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA. [Kim, Sungroul] Soonchunhyang Univ, Dept Environm Hlth Sci, Asan, South Korea. [Samet, Jonathan M.] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA. [Hecht, Stephen S.] Univ Minnesota, Ctr Canc, Minneapolis, MN USA. RP Avila-Tang, E (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Inst Global Tobacco Control, 2213 McElderry St,4th Floor, Baltimore, MD 21205 USA. EM etang@jhsph.edu OI Hecht, Stephen/0000-0001-7228-1356 FU Flight Attendant Medical Research Institute's grant for the Centers of Excellence at Johns Hopkins; University of California, San Francisco Bland Lane; American Academy of Pediatrics Julius B Richmond FX This work was supported by the Flight Attendant Medical Research Institute's grant for the Centers of Excellence at Johns Hopkins; the University of California, San Francisco Bland Lane; and the American Academy of Pediatrics Julius B Richmond. The funding organisation had no role in the preparation of the manuscripts. NR 95 TC 58 Z9 61 U1 1 U2 57 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0964-4563 EI 1468-3318 J9 TOB CONTROL JI Tob. Control PD MAY PY 2013 VL 22 IS 3 BP 164 EP 171 DI 10.1136/tobaccocontrol-2011-050298 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 126DC UT WOS:000317590900006 PM 22940677 ER PT J AU Millen, K Kugeler, KJ Hinckley, AF Lawaczeck, EW Mead, PS AF Millen, Katharine Kugeler, Kiersten J. Hinckley, Alison F. Lawaczeck, Elisabeth W. Mead, Paul S. TI Elevated Lyme Disease Seroprevalence Among Dogs in a Nonendemic County: Harbinger or Artifact? SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Lyme disease; Borrelia burgdorferi; Seroprevalence; Nonendemic area ID STATES AB Lyme disease, a tick-borne illness caused by Borrelia burgdorferi, infects humans and other species, including dogs. Canine seroprevalence has been suggested as a sentinel marker of human disease risk. A recent publication reported high canine seroprevalence (>5%) in Routt County, Colorado, an area where Lyme disease is generally considered nonendemic. We surveyed veterinarians in Routt County and discovered that 11 of 12 seropositive dogs (>90%) had a documented history of travel to or residence in a Lyme disease endemic area. These findings do not support the presence of an undocumented disease focus and reveal that despite its high sensitivity, there are limitations in the specificity and positive predictive value of elevated canine seroprevalence as a marker of human risk. C1 [Millen, Katharine; Kugeler, Kiersten J.; Hinckley, Alison F.; Mead, Paul S.] Ctr Dis Control & Prevent, Ft Collins, CO USA. [Lawaczeck, Elisabeth W.] Colorado Dept Publ Hlth & Environm, Denver, CO USA. RP Mead, PS (reprint author), Ctr Dis Control & Prevent Ft Collins, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM pfm0@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention. We would like to thank the Colorado Veterinary Medical Association for their assistance in carrying out this survey. We are grateful to the veterinarians that took the time to participate. NR 6 TC 3 Z9 3 U1 0 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD MAY PY 2013 VL 13 IS 5 BP 340 EP 341 DI 10.1089/vbz.2012.1025 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 132LE UT WOS:000318068600009 PM 23421882 ER PT J AU Gill, SK Shults, RA Cope, JR Cunningham, TJ Freelon, B AF Gill, Simerpal K. Shults, Ruth A. Cope, Jennifer Rittenhouse Cunningham, Timothy J. Freelon, Brandi TI Teen driving in rural North Dakota: A qualitative look at parental perceptions SO ACCIDENT ANALYSIS AND PREVENTION LA English DT Article DE Graduated driver licensing; Teen driving risks; Parental perceptions; Qualitative analysis ID MOTOR-VEHICLE CRASHES; CONTRIBUTING FACTORS; FATAL CRASHES; DRIVERS; RISK; PASSENGERS; TEENAGERS; VIEWS AB Motor vehicle crashes are the leading cause of death among teens in the United States. Graduated driver licensing (GDL) programs allow new drivers to gain driving experience while protecting them from high-risk situations. North Dakota was one of the last states to implement GDL, and the current program does not meet all of the best practice recommendations. This study used qualitative techniques to explore parents' perceptions of the role teen driving plays in the daily lives of rural North Dakota families, their understanding of the risks faced by their novice teen drivers, and their support for GDL. A total of 28 interviews with parents of teens aged 13-16 years were conducted in four separate rural areas of the state. During the face-to-face interviews, parents described their teens' daily lives as busy, filled with school, sports, and other activities that often required traveling considerable distances. Participation in school-sponsored sports and other school-related activities was highly valued. There was nearly unanimous support for licensing teens at age 14 1/2, as was permitted by law at the time of the interviews. Parents expressed that they were comfortable supervising their teen's practice driving, and few reported using resources to assist them in this role. Although few parents expressed concerns over nighttime driving, most parents supported a nighttime driving restriction with exemptions for school, work or sports-related activities. Despite many parents expressing concern over distracted driving, there was less consistent support among parents for passenger restrictions, especially if there would be no exemptions for family members or school activities. These findings can assist in planning policies and programs to reduce crashes among novice, teen drivers, while taking into account the unique perspectives and lifestyles of families living in rural North Dakota. Published by Elsevier Ltd. C1 [Gill, Simerpal K.; Cope, Jennifer Rittenhouse; Cunningham, Timothy J.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30341 USA. [Gill, Simerpal K.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA. [Gill, Simerpal K.; Shults, Ruth A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Cope, Jennifer Rittenhouse] Ctr Dis Control & Prevent, North Dakota State Field Assignments, Atlanta, GA 30341 USA. [Cunningham, Timothy J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis & Hlth Promot, Atlanta, GA 30341 USA. [Freelon, Brandi] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Adolescent & Sch Hlth, Atlanta, GA 30341 USA. RP Gill, SK (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,MS F 62, Atlanta, GA 30341 USA. EM rshults@cdc.gov NR 37 TC 3 Z9 3 U1 2 U2 17 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0001-4575 J9 ACCIDENT ANAL PREV JI Accid. Anal. Prev. PD MAY PY 2013 VL 54 BP 114 EP 121 DI 10.1016/j.aap.2013.02.010 PG 8 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 129ZV UT WOS:000317883400014 PM 23499983 ER PT J AU Tack, DM Blanton, JD Holman, RC Longenberger, AH Petersen, BW Rupprecht, CE AF Tack, Danielle M. Blanton, Jesse D. Holman, Robert C. Longenberger, Allison H. Petersen, Brett W. Rupprecht, Charles E. TI Evaluation of knowledge, attitudes, and practices of deer owners following identification of a cluster of captive deer with rabies in Pennsylvania in July 2010 SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION LA English DT Article ID PUBLIC VETERINARY-MEDICINE; UNITED-STATES; HEALTH; EXPOSURE; RISK AB Objective-To evaluate knowledge, attitudes, and practices of deer owners following identification of a cluster of captive deer with rabies as an aid for the development of rabies prevention educational materials. Design-Cross-sectional study. Population-Captive-deer owners who were members of the Pennsylvania Deer Farmers Association. Procedures-Information was obtained via a mailed, self-administered questionnaire. Results-The questionnaire response rate was 59% (249/425). One hundred three of 206 (50%) respondents had incomplete knowledge of rabies virus vectors, transmission, severity, and prevention measures. Birds or snakes were incorrectly identified as rabies vectors by 96 of 213 (45%) respondents, and most' (>= 94%) respondents identified rabies virus reservoirs as vectors. Ninety of 231 (39%) respondents identified death as an outcome of rabies, and 184 of 235 (78%) respondents would seek emergency treatment if they suspected exposure. Only 62 of 235 (26%) respondents would wash a wound immediately. The majority of respondents (173/239 [72%]) did not know the clinical signs of rabies in deer. Nine respondents indicated that they vaccinated their deer against rabies, and the majority of respondents (158/214 [74%]) would be willing to vaccinate. Conclusions and Clinical Relevance-Findings suggested that deer owners in Pennsylvania have a basic knowledge of rabies; however, knowledge, attitudes, and practices regarding prevention of rabies transmission could be improved considerably. Rabies educational materials for deer owners should focus on postexposure procedures, disease severity, recognition of rabies in deer, and changes in management practices such as vaccination to prevent rabies. (J Am Vet Med Assoc 2013;242:1279-1285) C1 [Tack, Danielle M.; Blanton, Jesse D.; Holman, Robert C.; Petersen, Brett W.; Rupprecht, Charles E.] CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Tack, Danielle M.; Longenberger, Allison H.; Petersen, Brett W.] CDC, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. [Longenberger, Allison H.] Penn Dept Hlth, Harrisburg, PA 17120 USA. RP Tack, DM (reprint author), Georgia Dept Publ Hlth, 40 Pryor St,4th Floor, Atlanta, GA 30303 USA. EM dot7@cdc.gov NR 16 TC 1 Z9 1 U1 0 U2 11 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0003-1488 J9 JAVMA-J AM VET MED A JI JAVMA-J. Am. Vet. Med. Assoc. PD MAY 1 PY 2013 VL 242 IS 9 BP 1279 EP 1285 PG 7 WC Veterinary Sciences SC Veterinary Sciences GA 129XJ UT WOS:000317877000017 PM 23600787 ER PT J AU Seyler, TH Kim, JG Hodgson, JA Cowan, EA Blount, BC Wang, LQ AF Seyler, Tiffany H. Kim, Jenny G. Hodgson, James A. Cowan, Elizabeth A. Blount, Benjamin C. Wang, Lanqing TI Quantitation of Urinary Volatile Nitrosamines from Exposure to Tobacco Smoke SO JOURNAL OF ANALYTICAL TOXICOLOGY LA English DT Article ID N-NITROSO COMPOUNDS; CHEMILUMINESCENCE DETECTION; ENDOGENOUS FORMATION; ESOPHAGEAL CANCER; DIRECT EXTRACTION; SIDESTREAM SMOKE; DRINKING-WATER; EXCRETION; NITRATE; CIGARETTES AB A sensitive and selective method was developed and validated to detect six volatile nitrosamines (N-nitrosodimethylamine, N-nitrosomethylethylamine, N-nitrosodiethylamine, N-nitrosopiperidine, N-nitrosopyrrolidine and N-nitrosomorpholine) in human urine. This method uses a liquidliquid extraction cartridge followed by analysis with gas chromatographytandem mass spectrometry (GCMS-MS) and quantification based on isotopic dilution. This is the first GCMS-MS method reported for measuring volatile nitrosamines in human urine. This method reduces the sample volume required in other methods from 525 to 2 mL. The limits of detection (2.62, 1.99, 2.73, 0.65, 0.25, 3.66 pg/mL, respectively) were better than existing methods, largely because of improved positive chemical ionization achieved by using ammonia gas and reducing background noise. Using nitrogen as the collision gas allowed the confirmation transition in the low mass region to be monitored. The analysis of human urine using this validated method is accurate (relative bias of 019) and precise (relative standard deviation of 0.218 over two months of analyses). The validated method was applied to 100 urine samples and the levels of all six volatile nitrosamines were reported for the first time in urine specimens collected from smokers and nonsmokers, with smoking status determined by urinary cotinine measurement. Among 100 smokers and nonsmokers, the levels of three analytes (N-nitrosodimethylamine, N-nitrosomethylethylamine and N-nitrosopiperidine) were significantly higher in smokers than nonsmokers (p 0.05). C1 [Seyler, Tiffany H.; Kim, Jenny G.; Hodgson, James A.; Cowan, Elizabeth A.; Blount, Benjamin C.; Wang, Lanqing] Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Seyler, TH (reprint author), Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM tvh2@cdc.gov FU U.S. Food and Drug Administration Center for Tobacco Products FX This study was funded through an interagency agreement with the U.S. Food and Drug Administration Center for Tobacco Products. We would like to thank the following staff of the Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention: James McGuffey, Connie Sosnoff, and Joseph Alexander for their assistance with the urine cotinine analysis; Dr. Rey De Castro for his statistical analysis. NR 39 TC 7 Z9 7 U1 2 U2 36 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0146-4760 J9 J ANAL TOXICOL JI J. Anal. Toxicol. PD MAY PY 2013 VL 37 IS 4 BP 195 EP 202 DI 10.1093/jat/bkt020 PG 8 WC Chemistry, Analytical; Toxicology SC Chemistry; Toxicology GA 124AF UT WOS:000317434100001 PM 23508653 ER PT J AU Pittman, CT Guido, JM Hamelin, EI Blake, TA Johnson, RC AF Pittman, Christopher T. Guido, John M. Hamelin, Elizabeth I. Blake, Thomas A. Johnson, Rudolph C. TI Analysis of a Ricin Biomarker, Ricinine, in 989 Individual Human Urine Samples SO JOURNAL OF ANALYTICAL TOXICOLOGY LA English DT Article ID COMMUNIS; QUANTIFICATION; SPECTROMETRY; TOXICOSIS; MARKER; FOOD AB Ricinine (3-cyano-4-methoxy-N-methyl-2-pyridone) is a urinary biomarker that can be measured to confirm human exposure to castor bean products such as ricin. Because many consumer products contain castor oil, another castor bean product, ricinine may be detectable in the general population. The following study characterized urinary ricinine concentrations from 989 individuals who were presumed to be unexposed to ricin. An automated diagnostic method was utilized to simplify the analysis of this large sample set. Sample preparation included a 96-well polystyrene divinylbenzene high throughput extraction and preconcentration step. Purified samples were analyzed by an efficient dual column, reversed-phase liquid chromatography separation and C-13-isotope dilution tandem mass spectrometry. In this convenience sample set, only 1.2 of the urine specimens had detectable amounts of ricinine, randomly distributed between 0.186 and 4.15 ng/mL. C1 [Pittman, Christopher T.; Hamelin, Elizabeth I.; Blake, Thomas A.; Johnson, Rudolph C.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Guido, John M.] Oak Ridge Inst Sci Educ, Oak Ridge, TN 37831 USA. RP Johnson, RC (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway,MS F44, Atlanta, GA 30341 USA. EM rmj6@cdc.gov OI Blake, Thomas/0000-0001-8536-9998 FU Intramural CDC HHS [CC999999] NR 25 TC 3 Z9 4 U1 1 U2 19 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0146-4760 EI 1945-2403 J9 J ANAL TOXICOL JI J. Anal. Toxicol. PD MAY PY 2013 VL 37 IS 4 BP 237 EP 240 DI 10.1093/jat/bkt010 PG 4 WC Chemistry, Analytical; Toxicology SC Chemistry; Toxicology GA 124AF UT WOS:000317434100008 PM 23471955 ER PT J AU Mazurek, JM Knoeller, GE Moorman, JE Storey, E AF Mazurek, Jacek M. Knoeller, Gretchen E. Moorman, Jeanne E. Storey, Eileen TI Occupational Asthma Incidence: Findings from the Behavioral Risk Factor Surveillance System Asthma Call-Back Survey-United States, 2006-2009 SO JOURNAL OF ASTHMA LA English DT Article DE epidemiology; surveillance; work-related asthma ID WORK-RELATED ASTHMA; DIAGNOSIS; MEMBERS AB Background. Occupational asthma (OA) is new-onset asthma or the recurrence of previously quiescent asthma caused by workplace exposures. Objective. To estimate the incidence of population-based new-onset OA and the proportion of incident asthma that is work-related. Methods. Behavioral Risk Factor Surveillance System and Asthma Call-back Survey data collected from persons aged >= 18 years during 2006-2009 in 38 states and the District of Columbia were analyzed. Incident health professional-diagnosed new-onset OA cases were persons whose asthma was diagnosed for the first time within the past 12 months whose health professional indicated their asthma was related to their work. Incident potential new-onset OA cases were persons with asthma diagnosed within the past 12 months who did not have health professional-diagnosed work-related asthma but described their asthma as caused by workplace exposures. The proportion of incident asthma that is work-related was calculated using the 2006-2008 estimate of adult asthma incidence (3800 per million). Results. The estimated annual incidence of health professional-diagnosed new-onset OA was 179 (95% CI: 113-245) per million population. For combined health professional-diagnosed and potential new-onset OA the incidence was 692 (95% CI: 532-853) per million population. The proportion of incident asthma among adults that is work-related was 4.7% for health professional-diagnosed new-onset OA and 18.2% for combined health professional-diagnosed and potential new-onset OA. Conclusions. New-onset asthma in as many as one of six adult patients might be associated with work. Clinicians should consider the role of occupational exposures when evaluating adults with incident asthma which may uncover opportunities for early intervention and reversal of an otherwise chronic disease. C1 [Mazurek, Jacek M.; Knoeller, Gretchen E.; Storey, Eileen] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Moorman, Jeanne E.] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, Chamblee, GA USA. RP Mazurek, JM (reprint author), NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, MS HG 900-2,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM JMazurek1@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention. The authors, Jacek M. Mazurek, Gretchen E. Knoeller, Jeanne E. Moorman, and Eileen Storey, have participated in the conception, design, analysis, and interpretation of the data, have drafted and revised the submitted article, and have approved the final version to be published. NR 17 TC 5 Z9 5 U1 0 U2 5 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0277-0903 J9 J ASTHMA JI J. Asthma PD MAY PY 2013 VL 50 IS 4 BP 390 EP 394 DI 10.3109/02770903.2013.769267 PG 5 WC Allergy; Respiratory System SC Allergy; Respiratory System GA 126ZA UT WOS:000317660900010 PM 23394187 ER PT J AU Simon, AE Akinbami, LJ AF Simon, Alan E. Akinbami, Lara J. TI Receipt of Systemic Corticosteroids during Asthma Visits to US Emergency Departments, 2007-2009 SO JOURNAL OF ASTHMA LA English DT Article DE asthma; emergency departments; healthcare quality; national data; systemic corticosteroids ID ADULTS AB Background. National Asthma Education and Prevention Program recommended emergency department (ED) asthma treatment includes both providing systemic corticosteroids in the ED and a steroid prescription at discharge. Objective. To examine the prevalence of three types of substandard ED asthma care-providing a discharge prescription only, providing corticosteroids in the ED only, and providing neither- and how care varies with exacerbation severity. Methods. We used the National Hospital Ambulatory Medical Care Survey-Emergency Department (NHAMCS-ED) (2007, 2008, and 2009) to identify ED asthma visits (International Classification of Diseases-9th Revision Clinical Modification (ICD-9-CM codes 493.xx)) for patients aged 1 to <65 years. The primary outcome was the percent of visits receiving each type of substandard care, both overall and by exacerbation severity. Multinomial logistic regressions with predictive margins were used to obtain estimates adjusted for patient, visit, and hospital characteristics. Results. For 27.1% (confidence interval (CI): 24.0-30.2%) of visits, patients received corticosteroids both in the ED and as a discharge prescription. A discharge prescription only was provided for 12.3% of visits (CI: 10.2-14.6%), corticosteroids were provided in the ED only for 18.2% (CI: 15.6-21.2%), and no corticosteroids were provided for 42.4% (CI: 38.8-46.2%). Even among visits by patients with abnormal overall respiratory status (fast respiratory rates, pulse oximetry values <97%, or both), only 32.3% (CI: 27.8-36.8) were provided corticosteroids both in the ED and as a prescription, while the remainder received some type of substandard care. Adjusted and unadjusted results were similar. Conclusions. Substandard ED asthma care is common, even among visits by patients with more severe asthma exacerbations. C1 [Simon, Alan E.; Akinbami, Lara J.] Ctr Dis Control & Prevent, Infant Child & Womens Hlth Stat Branch, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Akinbami, Lara J.] US PHS, Rockville, MD USA. RP Simon, AE (reprint author), Natl Ctr Hlth Stat, 3311 Toledo Rd,Rm6122, Hyattsville, MD 20782 USA. EM fpa8@cdc.gov NR 22 TC 2 Z9 2 U1 0 U2 1 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0277-0903 J9 J ASTHMA JI J. Asthma PD MAY PY 2013 VL 50 IS 4 BP 419 EP 426 DI 10.3109/02770903.2013.769269 PG 8 WC Allergy; Respiratory System SC Allergy; Respiratory System GA 126ZA UT WOS:000317660900014 PM 23402384 ER PT J AU Burk, T Zarus, G AF Burk, Tonia Zarus, Gregory TI Community Exposures to Chemicals Through Vapor Intrusion: A Review of Past Agency for Toxic Substances and Disease Registry Public Health Evaluations SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article C1 [Zarus, Gregory] US Dept HHS, Div Community Hlth Invest, Agcy Tox Subst & Dis Registry, Atlanta, GA 30341 USA. RP Zarus, G (reprint author), US Dept HHS, Div Community Hlth Invest, Agcy Tox Subst & Dis Registry, 4770 Buford Hwy NE,Mailstop F-59, Atlanta, GA 30341 USA. EM gaz5@cdc.gov FU Intramural CDC HHS [CC999999] NR 8 TC 3 Z9 3 U1 2 U2 8 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD MAY PY 2013 VL 75 IS 9 BP 36 EP 41 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 130DD UT WOS:000317892000006 PM 23734531 ER PT J AU Hlavsa, M Beach, M AF Hlavsa, Michele Beach, Michael TI Healthy and Safe Swimming: Pool Chemical-Associated Health Events SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article C1 [Hlavsa, Michele] CDC, Hlth Swimming Program, Atlanta, GA 30333 USA. [Beach, Michael] Hlth Water, Atlanta, GA 30333 USA. RP Hlavsa, M (reprint author), Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd,MS C-9, Atlanta, GA 30333 USA. EM acz3@cdc.gov FU ACC FX Thanks to the generous financial support of ACC, NR 4 TC 3 Z9 3 U1 0 U2 5 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD MAY PY 2013 VL 75 IS 9 BP 42 EP 44 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 130DD UT WOS:000317892000007 PM 23734532 ER PT J AU Balajee, SA Hurst, SF Chang, LS Miles, M Beeler, E Hale, C Kasuga, T Benedict, K Chiller, T Lindsley, MD AF Balajee, S. Arunmozhi Hurst, Steven F. Chang, Loretta S. Miles, Macon Beeler, Emily Hale, Christa Kasuga, Takao Benedict, Kaitlin Chiller, Tom Lindsley, Mark D. TI Multilocus sequence typing of Histoplasma capsulatum in formalin-fixed paraffin-embedded tissues from cats living in non-endemic regions reveals a new phylogenetic clade SO MEDICAL MYCOLOGY LA English DT Article DE FFPE tissue; feline histoplasmosis; H. capsulatum ID PCR AMPLIFICATION; MOLECULAR-DETECTION; INFECTIONS; EXTRACTION; SPECIMENS; DIAGNOSIS; FIXATION; CANINE; TIME; DNA AB Infections caused by Histoplasma capsulatum are found most often in endemic regions of North, Central, and South America. H. capsulatum has been divided into eight geographic clades by multi-locus sequence typing (MLST). Recently, one isolate and five formalin-fixed paraffin-embedded (FFPE) tissue samples were received from six of 15 suspected cases of histoplasmosis in cats residing in areas not known to be endemic for H. capsulatum. Polymerase chain reaction (PCR) amplification and sequence analysis of the rDNA ITS-2 region confirmed the diagnosis of H. capsulatum. Since these cases were not, as noted, from the accepted endemic areas, it was of interest to understand the molecular epidemiology of these isolates. Results of molecular analysis indicated that the H. capsulatum recovered from the cats were most closely related to the North American-1 clade, but clustered separately outside this clade, suggesting that the H. capsulatum infecting the animals may represent a separate clade or phylogenetic species. This study also demonstrated the utility of obtaining valuable molecular subtype data directly from archived FFPE tissue blocks, particularly when a fungus culture was not performed or is otherwise unavailable. C1 [Balajee, S. Arunmozhi] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA 30333 USA. [Hurst, Steven F.; Chang, Loretta S.; Benedict, Kaitlin; Chiller, Tom; Lindsley, Mark D.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA. [Chang, Loretta S.; Hale, Christa] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Beeler, Emily] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Hale, Christa] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Kasuga, Takao] Univ Calif Davis, USDA ARS, Dept Plant Pathol, Davis, CA 95616 USA. [Miles, Macon] Anim Emergency & Referral Ctr, Torrance, CA USA. RP Lindsley, MD (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, 1600 Clifton Rd,Mailstop G-11, Atlanta, GA 30333 USA. EM mlindsley@cdc.gov NR 23 TC 8 Z9 8 U1 0 U2 8 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1369-3786 J9 MED MYCOL JI Med. Mycol. PD MAY PY 2013 VL 51 IS 4 BP 345 EP 351 DI 10.3109/13693786.2012.733430 PG 7 WC Infectious Diseases; Mycology; Veterinary Sciences SC Infectious Diseases; Mycology; Veterinary Sciences GA 126DR UT WOS:000317592600002 ER PT J AU Geiser, DM Aoki, T Bacon, CW Baker, SE Bhattacharyya, MK Brandt, ME Brown, DW Burgess, LW Chulze, S Coleman, JJ Correll, JC Covert, SF Crous, PW Cuomo, CA De Hoog, GS Di Pietro, A Elmer, WH Epstein, L Frandsen, RJN Freeman, S Gagkaeva, T Glenn, AE Gordon, TR Gregory, NF Hammond-Kosack, KE Hanson, LE Jimenez-Gasco, MD Kang, S Kistler, HC Kuldau, GA Leslie, JF Logrieco, A Lu, GZ Lysoe, E Ma, LJ McCormick, SP Migheli, Q Moretti, A Munaut, F O'Donnell, K Pfenning, L Ploetz, RC Proctor, RH Rehner, SA Robert, VARG Rooney, AP bin Salleh, B Scandiani, MM Scauflaire, J Short, DPG Steenkamp, E Suga, H Summerell, BA Sutton, DA Thrane, U Trail, F Van Diepeningen, A VanEtten, HD Viljoen, A Waalwijk, C Ward, TJ Wingfield, MJ Xu, JR Yang, XB Yli-Mattila, T Zhang, N AF Geiser, David M. Aoki, Takayuki Bacon, Charles W. Baker, Scott E. Bhattacharyya, Madan K. Brandt, Mary E. Brown, Daren W. Burgess, Lester W. Chulze, Sofia Coleman, Jeffrey J. Correll, James C. Covert, Sarah F. Crous, Pedro W. Cuomo, Christina A. De Hoog, G. Sybren Di Pietro, Antonio Elmer, Wade H. Epstein, Lynn Frandsen, Rasmus J. N. Freeman, Stanley Gagkaeva, Tatiana Glenn, Anthony E. Gordon, Thomas R. Gregory, Nancy F. Hammond-Kosack, Kim E. Hanson, Linda E. Jimenez-Gasco, Maria del Mar Kang, Seogchan Kistler, H. Corby Kuldau, Gretchen A. Leslie, John F. Logrieco, Antonio Lu, Guozhong Lysoe, Erik Ma, Li-Jun McCormick, Susan P. Migheli, Quirico Moretti, Antonio Munaut, Francoise O'Donnell, Kerry Pfenning, Ludwig Ploetz, Randy C. Proctor, Robert H. Rehner, Stephen A. Robert, Vincent A. R. G. Rooney, Alejandro P. bin Salleh, Baharuddin Mercedes Scandiani, Maria Scauflaire, Jonathan Short, Dylan P. G. Steenkamp, Emma Suga, Haruhisa Summerell, Brett A. Sutton, Deanna A. Thrane, Ulf Trail, Francis Van Diepeningen, Anne VanEtten, Hans D. Viljoen, Altus Waalwijk, Cees Ward, Todd J. Wingfield, Michael J. Xu, Jin-Rong Yang, Xiao-Bing Yli-Mattila, Tapani Zhang, Ning TI One Fungus, One Name: Defining the Genus Fusarium in a Scientifically Robust Way That Preserves Longstanding Use SO PHYTOPATHOLOGY LA English DT Article ID SOLANI SPECIES COMPLEX; SUDDEN-DEATH SYNDROME; PHYLOGENY; TUCUMANIAE; TAXONOMY; REVEALS; GENERA AB In this letter, we advocate recognizing the genus Fusarium as the sole name for a group that includes virtually all Fusarium species of importance in plant pathology, mycotoxicology, medicine, and basic research. This phylogenetically guided circumscription will free scientists from any obligation to use other genus names, including teleomorphs, for species nested within this clade, and preserve the application of the name Fusarium in the way it has been used for almost a century. Due to recent changes in the International Code of Nomenclature for algae, fungi, and plants, this is an urgent matter that requires community attention. The alternative is to break the longstanding concept of Fusarittm into nine or more genera, and remove important taxa such as those in the E solani species complex from the genus, a move we believe is unnecessary. Here we present taxonomic and nomenclatural proposals that will preserve established research connections and facilitate communication within alid between research communities, and at the same time support strong scientific principles and good taxonomic practice. C1 [Geiser, David M.; Jimenez-Gasco, Maria del Mar; Kang, Seogchan; Kuldau, Gretchen A.] Penn State Univ, Dept Plant Pathol, University Pk, PA 16802 USA. [Aoki, Takayuki] Natl Inst Agrobiol Sci, Genet Divers Dept, Tsukuba, Ibaraki 3058602, Japan. [Bacon, Charles W.; Glenn, Anthony E.] USDA ARS SAA, Athens, GA 30605 USA. [Baker, Scott E.] Pacific NW Natl Lab, Richland, WA 99352 USA. [Bhattacharyya, Madan K.; Yang, Xiao-Bing] Iowa State Univ, Dept Plant Pathol & Microbiol, Ames, IA 50011 USA. [Brandt, Mary E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Brown, Daren W.; McCormick, Susan P.; O'Donnell, Kerry; Proctor, Robert H.; Rooney, Alejandro P.; Ward, Todd J.] NCAUR ARS USDA, Peoria, IL 61604 USA. [Burgess, Lester W.] Univ Sydney, Fac Agr, Sydney, NSW 2006, Australia. [Chulze, Sofia] Univ Nacl Rio Cuarto, Dept Microbiol & Immunol, Cordoba, Argentina. [Coleman, Jeffrey J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Correll, James C.] Univ Arkansas, Dept Plant Pathol, Fayetteville, AR 72701 USA. [Covert, Sarah F.] Univ Georgia, Warnell Sch Forestry & Nat Resources, Athens, GA 30602 USA. [Crous, Pedro W.; De Hoog, G. Sybren; Robert, Vincent A. R. G.; Van Diepeningen, Anne] CBS KNAW Fungal Biodivers Ctr, Utrecht, Netherlands. [Cuomo, Christina A.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA. [Di Pietro, Antonio] Univ Cordoba, Dept Genet, Cordoba, Spain. [Elmer, Wade H.] Connecticut Agr Expt Stn, Dept Plant Pathol, New Haven, CT 06504 USA. [Epstein, Lynn; Gordon, Thomas R.; Short, Dylan P. G.] Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA. [Frandsen, Rasmus J. N.; Thrane, Ulf] Tech Univ Denmark, Dept Syst Biol, DK-2800 Lyngby, Denmark. [Freeman, Stanley] Agr Res Org, Volcani Ctr, Dept Plant Pathol & Weed Res, IL-50250 Bet Dagan, Israel. [Gagkaeva, Tatiana] All Russian Inst Plant Protect, Lab Mycol & Phytopathol, St Petersburg 196608, Russia. [Gregory, Nancy F.] Univ Delaware, Dept Plant & Soil Sci, Newark, DE 19716 USA. [Hammond-Kosack, Kim E.] Rothamsted Res, Ctr Sustainable Pest & Dis Management, Harpenden AL5 2JQ, Herts, England. [Hanson, Linda E.] ARS USDA Sugarbeet & Bean Res Unit, E Lansing, MI 48824 USA. [Kistler, H. Corby] ARS USDA Cereal Dis Lab, St Paul, MN 55108 USA. [Leslie, John F.] Kansas State Univ, Dept Plant Pathol, Manhattan, KS 66506 USA. [Logrieco, Antonio; Moretti, Antonio] CNR, ISPA Inst Sci Food Prod, I-70126 Bari, Italy. [Lu, Guozhong] Dalian Nationalities Univ, Res Ctr Bioresources & Environm, Liaoning, Peoples R China. [Lysoe, Erik] Bioforsk Norwegian Inst Agr & Environm Res, Dept Plant Hlth & Plant Protect, N-1432 As, Norway. [Ma, Li-Jun] Univ Massachusetts, Dept Plant Soil & Insect Sci, Amherst, MA 01003 USA. [Migheli, Quirico] Univ Sassari, Dipartimento Protez Piante, I-07100 Sassari, Italy. [Munaut, Francoise; Scauflaire, Jonathan] Catholic Univ Louvain, Earth & Life Inst, B-1348 Louvain, Belgium. [Pfenning, Ludwig] Univ Fed Lavras, Dept Fitopatol, Lavras, MG, Brazil. [Ploetz, Randy C.] Univ Florida, Ctr Trop Res & Educ, Dept Plant Pathol, Homestead, FL 33031 USA. [Rehner, Stephen A.] ARS, Systemat Mycol & Microbiol Lab, USDA, Beltsville, MD 20705 USA. [bin Salleh, Baharuddin] Univ Sci Malaysia, Sch Biol Sci, George Town, Malaysia. [Mercedes Scandiani, Maria] Lab Agr Rio Parana, Buenos Aires, DF, Argentina. [Short, Dylan P. G.] US Agr Res Stn, Salinas, CA 93905 USA. [Steenkamp, Emma; Wingfield, Michael J.] Univ Pretoria, FABI, Dept Microbiol & Plant Pathol, ZA-0002 Pretoria, South Africa. [Suga, Haruhisa] Gifu Univ, Gifu, Japan. [Summerell, Brett A.] Royal Bot Garden Sydney, Sydney, NSW 2000, Australia. [Sutton, Deanna A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Trail, Francis] Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA. [VanEtten, Hans D.] Univ Arizona, Div Plant Pathol & Microbiol, Tucson, AZ 85721 USA. [Viljoen, Altus] Univ Stellenbosch, Dept Plant Pathol, ZA-7602 Matieland, South Africa. [Waalwijk, Cees] Wageningen Univ & Res, Plant Res Int, NL-6700 Wageningen, Netherlands. [Xu, Jin-Rong] Purdue Univ, Dept Plant Pathol, W Lafayette, IN 47907 USA. [Yli-Mattila, Tapani] Univ Turku, Lab Plant Physiol & Mol Biol, Dept Biol, FIN-20014 Turku, Finland. [Zhang, Ning] Rutgers State Univ, Dept Plant Biol & Pathol, New Brunswick, NJ 08901 USA. RP Geiser, DM (reprint author), Penn State Univ, Dept Plant Pathol, University Pk, PA 16802 USA. EM dgeiser@psu.edu RI Jimenez-Gasco, Maria del Mar/A-9701-2011; Migheli, Quirico/B-7203-2009; Crous, Pedro/H-1489-2012; Geiser, David/J-9950-2013; Zhang, Ning/K-3046-2012; Wingfield, Michael/A-9473-2008; Coleman, Jeffrey/E-2981-2015; Di Pietro, Antonio/K-9220-2014; Thrane, Ulf/G-2978-2016; Steenkamp, Emma/B-7958-2009; OI Jimenez-Gasco, Maria del Mar/0000-0001-7329-0211; Migheli, Quirico/0000-0002-2459-5833; Crous, Pedro/0000-0001-9085-8825; Zhang, Ning/0000-0003-0755-2505; Di Pietro, Antonio/0000-0001-5930-5763; Thrane, Ulf/0000-0002-6040-4141; Steenkamp, Emma/0000-0003-0217-8219; Ma, Li-Jun/0000-0002-2733-3708; Coleman, Jeffrey/0000-0001-8579-1996; Frandsen, Rasmus John Normand/0000-0002-3799-6062; Moretti, Antonio/0000-0002-5232-6972; Logrieco, Antonio Francesco/0000-0002-8606-451X; Kistler, Harold/0000-0001-5312-6297 FU U.S. Department of Agriculture (USDA) FX We thank P. Cantino for his helpful comments on the PhyloCode statement. We thank all of our colleagues for their helpful input and discussions on this important issue. The mention of firm names or trade products does not imply that they are endorsed or recommended by the U.S. Department of Agriculture (USDA) over other firms or similar products not mentioned. The USDA is an equal opportunity provider and employer. Manuscript no. 13-006-J from the Kansas Agricultural Experiment Station, Manhattan. NR 46 TC 47 Z9 48 U1 5 U2 114 PU AMER PHYTOPATHOLOGICAL SOC PI ST PAUL PA 3340 PILOT KNOB ROAD, ST PAUL, MN 55121 USA SN 0031-949X J9 PHYTOPATHOLOGY JI Phytopathology PD MAY PY 2013 VL 103 IS 5 BP 400 EP 408 PG 9 WC Plant Sciences SC Plant Sciences GA 129VW UT WOS:000317873100001 PM 23379853 ER PT J AU Cramer, R Hogben, M Handsfield, HH AF Cramer, Ryan Hogben, Matthew Handsfield, H. Hunter TI A Historical Note on the Association Between the Legal Status of Expedited Partner Therapy and Physician Practice SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED INFECTIONS; CONTROLLED-TRIAL; NATIONAL-SURVEY; US PHYSICIANS; NOTIFICATION AB Potential legal liability for practicing expedited partner therapy is a common concern among providers, although it has been uncertain how these concerns translate into clinical practice. This study suggests that providers are more likely to practice expedited partner therapy in more favorable legal environments. C1 [Cramer, Ryan; Hogben, Matthew] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Handsfield, H. Hunter] Univ Washington, Ctr AIDS & STD, Seattle, WA 98195 USA. RP Cramer, R (reprint author), CDC Mail Stop E-02, Atlanta, GA 30333 USA. EM rcramer@cdc.gov FU Research Participation Program at the Centers for Disease Control and Prevention (CDC) FX Supported, in part, by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention (CDC) administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and CDC. NR 14 TC 4 Z9 4 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAY PY 2013 VL 40 IS 5 BP 349 EP 351 DI 10.1097/OLQ.0b013e3182853c61 PG 3 WC Infectious Diseases SC Infectious Diseases GA 126AK UT WOS:000317583300001 PM 23588121 ER PT J AU Won, H Ramachandran, P Steece, R Van Der Pol, B Moncada, J Schachter, J Gaydos, C AF Won, Helen Ramachandran, Padmini Steece, Richard Van Der Pol, Barbara Moncada, Jeanne Schachter, Julius Gaydos, Charlotte TI Is There Evidence of the New Variant Chlamydia trachomatis in the United States? SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID TESTS AB A specific real-time polymerase chain reaction followed by melt curve analysis was developed for the detection of the Swedish variant (nvCT) strain of Chlamydia trachomatis (CT). Surveillance was performed on 476 CT-positive clinical specimens obtained from 15 laboratories around the United States using nucleic acid amplification test assays, which would not miss the nvCT. All were negative for nvCT; thus, there is no evidence of the nvCT in the United States. C1 [Won, Helen; Gaydos, Charlotte] Johns Hopkins Univ, Div Infect Dis, Dept Med, Baltimore, MD 21205 USA. [Won, Helen; Ramachandran, Padmini; Gaydos, Charlotte] Johns Hopkins Univ, Dept Emergency Med, Div Infect Dis, Baltimore, MD 21205 USA. [Steece, Richard] Ctr Dis Control & Prevent, Infertil Prevent Program, Atlanta, GA USA. [Van Der Pol, Barbara] Indiana Univ, Dept Epidemiol & Biostat, Bloomington, IN USA. [Moncada, Jeanne; Schachter, Julius] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Gaydos, C (reprint author), Johns Hopkins Univ, Div Infect Dis, Dept Med, 855 N Wolfe St,Rangos Bldg,Rm 530, Baltimore, MD 21205 USA. EM cgaydos@jhmi.edu OI Van Der Pol, Barbara/0000-0003-3064-8564 FU HPTN NIAID/NIH [U01-AI 068613, U54EB007958] FX Funded, in part, by U54EB007958 and HPTN NIAID/NIH U01-AI 068613. NR 16 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAY PY 2013 VL 40 IS 5 BP 352 EP 353 DI 10.1097/OLQ.0b013e3182841786 PG 2 WC Infectious Diseases SC Infectious Diseases GA 126AK UT WOS:000317583300002 PM 23588122 ER PT J AU Owusu-Edusei, K Nguyen, HT Gift, TL AF Owusu-Edusei, Kwame, Jr. Nguyen, Hang T. Gift, Thomas L. TI Utilization and Cost of Diagnostic Methods for Sexually Transmitted Infection Screening Among Insured American Youth, 2008 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID INSURANCE CLAIMS DATA; UNITED-STATES; TRICHOMONAS-VAGINALIS; CHLAMYDIA-TRACHOMATIS; ADMINISTRATIVE DATA; URINE SPECIMENS; MEDICAL COST; POPULATION; MANAGEMENT; SERVICES AB Background: Private sector utilization and cost information on testing for sexually transmitted infections (STIs) in the United States is limited. Methods: We used current procedural terminology codes for tests for HIV, human papillomavirus (HPV), genital herpes simplex virus type 2, hepatitis B virus, chlamydia, gonorrhea, trichomoniasis, and syphilis. We extracted outpatient claims for persons aged 15 to 24 years in 2008 from the MarketScan database. Utilization was measured as the number of claims per 100,000 enrollees for tests specific to a given infection. We estimated claims rates and average costs by sex, compared these with Centers for Medicare and Medicaid Services (CMS) fees, and estimated the overall total cost of STI testing. Results: The claims rate for HPV was higher than for any other STI (P < 0.001) at 18,085/100,000, whereas that for trichomoniasis was lower than all other STIs (P < 0.001) at 517/100,000. Claims rates for females were higher than for males (P < 0.001) for all STIs. Average costs were as follows: $24 (HIV), $34 (HPV), $29 (hepatitis B virus), $25 (herpes simplex virus type 2), $43 (chlamydia), $42 (gonorrhea), $28 (trichomoniasis), and $24 (syphilis). Costs exceeded CMS fees for 67 of 78 current procedural terminologies by an average of 40%. The estimated total cost for all STIs was $403.1 million for the privately insured population aged 15 to 24 years. Conclusions: We found that the utilization rates and many test costs varied by sex. Private insurers typically paid more than the CMS fee schedule for testing. C1 [Owusu-Edusei, Kwame, Jr.; Nguyen, Hang T.; Gift, Thomas L.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. RP Owusu-Edusei, K (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS E-80, Atlanta, GA 30333 USA. EM Kowusuedusei@cdc.gov NR 31 TC 6 Z9 6 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAY PY 2013 VL 40 IS 5 BP 354 EP 361 DI 10.1097/OLQ.0b013e318285c58f PG 8 WC Infectious Diseases SC Infectious Diseases GA 126AK UT WOS:000317583300003 PM 23588123 ER PT J AU Chesson, HW Bernstein, KT Gift, TL Marcus, JL Pipkin, S Kent, CK AF Chesson, Harrell W. Bernstein, Kyle T. Gift, Thomas L. Marcus, Julia L. Pipkin, Sharon Kent, Charlotte K. TI The Cost-Effectiveness of Screening Men Who Have Sex With Men for Rectal Chlamydial and Gonococcal Infection to Prevent HIV Infection SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; ACID AMPLIFICATION TESTS; UNITED-STATES; SAN-FRANCISCO; GONORRHEA; TRANSMISSION; WOMEN; RISK; SEROCONVERSION; TRACHOMATIS AB Background: Men who have sex with men (MSM) who have a current or recent history of rectal Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) infection are at greater risk for HIV than MSM with no history of rectal infection. Screening and treating MSM for rectal CT/GC infection may help reduce any increased biological susceptibility to HIV infection. Methods: We used 2 versions of a Markov state-transition model to examine the impact and cost-effectiveness of screening MSM for rectal CT/GC infection in San Francisco: a static version that included only the benefits to those screened and a dynamic version that accounted for population-level impacts of screening. HIV prevention through reduced susceptibility to HIV was the only potential benefit of rectal CT/GC screening that we included in our analysis. Parameter values were based on San Francisco program data and the literature. Results: In the base case, the cost per quality-adjusted life year gained through screening MSM for rectal CT/GC infection was $16,300 in the static version of the model. In the dynamic model, the cost per quality-adjusted life year gained was less than $0, meaning that rectal screening was cost-saving. The impact of rectal CT/GC infection on the risk of HIV acquisition was the most influential model parameter. Conclusions: Although more information is needed regarding the impact of rectal CT/GC screening on HIV incidence, rectal CT/GC screening of MSM can potentially be a cost-effective, scalable intervention targeted to at-risk MSM in certain urban settings such as San Francisco. C1 [Chesson, Harrell W.; Gift, Thomas L.; Kent, Charlotte K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bernstein, Kyle T.; Marcus, Julia L.; Pipkin, Sharon] San Francisco Dept Publ Hlth, San Francisco, CA USA. RP Chesson, HW (reprint author), CDC Mailstop E-80,1600 Clifton Rd, Atlanta, GA 30333 USA. EM hbc7@cdc.gov NR 34 TC 21 Z9 21 U1 3 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAY PY 2013 VL 40 IS 5 BP 366 EP 371 DI 10.1097/OLQ.0b013e318284e544 PG 6 WC Infectious Diseases SC Infectious Diseases GA 126AK UT WOS:000317583300005 PM 23588125 ER PT J AU Leichliter, JS Chandra, A Aral, SO AF Leichliter, Jami S. Chandra, Anjani Aral, Sevgi O. TI Correlates of Self-Reported Pelvic Inflammatory Disease Treatment in Sexually Experienced Reproductive-Aged Women in the United States, 1995 and 2006-2010 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID RISK-FACTORS; DISPARITIES; INFERTILITY; VISITS; RATES AB Background: Few studies have examined recent temporal trends in self-reported receipt of pelvic inflammatory disease (PID) treatment. We assessed trends in receipt of PID treatment and associated correlates using national survey data. Methods: We used data from the National Survey of Family Growth, a multistage national probability survey of 15- to 44-year-old women. We examined trends in self-reported receipt of PID treatment from 1995, 2002, to 2006-2010. In addition, we examined correlates of PID treatment in 1995 and 2006-2010 in bivariate and adjusted analyses. Results: From 1995 to 2002, receipt of PID treatment significantly declined from 8.6% to 5.7% (P < 0.0001); however, there was no difference from 2002 to 2006-2010 (5.0%, P = 0.16). In bivariate analyses, racial differences in PID treatment declined across time; in 2006-2010, there was no significant difference between racial/ethnic groups (P = 0.22). Also in bivariate analyses, similar to 1995, in 2006 to 2010, some of the highest reports of receipt of PID treatment were women who were 35 to 44 years old (5.6%), had an income less than 150% of poverty level (7.5%), had less than high school education (6.7%), douched (7.7%), had intercourse before age 15 years (10.3%), and had 10 or more lifetime partners (8.0%). In adjusted analyses, differing from 1995, women at less than 150% of the poverty level were more likely (adjusted odds ratio [AOR], 2.60; 95% confidence interval [CI], 1.79-3.76) than women at 300% or more of the poverty level to have received PID treatment in 2006-2010. Conclusions: Receipt of PID treatment declined from 1995 to 2006-2010, with the burden affecting women of lower socioeconomic status. C1 [Leichliter, Jami S.; Aral, Sevgi O.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Chandra, Anjani] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat Hyattsville MD, Atlanta, GA 30333 USA. RP Leichliter, JS (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS E-44, Atlanta, GA 30333 USA. EM jleichliter@cdc.gov FU Intramural CDC HHS [CC999999] NR 31 TC 9 Z9 9 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAY PY 2013 VL 40 IS 5 BP 413 EP 418 DI 10.1097/OLQ.0b013e318285ce46 PG 6 WC Infectious Diseases SC Infectious Diseases GA 126AK UT WOS:000317583300013 PM 23588132 ER PT J AU Introcaso, CE Bradley, H Gruber, D Markowitz, LE AF Introcaso, Camille E. Bradley, Heather Gruber, DeAnn Markowitz, Lauri E. TI Missed Opportunities for Preventing Congenital Syphilis Infection SO SEXUALLY TRANSMITTED DISEASES LA English DT Letter C1 [Introcaso, Camille E.; Bradley, Heather; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Gruber, DeAnn] Louisiana Off Publ Hlth STD HIV Program, New Orleans, LA USA. RP Introcaso, CE (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. EM vie4@cdc.gov NR 4 TC 1 Z9 1 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAY PY 2013 VL 40 IS 5 BP 431 EP 431 DI 10.1097/OLQ.0b013e31828fce51 PG 1 WC Infectious Diseases SC Infectious Diseases GA 126AK UT WOS:000317583300017 PM 23584807 ER PT J AU Frye, V Henny, K Bonner, S Williams, K Bond, KT Hoover, DR Lucy, D Greene, E Koblin, BA AF Frye, Victoria Henny, Kirk Bonner, Sebastian Williams, Kim Bond, Keosha T. Hoover, Donald R. Lucy, Debbie Greene, Emily Koblin, Beryl A. CA Straight Talk Study Team TI "Straight Talk" for African-American heterosexual men: Results of a single-arm behavioral intervention trial SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV prevention; African-American; heterosexual; behavioral intervention; condom use; partner concurrency AB In the United States, heterosexual transmission is the second leading cause of HIV/AIDS, and two-thirds of all heterosexually acquired cases diagnosed between 2005 and 2008 occurred among African-Americans. Few HIV prevention interventions have been designed specifically for African-American heterosexual men not seeking clinical treatment. Here we report results of a single-arm intervention trial of a theory-based HIV prevention intervention designed to increase condom use, reduce concurrent partnering and increase HIV testing among heterosexually active African-American men living in high HIV prevalence areas of New York City. We tested our hypothesis using McNemar discordant pairs exact test for binary variables and paired t-tests for continuous variables. We observed statistically significant declines in mean number of total and new female partners, unprotected sex partners, and partner concurrency in both primary and nonprimary sex partnerships between baseline and 3 months postintervention. C1 [Frye, Victoria; Greene, Emily] New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Social & Behav Sci, New York, NY 10021 USA. [Frye, Victoria] Columbia Univ, Dept Sociomed Sci, Mailman Sch Publ Hlth, New York, NY USA. [Henny, Kirk; Williams, Kim] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Bonner, Sebastian; Bond, Keosha T.] New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY USA. [Hoover, Donald R.] Rutgers State Univ, Dept Stat & Biostat, Piscataway, NJ USA. [Hoover, Donald R.] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, Piscataway, NJ USA. [Lucy, Debbie; Koblin, Beryl A.] New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Infect Dis Prevent, New York, NY 10021 USA. [Greene, Emily] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. RP Frye, V (reprint author), New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Social & Behav Sci, New York, NY 10021 USA. EM vfrye@nybloodcenter.org OI Henny, Kirk/0000-0002-0886-8651 FU NCHHSTP CDC HHS [1-UR6/PS-000667-01, UR6 PS000667]; NIDA NIH HHS [K01 DA-020774, K01 DA020774, T32 DA031099] NR 7 TC 1 Z9 1 U1 0 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PD MAY 1 PY 2013 VL 25 IS 5 BP 627 EP 631 DI 10.1080/09540121.2012.722605 PG 5 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 122BW UT WOS:000317291300014 PM 23005899 ER PT J AU Cummings, KJ Gaughan, DM Green, BJ Beezhold, DH AF Cummings, Kristin J. Gaughan, Denise M. Green, Brett J. Beezhold, Donald H. TI Flu-like illness among workers at a soy processing plant SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Letter ID SENSITIZATION C1 [Cummings, Kristin J.] NIOSH, Ctr Dis Control & Prevent, Div Resp Dis Studies, Morgantown, WV 26505 USA. [Gaughan, Denise M.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm & Occupat Med & Epidemiol Program, Boston, MA 02115 USA. [Green, Brett J.; Beezhold, Donald H.] NIOSH, Ctr Dis Control & Prevent, Hlth Effects Lab Div, Morgantown, WV 26505 USA. RP Cummings, KJ (reprint author), NIOSH, Ctr Dis Control & Prevent, 1095 Willowdale Rd,MS 2800, Morgantown, WV 26505 USA. EM kcummings@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD MAY PY 2013 VL 56 IS 5 BP 520 EP 521 DI 10.1002/ajim.22131 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 127GA UT WOS:000317684400003 PM 23359382 ER PT J AU Akpinar-Elci, M White, SK Siegel, PD Park, JH Visotcky, A Kreiss, K Cox-Ganser, JM AF Akpinar-Elci, Muge White, Sandra K. Siegel, Paul D. Park, Ju-Hyeong Visotcky, Alexis Kreiss, Kathleen Cox-Ganser, Jean M. TI Markers of upper airway inflammation associated with microbial exposure and symptoms in occupants of a water-damaged building SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Editorial Material DE building-related symptoms; indoor air quality; nasal lavage; nasal nitric oxide ID NASAL NITRIC-OXIDE; RESPIRATORY SYMPTOMS; LAVAGE BIOMARKERS; WORKERS; DUST; ENVIRONMENTS; RHINITIS; PATENCY; ASTHMA; ATOPY AB Background Water damage in buildings has been associated with reports of upper airway inflammation among occupants. Methods This survey included a questionnaire, allergen skin testing, nasal nitric oxide, and nasal lavage on 153 participants. We conducted exposure assessments of 297 workstations and analyzed collected dust for fungi, endotoxin, and (13)--D-glucan to create floor-specific averages. Results Males had higher levels of nasal inflammatory markers, and females reported more symptoms. ECP, IL-8, and MPO were significantly associated with nasal symptoms, flu-like achiness, or chills. Fungi and glucan were positively associated with blowing out thick mucus. Endotoxin was significantly associated with ECP in overall models, and with ECP, IL-8, MPO, and neutrophils among non-atopic females. Conclusions In this study, we documented an association between endotoxin and nasal inflammatory markers among office workers. The results of our study suggest that a non-allergic response may contribute to symptoms occurring among occupants in this water-damaged building. Am. J. Ind. Med. 56:522530, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Akpinar-Elci, Muge; White, Sandra K.; Park, Ju-Hyeong; Visotcky, Alexis; Kreiss, Kathleen; Cox-Ganser, Jean M.] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Akpinar-Elci, Muge] St Georges Univ, Sch Med, Dept Publ Hlth & Prevent Med, Grenada, WI USA. [Siegel, Paul D.] NIOSH, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. RP White, SK (reprint author), 1095 Willowdale Rd,MS-2800, Morgantown, WV 26505 USA. EM sqg8@cdc.gov NR 37 TC 6 Z9 6 U1 4 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD MAY PY 2013 VL 56 IS 5 BP 522 EP 530 DI 10.1002/ajim.22165 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 127GA UT WOS:000317684400004 PM 23390064 ER PT J AU Helmkamp, JC Lincoln, JE Sestito, J Wood, E Birdsey, J Kiefer, M AF Helmkamp, James C. Lincoln, Jennifer E. Sestito, John Wood, Eric Birdsey, Jan Kiefer, Max TI Risk factors, health behaviors, and injury among adults employed in the transportation, warehousing, and utilities super sector SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE transportation; warehousing; utilities; risk factors; health behaviors; disability measures; injury ID SHORT-SLEEP DURATION; WORK-RELATED INJURY; INTERVIEW SURVEY; UNITED-STATES; TRUCK DRIVERS; PROFESSIONAL DRIVERS; US WORKERS; OCCUPATION; INDUSTRY; POPULATION AB Background The TWU super sector is engaged in the movement of passengers and cargo, warehousing of goods, and the delivery of services. The purpose of this study is to describe employee self-reported personal risk factors, health behaviors and habits, disease and chronic conditions, and employer-reported nonfatal injury experiences of workers in the TWU super sector. Methods National Health Interview Survey (NHIS) data for 19972007, grouped into six morbidity and disability categories and three age groups, were reviewed. Demographic characteristics and prevalence estimates are reported for workers in the TWU super sector and the entire U.S. workforce, and compared with national adult population data from the NHIS. Bureau of Labor Statistics employer-reported TWU injury data from 2003 to 2007 was also reviewed. Results An average of 8.3 million workers were employed annually in the TWU super sector. TWU workers 65 or older reported the highest prevalence of hypertension (49%) across all industry sectors, but the 20% prevalence is notable among middle age workers (2564). TWU workers had the highest prevalence of obesity (28%), compared to workers in all other industry sectors. Female TWU workers experienced the highest number of lost workdays (6.5) in the past year across all TWU demographic groups. Conclusions Self-reported high proportions of chronic conditions including hypertension and heart disease combined with elevated levels of being overweight and obese, and lack of physical activityparticularly among TWUs oldest workerscan meaningfully inform wellness strategies and interventions focused on this demographic group. Am. J. Ind. Med. 56:556568, 2013. (c) 2012 Wiley Periodicals, Inc. C1 [Helmkamp, James C.; Kiefer, Max] NIOSH, Western States Off, Ctr Dis Control & Prevent, Denver, CO 80225 USA. [Lincoln, Jennifer E.] NIOSH, Div Safety Res, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Sestito, John; Birdsey, Jan] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Wood, Eric] Univ Utah, Rocky Mt Ctr Occupat & Environm Med, Salt Lake City, UT USA. RP Helmkamp, JC (reprint author), NIOSH, Western States Off, Denver Fed Ctr, POB 25226, Denver, CO 80225 USA. EM jch4@cdc.gov FU Intramural CDC HHS [CC999999] NR 64 TC 7 Z9 7 U1 0 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD MAY PY 2013 VL 56 IS 5 BP 556 EP 568 DI 10.1002/ajim.22148 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 127GA UT WOS:000317684400008 PM 23255331 ER PT J AU Grubbs, V Plantinga, LC Tuot, DS Hedgeman, E Saran, R Saydah, S Rolka, D Powe, NR AF Grubbs, Vanessa Plantinga, Laura C. Tuot, Delphine S. Hedgeman, Elizabeth Saran, Rajiv Saydah, Sharon Rolka, Deborah Powe, Neil R. CA Ctr Dis Control Prevention CKD TI Americans' Use of Dietary Supplements That Are Potentially Harmful in CKD SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Dietary supplements; chronic kidney disease; risk factor ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; UNITED-STATES; ALTERNATIVE MEDICINE; SERUM CREATININE; NATIONAL-HEALTH; CHINESE HERBS; COMPLEMENTARY; NEPHROPATHY; POPULATION AB Background: The prevalence in the United States of dietary supplement use that may be harmful to those with chronic kidney disease (CKD) is unknown. We sought to characterize potentially harmful supplement use by individual CKD status. Study Design: Cross-sectional national survey (National Health and Nutrition Examination Survey, 1999-2008). Setting & Participants: Community-based survey of 21,169 nonpregnant noninstitutionalized US civilian adults (aged >= 20 years). Predictor: CKD status (no CKD, at risk of CKD [presence of diabetes, hypertension, and/or cardiovascular disease], stages 1/2 [albuminuria only (albumin-creatinine ratio >= 30 mg/g)], or stages 3/4 [estimated glomerular filtration rate of 15-59 mL/min/1.73 m(2)]). Outcome: Self-reported use of dietary supplements containing any of 37 herbs the National Kidney Foundation identified as potentially harmful in the setting of CKD. Measurements: Albuminuria and estimated glomerular filtration rate assessed from urine and blood samples; demographics and comorbid conditions assessed by standardized questionnaire. Results: An estimated 8.0% of US adults reported potentially harmful supplement use within the last 30 days. A lower crude estimated prevalence of potentially harmful supplement use was associated with higher CKD severity (no CKD, 8.5%; at risk, 8.0%; stages 1/2, 6.1%; and stages 3/4, 6.2%; P < 0.001). However, after adjustment for confounders, those with or at risk of CKD were as likely to use a potentially harmful supplement as those without CKD: at-risk OR, 0.93 (95% CI, 0.79-1.09); stages 1/2 OR, 0.83 (95% CI, 0.64-1.08); and stages 3/4 OR, 0.87 (95% CI, 0.63-1.18); all versus no CKD. Limitations: Herb content was not available and the list of potentially harmful supplements examined is unlikely to be exhaustive. Conclusions: The use of dietary supplements potentially harmful to people with CKD is common regardless of CKD status. Health care providers should discuss the use and potential risks of supplements with patients with and at risk of CKD. Am J Kidney Dis. 61(5): 739-747. (C) 2013 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. C1 [Grubbs, Vanessa; Tuot, Delphine S.] Univ Calif San Francisco, Div Nephrol, San Francisco Gen Hosp, San Francisco, CA 94110 USA. [Plantinga, Laura C.; Powe, Neil R.] Univ Calif San Francisco, Dept Med, San Francisco Gen Hosp, San Francisco, CA 94110 USA. [Hedgeman, Elizabeth; Saran, Rajiv] Univ Michigan, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA. [Saydah, Sharon; Rolka, Deborah] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. RP Grubbs, V (reprint author), Univ Calif San Francisco, Div Nephrol, San Francisco Gen Hosp, Renal Ctr, Box 1341,1001 Potrero Ave,Bldg 100,Rm 342, San Francisco, CA 94110 USA. EM grubbsv@medsfgh.ucsf.edu FU CDC [1U58DP003839-01]; National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) [R01 DK78124, R01 DK70939]; Robert Wood Johnson Foundation; National Center for Research Resources [KL2RR024130] FX This project was supported under a cooperative agreement from the CDC, grant 1U58DP003839-01. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. Dr Powe was partially supported by grant R01 DK78124 from the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK). Dr Grubbs was also supported by the NIDDK through a Diversity Supplement to grant R01 DK70939 and by the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. Dr Tuot was supported by award number KL2RR024130 from the National Center for Research Resources. NR 38 TC 11 Z9 11 U1 1 U2 9 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAY PY 2013 VL 61 IS 5 BP 739 EP 747 DI 10.1053/j.ajkd.2012.12.018 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 121WV UT WOS:000317276600015 PM 23415417 ER PT J AU Gupta, S Siddiqi, AEA Soucie, JM Manco-Johnson, M Kulkarni, R Lane, H Ingram-Rich, R Gill, JC AF Gupta, Sweta Siddiqi, Azfar-E-Alam Soucie, J. Michael Manco-Johnson, Marilyn Kulkarni, Roshni Lane, Heidi Ingram-Rich, Robina Gill, Joan C. CA Joint Outcomes Comm Universal Data Hemophilia Treatment Ctr Network TI The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Article DE secondary prophylaxis; episodic treatment; haemophilia; range of motion; target joint ID COST-EFFECTIVENESS; CHILDREN; DAMAGE; DISEASE; PATHOGENESIS; EXPERIENCE; ARTHRITIS; SYNOVITIS; BOYS AB This study prospectively compared the effect of secondary prophylaxis to episodic treatment on target joint (TJ) range of motion (ROM), number of joint haemorrhages and new TJ development in patients with moderate or severe haemophilia. Two-hundred and eighty-six males, 17% in prophylaxis, 83% in episodic treatment group, participating in the Centers for Disease Control and Prevention's Universal Data Collection project, fulfilled inclusion criteria: age >2years at enrolment, free of TJs at enrolment, developed at least one TJ after enrolment, and received either prophylaxis or episodic treatment continuously for two follow-up visits after TJ development. The outcomes of interest percentage change in TJ ROM, number of joint haemorrhages and new TJ development, were modelled using multivariate linear, Poisson and logistic regression techniques respectively. Individuals who received secondary prophylaxis in comparison to episodic treatment were younger at TJ development (P<0 center dot 01); there was no difference in the decrease in TJ ROM between the two groups (P=0 center dot 9). Factors significantly associated with a higher rate of haemarthroses included episodic treatment, severe haemophilia, age >5years at TJ development, obesity and inhibitor negative status. Secondary prophylaxis significantly decreased haemarthroses but was not associated with a significant improvement in TJ ROM or with new TJ development. C1 [Gupta, Sweta] Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN 46260 USA. [Siddiqi, Azfar-E-Alam; Soucie, J. Michael] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Manco-Johnson, Marilyn] Univ Colorado, Denver, CO 80202 USA. [Kulkarni, Roshni] Michigan State Univ, E Lansing, MI 48824 USA. [Lane, Heidi] Primary Childrens Med Ctr, Intermt Hemophilia & Thrombosis Ctr, Salt Lake City, UT 84103 USA. [Ingram-Rich, Robina] Oregon Hlth & Sci Univ, Oregon Hemophilia Ctr, CDRC Doernbecher Childrens Hosp, Portland, OR 97201 USA. [Gill, Joan C.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Gill, Joan C.] Blood Ctr Wisconsin, Comprehens Ctr Bleeding Disorders, Milwaukee, WI USA. RP Gupta, S (reprint author), Indiana Hemophilia & Thrombosis Ctr, 8402 Harcourt Rd,Suite 500, Indianapolis, IN 46260 USA. EM sgupta@ihtc.org RI Kerlin, Bryce/E-3369-2011 OI Kerlin, Bryce/0000-0002-1756-8271 FU NCATS NIH HHS [UL1 TR000055] NR 35 TC 6 Z9 7 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1048 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD MAY PY 2013 VL 161 IS 3 BP 424 EP 433 DI 10.1111/bjh.12267 PG 10 WC Hematology SC Hematology GA 126GV UT WOS:000317602300016 PM 23432684 ER PT J AU Raiford, JL Seth, P DiClemente, RJ AF Raiford, Jerris L. Seth, Puja DiClemente, Ralph J. TI What Girls Won't Do for Love: Human Immunodeficiency Virus/Sexually Transmitted Infections Risk Among Young African-American Women Driven by a Relationship Imperative SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Relationships; Sexual behavior; STIs; African-American; Adolescents ID INTIMATE PARTNER VIOLENCE; SEXUAL-BEHAVIOR; ROMANTIC RELATIONSHIPS; FEMALE ADOLESCENTS; UNITED-STATES; HIV; INTERVENTIONS; GENDER; ASSOCIATIONS; PREVALENCE AB Purpose: Rates of Human immunodeficiency virus (HIV) and other sexually transmitted infections (STIs) continue to increase among African-American youth. Adolescents who have a stronger identity in relation to others (relational identity) rather than to themselves (self-identity) may view intimate relationships as imperative to a positive self-concept, which may lead to risky sexual behavior and abuse. Therefore, the present study assessed the associations among a relationship imperative and HIV/STI-related risk factors and behaviors. Methods: Participants were 715 African-American adolescent females, aged 15 to 21 years. They completed measures that assessed how important a relationship was to them and HIV-related risk factors and behaviors. Participants also provided vaginal swab specimens for STI testing. Results: Multivariate logistic regression analyses, controlling for covariates, were conducted. Females who endorsed a relationship imperative (29%), compared to those who did not, were more likely to report: unprotected sex, less power in their relationships, perceived inability to refuse sex, anal sex, sex while their partner was high on alcohol/drugs, and partner abuse. Furthermore, participants with less power, recent partner abuse, and a perceived ability to refuse sex were more likely to test STI positive. Conclusion: These results indicate that if African-American adolescent females believe a relationship is imperative, they are more likely to engage in riskier sexual behaviors. Additionally, less perceived power and partner abuse increases their risk for STIs. HIV/STI prevention programs should target males and females and address healthy relationships, sense of self-worth, self-esteem and the gender power imbalance that may persist in the community along with HIV/STI risk. Published by Elsevier Inc on behalf of Society for Adolescent Health and Medicine. C1 [Raiford, Jerris L.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Seth, Puja; DiClemente, Ralph J.] Emory Univ, Dept Behav Sci & Hlth Educ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Seth, Puja; DiClemente, Ralph J.] Emory Ctr AIDS Res, Social & Behav Sci Core, Atlanta, GA USA. RP Raiford, JL (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,Mailstop E-37, Atlanta, GA 30333 USA. EM jraiford@cdc.gov FU National Institute of Mental Health [R01-MH061210] FX This study was supported by a grant from the National Institute of Mental Health (R01-MH061210) awarded to the third author. NR 37 TC 14 Z9 14 U1 2 U2 26 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD MAY PY 2013 VL 52 IS 5 BP 566 EP 571 DI 10.1016/j.jadohealth.2012.09.006 PG 6 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 126ZD UT WOS:000317661300011 PM 23298990 ER PT J AU Major, NE Peacock, G Ruben, W Thomas, J Weitzman, CC AF Major, Nili E. Peacock, Georgina Ruben, Wendy Thomas, Jana Weitzman, Carol C. TI Autism Training in Pediatric Residency: Evaluation of a Case-Based Curriculum SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE Autism; Medical education; Residency; Curriculum ID SPECTRUM DISORDERS; PRIMARY-CARE; MEDICAL HOMES; CHILDREN; HEALTH AB Despite recent studies indicating the high prevalence of autism spectrum disorders (ASDs), there has been little focus on improving ASD education during pediatric residency training. The objective of this study was to evaluate a new curriculum developed in partnership with the Centers for Disease Control and Prevention and the Maternal and Child Health Bureau about ASDs. "Autism Case Training (ACT): A Developmental-Behavioral Pediatrics Curriculum" consists of 7 case-based teaching modules. Modules were facilitated by faculty at 26 pediatric residency programs and data were obtained on 114 residents. Pre- and post-test data revealed significant short-term improvements in residents' knowledge and self-assessed competence regarding ASDs. Findings suggest that the ACT curriculum is effective in enhancing training about ASDs in pediatric residency programs. C1 [Major, Nili E.; Weitzman, Carol C.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA. [Peacock, Georgina] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ruben, Wendy; Thomas, Jana] Porter Novelli, Atlanta, GA USA. RP Major, NE (reprint author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St,POB 208064, New Haven, CT 06520 USA. EM nili.major@yale.edu; carol.weitzman@yale.edu NR 21 TC 4 Z9 4 U1 2 U2 9 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD MAY PY 2013 VL 43 IS 5 BP 1171 EP 1177 DI 10.1007/s10803-012-1662-1 PG 7 WC Psychology, Developmental SC Psychology GA 122YX UT WOS:000317355800015 PM 23008057 ER PT J AU Zulz, T Wenger, JD Rudolph, K Robinson, DA Rakov, AV Bruden, D Singleton, RJ Bruce, MG Hennessy, TW AF Zulz, Tammy Wenger, Jay D. Rudolph, Karen Robinson, D. Ashley Rakov, Alexey V. Bruden, Dana Singleton, Rosalyn J. Bruce, Michael G. Hennessy, Thomas W. TI Molecular Characterization of Streptococcus pneumoniae Serotype 12F Isolates Associated with Rural Community Outbreaks in Alaska SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID INVASIVE PNEUMOCOCCAL DISEASE; FIELD GEL-ELECTROPHORESIS; POLYSACCHARIDE VACCINE; CONJUGATE VACCINE; EPIDEMIOLOGIC EVIDENCE; NATIVE CHILDREN; IMPACT; RECOMMENDATIONS; COLONIZATION; CARRIAGE AB Outbreaks of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae serotype 12F were observed in two neighboring regions of rural Alaska in 2003 to 2006 and 2006 to 2008. IPD surveillance data from 1986 to 2009 and carriage survey data from 1998 to 2004 and 2008 to 2009 were reviewed to identify patterns of serotype 12F transmission. Pulsed-field gel electrophoresis was performed on all available isolates, and selected isolates were characterized by additional genetic subtyping methods. Serotype 12F IPD occurred in two waves in Alaska between 1986 and 2008. While cases of disease occurred nearly every year in Anchorage, in rural regions, 12F IPD occurred with rates 10- to 20-fold higher than those in Anchorage, often with many years between disease peaks and generally caused by a single predominant genetic clone. Carriage occurred predominantly in adults, except early in the rural outbreaks, when most carriage was in persons < 18 years old. In rural regions, carriage of 12F disappeared completely after outbreaks. Different 12F clones appear to have been introduced episodically into rural populations, spread widely in young, immunologically naive populations (leading to outbreaks of IPD lasting 1 to 3 years), and then disappeared rapidly from the population. Larger population centers might have been the reservoir for these clones. This epidemiologic pattern is consistent with a highly virulent, but immunogenic, form of pneumococcus. C1 [Zulz, Tammy; Wenger, Jay D.; Rudolph, Karen; Bruden, Dana; Singleton, Rosalyn J.; Bruce, Michael G.; Hennessy, Thomas W.] Ctr Dis Control & Prevent, Arctic Invest Program, DPEI, NCEZID, Anchorage, AK USA. [Rudolph, Karen; Robinson, D. Ashley; Rakov, Alexey V.] Univ Mississippi, Med Ctr, Dept Microbiol, Jackson, MS 39216 USA. RP Zulz, T (reprint author), Ctr Dis Control & Prevent, Arctic Invest Program, DPEI, NCEZID, Anchorage, AK USA. EM tsc3@cdc.gov OI Rakov, Alexey/0000-0003-1917-9189 FU Pfizer, Inc.; National Institutes of Health [AI079345] FX This work was supported by Pfizer, Inc., and the National Institutes of Health (grant AI079345 to D.A.R.). NR 29 TC 5 Z9 5 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAY PY 2013 VL 51 IS 5 BP 1402 EP 1407 DI 10.1128/JCM.02880-12 PG 6 WC Microbiology SC Microbiology GA 126GT UT WOS:000317602100009 PM 23408692 ER PT J AU Fuchs, EJ Grohskopf, LA Lee, LA Bakshi, RP Hendrix, CW AF Fuchs, Edward J. Grohskopf, Lisa A. Lee, Linda A. Bakshi, Rahul P. Hendrix, Craig W. TI Quantitative Assessment of Altered Rectal Mucosal Permeability Due to Rectally Applied Nonoxynol-9, Biopsy, and Simulated Intercourse SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE HIV rectal microbicide; epithelial disruption; mucosal permeability; Nonoxynol-9 ID INFLAMMATORY-BOWEL-DISEASE; INTESTINAL PERMEABILITY; COLONIC PERMEABILITY; HIV TRANSMISSION; VAGINAL GEL; SEX WORKERS; SAFETY; MICROBICIDE; TRIAL; CR-51-EDTA AB Methods. Ten subjects received 3 one-time interventions: 5 mL of Normosol-R fluid alone (negative control), 5 mL of 2% nonoxynol-9 (N-9) gel, and 5 mL of Normosol-R with coital simulation and sigmoidoscopic biopsy (CS + BX). Each dose of N-9 and Normosol-R contained 500 mu Ci of (99m)technetium-diethylene triamine pentaacetic acid. Plasma and urine radioactivity was assessed over 24 hours. Results. The plasma radioisotope concentration peaked 1 hour after N-9 dosing. The mean maximum radioisotope concentration after N-9 receipt was 12.0 times (95% confidence interval [CI], 6.8-21.0) and 8.4 times (95% CI, 5.2-13.5) the mean concentration after Normosol-R control receipt and CS + BX receipt, respectively; paired differences persisted for 24 hours. After N-9 dosing, the urine isotope level was 3.6 times (95% CI, 1.1-11.4) the level observed 8 hours after Normosol-R control receipt and 4.0 times (95% CI, 1.4-11.4) the level observed 4 hours after CS + BX receipt. Permeability after CS + BX receipt was greater than that after Normosol-R control receipt in 0-2-hour urine specimens only (mean permeability, 2.4; 95% CI, 1.0-5.8) but was not greater in blood. Conclusions. Plasma sampling after rectal radioisotope administration provided quantitative estimates of altered mucosal permeability after chemical and mechanical stresses. Permeability testing may provide a useful noninvasive adjunct to assess the mucosal effects of candidate microbicides. Clinical Trials Registration. NCT00389311. C1 [Fuchs, Edward J.; Bakshi, Rahul P.; Hendrix, Craig W.] Johns Hopkins Univ, Sch Med, Div Clin Pharmacol, Baltimore, MD 21287 USA. [Lee, Linda A.] Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21287 USA. [Grohskopf, Lisa A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Fuchs, EJ (reprint author), Johns Hopkins Univ, Sch Med, Div Clin Pharmacol, Blalock 569,600 N Wolfe St, Baltimore, MD 21287 USA. EM ejfuchs@jhmi.edu RI Hendrix, Craig/G-4182-2014; OI Hendrix, Craig/0000-0002-5696-8665; Bakshi, Rahul/0000-0003-1478-1031 FU Centers for Disease Control and HIV Prevention [200-2001-08015]; National Institutes of Health National Center for Research Resources [M01-RR000052] FX This work was supported by the Centers for Disease Control and HIV Prevention (contract 200-2001-08015) and the National Institutes of Health National Center for Research Resources (grant M01-RR000052 to the Johns Hopkins General Clinical Research Center). NR 29 TC 5 Z9 5 U1 0 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 1 PY 2013 VL 207 IS 9 BP 1389 EP 1396 DI 10.1093/infdis/jit030 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 124AJ UT WOS:000317434600006 PM 23325915 ER PT J AU Mahajan, R Moorman, AC Liu, SJ Rupp, L Klevens, RM AF Mahajan, Reena Moorman, Anne C. Liu, Stephen J. Rupp, Loralee Klevens, R. Monina CA Chronic Hepatitis Cohort Study TI Use of the International Classification of Diseases, 9th revision, coding in identifying chronic hepatitis B virus infection in health system data: implications for national surveillance SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID CLOSTRIDIUM-DIFFICILE INFECTIONS; CLINICAL-MODIFICATION CODES; CARE-ASSOCIATED INFECTIONS; OF-DISEASES; ADMINISTRATIVE DATABASES; VIRAL-HEPATITIS; 9TH-REVISION; PREVALENCE; DIAGNOSES; ACCURACY AB Objective With increasing use electronic health records (EHR) in the USA, we looked at the predictive values of the International Classification of Diseases, 9th revision (ICD-9) coding system for surveillance of chronic hepatitis B virus (HBV) infection. Materials and Methods The chronic HBV cohort from the Chronic Hepatitis Cohort Study was created based on electronic health records (EHR) of adult patients who accessed services from 2006 to 2008 from four healthcare systems in the USA. Using the gold standard of abstractor review to confirm HBV cases, we calculated the sensitivity, specificity, positive and negative predictive values using one qualifying ICD-9 code versus using two qualifying ICD-9 codes separated by 6 months or greater. Results Of 1 652 055 adult patients, 2202 (0.1%) were confirmed as having chronic HBV. Use of one ICD-9 code had a sensitivity of 83.9%, positive predictive value of 61.0%, and specificity and negative predictive values greater than 99%. Use of two hepatitis B-specific ICD-9 codes resulted in a sensitivity of 58.4% and a positive predictive value of 89.9%. Discussion Use of one or two hepatitis B ICD-9 codes can identify cases with chronic HBV infection with varying sensitivity and positive predictive values. Conclusions As the USA increases the use of EHR, surveillance using ICD-9 codes may be reliable to determine the burden of chronic HBV infection and would be useful to improve reporting by state and local health departments. C1 [Mahajan, Reena; Moorman, Anne C.; Liu, Stephen J.; Klevens, R. Monina] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Rupp, Loralee] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA. RP Mahajan, R (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Mailstop G37,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM vif5@cdc.gov FU CDC Foundation; Abbott Laboratories; Genentech; Janssen Pharmaceutical Companies of Johnson Johnson; Vertex Pharmaceuticals FX The Chronic Hepatitis Cohort Study (CHeCS) was funded by the CDC Foundation, which received grants from Abbott Laboratories, Genentech, a member of the Roche Group, Janssen Pharmaceutical Companies of Johnson & Johnson and Vertex Pharmaceuticals. Granting corporations do not have access to CHeCS data and do not contribute to data analysis or writing of manuscripts. NR 26 TC 3 Z9 3 U1 1 U2 18 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD MAY PY 2013 VL 20 IS 3 BP 441 EP 445 DI 10.1136/amiajnl-2012-001558 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA 124PP UT WOS:000317477500007 PM 23462875 ER PT J AU Jentes, ES Blanton, JD Johnson, KJ Petersen, BW Lamias, MJ Robertson, K Franka, R Briggs, D Costa, P Lai, I Quarry, D Rupprecht, CE Marano, N Brunette, GW AF Jentes, Emily S. Blanton, Jesse D. Johnson, Katherine J. Petersen, Brett W. Lamias, Mark J. Robertson, Kis Franka, Richard Briggs, Deborah Costa, Peter Lai, Irene Quarry, Doug Rupprecht, Charles E. Marano, Nina Brunette, Gary W. TI The Global Availability of Rabies Immune Globulin and Rabies Vaccine in Clinics Providing Direct Care to Travelers SO JOURNAL OF TRAVEL MEDICINE LA English DT Article ID INTERNATIONAL TRAVELERS; FOREIGN BACKPACKERS; KNOWLEDGE; RISK; ATTITUDES; ADVISERS; ASIA AB Background Rabies, which is globally endemic, poses a risk to international travelers. To improve recommendations for travelers, we assessed the global availability of rabies vaccine (RV) and rabies immune globulin (RIG). Methods We conducted a 20-question online survey, in English, Spanish, and French, distributed via e-mail to travel medicine providers and other clinicians worldwide from February 1 to March 30, 2011. Results were compiled according to the region. Results Among total respondents, only 190 indicated that they provided traveler postexposure care. Most responses came from North America (38%), Western Europe (19%), Australia and South and West Pacific Islands (11%), East and Southeast Asia (8%), and Southern Africa (6%). Approximately one third of 187 respondents stated that patients presented with wounds from an animal exposure that were seldom or never adequately cleansed. RIG was often or always accessible for 100% (n=5) of respondents in the Middle East and North Africa; 94% (n=17) in Australia and South and West Pacific Islands; 20% (n=1) in Tropical South America; and 56% (n=5) in Eastern Europe and Northern Asia. Ninety-one percent (n=158) of all respondents reported that RV was often or always accessible. For all regions, 35% (n=58) and 26% (n=43) of respondents felt that the cost was too high for RIG and RV, respectively. Conclusion The availability of RV and RIG varied by geographic region. All travelers should be informed that RIG and RV might not be readily available at their destination and that travel health and medical evacuation insurance should be considered prior to departure. Travelers should be educated to avoid animal exposures; to clean all animal bites, licks, and scratches thoroughly with soap and water; and to seek medical care immediately, even if overseas. C1 [Jentes, Emily S.; Johnson, Katherine J.; Marano, Nina; Brunette, Gary W.] Ctr Dis Control & Prevent CDC, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. [Blanton, Jesse D.; Petersen, Brett W.; Robertson, Kis; Franka, Richard; Rupprecht, Charles E.] CDC, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Lamias, Mark J.] CDC, Off Informat, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Lamias, Mark J.] Sci Applicat Int Corp, Atlanta, GA USA. [Briggs, Deborah; Costa, Peter] Global Alliance Rabies Control, Manhattan, KS USA. [Lai, Irene; Quarry, Doug] Int SOS, Med Informat & Anal, Sydney, NSW, Australia. RP Jentes, ES (reprint author), Ctr Dis Control & Prevent CDC, Div Global Migrat & Quarantine, 1600 Clifton Rd NE,MS E-03, Atlanta, GA 30333 USA. EM EFJ8@CDC.GOV OI Lai, Irene/0000-0002-2376-0593 NR 18 TC 19 Z9 19 U1 0 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1195-1982 J9 J TRAVEL MED JI J. Travel Med. PD MAY-JUN PY 2013 VL 20 IS 3 BP 148 EP 158 DI 10.1111/jtm.12024 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 127DZ UT WOS:000317677600004 PM 23577860 ER PT J AU Duffy, MR Reed, C Edelson, PJ Blumensaadt, S Crocker, K Griggs, A Biggerstaff, BJ Delorey, MJ Hayes, EB Fischer, M AF Duffy, Mark R. Reed, Christie Edelson, Paul J. Blumensaadt, Sena Crocker, Kimberly Griggs, Anne Biggerstaff, Brad J. Delorey, Mark J. Hayes, Edward B. Fischer, Marc TI A Survey of US Travelers to Asia to Assess Compliance With Recommendations for the Use of Japanese Encephalitis Vaccine SO JOURNAL OF TRAVEL MEDICINE LA English DT Article ID VIRUS AB Background Japanese encephalitis (JE) vaccine is recommended for travelers to Asia whose itineraries increase their risk of exposure to JE virus. The numbers of travelers with such itineraries and the proportion of those who receive JE vaccine are unknown. We performed a survey to estimate the proportion of US travelers to Asia who receive JE vaccine according to the Advisory Committee on Immunization Practices (ACIP) recommendations. Methods We surveyed US residents 18years old departing on 38 flights to Asia selected through a stratified random sample of all direct flights to JE-endemic countries from three US airports. We asked participants about planned itineraries and activities, sources of travel health information, JE vaccination status, and potential barriers to vaccination. Participants planning to spend 30days in Asia or at least half of their time in rural areas were defined as higher JE risk travelers for whom vaccination should have been considered. Results Of 2,341 eligible travelers contacted, 1,691(72%) completed the survey. Among these 1,691 participants, 415 (25%) described itineraries for which JE vaccination should have been considered. Of these 415 higher JE risk travelers, only 47 (11%) reported receiving 1 dose of JE vaccine. Of the 164 unvaccinated higher JE risk travelers who visited a health care provider before their trip, 113 (69%) indicated that they had never heard of JE vaccine or their health care provider had not offered or recommended JE vaccine. Conclusions A quarter of surveyed US travelers to Asia reported planned itineraries for which JE vaccination should have been considered. However, few of these at-risk travelers received JE vaccine. C1 [Duffy, Mark R.; Griggs, Anne; Biggerstaff, Brad J.; Delorey, Mark J.; Hayes, Edward B.; Fischer, Marc] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Reed, Christie] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. [Edelson, Paul J.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, New York, NY USA. [Blumensaadt, Sena] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Chicago, IL USA. [Crocker, Kimberly] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Los Angeles, CA USA. RP Fischer, M (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM mfischer@cdc.gov NR 23 TC 7 Z9 8 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1195-1982 J9 J TRAVEL MED JI J. Travel Med. PD MAY-JUN PY 2013 VL 20 IS 3 BP 165 EP 170 DI 10.1111/jtm.12020 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 127DZ UT WOS:000317677600006 PM 23577862 ER PT J AU Davis, XM Hay, KA Plier, DA Chaves, SS Lim, PL Caumes, E Castelli, F Kozarsky, PE Cetron, MS Freedman, DO AF Davis, Xiaohong M. Hay, Kelly A. Plier, D. Adam Chaves, Sandra S. Lim, Poh Lian Caumes, Eric Castelli, Francesco Kozarsky, Phyllis E. Cetron, Martin S. Freedman, David O. CA GeoSentinel Surveillance Network TI International Travelers as Sentinels for Sustained Influenza Transmission During the 2009 Influenza A(H1N1)pdm09 Pandemic SO JOURNAL OF TRAVEL MEDICINE LA English DT Article ID A H1N1 VIRUS; ENHANCED SURVEILLANCE; INFECTIONS; AGE AB Background International travelers were at risk of acquiring influenza A(H1N1)pdm09 (H1N1pdm09) virus infection during travel and importing the virus to their home or other countries. Methods Characteristics of travelers reported to the GeoSentinel Surveillance Network who carried H1N1pdm09 influenza virus across international borders into a receiving country from April 1, 2009, through October 24, 2009, are described. The relationship between the detection of H1N1pdm09 in travelers and the level of H1N1pdm09 transmission in the exposure country as defined by pandemic intervals was examined using analysis of variance (anova). Results Among the 203 (189 confirmed; 14 probable) H1N1pdm09 case-travelers identified, 56% were male; a majority, 60%, traveled for tourism; and 20% traveled for business. Paralleling age profiles in population-based studies only 13% of H1N1pdm09 case-travelers were older than 45 years. H1N1pdm09 case-travelers sought pre-travel medical advice less often (8%) than travelers with non-H1N1pdm09 unspecified respiratory illnesses (24%), and less often than travelers with nonrespiratory illnesses (43%; p<0.0001). The number of days from first official H1N1pdm09 case reported by a country to WHO and the first GeoSentinel site report of a H1N1pdm09-exported case in a traveler originated from that country was inversely associated with each country's assigned pandemic interval, or local level of transmission intensity. Conclusion Detection of travel-related cases appeared to be a reliable indicator of sustained influenza transmission within the exposure country and may aid planning for targeted surveillance, interventions, and quarantine protocols. C1 [Davis, Xiaohong M.; Hay, Kelly A.; Cetron, Martin S.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Plier, D. Adam; Freedman, David O.] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Chaves, Sandra S.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Lim, Poh Lian] Tan Tock Seng Hosp, Dept Infect Dis, Singapore, Singapore. [Caumes, Eric] Hop La Pitie Salpetriere, Dept Infect & Trop Dis, Paris, France. [Castelli, Francesco] Univ Brescia, Inst Infect & Trop Dis, Brescia, Italy. [Kozarsky, Phyllis E.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA. RP Freedman, DO (reprint author), Univ Alabama Birmingham, Sch Med, Dept Med, Div Infect Dis, 1530 3rd Ave South,BBRB 203, Birmingham, AL 35294 USA. EM freedman@uab.edu FU GeoSentinel Surveillance Network; Centers for Disease Control and Prevention (CDC) [5U50CI000359]; European Centre for Disease Prevention and Control (ECDC) [OJ/2008/07/08-PROC/2008/019]; International Society of Travel Medicine (ISTM); CDC; Baxter; Crucell; Sanofi FX This work was supported by the GeoSentinel Surveillance Network through a cooperative agreement with the Centers for Disease Control and Prevention (CDC; grant 5U50CI000359), by a tender from the European Centre for Disease Prevention and Control (ECDC; tender OJ/2008/07/08-PROC/2008/019), and by funding from the International Society of Travel Medicine (ISTM).; Payments from the CDC funding grant were made to authors or their institutions (D. A. P., P. L. L., E. C., F. C., P. E. K., and D.O.F). Consulting fees were paid by Baxter (to E. C.) and Crucell (to P. E. K.). Payment for development of educational presentations was paid by Sanofi (to P. E. K.). All other authors report no potential conflicts. NR 34 TC 2 Z9 3 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1195-1982 J9 J TRAVEL MED JI J. Travel Med. PD MAY-JUN PY 2013 VL 20 IS 3 BP 177 EP 184 DI 10.1111/jtm.12025 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 127DZ UT WOS:000317677600008 PM 23577864 ER PT J AU Chen, LH Barnett, ED Wilson, ME MacLeod, W Yanni, EA Ooi, W Karchmer, AW Kogelman, L Marano, N Hamer, DH AF Chen, Lin H. Barnett, Elizabeth D. Wilson, Mary E. MacLeod, William Yanni, Emad A. Ooi, Winnie Karchmer, Adolf W. Kogelman, Laura Marano, Nina Hamer, Davidson H. TI What to Do With Travelers Who Have Isolated Antibody to Hepatitis B Core Antigen? Response SO JOURNAL OF TRAVEL MEDICINE LA English DT Letter C1 [Chen, Lin H.] Mt Auburn Hosp, Travel Med Ctr, Cambridge, MA USA. [Chen, Lin H.] Harvard Univ, Sch Med, Fac Med, Boston, MA USA. [Barnett, Elizabeth D.] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA. [Barnett, Elizabeth D.] Boston Med Ctr, Int Clin, Dept Pediat, Boston, MA USA. [Wilson, Mary E.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA. [MacLeod, William; Hamer, Davidson H.] Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02215 USA. [MacLeod, William; Hamer, Davidson H.] Boston Univ, Sch Publ Hlth, Dept Int Hlth, Boston, MA USA. [Yanni, Emad A.; Marano, Nina] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Ooi, Winnie] Lahey Clin Med Ctr, Burlington, MA 01803 USA. [Karchmer, Adolf W.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA. [Kogelman, Laura] Tufts Med Ctr, Div Geog Med & Infect Dis, Boston, MA USA. [Hamer, Davidson H.] Boston Univ, Sch Med, Dept Med, Infect Dis Sect, Boston, MA 02118 USA. RP Chen, LH (reprint author), Mt Auburn Hosp, Travel Med Ctr, Cambridge, MA USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1195-1982 J9 J TRAVEL MED JI J. Travel Med. PD MAY-JUN PY 2013 VL 20 IS 3 BP 210 EP 210 DI 10.1111/jtm.12028_2 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 127DZ UT WOS:000317677600014 PM 23577870 ER PT J AU Burns, CC Shaw, J Jorba, J Bukbuk, D Adu, F Gumede, N Pate, MA Abanida, EA Gasasira, A Iber, J Chen, Q Vincent, A Chenoweth, P Henderson, E Wannemuehler, K Naeem, A Umami, RN Nishimura, Y Shimizu, H Baba, M Adeniji, A Williams, AJ Kilpatrick, DR Oberste, MS Wassilak, SG Tomori, O Pallansch, MA Kew, O AF Burns, Cara C. Shaw, Jing Jorba, Jaume Bukbuk, David Adu, Festus Gumede, Nicksy Pate, Muhammed Ali Abanida, Emmanuel Ade Gasasira, Alex Iber, Jane Chen, Qi Vincent, Annelet Chenoweth, Paul Henderson, Elizabeth Wannemuehler, Kathleen Naeem, Asif Umami, Rifqiyah Nur Nishimura, Yorihiro Shimizu, Hiroyuki Baba, Marycelin Adeniji, Adekunle Williams, A. J. Kilpatrick, David R. Oberste, M. Steven Wassilak, Steven G. Tomori, Oyewale Pallansch, Mark A. Kew, Olen TI Multiple Independent Emergences of Type 2 Vaccine-Derived Polioviruses during a Large Outbreak in Northern Nigeria SO JOURNAL OF VIROLOGY LA English DT Article ID IMMUNODEFICIENT PATIENT; UNITED-STATES; DEOXYINOSINE RESIDUES; PARALYTIC POLIOMYELITIS; WIDESPREAD CIRCULATION; POPULATION-DYNAMICS; CODON DEGENERACY; WILD POLIOVIRUS; GENETIC-BASIS; MIXED-BASE AB Since 2005, a large poliomyelitis outbreak associated with type 2 circulating vaccine-derived poliovirus (cVDPV2) has occurred in northern Nigeria, where immunization coverage with trivalent oral poliovirus vaccine (tOPV) has been low. Phylogenetic analysis of P1/capsid region sequences of isolates from each of the 403 cases reported in 2005 to 2011 resolved the outbreak into 23 independent type 2 vaccine-derived poliovirus (VDPV2) emergences, at least 7 of which established circulating lineage groups. Virus from one emergence (lineage group 2005-8; 361 isolates) was estimated to have circulated for over 6 years. The population of the major cVDPV2 lineage group expanded rapidly in early 2009, fell sharply after two tOPV rounds in mid-2009, and gradually expanded again through 2011. The two major determinants of attenuation of the Sabin 2 oral poliovirus vaccine strain (A(481) in the 5'-untranslated region [5'-UTR] and VP1-Ile(143)) had been replaced in all VDPV2 isolates; most A(481) 5'-UTR replacements occurred by recombination with other enteroviruses. cVDPV2 isolates representing different lineage groups had biological properties indistinguishable from those of wild polioviruses, including efficient growth in neuron-derived HEK293 cells, the capacity to cause paralytic disease in both humans and PVR-Tg21 transgenic mice, loss of the temperature-sensitive phenotype, and the capacity for sustained person-to-person transmission. We estimate from the poliomyelitis case count and the paralytic case-to-infection ratio for type 2 wild poliovirus infections that similar to 700,000 cVDPV2 infections have occurred during the outbreak. The detection of multiple concurrent cVDPV2 outbreaks in northern Nigeria highlights the risks of cVDPV emergence accompanying tOPV use at low rates of coverage in developing countries. C1 [Burns, Cara C.; Shaw, Jing; Jorba, Jaume; Iber, Jane; Chen, Qi; Vincent, Annelet; Henderson, Elizabeth; Williams, A. J.; Kilpatrick, David R.; Oberste, M. Steven; Pallansch, Mark A.; Kew, Olen] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. [Chenoweth, Paul; Wannemuehler, Kathleen; Wassilak, Steven G.] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA. [Bukbuk, David; Baba, Marycelin] Univ Maiduguri, Teaching Hosp, Maiduguri, Nigeria. [Adu, Festus; Adeniji, Adekunle] Univ Ibadan, Coll Med, Dept Virol, Ibadan, Nigeria. [Gumede, Nicksy] Natl Inst Communicable Dis, Div Virol, Johannesburg, South Africa. [Pate, Muhammed Ali; Abanida, Emmanuel Ade] Natl Primary Hlth Care Dev Agcy, Abuja, Nigeria. [Gasasira, Alex] World Hlth Org Nigeria, Abuja, Nigeria. [Naeem, Asif; Umami, Rifqiyah Nur; Nishimura, Yorihiro; Shimizu, Hiroyuki] Natl Inst Infect Dis, Dept Virol 2, Tokyo, Japan. [Tomori, Oyewale] Redeemers Univ, Redemption City, Ogun State, Nigeria. RP Burns, CC (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. EM CBurns@cdc.gov OI Adeniji, Johnson/0000-0002-0406-6707; Bukbuk, David Nadeba/0000-0003-3388-3842 FU Centers for Disease Control and Prevention; Polio Research Committee of the World Health Organization; Bill and Melinda Gates Foundation; Ministry of Education, Culture, Sports, Science, and Technology of Japan; Ministry of Health, Labor, and Welfare, Japan FX This work was supported in part by the Centers for Disease Control and Prevention; a grant from the Polio Research Committee of the World Health Organization; a Grand Challenges Exploration grant from the Bill and Melinda Gates Foundation; grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; and grants-in-aid for research on emerging and reemerging infectious diseases from the Ministry of Health, Labor, and Welfare, Japan. NR 98 TC 56 Z9 57 U1 0 U2 11 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD MAY PY 2013 VL 87 IS 9 BP 4907 EP 4922 DI 10.1128/JVI.02954-12 PG 16 WC Virology SC Virology GA 123UK UT WOS:000317416400012 PM 23408630 ER PT J AU Batan, M Li, RW Scanlon, K AF Batan, Marilyn Li, Ruowei Scanlon, Kelley TI Association of Child Care Providers Breastfeeding Support with Breastfeeding Duration at 6 Months SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Breast Feeding; Child care; Duration; Supports ID UNITED-STATES; EMPLOYMENT AB Many lactating mothers participate in the workforce and have their infants cared for outside of their home, yet little is known about their child care providers' (CCPs') support of breastfeeding. This study examines the association between CCPs' breastfeeding support as reported by mothers at 3 months and mother's breastfeeding at 6 months. Infant Feeding Practices Study II, a longitudinal study, followed mothers of infants via mail questionnaires almost monthly from late pregnancy throughout the first year. This study consisted of 183 mothers who breastfed and had their infant in child care at 3 months and answered 5 questions regarding CCPs' supports. Total number of CCPs' support was a summary of responses to individual items and categorized into 3 levels (0-2, 3-4, or 5 total supports). Multiple logistic regressions examined how each breastfeeding support and total number were associated with breastfeeding at 6 months. Breastfeeding at 6 months was significantly associated with CCP support to feed expressed breast milk (AOR = 4.55; 95 % CI = 1.09, 18.95) and allow mothers to breastfeed at the child care place before or after work (AOR = 6.23; 95 % CI = 1.33, 29.16). Compared to mothers who reported fewer than 3 total supports, mothers who reported 5 supports were 3 times as likely to be breastfeeding at 6 months (AOR = 3.00, 95 % CI = 1.11, 8.13). Our findings suggest that CCPs' breastfeeding support at 3 months, particularly feeding expressed breast milk and allowing mothers to breastfeed before or after work, may help mothers maintain breastfeeding at 6 months. C1 [Batan, Marilyn] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA. [Li, Ruowei; Scanlon, Kelley] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Batan, M (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, 4770 Buford Highway,Mail Stop K-10, Atlanta, GA 30341 USA. EM FPL8@cdc.gov; ril6@cdc.gov; kxs5@cdc.gov NR 26 TC 3 Z9 3 U1 5 U2 13 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD MAY PY 2013 VL 17 IS 4 BP 708 EP 713 DI 10.1007/s10995-012-1050-7 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 126IS UT WOS:000317608200018 PM 22706997 ER PT J AU Hinkle, SN Sharma, AJ Schieve, LA Ramakrishnan, U Swan, DW Stein, AD AF Hinkle, Stefanie N. Sharma, Andrea J. Schieve, Laura A. Ramakrishnan, Usha Swan, Deanne W. Stein, Aryeh D. TI Reliability of Gestational Weight Gain Reported Postpartum: A Comparison to the Birth Certificate SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Reliability; Birth certificate; Self-report; Weight gain; Pregnancy ID NORTH-CAROLINA; FETAL-GROWTH; PREGNANCY; WOMEN; VALIDATION; ACCURACY; VALIDITY; PROGRAM; HEIGHT; TARGET AB Gestational weight gain (GWG) is an important predictor of short- and long-term adverse maternal and child outcomes. As interest in long-term outcomes increases, utilization of maternal postpartum report is likely to also increase. There is little data available examining the reliability and identifying predictors of bias in GWG recalled by mothers postpartum. We used data from the Early Childhood Longitudinal Study-Birth Cohort, a national study of U.S. children born in 2001, to compare GWG recalled by mothers approximately 10 months postpartum to GWG recorded on the birth certificate, among 5,650 records. On average, the postpartum estimates were 2.1 lbs higher (standard error, 0.2 lbs.) than the birth certificate report; 54.7 % were within 5 lbs, 27.2 % were overreported by more than 5 lbs, and 18.2 % were underreported by more than 5 lbs. The difference between the two sources increased with GWG reported postpartum and was significantly greater among mothers who were obese prior to pregnancy, had inadequate prenatal care, or were multiparous. Bias also differed by birth outcome, indicating the potential for recall bias. When categorized by adequacy of the 2009 Institute of Medicine GWG recommendations, 70 % of women were similarly categorized, and associations between GWG adequacy and small- and large-birthweight-for-gestational-age did not differ meaningfully by source of GWG data. These results suggest that for future studies, mothers' estimates of their GWG, obtained within approximately 1 year postpartum, may be a reliable substitute when birth certificate GWG data are unavailable. C1 [Hinkle, Stefanie N.; Sharma, Andrea J.; Ramakrishnan, Usha; Stein, Aryeh D.] Emory Univ, Div Biol & Biomed Sci, Atlanta, GA 30322 USA. [Hinkle, Stefanie N.; Sharma, Andrea J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Schieve, Laura A.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA. [Ramakrishnan, Usha; Swan, Deanne W.; Stein, Aryeh D.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Sharma, AJ (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS K23, Atlanta, GA 30341 USA. EM ajsharma@cdc.gov RI Hinkle, Stefanie/F-8253-2013; Ramakrishnan, Usha/L-8921-2016; OI Hinkle, Stefanie/0000-0003-4312-708X; Stein, Aryeh/0000-0003-1138-6458; Sharma, Andrea/0000-0003-0385-0011 NR 39 TC 7 Z9 7 U1 1 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD MAY PY 2013 VL 17 IS 4 BP 756 EP 765 DI 10.1007/s10995-012-1057-0 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 126IS UT WOS:000317608200023 PM 22706998 ER PT J AU Schoendorf, KC AF Schoendorf, Kenneth C. TI Current Vision and Future Directions SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Article RP Schoendorf, KC (reprint author), Ctr Dis Control & Prevent, Infant & Child Hlth Studies Branch, Natl Ctr Hlth Stat, Room 6115, Hyattsville, MD 20782 USA. EM KSchoendorf@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-5022 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD MAY PY 2013 VL 27 IS 3 BP 228 EP 228 DI 10.1111/ppe.12050 PG 1 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA 123XG UT WOS:000317424600002 PM 23574409 ER PT J AU Hamner, HC Tinker, SC Flores, AL Mulinare, J Weakland, AP Dowling, NF AF Hamner, Heather C. Tinker, Sarah C. Flores, Alina L. Mulinare, Joe Weakland, Aliki P. Dowling, Nicole F. TI Modelling fortification of corn masa flour with folic acid and the potential impact on Mexican-American women with lower acculturation SO PUBLIC HEALTH NUTRITION LA English DT Article DE Fortification; Corn masa flour; Acculturation; Folic acid ID NEURAL-TUBE DEFECTS; NUTRITION EXAMINATION SURVEY; UNITED-STATES; SPINA-BIFIDA; NATIONAL-HEALTH; BIRTH-DEFECTS; PREVENTION; HISPANICS; PREVALENCE; VITAMIN AB Objective: Hispanics with lower acculturation may be at higher risk for neural tube defects compared with those with higher acculturation due to lower total folic acid intake or other undetermined factors. Modelling has indicated that fortification of corn masa flour with folic acid could selectively target Mexican Americans more than other race/ethnicities. We assessed whether fortification of corn masa flour with folic acid could selectively increase folic acid intake among Mexican-American women with lower acculturation, as indicated by specific factors (language preference, country of origin, time living in the USA). Design: We used dietary intake and dietary supplement data from the National Health and Nutrition Examination Survey 2001-2008, to estimate the amount of additional total folic acid that could be consumed if products considered to contain corn masa flour were fortified at 140 mu g of folic acid per 100 g of corn masa flour. Setting: USA. Subjects: Non-pregnant women aged 15-44 years (n 5369). Results: Mexican-American women who reported speaking Spanish had a relative percentage change in usual daily total folic acid intake of 30.5 (95% CI 27.8, 33.4) %, compared with 8.3 (95% CI 7.3, 9.4) % for Mexican-American women who reported speaking English. We observed similar results for other acculturation factors. An increase of 6.0 percentage points in the number of Mexican-American women who would achieve the recommended intake of >= 400 mu g folic acid/d occurred with fortification of corn masa flour; compared with increases of 1.1 percentage points for non-Hispanic whites and 1.3 percentage points for non-Hispanic blacks. An even greater percentage point increase was observed among Mexican-American women who reported speaking Spanish (8.2). Conclusions: Fortification of corn masa flour could selectively increase total folic acid intake among Mexican-American women, especially targeting Mexican-American women with lower acculturation, and result in a decrease in the number of pregnancies affected by neural tube defects. C1 [Hamner, Heather C.; Tinker, Sarah C.; Flores, Alina L.; Mulinare, Joe; Weakland, Aliki P.; Dowling, Nicole F.] Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30033 USA. RP Hamner, HC (reprint author), Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE,MS E-86, Atlanta, GA 30033 USA. EM hfc2@cdc.gov FU US Centers for Disease Control and Prevention FX The research was funded by the US Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 37 TC 8 Z9 8 U1 1 U2 13 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 1368-9800 EI 1475-2727 J9 PUBLIC HEALTH NUTR JI Public Health Nutr. PD MAY PY 2013 VL 16 IS 5 BP 912 EP 921 DI 10.1017/S1368980012004582 PG 10 WC Public, Environmental & Occupational Health; Nutrition & Dietetics SC Public, Environmental & Occupational Health; Nutrition & Dietetics GA 124AB UT WOS:000317433700018 PM 23113948 ER PT J AU Park-Lee, E Sengupta, M Bercovitz, A Caffrey, C AF Park-Lee, Eunice Sengupta, Manisha Bercovitz, Anita Caffrey, Christine TI Oldest Old Long-Term Care Recipients: Findings From the National Center for Health Statistics' Long-Term Care Surveys SO RESEARCH ON AGING LA English DT Article DE oldest old; long-term care; nursing home; home health; hospice care; national surveys ID YOUNG OLD; DISABILITY; MORTALITY; FUTURE; TRENDS; AGE AB The purpose of this study was to examine socio-demographic and health characteristics of the oldest old receiving services from three types of long-term care (LTC) providers. About 45% of nursing home residents in 2004 and 22% of home health care patients and 38% of discharged hospice care patients in 2007 were 85 years and older. The oldest old across the three LTC settings were predominantly White and women. More than two thirds of oldest old nursing home residents, home health care patients, and discharged hospice care patients needed assistance in performing three or more activities of daily living (ADLs) and were bladder incontinent. Hypertension and heart disease were the two most common chronic health conditions that the oldest old LTC recipients had across the care settings. Results provide a baseline that can be used to make comparisons with other new and emerging LTC providers like residential care and home care. C1 [Park-Lee, Eunice; Sengupta, Manisha; Bercovitz, Anita; Caffrey, Christine] Ctr Dis Control & Prevent, Div Hlth Care Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Park-Lee, E (reprint author), Natl Ctr Hlth Stat, Div Hlth Care Stat, 3311 Toledo Rd,Room 3434, Hyattsville, MD 20782 USA. EM eparklee@cdc.gov NR 21 TC 1 Z9 2 U1 2 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0164-0275 J9 RES AGING JI Res. Aging PD MAY PY 2013 VL 35 IS 3 BP 296 EP 321 DI 10.1177/0164027512442937 PG 26 WC Gerontology SC Geriatrics & Gerontology GA 126NC UT WOS:000317623200003 ER PT J AU Killian, ML Swenson, SL Vincent, AL Landgraf, JG Shu, B Lindstrom, S Xu, X Klimov, A Zhang, Y Bowman, AS AF Killian, M. L. Swenson, S. L. Vincent, A. L. Landgraf, J. G. Shu, B. Lindstrom, S. Xu, X. Klimov, A. Zhang, Y. Bowman, A. S. TI Simultaneous Infection of Pigs and People with Triple-Reassortant Swine Influenza Virus H1N1 at a U.S. County Fair SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE Swine influenza; transmission ID EVOLUTIONARY GENETICS ANALYSIS; UNITED-STATES; A VIRUS; SOFTWARE; OUTBREAK AB Influenza-like illness was noted in people and pigs in attendance at an Ohio county fair in August 2007. The morbidity rate in swine approached 100% within 12days of initial clinical signs being recognized, and approximately two dozen people developed influenza-like illness. Triple-reassortant swine H1N1 influenza viruses were identified in both pigs and people at the fair. The identified viruses (A/Sw/OH/511445/2007, A/Ohio/01/2007, and A/Ohio/02/2007) were similar to H1N1 swine influenza viruses currently found in the U.S. swine population. This case illustrates the possibility of transmission of swine influenza in settings where there is close human/swine interaction. C1 [Killian, M. L.; Swenson, S. L.; Landgraf, J. G.] US Anim & Plant Hlth Inspect Serv, Diagnost Virol Lab, Natl Vet Serv Labs, USDA, Ames, IA USA. [Vincent, A. L.] ARS, Virus & Prion Dis Livestock Res Unit, Natl Anim Dis Ctr, USDA, Ames, IA USA. [Shu, B.; Lindstrom, S.; Xu, X.; Klimov, A.] Ctr Dis Control & Prevent, Virus Surveillance & Diagnost Branch, Influenza Div, Atlanta, GA USA. [Zhang, Y.] Anim Dis Diagnost Lab, Reynoldsburg, OH USA. [Bowman, A. S.] Ohio State Univ, Columbus, OH 43210 USA. RP Swenson, SL (reprint author), USDA, Natl Vet Serv Labs, POB 844,1920 Dayton Ave, Ames, IA 50010 USA. EM sabrina.l.swenson@aphis.usda.gov RI Bowman, Andrew/B-4321-2012 OI Bowman, Andrew/0000-0002-0738-8453 NR 10 TC 13 Z9 14 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1863-1959 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD MAY PY 2013 VL 60 IS 3 BP 196 EP 201 DI 10.1111/j.1863-2378.2012.01508.x PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA 126BP UT WOS:000317586500002 PM 22776714 ER PT J AU Taylor, EV Herman, KM Ailes, EC Fitzgerald, C Yoder, JS Mahon, BE Tauxe, RV AF Taylor, E. V. Herman, K. M. Ailes, E. C. Fitzgerald, C. Yoder, J. S. Mahon, B. E. Tauxe, R. V. TI Common source outbreaks of Campylobacter infection in the USA, 1997-2008 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Bacterial infections; Campylobacter; epidemiology; foodborne infections; outbreaks ID UNITED-STATES; SOURCE ATTRIBUTION; MILK; ENGLAND; JEJUNI; WALES AB Campylobacter is a common but decreasing cause of foodborne infections in the USA. Outbreaks are uncommon and have historically differed from sporadic cases in seasonality and contamination source. We reviewed reported outbreaks of campylobacteriosis. From 1997 to 2008, 262 outbreaks were reported, with 9135 illnesses, 159 hospitalizations, and three deaths. The annual mean was 16 outbreaks for 1997-2002, and 28 outbreaks for 2003-2008. Almost half occurred in warmer months. Foodborne transmission was reported in 225 (86%) outbreaks, water in 24 (9%), and animal contact in seven (3%). Dairy products were implicated in 65 (29%) foodborne outbreaks, poultry in 25 (11%), and produce in 12 (5%). Reported outbreaks increased during a period of declining overall incidence, and seasonality of outbreaks resembled that of sporadic infections. Unlike sporadic illnesses, which are primarily attributed to poultry, dairy products are the most common vehicle identified for outbreaks. C1 [Taylor, E. V.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Enter Dis Epidemiol Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Herman, K. M.; Fitzgerald, C.; Yoder, J. S.; Mahon, B. E.; Tauxe, R. V.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Ailes, E. C.] Ctr Dis Control & Prevent, IHRC Inc, Atlanta, GA USA. RP Taylor, EV (reprint author), Div Foodborne Waterborne & Environm Dis, Enter Dis Epidemiol Branch, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30333 USA. EM idp4@cdc.gov NR 39 TC 39 Z9 40 U1 0 U2 33 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD MAY PY 2013 VL 141 IS 5 BP 987 EP 996 DI 10.1017/S0950268812001744 PG 10 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 118YZ UT WOS:000317064800013 PM 22892294 ER PT J AU Tiao, N Darrington, C Molla, B Saville, WJA Tilahun, G Kwok, OCH Gebreyes, WA Lappin, MR Jones, JL Dubey, JP AF Tiao, N. Darrington, C. Molla, B. Saville, W. J. A. Tilahun, G. Kwok, O. C. H. Gebreyes, W. A. Lappin, M. R. Jones, J. L. Dubey, J. P. TI An investigation into the seroprevalence of Toxoplasma gondii, Bartonella spp., feline immunodeficiency virus (FIV), and feline leukaemia virus (FeLV) in cats in Addis Ababa, Ethiopia SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Bartonella; cats; epidemiology; Ethiopia; humans; Toxoplasma gondii ID EPIDEMIOLOGIC OBSERVATIONS; UNITED-STATES; SPECIES DNA; BLOOD; INFECTIONS; DIAGNOSIS; PREVALENCE; ANTIBODIES; BALTIMORE; FLEAS AB Toxoplasma gondii and Bartonella spp. are zoonotic pathogens of cats. Feline immunodeficiency virus (FIV), and feline leukaemia virus (FeLV) are immunosuppressive viruses of cats that can affect T. gondii oocyst shedding. In this study, the prevalence of antibodies to T. gondii, Bartonella spp., FIV, as well as FeLV antigens were determined in sera from feral cats (Felis catus) from Addis Ababa, Ethiopia. Using the modified agglutination test, IgG antibodies to T. gondii were found in 41 (85.4%) of the 48 cats with titres of 1:25 in one, 1:50 in one, 1:200 in six, 1:400 in six, 1:800 in six, 1:1600 in eight, and 1:3200 in 13 cats. Toxoplasma gondii IgM antibodies were found in 11/46 cats tested by ELISA, suggesting recent infection. Antibodies to Bartonella spp. were found in five (11%) of 46 cats tested. Antibodies to FIV or FeLV antigen were not detected in any of the 41 cats tested. The results indicate a high prevalence of T. gondii and a low prevalence of Bartonella spp. infection in cats in Ethiopia. C1 [Tiao, N.; Darrington, C.; Molla, B.; Saville, W. J. A.; Gebreyes, W. A.] Ohio State Univ, Coll Vet Med, Dept Vet Prevent Med, Columbus, OH 43210 USA. [Tilahun, G.] Univ Addis Ababa, Aklilu Lemma Inst Pathobiol, Addis Ababa, Ethiopia. [Kwok, O. C. H.; Dubey, J. P.] ARS, USDA, Anim & Nat Resources Inst, Parasite Biol Epidemiol & Systemat Lab, Beltsville, MD USA. [Lappin, M. R.] Colorado State Univ, Coll Vet Med, Dept Clin Sci, Ft Collins, CO 80523 USA. [Jones, J. L.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. RP Dubey, JP (reprint author), USDA, APDL, ANRI, BARC, Bldg 1001, Beltsville, MD 20705 USA. EM jitender.dubey@ars.usda.gov NR 24 TC 13 Z9 13 U1 2 U2 21 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD MAY PY 2013 VL 141 IS 5 BP 1029 EP 1033 DI 10.1017/S0950268812001707 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 118YZ UT WOS:000317064800017 PM 22857007 ER PT J AU Eremeeva, ME Berganza, E Suarez, G Gobern, L Dueger, E Castillo, L Reyes, L Wikswo, ME Abramowicz, KF Dasch, GA Lindblade, KA AF Eremeeva, Marina E. Berganza, Elsa Suarez, Gloria Gobern, Lorena Dueger, Erica Castillo, Leticia Reyes, Lissette Wikswo, Mary E. Abramowicz, Kyle F. Dasch, Gregory A. Lindblade, Kim A. TI Investigation of an outbreak of rickettsial febrile illness in Guatemala, 2007 SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Amblyomma cajennense; Spotted fever rickettsiosis; Spotted fever group rickettsiae; Guatemala ID MOUNTAIN-SPOTTED-FEVER; UNITED-STATES; COSTA-RICA; TICKS; MEXICO; IDENTIFICATION; TYPHUS; ARIZONA; BRAZIL; PANAMA AB Objectives: We describe an outbreak of spotted fever group (SFG) rickettsiosis that occurred in 2007 in a farming community in southeastern Guatemala. We identified 17 cases of an acute febrile illness, among which 10, including two fatalities, were confirmed or probable cases of rickettsial disease (case-fatality proportion 12%). Methods: PCR, a microimmunofluorescence assay (IFA), and Western blotting were performed on patient samples, and PCR was performed on ticks. Results: Using an indirect IFA, seven of 16 (44%) ill persons tested had both IgM and IgG antibodies reacting with one or more Rickettsia spp antigens; the other nine (56%) had only IgM titers or were seronegative. Antibodies to SFG protein and lipopolysaccharide were detected by Western blotting with antigens of Rickettsia typhi, Rickettsia rickettsii, and Rickettsia akari. Only one sample, from an ill person who died, tested positive by PCR for a SFG Rickettsia. PCR analysis of Amblyomma cajennense ticks from domestic animals in the area detected the presence of SFG Rickettsia DNA in one of 12 ticks collected. Conclusions: Further studies in Guatemala are warranted to establish the prevalence of rickettsioses and to fully characterize the identity of the etiologic agents and vectors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. C1 [Eremeeva, Marina E.; Wikswo, Mary E.; Abramowicz, Kyle F.; Dasch, Gregory A.] US Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Vector Borne Dis, Natl Ctr Emerging Zoonot Infect Dis, Atlanta, GA 30333 USA. [Berganza, Elsa] Area Salud, Jutiapa, Guatemala. [Berganza, Elsa] CDC Reg Off Cent Amer & Panama, Field Epidemiol Training Program, Guatemala City, Guatemala. [Suarez, Gloria; Dueger, Erica] Minist Salud Publ & Asistencia Social, Ctr Nacl Epidemiol, Guatemala City, Guatemala. [Gobern, Lorena; Castillo, Leticia] Minist Salud Publ & Asistencia Social, Lab Nacl Salud Guatemala, Guatemala City, Guatemala. [Reyes, Lissette] Area Salud, Santa Rosa, Guatemala. [Reyes, Lissette] US Ctr Dis Control & Prevent, Global Dis Detect Branch, Div Global Dis Detect & Emergency Response, Ctr Global Hlth, Atlanta, GA 30333 USA. [Lindblade, Kim A.] CDC Reg Off Cent Amer & Panama, Int Emerging Infect Program, Guatemala City, Guatemala. [Lindblade, Kim A.] US Ctr Dis Control & Prevent, Malaria Branch, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Lindblade, KA (reprint author), CDC Reg Off Cent Amer & Panama, Int Emerging Infect Program, Guatemala City, Guatemala. EM kil2@cdc.gov OI Dasch, Gregory/0000-0001-6090-1810 FU Oak Ridge Institute for Science and Education FX We thank Joseph Singleton for assistance with the IFA, Sandor E. Karpathy, Maria Zambrano, and Michele Sturgeon for laboratory assistance, Michael Levin for his contribution to the morphological identification of ticks, the CDC Biotechnology Core Facility Branch for synthesis of primers and cell culture, Edgar Manuel Santos and Rafael Sirai for assistance with the field investigation and rodent trapping, and David Moran for assistance with the preparation of figures. The National Hospital of Cuilapa was instrumental in the identification of the initial cases. Kyle F. Abramowicz and Mary E. Wikswo were supported by fellowships from the Oak Ridge Institute for Science and Education. NR 38 TC 6 Z9 6 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAY PY 2013 VL 17 IS 5 BP E304 EP E311 DI 10.1016/j.ijid.2012.11.011 PG 8 WC Infectious Diseases SC Infectious Diseases GA 122VD UT WOS:000317345300005 PM 23266334 ER PT J AU Lindley, MC AF Lindley, Megan C. TI Billing Practices of Local Health Departments Providing 2009 Pandemic Influenza A (H1N1) Vaccine SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE human influenza; pandemic; public health practice; vaccination AB Context: In June 2009, the World Health Organization officially declared an influenza pandemic. In the United States, the federal government supplied 2009 H1N1 vaccine at no cost and provided funding for states to implement vaccination programs. Vaccine providers including health departments were permitted to bill insurance plans for administering 2009 H1N1 vaccine. Objective: To determine the extent to which local health departments (LHDs) billed for administering 2009 H1N1 vaccine, specific billing practices of LHDs, and factors associated with LHD billing. Design: Cross-sectional study using an Internet-based survey, and semistructured interviews. Participants and Setting: Nationally representative stratified random sample of 527 LHDs in the United States. Interviews were conducted among a convenience sample of LHDs. Main Outcome Measure: Proportion of LHDs reporting billing for administering 2009 H1N1 vaccine. Results: A total of 308 health departments (58%) provided responses complete enough for analysis. Most LHDs (82%) had previous experience billing for seasonal influenza vaccination, but only 20% (n = 57) billed for administration of 2009 H1N1 vaccine. Medicare (74%) and Medicaid (80%) were the most commonly billed health care payers; more than half (55%) of LHDs billing for 2009 H1N1 vaccine administration sought reimbursement from one or more private insurance plans. Billing for 2009 H1N1 vaccine administration was more common among LHDs that previously offered seasonal influenza vaccination (P = .003), previously billed for seasonal influenza vaccination (P = .04), and conducted school-located influenza vaccination clinics prior to the 2009-2010 influenza season (P = .002). Conclusions: Most LHDs elected not to bill for 2009 H1N1 vaccine administration despite prior experience billing for influenza vaccination. It is important to understand barriers to billing and resources needed by LHDs to facilitate billing for vaccination. Developing public health billing capacity will allow LHDs to recoup the costs of providing vaccines to insured persons and may also prepare them to conduct billing activities for other services or during future public health emergencies. C1 [Lindley, Megan C.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Lindley, MC (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A-19, Atlanta, GA 30333 USA. EM MLindley@cdc.gov FU Intramural CDC HHS [CC999999] NR 8 TC 2 Z9 2 U1 0 U2 24 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAY-JUN PY 2013 VL 19 IS 3 BP 220 EP 223 DI 10.1097/PHH.0b013e31825874c3 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 117ID UT WOS:000316945900009 PM 23360957 ER PT J AU Pfefferbaum, RL Pfefferbaum, B Van Horn, RL Klomp, RW Norris, FH Reissman, DB AF Pfefferbaum, Rose L. Pfefferbaum, Betty Van Horn, Richard L. Klomp, Richard W. Norris, Fran H. Reissman, Dori B. TI The Communities Advancing Resilience Toolkit (CART): An Intervention to Build Community Resilience to Disasters SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE CART; community; community assessment; community resilience; disaster; disaster preparedness; terrorism ID DIAGRAMMATIC ASSESSMENT; FAMILY RELATIONSHIPS; CAPACITY AB Community resilience has emerged as a construct to support and foster healthy individual, family, and community adaptation to mass casualty incidents. The Communities Advancing Resilience Toolkit (CART) is a publicly available theory-based and evidence-informed community intervention designed to enhance community resilience by bringing stakeholders together to address community issues in a process that includes assessment, feedback, planning, and action. Tools include a field-tested community resilience survey and other assessment and analytical instruments. The CART process encourages public engagement in problem solving and the development and use of local assets to address community needs. CART recognizes 4 interrelated domains that contribute to community resilience: connection and caring, resources, transformative potential, and disaster management. The primary value of CART is its contribution to community participation, communication, self-awareness, cooperation, and critical reflection and its ability to stimulate analysis, collaboration, skill building, resource sharing, and purposeful action. C1 [Pfefferbaum, Rose L.] Phoenix Community Coll, Liberal Arts Dept, Phoenix, AZ USA. [Pfefferbaum, Betty] Univ Oklahoma, Dept Psychiat & Behav Sci, Coll Med, Hlth Sci Ctr, Oklahoma City, OK 73126 USA. [Pfefferbaum, Rose L.; Pfefferbaum, Betty; Van Horn, Richard L.] Univ Oklahoma, Hlth Sci Ctr, Terrorism & Disaster Ctr, Oklahoma City, OK 73126 USA. [Klomp, Richard W.] Ctr Dis Control & Prevent, Off Safety Hlth & Environm, US Dept HHS, Atlanta, GA USA. [Norris, Fran H.] Geisel Sch Med Dartmouth, Hanover, NH USA. [Norris, Fran H.] Natl Ctr Posttraumat Stress Disorder, White River Jct, VT USA. [Reissman, Dori B.] Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Hlth, US Dept HHS, Washington, DC USA. RP Pfefferbaum, B (reprint author), Univ Oklahoma, Dept Psychiat & Behav Sci, Coll Med, Hlth Sci Ctr, POB 26901,WP 3470, Oklahoma City, OK 73126 USA. EM Betty-Pfefferbaum@ouhsc.edu RI Magdaleno Escalante, Jorge-Alberto/D-3610-2017 OI Magdaleno Escalante, Jorge-Alberto/0000-0002-2696-3054 NR 35 TC 15 Z9 15 U1 8 U2 49 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAY-JUN PY 2013 VL 19 IS 3 BP 250 EP 258 DI 10.1097/PHH.0b013e318268aed8 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 117ID UT WOS:000316945900013 PM 23524306 ER PT J AU Wiedrich, TW Sickler, JL Vossler, BL Pickard, SP AF Wiedrich, Tim W. Sickler, Juli L. Vossler, Brenda L. Pickard, Stephen P. TI Critical Systems for Public Health Management of Floods, North Dakota SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE communication; disasters; floods; public health AB Availability of emergency preparedness funding between 2002 and 2009 allowed the North Dakota Department of Health to build public health response capabilities. Five of the 15 public health preparedness capability areas identified by the Centers for Disease Control and Prevention in 2011 have been thoroughly tested by responses to flooding in North Dakota in 2009, 2010, and 2011; those capability areas are information sharing, emergency operations coordination, medical surge, material management and distribution, and volunteer management. Increasing response effectiveness has depended on planning, implementation of new information technology, changes to command and control procedures, containerized response materials, and rapid contract procedures. Continued improvement in response and maintenance of response capabilities is dependent on ongoing funding. C1 [Sickler, Juli L.] North Dakota Dept Hlth, Publ Hlth Emergency Preparedness Div, Bismarck, ND USA. [Vossler, Brenda L.] North Dakota Dept Hlth, Hosp Preparedness Div, Bismarck, ND USA. [Wiedrich, Tim W.] North Dakota Dept Hlth, Emergency Preparedness & Response Sect, Bismarck, ND USA. [Pickard, Stephen P.] Ctr Dis Control & Prevent, Career Epidemiol Field Officer Program, Off Sci & Publ Hlth Practice, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. RP Pickard, SP (reprint author), Ctr Dis Control & Prevent, Career Epidemiol Field Officer Program, Off Sci & Publ Hlth Practice, Off Publ Hlth Preparedness & Response, 600 E Blvd Ave, Bismarck, ND 58505 USA. EM spickard@nd.gov NR 12 TC 2 Z9 2 U1 0 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAY-JUN PY 2013 VL 19 IS 3 BP 259 EP 265 DI 10.1097/PHH.0b013e3182641b39 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 117ID UT WOS:000316945900014 PM 23348522 ER PT J AU Peterson, CA Wall, S Jeon, HJ Swanson, ME Carta, JJ Luze, GJ Eshbaugh, E AF Peterson, Carla A. Wall, Shavaun Jeon, Hyun-Joo Swanson, Mark E. Carta, Judith J. Luze, Gayle J. Eshbaugh, Elaine TI Identification of Disabilities and Service Receipt Among Preschool Children Living in Poverty SO JOURNAL OF SPECIAL EDUCATION LA English DT Article DE early childhood special education; Part C services; early identification ID EARLY HEAD-START; UNITED-STATES; DEVELOPMENTAL TRAJECTORIES; EARLY INTERVENTION; SPECIAL-EDUCATION; PROGRAMS; LANGUAGE; CARE; PREDICTORS; 2ND-GRADE AB This study examined the prevalence of indicators of disability or potential disability among preschool-aged children enrolled in the Early Head Start Research and Evaluation Longitudinal Follow-Up. Three categories of indicators were established: received Part B services, developmental risk, and biological risk. The majority of participating children (62%) were classified into at least one category. Children living in poverty from birth through preschool and of minority status were among those most likely to be classified; these children were likely to have received a variety of services. The majority of children who received Part C services (79.8%) received Part B services as preschoolers, but 33% of the children with a developmental risk identified before age 3 continued to have a developmental risk during preschool yet did not receive specialized services. Results highlight the importance of understanding the relations among child and family characteristics and service receipt to inform policy and practice. C1 [Peterson, Carla A.; Luze, Gayle J.] Iowa State Univ, Ames, IA 50011 USA. [Wall, Shavaun] Catholic Univ Amer, Washington, DC 20064 USA. [Jeon, Hyun-Joo] Univ Alabama, Tuscaloosa, AL USA. [Swanson, Mark E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Carta, Judith J.] Univ Kansas, Lawrence, KS 66045 USA. [Eshbaugh, Elaine] Univ No Iowa, Cedar Falls, IA 50614 USA. RP Peterson, CA (reprint author), Iowa State Univ, E262 Lagomarcino Hall, Ames, IA 50011 USA. EM carlapet@iastate.edu NR 48 TC 0 Z9 0 U1 4 U2 15 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0022-4669 J9 J SPEC EDUC JI J. Spec. Educ. PD MAY PY 2013 VL 47 IS 1 BP 28 EP 40 DI 10.1177/0022466911407073 PG 13 WC Education, Special SC Education & Educational Research GA 119BZ UT WOS:000317073200003 ER PT J AU Yang, C Latkin, C Tobin, K Patterson, J Spikes, P AF Yang, Cui Latkin, Carl Tobin, Karin Patterson, Jocelyn Spikes, Pilgrim TI INFORMAL SOCIAL SUPPORT AND DEPRESSION AMONG AFRICAN AMERICAN MEN WHO HAVE SEX WITH MEN SO JOURNAL OF COMMUNITY PSYCHOLOGY LA English DT Article ID INJECTION-DRUG USERS; GAY MEN; RESOURCE GAIN; HIV-INFECTION; HEALTH; RISK; AIDS; RECIPROCITY; SYMPTOMS; POPULATION AB Men who have sex with men (MSM) experience greater mental health problems as compared with heterosexual populations. Informal social support plays a critical role in emotional well-being. The primary goal of this article is to examine the relationship between depressive symptoms and received social support from family, friends, and sex partners within the social network from a sample of 188 African American MSM in Baltimore, Maryland. We found that receiving emotional support from a family member or a sex partner was associated with reduced odds of having depressive symptoms. Receiving financial support from a family member or a friend was associated with increased odds of having depressive symptoms. The results suggest the importance of emotional support provided by family and sex partner in mental health and the potential value of training African American MSM in skills to enhance the quality of the relationships. C1 [Yang, Cui; Latkin, Carl; Tobin, Karin] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA. [Patterson, Jocelyn; Spikes, Pilgrim] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Yang, C (reprint author), Johns Hopkins Bloomberg Sch PublicHealth, Dept Hlth Behav & Soc, 2213 McElderry St,2nd Floor, Baltimore, MD 21205 USA. EM cyang@jhsph.edu FU NIAAA NIH HHS [K99 AA020782] NR 35 TC 4 Z9 4 U1 2 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0090-4392 J9 J COMMUNITY PSYCHOL JI J. Community Psychol. PD MAY PY 2013 VL 41 IS 4 BP 435 EP 445 DI 10.1002/jcop.21548 PG 11 WC Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Social Work SC Public, Environmental & Occupational Health; Psychology; Social Work GA 113TW UT WOS:000316692600004 PM 23935226 ER PT J AU Fuller, JA Njenga, MK Bigogo, G Aura, B Ope, MO Nderitu, L Wakhule, L Erdman, DD Breiman, RF Feikin, DR AF Fuller, James A. Njenga, M. Kariuki Bigogo, Godfrey Aura, Barrack Ope, Maurice O. Nderitu, Leonard Wakhule, Lilian Erdman, Dean D. Breiman, Robert F. Feikin, Daniel R. TI Association of the CT values of real-time PCR of viral upper respiratory tract infection with clinical severity, Kenya SO JOURNAL OF MEDICAL VIROLOGY LA English DT Article DE viral pneumonial; PCRl; influenza; respiratory syncytial virus ID HUMAN METAPNEUMOVIRUS INFECTION; SYNCYTIAL VIRUS-INFECTION; PANDEMIC H1N1 2009; DISEASE SEVERITY; INFLUENZA-VIRUS; PNEUMOCOCCAL PNEUMONIA; HOSPITALIZED INFANTS; CHILDREN; LOAD; COMMUNITY AB Quantitative real-time polymerase chain reaction (qRT-PCR) assay of the upper respiratory tract is used increasingly to diagnose lower respiratory tract infections. The cycle threshold (CT) values of qRT-PCR are continuous, semi-quantitative measurements of viral load, although interpretation of diagnostic qRT-PCR results are often categorized as positive, indeterminate, or negative, obscuring potentially useful clinical interpretation of CT values. From 2008 to 2010, naso/oropharyngeal swabs were collected from outpatients with influenza-like illness, inpatients with severe respiratory illness, and asymptomatic controls in rural Kenya. CT values of positive specimens (i.e., CT values<40.0) were compared by clinical severity category for five viruses using MannWhitney U-test and logistic regression. Among children <5 years old we tested with respiratory syncytial virus (RSV), inpatients had lower median CT values (27.2) than controls (35.8, P=0.008) and outpatients (34.7, P<0.001). Among children and older patients infected with influenza virus, outpatients had the lowest median CT values (29.8 and 24.1, respectively) compared with controls (P=0.193 for children, P<0.001 for older participants) and inpatients (P=0.009 for children, P<0.001 for older participants). All differences remained significant in logistic regression when controlling for age, days since onset, and coinfection. CT values were similar for adenovirus, human metapneumovirus, and parainfluenza virus in all severity groups. In conclusion, the CT values from the qRT-PCR of upper respiratory tract specimens were associated with clinical severity for some respiratory viruses. J. Med. Virol. 85:924932, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Fuller, James A.; Feikin, Daniel R.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Njenga, M. Kariuki; Bigogo, Godfrey; Aura, Barrack; Nderitu, Leonard; Wakhule, Lilian; Breiman, Robert F.; Feikin, Daniel R.] Ctr Dis Control & Prevent Kenya, Global Dis Detect Div, Int Emerging Infect Program, Nairobi, Kenya. [Njenga, M. Kariuki; Bigogo, Godfrey; Aura, Barrack; Ope, Maurice O.; Nderitu, Leonard; Wakhule, Lilian; Breiman, Robert F.; Feikin, Daniel R.] Ctr Dis Control & Prevent Publ Hlth & Res Collabo, Kenya Med Res Inst, Kisumu, Kenya. [Ope, Maurice O.] Minist Publ Hlth & Sanitat, Nairobi, Kenya. [Erdman, Dean D.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Fuller, JA (reprint author), 1415 Washington Hts, Ann Arbor, MI 48109 USA. EM jafuller@jhsph.edu OI Fuller, James/0000-0003-4020-3665 NR 51 TC 15 Z9 17 U1 0 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0146-6615 J9 J MED VIROL JI J. Med. Virol. PD MAY PY 2013 VL 85 IS 5 BP 924 EP 932 DI 10.1002/jmv.23455 PG 9 WC Virology SC Virology GA 117RT UT WOS:000316971500025 PM 23508918 ER PT J AU He, Q Ananaba, GA Patrickson, J Pitts, S Yi, YM Yan, FX Eko, FO Lyn, D Black, CM Igietseme, JU Thierry-Palmer, M AF He, Qing Ananaba, Godwin A. Patrickson, John Pitts, Sidney Yi, Yeming Yan, Fengxia Eko, Francis O. Lyn, Deborah Black, Carolyn M. Igietseme, Joseph U. Thierry-Palmer, Myrtle TI Chlamydial infection in vitamin D receptor knockout mice is more intense and prolonged than in wild-type mice SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY LA English DT Article DE Chlamydial infection; 1,25-Dihydroxyvitamin D-3; Vitamin D receptor knock out mouse; HeLa cells; Leukocyte elastase inhibitor ID LEUKOCYTE-ELASTASE-INHIBITOR; L-DNASE-II; INNATE IMMUNITY; ACTIVATION; APOPTOSIS; SERPINB1; EXPRESSION; MECHANISM; RESPONSES; TRACT AB Vitamin D hormone (1,25-dihydroxyvitamin D) is involved in innate immunity and induces host defense peptides in epithelial cells, suggesting its involvement in mucosal defense against infections. Chlamydia trachomatis is a major cause of bacterial sexually transmitted disease worldwide. We tested the hypothesis that the vitamin D endocrine system would attenuate chlamydial infection. Vitamin D receptor knock-out mice (VDR-/-) and wild-type mice (VDR+/+) were infected with 10(3) inclusion forming units of Chlamydia muridarum and cervical epithelial cells (HeLa cells) were infected with C. muridarum at multiplicity of infection 5:1 in the presence and absence of 1,25-dihydroxyvitamin D-3. VDR-/- mice exhibited significantly higher bacterial loading than wild-type VDR+/+ mice (P < 0.01) and cleared the chlamydial infection in 39 days, compared with 18 days for VDR+/+ mice. Monocytes and neutrophils were more numerous in the uterus and oviduct of VDR-/- mice than in VDR+/+ mice (P < 0.05) at d 45 after infection. Pre-treatment of HeLa cells with 10 nM or 100 nM 1,25-dihydroxyvitamin D-3 decreased the infectivity of C. muridarum (P < 0.001). Several differentially expressed protein spots were detected by proteomic analysis of chlamydial-infected HeLa cells pre-treated with 1,25-dihydroxyvitamin D-3. Leukocyte elastase inhibitor (LEI), an anti-inflammatory protein, was up-regulated. Expression of LEI in the ovary and oviduct of infected VDR+/+ mice was greater than that of infected VDR-/- mice. We conclude that the vitamin D endocrine system reduces the risk for prolonged chlamydial infections through regulation of several proteins and that LEI is involved in its anti-inflammatory activity. (C) 2012 Elsevier Ltd. All rights reserved. C1 [He, Qing; Eko, Francis O.; Lyn, Deborah; Igietseme, Joseph U.; Thierry-Palmer, Myrtle] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA. [He, Qing; Ananaba, Godwin A.] Clark Atlanta Univ, Dept Biol, Atlanta, GA 30314 USA. [Patrickson, John; Pitts, Sidney] Morehouse Sch Med, Dept Anat & Neurosci, Atlanta, GA 30310 USA. [Yi, Yeming; Black, Carolyn M.; Igietseme, Joseph U.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Yan, Fengxia] Morehouse Sch Med, Clin Res Ctr, Atlanta, GA 30310 USA. RP He, Q (reprint author), Morehouse Sch Med, Dept Microbiol Biochem & Immunol, 720 Westview Dr,SW, Atlanta, GA 30310 USA. EM qhe@msm.edu FU Georgia Research Alliance Collaboration Planning Grant [GRA VAC10.C]; Centers for Disease Control and Prevention; Morehouse School of Medicine; National Institutes of Health/National Center for Research Resources [G12-RR03034, 1 C06 RR18386, 1 U54 RR026137, RR03062, 08247] FX This work was funded by Georgia Research Alliance Collaboration Planning Grant GRA VAC10.C, the Centers for Disease Control and Prevention, and Morehouse School of Medicine. Facilities and support services were partially funded by National Institutes of Health/National Center for Research Resources grants G12-RR03034, 1 C06 RR18386, 1 U54 RR026137 (to Morehouse School of Medicine) and RR03062 and 08247 (to Clark Atlanta University). NR 40 TC 7 Z9 7 U1 0 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-0760 J9 J STEROID BIOCHEM JI J. Steroid Biochem. Mol. Biol. PD MAY PY 2013 VL 135 BP 7 EP 14 DI 10.1016/j.jsbmb.2012.11.002 PG 8 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 117AL UT WOS:000316924400002 PM 23201171 ER PT J AU Alyousefi, NA Mahdy, MAK Lim, YAL Xiao, L Mahmud, R AF Alyousefi, N. A. Mahdy, M. A. K. Lim, Y. A. L. Xiao, L. Mahmud, R. TI First molecular characterization of Cryptosporidium in Yemen SO PARASITOLOGY LA English DT Article DE Cryptosporidium; genotyping; subtyping; Yemen ID FRAGMENT LENGTH POLYMORPHISM; ZOONOTIC TRANSMISSION; SUBGENOTYPE ANALYSIS; HUMANS; PARVUM; CATTLE; SPP.; IDENTIFICATION; EPIDEMIOLOGY; SUBTYPES AB Cryptosporidium is a protozoan parasite of humans and animals and has a worldwide distribution. The parasite has a unique epidemiology in Middle Eastern countries where the IId subtype family of Cryptosporidium parvum dominates. However, there has been no information on Cryptosporidium species in Yemen. Thus, this study was conducted in Yemen to examine the distribution of Cryptosporidium species and subtype families. Fecal samples were collected from 335 patients who attended hospitals in Sana'a city. Cryptosporidium species were determined by PCR and sequence analysis of the 18 s rRNA gene. Cryptosporidium parvum and C. hominis subtypes were identified based on sequence analysis of the 60 kDa glycoprotein (gp60) gene. Out of 335 samples, 33 (9.9%) were positive for Cryptosporidium. Of them, 97% were identified as C. parvum whilst 1 case (3%) was caused by C. hominis. All 7 C. parvum isolates subtyped belonged to the IIaA15G2R1 subtype. The common occurrence of the zoonotic IIa subtype family of C. parvum highlights the potential occurrence of zoonotic transmission of cryptosporidiosis in Yemen. However, this postulation needs confirmation with future molecular epidemiological studies of cryptosporidiosis in both humans and animals in Yemen. C1 [Alyousefi, N. A.; Mahdy, M. A. K.; Lim, Y. A. L.; Mahmud, R.] Univ Malaya, Fac Med, Dept Parasitol, Kuala Lumpur, Malaysia. [Mahdy, M. A. K.] Sanaa Univ, Fac Med, Dept Parasitol, Sanaa, Yemen. [Xiao, L.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Mahdy, MAK (reprint author), Univ Malaya, Fac Med, Dept Parasitol, Kuala Lumpur, Malaysia. EM alsharaby9@yahoo.com RI MAHMUD, ROHELA/B-9593-2010; Xiao, Lihua/B-1704-2013; Alyousefi, Naelah/D-2006-2010; LIM, YVONNE /B-5276-2010; Mahdy, Mohammed/C-1187-2010 OI Xiao, Lihua/0000-0001-8532-2727; Alyousefi, Naelah/0000-0001-8871-1824; LIM, YVONNE /0000-0003-4050-6332; Mahdy, Mohammed/0000-0002-8340-5219 FU University of Malaya [RG302/11HTM, HIR J-00000-73587] FX We thank the staff of the participating hospitals for the collection of samples and data. This work was supported by University of Malaya funded projects (RG302/11HTM and HIR J-00000-73587). NR 52 TC 6 Z9 6 U1 1 U2 16 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0031-1820 EI 1469-8161 J9 PARASITOLOGY JI Parasitology PD MAY PY 2013 VL 140 IS 6 BP 729 EP 734 DI 10.1017/S0031182012001953 PG 6 WC Parasitology SC Parasitology GA 115MJ UT WOS:000316816000006 PM 23369243 ER PT J AU Wang, D Krilich, J Baudys, J Kalb, SR Barr, JR AF Wang, D. Krilich, J. Baudys, J. Kalb, S. R. Barr, J. R. TI Optimization of Peptide Substrates for the Sensitive Detection of Type E Botulinum Neurotoxin by the Endopep-MS Assay SO BIOPOLYMERS LA English DT Meeting Abstract CT 23rd American Peptide Symposium CY JUN 22-27, 2013 CL Waikoloa, HI C1 [Wang, D.; Krilich, J.; Baudys, J.; Kalb, S. R.; Barr, J. R.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0006-3525 EI 1097-0282 J9 BIOPOLYMERS JI Biopolymers PD MAY PY 2013 VL 100 IS 3 SI SI BP 286 EP 286 PG 1 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA AI0IL UT WOS:000336530200228 ER PT J AU Eyler, AA Brownson, RC Schmid, TL AF Eyler, Amy A. Brownson, Ross C. Schmid, Thomas L. TI Making Strides Toward Active Living: The Policy Research Perspective SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Editorial Material C1 [Eyler, Amy A.; Brownson, Ross C.] Washington Univ, Brown Sch, Prevent Res Ctr St Louis, One Brookings Dr, St Louis, MO 63130 USA. [Brownson, Ross C.] Washington Univ, Sch Med, Div Publ Hlth Sci, St Louis, MO 63130 USA. [Brownson, Ross C.] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63130 USA. [Schmid, Thomas L.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. RP Eyler, AA (reprint author), Washington Univ, Brown Sch, Prevent Res Ctr St Louis, One Brookings Dr, St Louis, MO 63130 USA. EM aeyler@wustl.edu FU NCCDPHP CDC HHS [U48 DP001946, U48 DP001903, U48 DP001938]; NIDDK NIH HHS [P30 DK092950] NR 30 TC 4 Z9 4 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAY-JUN PY 2013 VL 19 SU 1 SI SI BP S5 EP S7 DI 10.1097/PHH.0b013e31828c826c PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V43KN UT WOS:000209680400002 PM 23529056 ER PT J AU Lankford, T Hardman, D Dankmeyer, C Schmid, T AF Lankford, Tina Hardman, Dominique Dankmeyer, Chris Schmid, Tom TI Analysis of State Obesity Legislation From 2001 to 2010 SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE public health; obesity; legislation; policy AB Objective: The prevalence of obesity has increased significantly since the 1950s. Currently, more than one-third of adults are obese. This study includes the review of 611 bills that were introduced over the past 10 years for the purpose of reducing obesity. Design: Bills were obtained from state legislature Web sites and Centers for Disease Control and Prevention's (CDC's) Division of Nutrition, Physical Activity, and Obesity legislative database. Full text of bills was read and summed by year and the following categories: (a) Taskforce, (b) School, (c) Community, and (d) Health care. Bills were then coded according to strategies outlined in the Institute of Medicine publication, Accelerating Progress in Obesity Prevention. Results: Of the 611 obesity-specific bills proposed over the last decade, 93 (15.2%) passed and represented 30 states. The largest number of bills ("n") introduced was in the School category (n = 276), followed by Community (n = 126), Health care (n = 117), and Taskforce (n = 92). Percentages of bills passed were as follows: Taskforce (28%), Health care (16%), Schools (14%), and Community (7%). Institute of Medicine strategies were identified in most state legislations. Conclusion: Overall, 15% of obesity bills passed from 2001 to 2010. Legislation can be an important first step to change society and institutional norms to encourage and support people to develop healthier behaviors. Public health practitioners may find the Institute of Medicine guidance and the legislative database useful resources to further efforts in obesity prevention. C1 [Lankford, Tina; Hardman, Dominique; Dankmeyer, Chris; Schmid, Tom] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,MS K-46, Atlanta, GA 30341 USA. RP Lankford, T (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,MS K-46, Atlanta, GA 30341 USA. EM tlankford@cdc.gov NR 8 TC 9 Z9 10 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAY-JUN PY 2013 VL 19 SU 1 SI SI BP S114 EP S118 DI 10.1097/PHH.0b013e3182847f2d PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V43KN UT WOS:000209680400016 PM 23529050 ER PT J AU Pandalai, SP Schulte, PA Miller, DB AF Pandalai, Sudha P. Schulte, Paul A. Miller, Diane B. TI Conceptual heuristic models of the interrelationships between obesity and the occupational environment SO SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH LA English DT Article DE cardiovascular disease; diet; endocrine disruptor; intervention study; metabolism; musculoskeletal disease; occupational health; physical activity; risk assessment ID BODY-MASS INDEX; PERSISTENT ORGANIC POLLUTANTS; MANUFACTURING COMPANY WORKERS; OBSTRUCTIVE SLEEP-APNEA; CARPAL-TUNNEL-SYNDROME; FATTY LIVER-DISEASE; METABOLIC SYNDROME; RISK-FACTORS; CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY AB Objective Research and interventions targeting the relationship between work, its attendant occupational hazards, and obesity are evolving but merit further consideration in the public health arena. In this discussion paper, conceptual heuristic models are described examining the role of obesity as both a risk factor and health outcome in the occupational setting. Methods PubMed was searched using specific criteria from 2000 and onwards for evidence to support conceptual models in which obesity serves as a risk factor for occupational disease or an outcome of occupational exposures. Nine models are presented: four where obesity is a risk factor and five where it is an adverse effect. Results A broad range of work-related health effects are associated with obesity including musculoskeletal disorders, asthma, liver disease, and cardiovascular disease, among others. Obesity can be associated with occupational hazards such as shift work, sedentary work, job stress, and exposure to some chemicals. Conclusion Identification of combinations of risk factors pertinent to obesity in the occupational environment will provide important guidance for research and prevention. C1 [Pandalai, Sudha P.; Schulte, Paul A.; Miller, Diane B.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Pandalai, SP (reprint author), NIOSH, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,MS C-15, Cincinnati, OH 45226 USA. EM SPandalai@cdc.gov FU Intramural CDC HHS [CC999999] NR 138 TC 12 Z9 12 U1 3 U2 16 PU SCANDINAVIAN JOURNAL WORK ENVIRONMENT & HEALTH PI HELSINKI PA TOPELIUKSENKATU 41A, SF-00250 HELSINKI, FINLAND SN 0355-3140 EI 1795-990X J9 SCAND J WORK ENV HEA JI Scand. J. Work Environ. Health PD MAY PY 2013 VL 39 IS 3 BP 221 EP 232 DI 10.5271/sjweh.3363 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD0HW UT WOS:000332916100002 PM 23588858 ER PT J AU Novak, RM Debes, R Chmiel, JS Brooks, JT Buchacz, K Dean, B AF Novak, R. M. Debes, R. Chmiel, J. S. Brooks, J. T. Buchacz, K. Dean, B. TI DISPARITIES IN INITIATION OF HAART AND IN VIROLOGIC SUPPRESSION AMONG PATIENTS IN THE HIV OUTPATIENT STUDY (HOPS), 2000-2010 SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Novak, R. M.] Univ Illinois, Chicago, IL USA. [Debes, R.] Cerner Corp, North Kansas City, MO USA. [Chmiel, J. S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Brooks, J. T.; Buchacz, K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dean, B.] Cerner Res, Culver City, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD MAY PY 2013 VL 16 IS 3 BP A97 EP A98 PG 2 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 144CE UT WOS:000318916401005 ER EF